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The technoscientific becomings of Tibetan medicines in-between India and Switzerland 
Jan M.A. van der Valk, School of Anthropology and Conservation, University of Kent 
 
This doctoral dissertation forges and explores connections, flows and frictions between two 
seemingly unrelated manufacturers of Tibetan medicines: Men-Tsee-Khang, the Tibetan 
Medical and Astrological Institute in Dharamsala (Himachal Pradesh, India), and PADMA AG 
in Wetzikon (Zürich, Switzerland). Adopting a translocal, multispecies approach by 
positioning plant-medicines as the central actors in this ethnography, I trace how four 
plants  W aru, ruta, tserngön and bongnak  W become part of medicine in and between these 
two establishments of Sowa Rigpa of similar age and output volume, situated in highly 
ĚŝǀĞƌƐĞ ĐŽŶƚĞǆƚƐ Ăƚ Ă ƐƚĞƌĞŽƚǇƉŝĐĂů  ‘ƉĞƌŝƉŚĞƌǇ ? ĂŶĚ  ‘ĐŽƌĞ ? ŽĨ tĞƐƚĞƌŶ ƚĞĐŚŶŽƐĐŝĞŶĐĞ
ƌĞƐƉĞĐƚŝǀĞůǇ ?/ŶƐƉŝƌĞĚďǇ^ĐŝĞŶĐĞĂŶĚdĞĐŚŶŽůŽŐǇ^ƚƵĚŝĞƐĂŶĚďǇWŽƌĚŝĠĂŶĚ'ĂƵĚŝůůŝğƌĞ ?Ɛ
(2014a ) ‘ƌĞĨŽƌŵƵůĂƚŝŽŶƌĞŐŝŵĞ ?ŽĨŝŶĚƵƐƚƌŝĂů Ayurvedic proprietary products, I analyse the 
on-going material, technoscientific, and regulatory reformulations of Tibetan materia 
medica as they are actualised in contemporary recipes based on classical texts.  
 
In this thesis, I describe how both PADMA and Men-Tsee-Khang refer to Tibetan medical 
texts yet also rely on botanical taxonomy for plant identification. Both face the 
uncertainties of sourcing raw materials in bulk from growers and traders on the Indian 
market, skilfully mass-produce pills by means of machines for grinding, mixing, sieving and 
packaging, and depend on in-house laboratory analyses and each-ŽƚŚĞƌ ?ƐĞǆƉĞƌƚŝƐĞ in the 
ĐŽŶƐƚƌƵĐƚŝŽŶ ŽĨ ŚǇďƌŝĚ  ‘ƋƵĂůŝƚŝĞƐ ? ? dŚĞǇ ĂƌĞ ĂůƐŽ ĨŽƌĐĞĚ ƚŽ ŝŶƚĞƌĂĐƚ ǁŝƚŚ ƚĞĐŚŶŽŵĞĚŝĐĂů
conceptions of drug safety and toxicity, and with European medicine and food registration 
legislation to varying degrees. I argue that in performing this series of technoscientific 
ƌĞĨŽƌŵƵůĂƚŝŽŶƐ ? dŝďĞƚĂŶ ŵĞĚŝĐŝŶĞƐ ĂƌĞ ďĞĐŽŵŝŶŐ  ‘ĂůƚĞƌŶĂƚŝǀĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? P ůŝŵŝŶĂů ?
iv 
 
paradoxical yet politically subversive things oscillating betwixt and between tradition and 
modernity, orthodoxy and innovation, East and West. Men-Tsee-Khang and PADMA could 
thus be interpreted as two possible instantiations of a quasi-industrial techno-Sowa Rigpa, 
but onlǇ ŝĨ ŽŶĞ ĚŝƐƚŝŶŐƵŝƐŚĞƐ  ‘ŝŐ ? ĨƌŽŵ  ‘^ŵĂůů ůƚĞƌŶĂƚŝǀĞ ? WŚĂƌŵĂ ? ĂŶĚ ŶĞǀĞƌ ǁŝƚŚŽƵƚ
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Note on Tibetan language terms 
 
 
In the main text of this thesis, Tibetan terms are italicised (except in personal names) and 
rendered in a simplified phonemic transcription (following the Tibetan & Himalayan Library, 
http://www.thlib.org/reference/transliteration/phconverter.php). This aims to give non-
specialist readers a more intuitive sense of their pronunciation, which is not 
straightforward to deduce from the standard scholarly transliteration system (Wylie 1959). 
The Glossary provides the latter, supplemented with a relevant, brief English translation of 
ĂůůƚŚĞƚĞƌŵƐŵĞŶƚŝŽŶĞĚ ?ZĞĨůĞĐƚŝŶŐĐŽŵŵŽŶƵƐĂŐĞŚŽǁĞǀĞƌ ?/ƵƐĞ ‘^ŽǁĂZŝŐƉĂ ? ?ŶŽƚsowa 
rikpa )ƚŽĚĞŶŽƚĞƚŚĞdŝďĞƚĂŶ ‘ƐĐŝĞŶĐĞ ?ŬŶŽǁůĞĚŐĞŽĨŚĞĂůŝŶŐ ? ? 
 
The link between Tibetan medicinal plant names and botanical taxonomy is problematic 
and should be treated with much caution, as I argue in Chapter 1. I provide Linnean names 
only to give a rough approximation of how a certain plant (or plant part) was identified by 
a specific author at a specific time and place. This however does not imply I necessarily 
agree, nor that I carried out or verified the botanical identification. Scientific names marked 
with an asterisk in the Glossary are my own tentative identifications, based on the 














ANT  Actor-Network-Theory 
AYUSH Ministry (previously Department) of Ayurveda, Yoga and Naturopathy, 
Unani, Siddha and Homoeopathy, Government of India 
CAM Complementary and Alternative Medicine 
CCTM Central Council of Tibetan Medicine, Central Tibetan Administration 
CITES Convention on International Trade of Endangered Species of Wild Fauna and 
Flora 
FDA US Food and Drug Administration 
GxP Good Practice guidelines; includes Good Agricultural (and Collection) 
Practices (GACP), Good Manufacturing Practice (GMP), Good Distribution 
Practice (GDP), etc. 
HPRD Herbal Product Research Department, Men-Tsee-Khang 
NMPB National Medicinal Plants Board, Government of India 
NTFP Non-Timber Forest Product, also called Minor Forest Product (MFP) in South 
Asia 
QAL Quality Assurance Laboratory, Men-Tsee-Khang 
STS Science and Technology Studies, or Science, Technology and Society 
SVKH Schweizerischer Verband der komplementärmedizinische Heilmittel-
hersteller  ? ‘^ǁŝƐƐƐƐŽĐŝĂƚŝŽŶŽĨŽŵƉůĞŵĞŶƚĂƌǇDĞĚŝĐŝŶĞWƌŽĚƵĐĞƌƐ ? ) 
TCM Traditional Chinese Medicine 
THMP Traditional Herbal Medicinal Product 


























Figure i. Map of North-West India. My main fieldsite was at Men-Tsee-Khang 
(Gangchen Kyishong, Dharamsala), but for Chapter 2 in particular I also travelled to 
New Delhi, Amritsar, Manali and surroundings. The scale bar is 100 km. Adapted from 
















Figure ii. In Switzerland I worked mainly at PADMA AG, in the outskirts of Zürich. The head office was situated 
in Hinwil until 2015, but then moved closer to the production and laboratory sites in the nearby town of 
Wetzikon. The scale bar is 1 km. Adapted from Google Maps (2016). 








 ‘Tibetan medicine in India and SwitzerlanĚ ? ?tŚǇĚŝĚŶ ?ƚǇŽƵŐŽƚŽdŝďĞƚ ? ? This is the most 
common question I got from friends and family in response to my pitiful attempts at 
explaining what my PhD was about. Many somehow continued to hold on to the idea I 
actually did fieldwork in Tibet, even after me telling them this was not the case. The reason 
ĨŽƌƚŚŝƐŝƐƵŶĚĞƌƐƚĂŶĚĂďůĞĂŶĚƐĞĞŵƐũƵƐƚŝĨŝĞĚ PĚŝĚ^ŽǁĂZŝŐƉĂ ? ‘ƚŚĞƐĐŝĞŶĐĞ ?ŬŶŽǁůĞĚŐĞŽĨ
ŚĞĂůŝŶŐ ? ? ŶŽƚ ŽƌŝŐŝŶĂƚĞ ŝŶ dŝďĞƚ ? zĞƐ ? ĂŶĚ ŶŽ ? dŚĞ ĞĂƌůǇ ŚŝƐƚŽƌǇ ŽĨ ^ŽǁĂ ZŝŐƉĂ Ănd its 
foundational compendium The Four Tantras (Gyüzhi, compiled and edited by Yutok the 
Younger in the twelfth century CE) is still fragmented and underexplored (Blezer et al. 2007, 
but see Ga 2010). Its origins  W /ŶĚŝĂŶ ?  ‘ƵĚĚŚĂ ?Ɛ tŽƌĚ ? ?  ‘ŝŶĚŝŐĞŶŽƵƐ ? dŝďĞƚĂŶor even 
Chinese  W have long been a source of controversy (Czaja 2005-2006, Ga 2010), whereas 
many Tibetan histories reconstruct the founding of  ‘Tibetan medicine ? as a synthesis based 
on a seventh-century conference of Greek, Chinese and Indian medical authorities at the 
court of King Songtsen Gampo (Garrett 2007, Yoeli-Tlalim 2012). These complex syncretic 
precedents notwithstanding, nowadays some scholars and practitioners adhere to a 
monolithic, traditionalist view which takes the establishment of classical orthodoxy in 17-
18th century early modern Tibet under the Fifth Dalai Lama (1617-1682) and his regent 
Sangyé Gyatso (1653-1705) as a reference point (Blezer et al. 2007, see Gyatso 2015). The 
idea that Sowa Rigpa in its purest form is to be found on the Tibetan plateau has however 
been compromised since the Chinese Communist invasion of the 1950s, often construed 
as the demise of traditional Tibetan society. Since His Holiness the Fourteenth Dalai Lama 
fled to India in 1959 and eventually settled in the Himalayan hill station of Dharamsala, the 
waves of Tibetans who followed him into exile were seen as the only true carriers of Tibetan 
culture (Prost 2008). This exile movement created the largest refugee group in India, and 
led to the re-establishment of >ŚĂƐĂ ?ƐDĞŶƚƐŝŬŚĂŶŐ ?mentsikhang ? ‘ŚŽƵƐĞŽĨŵĞĚŝĐŝŶĞĂŶĚ
ĂƐƚƌŽůŽŐǇ ? ) ŝŶŚĂƌĂŵƐĂůĂ ŝŶ  ? ? ? ? ? dŚŝƐ ƌĞ-established exile institution is now known as 
Men-Tsee-Khang, or The Tibetan Medical and Astrological Institute (TMAI). The attendant 
politics and ethics of compassion and national-cultural survival, which eventually led to the 
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official recognition of Sowa Rigpa as ĂŶ  ‘/ŶĚŝĂŶ^ǇƐƚĞŵŽĨDĞĚŝĐŝŶĞ ? ŝŶ  ? ? ? ? ? have been 
analysed in detail by anthropologist Stephan Kloos (2008, 2010, 2012, 2013, 2015). Men-
Tsee-Khang positioned itself as the  ‘ŐƵĂƌĚŝĂŶ ŽĨ ƚƌĂĚŝƚŝŽŶ ? ĞǀĞŶ ƚŚŽƵŐŚ ƚŚĞ ŶƵŵďĞƌ ŽĨ
ŝŶĚĞƉĞŶĚĞŶƚŽƌ ‘ƉƌŝǀĂƚĞ ?dŝďĞƚĂŶŵĞĚŝĐŝŶĞƉƌĂĐƚŝƚŝŽŶĞƌƐ ?amchi) continued to increase over 
the years, and even though other (smaller) educational and manufacturing organisations 
and the exile-government Central Council for Tibetan Medicine were founded. In this re-
invention of Tibetan medicine, engagements with modern biomedical science were 
granted a central role following the repeated instruction by the Dalai Lama himself (Kloos 
2010, 2015). The dynamic, multi-directional and multi-faceted interactions between these 
sciences and medicines is also the central theme of this thesis. This in itself is not an 
ĂƌŐƵŵĞŶƚĂƐƚŽǁŚǇ/ĚŝĚŶ ?ƚŐŽƚŽdŝďĞƚ ?ǁŚĞƌĞƚŚĞƌĞĐŶƚƌŝƐĞŽĨĂůĂƌge-scale Sowa Rigpa 
industry has already been described by Saxer (2013), but it does at least indicate why it 
made sense for me to go to Dharamsala. 
 
Ƶƚ ‘tŚǇ^ǁŝƚǌĞƌůĂŶĚ ? ?. Besides this being the title of a book which highlights its unique 
historical, linguistic, economic, religious and social features (Steinberg 1996), it also 
happens to be one of the first countries that accepted Tibetan refugees (Lauer 2013, 
Schlieter et al. 2014). The first wave of mostly orphaned children arrived in 1960, the year 
after the Tibetan uprising in Lhasa which led to the flight of the Dalai Lama. Switzerland 
currently houses the largest population of exiled Tibetans in Europe: roughly four thousand, 
of which a sizeable proportion consists of second-generation Tibetans who obtained Swiss 
nationality by birth. But this is not only why. Coincidentally, a Buryat-Russian family lineage 
of Sowa Rigpa was also settling in Switzerland in the early 1960s (Badmajew et al. 1982, 
Saxer 2004). The Poland-born biomedical surgeon Peter Badmajew was looking to preserve 
the precious knowledge and recipes of previous generations after the death of his father, 
an eminent Tibetan doctor who had been baptised in St.-Petersburg with Czar Alexander II 
as his godfather (as his father was court physician to the Romanovs) and who had himself 
treated two Polish presidents. After ruling out other options Peter Badmajew got in touch 
with the Swiss pharmaceutical businessman Karl Lutz, who had cultivated a keen interest 
in Tibetan medicine. Together, they experimented with the famed Badmajew formulas 
until they were able to reproduce several of them in Zürich. In 1969, the pharmaceutical 
3 
 
company PADMA AG was born. PADMA does not present itself as a bastion of tradition as 
Men-Tsee-Khang does; it is rather a pioneer within the contentious European 
Complementary and Alternative Medicine (CAM) industry (Schwabl and Vennos 2015). In 
this thesis, I seek to investigate connections, flows and frictions between these two 
seemingly unrelated manufacturers of Tibetan medicines. I argue that they face some 
fundamentally similar challenges, relating especially to their interfaces with modern 
Western technoscience. But how can you meaningfully compare Men-Tsee-Khang with 
PADMA? The former is located in a small touristic town on the lower flanks of the Indian 
Himalayas, ǁŚŝůĞƚŚĞůĂƚƚĞƌŝƐďĂƐĞĚŝŶƚŚĞŽƵƚƐŬŝƌƚƐŽĨ^ǁŝƚǌĞƌůĂŶĚ ?ƐůĂƌŐĞƐƚĐŝƚǇ ? PADMA is 
the only company that produces medicines and supplements within Europe based on 
Tibetan formulae and according to European and Swiss pharmaceutical standards, whereas 
Men-Tsee-Khang is considered by many to be the prime institution in exile involved in the 
education and production of Tibetan medicine. Serendipitous and superficial comparisons 
ƐƵĐŚĂƐŚĂƌĂŵƐĂůĂ ?ƐŶŽǁŽƵƚ-of-fashion and almost cynical ŶŝĐŬŶĂŵĞ ‘>ŝƚƚůĞ^ǁŝƚǌĞƌůĂŶĚ ? ?
referring to a past of more quiet and clean pine-forested mountain flanks, mask their vastly 
different ecologies and histories. Consider for instance the extreme wealth inequality 
between these countries: a one-litre bottle of mineral water has a fixed maximum retail 
price of twenty Indian rupees (0.30 USD) in India, while you can easily pay CHF 4.50 (4.6 
USD) in a Swiss restaurant; a fifteenfold difference. The arguments in this thesis, however, 
do not foreground this type of one-on-one correspondences, nor do they rely on macro-
economic or macro-political comparisons in general. I actually conducted two separate 
ethnographies with the same interests, discovered linkages, and endeavoured to integrate 
these into one overarching set of arguments. My approach is not just multi-sited, it is 
translocal, looking at the performance of technoscientific practices in  W and inter  W situ by 
tracing how four Tibetan medicinal plants are (re)formulated and transformed as they 
become (part of) medicine at PADMA and Men-Tsee-Khang. Both refer to classical Tibetan 
medical texts for their recipes, source plants from Indian growers and traders, use not too 
dissimilar machinery in their (mass-)production, rely on in-house laboratories for quality 
control of raw materials and medicines, and are forced to interact with biomedical notions 





Figure iii. A pictorial comparison of Men-Tsee-Khang (left) and PADMA AG (right). The first row shows the colourful 
ĂĐĐŽŵŵŽĚĂƚŝŽŶƐ ŝŶŚĂƌĂŵƐĂůĂ ?Ɛ ƚŽƵƌŝƐƚŝĐdŝďĞƚĂŶƚŽǁŶŽĨDĐ>ĞŽĚ'ĂŶũ ?ĂŶĚƐŽŵĞƐƚĂƚĞůǇďƵŝůĚŝŶŐƐĂůŽŶŐƺƌŝĐŚ ?Ɛ
Limmat river. The second row depicts the entrances to the head offices of both institutions (PADMA moved their office 
to a new address in Wetzikon as of 2015), and the last row to the areas where pharmaceutical production takes place.  
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The question: How do Tibetan materia medica become technoscientific? 
In this thesis, I propose to approach the Tibetan materia medica (men) under study  W 
processed and manufactured by Men-Tsee-Khang and PADMA  W ĂƐ  ‘ĂůƚĞƌŶĂƚŝǀĞ
ƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ?1, expressing the liminality of these institutions and their products. The 
political paradoxes and inherent tensions generated between these two wor(l)ds in the title 
of my thesis is what will be explored throughout the following chapters and returned to in 
the Conclusion. To sustain this argument, I describe how men  ‘ďĞĐŽŵĞƚĞĐŚŶŽƐĐŝĞŶƚŝĨŝĐ ?ŝŶ
and between these two places through innovative entanglements. I analyse their 
simultaneous material and symbolic transformations and reformulations as these 
manufacturers commensurate the situated knowledges of Sowa Rigpa and botanical 
taxonomy in their attempts to identify and name plants (Chapter 1), brave the paradoxes 
of the labyrinthine yet technocratically regulated Indian herbal markets (Chapter 2), 
skilfully mass-produce medicine in a human-machine-plant-environment meshwork as 
pharmaceutical artisans (Chapter 3), create and enact hybrid ontologies of quality in labs 
(Chapter 4), challenge and modulate the poison/medicine dichotomy (Chapter 5), and 
ĐŽƉƌŽĚƵĐĞ ĂŶ ŝĚĞŶƚŝƚǇ ĂƐ  ‘^ŵĂůů ůůƚĞƌŶĂƚŝǀĞ WŚĂƌŵĂ ? ƚŽŐĞƚŚĞƌ ǁŝƚŚ Ă ŵƵůƚŝƉůŝĐŝƚǇ ŽĨ 
medicine (re)formulations in response to dynamic European and national regulatory and 
political realities (Chapter 6). 
 
Methodologically, I adopt a multispecies and multi-sited  W or more precisely translocal  W 
ĞƚŚŶŽŐƌĂƉŚŝĐ ĂƉƉƌŽĂĐŚ ŽĨ  ‘ĨŽůůŽǁŝŶŐ ƚŚĞ ƚŚŝŶŐ ? (see Methodology), tracing how four 
commonly used Tibetan medicinal plants  W aru, ruta, tserngön and bongnak  W are 
reformulated as they are actualised in contemporary recipes based on classical texts in both 
India and Switzerland. This does not only allow for comparative insights  W even though this 
is problematic given the highly diverse contexts  W but more importantly aids in elucidating 
transmissions of knowledge, experience and technologies between these two 
establishments of Tibetan medicine of similar age and productive output volumes, situated 
in a  ‘ĐŽƌĞ ?ĂŶĚĂ ‘ƉĞƌŝƉŚĞƌǇ ?ŽĨmodern Western technoscience respectively but facing some 
                                                     
1 It should not come as a surprise to the reader that this idea has already been commercialised. See for 




surprisingly similar issues when it comes to matters of manufacture. Within these 
heterogeneous biosociotechnical networks in which the worlds of plants and pills collide, I 
thus emphasise  ? ? ) ƚŚĞ ĚǇŶĂŵŝĐ ŝĚĞŶƚŝƚŝĞƐ ĂŶĚ ĂŐĞŶĐŝĞƐ ŽĨ  ‘ŶŽŶŚƵŵĂŶƐ ? and materials, 
especially as witnessed in/through (2) technoscientific practices and in (3) varying 
regulatory realities. Inspired by Science and Technology Studies (STS), I position Tibetan 
plant-medicines as the central actors in this ethnography, showcasing their material, 
technoscientific and regulatory transformations and how these potent substances in turn 
transform their environments and other actors involved.  
 
A nuanced perspective is necessary ƚŽ ƌĞĚƌĞƐƐ ƚŚĞ ƉŽůĂƌŝƐĂƚŝŽŶ ŽĨ ďŽƚŚ  ‘ƐĐŝĞŶƚŝĨŝĐ ?
(anti-)alternative medicine discourses and their traditionalist, essentialist counterparts. I 
aim to go beyond superficial searches for scientific evidence and allegations that the public 
is being misled by inauthentic, non-efficacious Complementary and Alternative Medicine 
(e.g. Ernst 2008, Ernst and Singh 2008), recognising the productive effects and limitations 
of definitions for this socially, historically and legally varied spectrum of healing resources 
(Gale and McHale 2015).2  Over the past fifteen years there has been an explosion of 
ƐŽĐŝŽůŽŐŝĐĂůƐĐŚŽůĂƌƐŚŝƉŽŶ ‘ƚƌĂĚŝƚŝŽŶĂů ŵĞĚŝĐŝŶĞ ?ĂŶĚD ?ƌĞǀŝĞǁĞĚ ŝŶGale 2014). This 
work typically entails quantitative and qualitative studies of user and practitioner 
experiences, beliefs and practices, with newer research avenues exploring societal patterns 
of change and epistemological questions. The pragmatism of medical pluralism has been 
documented along with how  ‘integrative ? medicine strategies frequently retain colonial 
and modern power asymmetries, while not overlooking the creation of hybrid forms of 
                                                     
2 I concur with Gale and McHale (2015) who prefer the following operational definition for CAM by the 
Cochrane Collaboration (Zollman and Vickers 1999, p. 693), as it indicates the sociocultural basis for the 
conventional/alternative distinction and its dynamic, fluid nature:  ‘[c]omplementary and alternative 
medicine (CAM) is a broad domain of healing resources that encompasses all health systems, modalities, and 
practices and their accompanying theories and beliefs, other than those intrinsic to the politically dominant 
ŚĞĂůƚŚƐǇƐƚĞŵŽĨĂƉĂƌƚŝĐƵůĂƌƐŽĐŝĞƚǇŽƌĐƵůƚƵƌĞŝŶĂŐŝǀĞŶŚŝƐƚŽƌŝĐĂůƉĞƌŝŽĚ ? ?dŚĞt,K ? ? ? ? ? )ƌĞĐŽŐŶŝƐĞƐƚŚĂƚ
CAM overlaps with traditionaůŵĞĚŝĐŝŶĞ ?ǁŚŝĐŚŝƐŽĨƚĞŶĐŽŶƐŝĚĞƌĞĚ ‘ŝŶĚŝŐĞŶŽƵƐ ?ĂŶĚĂƐŚĂǀŝŶŐĂůŽŶŐŚŝƐƚŽƌǇ ?
Ƶƚ ĨŽƌ t,K  ‘ƚƌĂĚŝƚŝŽŶĂů ? ĂůƌĞĂĚǇ ŝŵƉůŝĞƐ  ‘ŵŽĚĞƌŶŝƐĞĚ ?  ?Kadetz 2012, Schwabl 2009). Moreover, Swiss 
researchers have argued for a formal distinction between American CAM  W which generally advocates an 
integrative medicine paradigm and includes modalities such as prayer  W and Complementary European 
DĞĚŝĐŝŶĞŽƌD ?hĞŚůĞŬĞĂŶĚ^ĂůůĞƌ ? ? ? ? ) ?ĞƐŝĚĞƐ ‘dƌĂĚŝƚŝŽŶĂůƵƌŽƉĞĂŶDĞĚŝĐŝŶĞ ?ƚŚĞůĂƚƚĞƌǁŽƵůĚĂůƐŽ
include adapted Asian medical systems, amongst others. Nevertheless, biomedicine problematically remains 
the absent presence and often also the arbiter in these conceptualisations, so applying these categories may 
constitute an act of symbolic violence (Gale 2014). 
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practice. Importantly, subjecting CAM modalities to scientific scrutiny has been found to 
be one of the primary means through which biomedicine stays in control, in addition to 
selectively co-opting successful  ‘ĂůƚĞƌŶĂƚŝǀĞ ?aspects.  
 
ŶƚŚƌŽƉŽůŽŐǇŽŶƚŚĞŽƚŚĞƌŚĂŶĚŚĂƐƐƵƌƉƌŝƐŝŶŐůǇƉĂŝĚŵƵĐŚůĞƐƐĂƚƚĞŶƚŝŽŶƚŽƚŚĞƐĞ ‘ŶŽŶ-
ďŝŽŵĞĚŝĐĂů ? ĂƉƉƌŽĂĐŚĞƐ ƚo health compared to sociology and clinical researchers, 
particularly in industrialised countries (but see Nissen and Manderson 2013, for instance). 
In the introduction to her concise textbook on this subject, however, Ross (2012) sets out 
an explicitly anthropological approach to  ‘alternative medicine ?: the challenging, highly 
dynamic (across space and time), eclectic and elusive Other of modern biomedicine. She 
ĐŽŶƐĐŝŽƵƐůǇ ŽƉƚƐ ĨŽƌ ƚŚĞ ƚĞƌŵ  ‘ĂůƚĞƌŶĂƚŝǀĞ ? ŝŶ ƚŚĞ ĨĂĐĞ ŽĨ ƚŚĞ ǁŝĚĞƐƉƌĞĂĚ  ?ďƵƚ ƉĂƌƚŝĂů )
complementarity and integration within dominant healthcare systems since its Latin root 
alter ĐĂƉƚƵƌĞƐ ŝƚƐŽƉƉŽƐŝƚŝŽŶĂů ?ĞůƵƐŝǀĞĂŶĚŽĨƚĞŶƐƵďǀĞƌƐŝǀĞŶĂƚƵƌĞǁŚĞƌĞĂƐƚŚĞǀĞƌď ‘ƚŽ
ĂůƚĞƌŶĂƚĞ ? ĞǀŽŬĞƐ ƚŚĞ ĚǇŶĂŵŝƐŵ ŽĨ ĐƵůƚƵƌĞĚ ƚŚĞƌĂƉĞƵƚŝĐ ƉƌŽĐĞƐƐĞƐ ĂŶĚ ƚŚĞƌĂƉĞƵƚŝĐ
pluralism.  
 
Even though it may not be taken kindly by some proud proponents of Asian scholarly 
medicines (as opposed to the popular/folk nature of many CAM practices) that have long 
dominated the medical arena in their respective homelands and continue to be the main 
recourse to health in many places, I concur with Ross that granting these living traditions  W 
or at least many of their contemporary healing substances  W an alternative status should 
not be considered derogatory but seen as an endorsement for their continued uniqueness, 
resilience and potency. Asian industrial proprietary medicines have already been 
ŝŶƚĞƌƉƌĞƚĞĚ ĂƐ ŝŶƐƚĂŶƚŝĂƚŝŽŶƐ ŽĨ  ‘ĂůƚĞƌŶĂƚŝǀĞ ŵŽĚĞƌŶŝƚĞƐ ?  ?,ƐƵ  ? ? ? ? ? ĂůďĞŝƚ ƚentatively; 
Pordié 2012 and Kloos 2015, amongst others). In a similar vein, I extend Pordié and 
'ĂƵĚŝůůŝğƌĞ ?Ɛ  ? ? ? ? ?a )  ‘ƌĞĨŽƌŵƵůĂƚŝŽŶƌĞŐŝŵĞ ?ƚŽdŝďĞƚĂŶmateria medica, as these should 
equally be considered highly innovative, re-invented pharmaceutical reformulations. In this 
sense, the products of PADMA as well as Men-Tsee-Khang can be said to constitute 




A Eurocentric historical prelude: the rise of technomedicine  ? becoming 
pharmaceutical, becoming alternative 
dŚĞ ďŽƵŶĚĂƌŝĞƐ ďĞƚǁĞĞŶ  ‘ĐŽŶǀĞŶƚŝŽŶĂů ? ?  ‘ƌĞŐƵůĂƌ ? Žƌ  ‘ŽƌƚŚŽĚŽǆ ? ŵĞĚŝcine and its binary 
opposite have been fluid and permeable, as Roberta Bivins (2015) shows in her historical 
sketch of professional debates and the positions taken by medical consumers therein in the 
US and Britain. The rise of  ‘alternative medicine ? is intricately tied up with the history of 
 ‘biomedicine ?: the re-discovery, -translation and -invention of Greek and Roman classical 
medical texts in the academies of the late middle ages and renaissance as a humanistic, 
secular medicine; the onset of the Scientific Revolution in the sixteenth century with its 
valuation of experiment and mechanistic mathematics; and the seventeenth-century 
colonial enterprise and contacts with Asian medical systems. As medicine was increasingly 
defined as a science that engendered public confidence, the cultural capital of academic 
medicine rose and calls for state regulation were strengthened. A discourse of paternalistic 
ĐŽŶƐƵŵĞƌƉƌŽƚĞĐƚŝŽŶǁŚŝĐŚďƌĂŶĚŝƐŚĞĚƉĂƚŝĞŶƚƐĂƐ ‘ĚĞƐƉĞƌĂƚĞ ? ? ‘ŝŐŶŽƌĂŶƚ ? ? ‘ŚǇƐƚĞƌŝĐĂů ?ĂŶĚ
 ‘ŝƌƌĂƚŝŽŶĂů ? ǁĂƐ ŵŽďŝůŝƐĞĚ ? ǁŚŝůĞ ƚŚĞ ĞŵĞƌŐŝŶŐ  ‘ĂůƚĞƌŶĂƚŝǀĞ ? ƉƌĂĐƚŝƚŝŽŶĞƌƐ ǁĞƌĞ ŐĞŶĞƌĂůůǇ
more welcoming to women (as opposed to the white male medical establishment) and 
continued to hail the naturalness, harmlessness, and individuality of their therapies. 
Stringent medical market regulations heralded the twentieth century as the golden age of 
 ‘ƐĐŝĞŶƚŝĨŝĐŵĞĚŝĐŝŶĞ ?ƵŶƚŝů ƚŚĞ  ? ? ? ?Ɛ ?ǁŚĞŶĞƚŚŝĐĂůƐĐĂŶĚĂůƐ ? ŝĂƚƌŽŐĞŶŝĐĚŝƐĂƐƚĞƌƐĂŶĚƚŚĞ
increasing visibility of chronic diseases cemented in an anti-authoritarian counterculture 
which largely rejected the anti-quackery rhetoric. In a move away from regulatory 
paternalism towards neoliberal deregulation reforms and health consumerism, 
 ‘ŽŵƉůĞŵĞŶƚĂƌǇ ĂŶĚ ůƚĞƌŶĂƚŝǀĞ DĞĚŝĐŝŶĞ ?gained a new footing which once again 
provoked highly polemical and polarised debates that fail to reflect the historical, empirical, 
socioeconomic and cultural drivers for the ever-pervasive medical pluralism amongst 
patients/consumers. 
 
The cross-cultural transmission of medical expertise and knowledge is clearly not a uniquely 
contemporary phenomenon, nor was it ever a unidirectional process. This implies that the 
debates at the frontlines between orthodox and heterodox practitioners, patients and 
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policy-makers often rehearse longstanding historical debates as they continuously shift the 
balance of power (Bivins 2007). Although twentieth-century orthodox medicine, now 
ŬŶŽǁŶ ĂƐ  ‘ďŝŽŵĞĚŝĐŝŶĞ ? ? ƉƌĞƐĞŶƚƐ ŝƚƐĞůĨ ĂƐ ĂŶ ŽďũĞĐƚŝǀĞ ? ƐĐŝĞŶƚŝĨŝĐ ? ƵŶŝǀĞƌƐĂlly valid 
monolithic system, the triumphant authority of science is fairly new and never 
unquestioned. As the holistic balance of classical humouralism  W which itself questions the 
relevance of Western versus non-Western distinctions  W faded after its reign of more than 
ƚǁŽŵŝůůĞŶŶŝĂ ?ŶŽƚŝŽŶƐŽĨĞǆƉĞƌŝŵĞŶƚĂŶĚ ‘ƐĐŝĞŶĐĞ ?ŐĂŝŶĞĚƉƌĞĐĞĚĞŶĐĞŽǀĞƌ experience and 
scholarship. Biomedicine came into existence through the industrialisation of medicine, 
through rapid advancements in technology leading to far-reaching specialisation and 
institutionalisation supported by the modern nation-state.  
 
More recently still, the technoscientific transformations of biomedicine have been 
ĐŽŶĐĞƉƚƵĂůŝƐĞĚĂƐ ‘ďŝŽŵĞĚŝĐĂůŝƐĂƚŝŽŶ ?ďǇh^ƐŽĐŝŽůŽŐŝƐƚƐ(Clarke et al. 2003). In their view, 
American biomedicine underwent a second transformation from around 1985, which they 
argue is relevant to the European context as well. This transformation led to a shift from 
control over biomedical phenomena to fundamentally changing them through political-
economic reconfigurations of the health sector, an explicit focus on risk and surveillance, 
bio-technological and bio-engineering innovations, transformations in biomedical 
knowledge circulation and information management, and the creation of customisable 
technoscientific identities. As part of this ambiguous wave of transformations, 
corresponding to a shift towards the ills of late and postmodernity, the selective co-
optation and rebranding of aspects from competing knowledge systems and critical social 
movements was indicated as one of its key processes.  
 
The recent advent of technoscientific biomedicine and the dynamic co-constitution of its 
Others is equally reflected in therapeutic products. A Eurocentric history of pharmacy 
traces the origins of the pharmaceutical to the isolation of alkaloids (as the purported 
 ‘ĂĐƚŝǀĞ ƉƌŝŶĐŝƉůĞƐ ? ) Ĩrom plants, starting with the opium poppy (Papaver somniferum L., 
morphine, 1804) and cinchona bark (Cinchona spp., quinine, 1820) in the early nineteenth 
century (Anderson 2005). Deeply embedded in colonial enterprise, these potent 
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substances were then supplemented by chemically synthesised drugs such as acetylsalicylic 
acid (originally extracted from willow bark, Salix spp.; chemically synthesised at Bayer in 
1897) and psychoactive molecules such as barbiturates (developed as the hypnotic 
Veronal® in GermĂŶǇ ?  ? ? ? ? ) ?dŚĞ ůĂƚƚĞƌĐĂƚĞŐŽƌǇŽĨ  ‘ĨƵůůǇƐǇŶƚŚĞƚŝĐ ?ŵĚŝĐŝŶĂůĐŚĞŵŝĐĂůƐ
reflects the gradual integration of largescale laboratory-based pharmacy production with 
the organic chemical industry of coal tar-derived dyestuffs into a more or less unified 
pharmaceutical industry from the 1890s. The second half of the nineteenth century also 
brought new technologies for the mass production of sugar-coated pills, gelatine capsules 
and tablets. In the post World War II era, Big Pharma experienced exponential growth in 
the antibiotic era, but this ended in the early 1970s following increasing regulation in the 
wake of the 1961 thalidomide tragedy and spiralling healthcare, research and development 
costs. Since the 1980s the boundaries with the chemical-pharmaceutical, food and the new 
biotech industries have become ever more fluid through an intense process of mergers and 
acquisitions and inter-company financial and innovation networks, but therapeutic 
innovation has slackened nonetheless (see for instance Laird 2013). 
 
Historians have noted how earlier forms of state regulation were rendered ineffective in 
the course of industrialisation and the mechanical mass-production and marketing of 
pharmaceuticals (Gaudillière and Hess 2013), as was horribly evidenced by public health 
ƐĐĂŶĚĂůƐƐƵĐŚĂƐ ‘ƚŚĞƚŚĂůŝĚŽŵŝĚĞĚŝƐĂƐƚĞƌ ?ŝŶtĞƐtern Germany during the 1960s, resulting 
in the birth of more than four thousand severely deformed babies. In this complexified 
medical market ? ĚŝĨĨĞƌĞŶƚ  ‘ǁĂǇƐ ŽĨ ƌĞŐƵůĂƚŝŶŐ ? (professional, administrative, industrial, 
public, and juridical) should be seen as sociohistorical products whose articulation and 
arrangements are utterly dynamic. Regulations are tied up with the troubled 
professionalisation and crafting of pharmacy as an autonomous world of knowledge (first 
separating from botany, and later from chemistry), practice (medicine preparation and 
control), institutions (colleges, apothecaries) and administrative instruments (the 
pharmacopoeia) in nineteenth century Europe. Gaudillière (2013) for instance outlines how 
during World War II both Vichy France and Nazi Germany installed similar administrative 
procedures for the market authorisĂƚŝŽŶ ŽĨ ŶĞǁ ŵĞĚŝĐŝŶĞƐ ŝŶ ƌĞĐŽŐŶŝƚŝŽŶ ŽĨ ƚŚĞ  ‘ŐƌĞĂƚ
ƚƌĂŶƐĨŽƌŵĂƚŝŽŶ ?, which led industrially-made therapeutic agents to dominate the market. 
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The professional regulation of medicines by schooled pharmacists evolved into a virtual 
monopoly enshrined in state-sanctioned national pharmacopoeias and good practice 
recommendations by pharmacy and/or medical practitioner collectives. However, as the 
majority of medicines became mass-produced industrial goods during the interbellum, 
knowledge and control over these specialties slipped between their fingers, leading to the 
contested and gradual emergence of industrial regulation. Quality control and 
standardisation were emphasised as means to maximise revenues through resource-
efficient production, foregrounding technological issues, process management and 
marketing as regulatory tools.  
 
Nonetheless, plant extracts remained at the core of the European pharmacopoeia until well 
into the twentieth century. The industrialisation of these materia medica was equally 
controversial and reliant on the shifting intersections between different ways of regulating. 
Gaudillière (2013) documents ƚŚĞƐĞ ƐƚƌĂŶĚƐŽĨ  ‘ĂůƚĞƌŶĂƚŝǀĞƉŚĂƌŵĂĐǇ ? ŝŶ ƚŚĞ ĐŽŵƉĂŶŝĞƐ
Dausse (interwar France) and Madaus (Germany), both of which combined pharmaceutical 
innovation and mechanisation with a holistic vision that took into account synergies and 
the integrity of plants as complex healing agents. He notes that: 
[a]s boundary objects between alternative medicine, classic materia medica, biochemistry, 
and the industrial production of extracts, biological therapeutic agents had a critical 
importance with translation processes working in several directions, that is, rationalizing 
popular or classic practices, but also contributing to the molecularization of plant extracts. 
(Gaudillière 2013, p. 85)  
Aligning themselves with the increasingly influential popular natural medicine movement 
of the 1920s-1930s onwards while harnessing laboratory chemistry, the above-mentioned 
companies are examples of local cultures of innovation within the industrial way of 
regulating not too dissimilar from what I describe in the chapters that follow.3 Not only is 
                                                     
3  Gaudillière (2014) cautiously compares this process to analogous elements in the contemporary 
ƉŚĂƌŵĂĐĞƵƚŝĐĂůŝƐĂƚŝŽŶ ŝŶ /ŶĚŝĂ ? ůĞĂĚŝŶŐ ƚŽ  ‘ƚĞĐŚŶŽ-ǇƵƌǀĞĚĂ ? ? ,ŽǁĞǀĞƌ ? ŚĞ ƌĞŵĂŝŶƐ ĂƚƚĞŶƚŝǀĞ ƚŽ ƐĞǀĞƌĂů
important distinctions: the use of crude parts or extracts of entire plants and of complex multi-compound 
medicines, a much deeper divide between oral and scholarly knowledge traditions, and the current context 
of economic and health globalisation. According to Gaudillière, these peculiarities confer an alternatively 
modern status to this transformation, which is much more about the appropriation of industrial technology 
and the construction of markets than about professionalisation and institutionalisation. 
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the conventional/alternative medicine distinction historically contingent and politically 
ĐŽŶƚĞƐƚĞĚ ?ďƵƚƐŽƚŽŽŝƐƚŚĞĐĂƚĞŐŽƌǇ ‘ƉŚĂƌŵĂĐĞƵƚŝĐĂů ?, as it grew to include not only plant 
extracts but also petrochemicals, hormones, antibiotic molecules, vitamins and a whole 
series of other pharmacological groups while (nearly) excluding the complex multi-
compound mixtures which are considered healing substances in Asian scholarly traditions.  
 
State of the art: the transformations of Asian scholarly medicines 
Under the following two subheadings I briefly outline how academic conceptions of change 
in Asian medical traditions in our recent times of increasing interconnectivity have 
themselves evolved, positioning my contribution within the literature. The first section 
covers macro-ůĞǀĞů ‘ƐǇƐƚĞŵŝĐ ?ĐŽŶƐŝĚĞƌĂƚŝŽŶƐ ĂŶĚƐƵƉƉŽƌƚƐŵǇƵƐĞŽĨƚŚĞƚĞƌŵ ‘ĂůƚĞƌŶĂƚŝǀĞ ? ?
The second section concentrates on the transformations of therapeutic products, 
ƌĞǀŝĞǁŝŶŐƉĞƌƚŝŶĞŶƚƉĞƌƐƉĞĐƚŝǀĞƐŽŶ ‘ƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? ?
 
Becoming alternative? From modernisation and westernisation to globalisation and 
beyond 
The comparative study of Asian medical traditions  W across regional as well as 
classical/philological versus contemporary ethnographic boundaries  W emerged out of the 
foundational work by medical anthropologist Charles Leslie (1974, 1976; Leslie and Young 
1992; see Nichter and Lock 2002). Leslie emphasised the integrity and dynamic nature of 
these systems of medicine, while arguing for the recognition of medical pluralism and 
against modernisation discŽƵƌƐĞƐ ďĂƐĞĚ ŽŶ ƚŚĞ ŚĞŐĞŵŽŶǇ ŽĨ  ‘cosmopolitan medicine ?. 
Recognising the cross-cutting effects of modernity, Leslie early on cautioned against the 
reification of modern/traditional dichotomies as it builds on the false premise of static 
traditionalism and evokes a stereotyping rhetoric of medical ignorance and superstition. 
Similarly, the professionalisation and spread of  ‘tĞƐƚĞƌŶ ŵĞĚŝĐŝŶĞ ? ŝƐ ŝŶŚĞƌĞŶƚůǇ
transcultural, a misleading categorisation feeding on troublesome ethnic, colonial and 
ŶĂƚŝŽŶĂůŝƐƚƐĞŶƚŝŵĞŶƚƐ ?dŚĞƵŶƋƵĞƐƚŝŽŶĞĚŽŶƚŽůŽŐŝĐĂůƉƌŝǀŝůĞŐĞŐƌĂŶƚĞĚƚŽ ‘ƐĐŝĞŶĐĞ ?ĂŶĚŝƚƐ
logical empiricism in medicine, and the acceptance of the validity of modernisation and 
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westernisation by many intellectuals of the second half of the last century has itself co-
ƉƌŽĚƵĐĞĚƚŚĞǀĞƌǇŝĚĞĂŽĨĂŵĞĚŝĐĂů ‘ƐǇƐƚĞŵ ?ŝŶŝƚƐƐǇƐƚĞŵŝƐĂƚŝŽŶŽĨƌĞĂůŝƚǇ (Leslie 1980). 
Leslie and contributors to his seminal edited volumes have shown how the politics of 
(anticolonial) nationalism equally infuses and legitimiƐĞƐ  ‘ŝŶĚŝŐĞŶŽƵƐ ?ŵĞĚŝĐĂů ƌĞǀŝǀĂůŝƐŵ
and syncretism as well as self-conscious attempts at preserving authenticity.  
 
dŚŝƐĂƚƚĞŶƚŝŽŶƚŽŶĂƚŝŽŶĂůŝĚĞŶƚŝƚŝĞƐĂŶĚ ‘ƉŽůŝƚŝĐƐŽĨĐƵůƚƵƌĞ ?ǁĂƐƚŚĞŶƚĂŬĞŶĨŽƌǁĂƌĚǁŝƚŚŝŶ
ƚŚĞĐŽŶƚĞǆƚŽĨ ‘ŐůŽďĂůŝƐĂƚŝŽŶ ?ĂŶĚƚƌĂŶƐŶĂƚŝŽŶalism, to the production and dissemination of 
medical theories and practices beyond nation-states, and to the flexibility and anxieties 
created by increasing exchange (Alter 2005). Indeed, these politics have themselves 
contributed to the virtual impossibility of escaping the hegemonic categories of science and 
medicine. Countervailing this tendency, Alter proposes reconceptualising ƐŝĂŶ ‘ŵĞĚŝĐŝŶĞ ?
as a mimetic ŝŶƐƚĂŶƚŝĂƚŝŽŶŽĨŝŵŵŽƌƚĂůŝƚǇ ? ‘a devolved form ŽĨĂůĐŚĞŵǇ ?: 
perhaps it is better to conceptualize what has come to be called Asian medicine as being 
various experimental techniques concerned with embodied life and longevity. Consider 
alchemy, and the embodiment of alchemy, that is found in yoga and qigong. With reference 
to this, medicine as a conceptual category can be thought of as a pragmatic, body-oriented 
copy of techniques designed to transform nature itself.  
(Alter 2005, p. 18) 
This, he contends, helps ƚŽ ƌĞĐŽŶƐŝĚĞƌ  ‘ƐŝĂŶ ŵĞĚŝĐŝŶĞƐ ? as alternative to modernity, 
ŝŶƐƚĞĂĚŽĨ ‘ĂůƚĞƌŶĂƚŝǀĞŵĞĚŝĐŝŶĞ ? ?ƌĞůŝĂŶƚ on scientific legitimacy) or  ‘ĂůƚĞƌŶĂƚŝǀĞŵŽĚĞƌŶŝƚǇ ?
(following Knauft 2002). This notwithstanding, Langford (2002) documented an ayurvedic 
modernity that took its marginalisation as an opportunity for (neo)colonial reinvention 
over the twentieth century. Professional Ayurveda emerged as a parallel science and 
medicine, which at once also implicitly critiques and redefines science itself in a form of 
ŵŝŵŝĐƌǇ ‘not as a failed imitation but as an embodiment of power in which the terms of 
power can possibly be reǁƌŝƚƚĞŶ ? (Langford 2002, p. 9). Dismantling her own reliance on a 
modern episteme, she came to understand Ayurveda as itself a force of historical change 
while acknowledging that a complete escape from tautological modern/traditional 
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dichotomies seems impossible.4 Considering Chinese materia medica and the antimalarial 
artemisinin (derived from qing hao, Artemisia annua L.) in particular, Hsu (2009) similarly 
argues that their varied transformations into proprietary medicine deserve to be 
conƐŝĚĞƌĞĚ ŝŶƐƚĂŶƚŝĂƚŝŽŶƐ ŽĨ ĂŶ ĂůƚĞƌŶĂƚŝǀĞ ŵŽĚĞƌŶŝƚǇ ŝŶƐƚĞĂĚ ŽĨ ŵĞƌĞ  ‘tĞƐƚĞƌŶŝƐĂƚŝŽŶ ?,
even though their alterity is limited by strong commercial and biomedical influences which 
confuse and creatively combine categories such as Chinese/Western, natural/synthetic, 
and traditional/modern. 
 
In an edited volume on the globalisation and identity politics of Sowa Rigpa under various 
ethnic, national and regional guises (Pordié 2008a)  W ĂƐ ‘ŵĐŚŝŵĞĚŝĐŝŶĞ ?ŝŶEŽƌƚŚ-West 
/ŶĚŝĂ ? EĞƉĂůŝ  ‘,ŝŵĂůĂǇĂŶ ŵĞĚŝĐŝŶĞ ? ?  ‘ŚƵƚĂŶĞƐĞ ? Žƌ  ‘DŽŶŐŽůŝĂŶ ƚƌĂĚŝƚŝŽŶĂů ŵĞĚŝĐŝŶĞ ? Žƌ
 ‘ƵĚĚŚŝƐƚŵĞĚŝĐŝŶĞ ? W Pordié aims to capture its contemporary dynamics with the notion 
 ‘ŶĞŽƚƌĂĚŝƚŝŽŶĂůŝƐŵ ?:
Ă ĚŝǀĞƌƐŝĨŝĐĂƚŝŽŶ ŽĨ ŚĞĂůĞƌƐ ? ĂĐƚŝǀŝƚŝĞƐ ĂŶĚ Ă ŵƵůƚŝƉůŝĐĂƚŝŽŶŽĨ ůĞŐŝƚŝŵĂƚŝŶŐ ŝŶƐƚĂŶĐĞƐ ? ƚŚĞŝƌ
proximity to biomedicine on the practical, epistemological and symbolic planes, or the fact 
that they would be both subject to and participants in globalization (deterritorialization of 
actors and practices, modern transnationalization of knowledge) and that they would make 
ƐǇƐƚĞŵĂƚŝĐƵƐĞŽĨ ‘ƚƌĂĚŝƚŝŽŶ ?ƚŽůĞŐŝƚŝŵĂƚĞŶĞǁƉƌĂĐƚŝĐĞƐ ?  
(Pordié 2008a, p. 9) 
Neotraditionalism is characterised by the appropriation of modern ideologies, 
epistemologies, rhetoric and practices together with a selective accentuation or re-
presentation of classical (textual) ideals. This refashioned medical practitioner identity has 
in turn facilitated an integration into Euro-American populist, orientalist New Age 
discourses. Zimmermann (1992, p. 216) wrote that ayurvedic advertisements and medicine 
catĂůŽŐƵĞƐ ƌĞĨĂƐŚŝŽŶ ƚƌĞĂƚŵĞŶƚ ĂƐ  ‘the violence of catharsis is transformed with the 
ŶŽŶǀŝŽůĞŶĐĞ ŽĨ Žŝů ďĂƚŚ ? in accordance with Flower Power ideology, creating a modern 
ǇƵƌǀĞĚĂƚŚĂƚŝŶĐůƵĚĞƐƐǇŶĐƌĞƚŝĐĂĚĚŝƚŝŽŶƐƐƵĐŚĂƐ ‘ǇƵƌǀĞĚŝĐŵĂƐƐĂŐĞ ? (cf. Wujastyk and 
^ŵŝƚŚ ?Ɛ ? ? ? ?lineages of ayurvedic globalisation). Janes (2002) also points out that Western 
ĚĞƐŝƌĞƐĨŽƌĂŶ ‘ĂƵƚŚĞŶƚŝĐ ?ĂůƚĞƌŶĂƚŝǀĞƚŽďŝŽŵĞĚŝĐŝŶĞ ?ŚŽůŝƐƚŝĐŚĞĂůŝŶŐĂŶĚĂƐƚĞƌŶƐƉŝƌŝƚƵĂůŝƚǇ
                                                     
4 Refer to Adams (2001) for another attempt at particularising modernity in the case of Tibetan medicine, and 
to Saxer (2011) for its interface with early Russian modernities. 
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leads to a very different Tibetan medical practice in the US. Educational non-profit 
organisations provide adapted Tibetan medical and massage courses, greatly raising 
dŝďĞƚĂŶ ŵĞĚŝĐŝŶĞ ?Ɛ ƉƌŽfile by training Westerners while also heavily emphasising its 
Buddhist aspects in accordance with New Age ideologies of spiritual healing (Vargas 2008). 
Millard (2008, 2010; Soktsang and Millard 2013) has also documented how a Tibetan amchi 
necessarily adapted his practice (for instance omitting venesection and cauterisation), 
products (e.g. the substitution of animal and mineral ingredients) and language (patient 
communication through biomedical categories) to cater for patients in Europe. In these 
contexts, the clash with conflicting ideologies and the mingling of multiple theories and 
practices might be even more pronounced than in Asia: what is officially recognised as a 
medicine  W ĂŶĚ ĂƐ  ‘ƚƌĂĚŝƚŝŽŶ ?  W may be more strictly guarded (Schwabl 2009). Tibetan 
medicine practitioners thus have to operate within the alternative sector and interact with 
its patients/customers (see also Tokar in Pordié 2008, Kloos 2012).  
 
In line with the abovementioned shift from modernisation to a complex, multidirectional 
globalisation of Asian scholarly medicines I aim to strengthen the move away from these 
totalising narratives (following Kim 2009, Scheid 2013 and Zhan 2009, amongst others). 
Zhan (2009, p. 1) for instance, in her multi-sited ethnography of Chinese medical knowledge 
ƉƌŽĚƵĐƚŝŽŶ ?ŚŝŐŚůŝŐŚƚƐƚŚĂƚ  ‘ǁŚĂƚǁĞŚĂǀĞĐŽŵĞƚŽĐĂůů “ƚƌĂĚŝƚŝŽŶĂůŚŝŶĞƐĞŵĞĚŝĐŝŶĞ ? is 
made through  W rather than prior to  W various translocal encounters and from discrepant 
ůŽĐĂƚŝŽŶƐ ?, each of those three words themselves being sources of contingency and 
complexity leading to provisional outcomes in specific encounters. She writes against what 
she calls reductive globalism, instead offering an alternative account of translocal 
ĚŝƐƉůĂĐĞŵĞŶƚƐĂŶĚƌĞĨŝŐƵƌĂƚŝŽŶƐƐŚĞƚĞƌŵƐ ‘ǁŽƌůĚŝŶŐ ? ?/ŶĂƌĞĐĞŶƚǀŽůƵŵĞĞĚŝƚĞĚďǇScheid 
(2013, p. 6) on emotion-related disorders in East Asian medicines, the emphasis on regional 
historical flows equally creates oppoƌƚƵŶŝƚŝĞƐ ĨŽƌ  ‘escaping from the narratives of 





An analogous proposition has been made stemming from anthropological enquiries into 
Sowa Rigpa. Adams et al. (2011a) argue that the cross-cultural translation of scientific 
epistemologies is contingent on spatiotemporally embedded histories and politics of 
knowledge that trouble a priori relations between science, medicine and religion. In 
Tibetan contexts in particular the relation between Western science and biomedicine and 
Sowa Rigpa is one of multidirectional engagement, creating hybridised knowing practices 
and instances of Tibetanised or Tibetan-Western science. Complicating notions of science, 
ƚŚĞƐĞƐĐŚŽůĂƌƐƐƵŐŐĞƐƚ ‘Ă^ŽǁĂZŝŐƉĂƐĞŶƐŝďŝůŝƚǇ ?ĂƐĂƐƵďƚůĞƌĞƉŝƐƚĞŵŽůŽŐŝĐĂůƐƚĂƌƚŝŶŐƉŽŝŶƚ ?
a foundation that is upheld in the face of adaptability, permeability and flexibility of local 
practices on the ground. Innovation in Tibetan medicine continues to rest on textual 
research for instance, and to imply different models of efficacy. Neither biomedicine nor 
Sowa Rigpa are uniform or complete categories or even discrete medical systems. Both are 
inherently integrative and have been in conversation more intensively since the turn of the 
last century. A first wave of early modern encounters took place on the outskirts of British 
colonial power in Tibet, and of the Russian empire in Transbaikalia; the second wave was 
orchestrated by Chinese communism in the 1950s (Chinese biomedicalisation through the 
training of barefoot doctors, the expulsion of religious and superstitious elements, the 
setting-up of hospitals) and the reframing of medicine and public health in postcolonial 
India in exile; the third wave commenced at the onset of the new millennium, and is marked 
by the growth of a pharmaceutical industry as well as new colleges in various countries as 
part of a broader drive towards global, market-driven pharmaceutical research. As Samuel 
ĐŽŶĐůƵĚĞƐŝŶĂŶĞƉŝůŽŐƵĞƚŽĚĂŵƐĞƚĂů ? ?Ɛ ? ? ? ? ?a) work, there should be nothing to fear in 
genuine and mutually enriching exchange in this pragmatic context even though it will 
inevitably transform both sides.5  
 
                                                     
5 ^ĐŚĞŝĚ ĂŶĚ DĂĐWŚĞƌƐŽŶ ?Ɛ  ? ? ? ? ? )edited volume contains several critical contributions to the healthcare 
integration dilemma, emphasising culturally sensitive interdisciplinarity. Conversely, Adams and Li (2008) 
found an overall trend toward the substitution of Sowa Rigpa for biomedical options in integrated diagnosis 
and treatment at >ŚĂƐĂ ?ƐDĞŶƚƐŝŬŚĂŶŐ that is far removed from balanced integration, instead undermining 
its integrity and erasing difference. 
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Becoming pharmaceutical? From the social lives of medicines to 
pharmaceuticalisation and reformulation 
By virtue of its name, the anthropological study ŽĨ ‘ƚŚĞƐŽĐŝĂůůŝǀĞƐŽĨŵĞĚŝĐŝŶĞƐ ? (cf. Whyte 
et al. 2002; see also Das and Jeffery 2009, Lévy and Garnier 2007, Petryna 2006, van der 
Geest and Whyte 1988, and van der Geest et al. 1996) has focussed solely on biomedicines 
as a reaction to and critique of the subfield of ethnomedicine, which until at least the early 
 ? ? ? ?ƐŽŶůǇƐĞĞŵĞĚƚŽďĞŝŶƚĞƌĞƐƚĞĚŝŶĞǆƉůĂŝŶŝŶŐ ‘ĞǆŽƚŝĐ ?Žƌ ‘ŝŶĚŝŐĞŶŽƵƐ ?ŚĞĂůŝŶŐƉƌĂĐƚŝĐĞƐ ? 
More than two decades ago, Mark Nichter (1992, p. ix) noted that medical anthropology 
often had a biomedically-inspired, applied public health agenda while ethnomedical 
enquiry was haďŝƚƵĂůůǇ ĐŽŵƉĂƌƚŝŵĞŶƚĂůŝƐĞĚ ĂƐ  ‘the study of folk illnesses, traditional 
medical systems, herbaů ƌĞŵĞĚŝĞƐ ? ĂŶĚ ŚĞĂůŝŶŐ ƌŝƚƵĂůƐ ?. Critiquing this division and the 
related reification of disease as a universal construct versus illness as a culturally mediated, 
individual experience, Nichter reveals how nostalgic and paternalist scientific ƌĞƐĞĂƌĐŚĞƌƐ ?
sentiments construct accounts based on problematic assumptions of alterity. Along these 
lines, EŝĐŚƚĞƌ ĂŶĚ sƵĐŬŽǀŝĐ  ? ? ? ? ? ) ĂĚǀŽĐĂƚĞĚ ĨŽƌ  ‘ĂŶ ĂŶƚŚƌŽƉŽůŽŐǇ ŽĨ ƉŚĂƌŵĂĐĞƵƚŝĐĂů
ƉƌĂĐƚŝĐĞ ? ǁŝƚŚ Ă ďƌŽĂĚĞŶĞĚ ƐĐŽƉĞ: moving from rational drug use discourse to 
investigations of the rationales underlying the manufacture, prescription and demand of 
medications by approaching medicines as vehicles of ideology, constructers of illness 
identity and markers of social identity. As the anthropology of biomedical  W or more 
precisely biomolecular  W pharmaceuticals developed, the practices and products of the 
biomedical establishment and the pharmaceutical industry were thoroughly denaturalised.  
 
Regrettably however, non-biomedical materia medica were largely forgotten along the way, 
insinuating that they are not proper medicines or at least not pharmaceuticals.6 Indeed, 
 ‘medical anthropology has seemed hitherto to lack in full engagement with phytomedical 
                                                     
6  As the social lives approach gained prominence, issues of political economy and marketing were 
foregrounded in the study of Asian medicines as well, interpreting medicines as commodities and focusing 
on the elaboration of processes such as the commodification and pharmaceuticalisation of health and 
medicines (see Bode 2008, p. 1-17 for a review and also Banerjee 2009 and others in the same book series 
for early applications). In the case of Sowa Rigpa, this approach has been extended to how tŚĞdŝďĞƚĂŶ ‘ďŝƌƚŚ-
ŚĞůƉŝŶŐƉŝůů ? became involved in the development of a randomised controlled trial in Lhasa (Craig 2012), and 
to the medical, religious and political perceptions of tsotel (purified mercury-sulphide ash) manufacturing 
and use (Gerke 2013). 
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reality, and the acceptance that the health care practices of most people on this planet 
ĚĞƉĞŶĚŽŶƉůĂŶƚƐĂŶĚĂŶŝŵĂůƐ ? (Ellen 2006a, p. 10), reflecting a problematic gap between 
medical anthropology and ethnobotany (Waldstein and Adams 2006). But Hsu (2010) goes 
on to contrasts the empiricist ethnoscientific approach with the phenomenological tenet 
that the self is inseparable from perception, and the centrality of the body in medical 
anthropology. Nevertheless, in drawing selectively from Merleau-WŽŶƚǇ ?ƐƉŚĞŶŽŵĞŶŽůŽŐǇ ?
many medical anthropologists have wrongly separated the self from the environment 
much like in biomedicine, whereas its continuity with at least the technical environment 
has long been highlighted in STS. Inspired by Latour (2000), HƐƵ ? ? ? ? ? ?Ɖ ? ? ? )ĂƐŬƐ P ‘ŝĨǁĞ
trĞĂƚ ƉůĂŶƚƐ ĂƐ  “ƚŚŝŶŐƐ ŝŶ ŵĞĚŝĐĂů ƉƌĂĐƚŝĐĞ ?, would that mean that any medical 
anthropological-cum-ethnobotanical research project advances into the limelight of a 
>ĂƚŽƵƌŝĂŶ^d^ƉƌŽũĞĐƚ ? ?Even though materia medica are always (bio)cultural artefacts (Hsu 
2009, Pordié 2002), medical anthropologists have had disappointingly little to add to 
material culture (but see Farquhar and Lock 2007). Curiously, anthropologists of 
pharmaceuticals have eƋƵĂůůǇŝŐŶŽƌĞĚŵĂƚĞƌŝĂůŝƚǇĂŶĚ ‘have left the discussion of the drugs 
themselves and their physiological effects to biomedicine, accounted for socio-cultural 
aspects, and thereby inadvertently reinforced the Cartesian dualism that has set the 
agenda for the ŵĞĚŝĐĂů ĂŶƚŚƌŽƉŽůŽŐŝĐĂů ƉƌŽũĞĐƚ ? (Hsu 2010, p. 23). I aim to bridge this 
problematic divide between the symbolic emphasis of medical anthropology and 
ethnomedicine, and more materialist approaches in ethnobiology, by conducting an 
ethnography that revolves around medicinal plants and how they are transformed into 
Tibetan pharmaceuticals. By maintaining that these plant-medicines have inextricably 
social as well as material lives before and as (part of) pills, I aim to make medical 
anthropology more sensitive to non-humans.  
 
Along similar lines, Pordié and Gaudillière coineĚƚŚĞƚĞƌŵ ‘ƌĞĨŽƌŵƵůĂƚŝŽŶƌĞŐŝŵĞ ?ĨŽƌƚŚĞ
Indian Ayurvedic industry 
to qualify contemporary manufacturing and production practices in this industry, as well as 
their central role in reshaping the way traditional knowledge-based pharmaceutical 
innovations are appropriated and protected by law. The reformulation regime therefore 
deeply questions the economic, epistemological, and regulatory context of pharmaceutical 
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innovation. It is affected by fundamental tensions related not only to the epistemic status of 
the products and their problematic relationship with the ayurvedic texts and practices, but 
ĂůƐŽ ƚŽ ƚŚĞŝƌ ĞǆƉůŽŝƚĂƚŝŽŶ ĐŽŶĚŝƚŝŽŶƐ  ?Ɖ ?  ? ? ) ?  ? Q ?  ?/ƚ ? ĐŽŶƐŝƐƚƐ ŶĞŝƚŚĞƌ ŝŶ ŝŶƚĞŐƌĂƚŝŶŐ ƉůĂŶƚ
preparations into biomedicine nor in adapting traditional practices into an industrial context; 
ŝƚ ĐŽŶƐŝƐƚƐ ŝŶ ƌĞŝŶǀĞŶƚŝŶŐ Ă  ‘ƚƌĂĚŝƚŝŽŶĂů ? ĚƌƵŐ ďǇ ďŽƌƌŽǁŝŶŐ ? ĨŽƌ ŝƚƐ ĚĞǀĞůŽƉŵĞŶƚ ? ĨƌŽŵ
sometimes very distant medical paradigms. The reformulation regime is a work involving a 
recomposition based on unique knowledge-prospecting mechanisms and singular 
ŝŶĚƵƐƚƌŝĂůŝǌĂƚŝŽŶƐĐŚĞŵĞƐĨŽƌƚŚĞƌĞŵĞĚŝĞƐ ?dŚƵƐƵŶĚĞƌƐƚŽŽĚ ?ĚƌƵŐ ‘ƌĞĨŽƌŵƵůĂƚŝŽŶ ?ƌĞĚĞĮŶĞƐ
knowledge and preparation practices, focusing on the properties of complex medicinal 
materials produced and sold on a mass scale for uses in which medical cultures are mixed. 
An essential aspect of reformulation is that it feeds the emergence of an autonomous 
 ‘ƉŚĂƌŵĂĐǇ ?  ?ŝŶ ƚŚĞ ƐĞŶƐĞ ŽĨ Ă ǁŽƌůĚ ĞǆĐůƵƐŝǀĞůǇ ĚĞǀŽƚĞĚƚŽ ƚŚĞƌĂƉĞƵƚŝĐ ƐƵďƐƚĂŶĐĞƐ ) ƚŚĂƚ
breaks with ayurvedic clinical practice both from a sociological point of view (preparations 
are no longer made by doctors but by persons specializing in medicinal plants and their 
manipulation) and from an epistemic point of view (formulations are ready-to-use mixes for 
ƐƉĞĐŝĮĐ ŝŶĚŝĐĂƚŝŽŶƐ ? ŶŽ ůŽŶŐĞƌ ĂĚ hoc mixes that are part of an individualized treatment 
regime). Largely overlooking individual humoral variabilities, the mass production of drugs 
thus tends to simplify and depersonalize the act of healing.  
(Pordié and Gaudillière 2014a, p. 59, 61) 
For the purposes of my argument, it is instructive here to highlight some of the salient 
features of this notion further. This pharmaceutical innovation regime, which spurs re-
invented traditional(-based) pharmaceuticals with recombined and standardised formulas 
within the redefined therapeutic networks of industrial mass production is not to be 
confused with small-scale, local interpretations, variations and modifications of classical 
recipes by doctors even though it draws legitimacy from these widespread practices. 
Nevertheless, it should be recognised that this regime is highly complex and heterogeneous. 
Although mechanisation is paramount and goes hand in hand with pharmaceutical 
production practices and biomedical mélange, the detailed procedures and outcomes of 
reformulation are extremely diverse: varying from company to company, from product to 
product, and across national and international spatiotemporal scales. At the end of their 
article Pordié and Gaudillière (2014a) conclude that this regime does not constitute a form 
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of pharmaceuticalisation7 ŝŶǁŚŝĐŚƚŚĞ/ŶĚŝĂŶ ‘ĞƐƐĞŶĐĞ ?ŝƐĂůůďƵƚůŽƐƚ ?vide Banerjee 2009); 
it is an emerging reconfiguration of Ayurveda. Pordié subsequently applied this framework 
to The Himalaya Drug Company and its products, building on STS notions of objects (2014) 
and paying special attention to their multiple material trajectories (2015). The first article 
(Pordié 2014) ĂƌŐƵĞƐ ƚŚĂƚ ǇƵƌǀĞĚŝĐ ƉƌŽƉƌŝĞƚĂƌǇ ŵĞĚŝĐŝŶĞƐ ĂƌĞ ĞƉŚĞŵĞƌĂů ?  ‘ĞŵƉƚǇ ?
pharmaceutical objects. Often in response to regulatory necessities, innovative 
(im)material attributes may be inserted, thus challenging the very idea of scientific 
objectivity. Kudlu (2016) on the other hand argues thĂƚ <ĞƌĂůĂ ?Ɛ ƌĞŐŝŽŶĂů ŵĂƌŬĞƚ ŽĨ
aǇƵƌǀĞĚŝĐ  ‘ĐůĂƐƐŝĐĂů ŵĞĚŝĐŝŶĞƐ ? ƉƌŽĚƵĐĞĚ ďǇ ƉŚǇƐŝcian-manufacturers differs from the 
pharmaceuticalisation witnessed in mainstream industrial Ayurveda. The Keralan, clinic-
ĐĞŶƚƌĞĚĚŝƐƚƌŝďƵƚŝŽŶĨŽƌŵĂƚ ‘ŬĞĞƉƐƚŚĞĚŽĐƚŽƌŝŶƚŚĞůŽŽƉ ?ĂŶĚƚŚƵƐĐŽƉƌŽĚƵĐĞƐĂůƚĞƌŶĂƚŝǀĞ
value regimes as well as an alternative route to modernisation which countervails the 
dominant biomedical regime. In this thesis, I will expand and adapt the reformulation 
regime to the multiple transformations and reinventions evident in the different stages of 
manufacturing quasi-industrial Sowa Rigpa medicines both in India and in Switzerland. 
 
Conceptual meshwork: a postcolonial, post-ontological, Ingoldian STS of 
becoming 
To make an original contribution to the thematic bodies of literature introduced above, I 
am inspired by several theoretical strands at the intersections of anthropology and 
(postcolonial) science and technology studies, integrating ethnobotanical aspects. The 
focus of my dissertation necessitated this multi-faceted approach. Since I contend that 
Tibetan medicines are becoming alternative pharmaceuticals, I first have to lay out what 
ŬŝŶĚŽĨ ‘ďĞĐŽŵŝŶŐ ?I mean, and related to this ǁŚĂƚŬŝŶĚŽĨ  ‘ƚŚŝŶŐƐ ?/ĞŶǀŝƐŝŽŶ ?&ŽƌƚŚŝƐ ?/
                                                     
7 This term was first used in anthropology by Mark Nichter in 1989 (p. 268-335 in Nichter and Nichter 1996) 
as a descriptor for the commodification of health through the promotion of pharmaceuticals in India by public 
ŚĞĂůƚŚƉŽůŝĐŝĞƐĂŶĚƉŚĂƌŵĂĐĞƵƚŝĐĂůŵƵůƚŝŶĂƚŝŽŶĂůƐĞƐƉŽƵƐŝŶŐĂĐĂƉŝƚĂůŝƐƚŵŽĚĞƌŶŝƐĂƚŝŽŶŝĚĞŽůŽŐǇ ?  ‘WŚĂƌŵĂ-
ĐĞƵƚŝĐĂůŝƐĂƚŝŽŶ ?ǁĂƐŝŶƚƌŽĚƵĐĞĚƚŽƚŚĞƐŽĐŝŽůŽŐǇŽĨƉŚĂƌŵĂĐĞƵƚŝĐĂůƐďǇ:ŽŚŶďƌĂŚĂŵŝŶ ? ? ? ? ?ĂĐĐŽƌĚŝŶŐƚŽ
Gabe et al. 2015, but see Bell and Figert 2012), and later defined by Abraham (2009, quoted in 2010 on p. 
604) as  ‘the process by which social, behavioural or bodily conditions are treated or deemed to be in need of 
treatment, with medical drugs by doctors ŽƌƉĂƚŝĞŶƚƐ ? ?Williams et al. (2011) on the other hand have defined 
it as a heterogeneous socio-ƚĞĐŚŶŝĐĂůƉƌŽĐĞƐƐĂƐƉĂƌƚŽĨĂ ‘ƉŚĂƌŵĂĐĞƵƚŝĐĂůƌĞŐŝŵĞ ?ƐŝŵŝůĂƌ ǇƚŽ'ĂƵĚŝůůŝère and 
Pordié (2014a).   
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build on IngŽůĚ ?ƐƚŚŝŶŬŝŶŐŽŶŵĞƐŚǁŽƌŬƐ ?posthuman agency and materiality. Bringing his 
work into conversation with postcolonially and ontologically inflected strands of STS 
further allows for more nuanced attention to performative technoscientific practices, and 
situated constructions of more or less integrated sciences in ontologically fluid spaces.  
 
Becoming alive: Ingoldian agency, materiality and dwelling 
Tim Ingold (2011, p. 89-94) unfolds several criticisms of Latourian Actor-Network Theory 
(ANT), contrasting it with his own musings on agency. He distinguishes between a network 
ĂƐ ‘ĂƐĞƚŽĨŝŶƚĞƌĐŽŶŶĞĐƚĞĚƉŽŝŶƚƐ ? and a meshworŬĂƐ ‘ĂŶŝŶƚĞƌǁĞĂǀŝŶŐŽĨůŝŶĞƐ ?; material 
flows of life, growth and movement. According to Ingold, events are not caused by a 
network of distributed agency as in ANT, but along entangled (life) lines that are part of 
perceptive and thus enskilled organisms who are themselves entangled with an 
ŽŶƚŽůŽŐŝĐĂůůǇĨůƵŝĚƐƉĂĐĞ ?ƚŚĞ ‘ĞŶǀŝƌŽŶŵĞŶƚ ? ) ?dǁŽďƵƚƚĞƌĨůŝĞƐĨůƵƚƚĞƌŝŶŐĂƌŽƵŶĚĞĂĐŚ-other 
ŝƐƚŚĞŶŶŽƚĐŽŶĐĞŝǀĞĚĂƐĂ ‘ĚĂŶĐĞŽĨĂŐĞŶĐǇ ? ?ĐĨ ?Pickering 1995) but becomes an interaction 
of alive butterflies-in-air. Granting some magical agĞŶĐǇ ƚŽ Ăŝƌ ŝƐ ůƵĚŝĐƌŽƵƐ ? ŝŶ /ŶŐŽůĚ ?Ɛ 
opinion, and would still leave the butterfly behind as a dead object. From this perspective, 
Latourian nonhumans are inanimate  W even though they (inter)act through a network of 
effects  W and as such fail to be part of a true ecology, which for Ingold is a co-responsive 
movement within meshworks and along lines of becoming. Ingoldian agency is thus limited 
to organisms-in-ĞŶǀŝƌŽŶŵĞŶƚƐ ĂƐ  ‘agency calls for skill, and skill arises through 
ĚĞǀĞůŽƉŵĞŶƚ ? (Ingold 2011, p. 94), which in turn implies that their movement is coupled to 
perception. Ingold (2012 ) ƉƌŽƉŽƐĞƐ ĂŶ  ‘ĞĐŽůŽŐǇ ŽĨ ŵĂƚĞƌŝĂůƐ ? ƚŚĂƚ ƌĞĐŽŐŶŝƐĞƐƚŚĞ ŽƉĞŶ-
endedness of both skilled, living organisms and  ‘objects ? (as things-in-the-making) as 
becomings:   
The way to bring them together again is to reverse the assimilation of living nonhuman 
organisms to pseudoartifacts, by raising artifacts to the status of things that, similarly to 
organisms, both grow and are grown. To do this, however, requires a change of focus, from 
ƚŚĞ ‘ŽďũĞĐƚŶĞƐƐ ?ŽĨƚŚŝŶŐƐƚŽƚŚĞŵĂƚĞƌŝĂůŇŽǁƐĂŶĚĨŽƌŵĂƚŝǀĞƉƌŽĐĞƐƐĞƐǁŚĞƌĞŝŶƚŚĞǇĐŽŵĞ
into being. It means to think of making as a process of growth, or ontogenesis.  
(Ingold 2012, p. 431) 
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/ŶŐŽůĚ ?Ɛ(2000, p. 172-188) ontology of dwelling  W organism-in-environment immersion 
precedes world-making and involves enskilment, all of which are ongoing activities  W 
however, is not without its critics. Eschewing both neodarwinian evolutionism and cultural 
relativism and aiming to dissolve the nature (materialism, body) / culture (idealism, mind) 
ĚŝĐŚŽƚŽŵǇ ?/ŶŐŽůĚ ?ƐŽŶƚŽůŽŐǇŽĨůŝĨĞǁŽƌůĚƐŝƐƐƵƉƉŽƐĞĚƚŽƉƌĞƐĞŶƚĂŶĂůƚĞƌŶĂƚŝǀĞƚŽĚĞ- and 
re-contextualised (Western-ontology biased) constructivist representations of instead of in 
the world (Knudsen 1998). But this monist, contextualist approach assumes perceptional 
differences between organisms as well one continuous world they live in without 
explaining why this would be the case, simultaneously leaving the importance of 
classification ignored and the problem of cross-cultural translation unresolved. While 
remaining sympathetic toward his theoretical framework and following Nadasdy (2007), I 
ƚŚƵƐƌĞĐŽŐŶŝƐĞƐŽŵĞŽĨƚŚĞůŝŵŝƚĂƚŝŽŶƐŽĨ/ŶŐŽůĚ ?ƐŽŶƚŽůŽŐǇ ?ůƚŚŽƵŐŚƉĞƌŚĂƉƐĐŽŶgruent 
ǁŝƚŚŝŶĚŝŐĞŶŽƵƐƌĂƚŝŽŶĂůŝƚŝĞƐƚŽĂůĂƌŐĞĞǆƚĞŶƚ ?ĂƐŝŶEĂĚĂƐĚǇ ?ƐĐĂƐĞŽĨƐƵďĂƌĐƚŝĐ ? ‘ƐŚĂŵĂŶŝĐ ?
human-animal hunting relations), it cannot fully incorporate them, nor should it replace 
them. Nor is this frame equally insightful in all settings and for all purposes, particularly 
when involving intricate technoscientific processes. Hence the continued importance of the 
STS toolbox.  ‘ecoming ?ŚĂƐŝƚƐĞlf become a key concept in the so-called animal and species 
turns and within  ‘ŵƵůƚŝƐƉĞĐŝĞƐ ĞƚŚŶŽŐƌĂƉŚǇ ? (Kirksey and Helmreich 2010, Ogden et al. 
2013) ? ĨŽƌĞŐƌŽƵŶĚŝŶŐ  ‘nonhuman ? creatures and naturecultural borderlands and contact 
zones at the dawn of the anthropocene (see for example Dave 2014, Hustak and Myers 
2012, Knudsen 2014, Lien 2015, Maurstad et al. 2013 recently). I build on this movement, 
taking on board /ŶŐŽůĚ ?Ɛ ? ? ? ? ?Ă ) ĐƌŝƚŝƋƵĞŽĨƚŚĞĨĞƚŝƐŚŝƐĂƚŝŽŶŽĨ ‘ƐƉĞĐŝĞƐ-ďĞŝŶŐ ? ?ƐĞĞŵŽƌĞŝŶ
ŚĂƉƚĞƌ ? ) ?zĞƚƚŚĞŝĚĞĂƚŚĂƚĞǀĞƌǇƚŚŝŶŐŝƐ ‘ďĞĐŽŵŝŶŐ ?ŝƐŶŽƚƐŽůĞůǇ/ŶŐŽůĚ ?Ɛ ?ŝƚĂƌŝƐĞƐĨƌŽŵĂ
long tradition of processual ecology and anthropology. 
 
Becoming technoscientific postcolonially 
Within the young interdiscipline of STS and its generative interfaces with anthropology (de 
la Cadena et al. 2015, Fischer 2007),  ‘ǁŚĂƚƐĐŝĞŶƚŝƐƚƐĂĐƚƵĂůůǇĚŽ ?has been ethnographically 
analysed since at least the 1980s. In the twenty-first century however, ƉĂƌƚŝĐƵůĂƌ ‘ĞŵĞƌŐĞŶƚ
ĐŽƐŵŽƉŽůŝƚŝĐĂůƚĞĐŚŶŽƐĐŝĞŶƚŝĨŝĐǁŽƌůĚƐ ? ?Fischer 2007, p. 573) beyond Western Europe and 
North America have come to the fore which cannot be satisfactorily understood in 
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postcolonial relational terms (core-periphery thinking, imperial power relations) only, as 
they varyingly transform science and policy in specific locales and beyond. This 
technosciĞŶƚŝĨŝĐ ĐŽƐŵŽƉŽůŝƚŝĐƐ ƌĞƋƵŝƌĞƐ  ‘viewing the development of science and 
technology in a global  W political, economic, material, and network  W context rather than in 
ƐŝŵƉůŝĮĞĚĐŚĂŝŶƐŽĨŚŝƐƚŽƌŝĞƐŽĨŝĚĞĂƐǁŝƚŚŝŶĚŝƐĐŝƉůŝŶĞƐ ? (ibid., p. 576).  
 
Although postcolonial studies of technoscience are of recent lineage (Anderson 2002, 
Anderson and Adams 2008, see references cited in Lin and Law 2015), it has become clear 
ƚŚĂƚ  ‘[t]he history of almost all modern sciĞŶĐĞ ? Q ?ŵƵƐƚďĞƵŶĚĞƌƐƚŽŽĚĂƐ  “ƐĐŝĞŶĐĞŝŶĂ
ĐŽůŽŶŝĂů ĐŽŶƚĞǆƚ ? ?(Seth 2009, p. 374). In this respect, the heterogeneity of the 
anthropology-STS interface is itself instrumental, decentring or alternatively 
 ‘ƉƌŽǀŝŶĐŝĂůŝƐŝŶŐ ?ŶŐůŽ-European domination and its exceptionalist conception of anthropos 
(de la Cadena et al. 2015). This has been the main effort of ANT from its outset: to give non-
humans a new and fair place in society, seen as an on-going assemblage of heterogeneous 
bundles. We are all cyborgs (Haraway 1991). Herein lies a possible contribution of STS 
(Latour 2000, see also Farquhar and Lock 2007). In applying the principle of symmetry 
between the material and the social, my research can go beyond the artificial dichotomy 
between fetishes and (social) facts (Latour 1996). In accordance with ANT (Latour 2005), I 
consider Tibetan medicinal plants not as inert objects on to which meanings are projected, 
but as mediators that continuously transform and are transformed by the relational webs 
in which they are located. Observing the ways they enrol each other as well as other actors 
grants a unique insight into their dynamic and conflicting roles in the flows of materials, 
meanings, values and knowledge that coproduce Tibetan medicines. Moreover, by 
performing STS through Tibetan medical terms (following the work with Chinese medicine 
of Law and Lin 2015; Lin and Law 2014, 2015) I strive to decentre Anglo-European 
technoscience linguistically and conceptually. 
 
Becoming in practice: after the ontological turns in STS and anthropology 
After taking material and postcolonial turns, I now come to the ontological turn which 
recently gained momentum in STS (Jensen 2004, Woolgar and Lezaun 2013) and 
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anthropology (Kelly 2014, Kohn 2015).  In both fields this turn has been thoroughly and 
repeatedly criticized to the extent that both disciplines have definitively moved beyond the 
initial euphoria (see for instance Aspers 2015 and Sismondo 2015 for STS, and Bessire and 
Bond 2014, Hornborg 2015, and Vigh and Sausdal 2014 within anthropology). This is not 
the place to rehearse the many arguments for and against an ontological approach (see 
more in Chapter 4). However, I do want to indicate here briefly how an ontological 
sensibility contributes to my eclectic theoretical framework.  
 
&ŝƌƐƚůǇ ? ĂůƚŚŽƵŐŚ / ƉĞƌƐŽŶĂůůǇ ŝĚĞŶƚŝĨǇ ǁŝƚŚ /ŶŐŽůĚ ?Ɛ ďĞĂƵƚŝĨƵůůǇ ĞůĂďŽƌĂƚĞĚ ŽŶƚŽůŽŐǇ ŽĨ
dwelling as well as, similarly, with Pickering ?Ɛ (2009) ontological vision (and concomitant 
politics) of symmetrical, decentred, temporal and open-ended becoming, I have to concede 
that these (differing) definitions of reality are not necessarily commensurable with the 
emergent realities I encounter  ‘ŝŶ ƚŚĞ ĨŝĞůĚ ? ? Ǉ ƐƚƵĚǇŝng realities through reflexive and 
messy immersion in human-world engagements  W indeed never fully leaving the human 
behind  W through a broadly conceived nonreductive ontological anthropology (cf. Kohn 
2015), I can instead discern how ontologies are enacted practically in specific locales. That 
is, conducting an ethnography of becoming, an ontography (Lynch 2013), as part of the 
more than three-decade old empirical ontology tradition of STS (Law and Lien 2013). In this 
ƌĞƐƉĞĐƚ ?/ŶŐŽůĚ ?ƐĨƌĂŵĞǁŽƌŬƌĞŵĂŝŶƐƵƐeful as a heuristic, not as something to be rigidly 
enforced. Multiple epistemologies and ontologies are implicated in the technoscientific 
becomings of Tibetan medicines, and it is exactly their interaction, merging and clashing 
that is of interest to me. 
 
Outline of the dissertation 
In the next chapter I lay out my methodology, which builds on multi-sited and translocal, 
para-ethnographic, and multispecies inputs and also covers ethics, reflexivity and a listing 
of data sources and analyses. The main body of this thesis consists of six chapters, grouped 
into three larger parts: Plants (I), Becoming (II) and Medicines (III). Part I considers Tibetan 
medicinal plants before they are processed to become ingredients in pills, and starts off 
with a chapter (1) which introduces the four central plant actors of my thesis as they are 
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conceived at Men-Tsee-Khang and PADMA. Through a comparison with classical and 
contemporary written sources, I show that the commensuration of idealised identification, 
naming and classification practises of botany and Sowa Rigpa leads to a distorting and 
politically problematic simplification and solidification of the multiple, dynamic and 
complex identities of men by ignoring the situated nature of these knowing practices. Next, 
(2) I trace these medicinal plants as they are traded in Indian markets, arguing that the 
labyrinthine conditions of their sourcing and the evocation of discourses of illegality by 
ďŽƚŚƚƌĂĚĞƌƐĂŶĚƌĞŐƵůĂƚŽƌƐŝƐƐǇŵƉƚŽŵĂƚŝĐŽĨƚŚĞĨĂŝůĞĚĨŽƌŵĂůŝƐĂƚŝŽŶŽĨƚŚĞ ‘ŚĞƌďĂůƐĞĐƚŽƌ ?
by state policies and bureaucracies. After these commodities arrive on the exile-Indian and 
Swiss factory floors, they transform again as they formally become (part of) medicine (Part 
II). Industrial pharmaceutical production is as a craft, an enskilled material process of 
growth involving human-machine-plant meshworks (3). Scientific quality control in the 
laboratories of both institutions (4), however, redefines the qualities of Tibetan medicines 
pharmaceutically while also evidencing historŝĐĂů ĞǆĐŚĂŶŐĞƐ ďĞƚǁĞĞŶ  ‘dŝďĞƚĂŶ ? ĂŶĚ
 ‘tĞƐƚĞƌŶ ?ƉƌĂĐƚŝĐĞƐĂƐǁĞůůĂƐƚŚĞŝƌŽŶƚŽůŽŐŝĐĂůĨůƵŝĚŝƚǇ ?ǀĞŶŽƐƚĞŶƐŝďůǇ  ‘ĨŝŶŝƐŚĞĚ ?ƌĞĐŝƉĞƐ
and pills  W containing several of my plant subjects  W continue to be transformed and 
reformulated (Part III). In Chapter (5), differing conceptualisations of safety, efficacy and 
toxicity are found to impinge on the composition, production and prescription of a 
particularly popular and potent TibetaŶŵĞĚŝĐĂůĨŽƌŵƵůĂŶĂŵĞĚ ‘'ĂƌƵĚĂ- ? ? ?ƉƌĞƐĞŶƚĞĚĂƐ
khyung-nga and Grippe-Formel (Flu Formula) at Men-Tsee-Khang and PADMA respectively. 
Focussing on another mediciŶĞ ƚƌĂĚŝƚŝŽŶĂůůǇ ŶĂŵĞĚ  ‘ĂŵƉŚŽƌ- ? ? ?  ?gabur-nyernga) and 
marketed as PADMA 28 in Switzerland (6), I analyse how European and national regulations 
and politics have determined a series of innovations and reformulations leading to a 
PADMA 28 product family of similar but non-identical products. This final chapter also 
recapitulates the transformations revealed in the five previous chapters, adds a final layer 
of reformulation, and thus synthesises the overall argument of how Tibetan medicines can 
ďĞĐŽŵĞ  ‘ĂůƚĞƌŶĂƚŝǀĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? ƚŚƌŽƵŐŚ ƚĞĐŚŶŽƐĐŝĞŶƚŝĨŝĐ ƉƌĂĐƚŝĐĞƐ ĨŽƌ ƚŚĞ ĐĂƐĞ ŽĨ
PADMA. In the Conclusion, I summarise some of the main contributions of my work in the 









If anthropological research is a craft (Bernard 2011; Epstein 1979; Ingold 2013b, p. 4), then 
its practitioners are continually gaining expertise by cultivating their skills; they are 
becoming anthropologists. Fieldwork is fundamentally liminal (Jackson 1990): a temporary, 
ĞŵŽƚŝŽŶĂůůǇĐŚĂƌŐĞĚĂŵďŝŐƵŽƵƐƐƚĂƚĞ ‘ďĞƚǁŝǆƚĂŶĚďĞƚǁĞŶ ?ĐƵůƚƵƌĞƐĂŶĚƉůĂĐĞƐ, involving 
seclusion, role reversal and all the other familiar characteristics of rites of passage. In this 
transition, methods and field notes in particular mediate between these worlds and 
identities, and between observations and the ethnographic text they come to be partially 
reflected in. In Tibetan Buddhism any state of in-betweenness may be called bardo8, and is 
said to offer an opportunity for spiritual insight. As I will show in the following chapters, 
both the plants I follow in their transformation into medicine, and the two main institutions 
where I conducted fieldwork, can equally be approached as liminal entities. To grasp their 
intermediate nature, I need to rely on methods which themselves are able to straddle the 
ĚŝǀŝĚĞƐďĞƚǁĞĞŶ ‘ŚĞƌĞ ?Ɛ ) ?ĂŶĚ ‘ƚŚĞƌĞ ?Ɛ ) ?ĂŶĚďĞƚǁĞĞŶŚƵŵĂŶƐĂŶĚ ‘ŶŽŶŚƵŵĂŶƐ ? ?/ĂůƐŽŚĂǀĞ
to reflect on my ethical obligations in this translation exercise, and on the cultural and 
identity politics on which my positionality as a researcher is premised. Lastly, I summarise 
the data sources I collected as a basis for this dissertation.  
 
Refunctioning and re-envisaging ethnography: multi-sited, multispecies and 
beyond 
dŚĞĚĞĨŝŶŝƚŝŽŶŽĨĂŶĚƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶ ‘ƐƉĂĐĞ ? ? ‘ŝĚĞŶƚŝƚǇ ?ĂŶĚ ‘ĐƵůƚƵƌĞ ?ĂƌĞŶŽƚƚŽďĞ
taken for granted (Gupta and Ferguson 1992). The notion of space as a neutral grid onto 
                                                     
8 Bardo most commonly refers to the period between death and rebirth as described in the so-called Tibetan 
book of the dead (see Fremantle 2001), but is also applied to other suspensions of ordinary consciousness 
such as during meditation and dreaming. In its subtlest form, it includes every continuous moment of 
existence as the present is always suspended between past and future.  
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which difference, memory and social organisation can be projected in a way that nation-
states or ethnic territories seem to encapsulate culturally unitary groups is flawed. Instead, 
the identity of a place emerges through spatialised and hierarchical relations which 
contingently construct locality and community. But although mobility and 
interconnectedness blur boundaries, ideas of ethnically and culturally distinct places 
nonetheless remain salient. To problematise the spatialisation of cultural difference which 
underlies much of the construction of alterity in anthropological writing and to avoid the 
ƐƉĂƚŝĂůŝŶĐĂƌĐĞƌĂƚŝŽŶŽĨ ‘ƚŚĞŽƚŚĞƌ ? ?/ƚƵƌŶƚŽŵƵůƚŝ-sited ethnography. By tracking things (in 
my case plants-becoming-ŵĞĚŝĐŝŶĞƐ )ƚŚĞŽďũĞĐƚŽĨƐƚƵĚǇ ?ƚŚĞ ‘ƐƚƵĚǇĂƌĞĂ ?ĂŶĚƚŚĞĂƌŐƵŵĞŶƚ
are all coproduced through a self-conscious association of sites traversed by the 
ethnographer, crosscutting the local/global dichotomy (Marcus 1995). 9  This mobile 
mapping strategy decentres naïve identity politics, refraining from linear and bounded 
spatiotemporal comparisons. Nevertheless, it does retain an inherently comparative 
dimension through its emeƌŐĞŶƚŵĞƚŚŽĚŽůŽŐŝĐĂůĚĞƐŝŐŶŽĨ ‘ũƵǆƚĂƉŽƐŝƚŝŽŶƐŽĨƉŚĞŶŽŵĞŶĂ ? 
(ibid., p. 102), on which I capitalise in this thesis.  
 
Men-Tsee-Khang in India and PADMA in Switzerland are spatially distinct organisations, 
even though they have complex transnational histories and multinational operations. But I 
manifestly do not consider them to be unrelated, ŶŽƌƉĂƌƚŽĨĂƐŝŶŐůĞŽǀĞƌĂƌĐŚŝŶŐ ‘ǁŽƌůĚ
ƐǇƐƚĞŵ ? ? /Ŷ ƚŚŝƐ ƐĞŶƐĞ ŝƚ ŝƐ ďĞƚƚĞƌ ƚŽ ƵƐĞ ƚŚĞ ƚĞƌŵ  ‘ƚƌĂŶƐůŽĐĂů ? ĂƐ ŝƚ ĞŵƉŚĂƐŝƐĞƐ ůŝŶŬĂŐĞƐ
between locales (of which no complete, holistic understanding is posited), whereas 
classical comparative studies relied exactly on the absence of such connections (Hannerz 
2003). As the plant-medicines which I keep in ĨŽĐƵƐĂƌĞŵŽďŝůĞĂŶĚƚƌĂŶƐŝĞŶƚ ?ƚŚĞ ‘ƐŝƚĞƐ ?
constituted by this tracking  W including those constructed outside these institutions, for 
example in herbal markets in India  W may themselves be considered short-lived phenomena. 
Translocalism thus somewhat undermines the ability for  W but also the validity of  W classical, 
romanticised notions of fieldwork and participant observation while foregrounding the 
suitability of interviewing and other less-deeply immersive engagements (at least 
                                                     
9 Tracing the production and circulation of things is not novel, as Marcus (1995) already notes. It has long 
ďĞĞŶƐƵŐŐĞƐƚĞĚĂƐĂƐƚƌĂƚĞŐǇĨŽƌĐŽŵŵŽĚŝƚǇĐŚĂŝŶĂŶĂůǇƐĞƐ ?ŝŶƉƉĂĚƵƌĂŝ ?Ɛ ? ? ? ? ? )The Social Lives of Things, 
and in STS and particularly ANT, amongst others, including migration studies. 
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temporally, but not spatiĂůůǇ ) ?ƚŚŶŽŐƌĂƉŚǇƌĞŵĂŝŶƐ ‘ĂŶĂƌƚŽĨƚŚĞƉŽƐƐŝďůĞ ? nonetheless: 
partial, pragmatic and practical (Hannerz 2003, p. 202- ? ? ? ) ? ĂƐ ŝƐ  ‘ďĞŝŶŐ ƚŚĞƌĞ ? ĂŶĚ
becoming an ethnographer.  
 
I contribute to the heterogeneous body of second-generation multi-sited ethnography 
(Coleman and von Hellermann 2011, Falzon 2009), attending to several of its most-
criticised characteristics. These include a lack of self-critical reflection on its application and 
on methodological decisions on locations to be covered, as well as lack of depth and 
ethnographic responsibility. I am ĂǁĂƌĞƚŚĂƚƚŚĞ ‘ĨŽůůŽǁŝŶŐ ?ŵĞƚĂƉŚŽƌĂƉƉĞĂƌƐƚŽŝŵƉůǇĂ
pre-existing field and submission to a laid-out track rather than active co-production. 
Indeed, it may seem as if I am merely tracing some medicinal plant commodity chains from 
harvest to production to consumption. However, I not only question the singular identity 
of the things I am following but equally the existence of neatly organised supply chains, 
attending to the fundamental transformations and multiple reformulations of these 
healing substances-in-the-making and thus frequently losing track(s) altogether. I also 
follow the more recent methodological tendency to foreground the generative 
ƉƌŽďůĞŵĂƚŝĐƐ ?Žƌ ‘ĨƌŝĐƚŝŽŶƐ ? )ŽĨĐŽůůĂďŽƌĂƚŝŽŶ ?ŽůĞŵĂŶĂŶĚǀon Hellermann 2011), creating 
multi-sightedness through para-ĞƚŚŶŽŐƌĂƉŚǇƚŽŐĞƚŚĞƌǁŝƚŚ ƌĞĨůĞǆŝǀĞ  ‘ƐƵďũĞĐƚƐ ? or better 
 ‘ĞƉŝƐƚĞŵŝĐƉĂƌƚŶĞƌƐ ?(Holmes and Marcus 2012). The latter approach is particularly suitable 
for application in contemporary organisational contexts such as PADMA and Men-Tsee-
Khang, as professionals at these workplaces are not only familiar with academic theorising 
but also act as self-conscious, strategic cultural analysts and theorists themselves (cf. Islam 
2015). Giving due credit to this internal critique distributes authority and thus decenters 
the researcher, opening avenues for collaborative critical reflexivity. Challenges of para-
ethnography include the tendency to disregard low-service jobs, the risk of adopting of 
elitist managerial ideologies, and the loss of a clear researcher standpoint. In chapter 3 on 
medicine production, I explore these methodological conundrums further together with 




From the tracing of things through places it is not such a big leap to come to multispecies 
ethnography, which is inherently a multi-authored collaboration if one thinks imaginatively 
with and through nonhuman organisms and their ways of life (Choy et al. 2009). 
Multispecies methodologies, however, are still in their infancy and therefore often 
transdisciplinary, innovative and experimental. The Matsutake Worlds Research Group just 
cited for instance, is a cooperation involving joint multi-sited fieldwork and writing inspired 
by a Deleuzian rhizomatic, non-ĂƌďŽƌĞƐĐĞŶƚ ‘poetics ŽĨƚŚĞŽŶƚŽůŽŐǇŽĨŵƵůƚŝƉůŝĐŝƚǇ ? (ibid., 
p. 384) which mimics matsutake sociality in resisting hierarchical and reified nature/culture 
divisions. Accordingly, Tsing (2014) contends that social scientists can learn about 
entangled more-than-human soĐŝĂůŝƚŝĞƐ ďǇ ƉĞƌĨŽƌŵŝŶŐ  ‘ĐƌŝƚŝĐĂů ĚĞƐĐƌŝƉƚŝŽŶ ? Ăƚ ƚŚĞ
intersections of natural history and ethnography, through attention to heterogeneous 
assemblages (such as landscapes or bodies) and (plant) bodily form as materialisations of 
social relations. In this she aims to go beyond human- and technology-centred treatments 
of things as tools as conceived in Latourian ANT, instead attending to the interaction of 
multiple, dynamic, contingent histories in which humans act as decentred participants. In 
my ethnography centred on Tibetan medicinal plants  W perhaps then better called a 
 ‘ƉůĂŶƚŽŐƌĂƉŚǇ ? W which (or who?) do often exhibit a tree-like (modular, but indeterminate) 
morphology around a central axis of directional growth, I am of course not forced to think 
in terms of dichotomous branches. Paying close attention to their materiality from an 
Ingoldian perspective and to the meshworks in which they are entangled, I consider 
materia medica as biocultural becomings with varying degrees of aliveness and not just 
human artefacts. Following Ogden et al. (2013), to attend to multispecies contact zones 
and especially the companionship, mutual ecologies and domestication inherent in human-
plant intra-actions, speculative modes of wonder-full inquiry and writing are in order. 
 
However, Ingold has critiqued not ŽŶůǇ ‘ŵƵůƚŝƐƉĞĐŝĞƐĞƚŚŶŽŐƌĂƉŚǇ ? (2013a) but equally the 
current obsession of anthropologists with the term ethnography more generally (2014). He 
ĂƌŐƵĞƐƚŚĂƚ ‘ĞƚŚŶŽŐƌĂƉŚŝĐŶĞƐƐ ?ŚĂƐďĞĞŶŵƵĐŚŽǀĞƌƵƐĞĚĂŶĚĐŽŶĨůĂƚĞĚǁŝƚŚĨŝeldwork and 
ƉĂƌƚŝĐŝƉĂŶƚ ŽďƐĞƌǀĂƚŝŽŶ Žƌ  ‘ƚŚŝĐŬ ? ĚĞƐĐƌŝƉƚŝŽŶ ? ĚĞǀĂůƵĂƚŝŶŐ ƚŚĞ ǁŚŽůĞ ĚŝƐĐŝƉůŝŶĞ ĂŶĚ ŝƚƐ
public voice. Ingold calls for a return to an undivided anthropology that is not split into 
ethnography (reality) versus theory (imagination), moving away from popular stereotypes 
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of the ethnographer as a retrospective chronicler of disappearing lives and connoisseur or 
trader of exotic insights, and back to thinking in and not of the world as future-oriented 
correspondent observers. Nevertheless, in straddling the boundaries to STS I engage more 
in what Ingold (2013b, p. 2- ? )ĐĂůůƐ ‘ĞƚŚŶŽŐƌĂƉŚŝĐĚŽĐƵŵĞŶƚĂƚŝŽŶ ?, which is both empirical 
and theoretical. The transformative effects of this research project on the ethnographer, 
his lifeworld and future, are indeed not the centrepiece of this thesis. Secondly, 
multispecies ethnography is not only found to be nothing new by Ingold, but remains 
woefully anthropocentric in its terminology and reliance on the species concept. Societies 
and bodies are themselves always heterogeneous communities of be(com)ings (beings as 
ǀĞƌďƐ ŝŶƐƚĞĂĚ ŽĨ ƐƵďũĞĐƚƐ Žƌ ƐĞůǀĞƐ ) ? ŶŽƚ ďŽƵŶĚĞĚ ĞŶƚŝƚŝĞƐ ?  ‘ŶƚŚƌŽƉŽůŽŐǇ ďĞǇŽŶĚ
ŚƵŵĂŶŝƚǇ ?10 is about joining, studying and becoming with relationally, not separately. For 
me, this is also where ontography comes into the picture: the description of the co-
production of worlds in practice, collapsing epistemology into ontology. In chapter 4, I draw 
ŽŶ DŝĐŚĂĞů >ǇŶĐŚ ?Ɛ  ? ? ? ? ? ) ŽŶƚŽŐƌĂƉŚŝĐ ĂƉƉƌŽĂĐŚ ƚŽ ĚĞƐĐƌŝďĞ ƚŚĞ ŵĂŬŝŶŐ ŽĨ objective 
knowledge on herbal and pharŵĂĐĞƵƚŝĐĂů  ‘quality ? in laboratories and beyond. By 
historicising and situating these quality control practices, I show how hybrid ontologies of 
quality are performed in practice in and between Men-Tsee-Khang and PADMA. The 
methodological and ethical issues arising in ontological analyses are also considered in that 
chapter. 
 
Reflexivity and ethics 
According to Marcus (1995), multi-ƐŝƚĞĚĞƚŚŶŽŐƌĂƉŚĞƌƐŝŶĞƐĐĂƉĂďůǇďĞĐŽŵĞ ‘ĐŝƌĐƵŵƐƚĂŶƚŝĂů
ĂĐƚŝǀŝƐƚƐ ?ƐŝŶĐĞƚŚŝƐƚǇƉĞŽĨĨŝĞůĚǁŽƌŬrepeatedly generates cross-cutting and contradictory 
personal commitments which imply political and ethical self-identification. In different sites 
ƚŚĞƌĞƐĞĂƌĐŚĞƌ ?ƐŝĚĞŶƚŝƚǇƐŚŝĨƚƐĂŶĚŚĂƐƚŽďĞƌĞ-negotiated, a re-positioning which comes 
with circumstantial affiliations that do not fit with traditional idea(l)s of anthropologists as 
ƌĞƉƌĞƐĞŶƚĂƚŝǀĞƐŽĨĐĞƌƚĂŝŶƉĞŽƉůĞƐ ?dŚĞƐĞƉĂƌƚŝĂůƌĞƐƉŽŶƐŝďŝůŝƚŝĞƐŽƌ ‘ĐŽŵƉůŝĐŝƚŝĞƐ ? ?Marcus 
1997) alert us to the heterogeneous and multiple politics of (the creation of) location, 
                                                     
10 Kohn (2014) ĂůƐŽƌĞĐĞŶƚůǇƐŚŝĨƚĞĚĨƌŽŵ ‘ĂŶĂŶƚŚƌŽƉŽůŽŐǇŽĨůŝĨĞ ? W which predictably distinguishes between 
human and nonhuman, and between biology and geology in a Western modern way  W towards a more open-
ĞŶĚĞĚ ‘ďĞǇŽŶĚƚŚĞŚƵŵĂŶ ? ?ǁŚŝĐŚĐŽƵůĚŝŶĐůƵĚĞŶŽŶ-ƐĞŵŝŽƚŝĐ ‘ŶŽŶ-ůŝǀŝŶŐ ?ƌĞĂůŝƚŝĞƐ ? 
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where both fieldworker and participant are always partially anxious outsiders. Such a 
project is invested with postcolonial and political-economic power differentials, but the 
configurations of these complicities  W and the relevance of the metanarratives of 
colonialism and capitalism on which they rest  W cannot be determined a priori. Rather, in 
multi-ƐŝƚĞĚƌĞƐĞĂƌĐŚ ‘ƚŚĞĐŽŶƚĞǆƚ ?ŝƐĐŽ-produced along the way. The flows, counter-flows, 
and frictions within, between and beyond PADMA and Men-Tsee-Khang are not that easily 
enframed despite obvious intersections. It requires creative and imaginative labour on 
behalf of both writer, reflexive participants, and the reader (to a lesser extent, I hope) to 
envision how a Swiss pharmaceutical company and an exile-Tibetan educational institute 
become  ‘^ŵĂůůƚĞƌŶĂƚŝǀĞ WŚĂƌŵĂ ?.  
 
Doing research and writing about methodology is inherently reflexive and raises ethical 
issues, and so does conducting multi-sited, multispecies (and ontographic) fieldwork. In a 
postcolonial, postmodern and post-structural vein, anthropologists recognise that the 
power of the authorial voice and the inevitable distortions of personal and disciplinary 
histories are reflected in ethnographer- ‘ŝŶĨŽƌŵĂŶƚ ? ŝŶƚĞƌĂĐƚŝŽŶƐ ĂŶĚhave inseparable 
political and moral implications (see Davies 2008). Self-reference, however, can easily turn 
into self-absorption or on the other extreme, a mere disclaimer statement made up out of 
sociological categories: I am a Generation Y upper-middleclass (bourgeois?) able-bodied 
white male (queer, but this was muted during fieldwork) North-Western European (Flemish 
Belgian with a Dutch father) Tibetan Buddhist (with a Christian, pseudo-secular upbringing) 
biologist and ethnobotanist. This incomplete, annoying listing of seemingly inescapable 
classifications does not in itself add or detract much from my arguments. It is not 
particularly profound or revealing, but it does at least partially explain my interest(s) in 
plants and Tibetan medicine. As Lynch (2000) notes from an ethnomethodological 
perspective, reflexivity is unavoidable and ubiquitous and should not be considered to be 
an independent methodological act or virtue. I concur with this deflation of (radical) 
reflexivity to escape from ad infinitum house of mirrors reflections and ad nauseam 
discussions of ƚŚĞ ‘ĐƌŝƐŝƐŽĨƌĞƉƌĞƐĞŶƚĂƚŝŽŶ ? ?ƵƚƉĞƌŚĂƉƐŝƚŝƐǁŽƌƚŚǁŚŝůĞŶŽƚŝŶŐŚĞƌĞƚŚĂƚ
my Western (and perhaps even modernist Buddhist, cf. McMahan 2008), materialist, 
scientific and botanical background not only determined the object of study but also to a 
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certain extent my choice of theoretical frameworks and of course my conclusions. As such, 
my interest in technoscientific practices and reliance on Pordié and Gaudillière ?Ɛ ?2014a) 
reformulation regime do not just reflect their contemporary relevance but have the 
potential to underwrite the scientisation and pharmaceuticalisation of Tibetan medicine. 
Nonetheless, I acknowledge the need for a nonsecular medical anthropology (Whitmarsh 
and Roberts 2016) as well as the complex and dynamic position of Sowa RigpĂ ‘ŝŶďĞƚǁeen 
ŵĞĚŝĐŝŶĞ ĂŶĚ ƌĞůŝŐŝŽŶ ?  ?Adams et al. 2011a). Anthropologists and (ethno)botanists are 
indeed already implicated in the reformulation of Asian medicines (as noted by Ganguly 
2014 and Gaudillière 2014), which shifts the focus away from the clinical encounter by 
conceiving an independent herbal industry. On top of that, the positive valence I place on 
 ‘ĂůƚĞƌŶĂƚŝǀĞƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? W notwithstanding crucial tensions  W also betrays my support 
for the political plight of heterodox practices and substances for health and wellbeing in 
Europe and beyond.  
 
In the same way, ethics is part and parcel of the research process. Referring to professional 
codes of practice such as the UK Association of Social Anthropologists (ASA 2011) and the 
International Society of Ethnobiology (ISE 2006, with 2008 additions) is not sufficient, 
neither is the creation of a detached and self-serving moral high ground. The ASA 
emphasises the varied settings in which anthropological scholarship occurs and the 
responsibilities towards multiple stakeholders (including firstly research participants but 
also employers and funders, colleagues, governments, and the wider society), leading to 
conflicts of interest. It urges to anticipate problems and prevent any harm, acknowledging 
the long-term, open-ended and flexible nature of fieldwork and participant observation. 
 ‘ĚǀĂŶĐĞ ĐŽŶƐĞŶƚ ? ŝƐ ƉƌŝŽƌŝƚŝƐĞĚ ĂƐ ĂŶ ŝƚĞƌĂƚŝǀĞ ? ĐŽŶƚŝŶŐĞŶƚ ƉƌŽĐĞƐƐ ŽĨ ŶĞŐŽƚŝĂƚŝŽŶ ǁŚŝůĞ
recognising the unsuitability of bureaucratic forms in many contexts. dŚĞ /^ ?Ɛ 
ethnobiological code of ethics equally foregrounds  ‘ĞĚƵĐĂƚĞĚƉƌŝŽƌ ŝŶĨŽƌŵĞĚĐŽŶƐĞŶƚ ? as 
well as traditional resource rights, biocultural heritage and principles such as supporting 
ŝŶĚŝŐĞŶŽƵƐƌĞƐĞĂƌĐŚĂŶĚƚŚĞ ‘ĚǇŶĂŵŝĐŝŶƚĞƌĂĐƚŝǀĞĐǇĐůĞ ?ŽĨĐŽŵŵƵŶŝĐĂƚŝŽŶ ?ĨĞĞdback and 
implementation. Prior informed consent is difficult to implement as many factors are 
unpredictable and potential risks cannot all be foreseen, and since it requires cross-cultural 
communication and translation in a power-laden matrix (Alexiades and Peluso 2002). 
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Consent as a cultural category is somewhat arbitrary, indicating the limitations of 
ĞƚŚŶŽĐĞŶƚƌŝĐ ĂƉƉƌŽĂĐŚĞƐ ĂŝŵŝŶŐ  ‘ƚŽ ĞĚƵĐĂƚĞ ? ŶŽŶ-ŚŽŵŽŐĞŶŽƵƐ  ‘ĐŽŵŵƵŶŝƚŝĞƐ ? ǁŚŽ ŵĂǇ
have different (non-contractual) notions of trust and exchange. The rise of the informed 
consent doctrine in anthropology (only embraced by the American Anthropological 
Association in the 1990s) is predicated on post-war ethics reforms, particularly in 
experimental human subjects research, and built on the ideals of free choice and the 
rational, autonomous individual (Bell 2014). Nevertheless, Bell argues for resisting the 
commensurability of informed consent, its conflation with research ethics, and the 
positivist assumption of a unitary neutral standard. Re-inscribing inequality by creating 
voluntarily submissive subjects, it can even minimise responsibility and is therefore 
deemed fundamentally inappropriate to grapple with the complex ethical dilemmas 
underpinning anthropological practice.  
 
 ‘'ĂŝŶŝŶŐ ĂĐĐĞƐƐ ? ? Žƌ ƌĂƚŚĞƌ ? ĞƐƚĂďůishing and maintaining meaningful working 
relationships 
Space restrictions prevent me from telling the whole story of how I got in touch with and 
was eventually able to move through both Men-Tsee-Khang and PADMA more or less freely: 
making fieldnotes, taking photographs and recording conversations. First encounters with 
the former institution involved attending lectures by deputed amchi in Europe (starting 
with the late Pema Dorje, at the London School of Oriental and Asian Studies, 6 December 
2012), interviewing practicing Tibetan doctors who studied there (e.g. Tamdin Sither 
Bradley, Essex, Audio recording 4), and following consecutive five- and ten-day 
introductory courses on Tibetan medicine at Men-Tsee-Khang College (16 September  W 1 
October 2013). At a meeting afterwards with one of the teachers from the Materia Medica 
Department, amchi Tsultrim Kalsang, I offered my help in editing the botanical names and 
English in his book manuscript on the cultivation of Tibetan medicinal plants. This 
eventually resulted in the publication of his book (Tsultrim Kalsang 2016), and is still on-
going in virtual exchanges of expertise. As my spokesperson, he facilitated an officially-
sanctioned collaboration (see the Circular of 17 March 2014 in Appendix I), in which I taught 
Tibetan medical students botany and staff English on a weekly basis  W a stimulating, yet 
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demanding task  W in return for access and interview time with people working in the 
DĂƚĞƌŝĂDĞĚŝĐĂĞƉĂƌƚŵĞŶƚ ?ƚŚĞWŚĂƌŵĂĐĞƵƚŝĐĂůĞƉĂƌƚŵĞŶƚ ? ‘ƚŚĞƉŚĂƌŵĂĐǇ ? ) ?ƚŚe quality 
control lab, and the branch clinic of Gangchen Kyishong (Gangkyi). The promised outcomes 
of my work there ensure a continued relation beyond the scope of my PhD.  
 
In a similarly stepwise manner a modus operandi was agreed with PADMA. Following an 
initial phone call with its owner and CEO Dr Herbert Schwabl (Diary, 14 February 2013), a 
first two-day visit (8-9 July 2013) and more interviews during the International Congress on 
Traditional Asian Medicine in South Korea we both attended (ICTAM VIII, 9-13 September 
 ? ? ? ? ) ? ,ĞƌďĞƌƚ ƐŽŽŶ ďĞĐĂŵĞ ŵƵĐŚ ŵŽƌĞ ƚŚĂŶ Ă  ‘ŐĂƚĞŬĞĞƉĞƌ ? Žƌ  ‘ŬĞǇ ŝŶĨŽƌŵĂŶƚ ?  ?ƐĞĞ
especially Chapter 3). Over time, mutual understandings were formalised in a secrecy 
agreement (see Appendix II) aimed at safeguarding the confidential information I would 
ŽďƚĂŝŶĂƚWDŝŶƚŚĞƵŶůŝŬĞůǇĐĂƐĞŽĨ  ‘ďƌĞĂĐŚŽĨĐŽŶƚƌĂĐƚ ? ?11 I also aided PADMA with 
some translation work and other small things, but this clearly does not weigh up to the help 
and support I received from them. Interestingly, at both places it was the institutional 
context that instigated the need for formal documentation. Besides these forms (and initial 
University of Kent ethical and health and safety assessments), no further written 
agreements (including consent forms) were deemed appropriate at the individual, personal 
level and beyond the precincts of these institutions. In terms of plants, I also decided not 
to collect herbarium specimens  W relying instead on photographic vouchers  W to steer clear 
of the murky waters of bioprospecting/biopiracy. My field notes and diaries are kept strictly 
private and sensitive data are withheld from publication (sometimes on explicit request by 
participants). Anonymity was not expected or requested by anyone. To the contrary, due 
credit is warranted and anonymisation is anyway largely unfeasible in these very specific 
contexts. An exception to this rule is applied in this thesis to Indian herbal traders (in 
Chapter 2), who provided details of particularly politically and economically sensitive 
nature that equally reflect the informal nature of the trade. 
 
                                                     
11 This is only half of the story. Herbert told me, an ignorant doctoral student, that the secrecy agreement 
also served the purpose of acquainting me with the real-world environment of the pharmaceutical industry. 
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The influence of my reliance on and rapport with Tsultrim Kelsang and Herbert Schwabl 
should not be underestimated. These key interlocutors have certainly coloured my overall 
field experience, but in different ways and to varying extents. Amchi Tsultrim was in a less 
powerful position at Men-Tsee-Khang compared to Herbert at PADMA, which meant that 
my access to other departments was not directly overseen or mediated by him. This was 
both an advantage and a disadvantage, allowing for chance encounters but also leaving 
some doors closed. At PADMA, Herbert personally introduced me to his company in a tour, 
introducing me to key people and setting the parameters for future interactions. He 
ensured minimal disturbance of workflow, for instance, yet left the implementation of this 
to the employees themselves. In the end, it was them who decided exactly what to share 
and when, after initial clearance was obtained. Throughout my work at PADMA I reported 
some of my observations to Herbert, who was then able to comment and elaborate, thus 
shaping my interpretations. This happened to a much lesser extent with Dr Tsultrim, who 
kept the focus more on his own area of expertise. 
 
Data materials 
My fieldwork mainly consists of extended stays in India (September-October 2013, 
February-May 2014, July-August 2015) and Switzerland (July and December 2013; January-
February, August 2014; July 2016) spread over a period of more than three years, 
supplemented by a few interviews with Tibetan medicine practitioners and other activities 
such as lectures and workshops in the UK and the Netherlands. Regrettably, my stay in 
Dharamasala (less than six months) was not sufficient to master the Tibetan language 
enough to conduct interviews, intensive immersion courses notwithstanding. Besides 
(participant) observation in/of plant excursions, herbal markets, medicine production, and 
quality control laboratories, I also studied and discussed historical and contemporary 
materia medica texts (mainly at Men-Tsee-Khang) as well as archival and regulatory 
documents (mainly at PADMA). I filled eleven small notebooks, typed almost two hundred 
pages of diary, captured 118 audio-recordings (about 140 hours in total, averaging 1 hour 
12 minutes per recording) of which 56 in Switzerland, and made about 4,000 photographs 
in India and 1,500 in Switzerland. Only 27 recordings are with female participants, mirroring 
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a gender bias within Men-Tsee-Khang (especially in the pharmacy and Materia Medica 
Department) and in Indian herbal markets in particular (where all traders I worked with 
were male). The relative importance of interviewing is a characteristic of multi-sited 
fieldwork (Hannerz 2003), whereas para-ethnographic tendencies are clearly visible in the 
number of conversations with both Herbert (28) and Tsultrim (16). Finally, I also collected, 
photographed and labelled about fifty plant and medicine objects: predominantly Men-
Tsee-Khang and PADMA medicines and other products, but also market samples of my 
study herbs. Qualitative data analysis, including audio transcription and inductive coding, 
was carried out using QSR Nvivo 10 following a thematic narrative approach. Most of the 
interviews were carried out in English, both in India (where it is an official language, taught 
to Tibetan exiles) and Switzerland (where it is important for scientific and business 
communication). A Tibetan-English interpreter  W Dr Penpa, himself an amchi and pharmacy 
expert  W was only deemed necessary in two instances: when talking to the Head and the 
 ‘^ƚŽƌĞ/Ŷ-ĐŚĂƌŐĞ ?ŽĨDĞŶ-Tsee-<ŚĂŶŐ ?ƐƉŚĂƌŵĂĐĞƵƚŝĐĂůĚĞƉĂƌƚŵĞŶƚ ?'ĞƌŵĂŶǁĂƐƐƉŽŬĞŶŝŶ
less than ten audio recordings, and was then transcribed verbatim. 
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PART I  



















1 Commensurating situated 
knowledges  
Sowa Rigpa and botanical taxonomy 
 
 
After having decided that I definitely wanted to focus on the transformation of a handful 
of plants into Tibetan medicines, one of the first steps in planning my dissertation was to 
answer the following question: what are the plants I am studying? This question has stayed 
with me ever since. At the moment of writing it is still not fully resolved, and I very much 
doubt it will ever be. The aim of this chapter is to explain why this is the case. Incidentally, 
this penchant for accurate botanical identification and naming reflects a personality clash 
ǁŝƚŚŝŶƚŚĞĂƵƚŚŽƌ ?ƐŵŝŶĚ PďĞƚǁĞĞŶƚŚĞĂĐĂĚĞŵŝĐĂůůǇƚƌĂŝŶĞĚďŝŽůŽŐŝƐƚĂŶĚĞƚŚŶŽďŽƚĂŶŝƐƚ ?
the student of Tibetan medicine, and the budding reflexivity and sociocultural sensitivity of 
an anthropologist. 
 
Amchi Tsultrim Kelsang, amchi Ngawang Jinpa and I had arranged to go on a fieldtrip to 
look at plants (Diary, 26 April 2014). Starting off from the Main Square in the morning, we 
followed part of the gravel road from McLeod Ganj to Dharamkot, from which we diverted 
to hike the trail towards Triund Hill. It was not our intention that day to reach the ridge 
overlooking the Dhauladar mountain range Ăƚ ĂďŽƵƚ  ? ? ? ? ? ŵĞƚĞƌƐ ? ĂůƚŝƚƵĚĞ ? we had 
departed too late for that anyway and did not want to reach the snowline beyond which 
only very few plants would be in flower. The sky was nearly cloudless the whole day and 
the sharp sunrays pierced our skin and eyes. It was hot and all three of us were sweating 
and breathing heavily while walking uphill. Somehow I had romanticised going on a fieldtrip 
with a Tibetan doctor. The reality was certainly not disappointing, but it was not completely 
new to me either. I was surprised by how much I could contribute to the on-going 
conversation: by giving scientific names, describing plants, and commenting on ecology. 
Tsultrim, the deputy head of Men-Tsee-<ŚĂŶŐ ?ƐDĂƚĞƌŝĂDĞĚŝĐĂĞƉĂƌƚŵĞŶƚ ?was keen to 
hear this. He said it was good for him to get the right botanical names from me. Using this 
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he could find out the Tibetan names for the species and learn more.  ‘You are a botany 
expert ?, he declared. We both knew this was an exaggeration and laughed,  ‘maybe in ten 
years! ?. I had just studied a copy of the well-known field guide Flowers of the Himalaya 
(Polunin and Stainton 1997) that I had picked up at a bookshop in town. Along the way, I 
numbered each plant we identified  W more than twenty in total  W in my notebook (Field 
notes VIII). Diversity-wise Tibetan medicinal plants turned out to be almost a needle in a 
haystack on these Indian Himalayan foothills. Tsultrim had warned me Spring was not the 
best time to see many species, and was joking that the plants I asked about which were not 
used in Tibetan medicine were  ‘poor plants ? ?dŚĞǇĚŝĚŶ ?ƚĞǀĞŶŚĂǀĞĂname, even though 
the Four Tantras (Gyüzhi, the fundamental four-volume medical text) expounds that any 
substance can be used as a medicine once its taste (ro), potency (nüpa) and inherent 
qualities (yönten) are known. Fieldtrips did not seem to be the right place to discuss these 
medicinal characteristics at length, however, although the tastes and warming/cooling 
powers of some plants were mentioned. I realised that Tibetan medical plant classification 
is selective. Of course, the doctors did know names of plants that were not used medicinally 
but for ritual, food, or ornamental purposes. Tsultrim could also distinguish non-medicinal 
species from a genus containing medicinal ones. Often he remembered the genus name, 
but had some trouble pronouncing it correctly (temporarily confusing Codonopsis with 
Cotoneaster for example). Ngawang (stationed at Men-Tsee-<ŚĂŶŐ ?Ɛ ŶĞǁůǇ ŝŶĂƵŐƵƌĂƚĞĚ
Body, Mind and Life Department) did not know any scientific names, but did use some 
common English names like nettle, which he applied to stinging herbs that were not the 
familiar European stinging nettles (Urtica spp.).  
 
The first plant we stopped for, only a few steps up from the Main Square, was a species of 
Clematis which was now in flower all over Kangra valley. Its Tibetan name is yimong, and 
Tsultrim added that is the white variety (karpo), one of three that are distinguished. Close 
to this vine Ngawang noticed a patch of buttercups (Ranunculus sp.). He put a flower head 
on his tongue, instructing me to do so as well. I hesitated for a second. I knew that 
buttercups in general are poisonous and therefore ignored by cattle. I do it anyway, and 
after a few seconds I felt a hot sensation. It explains the name given to it in Tibetan: chétsa, 
ůŝƚĞƌĂůůǇ ‘ŚŽƚƚŽŶŐƵĞ ? ?dƐultrim added that this plant is pho rik, the male type that grows at 
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lower altitude. We stopped many times along the way to examine plants and to catch our 
breath: to taste the orange raspberries of gadra (Rubus ellipticus Sm.), to inspect the deep 
yellow and very bitter wood of a broken kyerpa karpo branch (Berberis lycium Royle), and 
so on. It dawned on me that the differentiation of ƉůĂŶƚ  ‘types ? based on medicinal 
superiority/inferiority or where it grows, or colours, is not easily equated with intraspecific 
variation. Tsultrim was using the same Tibetan name for what I considered to be other 
species or genera. Both doctors were much more hands-on with the plants than what I was 
used to. Touching and tasting them, breaking off branches, and uprooting whole plants. 
The root would almost never be diagnostically characteristic for taxonomic identification 
but it clearly is in Sowa Rigpa, which derives many of its medical substances from 
underground parts. Sometime later, before lunch, we went around a corner and I saw a 
large inflorescence with sky blue flowĞƌƐƉĞƌĐŚŝŶŐŽŶĂƐƚĞĞƉƐůŽƉĞ ? ‘tŚĂƚ ?ƐƚŚĂƚ ? ?, I almost 
yelled, pointing. We were all exalted. Tsultrim started climbing to get closer to take a 
picture. Laughingly, Ngawang warned him that he had a wife and children. After a few 
minutes, he finally remembered its name: jarkang (ůŝƚĞƌĂůůǇ  ‘ďŝƌĚ ůĞŐ ?), probably a 
Delphinium! Tsultrim was very surprised to find this plant here, not expecting it at such a 





Figure 1.1. Amchi Tsultrim Kalsang and the author on the way to Triund Hill, with Kangra valley in the background. 
The light blue flower is called jarkang, a rare species of Delphinium. Photograph by amchi Ngawang Jinpa, 26 April 
2014. 
 
The argument presented here questions the reliability of botanical identification of Tibetan 
medicinal plants, and aims to reveal its problematic political and practical implications for 
Sowa Rigpa, its practitioners, scholars and scientists, and for the plants themselves. It 
concerns studies of Tibetan plant nomenclature (Boesi 2007) and classification (Boesi 2005-
2006; Boesi and Cardi 2006; Ghimire and Aumeeruddy-Thomas 2009; Glover 2005, 2010), 
ethnobotanical knowledge surveys (e.g. Lama et al. 2001), materia medica texts and their 
illustrations (Hofer 2014b), and medical substitution practices (Arbuzov 2010, Dashiyev 
1999, Sabernig 2011). I bring two long-established but somewhat oppositional strands of 
ethnobotanical research into dialogue: ƚŚĞƐƚƵĚǇŽĨ ‘ĨŽůŬ ?ĐůĂƐƐŝĨŝĐĂƚŝŽŶƐ12 (which tends to 
                                                     
12 FolloǁŝŶŐĂƐĂŐƌĂŶĚĞ  ? ? ? ? ? ?Ɖ ?  ? ? ? )  ‘Ethnobiology is the systematic cross-cultural study of how people 
learn, name, use, and organize knowleĚŐĞ ĂďŽƵƚ ƚŚĞ ďŝŽƚĂ ĂƌŽƵŶĚ ƚŚĞŵ ? ? ǁŚŝůĞ  ‘ ?Folk biolŽŐǇ ? is a term 
commonly used by ethnobiologists to refer to biological classification and reasoning particular to cultural 
ŐƌŽƵƉƐ ? ? dŚĞ ĚĞƐŝŐŶĂƚŝŽŶ  ‘ĨŽůŬ ? ŚŽǁĞǀĞƌ ĐĂŶ ďĞ ŝŶƚĞƌƉƌĞƚĞĚ ĂƐ ĚĞƌŽŐĂƚŽƌǇ ďĞĐĂƵƐĞ ŝƚ ŝŵƉůŝĞƐ ƚŚĂƚ ƚŚĞ
classification or knowledge referred to is non-(Western- )ƐĐŝĞŶƚŝĨŝĐ ? /Ŷ ůŝŐŚƚ ŽĨ ƌƚŚƵƌ <ůĞŝŶŵĂŶ ?Ɛ  ? ? ? ? ? )
distinction between the popular, folk, and professional sectors of healthcare and the importance of written 
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generalise along cognitive/linguistic lines), and ƐƵƌǀĞǇƐ ŽĨ  ‘ŝŶĚŝŐĞŶŽƵƐ ? Žƌ ƚƌĂĚŝƚŝŽŶĂů
knowledge (which showcase variation and are frequently instrumentalised in biodiversity 
conservation and development, Nazarea 2006). 
 
Even though there is a general awareness that attributing Latin binomials to Tibetan 
materia medica ŝƐ ‘ĐŽŵƉůĞǆ ?, everyone continues to have a go at it, relying on a varied menu 
of classical and modern sources, personal or consulted expertise, or simply by comparing 
images somewhere on the internet or with a regional field identification manual. I argue 
that these acts of translation are fraught with misrepresentation, instability, and concealed 
ambiguity. These identifications constitute a process of standardisation along modern 
scientific lines in disguise, a standardisation which solidifies the multiplicity of Tibetan 
medical plant knowledges into unsuitably narrow and rigid categories while sometimes 
unintentionally universalising this flawed simplification as the one and only correct 
identification. In this process I call commensuration, the inaccurate translation may 
eventually replace the translated (perhaps in a future official Tibetan pharmacopoeia, see 
Blaikie 2015 and Kloos 2013 for Men-Tsee-<ŚĂŶŐ ?Ɛ ŽŶ-going efforts), at the same time 
denying the legitimacy of regional and local traditions, innovations, and substitutions, as 
well as flexibility in medicine formulation. I not only draw on postmodern conceptions of 
local knowledge as dynamic, partial, practical, and also political and contingent on and 
ƚƌĂŶƐĨŽƌŵĞĚďǇ  ‘ĞǆƚƌĂ-ůŽĐĂů ? ŝŶĨůƵĞŶĐĞƐ(Ellen 2006a; Ellen et al. 2000), but equally from 
ŽŶŶĂ ,ĂƌĂǁĂǇ ?Ɛ ƐĞŵŝŶĂů ƉĂƉĞƌ ƚŝƚůĞĚSituated Knowledges: The Science Question in 
Feminism and the Privilege of Partial Perspective (1988). Thinking with Haraway allows me 
to question the objectivity of (White, masculinist, capitalist, militarised) science without 
retreating into radical forms of social constructivism and historical specificity, which 
provide accounts of complexity but fail to communicate/translate knowledge across 
different, politically unequal communities. Instead, she advocates an embodied objectivity 
that allows for situated knowledge froŵĂƉĂƌƚŝĐƵůĂƌůŽĐĂƚŝŽŶĂƐŽƉƉŽƐĞĚƚŽƚŚĞ ‘ŐŽĚƚƌŝĐŬ ?
of universalist transcendence. These subjugated, partial positions are not to be 
romanticised, they are not innocent but critical, transformative and importantly, grounded. 
                                                     
texts in (Asian) scholarly  W and professional  W medical traditions (Bates 1995), the term is better avoided in 
referring to these sciences in their own right. 
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Translation from this perspective is always partial and vulnerable, resists the politics of 
simpůŝĨŝĐĂƚŝŽŶ ĂŶĚ ĐůŽƐƵƌĞ ? ĂŶĚ ŝƐ  ‘about heterogeneous multiplicities that are 
simultaneously salient and incapable of being squashed into isomorphic slots or cumulative 
ůŝƐƚƐ ? (Haraway 1988, Ɖ ? ? ? ? ) ?dŚĞ ‘ŽďũĞĐƚ ?ŽĨŬŶŽǁůĞĚŐĞ ?ŚĞƌĞ ‘ƉůĂŶƚƐ ? )ĂƌĞĞŶǀŝƐŝŽŶĞĚĂƐ
actors and agents, not as slaves of objectifying scientific authorities.  
 
Feminist science studies have also significantly prepared the ground for posthumanist 
approaches and the dawn of  ‘ŵƵůƚŝƐƉĞĐŝĞƐ ĞƚŚŶŽŐƌĂƉŚǇ ? (Kirksey and Helmreich 2010, 
Ogden et al. 2013). In this burgeoning field, recent discussions on the theoretical worth of 
 ‘ƐƉĞĐŝĞƐ ? ŝƐ ŽĨ ƉĂƌƚŝĐƵůĂƌ ƌĞůĞǀĂŶĐĞ ƚo my argument. Ingold (2013a) argues for an 
anthropology beyond the human (along with Kohn 2007, 2013) that steers away from 
 ‘ethnography ? and scientific species concepts, which both replicate human exceptionalism, 
foreclosing aliveness as a fluid relational process of multiple, heterogeneous becomings 
(see more in Chapter 3). Yates-Doerr (2015) raises the same issue. In the anthropological 
tradition of challenging the smooth translation of concepts from site to site and aware of 
the dangers of dualistic essentialist discourses that reassert what they supposedly 
overcome (e.g.  ‘ŵƵůƚŝĐƵůƚƵƌĂůŝƐŵ ? ) ? ƐŚĞ ƐŚŽǁƐ ŚŽǁ ƚŚĞ ĐĂƚĞŐŽƌǇ  ‘ŵĞĂƚ ? ĚĞĨŝĞƐ ƐŝŶŐƵůĂƌ
definition in the preparation and consumption of food by Guatemalan families. There are 
multiple, specific practices making meat come into being that do not depend on knowing 
its essence (blood) or origins (genetics):  
dŚĞ ‘ŵƵůƚŝ ?ŽĨŵƵůƚŝƐƉĞĐŝĞƐĞƚŚŶŽŐƌĂƉŚǇƐŚŽƵůĚƚŚƵƐďĞƚĂŬĞŶĂƐĂŶŝŶĐŝƚĞŵĞŶƚƚŽƐƚƵĚǇƚŚĞ
multiplicity of ways in which relations emerge  W and not the pluralist addition of yet more 
(given) species to the ethnographic canon. (Yates-Doerr 2015, p. 320) 
Conversely, Kirksey (2015)  W one of the original proponents of multispecies ethnography  W 
holds that the species concept remains a valuable tool to grapple with other animate beings 
and even an ethical imperative in today ?Ɛ biodiversity extinction crisis. Taking on 
ŶŶĞŵĂƌŝĞ DŽů ?Ɛ(2002) praxiographical method, Kirksey researched what practices 
scientists use to enact or perform species. He finds that taxonomy nowadays is low-status, 
low-tech work, especially when involving noncharismatic species. Many taxonomists are 
self-reflexive and accept the pluralist principle that there are multiple defensible 
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approaches towards biological classification, as well as the promiscuous realist position 
that these reality-imposed categories are shaped by economic and other interests. The 
classical definition based on isolated interbreeding natural populations does not provide 
much guidance in the huge number of organisms without sexual reproduction for a start, 
and is anyway difficult to assess empirically. BorrowiŶŐ ĨƌŽŵ ŽǁŬĞƌ ĂŶĚ ^ƚĂƌ ?Ɛ(1999) 
analysis of racial Apartheid categories in South Africa, Kirksey (2015) infers that reality is 
eminently material and solid, but that it may be torqued:  
Torque is generated at the intersection of ĐŽŵƉĞƚŝŶŐĐůĂƐƐŝĮĐĂƚŝŽŶƉƌŽũĞĐƚƐ ?ƐďŽƵŶĚĂƌŝĞƐ
ĂƌĞĞŶĂĐƚĞĚ ?ŽƌĚƌĂǁŶ ?ƚŚĞƐĞůŝŶĞƐĐĂŶƚǁŝƐƚŽďũĞĐƚƐŝŶƚŽŶĞǁĐŽŶĮŐƵƌĂƚŝŽŶƐ ?tŚĞŶĐĂƚĞŐŽƌŝĞƐ
are aligned, there is no sense of torque or stress, according to Bowker and Star, but when 
ĐŽŵƉĞƚŝŶŐĐůĂƐƐŝĮĐĂƚŝŽŶs pull on populations, these forces can produce novel modes of being 
ŽǀĞƌƚŝŵĞ ? ? Q ?dĂǆŽŶŽŵŝƐƚƐ ?ĂŶĚŵƵůƚŝƉůĞƐƉĞĐŝĞƐŽĨĂŐĞŶƚŝĂůďĞŝŶŐƐ ?ĐĂŶĂůƐŽƚƌĂŶƐĨŽƌŵŽƚŚĞƌ
ŽƌŐĂŶŝƐŵƐ ǁŝƚŚ ƚŚĞŝƌ ƉƌĂĐƚŝĐĞƐ ŽĨ ĐůĂƐƐŝĮĐĂƚŝŽŶ ? ƌĞĐŽŐŶŝƚŝŽŶ ? ĂŶĚ ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ? Ɛ ŶĞǁ
species emerge, they can torque human practices, political and economic systems, as well as 
ecological communities. (Kirksey 2015, p. 760) 
It is exactly this clash of classifications and its twisted outcomes  W here in the case of the 
impositioning of botanical species onto Tibetan medicinal plant categorisations  W  that are 
of interest in this chapter. 
 
1.1 Mixed introductions 
/ƚŵŝŐŚƚƐŽƵŶĚƐŝůůǇƚŽƉƌŽĐůĂŝŵƚŚĂƚ/ĚŽŶ ?ƚŬŶŽǁĐůĞĂƌůǇǁŚŽƚŚĞŵĂŝŶƉƌŽƚĂŐŽŶŝƐƚƐŽĨƚŚŝƐ
thesis are. How can I then even study them, or how did I even decide to pick these? In this 
section I show how I ended up focusing on four (though I am not sure about the exact 
ŶƵŵďĞƌ )ƉůĂŶƚƐ  ?ĂĚĞďĂƚĂďůĞĐĂƚĞŐŽƌǇ ?ďƵƚƐƉĞĐŝĞƐƐƵƌĞůǇĚŽĞƐŶ ?ƚǁŽƌŬ ) ?ĂŶĚǁŚĂƚǁĞŶƚ
 ‘ǁƌŽŶŐ ?ĂůŽŶŐƚŚĞ ǁĂǇ ?dŚĞ ƉƌŽďůĞŵ ŝƐŶot just about figuring out more or less reliable 
taxonomic identifications. Even when relying exclusively on Tibetan nomenclature and 
texts one ends up drowning quickly in a sea of mutually irreconcilable names, synonyms, 
substitutes and descriptions. This section represents my provisional, I must admit 
somewhat failed attempt to come up with some sort of consensus by relying on available 
specialised English-language (and translated) publications. I apologise in advance to the 
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reader for the ensuing quagmire of textual cross-referencing and comparison: it indeed 
seems impossible not to get lost in translation. Thousands of materia medica are 
mentioned in the literary corpus of Sowa Rigpa, not only in its foundational text the Gyüzhi 
and its many historical and contemporary commentaries but even more so within the vast 
pharmacological literature, particularly the genre on medical simples termed trungpé. 
 
To research possible material (dis-)connections between Men-Tsee-Khang and PADMA and 
in order to enable myself to observe the plants growing in their natural habitats, I started 
off my PhD looking for plants (or actually plant parts) used as ingredients by both 
institutions, and which grow in India.13 Surfing through PADMA`s English language website, 
I found the package insert of PADMA 28, tŚĞ ĐŽŵƉĂŶǇ ?s leading product commercially 
which also contains the largest number of ingredients. 
One capsule contains: 
Columbine 15 mg, valerian root 10 mg, D-camphor 4 mg, aconite 1 mg, lettuce leaf 6 mg, 
clove 12 mg, golden cinquefoil 15 mg, kaempferia galanga rhizome 10 mg, costus root 40mg, 
Icelandic moss 40 mg, cardamom fruit 30 mg, Bengal quince 20 mg, myrobalan fruit 30 mg, 
calcium sulphate 20 mg, allspice 25 mg, neem fruit 35 mg, calendula flower 5 mg, red 
sandalwood 30 mg, heart-leaved sida 10 mg, ribwort plantain 15 mg, liquorice root 15 mg, 
knotgrass 15 mg.  
The product also contains excipients. 
Depending on the audience however, PADMA has to resort to different sets of names for 
its raw materials: trade names when ordering herbs from suppliers and for patients (e.g. 
Baldrianwurzel, or valerian root in English), Linnean binomials in official registration and 
quality documents (Valeriana officinalis L. 14), or pharmaceutical names (Valerianae Radix). 
                                                     
13 This is already my first flawed assumption and a first instance of the insidious influence of modern botany. 
 ‘WůĂŶƚƐ ?ŝƐĂĐƚƵĂůůǇŶŽƚƌĞĐŽŐŶŝƐĞĚĂƐĂŚŝŐŚĞƌƌĂŶŬĐĂƚĞŐŽƌy in the Four Tantras, nor in the seminal eighteenth-
century pharmacological text Crystal Orb and its auto-commentary Crystal Garland (Shelgong Shelthreng). 
/ŶƐƚĞĂĚ ?ŐƌŽƵƉŝŶŐƐƐƵĐŚĂƐ  ‘ǁŽŽĚǇŵĞĚŝĐŝŶĞ ?  ?shingmen ) ?  ‘ĞǆƵĚĞŶƚŵĞĚŝĐŝŶĞ ?  ?tsimen ) ?  ‘ŵĞĚŝĐŝŶĞĨƌŽŵ the 
ƉůĂŝŶƐ ? ?thangmen )ĂŶĚ ‘ŚĞƌďƐŵĞĚŝĐŝŶĞ ? ?ngomen) are used, which can contain what modern scientists would 
variously label as plant, fungal, animal or mineral products (see Glover 2005). In practice, however, it may be 
present as a covert category or a rarely used high-level rank, see further discussion in section 1.3.2). 
14 I consciously choose to include the author name abbreviations (at least when first introducing a new species) 
to acknowledge how this suffix adds another possible layer of confusion (or clarity) to the thorny issue of 
botanical nomenclature. Author names reflect the importance of personal authority in taxonomic 
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Commonly traded herbs such as valerian are commodified, which implies the link between 
trade names and botanical binomials is fixed in commercial guidelines such as the German 
Code on Foods and Feedstuffs (Deutsche Lebensmittelbuch). In relation to quality control, 
the European and Swiss Pharmacopoeias should be referred to wherein entries are listed 
alphabetically according to Latinised pharmaceutical (pharmacopoeia) names. At this point 
there is not much confusion  W at least for insiders  W as there is a clear, predominantly one-
to-one correspondence between the different naming conventions.15  
 
/ŶĂƌƌŽǁĞĚĚŽǁŶWD ? ? ?Ɛ ůŝƐƚŽĨĐŽŵƉŽƵŶĚƐ by eliminating common culinary spices 
(cloves, galangal, cardamom, and allspice) as well as other herbs available in large 
quantities on the European market (valerian, calendula, plantain, liquorice), ending up with 
the following selection of three study herbs. First of all, aconite tuber (Aconiti Tuber in the 
Product Information File for medical professionals, corresponding to Aconitum napellus L.) 
was of interest due to its renowned toxicity. Secondly, costus root (Costi Amari Radix, 
Saussurea costus (Falc.) Lipsch.), since I was aware of its inclusion on CITES, the Convention 
on International Trade of Endangered Species of Wild Fauna and Flora. And finally 
myrobalan fruit (Myrobalani Fructus, Terminalia chebula Retz.), in light of its great 
frequency and quantity in Tibetan medical formulations, as well as its symbolic role as a 
panacea for all bodily ailments. I soon realised that these three plants are commonly used 
in Ayurveda and other Asian scholarly medicines, so I set out to find a fourth one that is not 
(it may tell a very different story): perhaps a species growing at high-altitude? After 
ƐĐĂŶŶŝŶŐƌĂǁĂ ?Ɛ16 (1999) Clear Mirror of Tibetan Medicinal Plants  W Men-Tsee-<ŚĂŶŐ ?Ɛ
most ambitious publication on the subject, and beautifully illustrated with European 
                                                     
identification. This furthermore reflects the rigour of an academically trained (ethno)botanist with research 
experience on herbal authentication (van der Valk 2017, in press). When I provide botanical names (although 
ŶŽƚǁŚĞŶƋƵŽƚŝŶŐŽƚŚĞƌƉĞŽƉůĞ ?ƐŝĚĞŶƚŝĨŝĐĂƚŝŽŶƐ ) ?/ƌĞůǇŽŶ dŚĞWůĂŶƚ>ŝƐƚĚĂƚĂďĂƐĞ ?www.theplantlist.org) for 
the currently accepted names and their synonyms. 
15  The global correspondence between scientific, pharmaceutical, trade and common herbal names is 
currently being mapped by Kew Gardens in the Medicinal Plant Names Services resource 
(www.mpns.kew.org).  
16  Dawa excelled in his studies at Lhasa Mentsikhang (1971-1975), where he joined the Pharmacology 
Department. In 1980 he attended the School of Botanical Art (Central Health Department, China) to learn 
about plant biology and the art of botanical illustration. In 1988 he set out for India to meet His Holiness, and 
to work at Dharamsala Men-Tsee-Khang, where he eventually became the Director for five years (2005-2010). 
ůƌĞĂĚǇŝŶdŝďĞƚ ?ŚĞŶŽƚŝĐĞĚ ‘the lack of unanimous ideŶƚŝĨŝĐĂƚŝŽŶŽĨŵĞĚŝĐŝŶĂůƉůĂŶƚƐ ? (Dawa 1999, p. 25), 
inspiring him to compose an illustrated book. 
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herbal-style drawings  W I came across ajak tserngön, identified as Meconopsis racemosa 
Maxim., although an asterisk indicates the identification is uncertain.  
 
The botanical identification of the three first-mentioned Tibetan materia medica was 
already fixed before the establishment of PADMA AG in 1969, through an intensive 
collaboration between Karl Lutz (the founder, who at the time was still the head of the 
Swiss branch of the German pharmaceutical company Schering-Plough) and Peter 
Badmajew, a biomedically trained physician who had inherited a Buryat tradition of Sowa 
Rigpa from his father (Saxer 2004). With the help of members from the Study Group for 
Tibetan Medicine (Studiengruppe für Tibetische Medizin, set up in 1965), consisting of a 
small group of interested doctors, scholars, scientists, and pharmacists ? WD  ? ? ?Ɛ
composition was scientifically translated and finally solidified as it was approved by the 
Swiss authorities as a medicine. Although the actual process through which these plants 
were identified botanically may be lost in history (but see more in Chapter 6), the outcome 
is nonetheless documented. Plants that are commonly used in the pharmaceutical industry 
are defined in monographs  W covering identity, quality, and purity parameters  W of national 
or international pharmacopoeias, which are legally binding publications. However, none of 
the four study herbs appeared (or appears) as such in the Pharmacopoeia Helvetica (nor in 
the current European Pharmacopoeia). This implies that PADMA had to construct its own 
in-house monographs when first applying for drug marketing approval based on the 
general pharmacopoeia template, and these had to be accepted by the national authority 
involved. For this process, they could rely on published (ethno)botanical, phytochemical, 
and analytical books, articles, and manuals.17 
 
Referring again to Men-Tsee-Khang sources, Dawa (2009) equates Saussurea lappa (Decne.) 
Sch.Bip. (Figure 1.2)  W a valid synonym for the accepted name S. costus used by PADMA 
(according to The Plant List 2013)  W with ruta while listing eight other Tibetan names. 
Terminalia chebula is arura, which has forty-five (!) Tibetan synonyms. At this point it seems 
                                                     
17 Aconiti Tuber was however listed until the sixth edition of the Swiss Pharmacopoeia in 1971, but later taken 
ŽƵƚĂƐŝƚǁĂƐĐŽŶƐŝĚĞƌĞĚ ‘ŽďƐŽůĞƚĞ ? ?ƐĞĞŚĂƉƚĞƌ ? ) ? 
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as if the issue of identification has been resolved for these two plants: a trade name (e.g. 
costus) is linked to pharmacopoeia name (Costi Amari Radix) as well as a botanical name 
(Saussurea costus/lappa), all corresponding with the Tibetan name ruta, and PADMA and 
Men-Tsee-Khang are in agreement. I wish it were always that simple. 
 
Figure 1.2. ĂǁĂ ?Ɛ ? ? ? ? ? ?Ɖ ? ? ? ? )ƉĂŝŶƚŝŶŐŽĨruta, identified as Saussurea lappa (Decne.) Sch. Bip. Note the inclusion 
of the root (the used part), which is generally rare in botanical illustration, as well as the detailed black-and-white 
drawings of a seed and a floret. 
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1.1.1 Tserngön, a prickly herb with a blue flower 
A first glimpse of suppressed multiplicity can be caught when we look at amchi Dawa ?Ɛ
publications (1999, 2009) once again for the remaining two plants. He discusses 
Meconopsis aculeata Royle as a type of tserngön, giving the abovementioned name ajak 
tserngön  W identified by him as M. racemosa  W as a Tibetan synonym, but the corresponding 
scientific names provided are not considered to be synonyms botanically. On page 74 of 
this entry, he translates and quotes the eighteenth century pharmacological text Crystal 
Garland (note the referral to other plants in establishing an identification): 
Its leaf, stem, calyx and fruit are spinous [i.e. prickly]18 with its growth form resembling that 
of the yellow Utpal [identified as M. paniculata Prain in the same volume], and its sky-blue 
flowers that of the blue Utpal [M. grandis Prain]. But the flower of blue Utpal is tinged with 
red and is relatively darker while that of Meconopsis spp. [his translation for tserngön here] 
is lighter. There are three types of 'tsher sngon' with similar potencies and characteristics: 
the one mentioned above [M. aculeata] has a hollow, thick and multi-branched stem; the 
second type [= M. racemosa from volume I?] has bigger leaves than the former and a Za shing 
(Urtica spp.) like stem with axillary flowers arising from its tree-like branches; and the third 
type [fits well with the description and drawing of mugchung denyön in volume I, another 
Meconopsis sp.] has numerous stalks with no main stem, developing from a single root like 
that of the poppy [this most likely refers to the opium poppy, Papaver somniferum L.].  
(Dawa 2009, p. 74) 
At this point we have come across three types of tserngön corresponding to multiple 
Meconopsis spp., of which two were identified to species level. A third Tibetan name 
(mukchung denyön) is found to partially overlap with the (ajak) tserngön (rik) category or 
categories. Dawa (1999) further presents us with a translation of an important seventeenth 
century medical text called the Blue beryl (Vaidur ngönpo), indicating historical 
disagreement on its identification (note the complicated cross-referencing): 
                                                     
18  The (mis)application of botanical morphological terminology, and not only nomenclature, is another 
problematic area of translation I will not delve into further. Consider for instance the distinction between a 
spine, a thorn, and a prickle, depending on from which part of the plant the structure is derived (see Beentje 
2010 for example) ?^ŝŵŝůĂƌĂƌŐƵŵĞŶƚƐĐĂŶďĞŵĂĚĞĨŽƌŽƚŚĞƌƚĞƌŵƐƐƵĐŚĂƐ ‘ĐĂůǇǆ ? ?ŽƌĞǀĞŶ ‘ĨƌƵŝƚ ? ? 
50 
 
Some people call sMug-chung mdan-yon19 as sMug-chung ber-mgo. Its growth pattern is 
similar to that of Ut-pal but the flowers are dark purple. It has a slightly bitter taste and is 
effective in healing fractured skull. Most of the late scholars such as Zur-mkhar-ba blo-dros 
rgyal-po consider sMug-chung mdan-yon to be the flower of Pa-yag (Lancea tibetica) [Dr 
Dawa disagrees]. But the scholars preceding rJe-rDa-rma sva-mi unanimously accept it as a 
variety of Tser-sngon (Meconopsis sp.) that grows on high mountains with small sword 
shaped leaves, slightly brown flower-stalks growing solitary or attached to each other and 
floral buds entirely covered with spines. (Dawa 1999, p. 224) 
Dawa played a key role in an international collaboration between Tibetan doctors and 
Austrian scientists to jointly document Tibetan medicinal plants, leading to a landmark 
publication of sixty monographs edited by Kletter and Kriechbaum (2001). Under the entry 
for tserngön ƚǁŽ ‘ƚǇƉĞƐ ?ĂƌĞĚŝƐƚŝŶŐƵŝƐŚĞd based on plant size, flower colour, and leaf shape 
and size: gozang (bigger size), and gongen (smaller). This is often glossed as superior versus 
inferior variety (see Dawa 1999, p. 19), indicating a perceived difference in medical efficacy. 
These two types, however, do not equate simply with the botanical ranks of variety (var.) 
or subspecies (subsp.), of which many have also been published within the genus 
Meconopsis (but with varying levels of acceptance; Taylor 1934, The Plant List 2013), and 
which may or may not be acknowledged as separate entities by amchi. In total, more than 
fifty species are described within this genus, of which forty-three can be found growing 
wild in China, and twenty-three of which are endemics (according to Flora of China, Wu et 
al. 1994 onwards). It is also widely acknowledged that Meconopsis species can hybridise 
(as has been put to use in the creation of numerous cultivars). Ecotypes with considerable 
morphological variation (polymorphism) are likely due to the presence of microclimates 
and significant barriers to gene flow between populations, especially in high altitude 
mountainous habitats (see references in Kletter and Kriechbaum, as well as Yang et al. 
2012). Kletter and Kriechbaum studied tserngön specimens collected at Rothang Pass 
(elevation about 4000 m, Himachal Pradesh, India), as well as from Jharkot (3500 m, Nepal) 
and from Lhasa Mentsikhang. The Indian accession was identified as Meconopsis aculeata, 
whereas the samples from Nepal and Tibet were found to be Meconopsis horridula Hook.f. 
                                                     
19 Or is it ƐŵƵŐĐŚƵŶŐ ?ĚĞŶǇŽŶ(Wylie 1959)? Authors may disagree on spelling and/or (mis)use one or more 
distinct systems of transliteration and (simplified) phonetic transcription, which is clearly another possible 
source of confusion. 
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and Thomson. This yet another species that is linked to this meshwork of Tibetan names in 





















Figure 1.3. A small sample of tserngön from Men-Tsee-<ŚĂŶŐ ?ƐWŚĂƌŵĂĐĞƵƚŝĐĂůĞƉĂƌƚŵĞŶƚ ?/ƚǁĂƐĐŽůůĞĐƚĞĚĨƌŽŵ
the cold storage unit on 7 April 2014 by a pharmacy worker, under the supervision of amchi D. Penpa and myself. 
Pharmacy staff barely know and use LatiŶ ƐĐŝĞŶƚŝĨŝĐ ŶĂŵĞƐ ? ďƵƚ dƐƵůƚƌŝŵ ĞǆƉůĂŝŶĞĚ ƚŽ ŵĞ ƚŚĂƚ  ?In India we use 
Meconopsis aculeata ?, which is wild-harvested during Monsoon. The scale bar is 1 cm. 
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1.1.2 Bongnak: black aconite? 
Trying to back-ƚƌĂŶƐůĂƚĞ ‘ĂĐŽŶŝƚĞ ? to a Tibetan plant name is even more problematic, and 
as such it has become an exemplar of the convoluted issue of Tibetan medicinal plant 
identification (Aschoff and Tashigang 2004, Sabernig 2007, Saxer 2013). A prominent 
reason for this is firstly that four colour types of bonga are distinguished (Dawa 1999, 
quoting an anonymous trungpé cited in Blue beryl): white, red, yellow, and black. Each of 
theƐĞŵĂǇďĞĚŝǀŝĚĞĚĨƵƌƚŚĞƌŝŶƚŽ ‘ƐƵďƚǇƉĞƐ ?, for instance the (again) white, red, yellow and 
black subtypes of black bonga (Dawa 1999, quoting Rinchen trungpé). Even though it may 
seem absurd, this categorisation is relevant in Tibetan pharmacology as different types may 
require different adjustments of dosage and detoxification processes when compounding 
medicine. Black bonga in particular requires attention as it is both poison and medicine 
(see Chapter 5), and highly toxic in crude form. Chapter 20 on the Powers of medicine in 
Gyüzhi ?ƐƐĞĐŽŶĚǀŽůƵŵĞƐƚĂƚĞƐƚŚĂƚǁŚŝƚĞ ?ǇĞůůŽǁĂŶĚƌĞĚbonga neutralise poison, and that 
the yellow and red varieties cure meat poisoning and poisoning by black bonga in particular 
(Clark 1995). In Dawa (1999), bongnak is identified as Aconitum sp. On top of the Tibetan 
intricacies, Kletter and Kriechbaum (2001) present the following caveat: 
Aconites display a wide variety that cannot be dealt with easily by conventional taxonomy. 
dŚƵƐ ? ƚŚĞǇ ĂƌĞ ĐŽŶƐŝĚĞƌĞĚ ƚŽ ďĞ Ă  ‘ĚŝĨĨŝĐƵůƚ ŐĞŶƵƐ ? ǁŚŽƐĞ ƚĂǆŽŶŽŵǇ ŚĂƐ ŶŽƚ ǇĞƚ ďĞĞŶ
conclusively studied, even regarding the thoroughly investigated Central European species. 
Therefore, it is impossible to give definite numbers of the aconite species occurring in a 
specific area. Of the some 300 species worldwide [Flora of China mentions about 400, of 
which 166 are endemic], more than 50 have been reported to occur within the areas where 
Tibetan medicine is practiced [here this refers only to the Himalayas and the Tibetan 
Autonomous Region]. (Kletter and Kriechbaum, p. 32) 
 
Up to now I have only considered a small selection of authoritative sources based mainly 
on the applied knowledge of amchi from Men-Tsee-Khang in Dharamsala and scientists 
collaborating with them. To answer how PADMA may have come to use Aconitum napellus, 




Table 1.1. Botanical names associated with bonga nakpo in six key publications on Tibetan materia medica. These 
works reflect national and regional influences. Seven different names are provided, the first two of which are synonyms 
(of the accepted name Aconitum lethale Griff., The Plant List 2013). 
author area of influence botanical identification of bong (nga) nak (po) 
Phuntsog 2006 Ladakh, India A. balfourii Stapf 
Lama et al. 2001 Dolpo, Nepal A. spicatum (Brühl) Stapf 
Jamphel et al. 2009 Bhutan A. laciniatum (Brühl) Stapf 
Gammerman and Semichov 
1963 
Soviet Union A. napellus L. 
Parfionovitch et al. 1992 Soviet Union A. ferox Wall., A. spicatum (Brühl) Stapf, A. 
balfourii Stapf 
Gawé Dorje 1995 Chamdo, Tibet 
(China) 
A. richardsonianum Lauener var. Crispulum W.T. 
Wang 
 
These sources at least reach some consensus around the notion that bongnak is one or 
several species of Aconitum. It is also clear now that PADMA could have found their species 
of aconite in Gammerman ?ƐĚŝĐƚŝŽŶĂƌǇ ?ǁŚŝĐŚǁĂƐŽŶĞŽĨƚŚĞĨĞw sources available at the 
time and which referred mainly to the Buddhist Republic of Buryatia. But a second look at 
WĂƌĨŝŽŶŽǀŝƚĐŚ ?ƐTibetan medical paintings (1992) 20 , which reproduces, translates and 
comments on a faithful 1920s facsimile of Sangyé 'ǇĂƚƐŽ ?ƐŝůůƵstrations  W originally created 
1687-1703  W indicates there is still more to it. How to make sense of all this? 
 
                                                     
20 In both the English version quoted here and the Russian edition (titled Atlas tibetskoj mediciny) published 
two years later, the scientific names were rendered by the Lithuanian pharmacologist and Tibetan materia 
medica expert Donatas Butkus, who passed away in Spring 2016. For Tibetan medical paintings (1992), Butkus 
ǁĂƐŽŶůǇŐŝǀĞŶƚǁŽǁĞĞŬƐ ?ƚŝŵĞƚŽĂĐĐŽŵƉůŝƐŚƚŚŝƐƚĂƐŬ ?ǁŚĞƌĞĂƐĨŽƌƚŚĞZƵƐƐŝĂŶƚƌĂŶƐůĂƚŝŽŶƚŚĞŶĂŵĞƐǁĞƌĞ





1.2 Sources of confusion, or evidence of plasticity? 
Glover (2010) surmises that the lack of descriptive detail in the Four Tantras may have 
inspired Sangyé Gyamtso to commission the medical paintings presented above, to settle 
conflicting identifications. This early collaboration between Tibetan doctors, 
pharmacologists and artists, plus the advice of Nepalese and Indian physicians, aimed to 
standardise medical substances across the Tibetan plateau and beyond, and subsequently 
became a template for several  W but certainly not all  W later works of illustrated materia 
medica (Hofer 2014a). Obviously, historical sources may disagree, as can their 
contemporary interpreters: practitioners from different places and backgrounds, but also 
philologists, historians, anthropologists and scientists.  
 
An American biologist named Mia Molvray (1988) put together a glossary on Tibetan 
medicinal plants, attempting to document regional variation in their identification and 
adding her own determinations of specimens obtained at Men-Tsee-Khang with the help 
of amchi Jigme Tsarong and Pasang Arya. In her short introduction, she summarises the 
main sources of what she teƌŵƐ ‘confusion ?: (1) local substitutions, (2) the vague nature of 
Tibetan descriptions and drawings, (3) regional variation in plant use (Chinese, Siberian, 
Mongolian, Indian), (4) misidentification by amchi, (5) different names for parts of the same 
plant, (6) inaccurate documentation (referring to earlier unprofessional specimen 
collectors), and (7) imprecise Tibetan spelling (several correct spellings, misprints). I would 
argue, however, that her negative valuation of variability is itself premised on a more 
fundamental confusion: the assumption that there is  W or at least should be  W a 
Figure 1.4. Two first rows of the third painting of the Supplementary materia medica section, illustrating Chapter 20, 
Volume II of the Blue beryl (Plate 31 in Parfionovitch 1992). The previous painting introduced three types of bonga (not 
mentioning ƚŚĞƌĞĚǀĂƌŝĞƚǇ ) ?ǁŚĞƌĞĂƐŚĞƌĞ ?a number of poisonous sub-ƐƉĞĐŝĞƐŽĨ ?ďůĂĐŬ ?ĂĐŽŶŝƚĞ ? (p. 77) are illustrated, 
ĂŵŽŶŐƚŚĞŵ ?goatsbane or blue aconite [ra-dug-ŐĂŵ ?Ěǌŝŵ-pa, Aconitum napellus] in its outer, inner and secret forms 
[all three identified as A. ferox, the secret one also as Allium microstemon Bge., with a question mark], wolfsbane 
[spyang-dug lugs-gcig, A. heterophyllum ? ?ĂŶĚďůĂĐŬĂĐŽŶŝƚĞ ?. 
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straightforward and ideally one-to-one correspondence between Tibetan and botanical 
names. 
 
Molvray further comments on one of the early works Bhagwan Dash (1976, Molvray 1988, 
p. 6) P  ‘he views the Tibetan plant names as translations or transliterations of the Indian 
ones  W an approach which is valid for his work but may not always be accurate for practical 
dŝďĞƚĂŶŵĞĚŝĐŝŶĞ ?, adding that he did not specify how he got to the Latin binomials. I met 
Dr Dash in person at his residence in New Delhi for an interview in 2014 (Audio recording 
71), and asked him exactly this question. He confirmed that in his view Ayurveda and 
Tibetan are one and the same tradition in two languages, originating in India; he uses the 
term Indo-Tibetan medicine to avoid what he denounces as parochialism. To find the 
corresponding botanical names for the Tibetan names he first back-translated them into 
Sanskrit, and then consulted modern Ayurvedic compendia such as Indian materia medica 
(Nadkarni 1955) and Indian medicinal plants (1994-1996). Later, in Dharamsala, 
professional translator Dr Gavin Kilty told me he had used the same strategy in his 
translation of Mirror of beryl (finished in 1703 by Sangyé Gyatso, translated in 2010) P ‘But 
no-one is to blame ŚĞƌĞ ? /ƚ ?ƐĂŶ ŝŵƉŽƐƐŝďůĞ ĨŝĞůĚ ? (Audio recording 82). Although he felt 
uneasy with this method, he saw no valid alternative at the time. In my opinion, this 
strategy relies on a particularly problematic set of assumptions: that a reliable Sanskrit 
translation exists (what about indigenous Tibetan plants and names?); that the referent of 
the historical plant name in both traditions has not changed over time (which has been 
described repeatedly in longitudinal studies on Chinese materia medica, see below); that 
the identities of Ayurvedic and Tibetan medicinal plants can be adequately represented by 
botanical names (which I question in this chapter); that the actual botanical identification 
of the Ayurvedic plant is correct; and that regional or local substitution (intentional or not) 
is irrelevant. Dash might rebuke me, arguing that the raised objections notwithstanding, 
identification turns out all right in many cases. In his Materia medica of Tibetan medicine 
(1994), he classifies the names of medical materials in three categories: pure Sanskrit forms, 
Tibetanised Sanskrit (considered the most ubiquitous), and pure Tibetan forms. 
dŚƌŽƵŐŚŽƵƚ ƚŚĞ ƚĞǆƚ ?ĞƋƵŝǀĂůĞŶƚƐ ĨƌŽŵ ƐĞǀĞƌĂů  ‘ĂƵƚŚĞŶƚŝĐ^ĂŶƐŬƌŝƚ ƚĞǆƚƐ ?ĂƌĞŐiven when 
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ĚĞĞŵĞĚ ƉŽƐƐŝďůĞ ? ǁŚĞƌĞĂƐ  ‘[f]orcibly and artificially coining and providing Sanskrit 
equivalents of the Tibetanised synonyms have ďĞĞŶƐĐƌƵƉƵůŽƵƐůǇĂǀŽŝĚĞĚ ? (ibid.: xviii). 
 
>Ğƚ ?ƐŚĂǀĞĂnother look at the four plants I am interested in. Tserngön and bongnak (and 
ƚŚĞŝƌĐŽŵŵŽŶƐǇŶŽŶǇŵƐ )ĂƌĞŶŽƚƌĞƉƌĞƐĞŶƚĞĚŝŶĂƐŚ ? ? ? ? ? ) ?,ŽǁĞǀĞƌ ? ‘U tpa la ? Wwhich 
is often equated with Meconopsis spp. (Dawa 1999, 2009)  W is translated here as Nymphaea 
spp.: water lilies. This may be an example of a Tibetanised Sanskrit name for a plant that 
was substituted and subsequently came to refer to the substitute exclusively, at least on 
the Tibetan plateau (Boesi 2007). Dash (1994) lists  ‘ha ri ta ki ? (from Sanskrit ŚĂƌţƚĂŬţ) as a 
synonym for  ‘a ru ra ?, which is identified as Terminalia chebula. Since it is so commonly 
used (and traded) for both Ayurvedic and Tibetan preparations, it could represent the least 
problematic instance of translation of all, a (nearly) perfect match. Still, one has to 
acknowledge that the distinction of medical varieties (see Figure 2.2), the attribution of 
pharmacological properties (including taste), indications and formulation do vary 
considerably, and that substitutes are mentioned in the literature (but seldom used). This 
global alignment of the results of the varied identification practices in Ayurveda, Tibetan 
medicine, and modern botany, resulting in equivalence, is rare. It is also limited to the 
species level only: at other ranks (family, subspecies, etc.) it utterly fails. Fourthly, by 
looking at ruta, we are quickly reminded of the pitfalls of universalism. Dash (1994) aligns 
it with Saussurea lappa (as does Dawa 2009) via the Sanskrit synonym kustha. But ruta has 
two types, white and black:  
The former grows in Kham (Eastern province of Tibet), and is used against disturbed fever 
and inflammation, while the latter is found as well as cultivated in India, Ladakh, and on high-
altitude places near Mt. Kailash; it is fragrant, used primarily in incense and against high rLung 
disorder. (according to the Crystal Garland, cited in Dawa 2009, p. 129) 
The white type is ignored and remains unidentified by the last two authors21, even though 
Dawa mentions its existence explicitly. Why? The distinction is important, as each type not 
only has a different distribution (and thus availability) but also dissimilar indications. Why 
does Dawa not acknowledge that ruta actually means several things, covers several species 
                                                     
21 It is however identified and illustrated in Gawé Dorjé (1995) as Vladimiri souliei (Franch) Ling. 
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at least? Leafing through both the works of Dash and Dawa provides a clue: under each 
plant entry there is only room for one drawing, illustrating one single  W never several  W 
ƐƉĞĐŝĞƐ ? /ƚ ƌĞĨůĞĐƚƐ ƚŚĞ ŵŽĚĞƌŶ tĞƐƚĞƌŶ ƉŚĂƌŵĂĐŽůŽŐŝĐĂů ĚŝĐƚƵŵ ŽĨ  ‘ŽŶĞ ŶĂŵĞ ? ŽŶĞ
ƐƵďƐƚĂŶĐĞ ? ƚŚĂƚ ƚŚĞƐĞ ƐĐŚŽůĂƌ-physicians (and many others in their footsteps) have 
internalised, and which is also increasingly applied to Chinese materia medica for reasons 
of patient safety (Bensky et al. 2004). Referring to the most recent edition of the 
Pharmacopoeia of the PeŽƉůĞ ?ƐZĞƉƵďůŝĐŽĨŚŝŶĂ ?2015), one can fairly easily distinguish 
ďĞƚǁĞĞŶƚŚĞ ‘ƐƚĂŶĚĂƌĚƐƉĞĐŝĞƐ ?ŽĨƚraditional Chinese medicine, which are included  W there 
can be more than one for the same drug, these are then official substitutes  W and non-
standard species which are termed customary herbs and often considered as adulterants. 
A fundamental difference, however, in the case of Sowa Rigpa, is the complete absence of 
an official, legally binding Tibetan pharmacopoeia. In spite of several more widely 
disseminated and comprehensive attempts at standardisation (Dawa 1999, 2009; but 
notably Gawé Dorjé 1995), recent literature within but even more so from outside India 
and China shows extensive variability in the identification of Tibetan herbs. 
 
The problems relating to the identification of Tibetan medicinal plants have not escaped 
the attention of Sowa Rigpa scholars and practitioners altogether. Gawé Dorjé for instance 
is keenly aware of issues arising out of the translation of Tibetan into Chinese terms. Not 
only are medical theories conflated, the proper identity of plants may also get lost in 
translation, as he has documented with many examples (Dorje and Gonkatsang 2009). In 
his view, borrowing terms from a foreign language ĂŶĚ ‘rampant copy[ing] from right and 
leĨƚ ? (ibid., p. 401) will inevitably lead to corruption over time. On the other hand, he also 
acknowledges that accurate translation is necessary in order to obtain standard raw 
materials through international trade. As a solution, he calls for a rigorous standardisation 
of translations, officially approved and enforced, and for the incorporation of modern 
biology into the curriculum of students of Tibetan medicine. Barry Clark (2000), a botanist 
and Tibetan medicine practitioner who studied for years under perhaps the most senior 
amchi in exile, Yeshi Dhönden, for instance points out the possibility of double substitution: 
a substitute for an initial substitute of a scarce herb, keeping the same name, eventually 
erasing the identity of what was originally and subsequently substituted. He explains that 
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 ‘the main reason the Tibetans attribute the same name to two completely different plant 
substances is that they consider them to have the same ƚĂƐƚĞ ?ƉŽƚĞŶĐŝĞƐĂŶĚƉƌŽƉĞƌƚŝĞƐ ? 
(Clark 2000, Ɖ ? ? ? ) ?/ŶƚĞƌĞƐƚŝŶŐůǇ ?ůĂƌŬĂůƐŽŵĞŶƚŝŽŶƐ ‘ĨůŽƌĂŽĨƚŚĞ ŐŽĚƌĞĂůŵƐ ?ĂƐǁĞůůĂƐ 
celestial animalƐ ?/ŶƚŚŝƐƌĞƐƉĞĐƚ ?ŚĞǁŽŶĚĞƌƐ ‘[h]ow can one identify the pools of urine left 
by the legendary snow frog, except from its effĞĐƚĂƐƚŚĞƐƵƉƌĞŵĞĂƉŚƌŽĚŝƐŝĂĐ ? ?(ibid., p. 
57). In this instance, the gap between Tibetan and modern scientific ontologies seems 
insurmountable. The theory and practice of substitution in Tibetan pharmacy indeed 
fundamentally challenges the utility of botanical classification for medical purposes, as well 
the concomitant reduction of efficacy to lists of active compounds (as noted by Schwabl et 
al. 2016 in their recent conference poster). The Russian philologist Dashiyev (1999) refers 
to the centuries-old Buryat branch of Sowa Rigpa, which has its own dictionaries of 
synonyms and formularies alongside the classical Tibetan and Mongolian texts. Dashiyev 
emphasises the fundamental importance of empirical innovation and the living 
transmission of knowledge on local substitute plants in Buryat manuscript formularies, 
estimating that over eighty percent of their ingredients has been replaced, creating 
amalgams of personal experience and literary classics. Even though the composition 
deviates to such a great extent, the names of the raw materials and of the formulas have 
remained unaltered. ,Ğ ǁĂƌŶƐ ƵƐ ƚŚĂƚ ŝŶ ůŝŐŚƚ ŽĨ  ‘this discrepancy between theory and 
ƉƌĂĐƚŝĐĞ  ? Q ? ƚƌĂŶƐůĂƚŝŽŶƐ ŽĨ ĂŶŽŶǇŵŽƵƐ ŵĞĚŝĐĂů ƚĞǆƚƐ ŽƵƚƐŝĚĞ ƚŚĞ ĐŽŶƚĞǆƚ ŽĨ ŝƚƐ
contemporary sources [meaning specific reference to its location in space and time] would 
be a waƐƚĞŽĨƚŝŵĞ ?ŐĞŶĞƌĂůůǇƐƉĞĂŬŝŶŐ ? (Dashiyev 1999, p. 4).  
 
Despite these insights, each of the three more critical authors included in the previous 
paragraph is directly involved in publications where botanical species names (mostly one, 
sometimes a few, rarely none) are generously provided as correct translations of Tibetan 
materia medica, even if cautionary statements on identifications may or may not be 
included in the introductions of these works. A historical, text-critical approach to the 
Tibetan medicinal plant descriptions that fully takes into account the differing opinions of 
various authors  W and more broadly of the two main medieval medical schools, the Jangluk 
and Zurluk  W is so far lacking in both modern Tibetan and Western scholarship on Sowa 
Rigpa (Czaja 2013). This equally counts for the distinctive and not rarely contradictory 
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knowledge traditions of clinical treatises, botanical compendia (trungpé) and pharmacy 
(menjor) books. Tibetan medicine should be approached as a multi-layered, diverse and 
ĚǇŶĂŵŝĐ ŬŶŽǁůĞĚŐĞ  ‘ƐǇƐƚĞŵ ? ǁŚŝĐŚ ŵĂǇ ŶŽƚalways be internally coherent. This is 
challenging for Western (ethno)botanists who strive to taxonomically identify plants and 
their uses, particularly since they customarily do not have the skill and/or interest to do 
textual comparative work in Tibetan. As a consequence, these scientists frequently rely on 
modern Tibetan botanical works that provide Latin binomials, even if these are exclusively 
based on narrow interpretations of a limited selection of canonical Tibetan materia medica 
texts. But as Czaja ŶŽƚĞƐ ? ‘a [Tibetan] doctor would hardly consult a botanical treatise for a 
remedy to cure ĂƐƉĞĐŝĨŝĐĚŝƐĞĂƐĞ ? (p. 111). Scholars in the meanwhile have realised the 
ŶĞĞĚƚŽ ‘reveal the composite, variegated and dynamic nature of Tibetan medical traditions, 
and to move away from obstinate (neo)traditionalist perspectives shaped by essentialist 
religious (Buddhist) and polished monolithic, syncretistic views of Tibetan medicine, 
standpoints that evolved in Tibetan literatƵƌĞĂĨƚĞƌƚŚĞĞƐƚĂďůŝƐŚŵĞŶƚŽĨ ‘ŽƌƚŚŽĚŽǆǇ ? in the 
17th-18th ĐĞŶƚ ?ƵƌŝĞƐ ?  ? (Blezer et al. 2007, p. 429). Regretably, this aim has not been 
fulfilled so far when considering plant identification and naming. 
 
Although the deliberate substitution of medical substances (tsapmen) is a widespread, 
extensively documented and historically discussed practice, it is often ignored when it 
comes to the identification of Tibetan medicinal plants. As we have seen, regional 
substitutions have been documented ĂƐ ‘ŐĞŽŐƌĂƉŚŝĐĂůďŝĂƐ ? and as a source of confusion 
(Molvray 1988). On the contrary, practitioners not linked directly to authoritative 
institutions in Tibet and their counterparts in exile are eager to substantiate their claim to 
authenticity by emphasising the diverse origins and adaptability of Sowa Rigpa to local 
circumstances. Alexander Arbuzov, a medical doctor who practices Tibetan medicine in St. 
Petersburg, for instance reiterates in his ĂƌƚŝĐůĞŽŶƐƵďƐƚŝƚƵƚŝŽŶƐƚŚĂƚ ‘it would be incorrect 
ƚŽƐĂǇƚŚĂƚ ? “Tibetan medicine is only for TibetĂŶƐ ?Žƌ “only plants collected in Tibet or in 
the Himalayas are suitable fŽƌƉƌĞƉĂƌŝŶŐdŝďĞƚĂŶŵĞĚŝĐŝŶĞƐ ? ?(Arbuzov 2010, p. 14). Across 
the Himalayan range, ethnobotanical and ethnoecological studies have indeed shattered 
the illusion of one classic literary body implying one uniform, centralised practice (Ghimire 
et al. 2004,  Salick et al. 2006). These studies document the plurality of plant use amongst 
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practitioners, as well as heterogeneity in environmental knowledge amongst different 
groups  W including lay Tibetan villagers (Byg et al. 2010)  W in relation to institutional and 
socioeconomic backgrounds.  
 
More recent scholarship has further uncovered the nature and extent of substitution 
practices, especially in the case of rare, expensive, or animal-based ingredients (Blaikie 
2015, Sabernig 2011). Sabernig (2011) focuses on a selection of frequently substituted, rare 
ingredients and notes that they are named in a surprisingly large percentage of recipes in 
modern formulary books and written on packages of products for sale. Considering the 
substantial amounts needed, she rightly questions the feasibility of financing and even 
accessing these materials. Even ƚŚŽƵŐŚ ^ĂďĞƌŶŝŐ ĐŽŶƐŝĚĞƌƐ ƚŚĂƚ  ‘it is a legitimate 
philological question to ask what gur gum  “ƌĞĂůůǇ ? (or, originally) means in the Rgyud bzhi ? 
(ibid., p. 88), in medical practice it may refer to at least four different species, as she 
documents. /Ŷ ƌĞĂůŝƚǇ ? ƚŚĞ ĂďŽǀĞŵĞŶƚŝŽŶĞĚ  ‘ŽƌŝŐŝŶĂů ? substances are (nearly) always 
substituted, only used in tiny amounts, or omitted altogether. Again according to Sabernig, 
the key to understanding substitution practices  W and by extension the identity of Tibetan 
medicinal plants  W is unveiling the secret (and multiple) meanings of materia medica names, 
which are seldom explained. Anthropologist Calum Blaikie (2015), in his analysis of the 
transition of the classical formulation Samphel-norbu (Samnor ŝŶ ƐŚŽƌƚ ? ŵĞĂŶŝŶŐ  ‘ǁŝƐŚ-
ĨƵůĨŝůůŝŶŐũĞǁĞů ? )ĨƌŽŵĞǆĐůƵƐŝǀŝƚǇƚŽƵďŝƋƵŝƚǇŝŶ,ŝŵĂůĂǇĂŶ/ŶĚŝĂ ?ƚĂŬĞƐƚŚŝƐĂƌŐƵŵĞŶƚŽŶĞďŝŐ
step further. He demonstrates the inherent multiplicity of this medicine, resulting in 
innumerable samnor variants or avatars. In doing so, Blaikie convincingly argues against the 
view that these multipůĞǀĞƌƐŝŽŶƐŽĨ ‘ƚŚĞƐĂŵĞ ?ĚƌƵŐ ‘represent the corruption of classical 
purity or inauthentic aƉƉƌŽǆŝŵĂƚŝŽŶƐŽĨĂƐƚĂƚŝĐŝĚĞĂů ? (Blaikie 2015, p. 12). On the contrary, 
invoking the dynamism of ^ĐŚĞŝĚ ?Ɛ(2007)  ‘ĐƵƌƌĞŶƚƐŽĨƚƌĂĚŝƚŝŽŶ ? ?ĐůĂƐƐŝĐĂůĨŽƌŵƵůĂƐĐĂŶŽŶůǇ
be instantiated as medicines through contemporary practices and thus as valid but 
contingent entities. I fully agree with this explicit critique of textual dogmatism, and 
contend that an analogous argument ought to be put forward for the components of 
formulations. These ingredients are equally laden with false connotations of stability and 
consistency across space and time. The preoccupation with weeding out sources of 
confusion (and diversity!) mirrors and has its roots in the emergence of modern pharmacy 
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and pharmacognosy, and particularly in the establishment of national pharmacopoeias  W 
based on earlier herbals  W within Europe and beyond (see for instance Griffin 2004 for the 
UK). 
 
Even though the need to create a collection of botanical voucher specimens is indicated in 
ethnobotany manuals (Alexiades 1996, Martin 2004), it is nearly always lacking in the 
literature on Tibetan medicinal plants. Notable exceptions that at least mention institutions 
where specimens may have been deposited are Kletter and Kriechbaum (2001), Lama et al. 
(2001) and Salick et al. (2006). Chan et al. (2012) have quite recently noted a similar lack of 
good practice in publications on Chinese herbal medicines, making it impossible to validate 
ŝĚĞŶƚŝĨŝĐĂƚŝŽŶƐ ?ǀŝĚĞŶƚůǇ ? ‘[t]he use of a Latin scientific name does not always imply correct 
botanical identification sinĐĞƐƵĐŚŶĂŵĞƐĐĂŶďĞŵŝƐĂƉƉůŝĞĚ ? (ibid., p. 471). Despite these 
 ‘ŐŽŽĚƉƌĂĐƚŝĐĞƐ ?there is still considerable disagreement between taxonomists on species 
delineation, with problematic implications for ecology and biodiversity conservation, and 
for legislations based on these fields (Isaac et al. 2004). It is recognised that evolution by 
natural selection spawns a spatiotemporal continuum of variation in/across organisms that 
is not always suitably captured in separate taxonomical boxes. The dynamics of evolution 
render taxonomy inherently unstable. The number of described species also keeps growing 
ƌĂƉŝĚůǇǁŚŝĐŚŝƐƌĞůĂƚĞĚƚŽ  ‘ƚĂǆŽŶŽŵŝĐŝŶĨůĂƚŝŽŶ ? ?ĞƐƉ ĐŝĂůůǇ ŝŶĐŚĂƌŝƐŵĂƚŝĐŐƌŽƵƉƐƐƵĐŚĂƐ
primates),  ‘where known subspecies are raised to species as a result in a change in species 
concept, ƌĂƚŚĞƌƚŚĂŶƚŽŶĞǁĚŝƐĐŽǀĞƌŝĞƐ ? ?/ƐĂĂĐĞƚĂů ? ? ? ? ? ?Ɖ ? ? ? ? ) ?dŚŝƐƚĞŶĚĞŶĐǇƚŽ ‘ƐƉůŝƚ ?
ƚĂǆĂŝŶƚŽŵŽƌĞŶĂƌƌŽǁůǇĚĞĨŝŶĞĚƐƉĞĐŝĞƐ ?ĂƐŽƉƉŽƐĞĚƚŽ ‘ůƵŵƉŝŶŐ ?ƉƌĞǀŝŽƵƐƚĂǆĂƚŽŐĞƚŚĞƌ
under a more broadly conceived name is supported by many researchers nowadays. The 
debate between splitters and lumpers, however, first became a serious area of contention 
in the early nineteenth century, when the massive influx of specimens from far-flung 
colonies challenged the Eurocentric classification system as well its professional institutions 
both qualitatively and quantitatively (Bonneuil 2002, Endersby 2009). Whereas in the 
eighteenth century botany was seen as a highly logical and abstract philosophical pursuit 
that verged towards comprehensiveness, the many disagreements between systematic 
botanists were now considered an index of low scientific standard compared to 
ŵĂƚŚĞŵĂƚŝĐƐĂŶĚƉŚǇƐŝĐƐ ?/ŶĂŶĂƚƚĞŵƉƚƚŽƌĞƐƚŽƌĞƚŚŝƐĨŝĞůĚĂƐ ‘ŶĂƚƵƌĂůƉŚŝůŽƐŽƉŚǇ ?ĂŶĚŶŽƚ
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a merely descripƚŝǀĞ ‘ŶĂƚƵƌĂůŚŝƐƚŽƌǇ ? ?:ŽƐĞƉŚĂůƚŽŶ,ŽŽŬĞƌ ? ? ? ? ?-1911) followed by other 
metropolitan professional botanists based at burgeoning herbaria started a crusade against 
ƐƉůŝƚƚĞƌƐŽƌ  ‘ƐƉĞĐŝĞƐŵŽŶŐĞƌƐ ? ?ŵŽƐƚůǇƌĞĨĞƌƌŝŶŐƚŽŶ Ŷ-elite, domestic field botanists and 
collectors. Hooker created the order needed to revalorise their profession and for the 
British empire to prosper by propelling Kew Gardens as the imperial metrological centre of 
Ă  ‘ǁŽƌůĚ-ďŽƚĂŶǇ ? ? ƐƚĂďŝůŝƐŝŶŐ ƚĂǆŽŶŽŵŝĐĂů ŬŶŽǁůĞĚŐĞ ƚŚƌŽƵŐŚ ƚŚĞ ƉƵďůŝĐĂƚŝŽŶ of colonial 
floras and the Index Kewensis (Brockway 1979). Nowadays, with more taxonomists in more 
countries, plus the internet revolution, nomenclatural change is much faster and the 
illusion of stability more difficult to sustain despite international collaboration efforts. 
Taxonomic determinations are only ever provisional in this sense, which is an eternal 
frustration to non-ƚĂǆŽŶŽŵŝƐƚƐ ? ^ƵƌƉƌŝƐŝŶŐůǇ ? ĂƌǁŝŶ ?Ɛ  ?ƌ )ĞǀŽůƵƚŝŽŶĂƌǇ ŝĚĞĂƐ ŚĂĚ ůŝƚƚůĞ
impact on Victorian taxonomy at the time. Hooker was one of the first to publicly endorse 
ŚŝƐĨƌŝĞŶĚ ?ƐƚŚĞŽƌǇĞǀĞŶƚŚŽƵŐŚĐŽŶƐƚĂŶƚůǇĐŚĂŶŐŝŶŐƐƉĞĐŝĞƐĂƌĞĂŶŝŐŚƚŵĂƌĞƚŽƚĂǆŽŶŽŵŝƐƚƐ ?
His support was most likely because evolutionism provided biology with a scientific law, 
but with no immediate practical repercussions for every-day taxonomic work. In this 
manner, Darwinism became acceptable precisely because of its conservatism compared to 
earlier rejected theories. In the case of botany as well,  ‘the way we classify is ultimately a 
product of why ǁĞĐůĂƐƐŝĨǇ ? (Endersby 2009, p. 1496). 
 
1.3 Idealised identification, naming and classification practices 
The practices of identification, naming and classification in relation to Tibetan medicine 
have only been studied intensively by three scholars, as part of their doctoral research: 
Alessandro Boesi and Francesca Cardi (both in 2004 and at the same university), and Denise 
Glover (2005). Boesi and Cardi approach the topic from an ethnobiological and 
ethnomedical angle respectively, while Glover pays more detailed attention to the wider 
anthropological context as well as to sociocultural influences such as the role of ethnic and 
linguistic identity. Based on their extensive fieldwork with traditional doctors and laymen 
in several Tibetan cultural areas of China, India, and Nepal, Boesi and Cardi (2006) have 
summarised the process of identification, and the features that are generally considered. 
They distinguish two systems of identification that may take place in succession: 
 ‘ƉƌŽƚŽƚǇƉŝĐĂů ? ĂŶĚ  ‘ĐŽŵƉŽŶĞŶƚŝĂů-ĐŽŶĐĞƉƚƵĂů ?  ?ƐĞĞ ŽĞƐŝ  ? ?05 for examples). The first-
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mentioned refers to general similarity to an ideal model, while the second relies on more 
detailed evaluation of specific features in order to recognise the plant. In case of Tibetan 
medicine, the use of prototypes is rarely sufficient to complete the determination. Relying 
on his/her education and personal experience as well as explicitly referring to Tibetan 
pharmacological treatises, the physician takes into account the morphology (with 
parameters differering from plant to plant), taste, scent, and habitat (e.g. sun-exposed 
versus shaded mountain flank) of materia medica. These authors further note that it is 
impossible to identify plants a priori employing classical texts. The descriptions and 
illustrations are subjectively interpreted; true expertise only comes after years of guided 
practice and oral knowledge transmission.  
 
Boesi (2005-2006, 2007) has analysed Tibetan plant nomenclature in considerable detail. 
He finds that the naming criteria are fundamentally the same as iŶŽƚŚĞƌ ‘ĨŽůŬ ?Žƌ ‘ƚƌĂĚŝƚŝŽŶĂů ? 
classifications, and that it reflects our universal cognitive capabilities as well as local 
environmental influences and sociotechnical practices. So even though he extensively 
documents regional and local variability of names (and their referents) and takes into 
account differences in literacy and (medical) education, Boesi also maintains that the 
underlying principles of categorisation and higher classificatory ranks are essentially 
homogenous across Tibetan populations in different countries. Institutionally trained 
practitioners frequently make use of the standard names from works such as the Crystal 
garland while independent, lineage-based healers draw more from the popular register, 
the names of which are often also represented in historical texts as synonyms (Boesi 2007). 
In line with Conklin (1962) ĂŶĚƌĞŶƚĞƌůŝŶ ?Ɛ(1992, Berlin et al. 1973) ground-breaking 
ethnoscientific (and naturalist, universalist) classification studies22, plant names can be 
broken down into two elements: basic names (single or compound) and attributes 
(differentiates plants sharing a basic name). A name consisting of only a basic element is 
                                                     
22 Ethnobotany has been preoccupied with issues of plant identification and translation since its beginnings, 
ƚŽďĞĂďůĞƚŽĞƐƚĂďůŝƐŚŝƚƐďĂƐŝĐƵŶŝƚƐŽĨĂŶĂůǇƐŝƐ ?/ŶƚŚĞŵĂƉƉŝŶŐŽĨ ‘ůŽĐĂů ?Žƌ ‘ĨŽůŬ ?ĐĂƚĞŐŽƌŝĞƐŽŶƚŽƚĂǆŽŶŽŵŝĐ
science, two opposing stances have been advocated. Berlin and his followers emphasise cross-cultural 
similarities in the cognitive-linguistic structuring of natural kinds, whereas the relativist stance spearheaded 
by Roy Ellen (e.g. Ellen 2006b) foregrounds historical and sociocultural variation and embeddedness. Recently, 
Ellen reiterated tŚĂƚƚŚĞĐŽŶƐƚƌƵĐƚŝŽŶŽĨǀĞƌŶĂĐƵůĂƌĐůĂƐƐŝĨŝĐĂƚŝŽŶƐďǇĞƚŚŶŽďŽƚĂŶŝƐƚƐ ‘ĚŽŶŽƚĐŽŶĨŽƌŵƚŽĂŶǇ
pseudo->ŝŶŶĞĂŶůŽĐĂůŽŶƚŽůŽŐǇ ? ?dŚĞǇĂƌĞƌĂƚŚĞƌ ‘ƐŝŵƉůŝĨŝĞĚƌĞƉ ƐĞŶƚĂƚŝŽŶƐĚƌĂǁŝŶŐŽŶƐĞůĞĐƚĞĚĨĞĂƚƵƌĞƐŽĨ
plants put together in a particular scientific (etic) frĂŵĞǁŽƌŬ ?(Ellen 2016, p. 15). 
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called a primary name, a basic name plus an attribute is a secondary name. Taking an 
etymological approach, Tibetans devise basic names grounded on a small series of 
morphological, biological and ecological criteria, but also on metaphors, plant usefulness, 
and derivation from other languages, particularly Sanskrit and Mandarin Chinese. 
Attributes are equally based on plant features (often flower colour, plant size and gender, 
growing area), metaphor, or related to plant uses. Tserngön for instance is explained by 
Boesi (2005, 2007) as a compound basic name derived from morphological characteristics, 
namely the prickles that cover stems, leaves, and fruit pods and the blue colour of the 
flower petals. 
 
Boesi (2005, 2007) repeatedly ŽƉƉŽƐĞƐ  ‘ŶŽŶ-ŵŽĚĞƌŶ ?  ‘ƚƌĂĚŝƚŝŽŶĂů ? societies and modern 
science. The latter aims to classify each plant as a separate object within the plant kingdom, 
whereas the former is built to manage daily people-plant relationships in multiple contexts. 
He adds to this by noting that his informants did not show any interest in elucidating their 
system in its entirety. Boesi (2005-2006) reports a discrepancy between the more elaborate 
textual classifications (of ten or thirteen main groups of substances, see Glover 2005 and 
2010 for details), and the actual categories that are commonly employed by both 
practitioners and lay Tibetans in the field. On this practical level, only four or five forms are 
ƌĞĐŽŐŶŝƐĞĚƵŶĚĞƌ ‘ƉůĂŶƚƐ ?, which is a covert category, unnamed but implied: flowers and 
grasses (métok and tsa, also grouped together under tsa), woody plants (shingdong), 
woody vines thrishing), and mushrooms (shamo). A range of other hierarchical levels is 
further distinguished, including types (rik), varieties (subtypes) and sets (Boesi 2005, 2005-
2006). Lama et al. (2001, p. 10), as part of their applied ethnobotany project at Dolpo 
(Northwest Nepal), report a slightly different amchi ďŽƚĂŶŝĐĂů ĐůĂƐƐŝĨŝĐĂƚŝŽŶ P Ă  ‘ƉůĂŶƚ
ŬŝŶŐĚŽŵ ? is explicitly named and divided into two main lifeform ranks (herbaceous and 
woody plants), with further subdivisions equally present. This already indicates that it may 





On that note, Glover (2010)  W based on interviews with Tibetan doctors and pile sorting 
exercises, in Gyelthang (Kham, Western Tibet)  W further stresses the complexity and 
multiplicity of materia medica classifications among texts and among practitioners, as well 
as some remarkable hybridisation with modern (biological) science in contemporary works. 
These changes include a formal designation for the Linnean plant kingdom as well as the 
introduction of an overarching tripartite plant/animal/mineral structure, often by the use 
of neologisms. Efficacy on the other hand is downplayed as an organising principle. In her 
dissertation (Glover 2005), she underlines the fact that categorisation is equally a product 
of long-term historical dynamics and not only of recent (modern) aberrations, criticising 
the privileging of oral knowledge by ethnobiologists over written records. As has long been 
noted by Zimmermann, in European classical (meĚŝĞǀĂů )ƚĞǆƚƐƚŽŽ ‘[e]very medicament was 
covered in adjectives, and it came as no surprise to find in Ayurveda a luxuriance of 
synonyms, a mixture of wordy empiricism and phantasmagoria, an omnipresent dialectic 
ďĞƚǁĞĞŶ ĐŽŶƚƌĂƌǇ ƋƵĂůŝƚŝĞƐ ? (Zimmermann 1988, p. 198). In Ayurveda this is not mere 
verbiage however as the literary composition of ancient Sanskrit texts mirrors the very 
nature of Vedic reasoning, where knowledge transmission proceeded through the 
recitation of metred word series. In this sense, he argues that the Greco-Latin objectivist 
and argumentative logic that created disciplines such as physio-logy, zoo-logy and botany 
ŝƐŶŽƚĐŽŵƉĂƌĂďůĞƚŽƚŚĞĞŶĚůĞƐƐƵƐĞŽĨ ‘ŐĂƌůĂŶĚƐŽĨŶĂŵĞƐ ? ?ŶĈŵĂŵĈůĂ), where each name 
is a description that adds knowledge and upon which therapeutic tastes and qualities were 
grafted by means of geographical, agricultural and cooking metaphors. This is also largely 
applicable to Sowa Rigpa, where students until this day memorise large tracts of the Four 
Tantras as well as commentaries that include long lists of plants and medicines.  
 
1.4 Translation in medical and pharmaceutical practice 
Here, I introduce ethnographic vignettes to show how the idealised identification and 
naming practices summarised in the last section came into play during my fieldwork in 





1.4.1 In Men-Tsee-Khang 
During my fieldwork in Dharamsala in Spring and Summer 2014 I spent most of my time at 
Men-Tsee-Khang talking to amchi, in between teaching classes of botany and English to 
staff and students as a volunteer. After a while I realised that doctors in each department 
 W be it the Pharmacy, the Materia Medica department, or a branch clinic  W have cultivated 
a different knowledge of plants in relation to their day-to-day job.  
 
Sonam Wangmo (tenth batch Men-Tsee-Khang graduate) has over fifteen years of clinical 
experience, and on a normal day dozens of patients will come to cubicle C3 in the Gangkyi 
clinic for a consultation. In between patients, I asked her about plants. Like all other Men-
Tsee-Khang medical students, she has memorised large tracts of the Four Tantras. She 
referred me to chapters 19 to 21 of the second volume on the taste, efficacy and 
compounding of medical substances. Furthermore, in the fourth year of their education, 
students also have to learn by heart a 100-page booklet composed by Penpa Tsering 
(formerly lead pharmacist, now running his own private production unit in Dharamsala) 
that enumerates ninety-five formulations  W not specifying ingredients  W together with their 
potency, benefits (phenyön) and mode of administration. In the fifth year, a 35-page text 
containing a list of plant names and types is also memorised separately (originally compiled 
by Khyenrab Norbu, personal physician of the thirteenth Dalai Lama). On a more practical 
level, all students  W except those in their final, fifth year  W take part in a yearly medical 
excursion of about twenty days in the mountains near Manali during Monsoon (near Mahri, 
Rohtang Pass, Himachal Pradesh), where they collect and learn to recognise more than a 
hundred medicinal plants, culminating in an exam. At the college, students are also brought 
into contact with plants: through photographs on projected slides, with samples in dried 
and processed form, and by collecting small amounts of live plants growing in the vicinity 
of Dharamsala. To obtain her menrampa degree six years ago, the highest title formally 
awarded by the Institute through examination and only after ten years of clinical practice, 
Sonam had to thoroughly revise materia medica names, relying on books available in Men-
Tsee-<ŚĂŶŐ ?Ɛ ůŝďƌĂƌǇ ? EŽŶĞƚŚĞůĞƐƐ ? ƐŚĞ ĂĚŵŝƚƚĞĚ ƚŚĂƚ ŝĨ ǇŽƵ ĚŽŶ ?ƚ ƵƐĞ Žƌ ƌĞƉĞĂƚ ƚŚĞƐĞ
names regularly, after two years you almost forget all of them again. I was curious to know 
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whether during consultations, when prescribing medicines to patients, amchi think about 
plants and other medicinal ingredients or not.  
Ingredients not. Because we have a lot of medicines, the inŐƌĞĚŝĞŶƚƐǁĞĚŽŶ ?ƚƌĞŵĞŵďĞƌ ?
But hot and cold we separate, we have to. Which medicine is hot in potency and which is 
cold, according to the constitution and nature of the patient. If they have inflammation, then 
ĚŽŶ ?ƚŐŝǀĞǀĞƌǇŚŽƚŵĞĚŝĐŝŶĞƐĨŽƌƚŚĞƚŝŵĞďeing. If it [the disorder] is because of cold as well 
as inflammation, then for a while we can give hot medicine, and then cold medicine. First of 
all, we think which medicine is suitable for the patient. It is important to know the ingredients 
inside [the pills], but we forget. (Audio recording 77) 
I quickly realised the absurdity of my question. Men-Tsee-Khang produces more than 170 
formulations, which are then distributed to the branch clinics. Each of these usually 
contains five to thirty-five components or more (see for example Tsarong 1986); even 
expert pharmacologists have to refer to written sources when compounding. In clinical 
practice, it is the formulas that spring to mind. Sonam had no difficulty at all in listing 
medicines (together with their uses) that mention the plants I am interested in as part of 
their name, indicating they are the principal ingredient: Aru-7 (good for the spleen), Aru-
10 (for kidney inflammation and kidney function), Aru-18 (lower back pain and lumbar 
spine problems), etc. For ruta she quickly replied with Ruta-6 (very good for colitis and 
stomach problems, cramps, helps indigestion) and Ruta-13 (against H. Pylori in the stomach, 
as well as indigestion). However, tserngön and bongnak are not directly represented in any 
formula name even though at least the first-mentioned is a relatively common ingredient, 
making it impossible for her even to name with certainty a single pill containing this plant 
without referring to texts. 
 
In the Pharmaceutical Department, practitioners and pharmacy workers come into close 
contact with the crude (mostly dried) materials on a daily basis, especially during the 
cleaning and compounding processes. When the season is right, they also go on plant 
collection trips. Pharmacists equally visit markets, and get samples from suppliers before 
ordering a new batch. In the store-room strong and large bags made of jute or military 
canvass are neatly stacked on racks and sealed with cord, each carrying a laminated paper 
tag with the (only one) Tibetan name of the material, date of acquisition, and its weight (on 
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average 10-40 kg). The identity and quality of each incoming ingredient is checked by the 
 ‘Store In-Charge ?, who is responsible for the accounting and daily transactions in and out 
of the storage. He had first joined the pharmacy as a temporary worker on 1st December 
1989, having come to Men-Tsee-Khang because he was interested in becoming a doctor. 
But the next entrance exam was two years later, and by that time he was already employed 
as permanent staff. Together with the lead pharmacologist23, Dr D. Penpa, he checks the 
identity and quality of all incoming ingredients. This is according to their shared experience 
and based on visual, gustatory and olfactory cues. They do not usually refer to any books. 
If accepted, a sample is sent to the quality control lab (see Chapter 4), where the 
established link between the Tibetan name and the material is normally not disputed. In 
the course of the many conversations I had with Penpa at his office, it became clear that 
he never uses Latin scientific names to refer to plants or any other organism, even though 
they could be looked up in publications on his bookshelf. To communicate with suppliers 
in India, he uses Hindi names such as hara for arura, and kuth for ruta. Within the pharmacy, 
Tibetan names are used. Different Tibetan synonyms for the same plant may be used 
depending on the context. When I first asked him about bonga nakpo, he recognised the 
ŶĂŵĞďƵƚĂĚĚĞĚƚŚĂƚ ‘here we call it tsenduk ? (Field notebook VII, 18 March 2014), which 
translates as  ‘ǀŝŽůĞŶƚƐƉŝƌŝƚƉŽŝƐŽŶ ?. Nonetheless, the name menchen  ? ‘ŐƌĞĂƚŵĞĚŝĐŝŶĞ ? )ŝƐ
more current amongst pharmacy staff, perhaps not to be constantly reminded of its toxicity 
when handling the blackish roots and grinding them into powder.  
 
Dr Tsultrim, the deputy head of the Materia Medica Department, offered me some black 
tea laced with milk and sugar. It was 10:30, tea time, we were being served from a big 
thermos in his office. I wanted to know in more detail what the main role of this 
Department was. 
The Pharmacy and Materia Medica DĞƉĂƌƚŵĞŶƚ ?ƐƌĞůĂƚŝŽŶŝƐůŝŬĞĨĂƚŚĞƌĂŶĚƐŽŶ ?ǀĞƌǇĐůŽƐĞůǇ
related. We have to do the correct identification. This Department has the duty to identify 
the correct medicinal plant, where it is growing, where it should be collected, and provide 
                                                     
23 Jamyang Tashi is the current Director of the Pharmaceutical Department, and Tenzin Thaye the Deputy. 
They are both extremely knowledgeable on the subject, but have more supervisory, advisory, and 
administrative roles. Nonetheless, the Director also involves himself directly in manual labour such as 
cleaning to speed up the work, and in specialised tasks such as detoxification. 
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this information to the Pharmaceutical Department. The main function is to document the 
plants mentioned in the texts. There are some pictures drawn by artists, but that is not 
enough for us also. We have to see and take photos of the plants. Not only the whole plant 
structure, but also take a picture of the root as well. For example, we have seventy-nine 
thangkas [Buddhist scroll paintings]. These are some kind of illustrations of Gyüzhi and also 
include medicinal plants. But that is not enough. They are drawn by thangka painters. They 
are professional in painting but not in medicinal plants. That is not enough the see the 
structure of medicinal plants. That's why we are collecting specimens of medicinal plants, 
and keep these in the herbarium. Then we draw the picture. We have two special artists 
trained by Dr Dawa. After finishing my book [comparing Tibetan medicinal plants across 
Indian Systems of Medicine and Chinese medicine, Kalsang 2008] I was working on this 
project as well. First we have to write it in Tibetan, then after that it is translated. These books 
are very important. At the moment they are not valuable, but in the future. The important 
thing is that identification characters are mentioned already in the ancient texts. But 
additional characteristics are necessary. Former time Tibetan doctors when going to the field, 
ƚŚĞǇǁƌŽƚĞŝŶƉŽĞƚƌǇĨŽƌŵ ?EŽƚƚŚŝƐƐƉĞĐŝĨŝĐŬŝŶĚ ?ĚŝĚŶ ?ƚŵĞĂƐƵƌĞƚŚĞĐĞŶƚŝŵĞƚƌĞ ?ŵŝůůŝŵĞƚƌĞ ?
Just structure a little bit.24 These additional and more precise and profound characteristics, 
can be understood by botanists, professionals.  ? Q ? ŶĚ ŶŽƚ ŽŶůǇ ƚŚĂƚ ? ǁĞ ĂƌĞ ĂůƐŽ ŐŝǀŝŶŐ
ƚƌĂŝŶŝŶŐ ĨŽƌ ůŽĐĂůƉĞŽƉůĞ ? ůŽĐĂůĂŵĐŚŝƐ ?ǁŚŽĚŽŶ ?ƚŚĂǀĞŬŶŽǁůĞĚŐĞĂďŽƵƚ ƚĞǆƚƐ ?dŚĞǇŚĂǀĞ
good experience from their father, or who was amchi before. But textual knowledge is very 
rare for them. In the text there are many synonyms, but some names are well-known through 
the whole country of Tibet. We have to base ourselves on that, and give the right 
identification to local people. This is our work. (Audio recording 72, 24 March 2014) 
 
The importanĐĞ ŽĨ <ůĞƚƚĞƌ ĂŶĚ <ƌŝĞĐŚďĂƵŵ ?Ɛ  ‘interdiƐĐŝƉůŝŶĂƌǇ ĚĞǀĞůŽƉŵĞŶƚ ƉƌŽũĞĐƚƐ ? in 
collaboration with Men-Tsee-Khang doctors can hardly be understated. Originally, the 
intent ŽĨƌĞƐĞĂƌĐŚĞƌƐĂƚhŶŝǀĞƌƐŝƚǇŽĨsŝĞŶŶĂ ?Ɛ/ŶƐƚŝƚƵƚĞŽĨWŚĂƌŵĂĐŽŐŶŽƐǇǁĂƐƚŽŝĚĞŶƚŝĨǇ
a collection of Tibetan drugs obtained by a pharmacy student from TMAI and donated to 
the Institute in 1972. After a pilot project was started with Men-Tsee-Khang in 1992 
(funded by the Austrian Ministry for Foreign Affairs), the major goal shifted to 
                                                     
24 Dr Tsultrim later added that one has to differentiate between descriptions by classical Tibetan doctors of 
plants growing at high versus at low altitudes, the former being much more precise in general. In the past 




documentation for the dual purposes of preservation and development of Tibetan 
medicine. A second project was funded by the same body (1995-2000), culminating in a 
landmark publication:  
Western Science meets traditional Tibetan Medicine 
For the first time, Western scientists and Tibetan doctors jointly document Tibetan medicinal 
plants in accordance with Western scientific standards and Tibetan traditional methods. 
- The data on botany, chemistry and pharmacology represent the Western system. 
- The Tibetan plant identification and classification as well as the medical uses of the plants 
reveal the traditional point of view. (back cover, Kletter and Kriechbaum 2001) 
The result was an authoritative, meticulously researched volume that continues to be 
highly regarded by doctors in the Materia Medica department as well as by scientists in 
Men-Tsee-<ŚĂŶŐ ?ƐƋƵĂůŝƚǇĐŽŶƚƌŽůůĂď ?ŶŽƚůĞĂƐƚďĞĐĂƵƐĞŽĨŝƚƐŝŶƚĞŐƌĂƚŝŽŶŽĨƉĞƌƐƉĞĐƚŝǀĞƐ
and excellent macro- and microscopic colour photographs. In my communications with 
Krista Kletter (project coordinator and microscopy specialist), it became clear that Dawa 
played a key role in facilitating the collaboration, to which he was favourably inclined.25 
She noted that Men-Tsee-Khang at the time was interested in introducing Tibetan medical 
preparations in Europe, but they were not aware that their products needed to meet 
European standards. Dr Kletter elaborated that  
[i]t was extremely difficult to solve this problem [of differing viewpoints of Tibetan doctors 
on the correct source], because each doctor was convinced that only he used the proper drug. 
We explained to them, that it is common practice in science to cite different opinions. We 
did not judge their information but simply cited them.  




                                                     
25 In what seems to be a reversal of scientific stability and universalism, DaǁĂ ? ? ? ? ? ?Ɖ ? ? ? )ĐŽŶƚĞŶĚƐƚŚĂƚ ‘the 
scientific ŶĂŵĞƐǁĞƌĞŶŽƚĂĚĚĞĚƚŽŐŝǀĞĂ “ďĞƚƚĞƌ ? name to the contrary, the timeless correct names are the 
Tibetan ones. Scientific names are the result of a continuous process called scientific research and thus bound 
to change if sciĞŶƚŝĨŝĐŬŶŽǁůĞĚŐĞŝƐƉƌŽĐĞĞĚŝŶŐ ?. 
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1.4.2 At PADMA 
In both Men-Tsee-Khang and PADMA herbarium specimens are present in archives (Figure 
1.5), but these are rarely consulted and thus not used for identification on a daily basis. 
Similarly, both institutions house a library filled with relevant books, including historical 
and contemporary Tibetan medical texts, floras and field guides, (inter)national (herbal) 
pharmacopoeias, specialised scientific literature on pharmacognosy, and so on. A subset of 
these writings do influence identification practices, but only indirectly. In the case of 
PADMA, each medicinal ingredient  W be it in crude or powdered form  W is delivered in the 
warehouse accompanied by documents (the packing list and invoice) that identify the 
article by name and supplier reference number, and specify the date of delivery, quantity 
and price. Walter, the warehouse manager, has then to sign for receipt, and to follow and 
fill in the protocol for the receipt of goods. He checks the weight as well as the number and 
condition of the container(s), and assigns a new PADMA lot number to the delivery using a 
printed sticky label. To verify the identity of this particular lot, laboratory staff need a 
representative sample, for which Walter needs to go through the standard sampling 
procedure. When the samples reach the laboratory accompanied by the filled-in sampling 
protocol, Erich (the head of the laboratory) will first register it into the lab software 
database and print the sample labels (with batch and sample numbers), which will indicate 
to the laboratory technicians which analytical tests need to be undertaken. One of the 
technicians (Barbara, Brigitte or Emad) then prints the protocols on which the test results 
have to be written down. She or he also consults the in-house monograph for that 
particular drug26 throughout the analytical process (but large parts they know by heart), 
which details the steps to be followed as well as the specifications, the range of acceptable 
outcomes. The full analytical procedure consists of identity testing, purity, and a chemical 
assay (of essential oil content for instance). Identification is subdivided further into odour, 
taste, macro- and microscopic characteristics, and finally TLC (Thin-Layer Chromatography). 
                                                     
26 The dried and comminuted plant parts that eventually become medical ingredients are generally called 
drugs (Drogen). In their crude form they are referred to as raw materials (Rohstoffe), whereas after milling 
and germ reduction the powdered form becomes an active pharmaceutical ingredient (API or Wirkstoff in 
German). The processing state of the drug is also indicated as part of its pharmaceutical name, for instance 
Myrobalani Fructus totum or pulvis ? ‘ĐŽŵƉůĞƚĞ ?Žƌ ‘ƉƵůǀĞƌŝƐĞĚ ?ŵǇƌŽďĂůĂŶĨƌƵŝƚƐ ?dŚĞƐĞƉŚĂƌŵĂĐĞƵƚŝĐĂůŶĂŵĞƐ ?
ĂŶĚ ĂďďƌĞǀŝĂƚŝŽŶƐ ƐƵĐŚ ĂƐ  ‘Myrobalani ? ĂƌĞ ŶĞĂƌůǇ ĂůǁĂǇƐ ƵƐĞĚ ? ŶŽƚ >ĂƚŝŶ ƐĐŝĞŶƚŝĨŝĐ ŶĂŵĞƐ ? 'ĞƌŵĂŶ
equivalents such as Akonit for Aconitum napellus are seldom used for plants not growing in Europe.  
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ůůĨŝǀĞŽĨƚŚĞƐĞŝĚĞŶƚŝƚǇƉĂƌĂŵĞƚĞƌƐĂƌĞŝŶǀĞƐƚŝŐĂƚĞĚŝŶƚĞƌŶĂůůǇ ?ŝŶWD ?ƐŽǁŶůĂď ?dŚĞ
methods and limits used are copied from the European Pharmacopoeia whenever possible, 
and supplemented with specifics based on secondary scientific literature. For each 
parameter that is tested, a small quantity of the sample is compared to (the output based 
on) a reference sample, which generally comes from the last batch of the same drug that 
was released for production, ensuring continuity. 
Figure 1.5. A herbarium specimen of Terminalia chebula Retz. This specimen, along with duplicates showing flowers, is 
ƐƚŽƌĞĚĂƚƚŚĞĂƌĐŚŝǀĞŽĨWD ?ƐƉƌŽĚƵĐƚŝŽŶƵŶŝƚŝŶ<ĞŵƉƚĞŶ ?/ƚǁĂƐƉƌŽĐƵƌĞĚƚŽƐĂƚŝƐĨǇƚŚĞ^ǁŝƐƐƌĞŐƵůĂƚŽƌǇĂƵƚŚŽƌŝƚǇ
for medical product registration (Swissmedic) as it is the source of an ingredient of PADMA 28 which is currently not 
described in the Swiss or European Pharmacopoeia. 
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Not unexpectedly, the words used to describe raw materials in German and English in a 
PADMA monograph do not necessarily overlap with what is reported in the Tibetan medical 
literature. The odour and taste of Myrobalani Fructus for example has to conform to the 
ĨŽůůŽǁŝŶŐĚĞƐĐƌŝƉƚŝŽŶ P ‘characteristic, aciduloƵƐ ?ƌĞŵŝŶŝƐĐĞŶƚŽĨĚƌŝĞĚĨŝŐƐ ) ? ?ĂŶĚ ‘acidulous, 
ĂƐƚƌŝŶŐĞŶƚ ?ƐůŝŐŚƚůǇďŝƚƚĞƌ ?. In volume II of the Fourfold Treatise, arura is said to have five 
tastes (sweet, sour, bitter, hot, astringent), excluding saltiness. Dawa (2009, p, 144) 
ŵĞŶƚŝŽŶƐ ‘bitter, astriŶŐĞŶƚƚŽƐůŝŐŚƚůǇƐǁĞĞƚ ?, while referring the reader to a much more 
extensive discussion of aru varieties (five to eight) with specific tastes and potencies in 
Crystal Garland. Microscopic examination takes place on powdered material, which needs 
to show a minimal number of diagnostic criteria including vascular bundle fragments or 
endocarp stone cells for myrobalan. Lastly, Thin-Layer Chromatography (TLC) is a 
physicochemical technique to separate the test solution (a mixture of chemical compounds) 
into fractions due to variable solubility, which can then be visualised as coloured bands or 
zones on the TLC plate and compared to standard markers and/or a reference solution. 
One or several characteristic zones with a certain colour and intensity need to be present 
in the analysed sample under UV and daylight conditions. Even though these can be 
compared with markers on the plate and with previous TLC results, there is always some 
room for variation and subjectivity of interpretation, as will be discussed more in Chapter 
4 on quality. When all necessary tests are performed and the protocols are filled with hand-
written results and TLC photographs, the outcomes will be entered into the computer 
system. The documents and digital results will then be checked again by Erich. A certificate 
of analysis is furnished, and if the results turn out to be within specification, the analysed 
batch of raw materials may be released for use in production.  
 
On the production site, the identity and status (released or not and until what date, also 
indicated by a separate green label) of each raw material can again be read from a label 
with barcode on each container. Nonetheless, before the raw materials are weighed and 
then mixed mechanically, one production employee will inspect the colour and smell of the 
powder in each bag used  W not only of a representative sample as in the lab  W by comparing 
it to a set of reference samples. In the past this employee also tasted each batch of drugs, 
but this check was abandoned in light of health and safety reasons. It was also questioned 
74 
 
whether one can still accurately compare the taste after trying several ingredients 
consecutively. 
 
1.5 Commensuration, translation and identity politics  
Many names are written in Tibetan medical, materia medica and pharmacy texts, which 
are products of their time and place as well as the individual (and possibly conflicting) views 
of their authors and the medical lineages and schools to which they belong. These names 
are not always accompanied by descriptions, based on which it is moreover often nearly 
impossible to precisely identify what entity (or entities) the names refer to. A cornucopia 
of synonyms (some derived from other languages such as Sanskrit or Chinese) is provided 
as well as a significant body of literature on substitutions. As Sowa Rigpa spans from Tibet 
and China to Mongolia and Russia and across the Himalayas (Bhutan, Nepal and India) and 
to Europe and beyond more recently, the distinction between synonyms and substitutes 
blurs as plants with identical names (or their derivatives in other languages) and their 
synonyms come to refer to other locally-available substances. Although a lot of repetition 
and cross-referencing (often unacknowledged) is to be found, each text may be considered 
as a written, codified instance of situated and partial knowledge which is again interpreted 
and resituated by individual scholars both ancient and modern. Tibetan medicine itself was 
forged from and has been interacting with (medical) knowledge systems as well as local 
knowledge-practices since its inception. Tibetan scholar-physicians are indeed aware of 
this rich diversity, even if they often strongly identify with certain interpretations, which 
they consider authentic and superior.  
 
However, since early modern times  W at least from the early eighteenth century onwards 
(see Surkova et al. 2012 in Chapter 6), before the publication of Species Plantarum by 
Linnaeus in 1753 which was only recognised as the starting point of binomial botanical 
nomenclature in 1905  W the clash of Sowa Rigpa identification, nomenclature, and 
classifications with Western botany has been added on top of its already staggering 
complexity and multiplicity. Already in the earliest study focusing exclusively on Tibetan 
medicine in a European language (Aschoff 1996 ) ? :ŽƐĞƉŚZĞŚŵĂŶŶ ?ƐBeschreibung einer 
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Thibetanischen Handapotheke (published in St. Petersburg, 1811), Latin scientific names 
were correlated to names of Tibetan medicinals. Rehmann met a Mongolian lama-
physician on his travels near the Siberian-Chinese border, from which he bought a 
collection of about sixty raw materials. He recorded the pronunciation of the drug names 
by Lamas in German approximations, and had the plant materials identified by a botanist. 
Arura waƐ ůŝƐƚĞĚ ĨŝƌƐƚ ƵŶĚĞƌ ƚŚĞ ŐůŽƐƐ  ‘Azura ?  ?ZĞŚŵĂŶŶ  ? ? ? ? ? Ɖ ?  ? ? ) ĂƐ  ‘the nut of an 
unknown trĞĞ ?, although it was linkeĚďǇĂĐŽŶƐƵůƚĞĚƉŚĂƌŵĂĐŝƐƚƚŽ ‘Myroballani ?. It then 
took almost a century before this pioneering journal article was superseded by more 
systematic early Russian translations of the first two volumes of the Four Tantras 
(Pozdneyev 1908), also based on the collection and identification of botanical samples) and 
full-fledged dictionaries spanning the Tibetan, Latin (scientific) and Russian languages 
(Gammerman and Semichov 1963). During this period Hübotter (1957) also published on 
 ‘ŚŝŶĞƐĞ-dŝďĞƚĂŶ ? pharmacology in Germany, while it was only in in 1973 that the first 
modern (and also illustrated) materia medica work with Tibetan-Chinese-Latin coverage 
ǁĂƐ ƉƵďůŝƐŚĞĚ ŝŶ ƚŚĞ WĞŽƉůĞ ?Ɛ ZĞƉƵďůŝĐ  ?ƐĞĞ ,ŽĨĞƌ  ? ? ? a). This history of translation is 
clearly not exhaustive, but it does provide interesting leads to follow up in a similar vein to 
recent nuanced diachronic analyses of Chinese materia medica in particular (Hsu 2010; 
Kubo 2009; Nappi 2010, 2013; Winterbottom 2015), exposing the legacy of colonialism and 
the concomitant encroachment of Eurocentric scientific worldviews and practices on 
 ‘KƚŚĞƌƐ ?.  
 
The pioneering longitudinal studies on Chinese materia medica, by Kubo on mu dan (2009) 
and by Hsu (2010) on qing hao, have demonstrated that both the names as well as the 
substances they allude to are subject to considerable and unexpected change over time. 
Hsu (2009, 2010) has also made explicit that herbal medicines should be considered as 
cultural artefacts first of all because of their highly sophisticated and culture-specific 
processing and preparation, while bůƵƌƌŝŶŐ ƚŚĞ ďŽƵŶĚĂƌŝĞƐ ďĞƚǁĞĞŶ  ‘ƚƌĂĚŝƚŝŽŶĂů ? ĂŶĚ
 ‘ŵŽĚĞƌŶ ? drugs due to the not infrequent integration with biomedical rationales and 
chemicals. Recently however, historian Carli Nappi has taken this kind of object histories a 
critical step forward. In her work on caterpillar fungus (2010) and ginseng (2013) inspired 
ďǇƌƵŶŽ>ĂƚŽƵƌ ?ƐŚǇďƌŝĚĂĐƚŽƌ-networks, she argues that a single trans-historical object 
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does not exist  W there is no stable, coherent entity across time  W since facts cannot escape 
their network of production. What is left to be accounted for ŝƐĂ  ‘ŚŝƐƚŽƌǇŽĨ ůŝŬĞŶĞƐƐ ? or 
genealogy throughout a web of textual technologies and related practices of identification, 
synonymy and objectification. Arguing for plural histories in the context of the ongoing 
construction of Chinese national pharmacoloŐŝĐĂů ĐŽŚĞƌĞŶĐĞ ŝŶ ƌĞĂĐƚŝŽŶ ƚŽ  ‘tĞƐƚĞƌŶ ? 
biomedicine, she rightly observes: 
One need only to think of the contemporary practice of assigning Latin binomial 
nomenclature to classical Chinese plant and animal names as a common example of a 
seemingly innocuous practice that nonetheless is effectively a kind of textual and nominal 
imperialism: drugs are re-made and tamed into conveniently classifiable elements of a 
Linnean taxonomy, much as an increasing number of Chinese herbal medicines are 
epistemically transformed into bio-medical entities by being tested for active molecular 
compounds. (Nappi 2010, p. 22) 
/ŶĞĂƌůǇŵŽĚĞƌŶŚŝŶĂ  ‘ŐŝŶƐĞŶŐ ? (ren shen) as we more or less know it now was created 
through a shift in identification practices away from analogy through resemblance (with 
the human body, or other plant drugs), towards the observation of novel criteria such as 
features on its surface to assess quality. In parallel, practices of translation steered by the 
Qing court coalesced an assemblage of names, descriptions and representations into a 
 ?ŵƵĐŚ ŵŽƌĞ ) ƐŝŶŐƵůĂƌ ƐƚĂďůĞ ŽďũĞĐƚ  ?EĂƉƉŝ  ? ? ? ? ) ? &ŽůůŽǁŝŶŐ EĂƉƉŝ ?Ɛ ĂƉƉƌŽĂĐŚ ?
Winterbottom (2015) traces the early modern circulation of a famed anti-syphilis drug 
named China root, nowadays usually identified with Smilax spp., elucidating how colonial 
ŵĂƌŬĞƚĨŽƌĐĞƐƌĞĚĞĨŝŶĞŝƚƐ ‘ĚŝƐĐŽǀĞƌǇ ? in a shift from orientalist exoticism to xenophobia, 
even re-branding what first was a substitute as the authentic drug to avert a European 
wealth drain.  
 
I would like to call this commensuration, the process whereby the situated identification 
and naming practices of disparate currents of tradition  W in this case contemporary Sowa 
Rigpa and botany  W are forced to correspond, validating one-on-one translations of object-
names between traditions. This is an imposed equivalence based on premises of 
universalist common sense (as discussed in Hsu 2010a), functioning only after 
decontextualisation from people (culture), text (time), and locality (space) has taken place 
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(see Ellen and Harris 2000 for a critical review). It is therefore a neo-colonialist and 
unidirectional effort where the historical fluidity (à la Nappi) together with the practical 
multiplicity and flexibility of Tibetan materia medica (cf. Blaikie 2015) is annihilated through 
solidification and simplification, while the botanical science categories remain unaltered 
but expand their reach. The argument presented here can also be interpreted as a 
rephƌĂƐŝŶŐŽĨsŝŶĐĂŶŶĞĚĂŵƐ ?(2002) tour de force ŽŶ ‘ƌĂŶĚŽŵŝƐĞĚĐŽŶƚƌŽůůĞĚĐƌŝŵĞ ? in 
Tibetan-biomedical encounters, but in this case botanical classification becomes the gold 
standard, determining the rules of the game: plant categories are universal (one and the 
same cross-cultural knowledge currency), proper botanical identification is 
incontrovertible, and plants are reducible to lists of independently observable 
characteristics. Regrettably, even though commensuration comes at a considerable cost, 
creating problems that do not exist if one treats the respective taxonomies separately and 
disempowering Tibetan medicine and its practitioners, many scholars and scientists as well 
as practitioners of Asian medicines continue to subscribe to these practices. 
 
Why, what is the benefit, and for whom? Big (or Small) Pharma cannot be the scapegoat 
again and take all the blame.27 The modern botanical  ‘ĞƚŝĐ ? grid, building on Linnaeus, 
serves as the foundational paradigm of ethnobiology (see Ellen 2006), and is deemed to be 
a pragmatic necessity for effective communication, to be able to translate and apprehend 
the ethnographic Other. We are all caught up in the globalisation and commoditisation of 
indigenous knowledge through conservation-development discourses and concomitant 
efforts in the documentation and preservation of knowledge ostensibly on the verge of 
being lost, but I follow Pordié (2008b) and Alexiades (2009) in calling for more attention to 
the implications of identity politics in relation to competing claims of legitimacy. 
Notwithstanding its nefarious effects, botanical identification equally has the capacity to 
valorise amchi knowledge, to aid in the co-management of medicinal plants, and to 
strengthen local ownership over these resources. However, the parties involved have to 
                                                     
27 Ironically, in the already highly standardised Swiss/European context of PADMA the translation of Tibetan 
medicinal plants into fixed botanical species and their introduction as multi-compounds onto national 
markets could even be interpreted as an enrichment of the nowadays limited spectrum of allowed and 
recognised herbal medicines. /ŶƚŚĞƐĞĐŽƵŶƚƌŝĞƐƚŚĞĐŽŵŵĞŶƐƵƌĂƚĞĚƐƉĞĐŝĞƐĂƌĞŽĨƚĞŶĐŽŶƐŝĚĞƌĞĚ ‘ŶŽǀĞů ? ?




critically assess the partiality in these acts of commensuration and make explicit this 
uneven negotiation and the transformations that ensue, as has been exemplified by 
Aumeeruddy-Thomas and Lama (2008). Many are aware of the plasticity of Sowa Rigpa 
materia medica as it is essential in enabling contemporary situated practice, but most 
publications nonetheless subscribe to the rigidity of facile commensurations in a 
schizophrenic manner. This slippage may in turn feed back to society, in effect 
universalising partial, distorted truths. Even though I am very sympathetic to 
interdisciplinary conversations and collaborations beyond cultural and linguistic comfort 
zones (Craig and Glover 2009), we have to keep asking ourselves what is lost in translation, 
and why this matters. There lies a danger in covering up the local, regional and historical 
variability that extends far beyond written Sowa Rigpa pharmacopoeias by universalising 
their translations. Definite botanical identification of Tibetan materia medica can only 
make  W some, partial  W sense within a clearly specified, limited textual and spatiotemporal 
(and in extremis individual) context. Returning to politics, this is not to say that the 
juxtaposition of Linnean and Tibetan names is not mobilised extensively in nationalist 
projects of modernisation, standardisation, institutionalisation, and industrialisation (Kloos 
2010, 2013; Saxer 2013), rejecting the authenticity of smaller branches of Sowa Rigpa. This 
chapter invites researchers to reflect critically on their positionality within these processes, 
and for this the politics of identification and naming practices provides an important 












corruption and the failed 




I first visited the spice market of Old Delhi in October 2013. I was staying in a guesthouse 
in Majnu-Ka-Tilla, the Tibetan Colony that was established in the outskirts of New Delhi 
around 1960 in the wake of the first wave of refugees fleeing Chinese oppression. This small, 
shanty enclave on the bank of the heavily polluted Yamuna river is also where amchi Penpa 
would stay if he needed to come down to Delhi to find machine parts or to purchase herbs 
for Men-Tsee-<ŚĂŶŐ ?ƐWharmacy. Ugyen Tsewang, the Bhutanese manager of Men-Tsee-
Khang Exports I talked to the day before in Kalkaji (Audio recording 31), had advised me to 
go to Khari Baoli early. It was autumn and Diwali was coming up, the Hindu festival of light. 
Lots of people would go to the market to buy groceries and presents so the roads would be 
even more congested than usual. Ugyen knows the spice market well. He goes there when 
he receives an order from the Herbal Product Research Department (HPRD): to buy oils  W 
but not the crude herbs, which is WĞŶƉĂ ?ƐƚĞƌƌĂŝŶ Wto be used in the Sorig product range.28  
 
After taking a cycle rickshaw, the metro to Chandni Chowk and another short rickshaw ride, 
I was dropped off at a busy intersection and pointed in the right direction. As is normal for 
any first-ƚŝŵĞǀŝƐŝƚŽƌ ?/ĨĞůƚ ůŽƐƚĂŶĚǁĂƐŽǀĞƌǁŚĞůŵĞĚďǇ<ŚĂƌŝĂŽůŝ ?Ɛhustle and bustle. 
The main road is a long, broad lane lined by rows of shops, while the street itself is cluttered 
on both sides with more retailers, traders, stacks of jute bags and crates, and porters with 
                                                     
28  Men-Tsee-Khang Exports, located in the Kalkaji district of South Delhi, sells and sends herbal beauty 
products, teas, dietary supplements, incense and other items produced by Men-Tsee-Khang and showcased 
on their website (www.men-tsee-khang-exports.org) overseas to international distributors, retailers, and 




their long wooden carts (Figure 2.1). It is not just spices that are sold here, coconut and 
copal were being traded intensively along with an extensive range of dried fruits and nuts 
(cashew, almonds, walnuts, dates, raisins, pistachio, and so on) mainly for retail. What 
follows are some of my first clumsy interactions with sellers, as they give a good sense of 
what the trade is like for the uninitiated (28 October 2013, Diary).  
 
 
Figure 2.1. The main street of Old DĞůŚŝ ?ƐƐƉŝĐĞŵĂƌŬĞƚ ?<ŚĂƌŝĂŽůŝ ?WŚŽƚŽŐƌĂƉŚĞĚďǇƚŚĞĂƵƚŚŽƌŽŶ ? ?KĐƚŽďĞƌ ? ? ? ? ? 
 
I asked around where I could find herbal medicine suppliers. An older bystander guided me 
to a shop across the street. The three men (almost no female shopkeepers to be found 
here) in this small room only spoke a few words of English. One was more fluent, but he 
kept silent at first. I mentioned harad, which I thought corresponded to Terminalia chebula 
and to the famed arura used in so many Tibetan formulations. They had four types, from 
expensive to least expensive: harad  ‘<ĂďƵů ? ?harad  ‘ŽŵďĂǇ ? ?harad  ‘<ĂƚŶŝ ? ?ĂŶĚ ‘/ŶĚŝĂŶ ?Žƌ
 ‘ůŽĐĂů ?harad (Figure 2.2). The seller offered me some chai, and my  ‘helper ? left. The men in 
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the shop were laughing, especially because I thanked him for introducing me. The prices I 
got at first however, were commission prices, because that man wanted his share. Serious 
again ?ƚŚĞǇŐĂǀĞŵĞƚŚĞ ‘ĐƵƚ ?ƉƌŝĐĞƐ: 500, 200, 100, and 60 rupees (7.4, 3, 1.5, and 0.9 USD), 
which was still very high I found out later. Together, they explained that the price of herbs 
depends on whether it is in or out of season, but for harad there are no seasonal prices. 
The yearly price can fluctuate a little according to how successful the harvest was, in 
relation to the weather. Of course, depending on how much you buy, the price also changes 
(up to twenty rupees or 0.3 USD per kg). When I wondered out loud how long the herbs 
couůĚďĞŬĞƉƚ ?ƚŚĞƐĞůůĞƌƌĞƉůŝĞĚ ‘more than five years without ĂƉƌŽďůĞŵŝŶĐŽůĚƐƚŽƌĂŐĞ ?. 
But this was contrary to the storage methods I observed during my fieldwork, and indeed 
within the same and other shops that day. ThĞƐŚŽƉŽǁŶĞƌŐĂǀĞŵĞŚŝƐĐĂƌĚ P ‘call me if you 
ǁĂŶƚƚŽĚŽďƵƐŝŶĞƐƐ ?. We shook hands and said goodbye. By now the streets were bursting 
with cycle riskhaws, scooters, men carrying large sacks or transporting goods on carts, and 
shopping pedestrians. Getting out of Old Delhi was virtually impossible, as traffic came to 










I experienced first hand how unreasonable it is to enter this market armed only with a list 
of plant names and then hope you will be able to find the right thing or even find out about 
prices. A buyer needs to be aware of the current names, prices, and what exactly s/he 
wants in advance in order not to get the wrong item (perhaps an inferior substitute or a 
counterfeit) at an incredibly inflated rate. There will likely be several types of the same raw 
material, with each type subdivided further into quality grades. The quality, timing (year, 
season) and volume will all influence the price. There is not one standard name, no 
standard price, nor quality. This further implies trade surveys are only meaningful on a 
generalised level, which puts the recent spate of  ‘ŵĂƌŬĞƚĞƚŚŶŽďŽƚĂŶǇ ? in a different light 
as these do often assume these are a straightforward context for research (see section 2.2). 
All these aspects have to be bargained and agreed with the seller based on samples and 
also carefully checked when the order comes through. In this process, knowledge of the 
Figure 2.2. Some types of harad ĨŽƵŶĚŽŶĞůŚŝ ?Ɛ<ŚĂƌŝĂŽůŝŵĂƌŬĞƚ Pharad  ?ŽŵďĂǇ ? ?ƚŽƉůĞĨƚ ) ?harad  ?ŬĂƚŶŝ ? ?ƚŽƉ
middle), harad  ?ĐŚŝůŬĂ ? ?ƉŝƚƚĞĚ ?ƚŽƉƌŝŐŚƚ ) ? ?ůŽĐĂů ?Žƌ ?/ŶĚŝĂŶ ?harad  ?ďŽƚƚŽŵůĞĨƚ )ĂŶĚ ?<ĂďƵůŝ ?harad (the largest fruits, 
bottom right).  
83 
 
market and negotiation skills are of paramount importance. Since domestic transactions 
are largely undocumented, only the security of a long-term business relationship can 
ensure that both parties follow suit. Nevertheless, Khari Baoli is infamous for its short-term 
bargains and fast retail market on the one hand, and its huge turnover in volume on the 
other. Small and medium-sized pharmacies and factories in a radius of at least a hundred 
miles would all buy from Delhi as I was told by a long-time trader (Audio recording 70), 
while the huge companies mainly rely on their own networks of collectors and farmers. 
Both Men-Tsee-Khang and PADMA are neither fish nor fowl, roughly producing between 
forty and seventy tons of medicines a year which consist of a large number of ingredients 
in low volumes, preventing the benefits of economies of scale. The former has a handful of 
big suppliers (two or three in Delhi, four in Amritsar), while the latter shies away from the 
bazaar market as a whole in the search off smaller suppliers and individual contacts from 
whom they can get specific information on provenance. This is nearly impossible to get 
ĨƌŽŵǁŚŽůĞƐĂůĞƌƐ ?ǁŚŽĞŝƚŚĞƌĚŽŶ ?ƚŬŶŽǁĞǆĂĐƚůǇ ?ĂůŽƚŝƐƉƵƌĐŚĂƐĞĚǀŝa commission agents, 
ŽƌĂƚƚŝŵĞƐĨƌŽŵŽƚŚĞƌǁŚŽůĞƐĂůĞƌƐ ) ?ŽƌĚŽŶ ?ƚǁĂŶƚǇŽƵƚŽŬŶŽǁǁŚĞƌĞƚŚĞǇsourced their 
materials to prevent being sidestepped. 
 
The written, formal, statutory component of governance stands in stark contrast to the so-
called informal (though often very formalised) institutions and systems operating in many 
communities. Rooted in customary law and commonly coexisting together with statutory 
governance in the form of legal pluralism, these institutions are of paramount importance 
for effective regulation (Laird et al. 2010, Ostrom 1990). Governance is an oft-studied but 
hotly debated dimension of conservation-development, as is evidenced by the burgeoning 
literature on commodity chains (Gereffi et al. 2005; Gereffi and Lee 2016; Gibbon et al. 
2008) and NTFPs (Laird et al. 2010). The far-reaching impacts of (inter)national regulations 
on Tibetan medicine have also been highlighted in the anthropological literature (Craig 
2011; Craig and Adams 2008; Janes 1995; Saxer 2009, 2012), and the complexities 
surrounding Tibetan medicinal plant cultivation, trade and conservation are also 
increasingly being recognised (Aumeeruddy-Thomas and Lama 2008, Blaikie 2009, Craig 
and Glover 2009, Saxer 2009). Building on this literature, I respond to a series of calls for a 
more integrated approach to plant-based commodities that takes into account socio-
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political, economic and ecological aspects (Alexiades and Shanley 2005a, Neumann and 
Hirsch 2000, Shackleton et al. 2011, Shackleton et al. 2015, Wollenberg and Ingles 1998), 
tempering initial euphoria around their usefulness for biodiversity conservation and 
poverty alleviation (cf. Belcher and Schreckenberg 2007, Shackleton and Pandey 2014). 
 
Three anthropologists have thus far provided fine-grained ethnographic insights into the 
harvest and trade of Tibetan materia medica: Sienna Craig (2012), Martin Saxer (2009, 
2013), and Calum Blaikie (2009, 2014). In the chapter of her monograph titled Cultivating 
the Wilds, Craig (2012) explores intersections between political ecology and medical 
anthropology as Sowa Rigpa practitioners interact and at times clash with conservation-
development organisations, and the concomitant commodification of Himalayan natures 
and cultures. Amchi offer local critiques of conservation in pointing out the complicity of 
the government and big-business Tibetan medical factories in stimulating mass for-profit 
collection by locals, while they feel that governments seem to care more about the plants 
than the practitioners who rely on them for healing. Blaikie (2009) expands on these 
themes based on his long-term fieldwork in Ladakh. He contends that rural amchi and 
small-ƐĐĂůĞŵĞĚŝĐŝŶĞƉƌŽĚƵĐƚŝŽŶŚĂǀĞŝŶĨĂĐƚďĞĐŽŵĞ ‘ĐƌŝƚŝĐĂůůǇĞŶĚĂŶŐĞƌĞĚ ?ĚƵĞƚŽĂ push 
towards medicinal plant conservation through cultivation. This shift reconfigures local 
practices in unpredictable ways, but generally feeds in to increasing industrialisation, 
modernisation and professionalisation. In his doctoral dissertation (2014), Blaikie unsettles 
the oft-assumed teleological progression towards commercialisation for Ladakhi Sowa 
Rigpa by bringing the intricacies of amchi economics and materia medica network dynamics 
to the fore. Wild-collection by practitioners, gift-giving, sharing, lending, direct exchange 
and buying and selling of raw materials all contribute to the maintenance of del, a network 
of personal relationships through which materials and knowledge flow. The markets of 
Delhi and Amritsar I explore below also provide the major contribution to Ladakhi amchi 
supplies. But even though money has become the dominant medium of exchange, social 
dynamics between parties remain complex and unexplained solely by the principles of a 
market economy. Saxer (2009) highlights the fact that Sowa Rigpa has never been an 
exclusively local tradition, necessitating trans-Himalayan trade for some of its most prized 
medicinal raw materials since its conception. While cross-border trade is certainly not a 
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new phenomenon, the recent industrialisation of Sowa Rigpa in Tibet has engendered 
three new border regimes that govern the transit of herbs and traders to Nepal: (1) 
concerns over quality in relation to the massive surge in demand (licensing, the need for 
import permits, a limited number of authorised entry ports), (2) the stricter enforcement 
of CITES on the Nepalese side as a response to fears of resource depletion, and (3) 
constraints on the free movement of Tibetans due to the fragile political situation. Such 
regulations can nevertheless come with unintended side-effects, which eventually 
undermine their intended goals:  
[w]hereas the border regimes are designed to manage the transit of traders and goods, their 
ũƵƐƚŝĮĐĂƚŝŽŶĚĞƌŝǀĞƐŶŽƚŽŶůǇĨƌŽŵƚŚĞŝƌĐĂƉĂĐŝƚǇĨŽƌĐŽŶƚƌŽůďƵƚĂůƐŽ ?ĞǀĞŶŵŽƌĞŝŵƉŽƌƚĂŶƚůǇ ?
from facilitating successful trade. In this sense the survival of a border regime rests, ironically, 
ŽŶďŽƚŚŽĸĐŝĂůƐĂŶĚƚƌĂĚĞƌƐďƌĞĂŬŝŶŐŝƚƐ rules in order to make it work. (Saxer 2009, p. 337)  
 
dŚĞ ĂƌŐƵŵĞŶƚ / ǁŝůů ƉƌĞƐĞŶƚ ŚĞƌĞ ĂůŝŐŶƐ ƐƚƌŽŶŐůǇ ǁŝƚŚ ůĂŝŬŝĞ ?Ɛ ĂŶĚ ^ĂǆĞƌ ?Ɛ ǁŽƌŬ ? ǁŚŝůĞ
adding a hitherto missing critical analysis of the governance of Indian medicinal plant trade. 
My fieldwork however has led me far away from the specifics of Tibet and Tibetan trade 
(Cuomu 2013). Tracing Tibetan materia medica through Indian supply chains, one can easily 
lose touch with Sowa Rigpa altogether as it dissolves into the much larger Ayurveda-
dominated trade.29 In contrast to the rest of my dissertation, this chapter is not based 
mainly on fieldwork undertaken at Men-Tsee-Khang in Dharamsala or at PADMA in Zürich. 
Although I was able to get insight into the sourcing strategies and tactics employed by staff 
involved in the purchasing of raw materials at these institutions by focusing on the four 
plant subjects of this thesis, my aim in the field was to trace these herbs back from the 
manufacturers all the way to their places of origin. To their roots. This turned out to be a 
daunting task. Both producers put me in touch with two of their principal suppliers in India, 
who I subsequently visited in Delhi (October 2013, March 2014, and August 2015), Gurgaon 
(March 2014, August 2015), Amritsar (July 2015), and Manali (July-August 2015). Because 
and sometimes in spite of this personal introduction from one of their important customers, 
                                                     
29  A minority of Tibetan medicinal plants falls outside the remit of the mainstream Indian Ayurveda-
dominated herbal industry, which means that producers have to rely on different sourcing strategies. This 
was for instance the case for Meconopsis spp. (tserngön, utpel, etc.), which are sourced by Men-Tsee-Khang 
from Tibet via Nepal or wild-harvested by staff and students in Himachal Pradesh. 
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these four traders were surprisingly supportive of my research and open to enquiries. I also 
explored the large wholesale markets of Delhi and Amritsar independently, buying herb 
samples (being hopeless at bargaining) and questioning a number of sellers on trade names, 
quality grades, (incredibly inflated) prices, and (vague descriptions of) sourcing. A 
researcher identified as a tourist and treated as a wealthy, ignorant client stands little 
chance of gaining any reliable, in-depth information. Luckily I had my connections and was 
also able to join an Ayurvedic practitioner and friend on a shopping tour of his most trusted 
ƐŽƵƌĐĞƐŝŶŵƌŝƚƐĂƌ ?ƐŵĞĚŝĐŝŶĂůŵĂƌŬĞƚŵĂǌĞĨŽƌŵŽƌĞŝŶƚŝŵĂƚĞĞŶĐŽƵŶƚĞƌƐ ?dhe jump from 
suppliers and large wholesale markets to harvesting areas is a quantum leap that can only 
occur within a configuration of trust between harvesters, traders, manufacturers and the 
traveller himself. Despite my best efforts, I succeeded in physically following the trail of 
only one of my four study plants back to where it grows and is harvested: ruta (here 
equated with Saussurea costus Žƌ ‘ĐŽƐƚƵƐ ? ) ?ŽŶĞŽĨƚŚĞĨĞǁŚŝŐŚ-altitude Tibetan medicinal 
plants to be cultivated successfully in fields (Blaikie 2009). Cultivation obviously makes the 
plants easier to locate, but it still took us nearly two days of driving from Manali to reach 
the farms deep in Lahaul Valley. The trader who drove us there was also a cultivator, and 
incidentally he was selling to both PADMA and Men-Tsee-Khang. The larger lesson here is 
the fact that this kind of data, as important and central as it is for many analytical models 
of NTFP commodity chains, is extremely hard to obtain in a reliable manner.  
 
Following these tracks, I came across alleged instances of  ‘illegal trade ?,  ‘bribery ? and 
 ‘corruption ? ?Dy theoretical goal then became to examine how and why these notions are 
mobilised in the Indian medicinal plant trade. This proved to be fertile grounds for 
critiquing the moral high ground taken in the dominant conservation-development 
discourse and by the Indian state, which is based on a reified division between formal and 
informal economy and the concomitant assumption that strictly regulated, legal markets 
are always more beneficial for people and plants. In an increasingly formalised but highly 
dysfunctional state governance regime however, what many label as informal, illicit or 
corrupt may be the only viable option to stay in business. To drive this point home, I draw 
on  ‘ƐŽƌĐĞƌǇ ?ĂƐĂŶĂŶĂůǇƚŝĐĂůĚĞƐĐƌŝƉƚŽƌĨŽƌƚŚĞƐŽƵƌĐŝŶŐŽĨŵĞĚŝĐŝŶĂůƌĂǁŵĂƚĞƌŝĂůs from 
Indian soil to the factory. Sorcery and magic play a central albeit ambivalent role  W not 
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unlike corruption  W in anthropological debate, which I will start to unpack in the next 
section. The following characteristics associated with these practices turned out to be 
useful descriptors for the trade: opacity (of the full nature of the supply chain), the role of 
initiation and participation (a prerequisite for grasping how the market truly works), 
communion with higher authorities (i.e. government officials), and the moral, economic 
and ecological perils these practices may engender (charges of illegality, loss of business, 
and the risk of natural calamities due to the over-exploitation of resources). This  ‘magical ?
reality seems far removed from the disenchanted, formal vision promulgated by (non-) 
governmental institutions. The juxtaposition of the rigid frameworks of formal governance, 
designed by policymakers and supported by a number of scholars and scientists, with the 
labyrinthine realities of trade on the ground leads to inevitable gaps, mismatches and 
confusions.  
 
In the next section, I first briefly situate the main analytical tools utilised in this chapter 
within the anthropological literature. This is followed by an excursion into the history of 
the NTFP concept and its application in Himalayan and Indian medicinal plant surveys, in 
which I critically appraise the formal, disenchanted perspective on the trade. This sets the 
stage for sections 2.3 and 2.4, which are fieldwork-based, and seek to illustrate the 
observed incongruity between the idealised governance of the Indian herbal industry and 
actual trading practices. This chapter documents the becomings of (Tibetan) medicinal 
plants after their identities are gleaned from textual sources in dialogue with situated 
knowing practices (Chapter 1), and before they are transformed into ingredients of 
medicines (Chapter 3). The reformulation occurring on the market is the transition from 
living organism to commodity. But this shift cannot fully eradiĐĂƚĞ ‘ƚŚĞƵŶƌƵůŝŶĞƐƐŽĨƚŚĞ
ǁŝůĚ ? (Saxer 2013, p. 95). This is where the flexibility of informal economies plays its role. 
Therefore, I argue that policies aiming to formalise Indian medicinal plant trade fail to 
account for these unfathomable uncertaintieƐĂŶĚĐŽŵƉůĞǆŝƚŝĞƐ ? ‘^ŽƵƌĐĞƌǇ ? ?ƚŚĞŝĚĞĂŽĨĂ
risky and dark practice of sourcing raw materials, is the manifestation of a failed 




2.1 Sorcery and corruption as occult (counter-)politics  
Bubandt (2006) contends that magic is an extension of politics on another level30, as he 
witnessed how both sorcery and corruption are part of the same occult politics of the on-
going democratisation of Indonesia. Both are politically efficacious yet morally ambivalent, 
often go together, and share the common dilemma of the unknowability of the other:  
Sorcery and corruption are quintessentially activities of the other. Yet their prevalence 
amongst other people forces each individual, and each individual politician in particular, to 
seek magical counter-measures and to establish his or heƌŽǁŶŶĞƚǁŽƌŬƐŽĨ  ‘ŵƵƚƵĂůŚĞůƉ ? 
(Bubandt 2006, p. 426).  
The strong link between these practices and democracy in this case disrupts a priori 
ĚŝǀŝƐŝŽŶƐ ďĞƚǁĞĞŶ  ‘ŐŽŽĚ ? ĂŶĚ  ‘ďĂĚ ?politics (an assumption that prevents in-depth 
ethnography), as processes of decentralisation and increased transparency equally brought 
about new occult dangers while showcasing the interplay between formal and informal 
power discourses. In this light it seems the world was never fully disenchanted, demystified, 
secularised and rationalised, strong modernist forces notwithstanding (Jenkins 2000).  
 
To get to know the occult nature of the Indian medicinal plant sector the only option is to 
take part in it, or like a true anthropologist, at least pretend to be part of it by observing 
insiders from close by. This penchant for participation31 as a prerequisite for proper insight 
equally surfaces as a key characteristic in magic and witchcraft. Strikingly similar to analyses 
of corruption, anthropological research on these tantalising topics evidences its circularity 
(witchcraft can best be dealt with by witchcraft), ambivalent figures and their moral 
ambiguity (precarious distinctions between positive and negative forms), a troubled 
relationship with nation-states and capitalist economy, and paradoxical interactions with 
modernity (Geschiere 2001). Without delving deeper into these bodies of literature32, I use 
                                                     
30  See Rowlands and Warnier (1988, p. 121) for an early, very similar statement in the context of the 
modernising state of Cameroon. 
31 In a secularised and disenchanted modern world (vide Max Weber), participation  W vaguely defined as a 
mystical union of person/subject and thing/object  W is supossedly suppressed by an ideology of (scientific) 
instrumental causality (Hanegraaff 2003). 
32 In India, women are common targets of witchcraft accusations and witch hunts in tribal communities 
(Chaudhuri 2012, Mullick 2000). These have been interpreted as the result of profound socio-economic 
changes and gender inequalities and struggles that manifest as these indigenous societies integrate more 
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these generalised traits of sorcery and witchcraft as analytical tools to paint an alternative 
and often misunderstood picture of how the Indian trade in medicinals operates. 
 
/Ŷ ůŝďĞƌĂů ƉŽůŝĐǇ ĐŝƌĐůĞƐ ? ĐŽƌƌƵƉƚŝŽŶ ŝƐ ŽŶĞ ŽĨ ƚŚĞŵŽƐƚ ƐĂůŝĞŶƚ  ‘ŐůŽďĂů ƉƌŽďůĞŵƐ ?, which 
despite all efforts seems to continue more or less unabated. Opinions also vary widely 
across the social sciences on its definition, causes, countermeasures, impacts and 
management. Problematically, political corruption is mostly conceived at the level of the 
nation-state and as a public sector issue  W ignoring local embeddedness, sectorial specificity 
and trans-border operations  W though economic liberalisation (as well as commercial 
bribery) has blurred the public-private distinction even in its most superficial reading 
(Heywood 2015). In this light and through an anthropological lens (see Torsello 2011 for a 
review), seemingly universal and ĂĐƵůƚƵƌĂůĚĞĨŝŶŝƚŝŽŶƐƐƵĐŚĂƐ ‘the abuse of public office for 
ƉƌŝǀĂƚĞ ŐĂŝŶ ? have to be problematised (as indicated by Haller and Shore 2005, p. 5, 
referring to the World Bank). A modernist preoccupation with transparency and 
ůŝďĞƌĂůŝƐĂƚŝŽŶĂŶĚ ‘ŐŽŽĚŐŽǀĞƌŶĂŶĐĞ ?ƉŽůŝĐŝĞƐ ŚĂƐĨƌĂŵĞĚĐŽƌƌƵƉƚŝŽŶĂƐĐĂƵƐĞĚďǇ ‘ƌŽƚƚĞŶ
ĂƉƉůĞƐ ? ŝŶ ƚŚĞƉƵďůŝĐ ƐĞĐƚŽƌ ?ĂŶĚŶŽƚĂƐĂŶ ŝŶƐƚŝƚƵƚŝŽŶĂůŽƌƐǇƐƚĞŵŝĐƉƌŽďůĞŵ (conspiracy 
theories notwithstanding). When applied to  ‘ĚĞǀĞůŽƉŝŶŐ ĐŽƵŶƚƌŝĞƐ ?, however, this 
explanation is precariously reminiscent of colonial discourses that project unenlightened 
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ŽŶƚŽ  ‘ďĂĐŬǁĂƌĚ ? ƐŽĐŝĞƚŝĞƐ ? dŚĞƌĞ ŝƐ indeed a symmetry between the 
apparent chaos of sourcing plant materials in India, and that of the paper-mountains of 
herbal medicine legalisation efforts in Europe and the ensueing structural violence, 
elucidated in Chapter 6. Alluding to sorcery in the former case, and not the later, runs the 
risk of consolidating the traditional/modern dichotomy I try to overcome.  
 
My aim is thus ĐĞƌƚĂŝŶůǇŶŽƚƚŽũƵĚŐĞǁŚĂƚ ‘ĐŽƌƌƵƉƚŝŽŶ ?ŝƐĂŶĚǁŚĂƚ it is not; it is exactly the 
slippage of the legal, societal and moral judgement that ensures its widespread and varied 
                                                     
into the Hindu-dominated patriarchy (Mullick 2000), whereas police and other state actors attempt to stamp 
ŽƵƚƚŚĞƐĞĂĐƚŝǀŝƚŝĞƐ ?ǁŚŝĐŚƚŚĞǇƌĞŐĂƌĚĂƐ ‘ďĂĐŬǁĂƌĚ ? ?ĞƐĂŝ ? ? ? ? ) ?'ĞŶĚĞƌĚŝƐcrepancies also play into the 
Indian herbal industry: a large portion of the collectors are female (who are blamed for indiscriminate wild-
harvesting, which is low-prestige and arduous work), while middlemen and wholesalers seem to be 




currency. /ŶƐƚĞĂĚ ?/ĂƉƉƌŽĂĐŚĂůůĞŐĂƚŝŽŶƐŽĨ ‘ĐŽƌƌƵƉƚŝŽŶ ?ĂƐdiscursive devices that legitimise 
practices on the borderlands of in/formality and il/legality in the dealings of medicinal plant 
traders in India. I illustrate the irreconcilability of many day-to-day practices with 
government and NGO policies, argueing that the push towards formalisation of the trade 
ŚĂƐ ůĂƌŐĞůǇ ĨĂŝůĞĚ ? /ŶƐƚĞĂĚ ? ƚŚĞ ďƵƐŝŶĞƐƐ / ĐŽŶĐĞƉƚƵĂůŝƐĞ ĂƐ  ‘ƐŽƵƌĐĞƌǇ ? ƚĂŬĞƐ ƉůĂĐĞ ŝŶ Ă
convoluted legislative greyzone and through ambivalent economies of favours. Even 
though I borrow terms that are frequently associated with sorcery, witchcraft and magic I 
am cautious not to assume that  ‘informal ?,  ‘illegal ? and  ‘corrupt ? activities are necessarily 
hidden or occult. This would in itself represent an ethnocentric, puritan and rationalist bias 
and risks romanticising these practices in an act of political voyeurism. As noted by 
Ledeneva (2014) for late and post-communist Russia, these networks of mutual help are a 
ƚĂĐŝƚůǇĂĐĐĞƉƚĞĚ ‘ŽƉĞŶƐĞĐƌĞƚ ? ?Economies of favours outwit the constraints of centralised 
distribution systems while also evidencing that it is infeasible for the state to fully enforce 
its own far-reaching regulations. They thus simultaneously support and undermine the 
workings of estĂďůŝƐŚŵĞŶƚ ? ƚƌŝŐŐĞƌŝŶŐ ƚŚĞ  ‘ŵŽĚĞƌŶŝƐĂƚŝŽŶ ƚƌĂƉ ŽĨ ŝŶĨŽƌŵĂůŝƚǇ ?  ?Ledeneva 
 ? ? ? ? ?Ɖ ? ? ? ) P ‘one cannot use the potential of informal networks without triggering their 
negative long-term consequenceƐĨŽƌŝŶƐƚŝƚƵƚŝŽŶĂůĚĞǀĞůŽƉŵĞŶƚ ?. Due to its ambivalence, 
the boundaries between corruption and informality fade. Following Ledeneva, I ask if 
informal practices corrupt a corrupted regime  W ŝŶ ŵǇ ĐĂƐĞ /ŶĚŝĂ ?Ɛ Ed&W ƉŽůŝĐǇ
implementation  W can it still be referred to as corruption?  
 
I did not set out to study this phenomenon, but was struck by the prevalence of accusations 
of corruption towards state officials and bureaucrats  W a notorious feature of contemporary 
Indian society  W and of accusations of informality/illegality towards medicinal plant 
harvesters, growers and traders within Indian medicinal plant trade surveys and policy 
documents. In India, corruption has received ample consideration by anthropologists, 
particularly since the ground-breaking work by Akhil Gupta (1995, 2005, 2012). 33  His 
                                                     
33 In recent anthropological journal articles corruption in India has been interpreted as an  ‘ordinary space of 
ŶĞŐŽƚŝĂƚŝŽŶ ? ?ďĞƚǁĞĞŶůŽǁ-level state functionaries ĂŶĚƐƚƌĞĞƚŚĂǁŬĞƌƐŝŶDƵŵďĂŝ ?ŶũĂƌŝĂ ? ? ? ? ) ?ĂƐĂ ‘ŵĞĂŶƐ
to lower-ĐĂƐƚĞ ĞŵƉŽǁĞƌŵĞŶƚ ?  ?ŝŶ ŝŚĂƌ ? tŝƚƐŽĞ  ? ? ? ? ) ? ĂƐ ůĞŐŝƚŝŵŝƐŝŶŐ  ‘ƉƌŽǀŝƐŝŽŶĂů ĂŐĞŶĐǇ ?  ?ǁŝƚŚ ƉŽůŝĐĞ ŝŶ
Uttar Pradesh, Jauregui 2014) and as discursive re-constitution of the urban middle class and the state in 
rational and corporate-consumer terms (Khandekar and Reddy 2015). 
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analyses of popular narratives and media and fictional discourses of corruption in North 
Indian villages and beyond unravelled their contributions to reified, fetishised 
ƌĞƉƌĞƐĞŶƚĂƚŝŽŶƐŽĨ  ‘ƚŚĞƐƚĂƚĞ ? ĂŶĚ  ‘Đŝǀŝů ƐŽĐŝĞƚǇ ?ĂƐ Ɛƚ ďůĞ ?ƵŶŝƚĂƌǇĞŶƚŝƚŝĞƐ ? ƐĞƌǀŝŶŐ as an 
imperialist Western conceptual apparatus. Popular knowledge of the state is inextricably 
linked to notions of corruption as poor and illiterate villagers aim to cope with the structural 
violence inherent in bureaucratic encounters that is further exacerbated by corruption: 
The discourse of corruption turns out to be a key arena through which the state, citizens, and 
other organizations and aggregations come to be imagined. Instead of treating corruption as 
a dysfunctional aspect of state organizations, I see it as a mechanism through which the state 
itself is discursively constituted. Corruption is an essential lens for understanding the 
meaning of the state in the Indian context. (Gupta 2012, p. 78) 
 
 The argument I will elaborate in this chapter equally shows the shaping effect of corruption 
ĚŝƐĐŽƵƌƐĞƐŝŶƚŚĞĐŽŵƉŽƐŝƚŝŽŶŽĨƚŚĞƐƚĂƚĞ ?ŝŶƚŚŝƐĐĂƐĞŶŽƚďǇ ‘ƉŽŽƌǀŝůůĂŐĞƌƐ ?ŽƌƌĞŐŝŽŶĂů
media, but by (peri-)urban middle class herb wholesalers, traders and exporters. In addition, 
I look at how the state itself in the guise of policy makers and their documents mobilises a 
different (counter-)corruption discourse that accuses harvesters, cultivators and traders of 
illegal, unethical and corrupt practices in its struggle to come to terms with the messiness 
ŽĨĂƌĞŝĨŝĞĚŚĞƌďĂů  ‘ƐĞĐƚŽƌ ? ?DŽǀŝŶŐĨƵƌƚŚĞƌĂǁĂǇĨƌŽŵ'ƵƉƚĂ ?ƐǁŽƌŬĂŶĚŝŶ ůŝŶĞǁŝƚŚƚŚĞ
more recent and urban fieldwork in the East Indian industrial belt city of Jamshedpur 
(Sanchez 2012, 2015), I question informal/formal boundaries in the Indian economy in the 
wake of liberalisation. Sanchez collapses the distinctions between corruption and 
organised crime  W deĨŝŶĞĚ ĂƐ  ‘a cooperative practice that brings together capitalists, 
ĐŽƌƌƵƉƚŝŶƐƚŝƚƵƚŝŽŶĂůĂĐƚŽƌƐĂŶĚǀŝŽůĞŶƚĞŶƚƌĞƉƌĞŶĞƵƌƐŝŶŵƵƚƵĂůůǇďĞŶĞĮĐŝĂůƌĞůĂƚŝŽŶƐŚŝƉƐ
and is based upon the exchange of distincƚƐŬŝůůƐĂŶĚĂƌĞĂƐŽĨĂƵƚŚŽƌŝƚǇ ? (Sanchez 2015, p. 
68)  W as criminal entrepreneurs act as valves between licit and illicit economies. In so doing, 
the attention is shifted from public discourses on petty bribery (cf. Gupta, where villagers 
 ‘ŝŵĂŐŝŶĞ ?ĂĐŽƌĞŽĨƐƚĂƚĞĂĐĐŽƵŶƚĂďŝůŝƚǇĂƚŚŝŐŚĞƌůĞǀĞůƐ )ƚŽǀŝŽůĞŶƚĂŶĚƐǇƐƚĞŵĂƚŝc forms of 




2.2 Attempts at governing the wilds 
2.2.1 The global boom-bust cycles of the NTFP concept 
ƵƌŝŶŐ ŵŽƐƚ ŽĨ ƚŚĞ ůĂƐƚ ĐĞŶƚƵƌǇ  ‘ĨŽƌĞƐƚ ƉƌŽĚƵĐƚƐ ? ǁĂƐ Ă ƚĞƌŵ ƌĞƐƚƌŝcted essentially to 
industrially-processed timber and wood fibre, to the detriment of often equally or more 
valuable wild products, the majority of which descended into invisibility in natural resource 
policy and management across the globe (Laird et al. 2010). From the late 1980s onwards, 
however, the non-timber financial, socioeconomic and cultural values of forests were 
increasingly recognised due to a dramatic shift away from protectionist approaches  W 
epitomised by the creation of exclusive protected areas and restrictive treaties such as 
CITES in the 1970s, the Convention on International Trade in Endangered Species of Wild 
Fauna and Flora  W and towards the integration of sustainable use and social justice into the 
international conservation agenda. Propelled by the Brundtland Report that argued for 
sustainable development (World Commission on Environment and Development 1987), the 
ŽŶǀĞŶƚŝŽŶŽŶŝŽůŽŐŝĐĂůŝǀĞƌƐŝƚǇ ? ) ?ĂŶĚǀŽŝĐĞƐĨŽƌŝŶĚŝŐĞŶŽƵƐƉĞŽƉůĞƐ ?ƌŝŐŚƚƐ(Posey 
1996), NTFPs and their commercialisatŝŽŶĞŵĞƌŐĞĚŝŶƚŚĞŶŝŶĞƚŝĞƐĂƐ ‘ecologically benign 
and socially just income-ŐĞŶĞƌĂƚŝŶŐĂĐƚŝǀŝƚŝĞƐ ? (Laird et al. 2010, p. 3) that married the goals 
of conservation and development, ƌĞůǇŝŶŐŽŶƐůŽŐĂŶƐƐƵĐŚĂƐ ‘ƵƐĞŝƚŽƌůŽƐĞŝƚ ? (e.g. Akerele 
et al. 1991). The underlying assumption was that forests, and trees in particular, will be left 
intact despite and because of sustained NTFP collection (Neumann and Hirsch 2000). 
 
Although widely criticised for being vague, politically naïve and contradictory (see for 
example Escobar 1995), these conceptions are still pertinent to policy agendas of 
international NGOs and institutions such as the World Bank. Signed at the Rio Earth Summit 
of 1992 and legally binding for national government parties, the CBD further foregrounded 
access and benefit sharing as well as connections between the sustainable use of 
biodiversity and traditional knowledge although wild product governance was neglected. 
But as the gains of many NTFP commercialisation projects proved to be elusive, scientists, 
resource managers and policy makers were urged to face the real complexity of forest 
livelihoods (Alexiades and Shanley 2005b, Neumann and Hirsch 2000). Shackleton et al. 
(2011, p. 263 ) ĐŽŶĐůƵĚĞ ƚŚĂƚ  ‘the initial euphoria around using NTFPs for poverty 
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elimination and biodiversity conservaƚŝŽŶŚĂƐďĞĞŶƚĞŵƉĞƌĞĚ ?. Laird et al. (2010) add that 
international market-based conservation is often inappropriate and high risk (cf. Belcher 
and Schreckenberg 2007); local trade and subsistence use of NTFPs more often provide 
consistent opportunities for local communities. Moreover, commercial agriculture, logging 
and mining are frequently much more damaging to NTFP populations and forest than 
overharvesting. However, based on an extensive review of the NTFP literature, Pierce (2010) 
shows that NTFP commercialisation as a conservation-development tool is currently still 
the number one topic of interest. The number of NTFP studies has grown steadily during 
the last two decades, with the majority being published during the last few years 
(Shackleton et al. 2015).  Developing countries and rural areas are the most prevalent study 
sites, whereas Asia and India in particular have the most papers (Shackleton et al. 2011). 
 
Despite growing awareness of the significĂŶƚ ĐŽŶƚƌŝďƵƚŝŽŶ ŽĨ ƚŚĞƐĞ ĂůůĞŐĞĚůǇ  ‘ŵŝŶŽƌ ?
products to rural livelihoods and household income, most governmental agencies continue 
to considerably restrict the harvest of NTFPs because of the following reasons (Shackleton 
et al. 2015): (1) a colonial legacy from the previous century of prohibition, restriction and 
control; (2) global concerns of biodiversity loss seeming to justify stringent regulation, 
which often brings in revenue for authorities; and (3) a dearth of guidelines that promote 
ecologically sustainable harvesting, relating to the challenges of understanding, monitoring 
and managing a multitude of diverse species. As a consequence, many agencies have 
adopted a precautionary (Cooney 2004) instead of an adaptive governance approach, 
based on the stereotypical view of harvesting as a destructive activity with inevitable 
damaging effects for the individuals, species and ecosystems involved. Recently, NTFP 
experts have argued for the need to curb this dominant, pessimistic narrative by discussing 
case studies of ecologically sustainable harvesting approaches and of successful 
management (Shackleton et al. 2015), and by repositioning NTFPs on the development 
agenda (Shackleton and Pandey 2014). NTFPs have come full circle: oblivion and 
protectionism up to the 1980s, then euphoria over commercialisation into the 1990s, 
followed by disillusionment and critical appraisals of the complexities and difficulties 
involved at the outset of the new millennium, and now a careful reconsideration of their 
potential for ecological and socioeconomic sustainability. This process went hand in hand 
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with the late-twentieth century crisis of colonial, military top-town forestry  W related to 
lacking capacity, political will and legitimacy, as well as widespread rent-seeking  W and a 
global trend towards the decentralisation and devolution of forest management. Gradually, 
the FAO-backed stable equilibrium forestry model, with standardised sustained yields, is 
being replaced by ideas of dynamic, complex non-equilibrium human ecosystems and the 
management of common-pool resources as part of complex, responsive socio-ecological 
systems. Regrettably, as Laird et al. (2010) conclude, NTFP legal and policy frameworks are 
still largely unsuccessful. Common features leading to this failure are (1) broad policy 
prescriptions geared towards a single goal or category of products that are insensitive to 
differences between subsistence, local and commercial trade; (2) an overwhelming 
bureaucracy, especially inappropriate for small-scale harvesters and traders; (3) poorly 
coordinated regulations resulting in confusion about mandates and jurisdiction; and (4) 
underfunded, inconsistent policy implementation. The seemingly straightforward NTFP 
concept has itself gone through a series of boom-bust cycles reminiscent of the hype 
surrounding many natural products, while the effects of its (mis)application often leave 
much to be desired. This is also reflected in surveys of Himalayan and Indian medicinal 
plants, to which I now turn, to sketch both the trade itself and the discourses utilised in its 
description. 
 
2.2.2 Surveys of Himalayan and Indian medicinal plant trade 
The main human use of biodiversity by number of species is for medicinal purposes 
(Hamilton 2004, Schippman and Leaman 2006), amounting to more than 10,000 species in 
the Himalayas alone (Ghimire 2008).34 There is a large and growing global demand for 
herbal medicines (Hamilton 2004); trade surveys indicate that the botanical medicine 
industry is booming not only in the West (Laird 1999, Lange 2006), but especially in China 
(Liu et al. 2009) and the Himalayan region (Thomas et al. 2005). In China, a series of recent, 
fast and far-reaching transformations  W instigated by the institution of drug registrations 
                                                     
34  ‘DĞĚŝĐŝŶĂů ƉůĂŶƚ ? ŝƐ ŶŽƚ ĂůǁĂǇƐ Ă ĐůĞĂƌ-cut category because many  W if not most  W plants have several 
overlapping uses. This is why the acronym MAPs (Medicinal and Aromatic Plants) is often applied to indicate 
the confluence with spices, health foods and natural cosmetics (as for instance by Schippmann et al. 2002). 
/ŶƚŚĞh^ƚŚĞĞǀĞŶďƌŽĂĚĞƌƚĞƌŵ ‘ďŽƚĂŶŝĐĂůƐ ?ŝƐŝŶĐŽŵŵŽŶƵƐĂŐĞ ?>ĂŝƌĚ ? ? ? ? ) ?
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and the introduction of GMP  W led to the creation of a new Sowa Rigpa industry on the 
Tibetan plateau in less than a decade (Saxer 2013). This rapid industrialisation and 
concomitant commercialisation led to a thirtyfold increase in output value between 1996 
and 2006. 35  These findings clearly illustrate the growing importance of Himalayan 
medicinal plant trade, while it has been estimated that seventy to eighty percent of the 
Himalayan rural population continue to locally depend on medicinal plants for primary 
healthcare (Aumeeruddy-Thomas and Pei 2003). In the Himalayas, a high percentage of 
commercial NTFPs are medicinal plants  W estimates ranging between 143 and 161 in Nepal 
alone  W and an increasing trend towards large-scale commercial extraction is noticeable 
(Ghimire 2008). Malhotra and Bhattacharya (2010) estimate that 275 million 
underprivileged Indian rural people (more than a quarter of the total population) 
significantly depend on NTFPs for subsistence and cash income (see Tewari and Campbell 
1995 for a similar approximation). This NTFP sector annually provides roughly ten million 
workdays and the export value of NTFP-based products accounts for 68% of total forestry 
exports (Anonymous 2011). Forest-dwelling tribal communities, perhaps the poorest 
subset of the  ‘Scheduled Tribes ?, are especially dependent on forests and the majority is 
concentrated in the central-eastern dry deciduous forest belt where commercially valuable 
products such as myrobalan fruits and tendu leaves (Diospyros melanoxylon Roxb.) are 
available. It appears that India is the central, main market: Indian wholesalers import MAPs 
from all states across the Himalayan range worth millions of US dollars annually, and there 
is a huge domestic demand as well as considerable (re-)export (Mulliken and Crofton 2008, 
Olsen and Larsen 2003). 
 
How do these numbers relate to state interventions? In the Indian subcontinent, the 
harvest and trade of natural products has long been shaped and governed by smaller and 
larger kingdoms and empires, colonial powers, and recently the modern Republic. Indian 
systems of medicine as well as Sowa Rigpa are ancient traditions going back many centuries 
                                                     
35 In the Tibetan cultural areas in particular, Yunnan has seen a tenfold increase in harvested medicinal plant 
volumes over the last decade (Pei 2002). The two most valuable NTFPs in this area are the caterpillar fungus 
(yartsa günbu, Ophiocordiceps chinensis) and the matsutake mushroom (Tricholoma matsutake), both of 




(Ga 2010), and long-distance trade in many materia medica along the silk and musk routes 
likely even predates their origins (Akasoy and Yoeli-Tlalim 2007, Touwaide and Appetiti 
2013, van der Veen and Morales 2015). Customary laws and local institutions have 
presumably always played a major role in resource access and trade, and regional 
monarchies and princely states also had their say through a variety of legislation, 
administration and taxation systems. My interest in the statutory regulation of herbs and 
spices in the Indian subcontinent, however, begins with the institution of colonial 
governance under the rule of the British Crown in 1858. Succeeding the private rule of 
considerable parts of India by the English and later British East India Company (1600-1874), 
taking direct control of their overseas trade monopoly (initially mainly in spices, but 
dominated later by cotton textiles, tea and coffee) had been one of the main goals of the 
ƌŽǁŶƐŝŶĐĞƚŚĞŽŵƉĂŶǇ ?ƐŝŶĐĞƉƚŝŽŶ(Erikson 2014). The imperial period, the British Raj, 
ended in 1947 with interreligious violence and the partition into India and Pakistan. While 
the Republic was only established on 26 January 1950, the hallmarks of European-style 
modernity  W including state sovereignty, population surveillance (first all-India census in 
1872), citizen education (first Indian universities in 1857) and technological innovations 
(the first telegraph line between Calcutta and its harbour in 1851, railway construction 
from 1853, etc.)  W had already been introduced since the second half of the nineteenth 
century (Metcalf and Metcalf 2006). Modern, postcolonial India famously became the 
ǁŽƌůĚ ?Ɛ ůĂƌŐĞƐƚ ĚĞŵŽcracy, with its new constitution nonetheless retaining elements of 
colonial governance. Despite Hindu political and electoral dominance, India emerged as a 
ƐĞĐƵůĂƌ ƐƚĂƚĞ ŝŶ ƚŚĞ ǁĂŬĞ ŽĨ ƚŚĞ ƉĂŝŶĨƵů ŵĞŵŽƌŝĞƐ ŽĨ ƉĂƌƚŝƚŝŽŶ ĂŶĚ DĂŚĂƚŵĂ 'ĂŶĚŚŝ ?Ɛ
assassination. The new political order instigated by Prime Minister Jawaharlal Nehru and 
his party the Indian National Congress (INC, or the Congress) ushered in an era focusing on 
overcoming the colonial economic backwardness by agrarian reform and a state-controlled, 
planned economy along socialist lines. A full-fledged socialist (or Maoist) economy was 
never sought after nor achieved, however, despite tight regulations, as the following quote 
evidences:  
[o]ften little more than a tangle of permits, licenses, and credits, it never brought under its control the 
ǀĂƐƚǁŽƌůĚ ŝŶŚĂďŝƚĞĚďǇƚŚĞƉĞƚƚǇƚƌĂĚĞƌĂŶĚŵŽŶĞǇůĞŶĚĞƌ ?ĞŶĞĂƚŚƚŚĞ  ‘ƐŵĂůůŝƐŚƐŽĐŝĂůŝǌĞĚƐĞĐƚŽƌ ?
there existed what US Ambassador (1961- ? ? ? ? ) : ?< ? 'ĂůďƌĂŝƚŚ ŽŶĐĞ ĐĂůůĞĚ  ‘ƚŚĞ ǁŽƌůĚ ?Ɛ ŐƌĞĂƚĞƐƚ
example of functioninŐĂŶĂƌĐŚǇ ?. (Metcalf and Metcalf 2006, p. 246-247) 
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Even if aspects of the inefficient socialist regime endured, economic liberalisation opened 
up the country to the global multimedia and consumer culture. Notwithstanding an 
increasing urban middleclass, the income inequality gap has continued to widen since 
liberĂůŝƐĂƚŝŽŶ ?ĚŝǀŝĚŝŶŐ/ŶĚŝĂŝŶƚŽ ‘ĂůĂŶĚŽĨƚǁŽĞĐŽŶŽŵŝĞƐ ? (ibid., p. 297): a cosmopolitan, 
luxurious and urban consumer world versus the poverty in rural areas and squatter 
settlements with inadequate access to primary education and healthcare. Herbs, spices, 
medicinal and aromatic plants, and wild and agricultural products in general often straddle 
this rural-urban divide as they are traded in and (again) out of towns and cities, and their 
regional and global flows have been fundamentally altered by advances in technology, 
globalisation and trade liberalisation. Lele et al. (2010) present a national overview of 
historical shifts in Indian state  ƉŽůŝĐŝĞƐŽŶ ‘ŶŽŶ-ƚŝŵďĞƌĨŽƌĞƐƚƉƌŽĚƵĐƚƐ ? ?Ed&WƐ ) ?Žƌ ‘ŵŝnor 
forest products (MFPs) as they are commonly referred to across South Asia, observing a 
considerable gap between rhetoric and reality. The overview begins by noting how British 
colonial forestry  W with the primary objectives of maximising state revenue, supplying 
British industries and consolidating state control  W reserved large swathes of forest for 
exclusive state usage, focusing mainly on timber and a number of NTFPs with significant 
commercial value (e.g. pine resin or Acacia tree gum). After independence, forests 
continued to be viewed as national assets as they were exploited to support the on-going 
industrialisation. In the 1960s, protests against the exploitative forest policies were paying 
off as various commissions and committees pushed for more proactive and inclusive 
governance towards NTFP collectors, resulting in complicated institutional arrangements 
ƉĂƌƚŝĐƵůĂƌůǇ ŝŶƚŚĞĐĞŶƚƌĂů ĨŽƌĞƐƚďĞůƚƐƚĂƚĞƐ ?^ƵƐƚĂŝŶĂďŝůŝƚǇ ?ƵŶĚĞƌƚŚĞĨŽƌŵŽĨ  ‘ĞĐŽůŽŐŝĐĂů
ďĂůĂŶĐĞ ? ? ŽŶůǇentered the agenda in 1988. In the past two decades, several pieces of 
legislation pronounced the devolution of ownership and control towards forest, rural and 
tribal communities, but actual shifts in power have not been implemented in practice or 
even acknowledged; most interpretations of existing forestry law still take the state to be 
the owner of all NTFPs. 
 
Interestingly, the National Medicinal Plants Board (NMPB, Government of India) is absent 
from the abovementioned review. Founded in November 2000, iƚƐ ‘ĞŶƚƌĂů^ĞĐƚŽƌ^ĐŚĞŵĞ
for CoŶƐĞƌǀĂƚŝŽŶ ? ĞǀĞůŽƉŵĞŶƚ ? ĂŶĚ ^ƵƐƚĂŝŶĂďůĞ DĂŶĂŐĞŵĞŶƚ ŽĨDĞĚŝĐŝŶĂů WůĂŶƚƐ ? ǁĂƐ
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approved by the Government in 2008, and is now in its second, expanded edition (NMPB 
2015). In 2009, and in collaboration with WHO, NMPB also produced India-specific Good 
Agricultural Practices (GAP) and Good Field Collection Practices (GFCP) for medicinal plants 
in an attempt to educate industry stakeholders, and therefore ensure quality and 
sustainability. Based on interviews and documentary analysis, Gaudillière (2014) elucidates 
how NMPB and its cultivation policies have contributed to the creation, regulation and 
ƉŚĂƌŵĂĐĞƵƚŝĐĂůŝƐĂƚŝŽŶŽĨĂ ‘EĂƚŝŽŶĂůWůĂŶƚDĂƌŬĞƚ ? ?,ĞĐŽŵŵĞŶƚƐŚŽǁƚŚĞŝŶƚƌŽĚƵĐƚŝŽŶŽĨ
the Priority Species List  W based not on medicinal benefit but on market indicators for 
demand  W indicated the start of a new kind of federal policy, aiming to integrate the 
domains of forestry, agriculture, industrial pharmacy and the provision of health. But as 
NMPB did not succeed in improving the medicinal plant supply (evaluated in the available 
quantities of raw materials) within the first decade of its operations, its usefulness was 
highly contested in parliament in 2009 and 2010. Its focus on agricultural promotion and 
management had been a failure, with the lack of follow-up assessments and the mismatch 
between market prices and cultivation dynamics being major issues. Nevertheless, this new 
and emerging institutional landscape of agro-technical standardisation has led to 
increasing authority of a new group of scientists and experts, which further industrialised 
medicinal plant regulation. Clinical actors and medical concerns are increasingly 
marginalised as pharmacy comes to be equated with the drug industry and the mass-
production and management of medicinal plants.  
 
Between  ? ? ? ? ĂŶĚ  ? ? ? ? ĨŽƵƌ ŶĂƚŝŽŶĂů ƌĞƉŽƌƚƐ ŽŶ /ŶĚŝĂ ?Ɛ ŵĞĚŝĐŝŶĂů ƉůĂŶƚ ƚƌĂĚĞ ǁĞƌĞ
published. Possibly the first report of its kind and published under the auspices of the 
Canadian International Development Research Centre (IDRC) and the Medicinal and 
Aromatic Plants Programme in Asia (MAPPA, initially supported by the Ford Foundation), 
The Medicinal Plants Sector in India (Holley and Cherla 1998) is based on official macro-
level trade data and micro-case studies available in the literature, as well as discussions 
with experts in the field. In summary, the report concludes that India may be the largest 
supplier of raw materials globally (with many untapped opportunities) but that the sector 
is mostly informal (but functional) and based on wild-harvest which is unsustainable (with 
a declining resource base) and inequitable. Interestingly, Holley and Cherla (1998) note that 
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the sheer number of medicinal plants and the extreme diversity of stakeholders are actually 
not part of a single (formal) sector. Instead, they span across and beyond forestry, 
agriculture, healthcare and industry. The authors further note that there is an insufficient 
knowledge base for adequate and strategic development particularly from a socio-
economic perspective, as well as a tendency to oversimplify the market. Recommended 
interventions towards achieving an equitable and thriving medicinal plant industry involve 
setting-up a national and representative authority or board (i.e. the NMPB, founded in 
2000), strengthening cooperatives and importantly the formalisation and organisation of 
the market: 
A key task is to bring a greater degree of formality and organization to a market which has 
been shown to be inefficient, imperfect, informal, and opportunistic. If a greater degree of 
formality cannot be achieved in the market, it is unlikely that other efforts will be of 
significant use in preserving traditional medicine and its resource base. The call for formality 
is not, however, a call for state intervention per se; nor is it a call for a Marketing Board, as 
some have suggested. (Holley and Cherla 1998, p. 77) 
Carrying on in the same vein, Subrat et al. (2002) published a second national report. It 
covers the ĐŽƵŶƚƌǇ ?Ɛ ǇƵƌǀĞĚŝĐ ŵĞĚŝĐŝŶĞ ŝŶĚƵƐƚƌǇ, and is based on interviews with 
representatives from industry and research institutions, supplemented with a 
questionnaire sent to the largest manufacturers, and field data collection on trade volumes 
and prices in major cities. They assessed the then-current state as follows:  
Adjectives that most readily come to the mind while attempting to describe the nature of the 
ŵĞĚŝĐŝŶĂůƉůĂŶƚƐƚƌĂĚĞŝŶ/ŶĚŝĂĂƌĞ ‘ĞǆƚƌĞŵĞůǇĐŽŵƉůĞǆ ? ? ‘ƐĞĐƌĞƚŝǀĞ ? ? ‘ƚƌĂĚŝƚŝŽŶĂů ? ? ‘ĐŽŶĨƵƐŝŶŐ ? ?
 ‘ďĂĚůǇ ŽƌŐĂŶŝƐĞĚ ? ?  ‘ŚŝŐŚůǇ ƵŶĚĞƌ-ĞƐƚŝŵĂƚĞĚ ? ĂŶĚ  ‘ƵŶƌĞŐƵůĂƚĞĚ ? ? dŚĞƌĞ ŝƐ ŶŽ ŵĂĐƌŽ ůĞǀĞů
data/information available for assessing the nature and extent of the trade; whatever is 
ĂǀĂŝůĂďůĞ ĐŽŵƉƌŝƐĞƐ  ‘ŐƵĞƐƐƚŝŵĂƚĞƐ ? Žƌ ĞǆƚƌĂƉŽůĂƚŝŽŶƐ ďĂƐĞĚŽŶ ŵŝĐƌŽ ƐƚƵĚŝĞƐ ? dŚĞƌĞ ŝƐ ŶŽ
systematic local, regional or national level data regarding number of species traded 36 , 
volumes, prices etc. with any one agency. Most of the data is disjointed, scattered, grossly 
inadequate and incomparable. (Subrat et al. 2002, p. 23) 
                                                     
36 A considerable part of the problem with assessing species-level trade is the unreliability of the equivalence 
between trade and botanical names, as was also identified by Subrat et. al (2002). I discussed this issue for 
Tibetan medicinal plants in Chapter 1. 
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More than eight thousand licensed Ayurvedic manufacturing units were found, but that 
number should be more than doubled to include the many small-scale, unlicensed cottage 
industries. The overall turnover of the industry was estimated at Rs. 45 billion (roughly 672 
milion USD) in the year 1998. The formal section of the sector is dominated by a small 
number of very large companies of which the sales of the top four reached above one 
billion rupees (roughly 15 milion USD) in 1998-1999, while the biggest (Dabur India Ltd) was 
worth more than three billion INR. All transactions carried out with and by wholesalers are 
nonetheless informal and without written contracts. The three most common plant 
ingredients in Ayurvedic formulas are the fruits of Terminalia chebula, T. bellerica and 
Emblica officinalis, although roots are the most often-used plant part (estimated 29,6%) 
and herbs the most common plant habit (more than 50%). Of the roughly 500 species in 
commercial trade, only ten percent is cultivated in private fields. This includes well-known 
herbs and spices such as ginger, coriander, curcuma and garlic. The main supply channel 
starts with the collector, who sells her/his harvest on to a local agent in the village. This 
agent then ƐĞůůƐŚŝƐŐŽŽĚƐĂƚƚŚĞŶĞĂƌĞƐƚ ‘ŵandi ? (minor market) to a trader or wholesaler, 
who transports it to a major market, where it is sold again to larger wholesale dealers or 
exporters (who bring it to the main market), or retailers, often via a commission agent. 
Delhi is the main market of Northern India, and the second-largest exporting city after 
Mumbai, while Amritsar is the major market of the Punjab. Between 1998 and 2000 up to 
500 metric tons of T. chebula was traded yearly in Delhi. For these dried fruits, villagers 
received 7-8 Rs./kg (0.10-0.12 USD) on average, agents or middlemen 9 Rs. (0.13 USD), the 
regional commission agent 12 Rs. (0.18 USD), the commission agent in Delhi 15 Rs. (0.22 
USD), and the wholesaler 20-22 Rs. (0.30-0.33 USD) The final price for which they were sold 
by traders or retailers was then 27 Rs. per kg (0.40 USD). This means that collectors got a 
26-30% share of the final price for this product. 
The third report, Nagpal and Karki (2004) ?ƐĚĞƐŬ-based study of secondary resources (again 
under IDRC and MAPPA), once more confirms India as a key player at the heart of the South 
Asian trade in MADPs (Medicinal, Aromatic and Dye Plants) in unprocessed form. As was 
equally noted by Subrat et al. (2002), a huge demand-supply gap was noted in India for 
high-value, low-volume South Asian products. A factor fifty difference for Himalayan 
species such as Dactylorhiza hatagirea, Gentiana kurroo and Picrorhiza kurroa was 
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estimated, confirming the importance of trade with neighbouring countries and especially 
Nepal (and via Kathmandu with Lhasa). Interestingly, Nagpal and Karki describe the trade 
structure as highly secretive, but well-organised (as opposed to Subrat et al. 2002), albeit 
through strong informal business networks and almost exclusively without reliance on 
formal documentation.  
Fourthly, Ved and Goraya ?Ɛ (2008) short-term study is the most recent with a national focus. 
It was funded by NMPB and carried out by staff of the Foundation for Revitalization of Local 
Health Traditions (FRLHT, based in Bangalore/Bengaluru). Relying on literature review and 
fieldwork (surveys of a sample of trade centres and rural households and visits to 
cultivation sites), it reports 9,500 registered herbal industries (1,500 more than Subrat et 
al. 2000, who focused on Ayurveda) and attempts to give a comprehensive list of 960 
medicinal plant taxa (source of 1289 botanical raw materials) in trade, of which 176 species 
are in high trade (> 100 metric tons annually). Annual demand was estimated at 319,500 
metric tons of dried crude materials for 2005-2006, of which 177,000 (55%) from the 
domestic industry, 86,000 (21%) from rural households, and 56,500 (18%, based on 2004-
 ? ? ? ? )ĨƌŽŵĞǆƉŽƌƚƐ ? ‘Amla ? ?Emblica officinalis, dried fruit) is most important for domestic 
consumption, while Psyllium seed husks (Plantago ovata), Senna (leaves and pods), Henna 
(Lawsonia inermis, leaves and powder), and myrobalans account for nearly 70% of the total 
crude plant exports by volume. 
 
Because of the large trade volumes presented above, medicinal plants have been given a 
central role in conservation and development. The manipulation of markets and 
commercial ƚƌĂĚĞĨŽƌƚŚĞďĞŶĞĨŝƚŽĨďŽƚŚƉĞŽƉůĞ ?ĞƐƉĞĐŝĂůůǇ ‘ƉŽŽƌ ?ŝŐŶŽƌĂŶƚĂŶĚĞǆƉůŽŝƚĞĚ
ĐŽůůĞĐƚŽƌƐ ? ) ĂŶĚ  ‘ĞŶĚĂŶŐĞƌĞĚ ? ƉůĂŶƚƐ  W or more cynically to increase state control and 
revenues  W has gained centre stage. In relation to this, Larsen and Olsen (2007) have 
identified four commonly held assumptions concerning Himalayan medicinal plant trade 
and conservation based on a survey of 175 collectors, traders and government staff (Larsen 
and Smith 2004) and on a literature review of 119 publications by researchers, (I)N'K ?Ɛ
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and policy makers from Nepal37: (1) overall degradation of the resource base due to rising 
demand, (2) the prevalence of open-access harvesting, (3) cultivation as the optimal 
solution, and that (4) harvesters are cheated by middlemen. None of these preconceptions 
turned out to be well supported by empirical evidence. Although there are certainly 
reasons to be concerned about the conservation of certain Himalayan MAPs, we should be 
critical about the validity of the assumptions on which these concerns are based and on 
ǁŚĂƚƚŚĞƐĞŝŵƉůǇĨŽƌƉĞŽƉůĞ ?dŚĞƐĞƉĞƌĐĞƉƚŝŽŶƐŽĨƌƵƌĂůŝƌƌĞƐƉŽŶƐŝďŝůŝƚǇ ? ‘ƉŽŽƌ ?ŝŐŶŽƌĂŶƚĂŶĚ
ĞǆƉůŽŝƚĞĚĐŽůůĞĐƚŽƌƐ ? )ĂŶĚŽǀĞƌŚĂƌǀĞƐƚŝŶŐ W both seen in relation to rising demand  W seem 
to get perpetuated without much evaluation and are validating authoritarian policy 
interventions in the trade and conservation of Himalayan plants. This has in turn led to 
widespread illegal rent-seeking (Larsen and Olsen 2007). The current situation in some 
ǁĂǇƐ ƌĞƐĞŵďůĞƐ ƚŚĞ ĨůĂǁĞĚ ƚŚĞŽƌǇ ŽĨ  ‘,ŝŵĂůĂǇĂŶ ĞŶǀŝƌŽŶŵĞŶƚĂů ĚĞŐƌĂĚĂƚŝŽŶ ?(Forsyth, 
1998). This time it is not upland Nepali farmers, but harvesters who are the proclaimed 
culprits. Even though a whole suite of governmental and non-governmental institutions 
aims to understand and streamline the herbal industry, it often remains unfathomable. 
Studies alternatively emphasise its elaborate organisational structure (usually in the form 
of supply chains) or the rampant secrecy, chaos, illegality and corruption. These are two 
sides of the same coin, and cannot be easily correlated with macro/micro or 
outsider/insider perspectives. There have been some more recent efforts to come to terms 
with this two-sided nature. Pauls and Franz analyse the medicinal plant production network 
within Uttarakhand, aiming to identify how (partly) clandestine entities and structures 
constrain cultivation and rural development. They problematisĞ ƚŚĞ  ‘the hidden 
ĞŵďĞĚĚĞĚŶĞƐƐŽĨŵŝĚĚůĞŵĞŶ ? (Pauls and Franz 2013, p. 229) in overcoming illegality, and 
their ability to bypass taxation and certification systems. The so-called middlemen are said 
to act as patrons and service providers to small farmers while at the same time exploiting 
their lack of understanding of the trade (of prices, structure, and even what is legal). They 
further note that local norms may not consider illegal practices to be illegitimate. Including 
non-commercial and informal actors in the production network brings us one step closer 
to a more holistic insight (Figure 2.3). 
                                                     
37 A preliminary survey by the same authors has found the same assumptions in the literature on India and 
Pakistan, a finding confirmed by my own literature search and fieldwork. The medicinal plant trade of Nepal 




Figure 2.3 ?hƚƚĂƌĂŬŚĂŶĚ ?ƐŵĞĚŝĐŝŶĂůƉůĂŶƚƉƌŽĚƵĐƚŝŽŶŶĞƚǁŽƌŬĂĐĐŽƌĚŝŶŐƚŽWĂƵůƐĂŶĚ&ƌĂŶǌ ? ? ? ? ? ?Ɖ ? ? ? ? ) ? 
 
However, I intend to question the facile correlation of the legal with the formal, and the 
illegal with the informal, by exposing the ambiguities of current regulations and corrupt 
practices in state institutions, showing how traders are obliged to navigate across 
boundaries. Pauls and Franz indicate in their graph that collectors, farmers, wholesalers 
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and exporters are on this in/formal edge. I expand on this by arguing that all actors are 
 ‘ǁĂůŬŝŶŐŝŶƚŚĞĚĂƌŬ ? (ibid., p. 232), blurring distinctions between the informal and formal 
economies. Dejouhanet makes a similar argument for the Ayurvedic industry in Kerala 
(South India), which growth is slowing down as raw material prices have risen inordinately. 
She notes a shift from the use of fresh materials from nearby areas towards more dried 
ŚĞƌďƐ ?ĐĂůůĞĚ ‘ďĂǌĂĂƌĚƌƵŐƐ ? )ďĞŝŶŐƵƐĞĚƚŚĂƚĂƌĞƐŽƵƌĐĞĚĨƌŽŵĨĂƌƚŚĞƌĂǁay, evidencing the 
flexibility of traditional formulas in the face of market constraints and opportunities. The 
monopolistic, integrated government supply chain set up at the end of the 1970s in Kerala 
excluded non-tribal collectors, local middlemen and private merchants, thereby creating 
an illegal sector that organised itself (much more flexibly) and subsequently overtook (and 
partly appropriated) the official system in importance, as most manufacturers came to 
largely rely on their own informal supply networks. But as the supply area expanded to 
make up for the dwindling availability, the gap between collectors and manufacturers 
widened. This segmentation not only inhibits oversight by manufacturers and the potential 
implementation of sustainable harvesting practices, but also increases the number, and 
bargaining power, of middlemen, which in turn reduces incentives for local collectors 
(Dejouhanet 2014a). The paradox of Indian medicinal plant trade  W that the principal 
commercialisation networks that run in parallel with the highly regulated system are not 
recognised by the state and therefore characterised by opacity  W forced Dejouhanet (2014b) 
to think beyond the informal/formal dichotomy. In the official, state-sanctioned scheme, 
materials are only provided to the private sector via regional auction if there is a surplus 
remaining after the public industries have taken their share. But when mapping the real 
ĨůƵǆĞƐŽĨƚŚĞƐĞƉƌŽĚƵĐƚƐĨƌŽŵĐŽůůĞĐƚŽƌ ?ƐǀŝůůĂŐĞƐĂŶĚůŽĐĂůĐŽŵŵĞƌĐŝĂůŽƵƚůĞƚƐ ?ŶŽƐŝŵƉůĞ
distinctions between public and private were apparent. In this, stock keepers with a savvy 
eye for business play a dual, and in the eyes of the state, dubious role by supplying both 
sectors, creating hybrid networks. The messy intricacies and implications of this quasi-
formal business reality are often glossed over in NTFP analyses and trade surveys, or 
perhaps mentioned as a source of reduced data reliability. The function of these studies is 
exactly to elucidate and clarify, or at least to indicate potential policy actions in this 
direction. In what follows, I swim against the tide, highlighting the convoluted and 
labyrinthine nature of Indian medicinal plant trade through my own experiences in markets 
and with traders. 
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2.3 Domestic business- -usual: a quasi-formal economy 
2.3.1 The large wholesale markets of Delhi and Amritsar 
As I related at the outset of this chapter, it is easy to get lost, overwhelmed and misled in 
ĞůŚŝ ?ƐƐƉŝĐĞŵĂƌŬĞƚ ?In Amritsar, I encountered similar things. Close to Muslim-dominated 
Pakistan (hence the large number of Unani medicine practitioners, called hakim) and 
particularly well-known for its Himalayan herbs coming from the bordering states of Jammu 
and <ĂƐŚŵŝƌ ? ,ŝŵĂĐŚĂů WƌĂĚĞƐŚ ? ĂŶĚ hƚƚĂƌĂŬŚĂŶĚ ? ŵƌŝƚƐĂƌ ?Ɛmateria medica  ‘ŵĂƌŬĞƚ ?
(called Majith Mandi) is actually spread out over a network of narrow streets and alleys 
near Harmandir Sahib, the famous Sikh Golden Temple.  
 
Over the loud sounds of rickshaw horns and while sweating from a dust heat index of forty-
eight degrees Celsius and drinking copious amounts of chai, I learned that here too long-
established rĞůĂƚŝŽŶƐ ĂƌĞ ƚŚĞ ƚƌƵƐƚĞĚ ŶŽƌŵ P  ‘where my great-grandfather was taking 
medicine from his great-ŐƌĂŶĚĨĂƚŚĞƌ ?, as a local Ayurvedic vaidya confirmed (Audio 
recording 107). There is much distrust. Practitioners who have their own small pharmacies 
accuse large for-profit companies of leaving out essential ingredients or opting for sub-
standard quality, comparing market prices for raw materials with the sometimes 
surprisingly cheap commercial products that are supposed to contain them. Nonetheless, 
it is practically unheard of to ask wholesalers about their sources as a returning customer 
( ‘ŝƚŝƐƚŚĞŝƌďƵƐŝŶĞƐƐ ?, diary, 4 July 20 ? ? ) ?ůĞƚĂůŽŶĞĂƐĂŶŽƵƚƐŝĚĞƌ ? ‘that is our trade secret, 
please don ?ƚĂƐŬƚŚĂƚ ?/ƚŝƐŽƵƌƵŶĚĞƌƐƚĂŶĚŝŶŐǁŝƚŚƚŚĞŵ ?, Audio recording 106). Without 
prior expert knowledge, obtaining high-quality herbs for a good price is a lost cause, as a 
trader who has been in business for more than fifty years (and his father and grandfather 
before him since 1819), and who has been selling to Tibetans for forty years ensured me.  
You will know about that after quite a long time. From experience. You have to select a good 
shop to buy good things, I am telling you frankly. In India they show you something and give 
ǇŽƵ ƐŽŵĞƚŚŝŶŐ  ?ĞůƐĞ ? ?  ? Q ?  ŶĞǁ ƉĞƌƐŽŶ ĐĂŶ ?ƚ ĚŽ ďƵƐŝŶĞƐƐ ŝŶ ƚŚĞƐĞ ŚĞƌďƐ ? KŶůǇ ǁŝƚŚ
experience you can do this. [Otherwise,] you will see all things are same, but they are not, 
they are different. 
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These seasoned wholesalers may visit important clients but have no need to travel to 
sourcing areas themselves, instead relying on commission agents, who themselves work 
with an extended network of intermediaries. Enquiring about costus provided mixed 
reactions. Although it was still widely available, it was costly and sensitive. Rather vaguely 
aware of its legal status ( ‘ǇŽƵŶĞĞĚĂůŝĐĞŶƐĞƚŽƐĞůůŝƚ ? ? ‘ŝƚŝƐďĂŶŶĞĚ ?), I was told it would be 
illegal for me to carry it home ? ‘But do you still want a sample? ? 
 
 
Figure 2.4 ?dŚŝƌĚĂŶĚĨŽƵƌƚŚŐĞŶĞƌĂƚŝŽŶƐƚŽƌĞŬĞĞƉĞƌƐŝŶŵƌŝƚƐĂƌ ?ƐDĂũŝƚŚDĂŶĚŝ ?ǁŝƚŚƚǁŽƐŚŽƉĂƐƐŝƐƚĂŶƚƐ ?ĨƌŽŶƚůĞĨƚ
and background). Photograph taken by the author on 4 July 2015. 
 
2.3.2 An exporter in Gurgaon 
Before I met this exporter in person, I was ensured at PADMA that Dr Anton Saini38 would 
be an easy-going person to talk to (Audio recording 61). Part of the gardener sub-caste by 
                                                     
38 In contrast to the rest of the thesis, pseudonyms are used in this chapter in order not to reveal the exact 
identity and whereabouts of traders, to protect them and their relations from any possible negative 
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birth, he had studied botany in Germany (hence his first name) and obtained a doctoral 
degree in plant pathology. After that, he had worked as a consultant for the Swiss 
multinational Sandoz (which later became Novartis), writing a report on the precarious 
state of the agricultural sector in India. Along the way he became interested in medicinal 
plant cultivation as a potentially pesticide-free income alternative for farmers. Pursuing 
this interest with a critical mind but as a newcomer, Anton learned a lot about the herbal 
industry the hard way (see section 2.4). A friend suggested that he should make use his 
expertise by going into medicinal plant exports. He first contacted PADMA in 2003 and was 
consecutively employed as a consultant between 2004 and 2006, gathering information 
and herbarium specimens of PADMA 28 ingredients growing in India. Because of his 
friendly nature, scientific background, and familiarity with both Europe and India, he 
became an essential transcultural middleman and supplier. Dr Saini had returned to his 
parental home in Gurgaon to have a family after his studies. It was there that I first met 
him (Fieldnotes VII, Audio recording 70, 3 March 2014). 
 
Gurgaon city can be reached with the Delhi metro in less than an hour. Also called 
 ‘DŝůůĞŶŶŝƵŵŝƚǇ ? ?ŝƚƐƐƉƌĂǁůŝŶŐƵƌďĂŶŝƐĂƚŝŽŶĂŶĚŶƵŵĞƌŽƵƐƐŬǇƐĐƌĂƉĞƌƐƚĞƐƚŝĨǇŝƚƐƌŽůĞĂƐĂ
one of the leading financial and industrial centres of India over the last decade. Dr Saini and 
I had a leisurely lunch in a fancy restaurant with table linen and an extensive buffet, where 
we discussed his work with PADMA. He regularly exports dried myrobalan fruits (Terminalia 
chebula), pomegranate seeds (Punica granatum L.), bael fruits (Aegle marmelos (L.) Corrêa), 
cotton tree flowers (Bombax ceiba L.), and country mallow (Sida cordifolia L.). Anton 
sources chebulic myrobalan from the forests of Maydya Pradesh in central India, where 
 ‘tribals ? collect and dry the fruits. He found that he could not trust the Delhi wholesalers, 
especially since he is not local (even though Gurgaon is right next to Delhi) and since he 
needs to supply PADMA with batches of consistent high quaůŝƚǇ ?ƚŚŝƐǇĞĂƌ ?ƐŚĂƌǀĞƐƚ ?ǁŝƚŚ
uniform colour and shape).  
I never buy from them. I went to these markets; you cannot rely on them. I thought, better 
to go to the place where it is produced, find a local man, give him a bit more money, tell them 
                                                     
consequences of my and their actions and statements. Supplier details are generally considered economically 
sensitive information, making secrecy a typical trait of the industry. 
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what material we need, and go from there. It is easier to travel there, see the material, take 
what you want, and take money in cash and then transport. This is what I do. We need a 
middleman, but not the big wholesaler. 
 
A similar setup has worked for him for pomegranate, which grows abundantly on farmer 
private land on the hills of Himachal Pradesh, and for bael fruits. When the materials arrive 
at his place however, several days labour are often still required to manually clean, sort, 
and dry them further to reacŚ WD ?Ɛ ƐƚĂŶĚĂƌĚƐ ? ĨƚĞƌ ůƵŶĐŚ ? ǁĞ ĚƌŽǀĞ ŽǀĞƌ ƚŽ ŚŝƐ
parental house in the much quieter and older Gurgaon village. There, he had a small herb 
processing unit: a shaded drying area with two fans, two storage rooms, and more space 
to dry herbs on top of the roof. An older man and his son who had a room on the premises 
were employed as care-takers, and their woƌŬǁĂƐŽǀĞƌƐĞĞŶďǇŶƚŽŶ ?s wife. For some 
plants however, Anton was not able to find any reliable source.  
 
I went on a Sida collection trip with Anton and his most senior worker during a second visit 
to Gurgaon more than a year later (Fieldnotes XI, 11 August 2015). The monsoon was 
hitting hard, and many streets were flooded for days. While driving outside the city centre 
for about forty kilometres, he assured me that there was no pollution in Haryana, meaning 
that there was no heavy industry with smoking chimneys in the area (although the air 
quality is record-breakingly bad in nearby Delhi). Gurgaon is famous for its burgeoning auto, 
IT, and commercial industry, which are relatively clean. He admitted there was some waste 
disposal here and there, but said that at least it is not spoiling the air. It had initially taken 
him a lot of effort to locate the area to which we were headed, and to pinpoint the good 
patches that lay scattered across abandoned fields. Initially, he had attempted to organise 
a small group of local youngsters to do the harvesting but this experiment failed. They 
found the work too hard, harvested indiscriminately, and soon lost interest. When Anton 
came with his own men to collect, the locals resisted, so they looked for another spot a bit 
further along the road. It was vacant land, and here no questions were asked. The first time 
they harvested was in 2005, and the last Sida (Sanskrit name bala, Unani name khireti) 
order from PADMA that came through in 2012 was 500 kg. On a normal harvesting day, a 
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group of three to five men would reach the area around eleven and finish before four pm 
during the second half of August. Using scissors  W not sickles as these are less selective  W 
the group can gather roughly 30-35 kg of dried material a day (80% of the weight is lost 
during drying and sorting), so the whole operation would usually take about a month. The 
collectors are asked to only collect half of the plants to stimulate regeneration for later 
years. A worker would be paid a fixed salary of at least 400 rupees (6 USD) per day, with 
tea, food, transport, and processing further adding to the costs.  
 
We arrived in the harvesting area. We drove by one of their better patches, but the recent 
construction of a bus stand had obliterated it. New hotels, warehouses, a school, a hospital, 
and a mandir had all been constructed over the past few years along the main road, and 
more was underway. Sorghum was also being cultivated in small fields. We stopped at a 
small shack on the roadside. Over some chai, Dr Saini noted how a yellow-flowered 
herbaceous plant had become much ŵŽƌĞĐŽŵŵŽŶ ?,ĞǁŽŶĚĞƌĞĚǁŚǇ ? ‘ŝƚŵƵƐƚďĞƐŽŵĞ
ĐǇĐůĞ ?. On top of that, congress grass (Parthenium hysterophorus L.)  W a well-known invasive 
species that arrived in the country with imported wheat  W was increasingly dominating the 
landscape. The shopkeeper, dressed in a bright pink sari, agreed: she had suffered from 
severe allergic skin reactions after handling these plants. I joined Anton ?Ɛmost senior 
worker on a walk to assess the amount of Sida remaining. This herb emits a particular smell 
when growing, which helps in locating patches. The land on which it grows is near an 
electrical power distribution hub, hence the transmission towers. The outcome was not 
very encouraging. Anton concluded that they probably would not be able to collect the 
necessary amount of one thousand kilos dried material this year, even though we located 
some more promising patches later on. Since there was no order for more than two years, 
they had lost oversight, and because the order from PADMA only recently came in there 





Figure 2.5. Harvesting area of Sida cordifolia outside Gurgaon (Haryana) dominated by the toxic invasive species 
Parthenium hysterophorus. 
 
This failed harvesting excursion is but one example that helped me to re-evaluate the 
ubiquitous commercial overharvesting discourse as a small piece of a much larger puzzle: 
rapid urbanisation and concomitant land grabbing, invasive species, and complex 
interrelations between harvesting, disturbance and regeneration cycles. The collection 
area itself also diffuses romantic distinctions between rural and urban spaces and between 
ǁŝůĚĂŶĚĐƵůƚŝǀĂƚĞĚƉůĂŶƚƐ ?ǁŚŝůĞƐŚŽǁŝŶŐƚŚĂƚ ‘ĨŽƌĞƐƚƐ ?ĂƌĞďƵƚŽŶĞĂŵŽŶŐƐƚŵĂŶǇƐŽƵƌĐŝŶŐ
habitats and that adivasi39 are not the only harvesters. After the Sida plants have been fully 
dried, they are stored in large polyethylene bags that go into sealed drums. A transit permit 
is not necessary in this case, as so much traffic that crosses the Haryana state border to 
Delhi is export-oriented. Dr Saini has to prepare the invoice and the packing list. After 
                                                     
39 Adivasi is a Hindi umbrella term for often rural ethnic minorities. In the Indian Constitution these are 
ĐĂƚĞŐŽƌŝƐĞĚĂƐ ‘^ĐŚĞĚƵůĞĚdƌŝďĞƐ ?ĂŶĚŐƌĂŶƚĞĚĐĞƌƚĂŝŶĞǆĐůƵƐŝǀĞůĂŶĚƌŝŐŚƚƐƐƵĐŚĂƐƚŚĞŚĂƌǀĞƐƚŽĨ ‘DŝŶŽƌ&ŽƌĞƐƚ
WƌŽĚƵĐƚƐ ? ?ĂƚůĞĂƐƚŽŶƉĂƉĞƌ ?ƐĞĞĂŐĂŝŶ>ĞůĞĞƚĂů ? ? ? ? ? ) ?
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customs, the materials travel Delhi-Mumbai by train, where it is then shipped to Hamburg. 
This process, however, is fraught with difficulties, as we will see in sections 2.4. 
 
2.3.3 Cultivating and trading costus (and more) from Lahaul 
Costus has been cultivated as a cash crop in small fields for almost a hundred years (see 
Figure 2.6). It was first described botanically, as a new species with a binomial name, by Dr. 
Hugh Falconer (1808-1865, Falconer 1841, pp. 456-457), who was the superintendent of 
ƚŚĞĂƐƚ/ŶĚŝĂŽŵƉĂŶǇ ?ƐďŽƚĂŶŝĐĂůŐĂƌĚĞŶĂƚ^ĂŚĂƌƵŶƉŽƌĞ ?Uttar Pradesh) at the time. As 
was also noted by Falconer, Saussurea costus (Falc.) Lipsch. (now the accepted name) is 
endemic to a geographically restricted part of the Western Himalayas, growing wild in small 
patches on 2600-4000 m high moist slopes mainly in Kashmir, and perhaps also in Himachal 
Pradesh, Uttarakhand and Northwest Pakistan. NMPB scientists have prioritised Saussurea 
costus as one of the thirty-two  ‘ŝŵƉŽƌƚĂŶƚ ŵĞĚŝĐŝŶĂů ƉůĂŶƚƐ ŝŶ ƐŚŽƌƚ ƐƵƉƉůǇ ? ? ǁŚŝůĞ
acknowledging the lack of empirical population data and the limitations and problems of 
cultivation (Kala et al. 2006). Kumar et al. (2011) researched the distribution of MAPs in 
Ladakh, discussing and listing endemic and endangered species and their use in common 
Tibetan medical formulations. Besides coming up with a technocratic model for the 
conservation and sustainable development of the trans-Himalayan medicinal plant sector, 
Kumar et al. also ranked ruta as the single most important trans-Himalayan medicinal plant 
used in Tibetan medicine, based on the number of times it was mentioned as an ingredient 
in available formularies (Phuntsog 2006, Tsarong 1986). It is currently cultivated in small 
fields by families from Lahaul Valley and Uttarakhand who obtained export permits, as well 
as in Ladakhi herbal gardens (cf. Blaikie 2009). Blaikie (2009) describes how well-educated, 
ƌĞůĂƚŝǀĞůǇ ǇŽƵŶŐ  ‘ĐĂƌĞĞƌ ĂŵĐŚŝ ? ĂƌĞ ĐĂƵŐŚƚ ƵƉ ŝŶ ƚŚe paradox that arises from the 
(proto-)industrialisation of traditional medicine production, which is still largely reliant on 
wild-sourced raw materials. Increased production, fuelled by cultivation projects of a few 
species for the sake of biodiversity conservation, inescapably necessitates more harvest or 
purchase of many other, potentially threatened wild species which are not always easily 
substitutable. It also consolidates a specific model of urban clinical practice as part of 
medical modernisation and professionalization processes, while having ambiguous 
reverberations on small-scale medicine producers and rural practitioners. 
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China used to be completely reliant on Indian imports, but this changed drastically after 
the China-India war of 1962, when Chinese cultivation commenced. According to the CITES 
database, China exported 1,024 tons of roots and derivative products globally between 
1983 and 2009 compared to only 266 tons from India, while there is also considerable 
evidence for illegal trade. Described by Kuniyal et al. (2005, p. 1035) ĂƐ ‘the oldest cash 
crop ŝŶ ƚŚĞ ĐŽůĚ ĚĞƐĞƌƚ ĞŶǀŝƌŽŶŵĞŶƚ ?, kuth (the most common Hindi name for costus) 
cultivation was found to be in a bottleneck due to factors such as the lengthy reproductive 
cycle (up to three years), small land holdings, and fluctuating and low market prices that 
led to farmers shifting to the more profitable cultivation of peas, potatoes, and hops.40 
Based on their Review of the Status of Saussurea Costus, TRAFFIC India (2011, p. 15) has 
concluded the following (see Kuniyal et al. 2015 for a similar opinion): 
[t]here is little evidence to suggest that the uplisting of the species into Appendix I 25 years 
ĂŐŽŚĂƐĚŽŶĞŵƵĐŚƚŽĐŽŶƐĞƌǀĞƚŚĞƐƉĞĐŝĞƐŝŶƚŚĞǁŝůĚŝŶ/ŶĚŝĂ ? ? Q ?KŶƚŚĞĐŽŶƚƌĂƌǇ ?ƚŚĞŚŝŐŚ
and often complex level of regulations has only deterred potential cultivators with the result 
that commercial cultivation has also not picked up. This could have served as a buffer for wild 
ƉŽƉƵůĂƚŝŽŶƐ ? ? Q ?/ŶƚŚĞĐĂƐĞŽĨĐƵůƚŝǀĂƚŝŽŶ ?ƚŚĞƌĞŝƐŐƌĞĂƚƵŶĐĞƌtainty whether permits will be 
granted or not. There is also some confusion regarding the government agency responsible 
for issuing the permits. This is compounded by a lack of transparency regarding the rules and 
regulations and an unclear process of decision-making. This has led to a situation where 
Indian cultivators, those who venture into S. costus cultivation, do not find buyers while the 
market is flooded with Chinese imports from cultivated sources. 
 
                                                     
40 Kuniyal et al. (2015) cites the procurement prices for kuth roots from these two areas, which are usually 
fixed on a yearly basis: 20 to 56 rupees per kg from Lahaul (0.3-0.8 USD, between 1988-1989 and 2000-2001), 
and 53 to 120 per kg from Uttarakhand (0.8-1.8 USD in 2007-2010). Recently the volumes harvested and 
marketed in Uttarakhand (2,76 metric tons on average from 2007-2010) as well as the prices seem to be on 
the rise again (150 INR or 2.2 USD per kg in 2011-1012). Yet these amounts are still minute compared to 




Figure 2.6. Chronological summary of the major policies impacting the harvest, cultivation and trade of kuth (Saussurea 
costus, synonym S. lappa) in India, based on a 2011 TRAFFIC information document (submitted by the CITES Secretariat 




 ?Uttarakhand Forest Department starts registering kuth farmers, areas and quantities
2005
 ?complete ban on wild-collection by the Jammu and Kashmir Forest Department
2002




 ?inclusion on Negative List of Exports (Plant Notification No. 24, 1997-2002, Ministry of Commerce): free 
export only of products containing unrecognisable portions or extracts
1997
 ?S. costus listed nationally as Critically Endangered due to a 70% decline over the previous decade (CAMP 
workshop, Uttarakhand Forest Department), and as Endangered on the IUCN Red List
1991
 ?Amendment to Wildlife (Protection) Act of 1972 with Schedule VI: S. costus protected (prohibits harvest 
from Forest Land, possession, sale, transport and cultivation without license)
1985
 ?S. lappa uplisted to CITES Appendix I (CoP5); proposal submitted by india, argument is rapidly depleting wild 
population
1987
 ?Jammu and Kashmir Kuth Act: S. costus cultivation and trade (from extraction to sale) only by permission, 
jale and fines for violators 
1975
 ?Saussurea lappa listed on CITES Appendix II (1 July 1975), although India was only admitted as a Party to 
CITES on 18 October 1976; rationale behind listing unclear
1972
 ?Indian Wildlife (Protection) Act (not applicable to Jammu and Kashmir state under article 370 of the 
constitution)
1962
 ?China-India war: export market crashed, rapid decline in Indian cultivation, China initiates cultivation and 
export to India post-1962
1950
s





 ?first domestication trials in Kashmir, Garhwal (Uttarakhand) by the Forest Department, and Lahaul by 
missionaries (Himachal Pradesh)
1927
 ?Indian Forest Act Section 2(4) defines S. costus from any source as Forest Product (also if sourced outside 
forests or from cultivation)
1895
 ?costus reported as amongst the most valuable Kashmiri herbal exports in colonial times (in The Valley of 
Kashmir by Sir Walter Roper Lawrence)
?
 ?multiple traditional uses (especially medicinal, insect deterrent, perfumery and incense); harvest and trade 
guided by customary systems
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It was amchi Dolkar, one of the daughters of Ama Lobsang, who introduced both Men-Tsee-
Khang and PADMA to the costus grower, trader and exporter I got acquainted with in July 
2015. Both described Mr Mishra to me as an honest, simple, good man. Mishra was born 
into a Brahmin family of four brothers and four sisters in a small hamlet along the Lahaul 
valley more than fifty years ago (Audio recording 112). His father owned farmlands and also 
cultivated some Saussurea costus and Inula racemosa (manu in Tibetan), just like his 
grandfather. He remembers taking these roots on horseback over the pass to Manali to sell 
them there. In seventh class, during the two-month Summer holiday, they also went into 
the mountains, on steep ridges, to harvest kutki (hong len). They did not know the price 
and would just sell it to a man from Amritsar who came to buy from them. In 1993 a 
researcher from Lucknow came to their village, looking for hawthorn berry shrubs. Young 
Mishra helped him find some plants in the vicinity, which was the beginning of a fruitful 
business relationship. The researcher quit university, founded his own company, and soon 
both men were prospering. In 1998, they started officially by securing legal documentation, 
which Mishra learned how to obtain from the academic. In 2005 he then started exporting 
costus for the French perfume industry, at first via a commission agent in Delhi. As he was 
ŶĞǁŝŶƚŚĞƚƌĂĚĞ ? ‘aƚƚŚĂƚƚŝŵĞǁĞǁĞƌĞŶŽƚƐŬŝůůĞĚ ?) he was taken advantage of by the agent, 
ǁŚŽ ?Ɛ profit margin was three to five times higher than his. When he found out this 
collaboration ended, but luckily the buyer sent him a direct purchase order later, cutting 
out the middleman. From then onward, he was exporting directly to companies in France, 
Germany, Switzerland, Yemen and Dubai. Over time he also started supplying big domestic 
manufacturers such as Himalaya and Organic India, as well as more Tibetan doctors in 
Dharamsala and Delhi. He now rents several plots of land in two hamlets deep in Lahaul 
valley, where a manager oversees the maintenance and harvest of the crop in the growing 
season (May to October). Costus is the main crop, followed by Inula, and a small number 
of far less abundant fields containing Aconitum heterophyllum, Podophyllum hexandrum, 
and Picrorhiza kurroa. He has attempted to grow jatamansi (Nardostachys grandiflora) for 
several years, but has failed so far. To supplement the cultivated stock, Mishra maintains 
contact with a network of (mostly part-time) gatherers in Ladakh and the Kulu and Chamba 
valleys in Himachal from whom he buys directly or via an agent. When we met, he was only 
selling crude, dried herbs, even though he had a small distillation unit and was very keen 
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to go into costus oil. He employs around seven people year-round, including his wife and 
daughter and several Nepali domestic workers.  
 
A few days after we met, Mishra invited me to drive with him over Rohtang pass to his 
farmhouse (Diary, 27 July 2015). He was planŶŝŶŐƚŽĂƚƚĞŶĚƚŚĞǁĞĚĚŝŶŐŽĨŚŝƐŽůĚĞƌƐŝƐƚĞƌ ?Ɛ
grandson, and had bought a crate of Carlsberg beer and some bottles of whiskey for the 
occasion. We were lucky with the weather. The clear sky allowed for stunning vistas and 
almost made us forget the dangers of rockslides and steep cliffs. After the pass we 
descended from above 4000 m to around 3000 m. The vegetation changed once again, we 
now entered the cold desert of Lahaul. A dry, coarse wind irritated our eyes and nostrils as 
we endlessly opened and closed the car windows to avoid clouds of fine sand sturred up 
by passing trucks from entering. On the next day it took us another hour to drive twenty-
five kilometers to the farm as the road condition deteriorated further the deeper we 
headed into the valley. After we arrived and were offered some chai, we immediately went 
on an inspection tour of the fields.  
 
In the first year of costus cultivation seeds are planted in September using oxen or yak half-
bloods to make gullies, and in the third year the roots are harvested in October, just before 
winter kicks in. The fields are partly irrigated, and have to be watered to maintain the crop. 
Dried cow dung is used as a natural fertiliser. Fungus and insects are no problem at this 
altitude. Harvesting is by hand. The same is the case for manu, Inula racemosa, which is 
planted in April. Both ruta and manu were growing vigourously in dense monocultures. 
Some fields were first year, some second, some third, to ensure there would be a crop 
every year. On average, Mishra can harvest between 20 and 40 metric tons a year. One 
average field can yield up to a ton of ruta. The fields are fenced or surrounded by rock walls 





Figure 2.7. A field of ruta (Saussurea costus) in its third growing year. The dark greyish-black flower will develop into 
fruits after pollination (28 July 2015, Lahaul Valley, at about 3,000 masl). 
 
hƉŽŶŽƵƌ ƌĞƚƵƌŶ ? / ƐƚĂǇĞĚ ŝŶDŝƐŚƌĂ ?Ɛ house and observed his work at the company for 
several days. In particular, I learned more about the qualms of documentation necessary 
to export costus, a CITES-listed species, abroad. We also attended an auction of confiscated 
forest items at a local forĞƐƚ ĚŝǀŝƐŝŽŶ Ă ĨĞǁ ŚŽƵƌƐ ? ĚƌŝǀĞ ĂǁĂǇ ? dŚĞ ƚǁŽ ůĂƐƚ-mentioned 
activities are discussed in the next section. 
 
2.4 Behind the scenes of the maleficium: illegality, corruption and bribery 
Experience, trust and old connections turn out to be vital for successful business, with new 
traders frequently being cheated and having to learn the hard way. Scouring the streets of 
Khari Baoli and Majith Mandi, it comes across as if there is no effective state regulation 
whatsoever besides the influence of item bans on their selling price. Organising small, local 
harvesting parties  W especially in areas where one is familiar  W can also largely take place 
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under the radar. But interactions with state institutions and their officers cannot be 
avoided altogether as companies need to be registered and pay taxes, obtain legal 
documents and permits, and as goods pass by various checkpoints before reaching their 
destinations. These points of contact could be considered as nodes of formalisation, 
intersections where the usual informality is transformed  W at least partially and temporarily 
 W by forced official interventions that shine some light on the otherwise dark paths followed 
by herbs in India. The flash that produces this formal snapshot, however, often creates 
unrealistic artefacts that can only be dealt with by going back into the darkroom of 
informality. As many regulations are confusing and only partly enforced, a situation of 
ambivalence ensues in which reliance on the principles of an economy of favours becomes 
the only feasible option. In the following subsection I discuss the first-hand experiences and 
struggles of Dr Saini and Mr Mishra in coming to terms with state institutions and 
regulations and the need for documentation.  
 
A first example, related to me by Dr Saini (Audio recording 115b), gives insight into how the 
need for certain paper forms encourages corruption and bribery. For export, Anton has to 
prove by means of receipts and purchase orders at which prices he bought and will sell his 
materials to satisfy the Gurgaon Excise (inland tax) and Income office. Before the last 
national elections (it was cancelled by ruling politicians in an attempt to win votes), it was 
obliged to fill in Form 38 each time raw materials were purchased from another state at a 
cost of more than 20,000 rupees (300 USD). Dr Saini would usually employ an accountant 
to take care of this, but one day he wanted to find out why his accountant asked for 
thousands of rupees to take care of this, even though the official rate for the five forms 
requested was negligible. As he arrived at the office to get the blank forms, his contact and 
a lawyer were already waiting. He was served tea, and waited for two hours. Finally, the 
officer arrived and was ready to receive them. First, he disputed that the address given was 
ŶŽƚƌ^ĂŝŶŝ ?ƐŚŽŵĞĂĚĚƌĞƐƐ ?ƵƚĂĨƚĞƌƐŽŵĞĐŽŶǀŝŶĐŝŶŐ ?ŚĞbacktracked. The officer invited 
him for some more tea. After another hour of waiting, a second officer came in. A series of 
more non-sense arguments followed. In the end Anton agreed to pay the officer 700 rupees 
(10 USD). His lawyer also wanted 200 Rs (3 USD) for his presence, and the clerk who had to 
process the file another 100 (1.5 USD).  
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/ƚŝƐŽƌŐĂŶŝƐĞĚ ?dŚĞƌĞĂƌĞƌĂƚĞƐĨŝǆĞĚĨŽƌĞǀĞƌǇƚŚŝŶŐ ? Q ?zŽƵǁĂƐƚĞǇŽƵƌĚĂǇĂŶĚƐƚŝůůŚĂǀĞƚŽ 
ƉĂǇŵŽŶĞǇ ?KƌŝĨǇŽƵĚŽŶ ?ƚƉĂǇ ?ǇŽƵĚŽŶ ?ƚŐĞƚƚŚĞĨŽƌŵĞǀĞŶĂĨƚĞƌƚŚƌĞĞŽƌĨŽƵƌĚĂǇƐ ? Q ?zŽƵ
cannot complain to anyone, where will you go? The highest official sitting in that building is 
involved in that. 
  ‘HĂƌĂƐƐŵĞŶƚ ? ?  ‘ƵŶŶĞĐĞƐƐĂƌǇ ďŽƚŚĞƌĂƚŝŽŶ ?,  ‘ůŽŶŐ ƋƵĞƵĞƐ ? ? ĂŶĚ  ‘ĐŽƌƌƵƉƚŝŽŶ ? is how Saini 
describes this structural violence, which is also part of exporting herbs abroad. Even though 
ŚĞƉĂǇƐƐŽŵĞŽŶĞĂ ‘ĚŽĐƵŵĞŶƚĂƚŝŽŶĨĞĞ ?ƚŽĂƌƌĂŶŐĞƚŚĞƉĞƌŵŝƚƐĂŶĚĐĞƌƚŝĨŝĐĂƚĞƐŝŶŚŝƐƉůĂĐĞ, 
the transit permit may already cause trouble before the consignment even reaches the 
customs office. Normally there are no problems at this stage, as Anton hires a specialised 
private company that transports the materials in sealed trucks across state borders. But 
about three years ago tŚĞƌĞǁĂƐ ‘ĂĐŽŶƐƉŝƌĂĐǇ ? between the transport manager, the driver, 
and an officer at the border checkpoint of Haryana. The consignment was blocked, he was 
summoned and asked to pay 55,000 rupees (820 USD) or alternatively 25,000 rupees (373 
USD) if no receipt would be involved. Anton requested a receipt to win time. He had made 
a phone call to the father-in-law of his daughter, a big boss in the administration, to settle 
the matter. Alas, this intervention came fifteen minutes late. He had already paid the fee. 
One officer came running after him, apologising and blaming the driver. Officially, the 
reason why the materials were confiscated was that he could not provide a receipt 
documenting the purchase. This was the case because the middleman who organised the 
harvest of the pomegranate seeds in two or three Himachali villages was not an authorised 
sales person. Getting a license and paying taxes would be difficult for this man belonging 
to a deprived family, who only went through basic education. The reality of the situation 
however, is that the large majority of all transactions in this business are cash payments 
without receipts. The law is only strictly applied arbitrarily when local bureaucrats want a 
ƉŝĞĐĞŽĨƚŚĞĐĂŬĞ P ‘It is a big trouble in India, to be a tax ƉĂǇĞƌ PƚŚĞƐǇƐƚĞŵŝƐĐŽƌƌƵƉƚ ? ?. 
 
A third example narrated by Dr Saini of failed state involvement in the medicinal plant 
sector revolved around cultivation subsidies for farmers. As a botanist and agricultural 
scientist, he was initially genuinely interested in promoting organic cultivation of herbs as 
an alternative, pesticide-free income strategy for farmers. He soon abandoned this idea 
completely. One ƚƌĂĚĞƌĞǀĞŶƚŽůĚŚŝŵĚŝƌĞĐƚůǇ ‘ƉůĞĂƐĞĚŽŶ ?ƚĂĚǀŝƐĞĂŶǇĨĂƌŵĞƌƚŽĐƵůƚŝǀĂƚĞ
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 ?ŵĞĚŝĐŝŶĂů ƉůĂŶƚƐ ? ? ? ĂƐ ďŝŐ ǁŚŽůĞƐĂůĞƌƐ  ‘are supporting two hundred families, they owe 
ƚŚĞŵ ? ?  ‘If I start buying from farmers, what will happen to the families which have been 
working with them for hundreds of years. It is the local people still who collect. It works 
better I ƚŚŝŶŬ ? (Audio recording 70). Nonetheless, Dr ^ĂŝŶŝ ĚŝƐĐŽǀĞƌĞĚ ƚŚĂƚ  ‘cunning, 
dishonest money-ŵŝŶĚĞĚƉƌŝǀĂƚĞĐŽŶƐƵůƚĂŶƚƐ ? were promoting the cultivation of expensive 
herbs to farmers and making a good business out of selling seedlings. But after two to three 
years of growing nobody was interested in buying the crop, especially since it was often 
available cheaper wild-sourced on the market (Audio recording 115). On top of that, 
government subsidies to support farmers who cultivate medicinal plants were abused by 
corrupt entrepreneurs. At the mortgage bank that finances cultivation projects, Anton 
learned about how a loan could be obtained and what the charges and profit levels would 
be. But the banker did not want to give him details on who was cultivating what, how much 
and where. Even if on paper ten hectares would be in cultivation, in reality there would 
only be a few plants there, as Anton saw later with his own eyes. The local department of 
horticulture inspector who has to supply a certificate was also involved in this lucrative 
business, sharing the subsidy money with the bankers, consultants, nurserymen, and so on. 
Ɛ Ă ƌĞƐƵůƚ ? ŽŶůǇ  ‘fake ƉĞŽƉůĞ ƚŚĂƚ ƐƵďŵŝƚ ĨĂŬĞ ƉĂƉĞƌƐ ? would be granted funds, not 
benefitting farmers (let alone biodiversity) at all. Nevertheless, Dr Saini maintains that the 
government is at least making some progress, hoping that current Prime Minister Narendra 
Modi will keep some of his promises. 
 
Mr Mishra related very similar experiences in his dealings with the NMPB, AYUSH, forest 
department offices, and the wildlife crime control bureau in Delhi. He had tried to contact 
AYUSH for a long time (Audio recording 114). I saw a pamphlet in his office advertising a 
Centrally Assisted Scheme that provides financial assistance for the cultivation of medicinal 
plants. Even though he is formally cultivating, trading and exporting a critically endangered 
plant, he was unsuccessful in getting any support, or even a written response to his queries. 
DŝƐŚƌĂ ?ƐĞǆƉůĂŶĂƚŝŽŶŝƐƚŚĂƚ P 
Only if you know a good politician, then you will find benefits. These people are so dirty, the 
people who are running the Indian country: politicians and bureaucrats. Both are corrupted. 
 ? Q ?ǀĞƌǇ/ŶĚŝĂŶƐĂǇƐ ‘ǁĞĂƌĞŝŶĚĞƉĞŶĚĞŶƚ ? ?dŚĞƉĞŽƉůĞĂƌĞŶŽƚ ?ŽŶůǇƚǁŽ ?ŐƌŽƵƉƐŽĨƉĞŽple 
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are]. Who? One is the bureaucrat, one is the politician. They are doing everything, and have 
lots of money. Laws are nothing [to them], they make the law! The law is for poor people. 
He made clear that AYUSH has no influence on his work, all their schemes and guidelines 
remain in the realm of paper. The forest department on the other hand does enforce rules 
and regulations, and sales taxes have to be paid even though export itself is free. Harvesting 
permits specify the what, when, where, how much and by whom of wild-collection. These 
should be obtained from the local forest officer, who confirms which areas are open for 
harvest. The problem here is that many high-value plants such as Nardostachys (pangpö), 
Neopicrorhiza (honglen) and Dactylorhiza (wanglak) are rare and only grow in specific, 
restricted habitats. It is therefore likely that one obtains a permit for an area that is  ‘open 
to harvest ? ďƵƚǁŚĞƌĞƚŚĞƐƉĞĐŝĞƐǇŽƵĂƌĞĂĨƚĞƌĚŽŶ ?ƚĞǀĞŶŐƌŽǁ ?dŚĞĨŽƌĞƐƚŽĨĨŝĐĞƌŵĂǇďĞ
aware that there is nothing in that area, but can be swayed with a bribe. As there is no 
effective policing of the often difficult-to-reach harvesting areas themselves, the collection 
party is free to harvest in a nĞŝŐŚďŽƵƌŝŶŐ ‘ĐůŽƐĞĚĂƌĞĂ ? ?DŝƐŚƌĂĞŶƐƵƌĞĚ me that this is a 
common strategy (Audio recording 112), only a tiny portion of wild-collection is legal and 
most harvesters not even bothering to get approval anyway.  
 
After we had returned from our road trip to Lahaul, I was staying at the Mishra family 
residence for a while. On the third day, we drove past Mandi to Gohar, where forest items 
confiscated by the Nachan Forest Division (FD) of Himachal Pradesh were being sold by 
auction (Fieldnotes XI, 5 August 2015). Mr Mishra had received an official notification letter 
from the forest department which listed what was on offer: a dozen quintels of Taxus 
baccata leaves and Berberis aristata roots. He had predicted that the quality of these goods 
would be poor and added that most buyers would onůǇďĞŝŶƚĞƌĞƐƚĞĚĂŶǇǁĂǇŝŶƚŚĞ ‘ǀĞƌǇ
good ĚŽĐƵŵĞŶƚƐ ? that came with the purchase. They could then burn the original goods or 
get rid of them cheaply on the domestic market, and replace it with high-quality material 
sourced illegally from elsewhere for which they now had official export documents. Indeed, 
the Berberis roots were lying piled up outside in the open air on the soil of a courtyard in 
Mandi. This would negatively affect its berberine content, the yellow-coloured alkaloid that 
is commercially extracted from the roots. The Forest Division in Gohar was situated in a 
well-maintained garden of trees and flower patches and consisted of offices, a residence, 
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a parking space and a store. The staff consisted of a few forest officers (FOs) in uniform, 
clerks, assistants, workers and several armed guards. I was not allowed to accompany 
Mishra into the office, where he had to negotiate with the FO. In the end, it turned out he 
was the only potential buyer. The other people around were only there for timber. He 
sighed: 
There is no system at all here in India. The FD captures goods and just dumps them 
ƐŽŵĞǁŚĞƌĞ ?/ƚŝƐůŝŬĞƚĂŬŝŶŐĂŶĂƉƉůĞŽƵƚŽĨƐŽŵĞŽŶĞ ?ƐŚĂŶĚĂŶĚƚŚĞŶƚŚƌŽǁŝŶŐŝƚ ?ĂǁĂǇ ? ?dŚĞ
FO is also not knowledgeable on herbal trade. He only wanted to provide a transport permit 
to Delhi or Amritsar, but I need a legal procurement certificate as well since this is required 
by my buyer [a commercial extractor]. He had never issued that before and had to make 
enquiries first.  
 
While Anton deputes someone to take care of export documents, Mr Mishra takes care of 
that himself in Delhi. There he has to interact with five separate offices before the materials 
can go through customs. Certificates of Origin, Non-Objection Certificates (NOCs), 
phytosanitary documentation, CITES, and tax exemptions all have to be arranged (Audio 
recording 113). The more people are involved, the worse it becomes: 
tĞ ŚĂǀĞ ĞǀĞƌǇƚŚŝŶŐ ? tĞ ŚĂǀĞ ƚŚĞ ŶĞƚ ? ŵŽďŝůĞ ? ůĂƉƚŽƉ ? ďƵƚŝƚ ?Ɛ ƵƐĞůĞƐƐ ? zŽƵ ŚĂǀĞ ƚŽ ŐŽ
ƉĞƌƐŽŶĂůůǇ ?^ŽŵĞƚŝŵĞƐ ?ƚŚĞƌĞŝƐĂ ?ĐŽƌƌƵƉƚĞĚŽĨĨŝĐĞƌ ?ƚŚĞǇǁĂŶƚƐŽŵĞƚŚŝŶŐ ? ‘tŚĞƌĞŝs your 
ŝŶǀŽŝĐĞ ? ? ‘dŚŝƐŝƐǇŽƵƌŝŶǀŽŝĐĞ ?KŽŽŽŚ ?ĂůŽƚŽĨŵŽŶĞǇ ?tŚĂƚŝƐ ?ŝŶƚŚĞƌĞ ?ĨŽƌŵĞ ? ? ? Q ?ǀĞƌǇŽŶĞ
ƐĞĞƐƚŚĞŝŶǀŽŝĐĞ ?dŚŝƐŵĂŶŝƐĞǆƉŽƌƚŝŶŐĨŽƌ ? ? ? ? ? ?ĞƵƌŽ ?dŚĞǇĚŽŶ ?ƚŬŶŽǁŚŽǁǁĞŽďƚĂŝŶĞĚ
ƚŚŝƐ ?,ĞƚŚŝŶŬƐ ? ‘ŚĞƉƵƌĐŚĂƐĞĚƚŚŝƐĂƚƐŽŵĞůŝƚƚůĞĐŽƐƚ ?ǁĂŶƚƐto send and get a big proĨŝƚ ? ? Q ?
This is a big problem. 
 
The frustrating bureaucratic encounters I have sketched above are just some of the many 
stories I gathered during my fieldwork. Non-Indians who are economically active in these 
areas befall the same misfortune, and perhaps worse. An academically trained UK citizen 
who lived in Kullu valley for more than a decade and became friends with Mishra told me 
why eventually he had to give up his CITES-listed medicinal plant cultivation business (Audio 
recording 117).  
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Generally ƐƉĞĂŬŝŶŐ ?ƚŚĞǇ ?ďƵƌĞĂƵĐƌĂƚƐ ?ĂƌĞŶ ?ƚĐŽŵĨŽƌƚĂďůĞŝŶŽĨĨĞƌŝŶŐƚŚĞƵƐƵĂůƐŽůƵƚŝŽŶƐƚŽ
ĂĨŽƌĞŝŐŶĞƌ ?dŚĞǇĚŽŶ ?ƚŬŶŽǁŚŽǁǁĞĂƌĞŐŽŝŶŐƚŽƌĞƐƉŽŶĚ ?ǁŝƚŚǁŚŽŵǁĞĂƌĞĐŽŶŶĞĐƚĞĚ ?
We are a kind of wildcard. On one hand they expect us to do it properly, on the other hand 
ƚŚĞǇĚŽŶ ?ƚŬŶŽǁŚŽǁƚŽĚŽŝƚ properly. There is no system. 
Mr Mishra on the other hand as a Brahmin Indian from a modest background (but 
importantly, with land) had figured out his own system, had long-established connections 
and had been able to register his farms as CITES nurseries in the wake of a special 
conference on the topic that had created a window of opportunity. The sentiment that 
there is no functioning system was a recurring theme in my interviews. The formal trade 
channels are practically nearly impossible to navigate as a private trader (and particularly 
exporter) without resorting to informal exchanges and economies of favours to get through 
the highly dysfunctional bureaucracy. Dr Saini and Mr Mishra blame corruption for this 
sorry state of affairs while official policies and surveys lament the informal, secretive and 
unsustainable nature of the trade, labeling harvesters and cultivators as ignorant, 
middlemen as parasitic and wholesalers as greedy.  
 
2.5 Failed formalisation: the Dark Art of sourcing, the blinding light of governance 
Government interventions in the lives of NTFPs have generally made things worse for both 
people and plants (Laird et al. 2010). Formalisation  W ĚĞĨŝŶĞĚ ĂƐ  ‘the replacement of 
informal ownership, access, and economic activity through the recognition and inscription 
by the State of ƌŝŐŚƚƐĂŶĚĐŽŶĚŝƚŝŽŶƐŽĨĂĐĐĞƐƐ ? (Putzel et al. 2015, p. 457)  W is a defining 
characteristic of NTFPs globally as well as the Indian medicinal plant sector. Trade surveys 
indicate that conservation-development discourses have fostered a set of unfounded 
assumptions on the nature of this sector that motivate continued top-down intervention. 
Yet despite these attempts and its growing economic importance, the trade remains 
overwhelmingly informal, poorly understood and badly reŐƵůĂƚĞĚ ?/ŶĚĞĞĚ ?ĨŽƌŵĂůŝƐĂƚŝŽŶ ‘is 
often unsuccessful and entails risks including leakage, barriers to small or poor actors, elite 
capture, and negative effects ŽŶǁŽŵĞŶŽƌŵĂƌŐŝŶĂůŝǌĞĚŐƌŽƵƉƐ ? (ibid., p. 453). My aim in 
this chapter was  W ironically  W to document the informal, shadowy realities of the Indian 
herbal industry and to showcase its paradoxical interactions with state regulations and 
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their local enforcers and bookkeepers. In line with WynbeƌŐ Ğƚ Ăů ? ?Ɛ(2015) findings in 
Southern Africa (and several more studies mentioned by them), many actors sought 
alternative economic opportunities and a lighter regulatory load in the face of strict 
measures, becoming creative bricoleurs (as described by Ingram et al. 2015) for forest 
governance in Cameroon) of the multi-layered and overlapping institutional-regulatory 
landscape by necessity. Ingram et al. (2015, p. 50) therefore count  ‘institutionalised 
corruption ? and the resulting malgovernance as a distinct but parallel NTFP governance 
chain or lĂǇĞƌ  ‘shadowing and nested around staƚƵƚŽƌǇ ĂŶĚ ĐƵƐƚŽŵĂƌǇ ƐƚƌƵĐƚƵƌĞƐ ? ? ĂŶĚ
ƌĂŶŐŝŶŐ ‘ĨƌŽŵĂĚĚŝƚŝŽŶĂůƉĂǇŵĞŶƚƐ “ƚŽŐĞƚƚŚŝŶŐƐĚŽŶĞ ? in business, to elites engaging in 
state and power capture, and as a deliberate strategy of clientelism by state officials and 
ƚƌĂĚŝƚŝŽŶĂůĂƵƚŚŽƌŝƚŝĞƐ ?.  
 
This kind of governance flourishes when formal regulations and bureaucratic procedures 
are unknown, vague or arbitrarily enforced. Moreover, identical national policies may lead 
to varied and multiple governance arrangements for different products in different socio-
economic contexts and regions with corruption varying from case to case but often 
increasing for highly regulated, high-value and high-volume forest products such as costus, 
diminishing the perceived legitimacy of statutory law enforcement. The traders I 
introduced in this chapter were all crafting their own chains, filling in voids in the pluralist 
patchwork of regulations in unpredictable ways. Correspondingly, I see corruption not 
merely as the cause of failed state control, but as a systemic symptom of weak 
(mis)governance and cumbersome legislations and policies. Regulations can become tools 
of corruption as they are entangled with rent-seeking behaviour that privileges illegality, 
blurring distinctions between public/formal/licit versus private/informal/illicit activities.  
 
ƐƐƵĐŚ ?ďůĂŵŝŶŐ ‘ŝŐŶŽƌĂŶƚ ?ŚĂƌǀĞƐƚĞƌƐ ? ‘ƉĂƌĂƐŝƚŝĐ ?ŵŝĚĚůĞ ĞŶŽƌ ‘ĞǆƉůŽŝƚĂƚŝǀĞ ?ǁŚŽůĞƐĂůĞƌƐ
ĨŽƌƚŚĞĐƵƌƌĞŶƚƐƚĂƚĞŽĨƚŚĞ ‘ƐĞĐƚŽƌ ?ƐĞĞŵƐƉĂƌƚŝĂůƚŽƐay the least. In a highly dysfunctional 
and corrupt state bureaucracy where formality becomes a mere formality, government 
officials are in a powerful, lucrative position. On the other hand, as gatekeepers these men 
have to perform magical transformations from informality to legality, which is the only way 
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to keep the industry going. The current regulatory and bureaucratic structures overlook 
ĂŶĚ ?Žƌ ĐƌŝŵŝŶĂůŝƐĞ ŵĂŶǇ ƚƌĂŶƐĂĐƚŝŽŶƐ ĂƐ  ‘ŝůůĞŐĂů ? ? ǁŚĞƌĞĂƐ ƚƌĂĚĞƌƐ ĂŶĚ ŽĨĨŝĐŝĂůƐ ŽŶ ƚŚĞ
ground cannot but recognise their ubiquity and the necessity of these inputs and outputs 
for the functionality of the domestic and international markets. In this business-as-usual 
reality where the borders between the black and white markets are arbitrarily determined 
ďǇƉĂƉĞƌǁŽƌŬ ? ‘ĐŽƌƌƵƉƚŝŽŶ ?ĂŶĚ ‘ďƌŝďĞƌǇ ?ĂƌĞƚŚĞŶŽƵŶƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞƉĞŽƉůĞ ?ďŽƚŚ
officials and traders) who cross these boundaries. This white- and greenwashing operation 
in effect legalises the illegal in an illegal manner, bringing a formerly unknown commodity 
into the light. Yet considering all the steps that led to this moment, I argue that this is only 
a mirage, a superficial illusion. The herbal sector is at the most a quasi-formal economy. 
Sourcing is sourcery. Meddling in these affairs from the perspective of the enlightened 
regulator or NGO worker can bring even more misfortune and despair. All interested 
parties have to acknowledge its obscurity as a starting point to understand the tricks of the 
trade; its greyness, not the black-and-white ideals of documents. Governing or cultivating 
the wilds (Craig and Glover 2009, Craig 2012) is only possible if one concedes the true 
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3 Making things with humans  
skilled interactions along the 
pharmaceutical assembly line  
 
 
KŶƚŚĞƐƵŶŶǇĂĨƚĞƌŶŽŽŶŽĨ:ƵůǇ ? ? ? ? ?/ǀŝƐŝƚĞĚWD ?ƐƉƌŽĚƵĐƚŝŽŶƵŶŝƚĨŽƌƚŚĞǀĞƌǇĨŝƌƐƚ
time. It was a blitz visit, ŐƵŝĚĞĚďǇWD ?ƐŽǁŶĞƌĂŶĚK Pƌ,ĞƌďĞƌƚ^ĐŚǁĂďů ?,ĞŐĂǀĞ
me a quick tour of the warehouse and offices. Walking me through PADMA Produktion, I 
got parts of an introduction I imagined Herbert had already given a hundred different 
interested parties (Audio recording 9). 
We are in a very old building; we have rented these facilities since the Eighties. Unfortunately, 
the [neighbouring] houses come closer and closer, which is not very good for us. But anyway, 
we are here. Of course, we are highly mechanised. In total ten people are working in 
production: five in the offices, and five inside production. They have to do the thirty tonnes 
ĂǇĞĂƌ ?/ƚ ?Ɛ^ǁŝƐƐƐƚǇůĞ ?ŝƚŝƐƋƵŝƚĞƐŵĂůůƚŽŬĞĞƉƚŚĞĐŽƐƚƐĚŽǁŶ ?tĞĂƌĞĂůƐŽŝŶƐƉĞĐƚĞĚ ?ďǇƚŚĞ
Swiss regulatory authorities]. The packaging material has to be checked, everything. It is not 
just the herbs you have to concentrate on. The production process in our facility is in 
campaigns. We do four or five campaigns of one to three weeks of mixing and capsulation. 
The rest is just bringing all the materials together. It is a European problem. In Asia they have 
lots of people, all the time chaos. We have the chaos in our mind and are stressed. Work is 
so expensive here, that is the other side. The goods come here [in the storage hall], are 
packaged and then shipped to wholesalers in Switzerland and internationally. It's all about 
paper. We are all document and paper driven. This puts a lot of stress on our people. You 
have to be a manual worker and at the same time look for papers here, for figures there, sign 
the protocol. You cannot use anymore this old-ƐƚǇůĞ ďůƵĞ ĐŽůůĂƌ ǁŽƌŬĞƌ ǁŚŽ ĚŽĞƐŶ ?ƚ ĐĂre 
about paper. He has to know, and at the same time lift heavy stuff. It is one of the problems 




This chapter aims to foreground  ‘non-humans ?  W plants and machines in particular  W as part 
of the material, skilled processes of the mass-production of Tibetan medicines at PADMA.41 
This creative process lies at the junction between the worlds of plants and medicines, 
ingredients and products, as well as between (typically romanticised) nature and (scientific) 
technology. It is a case study of the pragmatic practicalities and limitations of the 
standardisation and innovation inherent in the manufacture of industrially reformulated 
 ‘ƚƌĂĚŝƚŝŽŶĂů ? multicompound medicines (Pordié and Gaudillière 2014a). Building particularly 
ŽŶ dŝŵ /ŶŐŽůĚ ?Ɛ ŵƵsings on materials, skill, and technology, I contend that enskilled 
operators in tandem with machines play a central role in crossing these intersections 
through a coming-together of material, mechanical and sensorial interactions, enabling the 
pharmaceutical transformation of plants to take place. Through this lens, and by providing 
 ‘ƚŚŝĐŬ ?ĚĞƐĐƌŝƉƚŝŽŶƐĂŶĚĞǆƚĞŶƐŝǀĞƋƵŽƚĂƚŝŽŶƐĂƐǁĞůůĂƐƐŽŵĞƉŚŽƚŽŐƌĂƉŚƐ ?/ĂůƐŽĂƚƚĞŵƉƚ
to bring the insider view of the manufacturers themselves into the picture, a perspective 
that is all but absent within the social sciences. As will hopefully become clear, this 
endeavour unveils the partiality of certain stereotypes pertaining to processes and 
members within this industry, including the flawlessly mechanistic nature of the 
pharmaceutical assembly line and the predominance of robot-like unskilled labour. 
 
Methodologically  W but characteristically spilling over into theory formation and fieldwork 
practice  W /ĚƌĂǁŽŶŽƵŐůĂƐ,ŽůŵĞƐĂŶĚ'ĞŽƌŐĞDĂƌĐƵƐ ?Ɛ(2012) most recent take on para-
ethnography, and particularly its application in research on/with contemporary, modern 
organisations (Islam 2015). This re-functioned ethnography shifts its purpose from 
ĚĞƐĐƌŝƉƚŝŽŶƚŽƉƉĞĚǁŝƚŚĂůĂǇĞƌŽĨĂŶƚŚƌŽƉŽůŽŐŝĐĂů ‘Đƌŝƚ ƋƵĞ ?, to an engagemenƚǁŝƚŚ ‘the 
para-ethnographic practices of oƵƌƐƵďũĞĐƚƐ ?ĂŶĚƚŚĞ  ‘ĚĞĨĞƌƌĂů ƚŽƚŚĞƐƵďũĞĐƚ ?ƐŵŽĚĞƐŽĨ
                                                     
41 Although this chapter on production focuses on PADMA, it would have been possible to build a similar 
argument based on my work beyond the iron gate of Men-Tsee-<ŚĂŶŐ ?Ɛ WŚĂƌŵĂĐĞƵƚŝĐĂů ĞƉĂƌƚŵĞŶƚ ? Ǉ
coincidence, I was able to observe seemingly out-of-the-ordinary interactions with materials and machines 
more at PADMA, and doing justice to their complexity requires my full attention here as these activities take 
place in an environment that is alien to most readers. Broadly speaking, the steps of production and material 
transformations are similar in both institutions (see also Chapter 5) even though the influence of GMP is much 
more pervasive at PADMA, which also houses some more technologically advanced machinery especially for 
air flow and temperature regulation as well as for instance the software-operated encapsulation machine. 
Electrical crushing, grinding and pill-making machines were already installed at Men-Tsee-Khang in 1967 
(Kloos 2008), two years before PADMA was founded. 
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ŬŶŽǁŝŶŐ ? (Holmes and Marcus 2012, p. 127). In epistemic communities, the reflexive 
subjects already have a research-based ethos and even a (counter para-)ethnographic 
consciousness, 42  experimenting with various narratives. This overt, mutually invested 
dialogue and creative negotiation  W or mutual appropriation  W fully integrates the analytical 
acumen of collaborator-ƐƵďũĞĐƚƐ ?ŝŶƐƚĞĂĚŽĨ ‘ŽƚŚĞƌƐ ? ) ?ĞǀĞůŽƉĞĚfrom within the complex 
 ‘ĐŽůůĂďŽƌĂƚŽƌŝĞƐ ? (Finholt 2002) of organisations in the global information age of knowledge 
economies, para-ethnography is eminently applicable to these settings. As a de-centred 
organisational ethnographer (cf. Islam 2015), I engage in this quasi-peer participatory 
story-telling side-by-side with Herbert Schwabl. This Austrian man (born 1961) with a 
longstanding interest in the green political movement and urban sustainability obtained a 
doctoral degree in physics at Technical University of Vienna and then moved to Switzerland 
with his wife (1994), who studied chemistry, to take over PADMA in 1998. He enjoys 
Baroque classical music. His true passion, however, lies in theoretical quantum mechanics 
(on which he has co-authored several ĂĐĂĚĞŵŝĐũŽƵƌŶĂůĂƌƚŝĐůĞƐ ‘ǁŝƚŚĨƌŝĞŶĚƐ ?), and in the 
groundbreaking but largely undervalued work of the Chilean neuroscientist, biologist and 
philosopher Francisco Varela (1946-2001, who cofounded The Mind and Life Institute in 
1987) on autopoiesis and second-order cybernetics. Varela influenced systems theory, and 
Herbert has recently applied this network perspective to explain the complex multi-level 
interactive effects of multi-ĐŽŵƉŽƵŶĚ dŝďĞƚĂŶ ŵĞĚŝĐŝŶĞƐ ĂƐ  ‘ƉůĞŝŽƚƌŽƉŝĐ ƐŝŐŶĂƚƵƌĞƐ ?
(Schwabl et al. 2013)43 in what he sees as a logical confluence of his interests. For more 
than two decades, he has also been very politically engaged; first as a representative of 
Swiss herbal medicine producers (www.svkh.ch), then pushing for state recognition of and 
support for complementary and alternative medicine (CAM), and later lobbying for the 
CAM community at European institutions (see Chapter 6). In relation to this, Herbert has 
published on the nefarious impacts of European pharmaceutical and food regulation on 
bringing Tibetan and multi-compound herbal medicines on the market (Schwabl 2009, 
                                                     
42 In this light, anthropologist Martin Saxer may be considered an informant for PADMA as his excellent 
ĚŽĐƵŵĞŶƚĂƌǇǁŽƌŬ ?^ĂǆĞƌ ? ? ? ? )ŽŶƚŚĞĂĚŵĂũĞǁƐĂŶĚWD ?ƐŝůůƵƐƚƌŝŽƵƐŚŝƐƚŽƌǇŶŽǁƐĞƌǀĞƐŶŽƚŽŶůǇĂƐĂ
ŵĂƌŬĞƚŝŶŐƚŽŽůďƵƚĂůƐŽŝŶWD ?ƐƐĞůĨ-conceived narratives of tradition and innovation (see Chapter 6).  
43 ^ĐŚǁĂďůĞƚĂů ?  ? ? ? ? ? ?Ɖ ?  ? ? )ĞǆƉůĂŝŶƚŚĂƚ  ‘ ?Ă ?ĚƌƵŐƐŝŐŶĂƚƵƌĞƌĞƉƌĞƐĞŶƚƐ ƚŚĞƉŚǇƐŝĐŽĐŚĞŵŝĐĂůƐƚŝŵƵůŝ ƚŚĂƚ
cause a reaction by the system [i.e. the human body], as well as the cross-links by which the entire connected 
system is affected at all levels. Phytotherapeutics, which chemically represent multi-component mixtures, 
have especially complex signatures. As multi-target medicines with a pleiotropic effect profile [consisting of 
multiple, independent mechanisms], they therapeutically affect different levels of the network, which is why 
ƚŚĞǇĂƌĞĂůƐŽƌĞĨĞƌƌĞĚƚŽĂƐŶĞƚǁŽƌŬŵĞĚŝĐŝŶĞƐ ? ? 
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2013; Schwabl and Vennos 2015). Having led PADMA and interacted with anthropologists 
and Tibetan and European practitioners of Sowa Rigpa (as well as with Men-Tsee-Khang) 
for years, he is the more experienced researcher and at times it felt like he was handing me 
full-fledged critical analyses on a plate. An important part of this para-ethnographic 
exercise thus entails an exploration of insider-outsider dynamics and the relative 
positioning of Herbert and myself vis-à-ǀŝƐƚŚĞ ‘ŽƚŚĞƌ ?ƐƵďũĞĐƚƐŝŶƚŚĞƐƚŽƌǇ ?ďĞŝŶŐŵŝŶĚĨƵů
of possible gaps and contradictions. This is clearly not an organisational para-ethnography 
 ‘ĨƌŽŵďĞůŽǁ ? ?ǀĞŶƚŚŽƵŐŚ/ĚŽŶŽƚĚĞŶǇƚŚĞƌĞĨůĞǆŝǀ ǀŽŝĐĞƐŽĨŽƚŚĞƌWADMA employees, 
their background and the nature of their work engenders a partially overlapping, but less 
theory-ĚƌŝǀĞŶƐŽƌƚŽĨ ŝŶƚĞƌŶĂůĐƌŝƚŝĐŝƐŵ ?ǇƌĞůǇŝŶŐŽŶ,ĞƌďĞƌƚ ?ƐĞǆƉĞƌƚŝƐĞƚŚĞƌĞŵĂǇďĞĂ
risk of adopting elitist managerialist ideologies, but recognising possible contradictions and 
critical possibilities in these otherwise hidden reflexive practices is exactly what there is to 
gain in the para-ethnographic bargain (Islam 2015). 
 
But before embarking on this co-produced montage, I first go into IngoůĚ ?Ɛ ĂŶĚ ĂůůŝĞĚ
writings on materiality, skill and technology to develop a theoretical foundation for my (our) 
argument. By considering PADMA products as substances-in-becoming in a responsive 
human-machine-substance meshwork, I expand the Ingoldian framework to the 
ethnographic study of pharmaceutical companies. I then briefly review the existing 
anthropological literature on the production of Asian scholarly medicines, further 
narrowing down to Tibetan medicine and previous considerations of materiality within the 
pharmaceutical process. Following my analysis of Tibetan medicinal plants in texts and in 
the trade in the previous two chapters, I now aim to bring the plants alive in a wholly 
different environment: enmeshed in a highly mechanised arena of pharmaceutical 
production in Kempten, a small village part of Wetzikon municipality in the outskirts of 
Zürich. 
 
3.1 Materiality, agency, skill and technology: making as growth 
/ŶŐŽůĚ ?ƐƌĞĨůĞĐƚŝŽŶƐŽŶŵĂƚĞƌŝĂůŝƚǇĐĂŶďĞƚƌĂĐĞĚďĂĐŬƚŽƚŚĞĞĂƌůǇ ? ? ? ?Ɛ ?ǁŚĞŶŚĞƐƚĂƌted 
thinking about the role of production in the differentiation between humans and non-
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humans (Ingold 1983). In going beyond production as the conversion of images into objects, 
he envisioned producers (human or not) as engaging in mutual processes of growth with(in) 
their lifeworlds. Next, he aimed to undo the opposition of collection (gathering readily 
available stuff) and production (the manufacture of raw materials) as the two only 
conceivable livelihood strategies, by considering gardening  W the cultivation of plants  W as 
an act of nurturing that establishes the right conditions for growth in a degree different to 
collection (Ingold 2000). This view was then extended to making things: it is not just a 
process of mechanical transcription of a pre-conceived idea, but of growth, moving away 
from modernist obsessions with artificial production as a claim towards the transcendence 
of Nature. Building on these ideas further, he then repeatedly critiqued the concept of 
materiality as conceived within material culture studies (Ingold 2011, 2012, 2013b), where 
the materials themselves  W as in the stuff things are made of  W are strangely enough not 
part of the main picture due to an entrenched polarisation of mind versus (and over) matter. 
Instead of looking at thĞĂďƐƚƌĂĐƚ ‘ŵĂƚĞƌŝĂůŝƚǇ ?ŽĨƉƌĞƐƵŵĞĚƐŽůŝĚŽďũĞĐƚƐƚŚĂƚƌĞƚŚĞĨŽĐƵƐ
of analyses of consumption (Miller 1995, 2005), Ingold proposes to be more attentive to 
the properties of the materials themselves. We are all immersed in an ecological world of 
material fluxes44 ?ĂůůŽƌŐĂŶŝƐŵƐĂŶĚƚŚŝŶŐƐĂƌĞ ‘hiveƐŽĨĂĐƚŝǀŝƚǇ ? (Ingold 2011, p. 29). Skilled 
artists or artisans thus work with materials through practical engagement and sensory 
perception, and very often continue their transformation (and incorporation), started by 
animals and plants, through further processing and combination.45 The division between 
ŐƌŽǁŝŶŐĂŶĚŵĂŬŝŶŐ ?ďĞƚǁĞĞŶ ‘ŶĂƚƵƌĂů ?ŽƌŐĂŶŝƐŵƐĂŶĚ ?ŵĂĐŚŝŶŝ  )ĐƵůƚƵƌĂůĂƌƚĞĨĂĐƚƐ ?ŝƐĨůƵŝĚ
as form is not imposed on materials but emergent in fields of relationships (see also Ingold 
and Hallam 2014).  In the example of stone, Ingold suggests that: 
 ^ƚŽŶŝŶĞƐƐ ?ƚŚĞŶ ?ŝƐŶŽƚŝŶƚŚĞƐƚŽŶĞ ?Ɛ ‘ŶĂƚƵƌĞ ? ?ŝŶŝƚƐŵĂƚĞƌŝĂůŝƚǇ ?EŽƌŝƐŝƚŵĞƌĞůǇŝŶƚŚĞŵŝŶĚ
of the observer or practitioner. Rather, it emerges through the stonĞ ?Ɛ ŝŶǀŽůǀĞŵĞŶƚ ŝŶ ŝƚƐ
                                                     
44 In his ecology of materials, and aiming to bring objects to life, Ingold (2011) draws on :ĂŵĞƐ'ŝďƐŽŶ ?Ɛ (1979) 
Ecological approach to visual perception Gibson (1979), who shows that the environment  W in its three 
components, namely medium (e.g. air transmitting visual and auditory stimuli), substances, and surfaces (the 
interactive interface between the former two)  W allows us to perceive and act. This perspective also agrees 
to a considerable extent with Merleau-WŽŶƚǇ ?ƐƉŚĞŶŽŵĞŶŽůŽŐǇ ? ? ? ? ? )ŝŶƚĞƌŵƐŽĨƚŚĞĨůĞƐŚǇĞŶƚĂŶŐůĞŵĞŶƚ
ŽĨŵŽǀĞŵĞŶƚĂŶĚĂĨĨĞĐƚ ?ĂŶĚǁŝƚŚĞůĞƵǌĞĂŶĚ'ƵĂƚƚĂƌŝ ?Ɛ ? ? ? ? ? )ŶŽŵĂĚŽůŽŐǇĂŶĚĐŽŶĐĞƉƚŝŽŶŽĨŵĞƚĂůůƵƌŐǇ
as the blacksmith following flows of iron (see Ingold 2012). 
45 Plant-people entanglements are fundamental to human existence, but plant materiality and agency have 




total surroundings  W including you, the observer  W and from the manifold ways in which it is 
engaged in the currents of the lifeworld. The properties of materials, in short, are not 
attributes but histories. (Ingold 2011, p. 32) 
In this sense, one can distinguish objects as completed form from things ĂƐ ‘gatherings of 
ŵĂƚĞƌŝĂůƐ ŝŶŵŽǀĞŵĞŶƚ ? (Ingold 2012, p. 439). Ingold therefore proposes to move away 
from Aristotelian hylomorphism (things are created by composing matter and form) 
towards an appreciation of the continual emergence of form, as substances-in-becoming 
(morphogenesis). We have to forget chemistry and return to an alchemical understanding 
of materials (Ingold 2013). In this sense, the properties of materials are not just concepts 
but realised in skilled practices. 
 
/ŶŐŽůĚ ?ƐƌĞĨůĞĐƚŝŽŶƐŽŶĂŐĞŶĐǇŝŶƌĞůĂƚŝŽŶƚŽƐŬŝůůĂŶĚŚŝƐďƌŝŶŐŝŶŐĂůŝǀĞŽĨŵĂƚĞƌŝĂůƐŚĂǀĞůĞĚ
ŚŝŵƚŽƌĞƚŚŝŶŬ ‘ƚŚĞƚĞĐŚŶŝĐĂů ?ĂůŽŶŐƚŚĞƐĂŵĞůŝŶĞƐ ?dŚĞŵŽĚĞƌŶtĞƐƚĞƌŶĚŝǀŝĚĞďĞƚǁĞĞŶ
ƚŚĞ ĨŝĞůĚƐ ŽĨ  ‘Ăƌƚ ? ĂƐ ĐƌĞĂƚŝǀĞ ? ŝŶƚĞůůĞĐƚƵĂů ĚĞƐŝŐŶ ? ĂŶĚ  ‘ƚĞĐŚŶŽůŽŐǇ ? ĂƐ ŵĞĐŚĂŶŝĐĂů
implementation, can be traced back to the advent of industrial capitalism and concurrently 
to a mechanistic, scientific cosmology (Ingold 2000). As part of this, the actual producer, 
the machine operative, is reduced to a robot-like labour unit and marginalised as the 
technical is pulled out of the social sphere. In reality however, Ingold argues, the operative 
has always remained a skilled practitioner:46 able to cope with machines through technical 
skill, becoming intimately familiar with them and the workplace. Humans interact with 
machines as persons, not just as suppliers of labour-ƉŽǁĞƌ ?ǀĞŶ ‘ĨƵůůǇĂƵƚŽŵĂƚŝĐ ?ŵĂĐŚŝŶĞƐ
that rely on nonhuman power are not self-sustaining living organisms, and thus require 
maintenance and repair, often carried out by a separate and more highly esteemed class 
of employees calůĞĚ ‘ĞŶŐŝŶĞĞƌƐ ?Žƌ ‘ŵĞĐŚĂŶŝĐƐ ? ?Following Marx, the operators are coerced 
to serve the machine and by extension ĐĂƉŝƚĂůŝŶĞŶĚůĞƐƐƌĞƉĞƚŝƚŝŽŶ P ‘FrŽŵƚŚĞĞŵƉůŽǇĞƌ ?Ɛ
point of view, tools are not made to be used by workers, rather workers are made to use 
ƚŽŽůƐ ? (ibid., p. 309). In the most extreme form of the mechanisation and dehumanisation 
of production, the technology of the industrial automaton and the underlying objectifying 
                                                     
46 Ingold (2000) defines skilled practice as having five essential characteristics: (1) the processual emergence 
of intentionality and function, (2) relationality, the artisan is immersed in her/his environment, (3) qualities 
of judgement, dexterity and care, (4) hands-on learning, and (5) craftsmanship generating form instead of the 
mechanical execution of a design. 
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logic of science replaces enskilled technique according to Ingold. He describes this 
production process as machinofacture:  
ƚŚĞƐŚĂƉĞŽĨƚŚĞƉƌŽĚƵĐƚŝƐĂůƌĞĂĚǇ ‘ǁƌŝƚƚĞŶŝŶ ?ƚŽƚŚĞŵĂĐŚŝŶĞ ?ƚŚĞŵŽǀĞŵĞŶƚƐŽĨǁŚŝĐŚĂƌĞ
predetermined. The consciousness of the machine operative is, so to speak, short-circuited. 
Though the worker probably knows, if only from prior observation, what the product will look 
ůŝŬĞ ? ŚĞ ĚŽĞƐ ŶŽƚ ĂĐƚƵĂůůǇ ŶĞĞĚ ƚŽ ŬŶŽǁ ? ĂŶĚ ƚŚĞ ƉƌŽĚƵĐƚ ?Ɛ ŵĂƚĞƌŝĂůŝƐĂƚŝŽŶ ŝƐ ŶŽƚ at all 
dependent on such knowledge. (Ingold 2000, p. 310) 
 It comes across here as if Ingold downplays the skills of the automaton operator, or at least 
attributes them a different degree of skill compared to tool manual use and man or animal-
powered machines. This is in opposition to the mechanical engineer, who is not part of the 
predetermined assembly line. In the close-up descriptions of operative-automaton co-
operation that follow I aim to show that these workers do need to possess intimate 
technical knowledge and skill  W blurring the distinction between operators (which as I argue 
should be considered a type of artisan) and mechanical engineers  W and how machines 
modulate the interaction between people and plants, the products-to-be.  
 
Cultural anthropologist Heather Paxson (2013), in her book on cheese making, notes that 
the artisan occupies an uneasy position in industrialised Europe and the US: a pragmatic 
compromise of the competing values of craftsmanship and business. In her chapter in The 
Life of Cheese entitled The Art and Science of Craft, she further examines what makes 
ĂƌƚŝƐĂŶĐŚĞĞƐĞ ‘ĂƌƚŝƐĂŶĂů ? ?ůƚŚŽƵŐŚĚĞĨŝŶĞĚŝŶŽƉƉŽƐŝƚŝŽŶƚŽƚŚĞŝŶĚƵƐƚƌŝĂů ?ǁŚŝĐŚŝƐůĂƌŐĞ-
scale, automated, with standardised recipes, hygienically removed and scientifically 
quality-controlled), artisanal production nowadays equally relies on technoscientific 
elements and strives for consistency. Cheesemakers speak of their craft in terms of a 
balance between art and science. In striking this balance (and similarly to PADMA 
employees), tinkering, curiosity and interpretation joins practical bodily knowledge with 
abstract objectivism through synesthetic, ecological reasoning that belies a form of 
technical intimacy and a tacit understanding that scientific manuals are suggestive rather 
than definitive ?EĞǀĞƌƚŚĞůĞƐƐ ?WĂǆƐŽŶ ?Ɛ (2013, p. 151) ĚĞĨŝŶŝƚŝŽŶŽĨĐƌĂĨƚŝŶĐůƵĚĞƐ ‘producing 
nonstandardized objects whose natural variation adds aesthetic and commercial value to 
the objects, yet that conform recognizably to a pre-imagined form ?. By looking closely at 
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WD ?Ɛ ƉƌŽĚƵĐƚŝŽŶ ? / ĐŽŶƚĞŶĚ ƚŚĂƚ ƚŚĞ ĚĞǀĞůŽƉŵĞŶƚĂŶĚ ŵĂŶƵĨĂĐƚƵƌĞ ŽĨ industrial 
Tibetan medicines equally relies on sensorially engaged craftsmanship. To learn about the 
broad ecology of cheese of which artisans themselves are a part one has to learn from the 
materials, which have their own emergent agency as heterogeneous assemblages.47 The 
cheese-ŵĂŬĞƌ ?ƐŬŶŽǁůĞĚŐĞĚŽĞƐŶŽƚŽŶůǇƌĞƐŝĚĞŝŶƚŚĞŵĂŬĞƌ ?ƐďŽĚǇ ?ŶŽƌŝŶǁƌŝƚƚĞŶƌĞĐŝƉĞƐ ?
but is inscribed onto and incorporated in its ecological environment (West 2013). 
Correspondingly, PADMA workers have to think with and through the interactivity of the 
raw materials and machines. In aiming to document this dynamic ecology of materials, I 
risk ignoring the rich sociopolitical, economic and symbolic dimensions of medicines that 
have been the hallmark of pharmaceutical anthropology and on which I elaborate more in 
Chapters 5 and 6. 
 
3.2 State- -the-art: production of Asian medicines 
In contrast to research on the impacts of commodification and pharmaceuticalisation, 
marketing practices, regulations, and the ǀĂŐĂƌŝĞƐ ŽĨ ĚƌƵŐ ĚĞǀĞůŽƉŵĞŶƚ ?  ‘ethnographic 
studies of pharmaceuticĂůĐŽŵƉĂŶŝĞƐĂƌĞĞǆƚƌĞŵĞůǇƌĂƌĞ ? (Whyte et al. 2002, p. 18). The 
reasons why social scientists may be reluctant or have not been able to seriously study the 
producers  W let alone the production process itself  W  have been listed repeatedly (Whyte 
et al. 2002, Abraham 2007, Busfield 2006). Although researchers on Asian materia medica 
have covered essential new ground as evidenced in the next few paragraphs, they were 
sometimes barred from observing the actual production process in its entirety due to 
economic, political or (in the case of mercury processing) even religious factors (e.g. Craig 
2012; Gerke 2012, 2013; Kloos 2010). There is therefore still a lack of attention to the 
material flows and frictions of medicine making itself, particularly beyond the closed doors 
of factories. 
                                                     
47 In his book chapter on knowledge transmission in contemporary artisan cheesemaking, West (2013) relies 
ŽŶ :ĂŶĞĞŶŶĞƚƚ ?ƐďŽŽŬVibrant Matter (201 ? ) ƚŽĚĞĨŝŶĞ  ‘ĂƐƐĞŵďůĂŐĞ ? ?ǁŚŝĐŚ ŝƚƐĞůĨďƵŝůĚƐŽŶĞůĞƵǌ ĂŶĚ
'ƵĂƚĂƌƌŝ ?Ɛ ? ? ? ? ? )A Thousand Plateaus P ‘ƐƐĞŵďůĂŐĞƐĂƌĞad hoc groupings of diverse elements, of vibrant 
materials of sorts. Assemblages are living, throbbing confederations that are able to function despite the 
persistent presence of energies that confound them from within ? ? Q ?n assemblage is never a stolid block 
but an open-ĞŶĚĞĚĐŽůůĞĐƚŝǀĞ ?Ă “ŶŽŶ-ƚŽƚĂůŝǌĂďůĞƐƵŵ ?. An assemblage thus not only has a distinctive history 
ŽĨĨŽƌŵĂƚŝŽŶďƵƚĂĮŶŝƚĞůŝĨĞƐƉĂŶ ? ?ĞŶŶĞƚ ? ? ? ? ?Ɖ ? ? ?-24). 
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As exceptions to the rule, several scholars have already ethnographically described steps 
in the production of Tibetan medicines in more detail and with an eye for the material. 
Gerke (2013) for instance, in her kaleidoscopic biography of purified mercurial ash, 
ƐƵŵŵĂƌŝƐĞƐƚŚĞ ‘ĐŽůĚƚĂŵŝŶŐ ?ŽĨŵĞƌĐƵƌǇĂƐĨŽůůŽǁƐ ?ďĂƐĞĚŽŶŝŶ-depth translation work 
and interviews: 
I later learnt that making drangdül involved rubbing liquid mercury (Hg) or ngülchu (dngul 
chu) with ginger powder, long and black pepper in a goatskin bag for eight hours to remove 
ƚŚĞ ‘ŽǆŝĚĞ ?Žƌ ‘ƚĂƌŶŝƐŚ ? ?Ő ǇĂ ?). Then mercury is boiled for several hours in various types of 
animal urine, washed frequently with water, then boiled for several hours with tarbu, and 
again rinsed many times with water. This process is meant to cleanse the mercury from 
oxides and adulterants. Then, mustard oil is heated in an iron pan and mercury is boiled in 
ƚŚŝƐŽŝůƚŽŐĞƚŚĞƌǁŝƚŚǀĞƌǇƚŚŝŶƐŚĞĞƚƐŽĨ ‘ƚŝŶ ? ?ŐƐŚĂ ?ĚŬĂƌ) for several hours. Finally the mixture 
is triturated in a stone mortar with pre-ƉƌŽĐĞƐƐĞĚǇĞůůŽǁ ‘ƐƵůƉŚƵƌ ?Žƌmuzi (mu zi) into a fine 
powder of a blackish deep blue colour until no silvery brightness remains.  
(Gerke 2013, p. 123) 
This coming-together of materials and practises clĞĂƌůǇƐŚŽǁƐŚŽǁŚƵŵĂŶĐƌĂĨƚĞƌƐ  ‘take 
over from where non-ŚƵŵĂŶƐ ŚĂǀĞ ůĞĨƚ ŽĨĨ ? (Ingold 2011, p. 24), how metals, minerals, 
plants, and animals are sourced for their properties, combined in highly original ways, and 
consequently transformed into something new, which is ever impermanent and thus alive.  
 
/Ŷ ŚĞƌ  ‘ĞƚŚŶŽŐƌĂƉŚǇ ŽĨ ƚŚĞ ĨĂĐƚŽƌǇ ĨůŽŽƌ ? ? ^ŝĞŶŶĂ ƌĂŝŐ  ?2011, 2012) on the other hand 
emphasises how a drive towards Good Manufacturing Practice (GMP) implementation in 
Tibetan medicine factories in Tibet, brought about a fetishisation of hygiene, recasting 
medicinal flower gardens and holy spring water as possible contaminants. In this new 
regime of pharmaceutical governance, human-nonhuman interactions changed drastically: 
Before increasing mechanization and now the GMP era, those assisting with medicine 
production had a strong sensory relationship with the plants, minerals, and animal products. 
Making medicines required physical strength and drew from local populations. In the highly 
mechanized era of GMP-certified factories, employees are physically separated from materia 
medica through ritualized acts of donning disposable scrubs, masks, and plastic gloves. While 
ƚŚŝƐŬĞĞƉƐƚŚŝŶŐƐ ‘ĐůĞĂŶ ? W and is even lauded as a positive change by many in the industry as 
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standards to which other small-scale producers should aspire  W it also changes the embodied 
nature of producing Tibetan medicine. This is not to say that factories are inimical places, but 
rather that spaces and times for social interaction have become distinct from those devoted 
to labor. In Marxian terms, this shift corresponds with a transition from conceiving of Tibetan 
medicines primarily for their use value, their direct utility, to seeing them as items that 
embody specific exchange values, linked with market prices and emblematic of processes of 
standardization and commodification. (Craig 2012, p. 162) 
 
In this context, Martin Saxer (2013) adds that GMP has come to stand for the entire 
industrialisation of Tibetan medicine, creating a chimera of seemingly incompatible 
knowledge systems and best practices. He summarises the general steps of production for 
Tibetan rilbu pills (the most commonly used dosage form, made by adding water to a 
powdered mixture) in these GMP plants: sourcing of raw materials, storage, pre-processing 
(simple cleaning and sorting, or complex detoxification), mechanical grinding, mixing, 
rolling the mixture into pills, microwave sterilisation (never carried out, even if the ovens 
are there), electrical drying, packaging and labelling. Based on a comparison of the 
traditional ideals represented by The seven limbs (yenlak dün) section of the Four Tantras 
with GMP regulations, and with how these pills are actually manufactured, Saxer argues 
that conflicts in practice are not caused by incommensurable rationales48, but rather stem 
from the side effects of the rapidly enforced and untested implementation of GMP in the 
planning and construction surge towards new, compliant factories between 2002 and 2004. 
According to the same author, the shift to mechanical grinding constitutes the biggest 
diversion from archetypical manual medicine making (with a stone mortar and pestle), 
saving the producer a lot of time and physical effort. Even though machinery  W on which 
Saxer focused, revealing their hybrid nature  W was already introduced decades before the 
introduction of GMP, the newer and faster grinding mills raised further concerns among 
some practitioners, notably about their material influences on the medicines in the making. 
The second-generation mills greatly reduce the amount of noise and dust as well as the 
                                                     
48 There is, however, a recurring and more fundamental conflict between universal, abstract knowledge and 
rules (the techne or episteme in Foucaultian terms, promulgated by modernist states and market forces) and 
pluralistic, contextual, and practical knowledge (ŵĤƚŝƐ) both within and between Sowa Rigpa and 
cosmopolitan technoscience (see Blaikie (2014), Craig (2011) and Saxer (2013) for detailed discussions). 
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need for sieving  W thus improving working conditions  W but this increase in efficiency and 
speed came at the cost of more heat production (through friction of the steel machine 
blades with the ingredients).49 Moreover, iron and by extension stainless steel, as some 
would argue, negatively affects the potency of (precious) pills, leading several 
manufacturers in China to look for alternatives such as mechanised marble pestles. This 
mechanisation of the production process at Tibetan medicine factories in the Tibetan areas 
under China is paralleled in observations of the Indian Ayurvedic and Unani industries, 
revealing the hegemony of modern science and technology in tandem with a capitalist 
market logic. Banerjee (2009) for instance details how at Dabur, the largest Ayurvedic 
pharmaceutical company, chemists and engineers were involved in translating the labour-
intensive and time-consuming processing of a herbal mixture in a buried earthen pot sealed 
with clay into machine-assisted temperature control. Bode (2008) also visited ultra-modern 
manufacturing units in India run by engineers trained ĂƚďŝŽŵĞĚŝĐĂůĨĂĐƚŽƌŝĞƐ ?ǁŚĞƌĞ ‘no 
hands touch the products until the machine-packed medicines are collected by personnel 
ĂŶĚƉƵƚŽŶůĂƌŐĞƉĂůůĞƚƐ ? (Bode 2008, p. 134), adding that the lack of artisanal skill is what 
makes traditionalists doubt the quality and efficacy of these medicines. 
 
ĂůƵŵ ůĂŝŬŝĞ ?Ɛ ĚŽĐƚŽƌĂů ĚŝƐƐĞƌƚĂƚŝŽŶ(2014) has delivered the most fine-grained 
ethnographic account of Tibetan medicine-making to date, focusing on small-scale 
producers and the emerging cottage industry in Ladakh, Himalayan India. Blaikie equally 
considers the sequence of production stages and reveals the unpredictable and ambivalent 
influences of commercialisation and standardisation. He consistently stresses the 
variability, adaptability and resilience of small-scale pharmacy practices and how this is 
expressed in the medicines themselves, doing justice to the inherent multidimensionality 
amchi men by acknowledging how the social and the technical are intrinsically intertwined: 
[e]ach medicine can be seen as a unique assemblage of heterogeneous components, 
including raw materials gathered in person or obtained through vast networks, which are 
                                                     
49  Men-Tsee-Khang still operates what Saxer (2013) calls first-generation grinding equipment. I became 
painfully aware of the dust and especially very loud noise generated by these mills during my time there, and 
was eventually able to arrange five safety ear protection headphones for the pharmacy workers at the 
request of Dr Penpa, who was not able to buy them in Delhi. They were kindly purchased and sent by PADMA 
as a donation. 
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transformed through abstract/theoretical and technical/applied knowledge gleaned from 
diverse sources, applied and adapted through ongoing praxis. (Blaikie 2014, p. 263) 
Since menjor practices are not explained in detail at all in classical texts or most handbooks, 
learning these procedures requires extensive practical instruction and experimentation 
aloŶŐƚŚĞůŝŶĞƐŽĨ/ŶŐŽůĚ ?Ɛ ? ? ? ? ? )ĐŽŶĐĞƉƚƐŽĨƚŚĞƚĂƐŬƐĐ ƉĞĂŶĚĞŶƐŬŝůŵĞŶƚ ?/ŶƉƌĂĐƚŝĐĞ ?ƚŚĞ
ĐůĂƐƐŝĐĂů ?  ‘ŝĚĞĂů ? ĨŽƌŵƵůĂĞ ĂƌĞ ŶĞĂƌůǇ ĂůǁĂǇƐ ĂůƚĞƌĞĚ ŝŶĂĐĐŽƌĚĂŶĐĞ ǁŝƚŚ ůŽĐĂů ŵĂƚĞƌŝĂů ?
environmental, economic, and empirical circumstances, as part of what Blaikie (2013) calls 
 ‘Đurrents of tradition in Sowa ZŝŐƉĂƉŚĂƌŵĂĐǇ ? ?ŽŵŝŶŐďĂĐŬƚŽŐƌŝŶĚŝŶŐŵĂĐŚŝŶĞƐ ?ůĂŝŬŝĞ
(2014) adds that it is not necessarily the equipment itself that is questioned by amchi, but 
the ability and diligence of its operators. Nevertheless, the voiced concerns here echo those 
of Tibetan practitioners, namely the metal and the heat as well as the electrical currents 
running through the machines. 
 
Theresia Hofer also explores  ‘ƚŚĞ Ăƌƚ ŽĨ ĐŽŵƉŽƵŶĚŝŶŐ ? Ăƚ dĂƐŚŝůƵŶƉŽ DŽŶĂƐƚĞƌǇ ĐůŝŶŝĐ
(Tibetan Autonomous Region, China) and describes it briefly using the example of a 25-
ingredient medicine named  ‘Vermillion Voice ? ?ĂƉŝůů ĨƌĞƋƵĞŶƚůǇƉƌĞƐĐƌŝďĞĚĨŽƌƌŚĞƵmatic 
disorders: 
ĨƚĞƌƚŚĞŝŶŐƌĞĚŝĞŶƚƐŚĂǀĞďĞĞŶĐůĞĂŶĞĚĂŶĚƉƌĞƉĂƌĞĚƚŽ>ŽǌĂŶŐdĂƐŚŝ ?Ɛ ?ƉƐĞƵĚŽŶǇŵĨor the 
monk-physician who oversees the production unit] satisfaction by the staff [who according 
ƚŽ,ŽĨĞƌ “ŚĂǀĞůŝƚƚůĞŽƌŶŽŬŶŽǁůĞĚŐĞŽĨƚŚĞŽǀĞƌĂůůƉƌŽĐĞƐƐŽĨŵĞĚŝĐŝŶĞƉƌŽĚƵĐƚŝŽŶ ? ?Ɖ ? ? ? ) ? ?
he individually weighs them on a hand scale and places most in a large metal container. A 
small number of ingredients are kept apart to be ground separately. This initial preparation 
of twenty-two of the ingredients is the outcome of three solid afternoons of work. In the next 
step the ingredients are mixed and then fed in small quantities into a machine for 
pulverization. The machine is turned off at intervals, to let it cool down. In the preparation 
of Trinsel 25 its cooling properties should be enhanced. The three harder ingredients that 
had been put aside are subsequently ground on their own, mixed in with those that had been 
pulverized, and left to cool. The following day, the powder is placed in a rotating machine. 
Round-shaped pills are formed by dropping water into the powdered ingredients. In some 
cases pills are also given a final shaping by hand before being dried in direct sunlight on the 
roof of the clinic or inside in the shade. (Hofer 2014b, p. 58) 
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Hofer contrasts this with what she learned during a visit to PADMA, where she interviewed 
and toured the company with Herbert, I imagine in much the same way I did at the start of 
my fieldwork there. However, in comparing these two very different lifeworlds directly, she 
risks aligning their differences along simplistic traditional/modern binaries. First of all, she 
invokes The Seven Limbs to describe the manufacturing unit at the monastery, while 
discussing GMP in relation to PADMA. But people in both contexts are aware of Seven limbs 
and GMP, and there is not necessarily a clash between them in practice as shown by Saxer 
(2013). Secondly, her use of contrastive ůĂŶŐƵĂŐĞ PƚŚĞ ‘ƚŝŶǇ ?ƵŶŝƚƚŚĂƚ ŝƐƉĂƌƚŽĨĂ ‘ƉůĞĂƐĂŶƚ
ŵŽŶĂƐƚŝĐĐŽƵƌƚǇĂƌĚ ?ǀĞƌƐƵƐWD ?Ɛ ‘ůĂƌŐĞĨĂĐƚŽƌǇŚĂůů ? ?WDŝƐŝŶĨĂĐƚƚŝŶǇĐŽŵƉĂƌĞĚƚŽ
the Chinese Tibetan medicine industry or to Big Pharma (cf. Chapter 6). Thirdly, the focus 
on embodied skills versus state-of-the-art machinery, a split I critique in this chapter. Hofer 
ƌĞĨĞƌƐƚŽWD ?ƐŵŝǆŝŶŐĚĞǀŝĐĞĂƐĂŶĞǆĂŵƉůĞŽĨƐƵĐŚƚĞĐŚŶŽůŽŐǇ ?ďƵƚŝƚŝƐĂĐƚƵĂůůǇĂďĂƐŝĐ
piece of equipment in use in the food industry for over half a century. Finally, her inaccurate 
statement that  ‘[a]ssessment of morphology and taste are almost nonexistent there [at 
WD ? ? (p. 63, see sections 1.4.2, 3.3.1 and ŚĂƉƚĞƌ ? ) ?dŚĞĐŽŵƉĂƌŝƐŽŶƚŽ ‘[a] Tibetan 
medical doctor [who] would judge the subtle differences of each batch, its hotness, 
bitterness, or astringency, in relation to its region of origin, and would then make 
ĂĚũƵƐƚŵĞŶƚƐĂĐĐŽƌĚŝŶŐůǇ ? (ibid.) seems unfair because of the dissimilar economies of scale 
Hofer herself refers to. In what follows, I will not focus on these habitus-specific differences, 
instead highlighting aspects that are fundamentally shared: the dealings with medicinal 
materials through various technologies and enskilled practices, and how these interact with 
each other to become transformed into medicine.  
 
3.3  ‘Production is mess ƚǇƉŝĐĂůĂƚǇƉŝĐĂůĚĂǇŽŶWD ?ƐĨĂĐƚŽƌǇĨůŽŽƌ ?ĂŶĂůǇƐĞĚ
through the voice of Herbert 
I think it's clear production is a hectic process if it is going on. You have to step out of the 
way. If it runs it runs. When it slows down there may be some time for discussion. Otherwise 
we have to stop this [i.e. my interferences]. We have enough to do; we are very limited in 




TǁŽĚĂǇƐĂĨƚĞƌ,ĞƌďĞƌƚ ?ƐĐĂǀĞĂƚ ?ŝĂƌǇ ? ?ĞĐĞŵďĞƌ ? ? ? ? ? Notebook IV), I had to get up 
early to reach PADMA before production commenced. I was excited: it was the first time I 
would witness the manufacturing process in person. It was still dark. The air was cold and 
crisp. It had snowed that night. When I arrived at the car park, Rolf  W WD ?ƐŚĞĂĚŽĨ
production who I had been introduced to the day before  W had just got out of his car. We 
entered the building together. As requested, I had brought a second pair of shoes. These 
were disinfected with an ethanol spray so that there was no need to don a pair of shoe 
protectors every time I enter ƚŚĞƌĞƐƚƌŝĐƚĞĚ ‘tŚŝƚĞŽŶĞ ?ǁŚĞƌĞƚŚĞĂĐƚƵĂůƚƌĂŶƐĨŽƌŵĂƚŝŽŶ
takes place from powdered ingredient to filled capsules in blisters ? /ŶƐŝĚĞ ƚŚĞ ŵĞŶ ?Ɛ
changing room, Rolf instructed me to put on a hair and beard mask and a white overcoat. 
The zipper should be closed up to the neck. I also disinfected my hands. We crossed the 
black-white divide in the wardrobe, and finally opened the door that led inside the White 
Zone. Rolf gave me a short tour of the different rooms and compartments, and explained 
what was going to happen today. Signposts near the doors indicated the stages of 
production that take place there: dosieren (dosing), mischen (mixing), sieben (sieving), 
kapseln (encapsulation), blistern (blistering), verpacken (packaging), and so on. He 
explained that if I wanted to change workplace from the mixing and sieving rooms to 
blistering, I would have to put on a new set of protective clothing to prevent cross-
contamination. Dosing and mixing produce more dust (Audio recording 39).50 
 
3.3.1 Dosing, mixing and sieving 
 ‘ĂƌĞĨƵů ? ? On my right side, an automated compartment door swiftly swept down, shutting 
us off from the White Zone entrance hall. Rolf summarised the dosing procedure for me, 
which I observed for several hours later that day. What in a first approximation seems like 
a very simple process  W weighing the necessary amounts of raw materials needed and 
loading these into the mixing device  W requires a series of steps that have to be carried out 
with pharmaceutical precision and documented in protocols. Each bag with herbal 
powdered material is weighed three times (incoming weight, weight of the powder in the 
                                                     
50 KƌĚŝŶĂƌǇ  ‘ĚƵƐƚ ? ŝƐĂǀĂŐƵĞƚĞƌŵĨŽƌǁŚĂƚ ŝƐĂĐƚƵĂůůǇƚŚĞĂĞƌŽƐ ůĨƌĂĐƚŝŽŶŽĨƚŚĞƉŽǁĚĞƌĞĚƌĂǁŵĂƚĞƌŝĂůƐ ?
released during various production stages. 
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dosing container, and outgoing weight), using two different scales, and the amount has to 
be read aloud and confirmed each time by both the control person and the dosing person 
in accordance with the four-eye principle. The control person has to compare the colour 
and smell of the pulverised herbs in each bag with a reference sample, even though 
samples of the same batch (not necessarily the same bag) have already received the green 
light ĨƌŽŵƚŚĞƋƵĂůŝƚǇĐŽŶƚƌŽůůĂď ? ‘It is a horizontal forced miǆŝŶŐŵĂĐŚŝŶĞ ? ?ZŽůĨĐŽŶƚŝŶƵĞƐ. 
 ‘The total volume is 3200 litres; the usable volume is 2500 litres. Power consumption is like 
a normal Volkswagen Golf; around one hundred KW. There are also two cutters which are 
helping to get in a more or less short time a ŚŽŵŽŐĞŶŽƵƐ ŵŝǆƚƵƌĞ ? ? Rolf effortlessly 
discussed all its details. He was schooled as a car mechanic forty years ago, and after thirty 
years running all stages of production he applŝĞĚƚŚĞƐĞƐŬŝůůƐĂƐĂŵĂŶĂŐĞƌ ?  ‘Around 890 
kilograms will be produced, which is about two million capsules. The amount of boxes 
depends on the size of the boxes  W there are different sizes. ? He added that today twenty-
two raw materials will be mixed, plus two components (Hilfstofffe, excipients) that increase 
the ductility of the mixture. The recipe is a variant of PADMA 28 internally labelled 
 ‘WƌĞƉĂƌĂƚŝŽŶ ? ? ? ? ?ĂĚapted for the Danish market. Meanwhile, the production workers had 
arrived on-site and had started the necessary daily control of the machinery, environment 
and initial documentation. Just outside the mixing room, the sacks containing the 
powdered ingredients were ready, lined in neat rows in white plastic containers. Mevlan 
and Liman were wearing blue overalls and safety footwear in addition to the hairnets, and 
 W depending on the procedure and their role in it  W they donned powder-free latex gloves, 
and facial protection masks. Both of these men are in their forties, and naturalised Swiss 
citizens off South-eastern European origins. They know each other well, have been working 
at PADMA for years, and occasionally switch from Swiss German (Schwyzerdütsch, often 
ĚĞƐĐƌŝďĞĚĂƐĂŶůůĞŵĂŶŝĐ ‘ĚŝĂůĞĐƚ ?ĂŶĚĂƚƚŝŵĞƐƵŶĞǆƉĞĐƚedly close to my native Flemish-
Dutch) to Macedonian. 
 
Surprised and caught by the sound of the action, I watched how Liman used a rather large 
blunt hammer to repeatedly hit a bag of pulverised Phyllantus emblicae Fructus  W the fruit 
of emblic myrobalan, one of the well-ŬŶŽǁŶdŝďĞƚĂŶ ‘dŚƌĞĞ&ƌƵŝƚƐ ? ?drébu sum)  W before 
pouring its contents into the dosing container. Rolf smiled, noticing my puzzled facial 
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expression, and explained that during storage the bags are compressed from the weight 
above, and that this compaction sometimes leads to hard blocks forming in the case of 
certain herbs. A grid covers the opening to the mixing container for safety reasons, making 
it impossible to fill it with larger chunks of material. Liman had to use quite a lot of force to 
break up the solid mass. He also crushed the large blocks in the container with a stainless 
steel shovel. Rolf ensured me that this is all part of normal procedure. He left and I carried 
on observing, continuously shifting places in the dosing room in a half-baked effort not to 
block or disrupt the process. Mevlan brought in the bags while Liman emptied them inside 
the container and then transported and lifted it onto the mixing machine with a small fork-
lift truck, to empty it. Again, the descriptive and mechanical nature of this sentence 
conceals the practices that only emerge clearly in moments of contingency: the skills, effort 
and sweat of brute force in lifting and hammering heavy bags immediately followed by 
pouring a precise amount into the container, at the same time paying attention to general 
and health and safety operating procedures, carefully documenting nearly every move in 
this rather disagreeable environment consisting of artificial light, machine buzzing, cool and 
dry (humidity-controlled) air flows, and disinfected surfaces. This physical interaction 
between the workers, the ingredients and the machines is not always predictable, and may 
require mediation by means of simple tools such as hammer and shovel to force the 





Figure 3.1. Mevlan watched from the forklift truck as Liman opened the shaft of the dosing container to release the 
powdered mixture into the mixing machine. A proportion of the material in the form of hard chunks (of powdered 
Phyllantus emblica fruits) was temporarily blocked by a grid covering the mixer.  
 
Mevlan was using the forklift truck to move and lift the container now filled with powder 
onto the mixing machine. Liman carefully opened the shaft to let the powder flow into the 
ŵŝǆĞƌ P ‘Scheisse ? ? ?ŚĞƌĞƉĞĂƚĞĚŵƵƚĞůǇŝŶƐĞǀĞƌĂůůĂŶŐƵĂŐĞƐ ?dŚĞŵĂƚĞƌŝ ůƐǁĞƌĞŶŽƚmoving 
through the grid smoothly. He opened and closed the shaft a few times, and then decided 
to hit the container lightly on the side with a rubber hammer. It did not help much. The 
emblic myrobalan was the problem again, the hard chunks he had tried to pierce earlier 
were still too big. Liman tried hitting harder. They lifted the container back down to the 
floor and used a disinfected stainless steel rod to pierce the blocks in the container. Mevlan 
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grimaced, pointing out how he was sweating because of all this action.  After almost half 
an hour, the problem was solved. But time was lost and the mixing could now not be 
finished before noon. It was striking to see all these simple tools being used, which were 
not mentioned explicitly in the procedures but were designated for use inside the White 
Zone. Two days later, I discussed this with Herbert (Audio recording 47), wondering if these 
tools are also validated before use similar to other production machines and processes. His 
response evoked the underlying paradigm of risk analysis (see Chapter 4) and the need to 
weed out contingencies and integrate them in improved protocols. 
No, of course not, but you are allowed to improvise. The idea with the hammer is intelligent, 
but at the same time, if you [as a production worker] report this happened and if this is very 
often the case with this Phyllantus, then the idea is not to keep using the hammer all the time 
but to devise a process so that the hammer is not needed [anymore]. When first 
encountering a problem, you have to do something. The worst case is to stop everything. But 
ŝĨ ƚŚĞ ƐĞĐŽŶĚ ĂŶĚ ƚŚŝƌĚ ƚŝŵĞ ǇŽƵ ĂůǁĂǇƐ ƵƐĞ ƚŚĞ ŚĂŵŵĞƌ Q ŽŬ ? ŵĂǇďĞ ƐŽŵĞƚŚŝŶŐ  ?ŝŶ ƚŚĞ
process] is wrong. Therefore, we need feedback [from inside production]. 
 
After a quick lunch with Mevlan and Liman at a Turkish kebab place close by in Kempten 
town, we continued the dosing. It was the turn for Myrobalani Fructus to be dosed into a 
second container, which Mevlan introduced as the king of Tibetan medicines. Three more 
ingredients, then another mixing cycle of twenty-four minutes, then the Hilfstoffe 
(excipients) needed to be added, and fertig! During the sieving process, which took place 
in a smaller adjacent room with the help of rapid machine-powered vibration, the fresh 
odour of herbs became ever more poignant. The sieved final mixture (Fertigmischung) was 
then transferred and sealed into six shiny metal drums and weighed one more time. Mevlan 
finished the admin. I watched Liman washing his face at the sink, coughing and spitting, his 
clothing full of dust. Even with all the precautions and protections, it was impossible not to 
get the fine herbal dust everywhere. Walking back to the train station, I still had the smell 




The next day, I observed the encapsulation process (Notebook V, Diary 12 December 2013). 
It was 7:20 AM, Pema was the first staff member to arrive. The offices were still closed. Five 
minutes later Mevlan arrived and suited up. He invited me to come and join him in 
production. We were both wearing ear protectors to muffle the loud buzz that filled the 
room as he started up the encapsulation machine, to enclose the finished mixture of 
 ‘Preparation 017 ? into gelatine caps. Mevlan needed to check everything before the 
production line is cleared (Linienfreigabe). He calibrated the balances, and completed the 
room, machine and balance logbooks. The machinery is comprised of three main units: a 
filling and closing part, a weighing unit, and the metal detector. The central unit of the 
machine itself consists of two partially overlapping, revolving cylinders: the lower one 
receives the product in the body of the capsule, and the upper puts on the cap. Mevlan first 
conducted a test of the built-in metal detector by inserting tiny test particles in the machine 
to verify if these are detected and sorted out. He introduced me to the machine software. 
Every single capsule is weighed separately at a speed of three milliseconds per cap, with a 
precision of one milligram, and for each hundred pills this is visualised as a data point on 
one of the graphs indicating machine performance, accessible via a large touchscreen. 
Capsule-filling started a little below the ideal weight, so the filling pressure was 
automatically increased slightly. Supply of the powder is automated, but a worker still has 
to change the bags in which the filled capsules are collected every now and then. This 
process can also be mechanised, but PADMA did not opt for it. There is not enough space 
in the current room, Mevlan noted. He also had to perform two sets of in-process controls 
(IPCs) per day: to read off the weight of a certain number of capsules from another balance, 
and to verify that the capsules are the correct size, using a special tool in which the capsule 
should fit perfectůǇ ?ƚŽƐĞĞŝĨƚŚĞǇĐůŽƐĞǁĞůů ?  ‘But you can already see this there [on the 







Figure 3.2. Mevlan is starting up the encapsulation machŝŶĞƚŽƉƌŽĐĞƐƐƚŽĚĂǇ ?ƐďĂƚĐŚŽĨWƌĞƉĂƌĂƚŝŽŶ ? ? ? ?ǁŚŝĐŚŝƐƚŚĞ
PADMA 28 formula for the Swiss market, also marketed as PADMED Circosan.  
 
Mevlan had only just left the room for a few seconds, when the machine stopped and 
several error messages flashed up on the touchscreen in red. Mevlan returned  W he had 
most likely heard the absence of the machine buzzing  W and checked the screen. He sighed, 
 ?Die Maschine ist high tech, die beste heute, aber ohne den Menschen funktioniert es nicht ‘: 
although this machine is top-notch equipment, it cannot operate without human 
intervention and support. I noticed how before handling the inside of the machine, he 
sprayed his gloves with disinfectant, swiftly, almost without looking at his hands. He 
removed two capsules that got stuck and were crushed together. This part of the machine 
alone had cost 40,000 Swiss francs (40,887 USD), he cautioned. He applied pressurised air 
to blow away the spilled capsule contents, and used a wrench to readjust the different 
machine parts to each other again. Mevlan told me he has been working here for seventeen 
years now and that he knows all the machines. He can take them apart completely and put 
them back together, if necessary. He saves PADMA a lot of money by preventing and solving 
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these problems efficiently: losing two hundred capsules  W let alone precious production 
time  W equals a loss of about thirty Swiss Francs (30.67 USD, the wholesaler price). The work 
plan stated two million capsules have to be filled in two days, but this is only possible if the 
machine ǁŽƌŬƐ ĐŽŶƚŝŶƵŽƵƐůǇ P  ‘Du kannst nicht mit zwei Löffel essen ? ? ǇŽƵ ĐĂŶ ?ƚ ĚŽ ƚǁŽ
things at the same time.  
 
Rolf, in a later conversation with me on machine operation and maintenance (Audio 
ƌĞĐŽƌĚŝŶŐ ? ? ) ?ƌĞŝŶĨŽƌĐĞĚDĞǀůĂŶ ?ƐƐƚĂƚĞŵĞŶƚƐon the novelty, high speed and complexity 
of the encapsulation equipment. He added that the machine is still relatively new to 
PADMA since they only started to work with it in September 2010. It has been running 
continuously for only about 1,300 hours in the last three years.  
We are not only learning more, but also gaining experience [he used the word Erfahrung]: 
how long the tools last, how the parts in it work together with our formulations, and so on. 
tĞĂůƐŽŚĂǀĞŬŶŽǁůĞĚŐĞĨƌŽŵƚŚĞƉĂƐƚ ? ? Q ?/ƚŚŝŶŬƚŚŝƐƋƵŝƚĞďŝŐĐŽŵƉůĞǆŝƚǇŵĂŬĞƐŝƚĂůƐŽ Q
As you know from using computers: sometimes they work (laughing)! We have to learn, and 
gain experience. 
He explained that they used to produce all formulas in tablet form, and that the steel 
stamps that pressed the powder together only had a life expectancy of 3-5 million tablets 
due to the abrasive properties of the herbal mixture. A similar process might be happening 
inside the capsule machinery, as was also hypothesised by a Bosch engineer who came to 




I headed over to the blistering and packaging unit. A sheet on the door indicated what was 
ďĞŝŶŐƉƌŽĐĞƐƐĞĚ P  ‘PADMA ŝŐĞƐƚŝŶ ? ŚĂƌŐĞ Eƌ ?  ? ? ? ? ? ? ? ? ? ?. A minor fault had just been 
identified, and the blister machine was temporarily stopped. Once more, a skilled 
intervention was vital to redirect the material agency of the worker-machine-pill 
assemblage. Pema Lhaning is a Tibetan who has been working for PADMA for more than 
two decades. He is a machine operative (Maschinenführer), implying he has to be present 
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to oversee the functioning of this machine. Pema used his bare (disinfected) hands and 
some tools to tweak the section of the machine that was supposed to seal the translucent 
gelatine capsules in a plastic well covered by aluminium foil (Figure 3.3 ) ? WĞŵĂ ?Ɛ
intervention did not succeed in entirely eliminating a very infrequent, small deformation in 
the separation of two capsules on the blisters. This meant the packagers had to temporarily 
perform a 100% visual control of each blister. Three other workers were involved with the 
machine in this room: in getting the blisters from the assembly line into packages together 
with the leaflet, and putting these into larger boxes.  
Jan: What was the problem? 
Pema:  dŚĞƚĞŵƉĞƌĂƚƵƌĞ ?tŚĞŶŝƚ ?ƚŚĞďůŝƐƚĞƌŝŶŐŵĂĐŚŝŶĞ ?ƐƚŽƉƐ ?ŝƚŐĞƚƐƚŽŽŚŽƚ QdŚĞŶǁĞ
ŚĂǀĞĚŝĨĨŝĐƵůƚŝĞƐ Q,ĞƌĞŝƐƚŽŽƐŽĨƚ QdŚŝƐŝƐǁŚĂƚǁĞĐĂůůƚŚĞƐĞĂůŝŶŐƉŽƐŝƚŝŽŶ ? ? ? ?>ŽƵĚ
pumping, cutting and buzzing sounds overrule our conversation, a radio is also 
playing in the background) 
Jan:  How many pills can you process in one hour? 
Pema: It depends. Maybe a hundred blisters in one minute. 
Jan: You cannot make it faster? 
Pema:  I can make it faster, but then I have to heat more, regulate the temperature. If the 
heat is too low the naps will not be closed. All things are connected, you know.51 
Sometimes I have to change it, I have to document exactly what I do. I alone cannot 
do it. The temperature has a minimum and maximum. 
Jan: Can there sometimes be a mistake, one capsule missing? 
Pema: The machine also knows. It [the blister with the flaw] will be dropped. We can check 
it. See. (He teases out one capsule from the input stream, and we watch how the 
blister with an empty space is separated out.) 
Jan: You sometimes use the microscope over there? 
Pema: I have to make in-process control every hour. I have to look at the batch number, 
and formation, that's all. The batch information has to be readable. Then sealing, 
                                                     
51 From the way he said this it was obvious that I was talking to a fellow Buddhist, who was referring to the 




every capsule must be sealed. If two together, no seal, is no good.   
(Audio recording 40) 
 
 
Figure 3.3. Pema manually tweaked the position of the sealing compartment, which applies heat and pressure to cover 
and seal the filled plastic pockets with aluminium foil. In subsequent steps, the batch number and expiry date is 
impressed, the blister packs (containing twenty capsules each) are cut out, and then slide down steadily towards the 
packaging workers. His intervention was called for in this instance because two blister pockets were not being perfectly 
separated from each other in a small minority of blisters.  
 
3.3.4 Packaging 
The 9 AM break. Overall, the atmosphere was friendly but stern. Everyone had been 
working hard and was on a tight schedule; a cup of tea or coffee with a biscuit helped. Some 
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teasing and joking during the break relieved some tension. Several staff laughingly said how 
it seemed that I was writing a novel, noting the most insignificant details  W which I did  W as 
some kind of sƉǇŽƌĚĞƚĞĐƚŝǀĞǁŽƵůĚ ?ƐƵĐŚĂƐ ‘Liman has ĂĚĞŶƚŝƐƚĂƉƉŽŝŶƚŵĞŶƚŽŶ&ƌŝĚĂǇ ?. 
Pema reported that the imperfect sealing issue was still there. A mechanic (Monteur) of 
the blistering machine company will have to come to fix it. Alexandra, the wife of Herbert 
and also part of the company management team, wanted to know why the dosing 
yesterday went slower than expected. Mevlan replied that Phyllantus and T. bellerica were 
rock hard. Alexandra contended that they should have noticed this in advance and asked 
for help. The interface of capitalism and pharmaceutical regulation, where time is (a lot of) 
money and where the show must go on as part of an ever-evolving GMP performance, is 
reflected in a somewhat tense working environment: the content, pragmatism and 
punctuality of meetings (the famous German and in this case Swiss Pünktlichkeit, typified 
by their high-end watchmaking industry), the looming presence of multiple deadlines, and 
in the weekly production ƐĐŚĞĚƵůĞƐǁŚĞƌĞĞĂĐŚĞŵƉůŽǇĞĞ ?ƐǁŽƌŬƚŝŵĞŝƐĂůůŽĐĂƚĞĚƚŽƚŚĞ
minute. On top of the many seemingly futile in-process controls and the high 
admninistrative burdain, the sequential nature of the assembly line entails that one 
significant mistake in bringing all the required materials and paperwork together can shut 
down the entire machinery. 
 
ĞƐŝĚĞƐ ƚŚŝƐ  ‘ŶŽƌŵĂů ? ƐŝƚƵĂƚŝŽŶ ? ƉƌŽĚƵĐƚŝŽŶ ǁĂƐparticularly stressful at this time  W as 
Herbert had told me earlier on  W  due to changes in staff composition, quality assurance, 
and the impending purchase of a new packaging line. This new machinery  W an investment 
of roughly 1.5 million Swiss francs (about the same number in USD)  W was set to replace 
the current blistering machine. The latter had been in use for more than twenty-three years 
and was failing because of old age and the increasing unavailability of spare parts and 
engineers with the necessary machine-specific expertise. From dosing to packaging, the 
blistering phase followed by manual packaging of the blisters into boxes was the weakest 
link, blocking faster output through the entire sequence. The new machine will have a cycle 
of 180 blisters per minute, drastically cutting down on processing time but also on the 
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amount of workers needed.52 These decisions do not correlate directly to the herbal and 
mineral ingredients of PADMA formulas, but they do show how the interplay between 
components of the ingredient-machine-operator assemblage is forced to change as a 
consequence of a peculiar combination of technical and economic considerations, 
repositioning the need for skilled labour from fine human sensorimotor movements to a 
more peripheral but no less skilled position, to automaton operation and maintenance. 
When I probed Herbert to comment on this, he replied as follows (Audio recording 50, 30 
January 2014): 
There are only fifty weeks available in the year. The bottleneck [i.e. the most time-intensive 
part] is [also, in this case] the most labour-intensive part. The problem is not the number of 
workers but the time they take. That's in brief the calculation we had. It is not so much about 
[increasing] demand, but the nervous situation, the tension you feel in production. There is 
no free time. Because when we lose a day, even in current production, they are thinking 
when do we fit in the next day, because we are always short on time, because it takes so long. 
It is not so much an issue of saving time or money. To expand the capacity at the moment, 
we actually need to reduce the work load. The work balance has to be better. Of course in 
the end, why not put here [at packaging] ten instead of two or three people. Because when 
ƚŚĞƌĞ ĂƌĞ ƚĞŶ ƉĞŽƉůĞ ? ǇŽƵ ŶĞĞĚ ĂŶ ĞůĞǀĞŶƚŚ ŽŶĞ ƚŽ ŵŽŶŝƚŽƌ ƚŚĞŵ ? ĞĐĂƵƐĞ ŝƚ ?Ɛ
pharmaceutical grade production, you have to train them and maintain ƚŚĞǁŚŽůĞĐǇĐůĞ ? ? Q ?
ĂĂĂƌŐŚ ?/ƚ ?ƐƚŚĞƐŽĐŝŽůŽŐǇŽĨƚŚĞǁŽƌŬŝŶŐĐůĂƐƐŬŝĐŬŝŶŐŝŶ ? 
This chapter is purposely not a political-economic Marxist sociology of work and industry 
(Watson 2008) that scrutinizes the unequal relations and contradictions between capitalist 
ƐƵƌƉůƵƐǀĂůƵĞĞǆƚƌĂĐƚŽƌƐĂŶĚĂůŝĞŶĂƚĞĚ ?ĞǆƉůŽŝƚĞĚƉƌŽůĞƚĂƌŝĂŶǁŽƌŬĞƌƐ ?ƌĂǀĞƌŵĂŶ ?Ɛ(1974) 
ĞĂƌůǇĨŽƌŵĂƚŝǀĞƐƚƵĚǇŽĨ ‘ƚŚĞůĂďŽƵƌƉƌŽĐĞƐƐ ?ŚŽǁĞǀƌĂŶĚŚŝƐƚŚĞƐŝƐƚŚĂƚƚŚĞŵĞĐŚĂŶŝƐĂƚŝŽŶ
of jobs instigated by human relations experts and managers leads to the deskilling and 
degradation of employees deserves to be mentioned here. Instead of simplistically 
portraying managers (such as Herbert and Rolf in this chapter) as an omniscient united 
block and problematically romanticising the skill of craft workers, I observed an at least 
partial alignment of employer-worker interests in a workplace based on continual skill 
                                                     
52 When the new blistering machine was first put into operation, Herbert told me that Mevlan and Pema had 
difficulties working through the thick German technical manual (Field Notes XI). This is indeed not how they 
would usually learn, solve problems and engage with the machines in practice.  
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upgrading and tweaking through in-house training and inspection to keep up with the GMP 
rat race of evermore stringent pharmaceutical regulation. Even if in PADMA the distinction 
between the stereotypical blue- and white-collar worker is blurred, and even if this still 
ultimately serves capitalist interests, managers and employers are equally caught up in it. 
Notwithstanding the many forms of control in pharmaceutical production (formalised 
under quality control, assurance and risk management, see Chapter 4), I show that workers 
ĞŶũŽǇĐŽŶƐŝĚĞƌĂďůĞ  ‘ƌĞƐƉŽŶƐŝďůĞĂƵƚŽŶŽŵǇ ?  ?ĐĨ ?Friedman 1977 )ǁŝƚŚŝŶWD ?ƐƐŚĂůůŽǁ
hierarchy and the paradoxes of instrumentalist-rationalist bureaucracy. 
 
Figure 3.4. Manual packaging of Arteria-vita, a product of the PADMA 28 family (with identical ingredients to both 
Swiss PADMA 28 and PADMED Circosan) that is marketed specifically to Swiss doctors by the independent company 
Permamed AG. The blisters were taken from the blistering machine (left) and put into the boxes together with the 
package leaflet by hand before the new packaging line was installed in early 2015. 
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After a first intensive week of following production processes, Herbert invited me for a 
drink at a hotel in Zürich. Over dinner, I enthusiastically related my experiences to him 
together with a series of questions arising from it. In response to my amazement 
concerning ƚŚĞ ĨƌĞƋƵĞŶĐǇ ŽĨ  ‘ƵŶĞǆƉĞĐƚĞĚ ƉƌŽďůĞŵƐ ? / ĞŶĐŽƵŶƚĞƌĞĚ Ăƚ ƐĞǀĞƌĂů
manufacturing stages, he replied as follows: 
Always something happens like this, as the demand [of pharmaceutical, GMP-certified 
production on workers and machines] is high. It is also some kind of error correction. The 
worst thing is if some external source points to a mistake. If they report directly to PADMA 
that is also good. But if it comes back by the official route, such a mistake triggers extra 
inspection. This is what we try to avoid. It is part of risk management. I think this is also 
reflected somehow in the informal way in which production is planned, in a self-organising 
manner. It has its schedule, the week plan, but this only solidifies as time progresses. We 
have this rolling planning. We want to [be able to] react on the circumstances. It is not a big 
thing. But there is not so much... How to say. Tibetan medicine as such is easy on the 
production level. The miracle or problem lies not at this level in our country, this 
 ‘ƚƌĂŶƐĨŽƌŵĂƚŝŽŶ ?ŽƌǁŚĂƚĞǀĞƌǇŽƵĂƌĞůŽŽŬŝŶŐĨŽƌ ?dŚĞŵǇƐƚĞƌŝŽƵƐƚŚŝŶŐĨŽƌŽƵƌƉĞŽƉůĞŝƐƚŚĞ
regulatory, it is in the paper. You ?ǀĞ got the problem of the blister machine, it was broken, 
we need to find a guy to fix it. Then the machine on the roof has a problem, the climate 
control. Because of this machine, the computer responsible for it... There is nobody coming 
with a big wrench fixing the problem. It is always connected with who is allowed to do it [a 
certified company engineer], whom can we call, who has the right permit. You cannot climb 
up on the roof and start... This is one of the differences to a situation in India where you are 
still more directly connected with the basics. (Audio recording 47) 
EŽƚǁŝƚŚƐƚĂŶĚŝŶŐ,ĞƌďĞƌƚ ?ƐƌĞƉĞĂƚĞĚƐƚĂƚĞŵĞŶƚƚŚĂƚŝƚ ?ƐĂůůĂďŽƵƚƉĂƉĞƌĂŶĚƌĞŐƵůĂƚŝŽŶƐ ?ĂŶ
assertion which I take seriously in Chapter 6), in the previous sections I showed how the 
circumstantial nature of manufacturing medicines cannot be reduced to a mere reading or 
mechanical execution of standard operating procedures and protocols, 53  a fact which 
PADMA employees are well aware of. This is indeed not just a story about the 
transformation of herbs, but a narrative of becoming together with skilled workers and 
                                                     
53 Experimental laboratory protocols have been described through new sociology of science approaches as a 
literary technology that aims to turn the reader into a virtual witness in order to make reproducibility possible 
(Shapin and Shaffer 1985). Nevertheless, these procedures often fall short of transferring the tacit knowledge 
and skills needed to perform the task at hand (Collins 1974, Polanyi 1966). 
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sensitive machines in a responsive, fluctuating environment of substances, surfaces and 
media. In the next section, I delve into one more example of how a PADMA staff member 
employed uniquely honed skills to overcome plant-machine incompatibility, by sensing and 
attuning the composition of a formula to the encapsulation machine. 
 
3.4 Rezeptentwicklung: sensing material properties and knowing machines 
intimately 
I observed another morning of dosing and mixing with Mevlan and Liman (14 February 2014, 
Notebook VI), but this time the event took place in a smaller place adjacent to the usual 
room because a different mixing installation is used to homogenise small batches. When I 
arrived around 7:30, they were already preparing the room: taking out unnecessary objects 
to create more space, filling in the mixer logbook, checking the balances and sieves, 
bringing the ingredients, and so on. They had to follow and fill in the protocol Herstellung 
Fertigmischung Präparat 179. Everything goes smoothly this time. Even though the 
myrobalan powder had cemented into hard clumps, this was not a problem with this model 
of mixer, which was not covered by a grid. Mevlan was routinely checking the colour and 
smell of each bag of powder with reference samples. He told me he has known myrobalan 
for a long time now. Sometimes the powder is a bit lighter or darker. Depending on the 
harvesting and drying, the fruits can be more greenish or brownish. At one instance, he 
spotted a conspicuous colour difference between the sample and the respective reference 
powder. Upon cross-checking, it turned out Liman had accidentally provided the wrong 
sack. The check worked flawlessly. After the mixing was finished (twelve minutes with 
chopping blades), Mevlan phoned Rolf to come over and check the consistency of the final 
mixture in order to find out if excipients would be needed for encapsulation. This batch 
was an eighty-kilogram test mixture to develop Swiss PADMA LAX (previously in tablets) 
into capsule form. 54 This change required a reformulation with regard to the excipients to 
be added.  
                                                     
54 PADMA LAX was the first formula to be registered historically by the company (in 1972, Swissmedic Nr. 
35872). Its current indications are for temporary constipation, the stimulation of digestive function, and to 
reduce flatulence (cf. English translation of Swiss-German package insert for patients, PADMA website). 
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Rolf arrives, wearing a full set of overclothing. After meticulously washing his hands, he 
dons a pair of white latex gloves, pulling them up over his sleeves. Standing on a small 
ladder to be able to reach inside the filled mixer, he carefully wades through the mixed 
powder using one hand. For about two minutes there is complete silence while he stirs, 
kneads, and watches the yellow-greenish powder aggregate and flow through his fingers. 
 ‘We will try without Hilfstofffe, but will first test a small amount on the [encapsulation] 
ŵĂĐŚŝŶĞ ? ? ŚĞ ĚĞĐŝĚĞĚ ? / ǁĂƐ ďĂĨĨůĞĚ ďǇ ZŽůĨ ?Ɛ ĚŝƐƉůĂǇ ŽĨ Ă ŵĂŶƵĂů ? ƐĞŶƐŽƌŝĂů ƐŬŝůů ŝŶ ƚŚŝƐ
pharmaceutical environment that cannot be learned from books or pharma trainings, 
which he himself developed experientially to be able to gauge and react to incompatibilities 
between the plant and machine worlds through the circumstantial use of excipients. A few 
days later I asked him why this was necessary. 
If you are producing capsules, you need only to bring the mixture in a cylindrical form, to fill 
this cylinder in the capsule body. For that mostly you need less ingredients. Less Hilfstofffe. 
But to produce the capsules, or this cylinder, the mixture needs to have flowability 
[Fließfähigkeit] in a certain range. During the production process, when the cylinder is formed 
in the capsule machine, there are five stations in which layers of mixture will be built on [top 
of] each other. In the first station there is a lower [volume], in second more mixture will fall 
into the holes of the Dosierscheibe, the round dosing plate. [The contents] will [then] be 
ƉƌĞƐƐĞĚĂůŝƚƚůĞďŝƚ ?^ŽǇŽƵĨŝůůĂŶĚďƵŝůĚƚŚŝƐĐǇůŝŶĚĞƌ ? ? Q ?dŽŚŽůĚƚŚĞŵŝǆƚƵƌĞƚŽŐĞƚŚĞƌǁĞĚŽ
ŶŽƚŶĞĞĚŝŶŐƌĞĚŝĞŶƚƐ ?ƚŚĞĐĂƉƐƵůĞƐŚĞůůŚŽůĚƐŝƚ ? ? Q ?EŽǁ ĨŽƌWD>y/ ?ŵĂǇ ?ŶĞĞĚŽƐŽŶ ?
as a lubricant, to bring the formed cylinder out of the holes [of the dosing plate]. It blocks 
without Boson. (Audio recording 68, 20 February 2014) 
dŚŝƐĞǆƉůĂŶĂƚŝŽŶŽĨƚŚĞ ‘ǁŚǇ ? ?ĐŽƵĐŚĞĚŝŶ ‘ŽďũĞĐƚŝǀĞ ?rational scientific language, seems far 
ƌĞŵŽǀĞĚĨƌŽŵƚŚĞ ‘ŚŽǁ ?, the actual skilled practice of sensing the material properties of 
these phyto-mineralogical mixtures. Rolf mentioned that in principle there are several 
formal tests available that one could carry out to determine the need for excipients, for 
instance using a specific cone to measure fluidity. Nonetheless, he asserts that this is not 
the same and is less reliable than feeling for oneself (spüren), touching (anfassen) the 
material and compressing it (zusammendrücken), seeing how it flows or sticks together. 
Even if he cannot feel the exact quantity of excipient needed, he can get an impression and 
based on that attempt a certain combination, which may or may not turn out to work. 
Another option is to adjust the dosing plate of the encapsulation machine to the mixture, 
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but the outcome always remains uncertain until tried out. Once the proper (proportion of) 
excipients has been empirically obtained, the formula has been fully developed. Only then 
can the composition of the ingredients be standardised for future reference. This minor 
ĂĚũƵƐƚŵĞŶƚŽƌĂĚĂƉƚĂƚŝŽŶŽĨƚŚĞ ‘ŽƌŝŐŝŶĂů ?ĨŽƌŵƵůĂƚŽůŽĐĂůĞŶǀŝƌŽŶŵĞŶƚĂů W and in this case 
technical  W circumstances further increases the variability of Tibetan medical recipes, while 
moving away from the often untenable and static, classical ideals of menjor in Sowa Rigpa, 
as argued by Blaikie (2014, 2015). The addition of excipients described here equally 
ƌĞƋƵŝƌĞƐ ‘carefully considered recalibrations [that] are the result of comparison between 
the prevalent environmental and elemental conditions and the projected conditions under 
which the formulae were first invented and ƉŽƉƵůĂƌŝǌĞĚ ? (Blaikie 2014, p. 282). Similarly, it 
also requires sound knowledge of the various ingredients as well as the confidence to act, 
while attesting to the now well-known flexibility and multiplicity of Tibetan pharmacy 
(Adams et al. 2011a, Blaikie 2014; Craig 2012, Saxer 2013). As such, these findings 
ƐƵďƐƚĂŶƚŝĂůůǇ ƐŽĨƚĞŶ ƚŚĞ ĐĂƚĞŐŽƌŝĐĂů ĚŝƐƚŝŶĐƚŝŽŶ ďĞƚǁĞĞŶ  ‘ĐůĂƐƐŝĐĂů ? ĂŶĚ  ‘ŝŶĚƵƐƚƌŝĂů ?
reformulation, as maintained by Pordié and Hardon (2015) in their introduction to a recent 
journal special issue on the social and material lives of Asian industrial medicines.  
 
3.5 Machinofacture brought to life, or Vajrayana and the art of pharmaceutical 
machine maintenance 
Each machine has its own, unique personality which probably could be defined as the 
intuitive sum total of everything you know and feel about it. This personality constantly 
changes, usually for the worse, but sometimes surprisingly for the better, and it is this 
personality that is the real object of motorcycle maintenance. The new ones start out as 
good-looking strangers and, depending on how they are treated, degenerate rapidly into 
bad-acting grouches or even cripples, or else turn into healthy, good-natured, long-lasting 
friends.  ?ZŽďĞƌƚD ?WŝƌƐŝŐ ?ƐZen and the Art of Motorcycle Maintenance, p. 50) 
 
The material nature of medicines should not be taken for granted. Materia medica are 
things-in-motion of which the properties are not only used therapeutically but also play a 
constitutive role in the process of making them. This is pre-eminently true for so-called 
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 ‘ŶĂƚƵƌĂů ?ŵƵůƚŝ-compound Tibetan medicines that are a fusion of many lines of becoming 
with machines operated by uniquely enskilled workers, who I argue could equally be called 
 ‘ƉŚĂƌŵĂĐĞƵƚŝĐĂůĂƌƚŝƐĂŶƐ ? ?ǀĞŶĂƚ ƚŚĞ ŝŶĚƵƐƚƌŝĂůŵĂƐƐ-production site of PADMA, where 
plant-machine-operative interactions are entangled in a strictly controlled yet complex 
material meshwork, there is considerable space for contingency, creativity, and skilled 
interventions beyond what is mechanistically described in GMP procedures and protocols. 
Machines perform a central role here, transforming ingredients into a medical product 
whilst facilitating the communication betweĞŶ ƉůĂŶƚƐ ĂŶĚ ƉĞŽƉůĞ ? Ǉ ĂƉƉůǇŝŶŐ /ŶŐŽůĚ ?Ɛ
notion of craftsmanship and his ecology of materials, it becomes possible to envision 
production at the nexus of the social, natural, and technical domains whilst avoiding the 
pitfalls of disconnected and overly theoretical ruminations on materiality and agency. As 
such, I concur with Ingold (2000) that the modern dichotomy between art and technology 
is only a superficial one when looked at from the perspective of artisans. However, Ingold 
singled out industrial production with automatons, machinofacture, as an exception where 
far-reaching mechanisation underscored by rigid scientific logic dehumanises and thus 
deskills the entire process except for the engineering part. I have shown that this does not 
apply at PADMA, where the distinction between machine operators and mechanics is also 
blurred, and suspect that this argument can be extended to other factories. Making things 
with humans  W these machines can still not operate fully independently  W is thus equally 
not just the automated execution of a pre-conceived form. The shape of the final product 
may be prefigured, but this does not imply that the entire process is similarly set in stone. 
ŽŵŝŶŐďĂĐŬƚŽWŽƌĚŝĠĂŶĚ'ĂƵĚŝůůŝğƌĞ ? ? ? ? ?Ă ) ?WD ?ƐĐŽŶƚĞŵƉŽƌĂƌǇƉƌŽĚƵĐƚƐmay be 
reinvented (re)formulations relying on mixed medical (and pharmacological!) paradigms. 
Yet this does not imply that the material, ƐŬŝůĨƵůŝŶƚĞƌĂĐƚŝŽŶƐŽĨŵĂŬŝŶŐ ‘ƚƌĂĚŝƚŝŽŶĂů ? formula 
ŵĞĚŝĐŝŶĞƐ ĂƌĞ ĐŽŵƉůĞƚĞůǇ ĂďƐĞŶƚ ? KŶ ĐůŽƐĞƌ ŝŶƐƉĞĐƚŝŽŶ WD ?Ɛ ƌĞůĂtively small-scale 
production retains workshop qualities. 
 
Likewise, machines are things that are in a continuous state of flux. As anything else, these 
machines are alive. They have histories and as such they co-produce products in a co-
responsive manner, requiring feedback from their material environment. The plants as well, 
previously perceptive organisms, are clearly not inert objects during the various phases of 
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turning them into medicine. As ingredients they remain alive as part of a dynamic, material 
and interactive lifeworld. On a more abstract level all this may sound strangely familiar to 
a Buddhist, as was hinted at by Pema, the Tibetan machine operator who pointed out the 
composite, interconnected, and impermanent nature of all phenomena through the 
ǁŽƌŬŝŶŐƐ ŽĨ WD ?Ɛ ďůŝƐƚĞƌŝŶŐ ŵĂĐŚŝŶĞ ?This is dependent arising, the notion that 
 ‘ ?ĐŽŶĚŝƚŝŽŶĞĚďǇ ? a certain phenomenon a certain otŚĞƌƉŚĞŶŽŵĞŶŽŶĐŽŵĞƐŝŶƚŽďĞŝŶŐ ? 
(Gethin 1998, p. 153). It is a Buddhist understanding of causality in which the interaction of 
multiple causes  W both fixed and undetermined  W gives rise to several results in a manner 
wholly different from Aristotelian monoconsequentialism or Newtonian mechanics. 
Dependent arising does not only apply to the ignorant mind and the process of (re)birth 
and death; it describes the very fabric of reality (Gethin 1998, p. 155, interpreting the 
Abhidharma textual tradition), and its connectedness.  
[R]eality is at heart something dynamic, something fluid; however one looks at it, reality is a 
process; analyse reality down to its smallest possible components or constituents, and what 
one finds are, not static building blocks, but dynamic processes. 
 
The unlikely conflation of philosophy and human-machine interaction also happens to be 
the subject of ZŽďĞƌƚ D ? WŝƌƐŝŐ ?Ɛ ĐĞůĞďƌĂƚĞĚ ŵŽĚĞƌŶ ĐůĂƐƐŝĐ ƚŝƚůĞĚZen and the Art of 
Motorcycle Maintenance (1999, orignally from 1974) ?,ĞƌďĞƌƚ ?WD ?ƐK ?ĂĚǀŝƐĞĚŵĞ
to read this. For him, machines are also spiritual things that have a certain kind of aura 
along thĞ ůŝŶĞƐ ŽĨ ƚŚĞ ƌŽŵĂŶƚŝĐ ǀŝĞǁ ƉƌĞƐĞŶƚĞĚ ďǇ WŝƌƐŝŐ ? ĨƚĞƌ ǁŝƚŶĞƐƐŝŶŐ WD ?Ɛ
production from close by and having discussed this with him at length, Herbert came up 
with the following statement when I brought up Motorcycle Maintenance again. 
&ŽƌŵĞŝƚ ?ƐĂůƐŽ Q I can also feel very comfortable in steel work, in an industrial site. Or in the 
ƉƌŽĚƵĐƚŝŽŶŽĨWD ? ? Q ?tŚĞŶǇŽƵƚĂůŬƚŽƉĞŽƉůĞ ?ĂďŽƵƚ ?ǁŚĂƚŝƐƉĞĂĐĞĨƵůĂŶĚďĞĂƵƚŝĨƵů ?
they always mention idealistic idyllic nature, when there is no machine, only sheep and 
laughing children. Seventeenth-century painting Arcadian paradise. Of course, it's nice. But 
what is the aesthetics or the Quality even in technical, or dirty or machine-like things. For me 
it was always important to understand a machine, when I studied physics. Somebody who is 
ĂŐŽŽĚǁŽƌŬĞƌƐĂǇƐ ‘/ŬŶŽǁƚŚĞŵĂĐŚŝŶĞ ?/ĐĂŶŚĞĂƌƚŚĞŵĂĐŚŝŶĞ ? ?ĂƐDĞǀůĂŶĂŶĚZŽůĨĚĞĐůĂƌĞĚ ?
and Pema exemplified]. Those who know listen to ŝƚ ?ůŝŬĞǁŚĞŶǇŽƵĚƌŝǀĞĂĐĂƌ ? ‘Something is 
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ǁƌŽŶŐ ?/ŚĂǀĞƚŽůŝƐƚĞŶĂŐĂŝŶ ? ?You can even bond with, connect with the machine. I believe 
ƚŚŽƐĞǁŚŽĐĂŶĚŽƚŚŝƐǁŽƌŬďĞƚƚĞƌǁŝƚŚƚŚĞŵĂĐŚŝŶĞ ?dŚŽƐĞǁŚŽĚŽŶ ?ƚůŝŬĞŝƚ ?ďƌĞĂŬŝƚ ?dŚŽƐĞ
ǁŚŽĚŽŶ ?ƚůŝŬĞƚŚĞŵĂĐŚŝŶĞĚŽŶ ?ƚŵĂŬĞŐŽŽĚƉƌŽĚƵĐƚƐďĞĐĂƵƐĞƚŚĞǇďƌĞĂŬ ?ƚŚĞǇƐƚƌĞƐƐƚŚĞ
machine. Very often those ƉĞŽƉůĞ ƐĂǇ ƚŚĞǇ ĚŽŶ ?ƚ ůŝŬĞŵĂĐŚŝŶĞƐ ďĞĐĂƵƐĞ ƚŚĞǇ ůŝŬĞ ŶĂƚƵƌĂů
things, they like Nature. For them, instead of really liking the world, they only like a part of 
the world. Therefore, I say we have to honour that we can use, are allowed also to use 
machines. zŽƵŚĂǀĞƚŽ ? ? ?zŽƵĚŽŶ ?ƚũƵƐƚŚĂǀĞƚŽĂĚĂƉƚƚŽƚŚĞŵĂĐŚŝne, it also has to adapt to 
us. There has to be a connectedness with the machine, it has to blend in. In my ideal world I 
would like to have this. But I am realist enough that it is not always nice. (Audio recording 48, 
13 January 2014) 
 
,ĞƌďĞƌƚ ?Ɛ ǁŽƌĚƐ ƐƵŵŵĂƌŝƐĞ ƐŽŵĞ ŽĨ ŵǇ ŽǁŶ ĨŝŶĚŝŶŐƐ ďƵƚ ĂůƐŽ ŝŶĚŝĐĂƚĞ ŚŽǁ ƉĞŽƉůĞ ?Ɛ
relationship to technology leads them to make value judgements about what is beautiful 
and thus good. I can see how this might play againƐƚWDĂƐĂ ‘ŐŽŽĚ ?ƉƌŽĚƵĐĞƌŽĨdŝďĞƚĂŶ
medicine when looked at through the eyes of scholars and practitioners who have a subtle 
(or not so subtle) aversion to industry and machines in general.55 They would  ‘ŶĂƚƵƌĂůůǇ ? 
sympathise more with romantic traditional-classicist ideals of manual, small-scale, and 
personal medicine making. However important, these idealised text-based prescriptions 
ƚƵƌŶŽƵƚ ƚŽďĞ ŝŵƉŽƐƐŝďůĞ ƚŽ ĨŽůůŽǁƚŽ ƚŚĞ ůĞƚƚĞƌ ŝŶ ƚŽĚĂǇ ?ƐǁŽƌůĚ  ?ĞƐƉĞĐŝĂůůǇ ŝŶƵƌŽƉĞ ) ?
which does not necessarily imply that contemporary formulations should no longer be 
regarded as authentic (instantiations of) classical recipes (ƐĞĞ ŚĂƉƚĞƌ  ? ) ? WD ?Ɛ
medicines and supplements are clearly the product of an intense and ongoing dialogue 
between Sowa Rigpa and biomedicine, modulated by the capitalist market system and 
European and national legislations. Nonetheless, at the hands-on material level of 




                                                     
55 The history of anti-technological sentiments and the rise of neo->ƵĚĚŝƐŵŝŶƚŽĚĂǇ ?ƐŝŶĚƵƐƚƌŝĂůƐŽĐŝĞƚŝĞƐ ?ƐĞĞ
Jones 2006) is beyond the scope of my argument, but it is necessary to flag it so as not to forget that relations 
with machines are not always positive, and may be ambiguous and even exploitative in a Marxist sense.  
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4  ‘YƵĂůŝƚŝĞƐ ? 
a comparative laboratory ontography 
 
 
In the early 21st century the lab has a special role, as does the factory. For expertise and 
control of labor are ubiquitous, and everywhere intertwined. The lab and the factory are the 
functional inverse of each other, each hiding what the other makes explicit, and their 
combination is a parable for the dynamics of manipulation and control at play throughout 
social life. Control over the means of knowledge production is implicated in control over the 
means of material production (and vice versa).   
(Doing 2004, p. 319) 
  
,ĂǀŝŶŐůŽŽŬĞĚĂƚWD ?ƐĂƐƐĞŵďůy line in the previous chapter through Ingoldian notions 
ŽĨƐŬŝůů ?ŵĂƚĞƌŝĂůƐ ?ĂŶĚƚĞĐŚŶŽůŽŐǇ ?/ŶŽǁƚƵƌŶƚŽǁĂƌĚƐ>ĂƚŽƵƌ ?ƐEdůĞŐĂĐǇƚŽƌĞǀĞĂůƚŚĞ
ĐŽŶƐƚƌƵĐƚŝŽŶŽĨ  ‘ƋƵĂůŝƚǇ ?ŝŶƚŚĞƐĐŝĞŶƚŝĨŝc quality control laboratories of both PADMA and 
Men-Tsee-Khang. These places are characterized by lab coats and benches, glasswork, 
 ‘tĞƐƚĞƌŶ ?technoscientific apparatus, and physico-chemical analytical procedures. Even 
though manual skill and tacit knowledge may be as important in working with these 
materials (see for instance Doing 2004 ) ?/ŚŽůĚƚŚĂƚ/ŶŐŽůĚ ?ƐƉĞƌƐƉĞĐƚŝǀĞŽŶƉƌŽĚƵĐƚŝŽŶĂƐ
making does not take us very far in providing insight into what lies at the heart of the 
laboratory: the execution and interpretation of experiments in a specific locale. The 
subfield of Laboratory Studies, lying at the foundation of STS, was born exactly out of this 
particular focus. It seeks to unravel the day-to-day practice of scientific knowledge 
production in situ, as a craft. In a review of this field, sociologist Karin Knorr Cetina (1995, 
see also Doing 2008) ĨŽƌĞŐƌŽƵŶĚƐ ‘ĐŽŶƐƚƌƵĐƚŝŽŶŝƐŵ ? W as opposed to the discovery of facts 
 W as the major tenet of this field, resulting in an increased popularity of ethnographic 
fieldwork in STS.56 She foregrounds some of the central aspects which underlie the notion 
                                                     
56 Fischer (2007) similarly listƐ ‘ĞƉŝƐƚĞŵŝĐŽďũĞĐƚƐ ?ĂƐŽŶĞŽĨ the four major contributions of ANT and other 




ŽĨ ƚŚĞ ůĂďŽƌĂƚŽƌǇ P ƚŚĞ ůĂď ĂĐƚƐ ĂƐ ĂŶ  ‘ŝĚĞĂů ? ĂŶĚ ĐŽŶƚĂŝ ĞĚ ĞŶǀŝƌŽŶŵĞŶƚ ƚŚĂƚ ĞůŝŵŝŶĂƚĞƐ
complexity by localising and restricting natural processes to manageable proportions. This 
domestication in turn relies on the ability to transform various objects and forces into their 
 ‘ƉƵƌŝĨŝĞĚ ? ǀĞƌƐŝŽŶƐ ? ^ĐŝĞŶƚŝĨŝĐ ĚŝƐĐŽǀĞƌǇ ĂŶĚ ƚŚe construction of facts is always localised, 
unveiling the power of locales and the importance of circumstance as opposed to the 
standardised and universalist claims of science. As Knorr Cetina (1995, p. 157) puts it, 
 ‘laboratory studies investigate how the successful working of a standard procedure is built 
out of painful processes of adaptation and learning ƚŚĂƚ  ‘Įƚ ?ƚĞĐŚŶŝƋƵĞƐƚŽƐĞƚƚŝŶŐƐ ?ĂŶd 
ƐĐŝĞŶƚŝƐƚƐƚŽƚŚĞŝƌŵĞƚŚŽĚƐ ? ? 
 
The post-humanist57  disposition of STS and its insistence on taking non-human actors 
seriously  W ƉĂƌƚŝĐƵůĂƌůǇ ŝŶ >ĂƚŽƵƌ ?Ɛ ĞĂƌůŝĞƌ ǁŽƌŬƐ(1982, 1987, 1988 [1984]; Latour and 
Woolgar 1986)  W has been instrumental in  ‘the shift from a representational to a 
performative idiom for analysing science and technology, and the closely related switch 
from an interest in epistemology to a concern with understanding how ontologies are 
shaped in action ? (Jensen 2004, p. 232). 
Stressing the intertwinement of human and nonhuman actors in science challenges 
traditional epistemology because activities such as observing or representing are not seen as 
distinct from intervening or constructing; rather, they arĞ ǀŝĞǁĞĚ ĂƐ ƐƉĞĐŝĮĐ ways of 
intervening and constructing. In this view, epistemology collapses into ontology and the 
sciences are reformulated as practical activities aimed at (re)building the world by adding 
new elements with new capabilities and new relationships to it. Knowing (and thinking about 
knowing) are turned into particular styles and methods for connecting and cooperating with 
ƐƉĞĐŝĮĐĂĐƚŽƌƐ ?ŚƵŵĂŶĂŶĚŽƚŚĞƌǁŝƐĞ ) W thus shaping reality, or doing ƉƌĂĐƚŝĐĂůŽŶƚŽůŽŐǇ ? ? Q ?
[I]ts focus is on the eventful ƌĞĐŽŶĮŐƵƌĂƚŝŽŶ of reality, taking place in laboratories and 
elsewhere, rather than on the replacement of naturalist explanations of science with social 
or cultural ones. (Jensen 2004, p. 248, emphasis in original) 
                                                     
ŽďũĞĐƚƐ ĂŶĚ ĐƵůƚƵƌĂů ĨŽƌŵƐ ĂƐ ƚŚŝŶŐƐ ƚŽ ďĞ ĚŝƐĐŽǀĞƌĞĚ ? ƚŽ ƌĞĐŽŐŶŝǌŝŶŐ ƚŚĂƚ ƚŚĞ ƉƌŽĐĞƐƐ ŽĨ  ‘ĚŝƐĐŽǀĞƌǇ ? ŝƐ
increasingůǇŽŶĞŽĨĂĐƚŝǀĞƉƌŽĚƵĐƚŝŽŶ ?ŽĨƌĞĐŽŶĮŐƵƌŝŶŐ ŽƵƌǁŽƌůĚƐŝŶƚŽŶĞǁĨŽƌŵĂƚŝŽŶƐ ? (p. 556-557, emphasis 
in original). 
57 ,ĞƌĞ ?/ƌĞĨĞƌƉƌŝŵĂƌŝůǇƚŽƚŚĞĚŝƐŵĂŶƚůŝŶŐĂŶĚĚŝƐĞŵďŽĚŝŵĞŶƚŽĨƚŚĞůŝďĞƌĂů ‘ƐƵďũĞĐƚ ?ŝŶŽƵƌĂŐĞŽĨĐǇďŽƌŐŝĂŶ




This assertion brings us directly to the ontological turn and its significance for STS (Woolgar 
and Lezaun 2013). This turn aims to circumvent epistemology and its representational 
ůĂŶŐƵĂŐĞ ? ŝŶĐůƵĚŝŶŐ ŶŽƚŝŽŶƐ ƐƵĐŚ ĂƐ  ‘ǁŽƌůĚǀŝĞǁƐ ? ?  ‘ƉĞƌƐƉĞĐƚŝǀĞƐ ? ?  ‘ŬŶŽǁůĞĚŐĞ ? ĂŶĚ
 ‘ŵĞĂŶŝŶŐ ? ?ƚŽĐŽŶƐŝĚĞƌƚŚĞǀĞƌy existence of entities, multiple worlds and world-making. 
However, STS studies have long since deflated universalist (and especially scientific) 
conceptions along these lines, pointing to their materialisation and situated use through 
the lenses of social construction, performativity, co-production and enactment. What does 
a turn towards ontology add to this, besides a synthesis or intensification of the sensibilities 
of previous turns within STS? Woolgar and Lezaun (2013) agree with Michael Lynch (2013) 
in that coming up with an overarching philosophical theory of objects would be detrimental. 
On the contrary, Lynch contends that: 
^d^ƌĞƐĞĂƌĐŚƚĞŶĚƐƚŽƉůƵƌĂůŝǌĞ ? ‘ŵƵŶĚĂŶŝǌĞ ? ?ĂŶĚŵĞƌŐĞƉŝƐƚĞŵŽůŽŐǇ ?ŽŶƚŽůŽŐǇ ?ĞƚŚŝĐƐ ?ĂŶĚ
aesthetics. By this, I mean that the central concepts become historicized and situated. 
Instead of construing them as a part of larger, abstract fields, empirical research posits them 
as discontinuous local epistemologies, petty ontologies, and so forth. Inventorying the 
furniture of the world and outlining how we may come to know about it are no longer the 
privileges of philosophical reflection, as epistemology and ontology become embedded in 
diverse practices in many fields within and beyond the sciences. (Lynch 2013, p. 451) 
To avoid the confusion with metaphysics, Lynch suggests ƚŚĞƚĞƌŵ  ‘ŽŶƚŽŐƌĂƉŚǇ ? ĨŽƌ ƚŚŝƐ
deflation to the mundane by means of historical or ethnographic analysis. To make my 
ĂƌŐƵŵĞŶƚŝŶƚŚŝƐĐŚĂƉƚĞƌ/ǁŝůůŶŽƚƋƵĞƐƚŝŽŶƚŚĞŐĞŶĞƌĂůŶĂƚƵƌĞŽĨ ‘ƌĞĂůŝƚǇ ? ?ŽƌƚŚĞƌĞĂůŝƚǇŽĨ
 ‘ŶĂƚƵƌĞ ? ) ?ŶŽƌǁŝůů/ĨŽĐƵƐŽŶĚĞƚĂŝůĞĚĚĞƐĐƌŝƉƚŝŽŶƐŽĨůĂďŽƌĂƚŽƌǇƉƌĂĐƚŝĐĞƐƚŽƉƌŽǀĞƚŚĞƐŽĐŝĂů
construction of scientific knowledge.  
 
More recently still, sociocultural anthropologists from both Europe and the US have 
thoroughly scrutinised the theoretical, methodological and political implications of the 
ontological turn. Vigh and Sausdal (2014) for instance observe a conceptual slippage from 
ontologising nonhumans, things and concepts  W which they consider less problematic  W to 
(groups of) people. Arguing for different worlds or multiple natures comes with a disavowal 
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of shared humanity, leading to an emphasis on incommensurability, radical essentialism 
and alterity. This fetishisation of Otherness in turn denies the possibility of the translation, 
interpretation and communication of ontologies and therefore minimises reflexivity, doubt 
and ambivalence. In an increasingly connected political world ontological analytical 
approaches thus run the risk of fuelling difference along racist, colonialist and xenophobic 
culturalist lines (vis-à-vis an overarching Euro-American cosmology), showing the same 
flaws as reified culture concepts. Bessire and Bond (2014) similarly attack the post-
humanist and post-social dissolution of the nature/culture division in the face of a 
universalising ecological planetary crisis as ironically founded on a radical modern-
ŶŽŶŵŽĚĞƌŶǁŽƌůĚďŝŶĂƌǇ ?ĚĞŵŽŶŝƐŝŶŐĂŶĚďůĂŵŝŶŐĂǀĂŐƵĞĐŽŶĐĞƉƚŝŽŶŽĨ ‘ƚŚĞDŽĚĞƌŶƐ ? ?
cf. Berliner et al. 2013). In its avoidance of epistemological critique, this speculative 
futurism consists of a totalising eschatological monism and a privileged ontological status 
(the anthropologist-diplomat who alone can interpret and shift between ontologies) akin 
to religious fundamentalism that ignores (shared) real-world contradictions and collisions.  
 
EĞǀĞƌƚŚĞůĞƐƐ ? ĞǀĞŶ ƚŚŽƵŐŚ ƚŚĞ ĂŶƚŚƌŽƉŽůŽŐŝĐĂů ƐƚƵĚǇ ŽĨ  ?ƚŚĞ ĂƉƉƌĞŚĞŶƐŝŽŶ ŽĨ )  ‘ƌĞĂůŝƚǇ ? ?
,ĞŝĚĞŐŐĞƌŝĂŶ  ‘ĞŝŶŐ ? Žƌ ĞůĞƵǌŝĂŶ  ‘ďĞĐŽŵŝŶŐ ? ŚĂƐ ďĞĞŶ ĐŽŶĐĞŝǀĞĚ ďǇ ƐŽŵĞ ĂƐ a French 
philosophical anthropology or European turn (Descola and Latour, building on Viveiros de 
Castro (Kelly 2014), Eduardo Kohn (2015) conceives it more broadly and less stereotypically. 
While staying true to the everyday messiness of and reflexive, immersive engagements 
with human lives, ontologically attuned ethnographers view human-world interactions as 
more than language-like, symbolic social (historical, political-economic, etc.) constructs by 
apprehending nature  W in materiality, nonhumans, the body, but also science, medicine and 
technologies  W not only as and through culture. As Kohn points out by referring to Donna 
,ĂƌĂǁĂǇ ?Ɛ ŽĞƵǀƌĞ ? ĂŶƚŚƌŽƉŽůŽŐŝƐƚƐ ĐĂŶ ĐŽŵďŝŶĞ ƚŚŝƐ ĐŽŵŵŝƚŵĞŶƚ ǁŝƚŚ ŚŝƐƚŽƌŝĐĂů ĂŶĚ
ƉŽůŝƚŝĐĂůĂĐƵŝƚǇ ?dŚŝƐŝƐĂĨĂƌĐƌǇĨƌŽŵĞƐƐŝƌĞĂŶĚŽŶĚ ?Ɛ ? ? ? ? ? ) ‘ŽŶƚŽůŽŐŝĐĂůĨƵŶĚĂŵĞŶƚĂůŝƐŵ ?
and politically problematic theoretical presumptions of radical difference. I agree with 
Kohn, and follow >ǇŶĐŚ ? ? ? ? ? )ŝŶŝŶǀĞƐƚŝŐĂƚŝŶŐ ‘how questions of identity and difference [of 
 ‘ŽďũĞĐƚ ?Ɛ ) ? ?ĐŽŶĐĞƉƚƐ ?ĂƌĞǁŽƌŬĞĚŽƵƚŝŶƐƉĞĐŝĨŝĐĐĂƐĞƐ ? ?Ɖ ? ? ? ? ) ? ‘in and through ĚŝƐƉƵƚĞƐ ? (p. 
450) on (objective) scientific knowledge and expertise. I thus recognise the possibility for 
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hybrid, (partially) shared practical ontologies in particular instances of world-making and -
sustaining. 
 
/ǁŽƵůĚůŝŬĞƚŽƌĞƐƉŽŶĚƚŽ>ǇŶĐŚ ?ƐĐĂůůĨŽƌŽŶƚŽŐƌĂƉŚy by comparing how quality is enacted 
in and around the laboratories of PADMA and Men-Tsee-Khang by looking out for instances 
where scientific-industrial-pharmaceutical and Sowa Rigpa ontologies of quality are forced 
to interact with one another practically, through historical knowledge exchange and in the 
creative material encounters of quality control tests. In these factories ingredients are 
compounded into medicines, but before this the ingredients-to-be have to be analysed to 
ensure they have all the necessary characteristics to be considered medicinal in the first 
place. The juxtaposition of European pharmaceutical and Tibetan medical ontologies of 
quality is complicated by the fact that each is based on concepts and categorisations that 
are not easily reconciled on a metaphysical level at first sight. How could a (stereotypical) 
traditionally trained amchi grapple with pharmacological (i.e. chemical) concepts of purity, 
contamination, and pesticide residues in ppm (parts per million) without atomic theory and 
molecules? The same goes for microscopic identification and the cell, and this line of 
thought can be replicated for other building blocks of the biomedical model. Conversely, 
can our modern Western minds and bodies truly fathom the universality of the five 
elements (jungwa nga) as the fundamental nature of body, disease and medicine, and how 
these elements determine the taste of substances, which in turn determines their potency 
(nüpa ) ? ŽƚŚ WD ?Ɛ ĂŶĚ DĞŶ-Tsee-<ŚĂŶŐ ?Ɛ ƋƵĂůŝƚǇ ĐŽŶƚƌŽů ƉƌŽĐĞƐƐĞƐ Ɛƚraddle these 
ƐĞĞŵŝŶŐůǇŝŶĐŽŵŵĞŶƐƵƌĂďůĞǁŽƌůĚƐ ?ĐƌĞĂƚŝŶŐŚǇďƌŝĚ ?ŵƵůƚŝƉůĞ ‘ƋƵĂůŝƚŝĞƐ ?ŽĨdŝďĞƚĂŶŵĞĚŝĐĂů
substances in practice. Paradoxically but not unexpectedly, their quality often has to be 
expressed as quantity in the lab aided by lab technologies. The term quality has taken on 
multiple specialist, technical connotations in pharmaceutical regulations and industry 
especially as part of compounds such as quality control, quality assurance, and quality risk 
management. But what does the adjective  ‘dŝďĞƚĂŶ ?ĂĚĚƚŽƚŚŝƐŵŝǆŝŶƚŚĞĐŽŶƚĞŵƉŽƌĂƌǇ
ŝŶĚƵƐƚƌŝĂůƉƌŽĚƵĐƚŝŽŶŽĨ ‘dŝďĞƚĂŶŵĞĚŝĐŝŶĞƐ ? ?ŽƌĚŝĨĨĞƌĞŶƚůǇƉƵƚ ?ǁŚĂƚŝƐƐƉĞĐŝĂůĂďŽƵƚƚŚĞ
quality control of Tibetan medical substances? I seek to illustrate the dynamic and hybrid 
nature of the ontologies that underůǇ ŚŽǁ  ‘ƋƵĂůŝƚǇ ? ŝƐ ƚĞĐŚŶŝĐĂůůǇ ĐŽŶƚƌƵĐƚĞĚ ĂŶĚ ŵĂĚĞ
ŵĞĂƐƵƌĂďůĞ ? ĂƌŐƵŝŶŐ ƚŚĂƚ ƚŚĞƐĞĞŶŐĞŶĚĞƌĚŝĨĨĞƌŝŶŐďƵƚ ŝŶƚĞƌĐŽŶŶĞĐƚĞĚ  ‘ƋƵĂůŝƚŝĞƐ ? Ăƚ ƚǁŽ
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similarly equipped laboratories in very different social, economic and political worlds. I thus 
aim to move beyond traditional/modern comparisons, showing how Sowa Rigpa and 
modern pharmaceutical science intermingle, appropriate aspects of one another, blurring 
their boundaries. Theoretically this chapter builds on the ontological turn within STS and 
anthropology, incorporating recent critiques to arrive at a more ethnographically and 
historically informed analysis by taking a practical, empirical, ontographic approach 
(following Jensen 2004, Law and Lien 2013, and especially Lynch 2013). This comparative 
laboratory ontography thus argues for multiple but hybrid  W as opposed to fundamentally 
incommensurable  W realities of quality. 
 
In what follows, I first place the laboratory within its broader postcolonial context of the 
interface between modern Western technoscience and Asian scholarly medicines. This sets 
the scene for sections 4.2 to 4.5, which are ethnographic in nature and aim: to introduce 
the labs of PADMA and Men-Tsee-Khang through an outline comparison of infrastructure 
and instrumentation, to discuss historical interactions between these labs, and to provide 
insight into their practices of quality assessment, which I construe as practical ontologies 
ĂŶĚĞŶĂĐƚŵĞŶƚƐŽĨ ‘ƋƵĂůŝƚŝĞƐ ? ?
 
4.1 The technoscience/Asian medicine intersection 
If truth claims are produced through and situated in local practices, how then do science 
and technology travel? How are knowledge and practices mobilised, distributed and 
extended to new places? Within medical anthropology, the interaction between 
biomedical and other medical beliefs has been a central topic for decades (Good 1994, 
Nichter 1996) ? ‘Yet laboratorǇƐĐŝĞŶĐĞ ?ĚĞĨĞƚŝƐŚŝǌĞĚĂƚŝƚƐ “ŽƌŝŐŝŶƐ ? ?still moves around the 
globe as a fetish, with its social relations conveniently erased. It seems to arrive with 
ĐĂƉŝƚĂůŝƐŵ ? “ůŝŬĞĂƐŚŝƉ ? ? then magically arrives elsewhere, just as powerful, packaged, and 
intact ? (Anderson and Adams 2008, p. 182). Here, postcolonial critique is paramount, to be 
able to envision alternative modernities as well as contemporary globalised rewritings of 
imperialism. Scientific practices are inherently multi-sited (Marcus 1998), shifting the focus 
to heterogeneous transactions and translations between a variety of contact or trading 
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ǌŽŶĞƐ ?ĂŶĚŵĂŬŝŶŐŝƐƐƵĞƐŽĨ ‘ŐĞŽŐƌĂƉŚǇ ?ĂƚůĞĂƐƚĂƐƉĞƌƚŝŶĞŶƚĂƐĞƉŝƐƚĞŵŽůŽŐŝĐĂů ?ŽŶƚŽlogical 
considerations. Over the last few years a small number of what can be labelled as 
postcolonial laboratory studies of Asian medicines has emerged, raising topics particularly 
relevant to my argument. 
 
Jongyoung Kim (2007) has researched how the encounter with pharmacological laboratory 
science translates the clinical practice of Korean medicine into an experimental one  W 
reversing the typical order of biomedical drug discovery  W in an act of legitimation fraught 
with uneven negotiations, tensions and ambivalent feelings. Being a subjugated 
 ‘ĂůƚĞƌŶĂƚŝǀĞ ?ŬŶŽǁůĞĚŐĞƐǇƐƚĞŵ ? ŝƚŶĞǀĞƌƚŚĞůĞƐƐƐƵĐĐĞĞĚƐĂƚ ůĞĂƐƚƉĂƌƚŝĂůůǇ ŝŶ ĐŽŶƚĞƐƚŝŶŐ ?
ƌĞĐŽŶƐƚƌƵĐƚŝŶŐ ĂŶĚ ĞǀĞŶ ĂƉƉƌŽƉƌŝĂƚŝŶŐ ƚŚĞ ůĂď ĂŶĚ ĐŽŶĐƵƌƌĞŶƚ ĚĞĨŝŶŝƚŝŽŶƐ ŽĨ  ‘ƐĐŝĞŶĐĞ ? ?
Korean scientists were thus able to defend and enhance the scientificity of their study 
object by entering the global scientific playing field. This however came at a high price: 
classical aetiological theory and categories were largely discarded, and herbal drugs and 
preparation methods standardised under the aegis of analytical chemistry, to finally publish 
the results in international scientific journals that further enforce these transformations. 
Consequently, controversies abound over the (hybrid) identity and authenticity of Korean 
medicine in tandem with vigorous debate between pro- and anti-scientisation factions. 
 
Ritika Ganguly (2012), in the third chapter of her doctoral dissertation on the instigation of 
self-ƉƌŽĐůĂŝŵĞĚ  ‘ŽƉĞŶ-ŵŝŶĚĞĚ ? ?  ‘ƚƌĂŶƐ-Ěŝ ĐŝƉůŝŶĂƌǇ ? ƐĐŝĞŶĐĞ ďǇ ƚŚĞ ,ŝŶĚƵ ĞůŝƚĞat an 
ǇƵƌǀĞĚŝĐ ůĂďŽƌĂƚŽƌǇŝŶĂŶŐĂůŽƌĞ ?ĚĞŵŽŶƐƚƌĂƚĞƐŚŽǁ ‘ĐůĂƐƐŝĐĂů ?ǇƵƌǀĞĚŝĐĂŶĚ ‘ŵŽĚĞƌŶ ?
pharmaceutical science together are complicit in reinforcing and reifying the power and 
privilege of expert vis-à-vis folk knowledge/practice. To this end, she attended a training 
ƉƌŽŐƌĂŵŽŶŚĞƌďĂůƋƵĂůŝƚǇĐŽŶƚƌŽůĂŝŵĞĚĂƚ ‘ǁĞĂŬĞƌƐĞĐƚŝŽŶƐ ?ŽĨƐŽĐŝĞƚǇŝŶ ? ? ? ? ?ŶƋƵŝƌŝŶŐ
ǁŚĂƚŬŝŶĚŽĨ ‘ƐĐŝĞŶƚŝĨŝĐ ?ŬŶŽǁůĞĚŐĞŽŶ ‘ƋƵĂůŝƚǇ ?ŝƐƉƌŽĚƵĐĞĚŝŶƚŚĞůĂď ?ĂŶĚŚŽǁŝƚŝƐƚŚĞŶ
distributed, she highlights the strategic application of narratives of lack and decline (see 
also Langford 2002). 
  ?Y ?ƵĂůŝƚǇ ?ŝŶĨŽƌŵĂůĚŝƐĐŽƵƌƐĞŝƐŶŽƚůŝŵŝƚĞĚƚŽƚŚĞƚŚŝŶŐŝ ĞƐƐŽĨŵĞĚŝĐŝŶĂůƉůĂŶƚƐĂůŽŶĞ ?/ƚŝƐ
assigned a temporal property, a distinctive characteristic of a time and an era when collecting 
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the right plants from the right habitat at the right time was a quality in itself, possessed by 
ƉůĂŶƚĐŽůůĞĐƚŽƌƐĂŶĚƉŚǇƐŝĐŝĂŶƐďǇǀŝƌƚƵĞŽĨƚŚĞŝƌ ‘ĞǆƉĞƌŝĞŶƚŝĂůǁŝƐĚŽŵ ? ?ŶŽƚŬŶŽǁůĞĚŐĞ ) ?Ƶƚ
 ‘ĞǆƉĞƌŝĞŶĐĞ ?ĂŶĚ ‘ǁŝƐĚŽŵ ?ĂƌĞŶŽƚƋƵĂůŝƚŝĞƐƚŚĂƚĐĂŶďĞĂƌƌĂŶŐĞĚƚŽďĞ disseminated from 
 ‘ƐĐŝĞŶƚŝĨŝĐĞǆƉĞƌƚƐ ?ƚŽ  ‘ĐŽŵŵƵŶŝƚŝĞƐ ? ? ‘<ŶŽǁůĞĚŐĞ ? ŝƐ ?dŚĞƌĞĨŽƌĞ ? ŝƚŵƵƐƚďĞƚŚĞŬŶŽǁůĞĚŐĞ-
about-quality as ĂƋƵĂůŝƚǇƚŚĂƚŵĂǇďĞĂƌƌĂŶŐĞĚƚŽďĞƐŽĐŝĂůůǇĞǆĐŚĂŶŐĞĚĂŶĚƚƌĂŶƐĨĞƌƌĞĚ ? ? Q ?
dŚĞĚŝƐƐĞŵŝŶĂƚŝŽŶŽĨĞǆƉĞƌƚŝƐĞĂďŽƵƚ  ‘ƋƵĂůŝƚǇ ?  ?ŝŶnglish) and of Ayurvedic terminologies 
critical to this training (in Sanskrit) gives rise to a specific kind of science imagination that is 
ƵŶŝǀĞƌƐĂů ?ƋƵĂůŝƚǇ ‘ƐƚĂŶĚĂƌĚƐ ?ĂƌĞƵŶŝǀĞƌƐĂů ) ?ǇĞƚŶĂƚŝŽŶĂů ?ƐŝŐŶĂůůĞĚďǇƚŚĞƌŽůĞƚŚĂƚƚŚĞŚŝƐƚŽƌǇ
and lineage of Sanskrit plays in the history and lineage of India). This dissemination also gives 
rise to a medium of instruction in science pedagogy that may be seen as foreign, alienating, 
oppressive, or opaque ƚŽƚŚĞ ‘ĨŽůŬ ?ƐƚƵĚĞŶƚ ?  
(Ganguly 2012, p. 75-76, p. 94)       
This excerpt raises a fundamental point, which is the areas of contrast, perhaps 
ĐŽŶƚƌĂĚŝĐƚŝŽŶĂŶĚĐŽŶĨůŝĐƚ ?ďĞƚǁĞĞŶĐƵƐƚŽŵĂƌǇĂŶĚŝŶĚƵƐƚƌŝĂůŶŽƚŝŽŶƐŽĨ ‘ƋƵĂůŝƚǇ ? ?/ƚƐŚŽǁƐ
ŚŽǁ ĞǆƉĞƌŝĞŶƚŝĂů ŬŶŽǁůĞĚŐĞ ŝƐ ĚĞǀĂůƵĞĚ ĂŶĚ ƐƵďƐƚŝƚƵƚĞĚ ďǇ  ‘ƵŶŝǀĞƌƐĂů ? ƚĞĐŚŶŽ-scientific 
standards evaluated in laboratories. In a later paper, Ganguly (2014) elaborates how the 
use of modern scientific tools and methodologies are poised to transform the unknowable 
of Ayurvedic pharmacology (i.e. that which escapes the logic of its own theories and 
principles) into the (hitherto) unknown of biomedical knowledge. This translation 
refashions laboratories as places where non-Western sciences are re-searched through 
scientific rationalities, co-ƉƌŽĚƵĐŝŶŐŶĞǁ ŝĚĞŶƚŝƚŝĞƐ  ?ƐƵĐŚĂƐ  ‘ƚŚĞŽƉĞŶ-miŶĚĞĚƐĐŝĞŶƚŝƐƚ ? )
and technological practices. She relates how an experiment in the standardisation of 
human sensory evaluations of medicinal plants in this lab attempted to make Ayurveda less 
subjective and more exact by normalising and calibrating the responses of a test group 
using international food science protocols. Not only was this homogenising exercise fraught 
with difficulty, it also relied on a Euro-American interpretation of the senses as separate 
from a sensing mind. Standardisation, then, does not just apply to materials but equally to 
the use of human senses and body parts as tools. 
 
Also in India, Tibetan medicine has had to come to terms with biomedical quality control 
along the same lines. As of yet, there has been no forced, state-led implementation of GMP 
here, even though Sowa Rigpa has been officially recognised as a medical system by both 
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the Tibetan exile administration and the Indian government (Kloos 2013). Because of its 
refugee status, a new discourse was fashioned that revolves around cultural survival and 
the preservation of traditional knowledge. In this context, modern science has been 
enlisted by exile Tibetan amchi to play the crucial dual role of proving the worth of this 
medical tradition to sceptic outsiders, and as an ornament and political tool to ensure 
international recognition and long-term survival (Kloos 2015). However, focusing on the 
advent of laboratory quality control of raw materials and medicines at Men-Tsee-Khang, 
Kloos argues that this involves more than mere dĞĐŽƌĂƚŝŽŶ ?/ƚŝƐƌĂƚŚĞƌ ‘ĂƐŝůĞŶƚƌĞǀŽůƵƚŝŽŶ ? ?
the beginning of the modern standardisation of Tibetan materia medica. The need for this 
arose when during a clinical study it became clear that the efficacy of Men-Tsee-Khang pills 
fluctuated from batch to batch. This challenge, the preservation of Tibetan medicine 
through the preservation of its efficacy, was eventually taken up by the establishment of a 
new quality assurance lab within the compounds of its pharmaceutical production unit in 
2009. Kloos explains why this became necessary: 
As altruism and compassion [in the form of Buddhist ethics and adherence to textual ideals 
by amchi] are lost in the market place of greed and corruption58, the potency of Tibetan 
medicine suffers. Therefore, it is not that traditional quality control is inadequate today, but 
ƚŚĂƚŝƚŚĂƐďĞĐŽŵĞŝŵƉŽƐƐŝďůĞƚŽƉƌĂĐƚŝĐĞŝŶƚŽĚĂǇ ?ƐŵĂƌŬĞƚĞĐŽŶŽŵǇ ?dŚĞŽŶůǇƐŽůƵƚŝŽŶƚŽ
ĞŶƐƵƌĞ Ă ĐĞƌƚĂŝŶ ůĞǀĞů ŽĨ ƋƵĂůŝƚǇ ? ƚŚĞŶ ? ŝƐ ƚŚĞ ƵƐĞ ŽĨ ŵŽĚĞƌŶ ƐĐŝĞŶƚŝĮĐ ŵĞƚŚŽĚƐ ? ƐƵĐŚ ĂƐ
microscopic and chemical analyses, with which adulterations, moisture levels, and pollution 
can be detected and measured. (Kloos 2015, p. 127) 
This moral decline goes hand in hand with a gradual shift in power from experienced amchi 
to the young university-trained natural scientists working in the quality control lab, 
although their influence is still mostly limited to documentation. Nonetheless, Kloos argues 
that modern scientific concepts of pharmaceutical quality will continue to shape the very 
foundation of Tibetan medicine, its efficacy and ethics. Broad analogies can be discerned 
between the pharmaceuticalisation of different Asian medical systems, especially in the 
ambivalent shifts from clinical to experimental validation regimes under the aegis of 
pharmaceutical science. 
                                                     
58 As Kloos (2015) notes, the vast majority of Men-Tsee-<ŚĂŶŐ ?ƐƌĂǁŵĂƚĞƌŝĂůƐĂƌĞƉƵƌĐŚĂƐĞĚĨƌŽŵǁŚŽůĞƐĂůĞ
markets nowadays, leaving the Institute with little knowledge or control over the sourcing process. The link 




4.2 An outline comparison 
Before delving into the laboratory worlds of PADMA and Men-Tsee-Khang in turn, I will first 
provide a rough sketch of both, by means of a superficial comparison of laboratory 
infrastructure and procedures. This simple, direct approach is, however, dangerous as it 
ignores the substantially different socio-political, economic, and historical backgrounds 
that are pertinent to these companies, and to Switzerland and India, potentially distorting 
their realities along either modernist or orientalist lines. Still, comparative laboratory 
studies can show the disunity of science; how lab organisation, methodology, and labour 
ethics vary between cultures and nations (see for instance Traweek 1992). When 
considering the construction and spread of accepted knowledge outside its seemingly 
singular place of origin  W  ‘ǁŝƚŚ ůĂďŽƌĂƚŽƌŝĞƐ ?  ?<ŶŽƌƌ ĞƚŝŶĂ  ? ? ? ? )  W then terms such as 
negotiation, translation, and the enrolment of actors more easily come to the fore. 
Nevertheless, what comes across to the uninitiated eye is first the sameness of both 
ĐŽŵƉĂŶŝĞƐ ? ůĂďƐ P ƚŚĞǇ ĂƌĞ ďŽƚŚ ŽƐƚĞŶƐŝďůǇ ŵŽĚĞƌŶ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ƋƵĂůŝƚǇ ĐŽŶƚƌŽů
laboratories of roughly the same size, structure, and activities, as evidenced by the 
presence of fume hoods, precision balances, glassware, and so on (Table 4.1). The 
university-educated staff working in both institutions pointed out to me that what they are 
doing are rather basic, routine tests well-known in the fields of microbiology, 
pharmacognosy and analytical chemistry for decades.59  But at times, there was also a 
palpable sense of novelty. Indeed, applying these methods to Tibetan medical ingredients 
(in crude, powder, and compounded form) requires innovation as well, as will be described 
below. Although PADD ?ƐLabor is slightly larger in terms of working space and staff and 
equipped with some more advanced analytical machinery (notably HPLC, High 
Performance Liquid Chromotography), many of its facilities and equipment are actually 
                                                     
59 The analysts know about and may have worked with more expensive, cutting-edge technologies previously 
during another job, internship or dissertation, such as DNA sequencing or mass spectrometry. One of 
WD ?ƐƚǁŽĨƵůů-time analysts for instance, Emad (in his forties, born in North Sudan) reminisced about 
working at a pharmaceutical multinational as part of a large, specialised team while Norlha (in her thirties, 
Tibetan born in India) shared stories about high-tech and fast-paced laboratory life at a South Korean 
University during her dissertation research. See Droney (2014) and Tousignant (2013) for the irony of core-
periphery dynamics and nostalgia for the temporalities of centres of innovation.  
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older (albeit very well-maintained). The work benches at PADMA are arranged in rows (see 
again  
Figure 4.2), whereas at Men-Tsee-Khang they line the walls of the lab and offer more spaces 
ƚŽ Ɛŝƚ ĚŽǁŶ ŽŶ ĐŚĂŝƌƐ ? WD ?Ɛ ůĂď ƐƚĂĨĨ ŝƐ ŽƌŐĂŶŝƐĞĚŝŶƚŽ Ă ĨŽƌŵĂů ƚhree-level 
organisational hierarchy that is absent in Dharamsala, although there they also report to 
the Heads of the Pharmaceutical and Herbal Products departments. A more conspicuous 
difference with Men-Tsee-<ŚĂŶŐ ?ƐYƵĂůŝƚǇƐƐƵƌĂŶĐĞ>ĂďŽƌĂƚŽƌǇ  ?Y> ) ŝƐthe absence of 
microbiological screening in-house  W a major activity at QAL  W and several more analyses 
that are carried out externally by specialised commercial labs for PADMA (including 
microbiology, and the costlier quantification of contaminants such as heavy metals, 
pesticides and aflatoxins). On the other hand, no Tibetan medicine practitioner is employed 
at the Swiss company to ascertain the taste, potency, and characteristics as prescribed by 
Tibetan classical texts. Finally, another contrast with far-reaching consequences concerns 
the paper worlds of documentation and regulation. Staff at both labs were occupied with 
reading and following quality monographs and specifications during each experiment, 
writing down or printing the obtained results on paper protocol sheets or in record 
notebooks and later inserting the numbers into a larger digital database. When a new 
sample arrives in the lab, it is first registered and given a unique identifier tag. Each piece 
of analytical equipment also comes with a logbook (at QAL for its distillation unit, fume 
hood, furnace and water bath), which documents its use and maintenance routines. At 
PADMA however, this pharmaceutical bookkeeping is necessarily taken to another level. 
After a few days, it quickly became clear that Barbara, Emad, and Brigitte spent much more 
time with documents and behind their computer screens than they do at the laboratory 
bench. As Kloos (2015) already noted, documentation remains a final challenge for Men-
Tsee-<ŚĂŶŐ ?ƐƉƌŽĚƵĐƚŝŽŶƵŶŝƚƚŽ be fully Indian GMP compliant, adding to the somewhat 
puzzling question as to whether documentation is for the sake of quality control or the 
ŽƚŚĞƌǁĂǇĂƌŽƵŶĚ ?WD ?ƐůĂďŽƌĂƚŽƌǇŽĨĨŝĐĞǁĂůůƐĂƌĞůŝŶĞĚǁŝƚŚƐŚĞůǀĞƐĂŶĚĐƵƉďŽĂƌĚƐ
filled with rows of thick ĨŽůĚĞƌƐƚŝƚůĞĚ ‘ZĂǁĚĂƚĂǀĂůŝĚĂƚŝŽŶŵĞƚŚŽĚƐ ? ? ‘KƵƚŽĨƐƉĞĐŝĨŝĐĂƚŝŽŶ
ƌĞƉŽƌƚƐ ? ?  ‘YƵĂůŝĨŝĐĂƚŝŽŶ ŽĨ ĞƐƚĂďůŝƐŚĞĚ ůĂďŽƌĂƚŽƌǇ ĞƋƵŝƉŵĞŶƚ ? ?  ‘WƌŽĐĞƐƐ ǀĂůŝĚĂƚŝŽŶ
WƌĞƉĂƌĂƚŝŽŶEƌ ? ? ? ? ? ?ĂŶĚƐŽŽŶ ?ƌĞƉƌĞƐĞŶƚŝŶŐĂŶŽǀĞƌĂƌĐŚŝŶŐůĞǀĞůŽĨƋƵĂůŝƚǇĂƐƐƵƌĂŶĐĞ ?ŶŽƚ
ũƵƐƚ ‘ĐŽŶƚƌŽů ? ) ?ǁŚŝĐŚǁŝůůďĞĞůƵĐŝĚĂƚĞĚƵŶĚĞƌƐĞĐƚŝŽŶ4.4.1.  
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4.3 Historical inter-laboratory exchanges: translocal flows and frictions 
From the previous paragraph it would seem that the two laboratories are separate entities 
even though there are significant parallels. The reasons for these similarities deserve more 
detailed attention here. As some within postcolonial studies caution (Anderson and Adams 
2008), it is too simplistic to assume that laboratory science and technology can just be 
duplicated or transplanted from some vague centre of modernity as a full package, without 
any (ex)change, negotiation and transformations. By introducing key historical moments of 
communication, technology transfer, and knowledge exchange between PADMA and Men-
Tsee-<ŚĂŶŐ ? / ŚŽƉĞ ƚŽ ƐŚŽǁ ŚŽǁ ƚŚĞƐĞ ŝŶƐƚŝƚƵƚŝŽŶƐ ƐŚĂƉĞĚĞĂĐŚ ŽƚŚĞƌ ?Ɛ ƋƵĂůŝƚǇ ĐŽŶƚƌŽů
practices as well as the ontologies on which these are premised. The first and also foremost 
interaction I will cover revolves around the Tibetan monk/physician Tenzin Thaye60, who 
acted as an important mediator between Men-Tsee-Khang and PADMA. In 2014, we had a 
nearly two-hour loŶŐĐŽŶǀĞƌƐĂƚŝŽŶĂƚƚŚĞĚŽĐƚŽƌƐ ?ŽĨĨŝĐĞŝŶƚŚĞWŚĂƌŵĂĐĞƵƚŝĐĂůĞƉĂƌƚŵĞŶƚ
(Audio recording 86). In the background, we could hear the buzz of a blistering machine 
packaging precious pills, as well as mechanics working outside of the machine maintenance 
workshop downstairs. 
JVDV: /ĚŽŶ ?ƚŬŶŽǁǁŚĞŶ ?ďƵƚǇŽƵĂůƐŽǁĞŶƚƚŽ^ǁŝƚǌĞƌůĂŶĚ ?ƚŽWDĨŽƌĂǁŚŝůĞĨŽƌĂ
visit. Why? 
TT: ĐƚƵĂůůǇ ? / ƚŚŝŶŬ ŝƚ ǁĂƐ ŝŶ  ‘ ? ? ĂďŽƵƚ ? Kƌ  ‘ ? ? ? dŚŝƐ ǁĂƐbecause Péma 28 [many 
Tibetans use this as the name for PADMA AG, the company as well as its main 
product] had contact with Men-Tsee-Khang, to send a doctor from the pharmacy. 
 ‘tĞǁĂŶƚƚŽƐŚŽǁĂůůƚŚĞǁŽƌŬ ?ĂŶĚĐĂŶƚĞůůŚŽǁƚŽĚŽŐŽŽĚƋƵĂůŝƚǇĐŽŶƚƌŽů ? ?dŚĂƚ
                                                     
60 Tenzin Thaye was born in 1965 at Amdo Ngawa, an Autonomous Prefecture of Sichuan Province, PRC. He 
started his formal study of Tibetan medicine in Amdo, in the late 1970s. First he attended a professional 
middle school in the city of Bangkam for a year, after which he transferred to a menkhang (Tibetan medical 
ŝŶƐƚŝƚƵƚĞ ?ůŝƚĞƌĂůůǇ ‘ŵĞĚŝĐŝŶĞŚŽƵƐĞ ? )ŝŶǌŽƌŐĠĨŽƌƚŚƌĞĞǇĞĂƌƐ ?ĨƚĞƌŵĞŵŽƌŝƐŝŶŐƚŚĞ&ŝƌƐƚ ?^ĞĐŽŶĚ ?ĂŶĚ&ŽƵƌƚŚ
Medical Tantras as well as Dési Sangyé 'ǇĂƚƐŽ ?Ɛmengak lhenthap (instead of the very lengthy Third Tantra), 
he worked in the clinic of a nearby town for two years. He was one of the youngest students of his year, and 
felt he needed more study. Since Lhasa Mentsikhang would not allow him, he fled to India in 1987. At Men-
Tsee-Khang in Dharamsala, he attended the college again from the second year onwards. In his fifth year he 
then completed a six-month internship in Bir. From 1992 to 1996 he spent most of his time in the remote 
Indian Himalayan state of Arunachal Pradesh, as a practitioner at Men-Tsee-<ŚĂŶŐ ?ƐďƌĂŶĐŚĐůŝŶŝĐƐŝŶdĂǁĂŶŐ
and Bumdila. In 1997 he was finally allowed to transfer to the Pharmacy Department, which was his main 
interest all along. Dr Thaye is currently appointed as Deputy Head of the Pharmaceutical Department, and 
has served as Personal Physician to His Holiness the Dalai Lama (the most prestigious title a Tibetan doctor 
can receive) since 2011.  
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time we had a few doctors in the pharmacy. Men-Tsee-Khang sent me away. I was 
there for three months. That time, my English was very very poor. So in Péma, we 
did a schedule. A few weeks in the main office [to see] how they are doing, two 
weeks in laboratory, and two weeks in production.  
JVDV: I also went to PADMA for my research. I have visited three times already, and stayed 
for six weeks last time. I visited the different departments just like you. How was 
this experience for you? 
TT: In a way, very good. When a doctor is producing medicine for individuals, you can 
compound this medicine according to your experience. In the pharmacy here...  
(his mobile phone rings, he apologises) 
But like here in a common pharmacy, it is very important: standards. What they are 
doing there [in PADMA] is very good. Whatever [they do], these people just follow 
steps. Also here, we are doing this and are trying to create this, to be clean, but not 
ůŝŬĞǁŚĂƚƚŚĞǇĚŽ ?dŚĞǇŽŶůǇŚĂǀĞĂĨĞǁƉůĂŶƚƐĂŶĚŵĞĚŝĐŝŶĞƐ ?dŚĞǇĂůƐŽĚŽŶ ?ƚŚĂve 
much raw material. They can order batch by batch, but here we have so many herbs, 
and produce so many different medicines (the official number of produced 
formulas is 172). It is hard to cut each step, it is impossible. But it is also really good 
to try to follow each batch, one time or a ƐĞĐŽŶĚƚŝŵĞ ?/ƚ ?ƐƌĞĂůůǇŝŵƉŽƌƚĂŶƚ ?ůƐŽ
storing and all this, we have really improved a lot compared to before. Of course 
Tibet is a very clean area, now here [in Dharamsala] not so. We have to be careful 
in cleaning and storage. These kinds of things they are doing very well and we have 
also improved a lot. Still we have to improve more, but it is already good.  
JVDV: When you came back after your internship, did you suggest some changes here? 
TT: Actually, after coming back that was my main aim. I explained all things to the 
doctors. What we can do. Like that.  
JVDV: You learned over there and here you tried to apply. 
TT: Mostly about the hygiene they [again PADMA] are doing very well. Now we have 
also improved a lot.  
JVDV: Were you also involved in setting up the quality control lab here? 




Dr Thaye speaks highly of PADMA but does so without denigrating Men-Tsee-<ŚĂŶŐ ?Ɛ
position, recognising that the circumstances of production are difficult to compare. 
Befitting a monk, he is also very humble when it comes to his own contribution to the 
establishment of GMP practices. PADMA employees at all levels fondly remember his visit, 
respect him, and consider him as a good friend of the company. Alexandra Schwabl, who 
leads PADMA as managing director together with her husband, shared that at the time 
when Tendzin Thayé was at PADMA, he looked at the raw materials, and that at this time 
they got the most transfer of ideas (Audio recording 102). A particular example of this was 
given to me by Walter, the warehouse manager, who has been employed here for more 
than fifteen years. While we were taking samples from recently arrived bags of costus root 
at one of the depots to take to the lab for analysis (3 February 2014, Notebook VI, 
translated from German), he said he knows the roots well from the time manual sorting of 
raw materials was still done at PADMA. Costus was one of those herbs that came with a lot 
of dust, makŝŶŐƐŽƌƚŝŶŐĂŶƵŶƉůĞĂƐĂŶƚũŽď ? ‘It smells sweet but the ƚĂƐƚĞŝƐďŝƚƚĞƌ ? ?ŚĞĂĚĚĞĚ ?
 ‘ƐŽŵĞƉĞŽƉůĞĚŽŶ ?ƚůŝŬĞƚŚĞƐŵĞůů ?ůŝŬĞƚŚĞŽǁŶĞƌŽĨƚŚŝƐǁĂƌĞŚŽƵƐĞ ? ? ‘We used to throw 
away the roots that were like rubber when you bend them, until that monk came and told 
ƵƐŝƚǁĂƐŶŽƌŵĂů ? ? 
 
A second important series of quality control exchanges took place about ten years after 
Tendzin ?ƐŝŶƚĞƌŶƐŚŝƉ ?ƚƚŚĂƚƚŝŵĞ ?ƚǁŽƐŵĂůůĚĞůĞŐĂƚŝŽŶƐŽĨWDƐƚĂĨĨǁĞƌĞĚŝƐƉĂƚĐŚĞĚ
to visit raw material suppliers in India. The recent enforcement of Good Agricultural and 
Collection Practices (GACP) urged the company to formally inspect and educate growers 
and harvesters at the source of their supply chain. As part of a first visit in 2006, Rolf (Head 
of Production) and Susanne (Purchasing Manager and Qualified Person at that time) also 
stayed in McLeod Ganj for three days. At Men-Tsee-Khang, they were given permission to 
enter the Pharmaceutical Department by Dawa, who was the Director during that period 
(2005-2010). They were given a detailed guided tour of the different rooms and technical 
installations, a rare opportunity for any outsider which likely presented itself in response 
ƚŽWD ?ƐŽƉĞŶŶĞƐƐƚŽTenzin Thaye a decade earlier. During an interview in his office at 
PADMA Produktion (Audio recording 99), I asked Rolf about the exchanges that went on. 
The Pharmacy was interested in getting some expert advice in two interrelated domains: 
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ŽŶ ƚĞĐŚŶŝĐĂů ĂƐƉĞĐƚƐ  ?ŵĂĐŚŝŶĞ ŽƉĞƌĂƚŝŽŶ ĂŶĚ ŵĂŝŶƚĞŶĂŶĐĞ ? ZŽůĨ ?Ɛ ĂƌĞĂ ) ? ĂŶĚ ŽŶ ŚŽǁƚŽ
implement quality assurance as a concept. In return, Rolf and Susanne had brought several 
samples of herbs (including myrobalans and costus) thĂƚĂƌĞƵƐĞĚŝŶWDƉƌŽĚƵĐƚƐ ? ‘to 
get them evaluatĞĚĨƌŽŵƚŚĞdŝďĞƚĂŶƉĞƌƐƉĞĐƚŝǀĞ ? ?ĂŶĚƚŽĐŚĞĐŬ ‘whether we had the right 
species and quality ?. Rolf added that Tibetan doctors judge identity and quality 
organoleptically, which is what they had asked them to do. The doctors approved. Within 
ƚŚĞ ƐĂŵĞ ŵŝŶƵƚĞ ? ZŽůĨ ĞǀŽŬĞĚ  ‘ƋƵĂůŝƚǇ ? ƚǁŝĐĞ ? ďƵƚ ǁŝƚŚ ĚŝĨĨĞƌĞŶƚ ŵĞĂŶŝŶŐƐ P ŵŽĚĞƌŶ
(Western) pharmaceutical versus traditional Tibetan medical quality. This rather 
stereotypical interaction in which each institution plays its own role  W PADMA instructs 
Men-Tsee-Khang on modern quality, and the other way round for tradition  W builds on the 
following underlying assumptions: (1) pharmaceutical and Tibetan quality (control) are 
separate entities (adhering to the modern/traditional dichotomy), (2) both are valid and 
necessary, as well as (3) complementary. Martin Saxer (2013), in his ethnography on the 
recently emerging Tibetan medicine industry in China, has made a similar point in respect 
to the complementarity of Chinese GMP standards (as laid down in the Chinese 
Pharmacopoeia) with classical textual prescriptions on the processing of herbal compounds 
(yenlak dün, Seven Essential Limbs) as mentioned in Gyüzhi, the foundational work of 
Tibetan medicine. They are not fundamentally incompatible per se according to Saxer. 
Different notions of quality do not necessarily contradict or preclude each other in practice, 
but mismatches have occurred as a side effect of the rapidly enforced implementation of 
GMP. Instead, the commercialisation of the raw materials trade is often blamed for the 
contemporary decrease in quality by Tibetan medicine professionals.   
 
In 2009, PADMA staff traveled to India a second time for the same purpose, again visiting 
Men-Tsee-Khang. Alexandra was interested to see how their production operated and 
what issues they were facing. This time, they could visit the brand-new Quality Assurance 
Laboratory as well. I spoke to Alexandra about her experiences there (Audio recording 102). 
She felt that the people in the lab were enthusiastic and open about their work, and was 
impressed by the presence of a number of modern laboratory instruments. But, she added 
that the analysts told her they have no power. 
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You have seen how it works at PADMA. If Erich (the Qualified Person, responsible for the final 
ŵĂƌŬĞƚƌĞůĞĂƐĞŽĨĞĂĐŚŶĞǁďĂƚĐŚŽĨƉƌŽĚƵĐƚƐ )ƐĂǇƐŶŽ ?ŝƚ ?ƐŶŽ ?ůůƉƌŽĚƵĐƚŝŽŶƐƚŽƉƐ ?dŚĂƚ ?Ɛ
not the same at Men-Tsee-Khang. They can give some advice, can talk, but cannot stop or 
change anything by their own. They are young people, and were very enthusiastic at this time. 
They are investing in instruments but not in structure, was my impression. At this time, they 
even had a new blistering machine. Tendzin Thayé was trying to make it work, it was just 
 ?ƐƚĂŶĚŝŶŐƚŚĞƌĞ ?ǁƌĂƉƉĞĚŝŶ ?ŝŶƉůĂƐƚŝĐ ?/ƚǁĂƐĂŶŝĐĞƚŚŝŶŐ ?ďƵƚĚŝĚŶ ?ƚƐŽůǀĞƚŚĞŵĂŝŶƉƌŽďůĞŵ P
ƚŚĞŚƵŵŝĚŝƚǇŽĨƚŚŝƐƉůĂĐĞ ?dŚĞǇŚĂǀĞƐŽŵĞŐŽŽĚƚŚŝŶŐƐůŝŬĞĂĐŽŽůŝŶŐŚŽƵƐĞ ?ďƵƚŝƚĚŽĞƐŶ ?ƚ
help much if they are facing what to do in this humid environment. It is some pieces, but no 
system. What was very impressive was to see the people sitting and sorting the materials. 
The way they are doing it is with passion, very carefully. That is very beautiful to see. The 
director at this time told us they are planning a new production site somewhere near Delhi. 
ůůďŝŐƉƌŽũĞĐƚƐ QdŚĞƌĞĂƌĞƐŽŵĞƐŵĂůůĞĂƐŝĞƌƚŚŝŶŐƐƚŽĚŽ ŝŶharamsala that would help 
more. 
Alexandra as well as other PADMA employees are equally careful and nuanced when it 
comes to making comparisons with Men-Tsee-Khang, just like Dr Thaye. There is a mutual 
recognition that they are in the same boat (Herbert once used the German expression 
Unter uns Klosterschwestern ? ‘ĂŵŽŶŐƐƚƐŝƐƚĞƌƐŽĨƚŚĞĐŽŶǀĞŶƚ ? ?ŝn this regard), in the same 
business. Facing some similar practical problems in production and quality control, but in 
very different national and regulatory contexts. Over the years, PADMA has learned to 
steer clear of sensitive topics such as mercury and ŚĞĂǀǇŵĞƚĂů ‘ĐŽŶƚĂŵŝŶĂƚŝŽŶ ?ĂŶĚƚŽǆŝĐŝƚǇ
of Tibetan medicines (see Chapter 5). Nonetheless, both parties involved are aware of each 
ŽƚŚĞƌ ?ƐǀŝĞǁƐ ?/ŶƚŚĞƋƵŽƚĞĂďŽǀĞ ?ůĞǆĂŶĚƌĂĨƵƌƚŚĞƌĐŽŶƚƌĂƐƚƐƚŚĞĞǆĞĐƵƚŝŽŶŽĨůĂďŽƌĂƚŽƌǇ
quality control tests with quality as a system, which will be discussed under section 4.4.1.  
 
Herbert related a third, less direct exchange between the labs of PADMA and Men-Tsee-
Khang (Audio recording 47). QAL was approached by an Indian representative of the Swiss 
company CAMAG, the self-professed world leader in thin-layer chromatography (TLC) 
instruments. The analysts were interested in purchasing the tools necessary for High 
Performance TLC or HPTLC, which includes an automatic sampler as well as a visualisation-
documentation system. The total budget was estimated at 8,284,000 INR or 142,828 CHF 
(more or less equivalent to USD) in September 2012, and a Large Project was developed 
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and published by Men-Tsee-Khang (Project B-02, men-tsee-khang.org 61 ). PADMA was 
subsequently contacted as a potential sponsor, and responded favourably on the condition 
that they would reconsider what equipment was actually needed and then compare offers. 
Herbert explained to me how this promising exchange came to an unfortunate end: 
tĞƵƐĞD'ĞƋƵŝƉŵĞŶƚ ?ŝƚ ?ƐĂ^ǁŝƐƐĐŽŵƉĂŶǇ ?tĞƚŽůĚƚŚĞŵ ? ‘ǁĞŬŶŽǁƚŚĞŝƌŵĂĐŚŝŶĞƐ
really well. It is a Swiss company. For 30 years we have used D'ŵĂĐŚŝŶĞƐ ?zŽƵĚŽŶ ?ƚ
need this and this equipment, you need this and that. We also ĚŽŶ ?ƚŚĂǀĞƚŚĞĨƵůůy automatic 
ǀĞƌƐŝŽŶ ?ĨƚĞƌ ? ?ǇĞĂƌƐǁĞƐƚŝůůǁŽƌŬǁŝƚŚƚŚĞŽůĚĞƐƚŽŶĞ ?/ƚ ?ƐĨŝŶĞĞŶŽƵŐŚ ?zŽƵĚŽŶ ?ƚŶĞĞĚƚŚĞ
top-computerised, highly expensive one. Take the almost cheapest one, it's good enough, 
ƐĞƌǀĞƐƚŚĞƉƵƌƉŽƐĞ ? ?dŚĞǇĚŝĚŶ ?ƚďĞůŝĞǀĞƵƐ ?DĂǇďĞƚŚĞǇ ŽƵght [that we meant] 'you Indian 
ŐƵǇƐ ?ǇŽƵĐĂŶƵƐĞƚŚĞůŽǁĞƌƋƵĂůŝƚǇŽŶĞ ? ? ? Q ?tĞĐƌŽƐƐĞĚ ƵƚĂŶǇƚŚŝŶŐǁĞŽƵƌƐĞůǀĞƐĚŝĚŶ ?ƚ
have. We know these are just add-ons. You can buy Rolls-Royce; it is also a car. If you need a 
ƚƌƵĐŬ ?ďƵǇĂƚƌƵĐŬ ?/ƚ ?ƐĞŶŽƵŐŚƚŽŐŽĨƌŽŵƚŽ ?ƐƉĞĐŝĂůůǇĂƚƚŚĞďĞŐŝŶŶŝŶŐ ?ĚŽŶ ?ƚďƵǇƚŚĞ
high-end stuff. This misunderstanding made our relation more difficult. Even after years, we 
still have this misunderstanding. But we did not stop to tell them our opinion somehow. 
This failed collaboration once again brings the specter of (post)colonialism to the stage in 
relation to what could be interpreted as an example of technology transfer. While the QAL 
staff were aiming to modernise their quality control by obtaining high-tech machinery, 
PADMA did not consider their choices to be efficient, economical or even necessary to a 
certain extent. This mismatch in turn gave PADMA the bad image of not granting Men-
Tsee-<ŚĂŶŐŝƚƐŶĞĞĚĞĚƉƌŽŐƌĞƐƐ ?ĞƐƉĞĐŝĂůůǇďĞǇŽŶĚWD ?ƐŽǁŶůĞǀĞů ) ?ǁŚŝůĞY>ƐĞĞŵĞĚ
to have fallen for the CAMAG sales pitch and the idea that newer is always better. The deal 
was off. No alternative funding has been obtained so far for the HPTLC installation. 
 
&ŝŶĂůůǇ ?,ĞƌďĞƌƚŵĂĚĞŵĞĂǁĂƌĞŽĨŚŽǁĂĐŚĂŶŐĞŝŶWD ?ƐƉƌŽĚƵĐƚŝŽŶŝŶĨůƵĞŶĐĞĚƚŚe 
quality of the medicines as perceived by amchi (Audio recording 47). Over the years, the 
whole production process (from dosing the powders until packaging) had become faster 
                                                     
61 The goal of project B- ? ?ǁĂƐĚĞĨŝŶĞĚĂƐĨŽůůŽǁƐ P ‘dŽŝŵƉƌŽǀĞƚŚĞƋƵĂůŝƚǇŽĨdŝďĞƚĂŶmedicine according to 
ƚŽĚĂǇ ?Ɛ'ŽŽĚ Manufacturing Practice (GMP) standard by maintaining the standard prescribed in the treatise 
of [the] Traditional Tibetan medical system ? ?dŚĞŽďũĞĐƚŝǀĞƐǁĞƌĞ ‘ ? ? )ƚŽĞǆƉůŽƌĞƐĐŝĞŶƚŝĨŝĐĞǀŝĚĞŶĐĞŽĨdŝďĞƚĂŶ




and more efficient following the increasingly stringent implementation of GMP. 
Throughout the manufacturing, the product is always kept in a sealed, protected 
environment: as a powder in drums, as capsules in sealed bags, and then in blisters and 
boxes. There is no opportunity for the mixed powder to come into contact with air for 
longer than two or three hours in total. This is in stark contrast to how pills are made at 
Men-Tsee-Khang (see Chapter 5), where the compounded powder is rolled and compacted 
into small balls by adding water to it in a slowly spinning vessel. These rounded pills are 
then left to dry in open air and fully exposed to the sun for several days, depending on the 
weather. Not even considering the GMP compliance of the drying location, method, and 
air, this would be disastrous from a European perspective: as the plant cell walls were 
destroyed by grinding, nearly all essential oils oxidise and evaporate, severely affecting 
(European herbal) quality and efficacy.  
Some [Tibetan] doctors even complain that the PADMA 28 formula has become sharper. 
From the Western concept it is fresher, from the Tibetan medicine point of view it should 
age more. This is definitely a contradiction we cannot solve. The concept of how herbs are 
active by essential oils is so deeply rooted in Western science. When you say you want to get 
rid ŽĨƚŚĞŵďǇĂŐĞŝŶŐ Qŝƚ ?ƐĂƚĂƐŬƚŽŽĐŽŵƉůŝĐĂƚĞĚ ?zŽƵŚĂǀĞƚŽĂƌŐƵĞ ‘ǁŚǇ ? ? ?ĂďĂƚƚůĞ ?ǁŝƚŚ
EU and Swiss regulatory authorities] you cannot win. That's a quite unexpected feature of 
ŵŽĚĞƌŶŝƐĞĚ ƉƌŽĚƵĐƚŝŽŶ ?  ? Q ? dŚĞƌĞ ŝƐ ůĞƚ ?Ɛ ƐĂǇ Ă ĐŽŶƚƌĂĚŝĐƚŝŽŶ ?  ƉĞƌĐĞƉƚŝŽŶhow plants 
function in Western pharmacology; what we think is a high quality plant, and apparently the 
Tibetan concept of quality. (Herbert, Audio recording 47) 
This led Herbert to conclude that Tibetan medicine has no concept of stability in the 
modern pharmacological sense, even though there are limits to how long you should ideally 
keep herbs and medicines. It also relates to the classical prescription that warming potency 
herbs should be dried in the sun while cooling herbs should be kept in the shade to maintain 
and strengthen their inherent qualities. However, this turned out to be as good as 
impossible to ensure for both PADMA and Men-Tsee-Khang since they both have to rely on 
external harvesters, growers and suppliers enmeshed in the Indian herbal trade and 
beyond (see Chapter 2). An ontology of quality may be present in classical texts, but 
practical performances of these ideals are always partial. Similarly, people, concepts and 
technologies do not travel easily between dissimilar locales as presumed by diffusionist 
theories of science, but are transformed along the way.  
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4.4 PADMA  Labor 
Since the inception of in-house laboratory facilities at PADMA in 1985, three members of 
staff have been key in its development: Rolf, Alexandra and Erich. I was able to interview 
each of them on their role in working in, managing and expanding the Labor over the years 
even though Rolf retired later in 2016. It was Rolf Lienhard, the son-in-law of Karl Lutz 
 ?WD ?ƐĨŽƵŶĚĞƌ ) ?ǁŚŽŝŶƐƚĂŶƚŝĂƚĞĚƚŚĞĨŝƌƐƚůĂďŽƌƚ ǇŝŶƚŚĞ 1980s. He explained to me 
why they decided to do so (Audio Recording 55). In 1985, PADMA got a quite large order 
from the US, for which the first production site was considered too small. Rolf and Mr Lutz 
(or Herr Lutz, as he is still addressed by PADMA veterans) found a new suitable location 
that could house larger production rooms for dosing and mixing. In April 1986, they moved 
to the same building still used to date. Until then, all analyses of raw materials (mainly 
organoleptic testing and microscopy) were carried out externally by one single person: the 
Zürich pharmacist Dr Andres. The game changer here was however not only increased 
production, but also more stringent government control. Since its registration as a 
medicine in 1977 (Swissmedic No 35872), the Swiss health authorities revisited the dossier 
of PADMA 28 every five years. This time they came with critical questions on quality, as did 
the German authorities where the company was exploring to enter the market. Lutz 
decided to install his own lab in one of the vacant rooms of the new production site. Rolf 
and Rüedi  W ƌŶĚƌĞƐ ?ƐŽŶǁŚŽǁĂƐƚŚĞŶĂƉŚĂƌŵĂĐǇWŚƐƚƵĚĞŶƚĂƚhŶŝǀĞƌƐŝƚǇŽĨĞƌŶ W 
developed the laboratory together: a microscope was purchased (still used today), as well 
as quantitative TLC equipment (the scanner is also still in operation). Rüedi Andres trained 
ZŽůĨŝŶƚŚĞƐĞŵĞƚŚŽĚƐ ?ĂŶĚƚŽŐĞƚŚĞƌƚŚĞǇƉƵƚƚŽŐĞƚŚĞƌWD ?ƐĨŝƌƐƚŝŶ-house monographs 
ĨŽƌƚŚĞ ‘ƐŝĂŶŚĞƌďƐ ?ŽĨWD ? ?ƚŚĂƚǁĞƌĞŶŽƚƚŽďĞĨŽƵŶĚŝŶƚŚĞ^ǁŝƐƐWŚĂƌŵĂĐŽƉŽĞŝĂ
as well as for the mixture, under the supervision of Andres senior. These were exciting 
ƚŝŵĞƐ ?ĞƚǁĞĞŶ ? ? ?ĂŶĚ ‘ ? ? ?ŶĚƌĞƐũƵŶŝŽƌŵĂĚĞĂƐĞƌŝƐŽĨĐŽůŽƵƌĚƌĂǁŝŶŐƐ ?ĚĞƚĂŝůŝŶŐƚŚĞ
macro- and microscopic structure of each raw ingredient of PADMA 28 (see Figure 4.1 
below for aconite). Rolf enjoyed developing proper TLC methods, chiefly relying on two 
German publications ƚŚĂƚǁĞƌĞĞƐƚĂďůŝƐŚĞĚƌĞĨĞƌĞŶĐĞƐĂƚƚŚĞƚŝŵĞ PtĂŐŶĞƌĞƚĂů ? ?Ɛ(1983) 
illustrated TLC atlas for medicinal plants and the fourth edition of ,ĂŐĞƌ ?Ɛ,ĂŶĚďƵĐŚĚĞƌ
Pharmazeutischen Praxis (Kern et al. 1969). Finally, the Swiss health authorities accepted 





Figure 4.1. Photograph of part of the original documents with pen and aquarelle drawings of PADMA 28 herbal 
ingredients by Rüedi Andres. This page is titled Aconiti Tuber (Aconitum napellus ) ?ĂŶĚŚŝƐŶĂŵĞĂŶĚƚŚĞǇĞĂƌ ? ? ? ? )ĂƌĞ
written in the bottom right corner (not included here). It includes illustrations of the crude herb (mother and daughter 
roots, cross section), and of cellular structures present in the powdered drug and visible through a microscope at 




After talking through this early history with Rolf at his office, I asked him if he thought that 
the quality of individual herbs and thus also of PADMA 28 could change over the years 
because of changing suppliers, or perhaps changing quality control or production processes. 
This leading question provided me with the following response: 
Mainly the method of analysis has changed. You have not to forget that humans are also 
quite good analysis tools. You have taste, and you can see it and feel it. It is not so bad. 
What we have done when we developed the analysis methods, we took the material we 
ŚĂĚĂŶĚdŝďĞƚĂŶĚŽĐƚŽƌƐƚŽůĚƵƐ P ‘ǇŽƵŚĂǀĞƚŽƵƐĞƚŚŝƐŵǇƌŽďĂůĂŶ ? ?dŚĞĨŝǀĞ ?ĂƐŝŶĚŝĐĂƚĞĚ
ŝŶZƺĞĚŝŶĚƌĞƐ ?ĚƌĂǁŝŶŐŽĨƚŚŝƐƐƉĞĐŝĞƐ )ŽƌƐĞǀĞŶ-ribbed one. We have developed our 
ĂŶĂůǇƚŝĐĂůŵĞƚŚŽĚƐŽŶƚŚŝƐďĂƐŝƐ ? ? Q ?ƵƌŝŶŐƐŽƌƚŝŶŐ ? we have sorted out the other types. 
When we started to find our own suppliers in India, we gave them samples. That's what 
we wanted, what we are looking for. Then they delivered us the material. We told them 
also a range in the size, and how the colour had to be after drying. When they dry them 
too hot, they are burned, they are more black. We gave them some simple parameters. 
hƐŝŶŐŵǇƌŽďĂůĂŶĂƐĂŶĞǆĞŵƉůĂƌ ĨŽƌ  ‘dŝďĞƚĂŶ ?Žƌ  ‘ƐŝĂŶ ?ŚĞƌďƐ ?ŚĞĂƌŐƵĞĚƚŚĂƚƐĐŝĞŶƚŝĨŝĐ
quality control techniques have not fundamentally changed the identification and quality 
of the plants involved since (at least some) of the parameters are based on traditional, 
textually-traceable Tibetan medical knowledge. Within the constraints of the available 
knowledge on Tibetan medicine and technoscientific sources, technologies and regulations 
at the time, Rolf together with Andres junior still had considerable freedom to decide on 
the quality parameters at least for plants not listed in the Swiss Pharmacopoeia, allowing 
them to craft a sciĞŶƚŝĨŝĐŵŽŶŽŐƌĂƉŚǁŚŝĐŚŝŶƚĞŐƌĂƚĞĚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ĐŚĂƌĂĐƚĞƌŝƐƚŝcs. As such, 
they created a new, practical ontology of quality. 
 
&ƌŽŵ ? ? ? ?ŽŶǁĂƌĚƐ ?WD ?Ɛ ůĂďǁĂƐĞǆƉĂŶĚĞĚĂŶĚŵŽĚĞƌŶŝǌ ĚƵŶĚĞƌƚŚĞ ŝŵƉĞƚƵƐŽĨ
Alexandra, who became the new Head. The lab was physically separated from the 
production site and its manager (Rolf), and moved to the Cosmina industrial area nearby 
where facilities were available for rent. Academically trained as a chemist, Alexandra 
immediately felt at home in the laboratory, but not so much with plants initially (Audio 
recording 44). She was used to chemical analyses such as chromatography with precisely 
defined standards and chemical substances, not with herbs where it is difficult to even 
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decide on the proper markers. Plants are what chemists would call a complex and variable 
matrix according to Alexandra, even the same material coming from the same supplier. This 
makes quality control very exciting and less routine compared to chemicals. PADMA 28 is 
not the same every time, and one has to find out what is significant and what not. Still, she 
maintains that the basic problems and methods are not so special for analytical chemistry, 
but similar to water or soil analyses for instance.  Some of the changes that were gradually 
implemented in the lab are (Audio recording 56): a fridge for the standard materials, the 
introduction of a lab journal, and new analytical machinery including a UV photometer, gas 
chromatography (GC), and finally HPLC (High-Performance Liquid Chromatography). The 
primary reason for this expansion was again related to a strong increase in yearly 
production: from five batches in former times to twenty. Before, some analyses were 
outsourced to an external lab, but this avenue became financially unattractive. PADMA also 
wanted to be more independent. This increased control over the quality control of its 
products granted the company more power to directly influence not only the initial 
ĚĞĨŝŶŝƚŝŽŶŽĨǁŚĂƚƋƵĂůŝƚǇ ‘ŝƐ ? ?ďƵƚĂůƐŽŚŽǁƋƵĂůŝƚǇŝƐŵĞĂƐƵƌĞĚ ?ŝ ?Ğ ?ĐŽŶƐƚƌƵĐƚĞĚ )ŝŶ practice. 
 
ƌŽƵŶĚ ƚŚĞ ƐĂŵĞ ƉĞƌŝŽĚ ? WD ?Ɛ ƉŽƉƵůĂƌŝƚǇ ƌĞĂĐŚĞĚ ƵŶƉƌĞĐĞĚĞŶƚĞĚ ŚĞŝŐŚƚƐ ŝŶ
Switzerland and beyond after the widely disseminated documentary film by Franz Reichle 
on Tibetan medicine: Das Wissen vom Heilen (1996), or The Knowledge of Healing in the 
English-language format.62 Moreover, PADMA 28 was put on the national list of medical 
products reimbursed by the Swiss health insurance from 1998 onwards, further boosting 
its sales figures. Erich fondly remembers these first years of his career, which started in 
1999 as a deputy under Alexandra (Audio recording 67). The documentary had created a 
veritable hype. Production at PADMA was now taking place in day and night shifts (which 
is not the case anymore presently), and even then there were times betwĞĞŶ ? ? ?ĂŶĚ ? ? ?
where apothecary windows across Switzerland would have a notice to customers saying 
ƚŚĂƚ  ‘WD  ? ? ŝƐ ƚĞŵƉŽƌĂƌŝůǇ ƐŽůĚ ŽƵƚ ? ? ƵĞ ƚŽ ƚŚŝƐƉĞĂŬ ŝŶ ĚĞŵĂŶĚ ĂŶĚ ƉƌŽĚƵĐƚŝŽŶ ?
quality control had to be strengthened to keep track. In the euphoria of the moment new 
product development projects were initiated at the laboratory (PADMA 69, PADMA 8), and 
                                                     
62 dŚŝƐĞǀĞŶƚǁĂƐĂůƐŽďƌŝĞĨůǇĐŽǀĞƌĞĚŝŶ^ĂǆĞƌ ?Ɛ ? ? ? ? ? )ĚŽĐƵŵĞŶƚĂƌǇ ?ƐĞĞŵŽƌĞŝŶŚĂƉƚĞƌ ? ?
182 
 
steps were undertaken to gain a foothold in the American market. Staff at production and 
in the lab more than doubled. As the hype faded out from the year 2000 onwards and as 
production stabilised, many of these ambitions were put on hold as the amount of 
personnel was reduced. A lasting change however, was the separation of the laboratory 
office space from the workbenches where the actual analyses take place. This not only 
reflects ever more detailed GMP regulation of all aspects of pharmaceutical production 
(including the need to compartimentalise), but also likely the increase in time spent by 
analysts behind their desks. The dread of endless GMP documentation duties was a 
frequent lament by workers at all levels of the company, but this trend towards increasingly 
administration-based quality concepts proved to be unstoppable.  
 
 





Arriving at the ethnographic present (2014 in this case), the analysts have to follow a strict 
set of procedures in conducting the experiments using pharmacopoeia-standard methods 
and instruments, observing if the values obtained for each batch produced are within the 
specified limits, if they conform or are out of specification. Founded in 1964 as a subsidiary 
of the Council of Europe in Strasbourg, the European Directorate for the Quality of 
Medicines and Healthcare (EDQM) aims to protect public health and ensure equal access 
to medicines and healthcare of good quality to all EU citizens by developing, harmonising, 
and monitoring quality standards for medical substances. Its main legal and scientific 
reference is the European Pharmacopoeia (Ph. Eur., fully incorporated in EU legislation 
since 1975), which is legally binding in thirty-seven states of the Council of Europe 
(including the twenty-eight EU members).63 Its governing body, the Ph. Eur. Commission 
consists of members from government, academia and industry who meet three times a 
year as well as separately in Groups of Experts and ad-hoc Working Parties. Twelve percent 
of edition 8.0 (2013) is directly related to herbs (Bouin and Wierer 2014), including 187 
herbal monographs and eighty-five herbal drug preparations. Besides laying out 
pharmacognostical and microbial testing methods, the monographs themselves typically 
cover the following sections: (1) definition (processing state of the drug, scientific name, 
sometimes minimum content of certain constituents), (2) identification (macro- and 
microscopic botanical characters, thin-layer chromatography profile), (3) purity tests 
(foreign matter, loss on drying, heavy metals, etc.), and (4) a quantitative assay (of 
therapeutically active or analytical markers). This set of parameters and the limits set to 
them sufficiently define the pharmaceutical (laboratory) quality of plants. Obviously, there 
is  ‘no modern discoƵƌƐĞǁŝƚŚŽƵƚƚŚĞĂƚŽŵŝĐĐŽŶĐĞƉƚ ? (Schwabl et al. 2013, p. 191) as applied 
in analytical chemistry, nor without the species concept and the practices of botanical 
                                                     
63 The historical emergence of pharmaceutical quality control by means of pharmacopoeial standards lies 
outside of the scope of this chapter, but is of course interwoven with the modernising projects of state 
formation, industrialisation (the dangers of mechanised mass-production) and the rise of global (supply chain) 
capitalism. Nonetheless, it is interesting to note here how doubts on the composition and later the efficacy 
of multi-ĐŽŵƉŽƵŶĚ ƉĂŶĂĐĞĂƐ ƐƵĐŚ ĂƐ  ‘ƚŚĞƌŝĂĐ ? ƐƚŝŵƵůĂƚĞĚ ŵĞĚŝĐŝŶĞ ƌĞŐƵůĂƚŝŽŶ ĂŶĚ ƚŚĞ ƐƚĂŶĚĂƌĚŝƐĂƚŝŽŶ ŽĨ
quality from the eighteenth century onwards in Great Britain (Griffin 2004). Obviously, pharmacopoeias do 
not just specify standards. Anderson (2010) for instance shows that consecutive versions of the British 
Pharmacopoeia served as an imperialist instrument in India: regulating trade in herbs and medicines in favour 
of the coloniser, promoting Western medicine while suppressing others, and infiltrating medical education. 
The historical and political-economic dimensions of the standardisation/commercialisation/ 
industrialisation/pharmaceuticalisation of Ayurvedic and Unani medicines have already been detailed by 
Bode (2008) and Banerjee (2009). 
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taxonomy (cf. Chapter 1). Nonetheless, aspects of textual Sowa Rigpa quality may still be 
incorporated. 
 
A short excerpt of an interaction between me and the most experienced analyst, Barbara, 
during an organoleptic test of PADMA 28 powder from capsules (Audio recording 46, 
translated from German) illustrates that there is still room for the same sensorial 
characteristics used by Tibetan doctors in modern laboratory quality control. Barbara was 
trained as a nurse, and started working in the lab three months before Erich arrived in 1999. 
She was initially hired to maintain the lab equipment, and then gradually took on more and 
more analytical duties.   
Barbara: You have to compare like with like. I have been working in this manner for 
years [referring to the relative positions of sample and reference]. This is 
the sample (die Probe) and this is the reference. Here we have the 
ƐƉĞĐŝĨŝĐĂƚŝŽŶ P  ‘ŚĂƌĚŐĞůĂƚŝŶĐĂƉƐƵůĞƐ ?ƚƌĂŶƐƉĂƌĞŶƚ ?ĂŶĚƐŽŽŶ ? ?zŽƵĐĂŶƚƌǇ
ŽƵƚ ŚŽǁ ŝƚ ƚĂƐƚĞƐ ? ƚŚĞ ƐĂŵƉůĞ ? ŽŶ ?ƚ ƌĞĂĚ  ?ƚŚĞ ĞǆƉĞĐƚĞĚ ƌĞƐƵůƚ ? ĨŝƌƐƚ
(laughing)! What taste (Geschmack) do you get? 
Jan: Are there not several? (I try to remember the taste and potency of camphor 
 W  PD ? ? ?ƐůĞĂĚŝŶŐƌĞĚŝĞŶƚ W according to Tibetan medicine, but remain 
in doubt.)64 
Barbara: Yes, but is it more sweet, salty, sour? Here [in the specification] it says it is 
bitter, and a bit hot. Now you can try the reference. You can take it with a 
bit of water if you like.  
Jan: ŝƚƚĞƌĐŽŵĞƐůĂƚĞƌ ?ŝƚ ?ƐŶŽƚƐĂůƚǇŽƌƐǁĞĞƚ ? 
Barbara: And not sour! You taste sour (we laugh)? Every person tastes differently, 
ďƵƚǁŚĞŶǇŽƵĚŽŝƚĂůŽƚ QtŽƵůĚǇŽƵƐĂǇƚŚĞƐĂŵƉůĞĐŽŶĨŽƌŵƐ ?dŚĞŶĐŽŵĞƐ
odour (Geruch ) ? ? Q ?/ŶŽƵƌĨŝŶished product [monograph of] PADMA 28 it 
ĂůƐŽƐĂǇƐ ‘ƚĂƐƚĞƐůŝŬĞĐĂŵƉŚŽƌ ? ?These are the gelatin capsules. I could make 
ĂŶŽƚĞ ?ŝĨŶĞĐĞƐƐĂƌǇ ? P ‘ĐĂƉƐĂƌĞŶŽƚŐŽŽĚ ? ? 
                                                     
64 According to Gyüzhi ?s famous commentary the Blue beryl P ‘ ?Đ ?ĂŵƉŚŽƌŝƐƐĂŝĚƚŽŚĂǀĞĂƉƌŝŵĂƌǇďŝƚƚĞƌƚĂƐƚĞ
with threefold combination of bitƚĞƌ ?ŚŽƚĂŶĚĂƐƚƌŝŶŐĞŶƚ ? ?ůĂƌŬ ? ? ? ? ?Ɖ ? ? ? ? ) ?ĂŵƉŚŽƌŝƐĐ ƚĞŐŽƌŝǌĞĚĂƐĂ
tree medicine, and the resin is of three types. All three treat high and chronic fevers.   
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Jan:  Can it be that the taste is not correct? 
Barbara:  Yes, in the case of the raw materials it is very important we do it. There 
could be a mistake, something else inside the bottle. I can [also] see if this 
is brown, and that is yellow. Under the microscope and with 
ĐŚƌŽŵĂƚŽŐƌĂƉŚǇǇŽƵ ǁŝůů ƐĞĞ ŝƚ ĚŽĞƐŶ ?ƚ ĐŽŵƉůǇ ? ŽƵůĚďĞ ĂǁƌŽŶŐ ůĂďĞů ?
That's ǁŚǇǁĞĂůǁĂǇƐŚĂǀĞƚŽĚŽĂůůƚŚĞƉĂƌĂŵĞƚĞƌƐ ?tĞĐĂŶŶŽƚƐĂǇ ‘ŶŽƚ
ƚŽĚĂǇ ? ? 
The importance, meaning and purpose of taste (ro) in Tibetan medicine is very different 
from its application in the situation above. Instead of an element-based carrier and 
indicator of potency, taste here is applied as a rather straightforward test  W which is clearly 
still subjective (see again Ganguly 2014)  W that helps establish the identity of single-
ingredient powders or mixtures. In this context, this assessment does not impinge on 
pharmaceutical quality sensu stricto (as defined by the presence/quantity of specific active 
substances or markers), nor on efficacy (which is not even evaluated during quality control, 
but proven before and during medicine registration). As ethnopharmacological studies 
have shown, chemosensory perception is a key criterion for the classification, selection and 
medicinal use of plants that is both individually and culturally specific, reflecting differing 
notions of illness and efficacy (Pieroni and Torry 2007, Shepard 2004). Organoleptic 
assessment is yet another instance of the enactment of a hybrid ontology of quality unique 
to PADMA.  
 
4.4.1 Quality beyond the lab: The Qualified Person, Quality Assurance and risk analysis 
The conception of pharmaceutical quality utilised at PADMA is not confined to a single 
laboratory or to laboratories in plural, including externally consulted labs where analyses 
are performed to verify parameters of physicochemical and microbiological contamination. 
More than two hundred tests need to be done in total for the quality control of one batch 
of PADMA 28. Not only each raw material (Droge), but also every active pharmaceutical 
ingredient (Wirkstoff, in powder form), and once again the powdered mixture 
(Fertigmischung) contained in the final medical product (Arzneimittel, including the 
capsules enveloped within primary and secondary packaging materials, blisters and boxes) 
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ideally have to conform to a specific list of specifications. When all necessary tests on a 
batch of finished medical product have been conducted, the results are summarised in a 
Certificate of Analysis. Yet there is another vital step before the medicines are allowed to 
be distributed and sold (i.e. released on the market): oversight and certification by a 
Qualified Person (QP). The QP indeed has to be qualified: s/he needs a relevant academic 
qualification (in the case of Erich a Masters in Biology), years of pharmaceutical experience, 
and has to pass particular training and examinations. It is Erich as an individual who is legally 
liable for bringing PADMA products on the Swiss market, a great responsibility. The decision 
to release a batch onto the market is not just a black-and-white assessment of the test 
results, but requires careful consideration. It is not difficult to imagine a case where over 
more than two hundred tests on more than twenty different ingredients, one or two 
parameters could be out of specification. A slightly elevated ash content of costus root 
powder for instance (say 10,4% instead of the specified 10,0%), indicating the presence of 
some more inorganic (soil) particles than usually allowed. This then has to be formally 
documented as a deviation and the results monitored across batches and presented to the 
regulatory authorities, but the Qualified Person can decide it has no significant effect on 
the overall quality of that particular batch of final product. This flexibility of interpretation 
is an example of where the seemingly incontrovertible pharmaceutical quality parameters 
can be re-assessed and overruled, leaving some space for more pragmatic re-definitions of 
quality in practice. This is especially important when dealing with multi-compound plant-
based products that are inherently variable. Here, the limits of standardisation are reached 
in the literal sense. Erich explained that his assessment depends on the extent of the 
deviation, the specific parameter involved, if it pertains to identity, quality or purity, on 
where in the production process the materials are, the dosage, on his knowledge of the 
raw material supplier, and so on (Audio recording 100b). The underlying logic of his decision 
is risk estimation, which brings us to another, encompassing layer of quality: quality 
assurance (QA) and risk analysis. 
 
Holger summarised his job description for me (Audio recording 63). It stated that he is 
responsible: (1) for the QA concept of the company (German QS: Qualitätssicherung) and 
the more than a thousand documents of the QA system (including SOPs, manuals, and 
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operating instructions) to manage, revise and release these, (2) to keep track of the 
developments of (inter)national guidelines and implement where appropriate and 
necessary, (3) to make sure that qualifications, validations and process analytics are carried 
out correctly, (4) for all staff GMP education, and (5) to do internal and external audits 
(commercial manufacturers and analytical labs) to assess and improve the system. Since 
the Head of QA cannot inspect himself, it is the QP (Erich) who performs this role. On top 
of that, every two years there is a general GMP inspection of the entire company by 
Swissmedic. When I asked Holger about how risk analysis is undertaken, he replied that 
every company can decide on its own how exactly it is done, but one has to adhere to the 
relevant legislation and guidelines. He opened the Eudralex website on his computer P ‘Ah, 
Pharmaceutical Quality System (Eudralex Volume 4, Chapter 1), ƚŚĂƚ ?Ɛ YƵĂůŝƚǇ ZŝƐŬ
DĂŶĂŐĞŵĞŶƚ ?. This guideline is meant to aid in the interpretation of the EU directive on 
GMP for medicinal products for human use (2003/94/EC). It clarifies the hierarchical 
inclusion of Quality Control as part of GMP, and of GMP as part of Quality Management. 
The overarching Pharmaceutical Quality System then includes Quality Management (QM) 
and Quality Risk Management (QRM). ThĞůĂƚƚĞƌŝŶƚƵƌŶŝƐĚĞĨŝŶĞĚĂƐ ‘a systematic process 
for the assessment, control, communication and review of risks to the quality of the 
medicinal product. It can be applied both ƉƌŽĂĐƚŝǀĞůǇ ĂŶĚ ƌĞƚƌŽƐƉĞĐƚŝǀĞůǇ ? (p. 8). The 
ƉƌŝŶĐŝƉůĞƐ ŽĨ YZD ĂƌĞ ƚŚĂƚ P  ‘The evaluation of the risk to quality is based on scientific 
knowledge, experience with the process and ultimately links to the protection of the 
ƉĂƚŝĞŶƚ ? ĂŶĚ ƚŚĂƚ  ‘The level of effort, formality and documentation of the quality risk 
management process is commĞŶƐƵƌĂƚĞǁŝƚŚƚŚĞ ůĞǀĞůŽĨƌŝƐŬ ?. These general definitions, 
again, still leave Holger (and by extension PADMA) with considerable freedom to devise 
ƚŚĞŝƌŽǁŶƋƵĂůŝƚǇƐǇƐƚĞŵ ?ŝ ?Ğ ?WD ?ƐŽǁŶƉƌĂĐƚŝĐĂůŽŶƚŽůŽŐǇŽĨƋƵality. Depending on the 
size and complexity of the company, risks can be assessed in different ways, as Holger 
explained to me patiently. Mistakes can happen everywhere: human failure, machine 
problems, everything. The idea is to detect which mistakes can happen where, to analyse 
their importance, and to minimise their occurrence and impact. It is based on an estimation 
of mistake prevalence, seriousness, and possibility of detection, requiring intimate 
familiarity with the processes and products involved. At one point in our conversation, 
,ŽůŐĞƌƐƚĂƚĞĚƚŚĂƚ ‘ƋƵĂůŝƚǇŝƐĞǀĞƌǇǁŚĞƌĞ ?, which prompted me to think of instances that 
would not be formally covered by the quality system (Audio recording 101). Surely, not 
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every step of each action in PADMA is laid out in Standard Operating Procedures? GMP 
relevance turned out to be the crucial category delimiting the formal boundaries of the 
Pharmaceutical Quality System. Notably, plant raw materials in crude form are not GMP 
relevant, but are governed by a separate set of regulations (Good Agricultural and 
Collection Practices) that was implemented fairly recently and is generally less stringent 
compared to GMP compliance (see also Chapter 2 on sourcing). However, as Holger 
indicated, reading legislations and guidelines is insufficient to actually know what is to be 
considered part of the system, part of pharmaceutical quality. Since he is the head of QA 
and in charge of GMP education, he needs to appeal to a higher authority for his own 
training. This is where quality definitely expands beyond the company, towards specialised 
consulting enterprises who organize in-house teaching and workshops on a variety of topics. 
They are expert at interpreting the regulations and are constantly communicating with the 
authorities to get it right. A consultant may tell you how to interpret a new guideline, 
preventing companies from doing unnecessary extra work. Pharmaceutical companies do 
not act in isolation; they are part of an elaborate network, which helps to communicate 
and maintain standards. 
 
4.4.2 Quality beyond Padma and Pharma 
In a similar vein to the layered aspects of quality already covered  W which is rather like 
opening a set of Russian Matryoshka dolls  W I can only offer a glimpse of the construction 
of pharmaceutical quality beyond PADMA. Needless to say, medical regulations and 
regulatory authorities external to the company play a definitive role in shaping quality at 
every level (see Kroes 2014 for a concise overview of the EU legal framework on the quality 
of herbal medicinal products). This does not mean however that communication and 
negotiation with authorities and consensus building within the industry do not have an 
important impact (see Chapter 6).  
 
tŚĂƚ ŚĂƉƉĞŶƐ ƚŽ WD ?Ɛ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ƋƵĂůŝƚǇ ŽƵƚƐŝĚĞ ƚŚĞ ďŽƵŶĚƐ ŽĨ ƚhe 
pharmaceutical realm? Medical doctors, pharmacists, Tibetan and complementary 
medicine practitioners and patients/consumers may define and perceive quality in their 
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own particular ways. Nonetheless, the political position taken by the biomedical 
establishment and marketing by pharmaceutical companies strongly influence public 
ƉĞƌĐĞƉƚŝŽŶƐ ?KŶĞŽĨƚŚĞŵŽƌĞƉƌĞǀĂůĞŶƚĚŝƐĐŽƵƌƐĞƐƌĞǀŽůǀĞƐĂƌŽƵŶĚƚŚĞŽƉƉŽƐŝƚŝŽŶŽĨ ‘^ǁŝƐƐ ?
ǀĞƌƐƵƐ ‘ƐŝĂŶƋƵĂůŝƚǇ ? ?KŶWĂĚŵĂ ?ƐǁĞďƐŝƚĞĂŶĚƉƌŽŵŽƚŝŽŶĂůŵĂƚĞƌŝĂůƐŝŶƚĞƌĞƐƚĞĚƉĂƌƚŝĞƐ
ǁŝůů ĨŝŶĚ ƚŚĞ ƐůŽŐĂŶ  ‘PADMA  W Tibetan formuůĂƐ ŵĂŶƵĨĂĐƚƵƌĞĚ ŝŶ ^ǁŝƚǌĞƌůĂŶĚ ?. I asked 
,ĞƌďĞƌƚ ?WD ?ƐK ?ƚŽĞůĂďŽƌĂƚĞ ?ƵĚŝŽƌĞĐŽƌĚŝŶŐ ? ? ) P 
^ǁŝƐƐŝƐĂŐŽŽĚĞǆĐƵƐĞ ?/ĚŽŶ ?ƚǁĂŶƚƚŽďůĂŵĞƚŚĞƐŝĂŶƐŝĚĞĂĐƚƵĂůůǇ ?/ĐĂŶďĞĐǇŶŝĐĂů ?ďƵƚƚŚĂƚ
is not my real nĂƚƵƌĞ ?/ƚƌǇƚŽƉƌŽŵŽƚĞƚŚĞƚŚŝŶŐƐǁĞĚŽ ?ŶŽƚƚĂůŬĂďŽƵƚǁŚĂƚƚŚĞŽƚŚĞƌƐĚŽŶ ?ƚ
do or cannot do. Is actually a very nice idea to say Tibetan medicine from Switzerland. To 
ĚŝƐƚŝŶŐƵŝƐŚƵƐĨƌŽŵŽƚŚĞƌƐǁŝƚŚŽƵƚƐĂǇŝŶŐǁŚĂƚŽƚŚĞƌƐĚŽŽƌĚŽŶ ?ƚĚŽ ?/ƚ ?ƐůŝŬĞĐŚŽĐŽůate from 
Belgium. What is special about this? But definitely chocolate from Belgium and Switzerland 
is ok, chocolate from Luxemburg. Ok!? We are from Germany, excellent. Music from Austria 
for example. Not Italian beer. Some countries are connected with certain things. 
KŶĞĐĂŶǁŽŶĚĞƌǁŚĂƚŝƐĂĐƚƵĂůůǇ^ǁŝƐƐĂďŽƵƚWD ?ƐƉƌŽĚƵĐƚƐĂŶĚǁŚĂƚŝƐŶŽƚ ?ĞŶĚŝŶŐ
up in familiar arguments on neo-traditionalism (Pordié 2008a), identity politics (Craig and 
Adams 2008) ?  ‘dŝďĞƚĂŶŶĞƐƐ ?(Saxer 2013) and the politics of naming (Hsu 2013). Even 
ƚŚŽƵŐŚWDƉƌŽĚƵĐƚƐĚŽŶŽƚĐĂƌƌǇƚŚĞƌĞŐƵůĂƚĞĚ ‘^ǁŝƐƐŵĂĚĞ ?ůĂďĞůƚŚĂƚŝƐĨĂŵŽƵƐůǇƵƐĞĚ
ĨŽƌǁĂƚĐŚĞƐ ? ‘^ǁŝƐƐŶĞƐƐ ?ĐůĞĂƌůǇƌĞŵĂŝŶƐĂŶĂƐƐĞƚ ?tŚĂƚŵĂƚƚĞƌƐŵŽƐƚƚŽWDŚŽǁĞǀĞƌ ?
is to escape scrutiny from the medical community who basically consider products from 
Asian origins to be unreliable and even dangerous.65 This prejudice is not often voiced 
ŽƉĞŶůǇ ? ƚŽ ĂǀŽŝĚ ĂĐĐƵƐĂƚŝŽŶƐ ŽĨ ĚŝƐĐƌŝŵŝŶĂƚŝŽŶ ƚŚĂƚ ŽƵŐŚƚ ƚŽ ďĞ ĂďƐĞŶƚ ŝŶ ƚŽĚĂǇ ?Ɛ
multicultural and postcolonial societies, but remains palpable also to PADMA in its dealings 
with the authorities, the medical establishment, and critical customers. On the other hand, 
the Tibetan aspect is equally emphasised on PADMA products, and can also serve 
marketing purposes for more alternative-inclined patients. Ontologies of quality and their 
enactment are entangled with identity politics. 
 
                                                     
65 The quality of Asian herbs on the European market has barely been assessed in a systematic manner (but 
see van der Valk et al., in press, for a UK survey of Chinese materia medica samples consisting of small seeds 
and fruits). Another recent survey of EU TCM practitioners indicates that the herbs used are generally safe 
(Williamson et al. 2013). See also Chapter 5, section 5.2.2, on Asian medicine poisoning schandals. 
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4.5 Men-Tsee-<ŚĂŶŐ ?ƐYƵĂůŝƚǇƐƐƵƌĂŶĐĞ>ĂďŽƌĂƚŽƌǇ 
In his historical outline of the development of Tibetan medicine in exile, Kloos (2008) 
highlights the most recent period (2004-ƉƌĞƐĞŶƚ )ĂƐďĞŝŶŐ ‘ƌĞǀŽůƵƚŝŽŶĂƌǇ ? ?dŚĞŵĂũŽƌĞǀĞŶƚƐ
marking this revolution all directly relate to issues of quality. Firstly, the Central Council of 
Tibetan Medicine (CCTM) was founded to safeguard the traditional standards of Tibetan 
medicine from unscrupulously profiteering private individuals who were blamed for several 
ŝŶĐŝĚĞŶƚƐĨŽůůŽǁŝŶŐdŝďĞƚĂŶŵĞĚŝĐŝŶĞ ?ƐŝŶĐƌĞĂƐŝŶŐŝŶƚĞƌŶĂƚŝŽŶĂůĞǆƉŽƐƵƌĞ ?ĂŶĚůĂďƌĞƐƵůƚƐŽĨ
Tibetan pills with heavy metal concentrations far exceeding European safety norms. 
SecondůǇ ?ĂǁĂ ?ƐĞůĞĐƚŝŽŶĂƐDĞŶ-Tsee-Khang director and his agenda to introduce GMP 
and a quality control laboratory to the existing pharmacy constituted a more silent but 
ƉĞƌŚĂƉƐĞǀĞŶŵŽƌĞĨƵŶĚĂŵĞŶƚĂůĐŚĂŶŐĞ ?<ůŽŽƐ ? ? ? ? ? )ĨƵƌƚŚĞƌĂƌŐƵĞƐƚŚĂƚ ‘ƚŚĞŝŵƉŽƚĞŶĐĞ
of ƚƌĂĚŝƚŝŽŶ ?ŝŶŵĂƚƚĞƌƐŽĨƋƵĂůŝƚǇĐŽŶƚƌŽů Wdue to the vices of the capitalist marketplace  W 
necessitated the help of modern science, which is itself unable to grasp or measure what it 
is supposed to save (i.e. quality in the traditional sense). A major consequence of these 
events was a double  W yet partial  W shift in authority and responsibility: away from Men-
Tsee-<ŚĂŶŐǁŚŽŝƐŶŽůŽŶŐĞƌƚŚĞƐŽůĞŐƵĂƌĚŝĂŶŽĨ^ŽǁĂZŝŐƉĂ ?ƐƌĞƉƵƚĂƚŝŽŶ ?and away from 
experienced amchi as the sole arbitrators of pharmaceutical quality. 
 
In Men-Tsee-<ŚĂŶŐ ?ƐYƵĂůŝƚǇƐƐƵƌĂŶĐĞ>ĂďŽƌĂƚŽƌǇ ?WŚƵƌƉƵĂŶĚEŽƌůŚĂĂƌĞĐƵƌƌĞŶƚůǇƚŚĞ
analysts who carry out the large majority of experiments. University graduates in their 
thirties and married mothers, they both benefitted from sponsored scholarships to pursue 
academic training in India and abroad (in biochemistry and genetics respectively) before 
settling down in McLeod Ganj. They were hired firstly by the Herbal Product Research 
Department (established in 1997), which acquired a small lab in 2002 to ensure the quality 
of the Sorig healthcare product range in accordance with the Cosmetics Act by the 
Government of India. The focus was mainly on microbiology, but also included analyses of 
water content and fatty acids on creams. During my first interview with her at the lab office 
(Audio recording 73), Phurpu explained how the small HPRD lab merged with another small 
facility specialised in microscopic plant identification (funded by the Austrian Foreign 
Ministry as part of Kletter et al. ?Ɛ (2001) project, previously attached to the herbarium at 
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the Materia Medica Department66) as it was relocated to the current premises behind the 
iron gates of the pharmacy in 2009. After moving, new instruments were purchased 
(spectrophotometer, fume hood, vortex, etc.) and from then on quality testing was 
expanded to include raw materials, herbal products as well as medicines. The influence of 
CCTM (Men-Tsee-<ŚĂŶŐ ?ƐƉŚĂƌŵĂĐǇǁĂƐŽĨĨŝĐŝĂůůǇƌĞŐŝƐƚĞƌĞĚ ?st of July 2010) and AYUSH 
(since the recognition of Sowa Rigpa in 2011)  W which both came after the new lab was 
properly installed  W  on actual quality control practices has so far been virtually non-existent. 
Once every five years there is an inspection, when the license for the Sorig products has to 
be renewed. Phurpu and Norlha shared with me that this has never raised any problems in 
the past (Audio recording 87).  
Norlha: They are quite impressed. 
Jan: I heard this also in the pharmacy, the inspectors are happy. 
Norlha: Compared to the Ayurvedic factories, ours is better. Those are very dirty. The 
maintenance in the lab is quite poor compared to us. A Jogindernagar-based lab 
also produces some Ayurveda pills. We also visited the lab there. They have quite 
up-to-date instruments, but the conditions and cleanliness inƐŝĚĞ ƚŚĞ ůĂď QƚŚĞ
hygiene. It was very dirty when we visited, that was our first impression. Although 
they do have high tech instruments like HPTLC. 
Jan: You are a centre of excellence! Why if they have better machines, more money, 
why not higher standards also? Is it due to training or mentality? 
Norlha: Maybe different mentality. Those are government-run factories, they are getting 
funds easily to buy instruments. We also visited a private one in the past two years, 
but it is very small compared to us. They produce some creams and medicines; it is 
ŽŶƚŚĞǁĂǇƚŽWĂƚŚĂŶŬŽƚ ?  ? Q ?KŶƐŽŵĞ ŝŶƐƚƌƵŵĞŶƚƐǁĞĐĂŶŐĞƚŬŶŽǁůĞĚŐĞ ĨƌŽŵ
                                                     
66 Only in 2014 Tenzin Tadzé was hired as a third researcher at Men-Tsee-<ŚĂŶŐ ?ƐůĂďto continue working on 
botanical aspects. Tadze (as he is called by friends) recently obtained his BSc in Plant Biology and 
Biotechnology at Loyola College in Chennai. He works together with Dr Tsultrim from the Materia Medica 
Department on the botanical identification and microscopic characterisation of selected Tibetan medicinal 
plants, which is intended to contribute to raw material quality monographs in the future. From the 
perspective of pharmacy doctors however, there is no real need for this aspect of modern quality control 
since they can already identify the raw materials in the field and in dried form on the market by using Tibetan 
and Hindi names. Botanical names seem to be of special interest mainly for doctors interested in 
disseminating knowledge via books to a wider audience of scientists and Western enthusiasts. See Chapter 1 
for more on issues of identification. 
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them. Like through steam they are preparing decoctions. Steam distillation. That 
ǁĞĚŽŶ ?ƚŚĂǀĞ ?ŝƚ ?ƐŬŶŽǁůĞĚŐĞǁĞĐĂŶŐĂŝŶ ? 
 
Even though the daily operation of QAL is fairly independent from the rest of Men-Tsee-
Khang  W due to the specialist technical knowhow necessary to really check what they are 
doing  W and from other external influences, the quality of the laboratory is improved 
through benchmarking with similar Ayurvedic facilities, through exchange of knowledge, 
and rarely by staff training (for example at the Shriram Institute for Industrial Research in 
New Delhi, on microbiology). On 5th of June 2013 there was also the first official inspection 
by an AYUSH-representative from Shimla. The inspector was working at the lab mentioned 
by Norlha, in Jogindernagar. In the lab visitors book he left the following note, indicating 
that the impact of AYUSH is likely to increase in times to come:  ‘Excellent facilities coming 
up. WiůůďĞ ǀĞƌǇƵƐĞĨƵů ŝŶ ƚŚĞ ĨƵƚƵƌĞ ?. Internal communication between the lab and the 
pharmacy is mainly by a Certificate of Analysis document, which indicates the batch results 
for all performed tests as well as the WHO limits for the bacterial, fungal (mould), and E. 
coli (faecal contamination) counts. A remark specifies whether the found results are within 
specification (in case of microbiology only), and if other findings such as alcohol and water 
extractive value are similar to previous batches or not. A final statement indicates whether 
the analysed batch is applicable for further use or not. Based on this, decisions are made 
ďǇƚŚĞƉŚĂƌŵĂĐǇĚŽĐƚŽƌƐŽŶŚŽǁƚŽƉƌŽĐĞĞĚ ?ĐĐŽƌĚŝŶŐƚŽƚŚĞ ůĂď ?ƐƐĂŵƉůĞƌĞŐŝƐƚƌĂƚŝŽŶ
book covering the financial year 2013-2014 (starting in April), more than 400 samples were 





Figure 4.3. The final step in the determination of the alcohol extractive value of gurgum (here identified as Carthamus 
tinctorius L.). Norlha is weighing the dish with the dried extract, and Phurpu writes down the result and then calculates 
the percentage (photograph taken on 23 April 2014). 
 
A full-fledged pharmaceutical quality system (including SOPs, a Qualified Person, and risk 
analyses, as at PADMA) is not formally implemented at Men-Tsee-Khang, even though the 
more practical aspects of GMP are mostly carried out. In the lab, the analysts follow in-
house protocols and write down the results in logbooks before transferring these into 
spreadsheets. Since no conventional, scientific Tibetan pharmacopoeia is available (only 
classical materia medica texts and contemporary interpretations), they have to rely on 
other authoritative publications such as the Ayurvedic Pharmacopoeia and related books 
published by institutes affiliated to the Government of India (foremostly the Quality 
Standards of Indian Medicinal Plants and Database on Medicinal Plants in Ayurveda series). 
Based on this, Phurpu and Norlha have started constructing uniquely Tibetan quality 
monographs for all medicines produced at Men-Tsee-Khang. So far, draft monographs have 
been printed for about thirty commonly used formulas (2010, volume I and II) and eight 
precious pills have also been covered (2011). Each monograph commences with a 
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photograph of the medicine and its name in Tibetan, and then describes the average values 
obtained (no binding limits are specified yet, except for microbiology) for the following list 
of parameters: description (colour, weight, pill diameter, and hardness), moisture (of 
powder and pill form), physicochemical tests (total ash, acid and water soluble ash, alcohol 
and water extractive values), phytochemical constituents (presence/absence of volatile oil, 
alkaloids, carbohydrates, tannins, and protein), microbiology (total bacterial and fungal 
counts, E. coli), and TLC (under different visualisation and solvent systems, with separation 
values). In the appendices, the applied materials, methods and calculations are described 
in detail. When comparing TLC fingerprints from different batches of the same medicine, 
one can visually observe inter-batch variability (and possibly detect adulteration). 
Nevertheless, without the use of marker compounds or further quantitative analysis, it is 
difficult to determine the cause and extent of this variation. Moreover, the phytochemical 
tests performed at Men-Tsee-Khang are qualitative, making it impossible to detect (and 
thus standardise) variation in the concentration of what supposedly should be the active 
compounds. The analysts are well-aware of these limitations, and of the difficulties of 
analysing multi-compound herbal products. QAL is restricted by a lack of funds in 
purchasing the necessary chromatographic instrumentation to quantify individual 
compounds (HPLC, see section 4.3 above), and does not pay external labs to search for 
heavy metal, aflatoxin, and pesticide contamination. Phurpu summarised what she 
considered to be currently some of the most important contributions of laboratory quality 
control (Audio recording 73):  
Earlier the Tibetan doctor used to check whether pills were dry or not by crushing them with 
ƚŚĞƚĞĞƚŚ ?ƚƚŚĂƚƚŝŵĞ ?ƚŚĞǇĚŝĚŶ ?ƚŚĂǀĞĂŵŽŝƐƚƵƌĞĂŶĂůǇƐĞƌ ?EŽǁƚŚĞǇĂƌĞƐĞŶĚŝŶŐƐĂŵƉůĞƐ
to us, we actually check the moisture content by using the moisture analyser. We are getting 
accurate results. Every morning they are giving samples to us, to check whether it is dry or 
ŶŽƚ ? ? Q ?ĂƌůŝĞƌǁĞƵƐĞĚƚŽĨĂĐĞƚŚĞƉƌŽďůĞŵŽĨĨƵŶŐĂůĐŽŶƚĂŵŝŶĂƚŝŽŶ ?ŝŶdŝďĞƚĂŶŵĞĚŝĐŝŶĞ ?
ůŽŶŐďĂĐŬ ?ďĞĐĂƵƐĞƚŚĞǇĚŝĚŶ ?ƚŚĂǀĞƚŚĞŵŽŝƐƚƵƌĞĂŶĂůǇƐĞƌ ?dŚĞƐƚƌĞŶŐƚŚŽĨƚĞĞƚŚǀĂƌŝĞƐĨƌŽŵ
ƉĞƌƐŽŶƚŽƉĞƌƐŽŶ ? ŝƚĐĂŶ ?ƚŐŝǀĞƚŚĞĞǆĂĐƚǀĂůƵĞ ?dŚĞǇĨĂĐĞĚĂ ůŽƚŽĨƉƌŽďůĞŵƐ ?EŽǁŝƚ ŝƐŶŽ
ůŽŶŐĞƌ ƚŚĞƌĞ ?  ? Q ? ĐƚƵĂůůǇ ? ƐŽŵĞƚŝŵĞƐ ǁĞ ĂƌĞ ŐĞƚƚŝŶŐ ŵĞĚŝĐŝŶĞ ƐĂŵƉůĞƐ Ĩrom the branch 
clinics. They are sending the samples to us, [to know] whether the pills are applicable for 




The most radical change compared to pre-laboratory times is the attention to micro-
organisms, and how this relates to drying and storage. In these aspects, the laboratory 
analysts have truly become the new authority since there are clearly defined limits to which 
the samples must adhere. The creation of quality control monographs adapted to Tibetan 
medicine is also innovative, but what is even more remarkable is the sensitivity and 
humbleness with which the analysts have approached the definition of new standards. 
They are themselves Tibetan, respectful towards Sowa Rigpa, and their power is curbed by 
experienced pharmacy doctors. Phurpu and Norlha have not merely copied specifications 
from Chinese or Indian sources (even though in general the results fall within the limits set 
for Ayurveda), but have been empirically recording the values they obtain at their lab since 
more than five years. Instead of enforcing unsuitable and rigid definitions of quality, these 
findings will actually make it possible to attend to the variability inherent to Tibetan 
medical production at Men-Tsee-Khang. For instance, results show that some pills are 
inherently less hard or more humid compared to others, and that depending on local 
weather conditions the moisture content is also significantly affected. If and when the 
averages obtained will be transformed into limits, care will be taken to make them realistic 
and feasible, with an underlying rationale as to why the limits were chosen in the first place. 
Y> ?ƐĐŽŶĐĞƉƚŝŽŶŽĨƋƵĂůŝƚǇŝƐŝŶĨůƵǆ ?ĂƐŝƐWD ?Ɛ.
 
ŽŵŝŶŐ ďĂĐŬ ƚŽ <ůŽŽƐ ?  ? ? ? ? ? ) ĂƌŐƵŵent, it would be appropriate to describe the 
introduction of laboratory quality control as part of Men-Tsee-<ŚĂŶŐ ?Ɛ ƉŚĂƌŵĂĐǇ as a 
 ‘silent revolution ? and not merely as ornamental, or a political tool to prove the scientificity 
of Sowa Rigpa. I partly disagree however with how this revolution was portrayed by him. 
<ůŽŽƐ ? ? ? ? ? ?Ɖ ? ? ? ? )ŵĂŝŶƚĂŝŶƐƚŚĂƚ ‘the preservation of Tibetan medicine is nothing but the 
ƉƌĞƐĞƌǀĂƚŝŽŶŽĨŝƚƐĞĨĨŝĐĂĐǇ ?, that fluctuations in efficacy were deemed problematic by Men-
Tsee-Khang doctors (especially when observed in the context of a diabetes clinical trial in 
1997), and that modern science had to come in to eradicate this variability between 
batches through standardisation enforced by a newly installed lab. If it is true that their 
centƌĂůĐŽŶĐĞƌŶŝƐ ‘the stanĚĂƌĚŝǌĂƚŝŽŶŽĨŵĞĚŝĐĂůĞĨĨŝĐĂĐǇ ?, I do wonder how this can be 
pulled off by the QAL given the impotence of science to grasp traditional notions of potency 
of Tibetan formulas. The lab cannot regulate, standardise or even measure the efficacy of 
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dŝďĞƚĂŶ ŵĞĚŝĐŝŶĞƐ ĚŝĂĐŚƌŽŶŝĐĂůůǇ ? dŚĞ  ‘ƐƚĂŶĚĂƌĚŝƐĂƚŝŽŶ ŽĨ ĞĨĨŝĐĂĐǇ ? ŝƐ Ă ŵŝƐŶŽŵĞƌ ?
Laboratory tests check the identity, purity, and quality of samples, not their efficacy. This 
is especially the case for Men-Tsee-Khang, where the supposedlǇ ‘ĂĐƚŝǀĞ ?ĐŽŵƉŽƵŶĚƐĂƌĞ
not isolated nor quantified or standardised. Instead, quality is redefined and enacted in 
practice in specific places and by specific people, rendering obsolete the need to fall back 
to the reified modern/traditional dichotomy. The analysts at Men-Tsee-<ŚĂŶŐ ?ƐůĂďŽƌĂƚŽƌǇ
have been attuned to the variability in and between medicines, and do not condemn it.  
ĞƌƚĂŝŶĂƐƉĞĐƚƐŽĨdŝďĞƚĂŶŵĞĚŝĐŝŶĞŵŝŐŚƚďĞ  ‘ďĞǇŽŶĚƐĐŝĞŶĐĞ ? ?ďƵƚƚŚĂƚĚŽĞƐŶŽƚŵĞĂŶ
ƚŚĂƚƉĞŽƉůĞŝŶůĂďŽƌĂƚŽƌŝĞƐŚĂǀĞŶ ?ƚƚƌŝĞĚtheir best to close the gap and accommodate these 
differences by creating hybrid ontologies of quality. 
 
4.6 Qualities in the pluriverse as ontological hybrids 
quality, n. 
With reference to a thing: 
- An attribute, property; a special feature or characteristic  
In early medical use [from the thirteenth century or earlier, in Anglo-Norman] 
synonymous with humour, n. In ancient and medieval physiology and medicine: any of 
four fluids of the body (blood, phlegm, choler, and so-called melancholy or black bile) 
believed to determine, by their relative proportions and conditions, the state of health 
and the temperament of a person or animal. In early use also: any of the four qualities 
(hotness, coldness, dryness, and moistness) believed to be associated with these 
- Originally: the nature, kind, or character (of something). Later [seventeenth century 
onwards, initially with reference to merchandise]: the standard or nature of something 
as measured against other things of a similar kind; the degree of excellence possessed by 
a thing.  
Compare quantity, n., with which the word is frequently contrasted. 
Adapted from the online Oxford English Dictionary, Third Edition 
 
The abridged dictionary excerpt above indicates that in English vernacular language the 
ŵĞĂŶŝŶŐŽĨƚŚĞŶŽƵŶ ‘ƋƵĂůŝƚǇ ?ŝŶƌĞůĂƚŝŽŶƚŽƚŚŝŶŐƐŚĂƐƐŚŝĨƚĞĚĨƌŽŵĚĞŶŽƚŝŶŐĂŶĞƐƐĞŶƚŝĂů
property or character (as in medieval humoral medicine), towards an inherently 
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comparative as well as measureable concept carrying with it a clear value judgement 
(originally in an economic sense): good or bad quality of goods. What is quality? Laboratory 
analysts directed me towards state pharmacopoeias and in-house monographs that 
provide a set of parameters and specifications (often in the form of limits) to be upheld. In 
this respect, quality can be said to be measurable both by qualitative and quantitative 
means. By various tests and with the help of analytical equipment, ingredients and 
compounds are identified, their purity checked, and important active or marker 
compounds determined in assays (quality in the narrowest sense). These quality control 
methods are not only inherently comparative, relying on chemical standards or reference 
samples as a baseline, but they also visualise only a tiny window within the physicochemical 
spectrum that constitutes complex multi-compound and multi-ingredient mixtures. This 
quality concept is clearly not all-encompassing. Many aspects will remain unknown or even 
unknowable, even to modern science. The question then becomes what has to be 
controlled legally. What is actually checked, but more pressingly: what is not? To what 
extent can quality control capture or (mis)represent the nature of medical substances? 
 
 For the Qualified Person, who holds the final (and juridical) responsibility for the safety, 
quality, and efficacy of products released on the market by a pharmaceutical company, 
these questions are equally pertinent. This person has the power to decide based on the 
data available and their own knowledge and experience: a meta-assessment or 
qualification of the quality controls. Market-releasable quality then becomes a semi-
subjective decision where trust in the analysts and techniques involved as well as a 
consideration of risk are brought to the fore. We enter the domain of the Quality Assurance 
Officer, whose activities of risk analysis, management and mitigation span across all 
departments and beyond. From general health and safety measures, over staff education 
on proper cleaning, maintenance, and documentation, to external inspections of suppliers. 
The quality of Quality Assurance is everywhere. It is a system designed to reduce all sorts 
of risks for consumer/patients, staff, as well as potential economic losses. Yet quality can 
be traced even further outside of the lab and the company and its supply chain within the 
pharmaceutical production realm. Not merely because of the existence of other industrial 
Good Practices (GxPs) like GACP (Good Agricultural and Collection Practices), GDP (Good 
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Distribution Practices), GVP (Good Pharmacovigilance Practices), and so on, but more 
fundamentally because of the wider networks of competition, exchange, training, and joint 
consensus and policy building in which suppliers, producers, consultants, and state 
departments are involved. Quality at any of these levels cannot be interpreted or 
(re)defined in isolation. Pharmaceutical quality is an amalgam of multiple concepts, it is 
multi-layered but also cross-cutting and reaches far beyond legally binding documents. In 
ƐŚŽƌƚ ?ĂďƐƚƌĂĐƚ ‘ƋƵĂůŝƚǇ ?ŝƐƵŶŬŶŽǁĂďůĞĞven to laboratory science. 
Quality as such is not an isolated concept. This is the article my wife wrote in this journal 
(Schwabl and Gämperle, 2013). There is not a single test, it is a concept. GMP is a concept. It 
is never the measurement. Every single measurement is needed for establishing the quality, 
but not in a way that you do one measurement and then have established everything. How 
you purchase, do you know the people, do you know the methods, apply them in a regular 
way, which methods. A cascade of different events. This establishes quality. You cannot 
measure quality as such. You cannot therefore simply say they do five tests and then you 
have the quality. It is also risk-based; first you have to make an analysis of the risks. It's a risk 
analysis. What are the potential risks you have with a certain ingredient or process? A better 
risk analysis gives a better concept. Just doing measurements because one is obliged to do it 
ŝƐŵŽƐƚƐƚƵƉŝĚ ?ŝƚ ?ƐŚŽǁƚŚĞǇĚŽŝƚŝŶŚŝŶĂ ?ƐǇŽƵŬŶŽǁĨƌŽŵĂŶĂůǇƚŝĐƐ ?you only find that 
ǁŚĂƚǇŽƵĂƌĞůŽŽŬŝŶŐĨŽƌ ? ‘/ƐƚŚĞƌĞŶŽƉĞƐƚŝĐŝĚĞŝŶƐŝĚĞ ? ?&ƌŽŵĂƐĐŝĞŶƚŝĨŝĐƉŽŝŶƚŽĨǀŝĞǁƚŚŝƐŝƐ
an unanswerable question, first define what is a pesticide. On a worldwide list there might 
be hundreds or thousands of different chemical substances. One can only look for the most 
ƉƌŽŵŝŶĞŶƚŽŶĞƐ ?tŚŽǁŝůůƉĂǇĨŽƌůŽŽŬŝŶŐĨŽƌƚŚĞƐƚƌĂŶŐĞƐƚŵŽůĞĐƵůĞƐ ? ? Q ?dŚĞ ?ƵƌŽƉĞĂŶ ?
Pharmacopoeia prescribes certain analytical methods, but you have to validate the method. 
You have to challenge your method. You cannot just buy a kit at Merck and do one test and 
ƐĂǇ ?/ĚŝĚŶ ?ƚĨŝŶĚĂŶǇƚŚŝŶŐ ? ?dŚĂƚŝƐĂŐĂŝŶƵƐĞůĞƐƐ ?WDŝƐĞŵďĞĚĚĞĚŝŶĂŶĞŶǀŝƌŽŶŵĞŶƚ ?/ƚ
 ?ŝ ?Ğ ?ƋƵĂůŝƚǇ ?ŝƐĂŵĂĐŚŝŶĞƌǇ ?dŚĞƐŝŵƉůĞĂŶƐǁĞƌƚŽ ‘ĚŽǇŽƵĚŽƚŚŝƐƚĞƐƚ ? ?ŝƐ P ‘ǇĞƐ ?ǁĞĚŽ ? ? ?Ƶƚ ?
[y]ou have to understand the concept. (Herbert Schwabl, 9 July 2013, Audio recording 9) 
 
What ĂďŽƵƚ  ‘ƋƵĂůŝƚǇ ?ŝŶdŝďĞƚĂŶ medicine? Firstly, this word is commonly used in English 
translations of Tibetan pharmacological categories such as nüpa gyé (the eight powers or 
types of potency of medicines, sometimes called primary qualities), yönten chudün (the 
seventeen attributes or secondary qualities), and ngowo (the essence or natural quality of 
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a specific substance) (see for instance Drungtso and Drungtso 2005, Gonpo 2008). Quality 
refers here to certain inalienable characteristics of objects, corresponding to the older, 
humoral dictionary definition introduced above. Secondly, when mentioning GMP to Men-
Tsee-Khang doctors involved in the production of medicines, they will point out that 
Gyüdzhi (volume IV, chapter 12) contains its own guidelines to ensure that (particularly 
herbal) medicines have the optimal qualities: yenlak dün, sometimes rendered by amchi as 
the Seven essential limbs of standardisation. GMP and yenlak dün can correspond, or at 
least do not necessarily exclude or contradict one another (as elaborated by Saxer 2013).67 
Thirdly, Gyüdzhi (volume II, chapter 31) also enumerates the six qualities (or prerequisites) 
of eminent physicians, which are founded on Mahayana Buddhist ethics. As I have indicated, 
<ůŽŽƐ ? ? ? ? ? )ĂƌŐƵĞƐƚŚĂƚdŝďĞƚĂŶŵĞĚŝĐŝŶĞ ?ƐĞǆƉŽƐƵƌĞƚŽĐůŝŶŝĐĂůƚƌŝĂůƐĂŶĚƚŚĞǀŝĐĞƐŽĨƚŚĞ
marketplace instigated the need for laboratory quality control at Men-Tsee-Khang as 
Buddhist ethics and textual ideals proved incapacitated. This credible standardisation 
discourse notwithstanding, I showed that what is actually taking place in the QAL does not 
greatly increase the homogeneity within or between batches of medicine  W so far variability 
is merely documented, not erased  W  except in terms of moisture content and microbial 
counts. Similarly, when dealing with complex processed plant-mineral assemblages that 
are not fully knowable scientifically, standardisation at PADMA is not a matter of fact but a 
matter of degree where the compliance of each batch has to be risk-assessed individually 
before being released onto the market. Men-Tsee-Khang only started formally assessing its 
medicines using modern laboratory standards in 2009, but this is still secondary to the 
traditional checks and the final decisions are still taken by Tibetan doctors. It seems that 
both companies adhere to the idea of complementarity, while disagreeing on priorities. By 
paying attention to what happens inside (the labs of) firms as part of more encompassing 
reformulation regimes (as suggested by Pordié and Gaudillière 2014a) through a practical 
ontological lens, I was able to tease out dissonances between narratives and actions as well 
ĂƐƋƵĞƐƚŝŽŶƚŚĞƌĞŝĨŝĐĂƚŝŽŶŽĨ ‘ƚŚĞŽƌǇ ?ǀĞƌƐƵƐ ‘ƉƌĂĐƚŝĐĞ ? ? 
 
                                                     
67 The Tibetan Seven Limbs procedure is comparable to the Chinese medical quality concept of dao di, defined 
ďǇŚĂŽĞƚĂů ?  ? ? ? ? ? ?Ɖ ?  ? ? ? )ĂƐ  ‘medicinal material that is produced and assembled in ƐƉĞĐŝĮĐ geographic 
regions with designated natural conditions and ecological environment, with particular attention to 
cultivation technique, harvesting and ƉƌŽĐĞƐƐŝŶŐ ? ? 
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Geoffrey Samuel (2006) suggests that it is useful to make a general distinction between 
practical medical situations on the one hand and concerns about theoretical and 
epistemological underpinnings on the other when considering the interface of Asian 
scholarly medical traditions with biomedicine. The former are characterised by hybridity in 
presentation and practice, medical pluralism and pragmatic decisions by patients and 
practitioners, whereas paradigmatic conflicts more often surface when politics of 
(il)legitimation are mobilised (as epitomised in clinical trials; see Adams 2002, Adams et al. 
2005, Witt et al. 2012 for Sowa Rigpa). Although analytically satisfying, I contend that this 
distinction conceals that the performance of hybrid knowing practices (Farquhar 1994) 
distorts their conceptual underpinnings, even if the Four Tantras are ostensibly unaltered. 
Coming from a posthuman ontographic perspective and following Jensen (2004), ways of 
knowing are instantaneously seen as specific ways of constructing realities, collapsing 
epistemology into the enactment of practical ontologies. Quality control is not a mere act 
of observation or representation of inherent qualities in comparison to idealised references, 
but rather a localised intervention that builds on relations with new sociotechnical 
elements. I am sympathetic to ĚĂŵƐĞƚĂů ? ?Ɛ(2011b)  ‘^ŽǁĂZŝŐƉĂƐĞŶƐŝďŝůŝƚǇ ?ǁŚŝĐŚƌĞǀĞĂůƐ
the translation efforts that may lead to  ‘a culturally Tibetan way of doing science ? (ibid., p. 
23), mapping the multidirectional flows of ideas and practices and their local adaptations 
from the epistemological perspective of Tibetan medicine. But again, even though this 
statement grants agency to medical practitioners (who are not present in the labs) this 
perspective cannot incorporate or explain the hybrid qualities I came across at Men-Tsee-
Khang and PADMA. What quality and (Tibetan) science is, is itself transformed by 
laboratory practices, reconfiguring (Tibetan) onto-epistemologies and knowledge/practice. 
Adopting a constructivist-relativist epistemology which espouses fundamental 
incommensurability, some scholars of Chinese medicine have rejected the application of 
biomedical standards as flawed reductionism (Fan 2003, Fan and Holliday 2007). In her 
literature review on this topic, however, Shea (2006) maintains that adopting dual 
ƐƚĂŶĚĂƌĚƐŝƐĂŶƵŶƌĞĂůŝƐƚŝĐĂůƚĞƌŶĂƚŝǀĞŝŶƚŽĚĂǇ ?ƐƌĞŐƵůĂƚŽƌǇƌĞĂůŝƚǇ ?The perceived difference 
between ƚŚĞƐĞƐǇƐƚĞŵƐŝƐĞǆĂŐŐĞƌĂƚĞĚĂŶĚďĂƐĞĚŽŶĂŶŽǀĞƌƐŝŵƉůŝĨŝĐĂƚŝŽŶŽĨ ‘ƚƌĂĚŝƚŝŽŶĂů
ChinĞƐĞ ŵĞĚŝĐŝŶĞ ?  ?ďĂƐĞĚ ŽŶScheid 2002, see also Samuel 2006 for Sowa Rigpa). 
Recognising the plurality, emergent syntheses of knowing practice (Scheid 2002) as well as 
the alternative modernities (Hsu 2009) ĂŶĚƚƌĂŶƐŶĂƚŝŽŶĂů ‘ǁŽƌůĚŝŶŐ ?(Zhan 2009) of Asian 
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medicines, the production of good quality Tibetan medicines can be understood as more 
than either a pharmaceutical or Tibetan medical endeavour.  
 
PADMA and Men-Tsee-KhĂŶŐ ?ƐůĂďƐĂƌĞƉůĂĐĞƐǁŚĞƌĞpharmaceutical and Tibetan qualities 
intersect and mingle. Following Ganguly (2012), scientific experts and their knowledge-
about-ƋƵĂůŝƚǇ ĂƌĞ ĐůĞĂƌůǇ ƉƌŝǀŝůĞŐĞĚ ŽǀĞƌ  ‘ƚƌĂĚŝƚŝŽŶĂů ? ƉƌĂĐƚŝƚŝŽŶĞƌƐ ĂŶĚ ƉƌĂĐƚŝĐĞƐ ŝŶ ĂŶǇ
laboratory setting. But that is not the end of the story. In making quality measurable in the 
lab, we have to attend to what is actually being measured and what this is supposed to 
stand for. What is quality? This is where an ontographical approach proves fruitful. PADMA 
and Men-Tsee-Khang are involved in the creation of local, practical ontologies of quality. In 
rendering these efforts into ethnography, I have aimed to implement Lynch's (2013) 
ontography approach. However, even though particular constructions of quality can be 
situated within these laboratories and historicised, I also show that ideas and practices can 
travel. Thus, the ontological frameworks I observed are not only locally anchored, but also 
fluid and in partial overlap with other ontologies. There is an ongoing struggle to increase 
the partial overlap between pharmaceutical science and Sowa Rigpa, wherein 
standardisation plays a central role. Nevertheless, notions of quality do not remain fixed. 
dŚĞǇŶĞǀĞƌŚĂǀĞ ?dŚĞƉƌĞƐƵŵĂďůǇŝŶĚĞƉĞŶĚĞŶƚ ?ƌĞŝĨŝĞĚ ‘ŵŽĚĞƌŶ ?ĂŶĚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ƋƵĂůŝƚǇ
standards are themselves intercultural to begin with as they are constantly reinterpreted 
and re-enacted in specific spatiotemporal and sociopolitical contexts, often by people who 
are conscious but careful neo-traditionalists (see Pordié 2008, p. 9-19, for its characteristics 
and application to Tibetan medicine). Surely, heavy contamination with pesticides cannot 
be condoned by even the staunchest traditionalist amchi, once they have been made aware 
of the problem. Does this then count as a new ontology of quality, or a modification of a 
much older one based on cŽŵƉĂƐƐŝŽŶ ? / ǁŽƵůĚ ƐĂǇ ŝƚ ?Ɛ ŝŶ ƚŚĞ ŵŝǆ ? dŚĞ ďŽƵŶĚĂƌŝĞƐ ŽĨ
ontological frames are fluid and therefore hybrid. Quality is continuously redefined and 
hopefully reinvigorated at and in-between PADMA and Men-Tsee-Khang as they rework 
the interface between differing scientific ontologies, creating uniquely Tibetan alternative 





PART III  


















5 Garuda-5:  




My attention was initially drawn to Garuda-5 by coincidence. I came across the 
unmistakable shiny, little black pills known in Tibetan as khyung-nga while assisting in some 
manual work at Men-Tsee-<ŚĂŶŐ ?ƐPharmaceutical Department on a sunny Monday 
morning (Diary, 14 April 2014). Amchi Tenzin Thaye and Penpa were at their office, and 
several junior doctors were also there chatting. I asked Penpa, my main contact here 
appointed by the Director, what was going on at the moment and was accompanied to the 
packaging section. I was introduced to two middle-aged Tibetan women and a young 
Tibetan man with a single Tibetan sentence. Penpa left, and the young Tibetan guy called 
Karma, whose English was very good, helped me to start. I first needed a square cushion to 
sit on the floor around the blanket on which thousands of tiny black pills were piled up. I 
put the blanket over my knees and lap, and was given one of the ingeniously designed pill 
counting tools made of stainless steel (Figure 5.1). Karma said some doctors had once 
instructed them to test the potency of the Garuda-5 pills by keeping them in their mouth. 
Trying a few together, several workers felt a burning sensation and some also dizziness. 
Before he came here, Karma did not have much knowledge of Tibetan medicine. Now that 





Figure 5.1. Counting Garuda-5 (khyung-nga) pills together in the packaging section of Men-Tsee-<ŚĂŶŐ ?Ɛ
Pharmaceutical Department (14 April 2014). 634 kg was compounded on February 27th and stored in more than ten 
large bags. It will take up to four or five months of work  W in between other jobs  W to count all of these pills because 
they are so small. 
 
This chapter revolves around one Tibetan medical formula that is produced by both Men-
Tsee-Khang and PADMA: Garuda-5 (khyung-nga ) ?dŚŝƐŵĞĚŝĐŝŶĞ ?ƐĞĨĨŝĐĂĐǇ ŝƐĚƵĞ ŝŶ ůĂƌŐĞ
ƉĂƌƚ ƚŽ Ă ƉĂƌƚŝĐƵůĂƌůǇ ƉŽƚĞŶƚ ŵĞĚŝĐŝŶĂů ƉůĂŶƚ ǀĂƌŝŽƵƐůǇ ĐĂůůĞĚ  ‘ďůĂĐŬ ĂĐŽŶŝƚĞ ?  ?bongnak), 
 ‘ǀŝƌƵůĞŶƚƉŽŝƐŽŶ ? ?tsenduk )Žƌ ‘ƚŚĞŐƌĞĂƚŵĞĚŝĐŝŶĞ ? ?menchen) and equated with a variety of 
Aconitum species. Its strong potency, however, is potentially dangerous or even deadly. 
How can these poisonous plants be used in medicine, or conversely: when does a medicine 
become a poison? How can ostensibly the same substance be both harmful and helpful? 
These questions beg a more nuanced explanation than mere dose-ĚĞƉĞŶĚĞŶĐǇ ? ‘dŚĞĚŽƐĞ
ŵĂŬĞƐ ƚŚĞ ƉŽŝƐŽŶ ?68  is the famous adage formulated by the sixteenth-century scholar 
                                                     
68  ?Sola dosis facit venenum ‘ ?ŽƌŝŶƚŚĞ'ĞƌŵĂŶƚƌĂŶƐůĂƚŝŽŶ P ?Alle Dinge sind Gift und nichts ist ohne Gift, allein 
die Dosis macht es, dass ein Ding kein Gift ist. ‘(Paracelsus 1538, p. 510). The universal validity of this tenet is 
also increasingly being challenged by toxicologists, particularly in the light of the chronic toxicity of endocrine-
disrupting contaminants, which turns out not to be predictable based on dose-response curves (Myers et al. 
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Paracelsus (1493-1541) whose ideas lie at the foundation of modern toxicology. Dosage 
does plays a vital role in the biomedical evaluation of toxicity, and in the formulation and 
prescription of Tibetan medicines, as will be shown below. Yet I argue that attending to the 
ďƌŽĂĚĞƌ  ‘ĞĐŽůŽŐŝĞƐŽĨ ƚŽǆŝĐŝƚǇ ? ŝŶ ǁŚŝĐŚ ƚŚĞƐĞ ĂƌĞ ĞŶŵĞƐŚĞĚ ? ŝŶ ůŝŶĞ ǁŝƚŚ ^ŝĞŶŶĂ ƌĂŝŐ ?Ɛ
(2012) Efficacy and the Social Ecologies of Tibetan Medicine, provides fertile ground for 
better understanding the variable effects of khyung-nga and of potent substances in 
general. I aim to unpack the opposition between men and duk in Sowa Rigpa by elucidating 
the multiple and partially overlapping dimensions which determine the activity of the 
Garuda- ?ĨŽƌŵƵůĂ ?/ƚŚƵƐĞǆƉĂŶĚƌĂŝŐ ?ƐĂƉƉƌŽĂĐŚƚŽŝŶĐůƵĚĞƚŚĞfull spectrum of potency 
 W ƚŚĞ  ‘ŐŽŽĚ ? ĂŶĚ ƚŚĞ  ‘ďĂĚ ? ? ƚŚĞ  ‘ǁĂŶƚĞĚ ? ĂŶĚ ƚŚĞ  ‘ƵŶǁĂŶƚĞĚ ?  Wwithout presuming the 
universal validity of biomedical notions of toxicity, side effects and risk, by turning to 
anthropological conceptions of the body. 
 
Medical anthropologist Margaret Lock (1993) ĐŽŝŶĞĚ ƚŚĞ ƚĞƌŵ  ‘ůŽĐĂů ďŝŽůŽŐŝĞƐ ? ŝŶ ŚĞƌ
seminal comparative ethnography on American and Japanese understandings and lived 
experiences of menopause. With this, Lock sought to prevent Euro-American hegemonic 
biomedical discourse from marginalisŝŶŐ:ĂƉĂŶĞƐĞǁŽŵĞŶ ?Ɛbodies as anomalous exotica 
and to challenge the medicalisation of the end of menstruation. Moving beyond the narrow 
purview of ethnomedicine as well as meaning-centred analyses, Lock saw the need early 
on to transcend the nature/culture dichotomy and to question the epistemologically 
ƵŶƚŽƵĐŚĂďůĞ ƉŽƐŝƚŝŽŶ ŽĨ ďŽƚŚ ƚŚĞ ŚƵŵĂŶ ďŽĚǇ ĂŶĚ ƚŚĞ ŵĞĚŝĐĂů ƐĐŝĞŶĐĞƐ ĂƐ  ‘ŶĂƚƵƌĂů ?
categories. In a later review of the development of medical anthropology she summarised 
this key concept as follows: 
[It] does not refer to the idea that the categories of the biological sciences are historically 
and culturally constructed (although this is indeed the case) nor to measurable biological 
difference across human populations. Rather, local biologies refers to the way in which the 
embodied experience of physical sensations, including those of well-being, health, illness, 
and so on, is in part informed by the material body, itself contingent on evolutionary, 
environmental, and individual variables. [ Q ?/ŶŽƚŚĞƌǁŽƌĚƐ ?ƚŚĞďŝŽůŽŐŝĐĂůĂŶĚƚŚĞƐŽĐŝĂůĂƌĞ
                                                     
2009). Other research points out that timing is also a crucial factor in the metabolism and detoxification of 
drugs (Gachon and Firsov 2011). 
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coproduced and dialectically reproduced, and the primary site where this engagement takes 
ƉůĂĐĞ ŝƐ ƚŚĞƐƵďũĞĐƚŝǀĞůǇĞǆƉĞƌŝĞŶĐĞĚ ?ƐŽĐŝĂůŝǌĞĚďŽĚǇ ?   Q ?dŚĞŵĂƚĞƌŝĂůĂŶĚƚŚĞƐŽĐŝĂůĂƌĞ
both contingent  W both local. (Lock 2001, p. 483-484) 
Local biologies are embodied, contingent, and coproduced, simultaneously steering clear 
of the essentialising extremes of genetic determinism and cultural constructivism of our 
bodies and the impinging medical practices. Lock and Farquhar (2007) expanded on this by 
setting the agenda for an anthropology of embodiment and material life Beyond the Body 
Proper, beyond the object-body as the lesser pole of Cartesian mind-body dualism. Instead 
and inspired by phenomenology, everyday lived and socialised bodies take centre stage. 
More recently, Brotherton and Nguyen (2013) specified the usefulness of this approach: 
biology (and biomedicine) can be taken seriously  W not merely as representation or 
ideology  W necessitating ethnographic sensitivity to the lived experiences of people, which 
in turn makes it possible to subvert dominating paradigms through critical engagement. 
This is also the approach of this chapter, and the multi-sited nature of this thesis equally 
paƌĂůůĞůƐ>ŽĐŬ ?ƐƉŝoneering work.  
 
I am certainly not the first to pay attention to the import of local biology and lived bodies 
ĨŽƌƐŝĂŶƐĐŚŽůĂƌůǇŵĞĚŝĐŝŶĞƐ ?/ŶƚŚĞƐĞĐƚŝŽŶŽŶĐŽůŽŶŝƐĞĚďŽĚŝĞƐŽĨ>ŽĐŬĂŶĚ&ĂƌƋƵŚĂƌ ?Ɛ
volume  W whose work has itself focused on Japanese and Chinese traditions respectively  W 
Jean Langford discusses how doctors in contemporary Ayurvedic hospitals both work with 
and contest the disciplined, docile modern anatomical body, allowing for moments of 
slippage in which the dosic body overflows somatic borderlines. This dosic body is  
a fluent body, coursing with climates and appetites, messages and passions, winds and 
tempers. The dosic body spans the divide between text and world. It is inscribed with signs 
that are more productively understood as versatile signifiers than visualized as definite 
objects. To say that it is a fluent body is to say that it is overflowing not only with dosic 
currents, but also with polyvalent syntax. (Langford 2007, p. 376) 
Similarly, alternative and multiple medico-religious bodies have been identified also in 
Tibetan societies (Adams 1992, Garrett 2008, Gyatso 2015). These embodiments, however, 
mostly pertain to (discourses about) the social body and/or the body politic (cf. Scheper-
Hughes and Lock 1987). My investigations, however, ĂůƐŽ ĂƌƚŝĐƵůĂƚĞ ǁĞůů ǁŝƚŚ ,ƐƵ ?Ɛ 
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ĂĚĚŝƚŝŽŶŽĨƚŚĞ ‘ďŽĚǇĞĐŽůŽŐŝĐ ?ĂƐanother approach to theorise the body. In her genealogy 
of the five elemental agents of contemporary Chinese medicine, Hsu traces how ecological 
realities come to be encapsulated in concepts of learned medical reasoning. In doing so she 
ŝŶƐŝƐƚƐƚŚĂƚ ‘those interested in how biology is contained in ĐƵůƚƵƌĞŚĂǀĞƚŽƚƵƌŶƚŽŚŝƐƚŽƌǇ ?
(Hsu 2007, p. 122). Craig (2012) ĞŵƉůŽǇƐ  ‘ƐŽĐŝĂůĞĐŽůŽŐŝĞƐ ? ƚŽ ŵĂƉ ƚŚĞŵƵůƚŝƉůĞ ǁĂǇƐ ŝŶ
which human-environment interdependencies shape the efficacy of Tibetan medicine in 
her multi-sited ethnography in Nepal and Tibetan areas in China. She defines efficacy69 as: 
 ? Q ?ƉƌŽĚƵĐĞĚĂƚ ƚŚĞ ŝŶƚĞƌƐĞĐƚŝŽŶƐŽĨ ƌŝƚƵĂůĂĐƚŝŽŶĂŶĚƉŚĂƌŵĂĐŽůŽŐǇ ?ǁŝƚŚŝŶĚŝƐƚŝŶĐƚƐŽĐŝĂů
ecologies. Efficacy is a measurement of micropolitical power, biopsychosocial effects, and 
cultural affect. It is an intersubjective phenomenon, by which I mean that one cannot really 
know whether a medicine or therapeutic approach is efficacious until a practitioner makes 
and/or prescribes it, a patient uses it, and then reacts to its use. (Craig 2012, p. 7) 
I subscribe to this nuanced definition, which recognises the medico-pharmacological-ritual 
nexus and its social, sensorial and material embodiment. But academic coverage of 
Buddhist and medical perspectives on suffering and healing  W evoking the (dis)balance of 
the three emotional poisons (duk sum) and their corresponding psycho-physical forces or 
 ‘ŚƵŵŽƵƌƐ ? ?nyépa)  W and of the principles of Tibetan pharmacology has remained limited 
to literal translations and interpretations of a few classics. Building on these pioneering 
studies which elaborate the principles of medicine compounding (elements, tastes and 
post-digestive tastes, potencies, and attributes; Cardi 2005-2006, Hofer 2014, Tsultrim 
Tsona and Dakpa 2009), I contend that there is still a lack of ethnographic and text-critical 
attention to the material flows and frictions that make up the efficacy of potent substances.  
 
The explanation of efficacy has long tantalised scholars across the range of academic 
disciplines contributing to the medical humanities and biomedical sciences. From symbolic, 
constructivist approaches and meaning-centred analyses  W ƐƵĐŚ ĂƐ DŽĞƌŵĂŶ ?Ɛ(2002) 
rendering of the placebo effĞĐƚĂƐ ‘ƚŚĞŵĞĂŶŝŶŐƌĞƐƉŽŶƐĞ ? W on the one end to materialist 
causality and neuro-reductionism on the other, the role of materiality has often either been 
ignored or equated wiƚŚƉŚǇƐŝĐŽĐŚĞŵŝĐĂůƌĞĂĐƚŝŽŶƐ ?dŚĞƐƚƵĚǇŽĨƚŚĞĞĨĨŝĐĂĐǇŽĨ ‘ŝŶĚŝŐĞŶŽƵƐ ?
                                                     
69 As Craig (2012) notes, the most common Tibetan translation for efficacy is phenü. This is a contraction of 
the words for benefit (phenthok) and potency (nüpa), effectively coupling the useful with the powerful. 
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healinŐ ĂŶĚ  ‘ƚƌĂĚŝƚŝŽŶĂů ? ŵĞĚŝĐŝŶĞ ŝŶ ƉĂƌƚŝĐƵůĂƌ ŚĂƐ ƉƌŽǀĞŶ ƉƌŽďůĞŵĂƚŝĐ ĨŽƌ ŵĞĚŝĐĂů
anthropologists on both theoretical and methodological levels as they struggle with 
Eurocentric and biomedical biases, issues of authority (differing stakeholder perspectives), 
and the disentanglement of preventative and therapeutic efficacy, proximate and ultimate 
effects, restorative versus transformative healing and the food/medicine dichotomy (Etkin 
1988, 2006; Waldram 2000, 2013). In light of the abovementioned studies, I find it useful 
ƚŽ ĞǆƉĂŶĚ >ŽĐŬ ?Ɛ ĐŽŶĐĞƉƚ ŽĨ ůŽĐĂů ďŝŽůŽŐŝĞƐ ĂŶĚ ƌĂŝŐ ?Ɛ ƐŽĐŝĂů ĞĐŽůŽŐŝĞƐ ŽĨ ĞĨĨŝĐĂĐǇ into 
 ‘ĞĐŽůŽŐŝĞƐŽĨƚŽǆŝĐŝƚǇ ? for the purpose of my argument. There is an inextricable link between 
medical efficacy and toxicity, which I aim to show by emphasising the often-ignored 
metaphorical flipside of the potency of materia medica. Conceiving the body ecologically 
as a dynamic microcosm based on and overflowing in the local environmental macrocosm, 
I argue that medical toxicity emerges in particular bodily configurations which in turn 
implies that the poison/medicine dichotomy is in effect a spectrum of possibilities 
constrained by local interactions.  
 
These sensitivities notwithstanding, the deployment and contestation of the biomedical 
notionƐŽĨ ‘ƌŝƐŬ ? and  ‘ƐŝĚĞĞĨĨĞĐƚ ?ƉůĂǇƐĂĐƌƵĐŝĂůƌŽůĞŝŶǁŚĂƚĨŽůůŽǁƐ ?ƚŚŶŽƉŚĂƌŵĂĐŽůŽŐŝƐƚ
Nina Etkin (1992) ĐƌŝƚŝĐĂůůǇĂŶĂůǇƐĞĚƚŚĞƌĞĚƵĐƚŝŽŶŝƐƚďŝŽŵĞĚŝĐĂůĚĞĨŝŶŝƚŝŽŶŽĨ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?
and how these effects are interpreted and employed in unexpected ways in various 
socŝŽĐƵůƚƵƌĂů ƌĞĂůŝƚŝĞƐ ? ŝŶ ƚŬŝŶ ?Ɛ ĞǆĂŵƉůĞ ƚŚĞ ŝŶĚŝŐĞŶŝƐĂƚŝŽŶ ŽĨ ƉŚĂƌŵĂĐĞƵƚŝĐals by the 
Hausa of rural norƚŚĞƌŶEŝŐĞƌŝĂ ?^ŚĞĂƌŐƵĞƐƚŚĂƚ ‘the primacy or subordination of effects 
depends on why a medicine is administered, the intentions of the user and prescriber, and 
the anticipated outcome  W ŝŶƐŚŽƌƚ ?ŝƚƐĐƵůƚƵƌĂůĐŽŶƚĞǆƚ ? (Etkin 1992, p. 102). Contrary to 
the general opinion, traditional medical systems relying mainly on a pharmacopoeia of 
plants are markedly sensitive to a multiplicity of effects. Indeed, as plant-based medicines 
are complex mixtures to which multiple benefits are often ascribed, one would logically 
ĞǆƉĞĐƚƚŚĞƌĞƚŽďĞŵŽƌĞ ‘ƐĞĐŽŶĚĂƌǇ ?ĞĨĨĞĐƚƐĂƐǁĞůů ?,ĞĂůĞƌƐƚŚƌŝǀĞŽŶƚŚĞŝƌĂǁĂƌĞŶĞƐƐŽĨ
this complex chemical ecology (see also Johns 1996) far removed from the unrealistic one-
dimensional efficacy/toxicity or main/side effect of highly concentrated pharmaceutical 
molecules. The myth that pharmaceuticals have both a stronger efficacy as well as less side 
effects belies their sociocultural and biological complexity as secondary effects are 
209 
 
relegated to a post-ŵĂƌŬĞƚŝŶŐƌŚĞƚŽƌŝĐŽĨ ‘ŶŽŶĐŽŵƉůŝĂŶĐĞ ?ĂŶĚ ‘ŵŝƐƵƐĞ ? ?ŵĂƐŬŝŶŐǁŚĂƚĂƌĞ
often purposeful appropriations.  
 
ƚŬŝŶ ?Ɛ ĂƐƚƵƚĞ ŽďƐĞƌǀĂƚŝŽŶƐhave been corroborated and expanded more recently by 
historians, social scientists and anthropologists working on scientific, biomedical and 
regulatory conceptions of risk and safety. Marks (2013) contends that adverse drug 
reactions are a long-standing controversy that emerged with the rise of modern 
therapeutics. He argues that the foundation of the US drug regulatory system and the Food 
and Drug Administration (FDA) on the 1938 Drug Law was premised on the maintenance of 
professional medical autonomy at all costs. Drug labelling in the form of safety data and 
therapeutic claims is regulated, but not prescription itself, largely limiting regulation to 
information management. Within an ideological and political climate in which the industry 
invokes the autonomy of physicians, freedom, innovation and medical need as inviolable 
principles, making the risks of adverse reactions visible is problematic. Over the years, the 
basic toxicological and statistical dilemma has nonetheless remained the same: many 
effects only appear when present in a large number of patients (with complications more 
common in the study population requiring bigger samples), and interpreting the strength 
of association and causal drug-effect relationships is difficult and clearly does not indicate 
directly how best to regulate. Since World War II and in the wake of the 1960s Thalidomide 
disaster in Western Germany and beyond, the pharmaceutical industry has become 
perhaps the most stringently regulated economic sector. Nonetheless, drug safety has 
remained a clinically uncertain, politically contested moving target.  
 
An extra problematic layer of contingency is added when these biomedical safety standards 
ĂƌĞŐůŽďĂůůǇĂŶĚƵŶŝĨŽƌŵůǇĂƉƉůŝĞĚƚŽ ‘ƚƌĂĚŝƚŝŽŶĂůŵĞĚŝĐŝŶĞ ?ĂƐĚĞĨŝŶĞĚďǇƚŚĞtŽƌůĚ,ĞĂůƚŚ
Organization (with its headquarters in Geneva). As Kadetz (2015a) convincingly shows, the 
t,K ?ƐĐƵƌƌĞŶƚŶŽƌŵĂƚŝǀĞƐĂĨĞƚǇĚŝƐĐŽƵƌƐĞǁĂƐĐŽŶƐĞĐƵƚŝǀĞůǇƐŚĂƉĞĚďǇƚŚĞĞǆƉĂŶƐŝŽŶŽĨ
biomedical hegemony in the US from the nineteenth century onwards, and the 
international dissemination of scientific medicine through the Rockefeller Foundation and 
other philanthropies along with American capitalism and political-economic, technocratic 
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ideologies. Heavily funded long-term projects in China from 1914 onwards professionalised 
American medicine there, installed newly educated elites in government health institutions, 
ĂŶĚ ĞǀĞŶƚƵĂůůǇ ĐŽŶƚƌŝďƵƚĞĚ ƚŽ ƚŚĞ ŝŶƚĞŐƌĂƚŝŽŶ ŽĨ ƚŚĞ ƌĞĐĞŶƚůǇ ƌĞŝŶǀĞŶƚĞĚ  ‘dƌĂĚŝƚŝŽŶĂů
ŚŝŶĞƐĞDĞĚŝĐŝŶĞ ?ƵŶĚĞƌĂďŝŽŵĞĚŝĐĂůůǇ-dominated hierarchical paradigm. In the 1990s the 
t,K ?Ɛ dƌĂĚŝƚŝŽŶĂů DĞĚŝĐŝŶĞƐ hŶŝƚ ǁas moved under the Essential Medicines Division, 
which led to a further shift from primary healthcare towards economic efficiency and 
commodification as reflected in WHO publications on Good Agricultural and Collection 
Practices, Good Manufacturing Practices, herbal quality control guidelines and 
pharmacovigilance. Based on his long-term fieldwork in the rural Philippines and at the 
WHO Western Pacific Regional Office, Kadetz (2015b) further problematises the 
ƵŶŝǀĞƌƐĂůŝƚǇ ŽĨ  ‘ƐĂĨĞƚǇ ? ĂƐ ĂƉƉůŝĞĚ ƚŽ ƉůĂŶƚ-based medicines by revealing three flawed 
assumptions: the paternalistic assumption that safety is an issue for people in their local 
healthcare practices, the ethnocentric idea that biomedical constructions of safety are 
shared by all, and another paternalistic assumption that a person cannot her/himself 
decide whether a treatment is beneficial or not. He further notes the disparity between 
global WHO standards and the realities of state and local implementation which often 
seems to marginalise local practitioners in exchange for the profits of commodification (as 
in Adams 2002). Arguing for a reframing of the discourse and regulation of herbal medicines, 
he observes that  
ƚŚĞ ŐůŽďĂů ĐŽŵŵŽĚŝĮĐĂƚŝŽŶ ŽĨ ƉůĂŶƚ-ďĂƐĞĚ ŚĞĂůƚŚ ĐĂƌĞ ƉƌŽĚƵĐƚƐ ŚĂƐ ďĞĞŶ ũƵƐƚŝĮĞĚ ĂƐ ƚŚĞ
means by which to prove and improve the intrinsic effectiveness, quality and especially safety 
ŽĨ ƚŚĞ ƉůĂŶƚƐ ŝŶƚĞŶĚĞĚ ĨŽƌ ŚƵŵĂŶ ŚĞĂůƚŚ ?  ? Q ďƵƚ ƉĂƌĂĚŽǆŝĐĂůůǇ ? ƚŚĞ ĞǆƚƌŝŶƐic factors of 
ƉƌŽĚƵĐƚŝŽŶ ?ŵĂƌŬĞƚŝŶŐĂŶĚƌĞŐƵůĂƚŝŽŶŽĨƚŚĞƐĞƉůĂŶƚƐŵĂǇƌĂŝƐĞŵŽƌĞƐŝŐŶŝĮĐant concerns of 
safety. (Kadetz 2015b, p. 115) 
 
DĞĚŝĐĂůĂŶƚŚƌŽƉŽůŽŐŝƐƚĂƌďĂƌĂ'ĞƌŬĞ ?ƐŽŶŐŽŝŶŐǁŽƌŬŝƐĂƚƚŚĞĨŽƌĞĨƌŽŶƚŽĨ nuanced socio-
cultural research on toxicity in Tibetan medicine. A three-year project on pharmacological 
detoxification methods with practitioners in India and Nepal led her to investigate The 
Social Life of Tsotel (Gerke 2013), a highly processed and expensive mercury sulphide 
compound considered tŽďĞ ‘the pŝŶŶĂĐůĞŽĨdŝďĞƚĂŶƉŚĂƌŵĂĐŽůŽŐǇ ? (p. 123) as an essential 
ingredient for several of the most complex, potent, and popular Tibetan medicines named 
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 ‘precious ? or  ‘jewel pills ? (rinchen rilbu). Gerke describes a dilemma faced by the Tibetan 
medical community: tsothel is variously perceived as the supreme medicinal substance or 
as the most dangerous neurotoxin, implicated in Asian medical product poisoning 
schandals. Practitioners and institutions are thus challenged to prove its safety, whereas 
Tibetans ŚĂǀĞ ŶŽ ĚŽƵďƚƐ ŽŶ ŝƚƐ ďĞŶĞĨŝƚƐ ĂŶĚ ĂƌĞ ŬĞĞŶůǇ ĂǁĂƌĞ ŽĨ ŵĞƌĐƵƌǇ ?Ɛ ƚŽǆŝĐŝƚǇ ŝŶ
unprocessed form. This focal shift from efficacy to safety was noticed by Gerke (2015) as a 
more general trend in the biomedical and regulatory literatures which has hitherto not 
been taken on by pharmaceutical anthropologists (except in the recent work of Kadetz, 
cited above). Within medical anthropology, discourses of harm reduction, prevention and 
risk have been found to reinforce prejudice towards marginalised groups under the guise 
of scientific objectivity, engendering complex dynamics and politics of responsibility. The 
pharmaceutical industry furthermore feeds (on) the creation of health anxieties through 
the marketing and sale of medical solutions, fueling (bio)medicalisation (Nichter and Lock 
2002). In a similar vein, I am sensitive to how biomedical notions of risk can be mobilised 
ƚŽ ĐŽŶĚĞŵŶ  ‘ĨŽƌĞŝŐŶ ? ŵĞĚŝĐŝŶĞƐ ŝŶ ƚŚŝƐ ĐŚĂƉƚĞƌ ƚŚƌŽƵŐŚ ƚŚĞ ĐŽŶĐĞƉƚŝŽŶ ŽĨ ŚĂǌĂƌĚŽƵƐ
entities. 
 
Under the next heading, I trace the mythological origins of aconite and Garuda-5 and their 
appearance in classical medical texts, to then arrive at their contemporary use in and as 
medicine. This not only presents the broader textual-historical framework for explanations 
of toxicity and efficacy but also links it to contemporary medicine making, pinpointing 
transformations in practice. The remainder of the chapter is divided into two larger parts 
that cover the manifestations of Garuda-5 at PADMA and Men-Tsee-Khang respectively, 
bringing several dimensions of its ecologies of toxicity to the fore. The latter institution 
deserves extra attention in this chapter since it provided me with crucial insights into the 
possibly dramatic consequences of not being sensitive to local biologies and ecologies, to 
the controversial role of detoxification in dealing with this variability, and to the 




5.1 From myths to pharmaceutical realities 
Scratching the surface of the etymology of the Latin scientific name Aconitum napellus L. 
 ?WD ?Ɛ ŝĚĞŶƚŝĨŝĐĂƚŝŽŶ ŽĨtsenduk) brings us directly to its Greco-Roman mythological 
origins. Aconitum ŽƌĂĐŽŶŝƚĞŵĂǇƐŝŵƉůǇďĞĚĞƌŝǀĞĚĨƌŽŵ ‘aconae ? ?>ĂƚŝŶĨŽƌ ‘ďĂƌƌĞŶƌŽĐŬ ?
Žƌ  ‘ŵŽƵŶƚĂŝŶ ? )ĂĐĐŽƌĚŝŶŐ ƚŽ WůŝŶǇ ƚŚĞ ůĚĞƌ  ? ? ? ?Naturalis Historia XXVII, II), or could 
alternatively refer to the Akóne (a coastal city of the Black Sea). Akóne lies near to the 
entrance to the Underworld, from where Hercules brought forth the hellhound Cerberus. 
Upon witnessing the sun, the creature howled ferociously. From its saliva that touched the 
earth, aconite sprouted. The ŵƵŶĚĂŶĞ ĞƉŝƚŚĞƚ  ‘napellus ? ůŝŬĞůǇ ƌefers to the turnip-like 
roots (Stern 2004). A not too dissimilar Scandinavian myth explains the Nordic names for 
this plant referring to the Gods of thunder and war (ĂƐ  ‘ŚĂƚ ?ŚĞůŵ ŽĨ dŚŽƌ ?dǇƌ ? ) ? dŚĞ
voriacious wolf Fenris was chained to two rocks in Asgard by Tyr, but it managed to tear 
itself lose during the demise of the heavenly realm. Thor battled the wolf while 
simultaneously fighting the poisonous snake Joermungan. As he slayed the viper, Thor also 
ƉĞƌŝƐŚĞĚďǇŝƚƐƚŽǆŝĐďƌĞĂƚŚ ?dŚŽƌ ?ƐƐŽŶtŝĚĂƌƚŚĞŶĂǀĞŶŐĞĚŚŝƐĨĂƚŚĞƌ ?ƐůĂǇŝŶŐƚŚĞǁŽůĨďǇ
thrusting his ƐǁŽƌĚĚĞĞƉďĞƚǁĞĞŶ&ĞŶƌŝƐ ?ũĂǁƐ ?piercing his heart. From that day onwards, 
 ‘dŚŽƌ ?ƐŚŽŽĚ ? (i.e. aconite) wreaks death and destruction amongst wolves. This is reflected 
also in the English name wolfsbane, and in the historical application of meat drenched in 
aconite extract as poisoned bait to kill wolves (De Cleene and Lejeune 2003). 
 
It seems that Aconitum species equally play a role in the Indian mythical origins of naturally 
occurring poisons. Three alternative accounts are depicted and summarized in 
Parfionovitch et al. ?ƐTibetan Medical Paintings (volume 1, p. 117-118, see Figure 5.2).70 In 
the first, various types of aconite are said to be derived from the shattered body of Poison 
Incarnate, who was vanquished by the Hindu Gods in their search for the nectar of 
immortality. Another myth recounts the origins of the medications that suppress poison as 
ĚĞƌŝǀĞĚĨƌŽŵƐŽŵĞŽĨƚŚĞŶĞĐƚĂƌƐĐĂƚƚĞƌĞĚŽŶƚŚĞĞĂƌƚŚďǇDĂŚĞƑǀĂƌĂ ?/ŶƚĞƌĞƐƚŝŶŐůǇ ?ƚŚĞ
                                                     
70 The production of this seventeenth-century encyclopaedic set of seventy-nine thangka scroll paintings was 
commissioned and overseen by Dési Sangyé Gyatso (1653-1705, the chief minister and regent of the Fifth 
Dalai Lama). It was based on his comprehensive written commentary (the Blue Beryl) on the Fourfold Treatise, 
and is a testimony of state investment in and control of medical learning (see Gyatso 2015). 
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same connection between aconite, poisoning, and wolves is also expressed in the Tibetan 
plant name changduk  ?ůŝƚ ?  ‘ǁŽůĨ ƉŽŝƐŽŶ ? ) ? dŚŝƐ ŚĞƌď ŝƐ ŝůůƵƐƚƌĂƚĞĚ ĂƐ an exemplar of the 
naturally occurring, organic, immobile poisons derived from plants in Tibetan medical 
paintings (and identified there as A. lycoctonum L.), in between tsenduk  ? ‘ǀŝƌƵůĞŶƚƉŽŝƐŽŶ ? ?
A. fischeri) and raduk  ? ‘ŐŽĂƚƉŽŝƐŽŶ ? ?ŐŽĂƚƐďĂŶĞŽƌďůƵĞaconite, A. napellus). As we have 




Figure 5.2. This upper section of the fifty-first painting from Parfionovitch et al. (1992, p. 117) depicts the origins of 
natural poisons according to Indian mythology. The large, red creature in the centre is ŬĈůĂŬƵܩa or ŚĈůĂŚĂůĂ, Poison 
Incarnate, who was destroyed and whose body was shattered by Brahma and the other Gods upon invoking the syllable 
,ƻ܉. On the right, several poisonous substances derived from poison incarnate are illustrated. 
 
Moving on from aconite as an ingredient towards Garuda-5 as a formula, Gyatso and Hakim 
(2010) present a convenient summary of a legend narrating its origins: 
There was once a kingdom in eastern India whose inhabitants were bothered by lymph (chu 
ser) disorders and diseases caused by klu (subterranean or aquatic elemental spirits) and by 
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microorganisms; it was possibly leprosy. Not knowing where to turn, the king and his subjects 
took refuge in the Three Jewels (Buddha, dharma, and sangha). As a result of this observance, 
Garuda (a mythical bird) manifested to help the kingdom and cleared away the obstacles 
faced by the people. When he was about to die, Garuda offered his body as medicine so that 
the people could continue to enjoy his blessings in the form of pills to be taken internally or 
worn as amulets. Garuda further promised that when the materials of his body were 
exhausted, his blessings would continue in the form of drugs. Thus it is said that a ru ra 
 ?ĐŚĞďƵůŝĐŵǇƌŽďĂůĂŶ )ƐǇŵďŽůŝǌĞƐ'ĂƌƵĚĂ ?ƐĨůĞƐŚ ?ru rta  ?ĐŽƐƚƵƐ )ƐǇŵďŽůŝǌĞƐ'ĂƌƵĚĂ ?ƐďŽŶĞƐ ?
shu dag nag po  ?ƐǁĞĞƚĨůĂŐ )ƐǇŵďŽůŝǌĞƐ'ĂƌƵĚĂ ?ƐŵƵƐĐůĞƐ ?gla rtsi (musk) symbolizes 'ĂƌƵĚĂ ?Ɛ
blood, and bonga nakpo (dark-blue aconŝƚĞ )ƐǇŵďŽůŝǌĞƐ'ĂƌƵĚĂ ?ƐŚĞĂƌƚ ? 
(Gyatso and Hakim 2010, p. 317) 
The five ingredients of Garuda- ? ĐŽƌƌĞƐƉŽŶĚ ƚŽ ƚŚĞ 'ĂƌƵĚĂ ?Ɛ ďŽĚǇ ƉĂƌƚƐ ? DǇƌŽďĂůĂŶ ŝƐ
mentioned first as the main ingredient (as the flesh would be the heaviest part), whereas 
aconite represents the heart of this mythical bird.71 Khyung-nga is mentioned sparingly in 
the Three Tantras, excluding the large and hitherto untranslated Third Tantra on pathology. 
At the beginning of chapter 28 of the Second Tantra on specific therapeutic techniques 
(Clark 1995)  ‘bya khyung lnga (pa) ? is suggested in case the practitioner has doubts 
concerning the diagnosis when presented with symptoms of infection, parasites, or 
stomach and large intestine disorders. The compound may then be prescribed as a probe 
or trial to which the response will help ascertain the nature of the disease. In chapter 5 of 
the Subsequent (Fourth) Tantra on the subject of pills (rilbu), Garuda-5 and its ingredients 
are listed once more (Gonpo 2011, p. 91). Here, the compound is advised as a basis to cure 
cold disorders to which supplementary ingredients can be added to target specific organs 
and pathologies. The dosage is according to the need, but five, seven or nine pills at dusk 
are suggested. Its common usage, however, springs from its relatively frequent occurrence 
in the Third Tantra, from which Garuda- ? ?ƐďĞŶĞĨŝĐŝĂůƋƵĂůŝƚŝĞƐŽƌǀŝƌƚƵĞƐ ?phenyön) may be 
summarised as follows (translated from Tsering 2013, which is memorized by fourth year 
medical students at Men-Tsee-Khang): treats severe stomach pain, inflammation of the 
head (including ears, nose, and gums), pain due to intestinal parasites (sin), tonsillitis, 
                                                     
71 The Garuda (Tibetan: khyung) is a popular mythical creature in both Hindu and Buddhist traditions which 
later merged with the Bonpo  ‘ƐŬǇ-soarĞƌ ? in Tibet. This king of birds has the torso of a man and holds a naga 
(serpent) king between his hands and sharp beak. In Tibetan Buddhist iconography, the Garuda assumes 
multiple roles (Beer 2003). 
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itching and cracking skin, and is particularly excellent against leprosy and  ‘ǇĞůůŽǁ ĨůƵŝĚ ? 
(chuser) disorders. Its potency is neutral, and the mode of administration mentioned here 
is four pills taken together with boiled water.  
 
Following Blaikie (2015) and my argument on situated knowledge in Chapter 1, the 
multiplicity of the composition (and dose) of Garuda-5 should not come as a surprise. 
Nonetheless, when comparing the small number of English-language publications detailing 
Tibetan formulations, then it seems that the variation is relatively minor. Dash (1994)72, an 
Ayurvedic scholar-physician, Phuntsog (2006), a lineage-based Ladakhi amchi, and Tsarong 
(1986), Tibetan exile and former Men-Tsee-Khang director, basically agree on the formula. 
This may be due to the standardising effects of the Four Tantras as well as the widespread 
ƵƐĂŐĞ ŽĨ<ŚǇĞŶƌĂďEŽƌďƵ ?Ɛ (2007, originally early 20th century) Excellent Vase of Elixirs 
(Düdtsi Bumzang)  W a foremost reference for both Lhasa and Dharamsala pharmacists and 
beyond, especially on ingredient quantities which are seldom published (Table 5.1). Yet, 
when one then compares these paper formulas with the actualised compositions of 
Garuda-5 by Men-Tsee-Khang and PADMA, a different story emerges (Table 5.2). 
Nowadays at Men-Tsee-<ŚĂŶŐ ?ƐƉŚĂƌmacy, the amount of aconite is generally much lower 
(from 25% to less than 10% of the total weight in this case), and musk (latsi) is commonly 
substituted by the resin of gulnak (the black type of gugul, mostly identified as Commiphora 
wightii (Arn.) Bhandari and well-known for its use in Indian dhoop incense).73 The pills are 
given a black coating ?WD ?ƐGrippe-Formel deviates much further from the purported 
ƐƚĂŶĚĂƌĚ P ŝƚ ĐŽŶƚĂŝŶƐ ŽŶůǇ ƚŚƌĞĞ ŽĨ ƚŚĞ  ‘ŽƌŝŐŝŶĂů ? ĐŽŵƉŽƵŶĚƐ  ?ĐŽƐƚƵƐ ? ŵǇƌŽďĂůĂŶ ? ĂŶĚ
aconite), six other ingredients, as well as excipients. Here, aconite accounts for only 1,4% 
of the formula.  
 
                                                     
72 Dash (1994, p. 11-12) warns the reader that tsenduk (which he considers to be a type of the Ayurvedic 
sĂƚƐŶĈďŚĂ) is exceedingly poisonous, and that it should be detoxified before use, which involves prolonged 
soaking in cow urine until the purified aconite does not produce tingling sensations or numbness on the 
tongue. Khyenrab Norbu (in his Excellent Vase of Elixirs) on the other hand advises soaking in eight-year-old 
child's urine for three days. 
73 Substitutions across kinds and kingdoms are not uncommon in Sowa Rigpa (Gerke 2016 in press, Sabernig 
2011), and are not easy to explain fully based on the pharmacological principles of tastes and powers. 
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Table 5.1. The five ingredients of khyung-nga tshéden  ? ?ĂƵƚŚĞŶƚŝĐ'ĂƌƵĚĂ- ? ? )ĂƐŵĞŶƚŝŽŶĞĚŝŶ<ŚǇĞŶƌĂďEŽƌďƵ ?ƐDüdtsi 
Bumzang (p. 150-151, republished by Arura in 2007) together with the quantities and the body parts of the Garuda 
mythical bird to which they correspond. Gyatso and Hakim (2010) summarised the function of each component in the 
formula, which was not specified by Khyenrap Norbu but which can be found in various materia medica texts. 
 
 
Table 5.2. The Garuda-5 avatars currently manufactured by Men-Tsee-Khang (as compounded on 27 February 2014, 
under supervision of amchi Penpa, Audio recording 90) and PADMA (translated from the Swiss package insert). This 
list does not adequately reflect all necessary (pre-)processing and detoxification procedures. The aconite/myrobalan 
ratio74 is 1/5 and 1/10 respectively, which is much less than 1/2 in <ŚǇĞŶƌĂďEŽƌďƵ ?ƐĨŽƌŵƵůĂƌǇĂƐƐŚŽǁŶĂďŽǀĞ ?dŚĞ
amounts of several Men-Tsee-Khang ingredients were left unspecified on purpose to respect their intellectual property. 
 
 
In Chapter 6, I analyse how aconite (1 mg of powdered tuber is present on average in one 
capsule containing 403 mg of PADMA 28) was excluded from several later products in the 
PADMA 28 series due to European national regulatory pressures. But this can hardly clarify 
the large drop in aconite content, which lies at the heart of Garuda-5, particularly at Men-
Tsee-Khang. My conversations with doctors and experiences at Indian wholesale markets 
                                                     
74 Besides the total percentage of aconite in each formula, I also calculated the ratio between the weights of 
aconite and myrobalan. This not only provides a second means of comparison between formulas, but also 
makes pharmacological sense. Aru is used in Tibetan medicines as a balancing and detoxifying agent, it thus 
neutralises potentially negative effects of the other ingredients. Phytochemically, chebulic myrobalan is 
known for its high tannin content. Tannins bind and precipitate proteinaceous molecules including alkaloids, 
ǁŚŝĐŚĂƌĞĐŽŶƐŝĚĞƌĞĚƚŽďĞĂĐŽŶŝƚĞ ?ƐŵĂũŽƌĂĐƚŝǀĞĐŽŵƉŽƵŶĚƐ ? 
aru , 40 (50%) flesh [chebulic myrobalan] treats all ailments and balances the humors
ruta , 10 (13%) bones [costus] treats wind and bile and benefits the stomach
shudak , 6 (8%) muscles (tendons) [sweet flag] treats wind and contagious fever, supports the digestive system
tsenduk, 20 (25%) heart [dark-blue aconite] alleviates pain and inflammation
latsi , 3 (4%) blood [musk] treats infectious disorders
Khyenrab Norbu's 
Excellent Vase of Elixirs
beneficial qualities of ingredients (Gyatso and Hakim 2010, p. 317)Garuda body parts
aru  (fruit, 250 kg or 39%) costus (root, 75 mg or 20%)
ruta  (root, ? kg) angelica (root, 50 mg)
shudak  (root, ? kg) chebulic myrobalan (fruit, 50 mg or 14%)
mänchen  (root, 55 kg or 9%) fenugreek (seed, 37.5 mg)
gulnak  (resin, ? kg; gla rtsi  substitute) restharrow (root, 37.5 mg)
black-coloured pill coating hemp-nettle (herb, 37.5 mg)
peppermint (herb, 37.5 mg)
634 kg in one batch (100%) sage (herb, 37.5 mg)
aconite (root, 5 mg or 1.4%)
excipients
367.5 mg in one capsule (100%)





(Chapter 2) ensured me that this was certainly not due to a lack of availability or the high 
price of black aconite: 155.3 kg was used in the administrative year 2013-2014, bought for 
an average price of 475 INR (roughly 7 USD) per kg. In comparison, 565.6 kg of the non-
toxic white aconite (bongkar, known to be critically endangered; Beigh et al. 2008) was 
purchased at 4,200 INR/kg (63 USD). Penpa explained that the former is cheaper because 
it is in much less demand (Notebook VIII, 12 May 2014). The inclusion of well-known 
European herbs in PADMA Grippe-Formel, on the other hand, was traceable to formula 173 
on the list of recipes provided by Peter Badmajew to PADMA founder Karl Lutz in the 1960s. 
It is a testament to the innovative nature of Buryat Sowa Rigpa (Dashiyev 1999, see also 
Chapter 6). 
 
 In the following sections, my aim is to investigate the reasoning behind and the 
circumstances that led to these contemporary reformulations and to highlight the impact 
ŽĨ ĚŝĨĨĞƌŝŶŐ ĞĐŽůŽŐŝĞƐ ŽĨ ƚŽǆŝĐŝƚǇ ? WD ?Ɛ ĐĂƐĞ ƐŚŽǁƐ ƚŚĞ ŝŶĨůƵĞŶĐĞ ŽĨ ƌĞŐƵůĂƚŝŽŶƐ ĂŶĚ
biomedical notions of toxicology and drug safety, while at Men-Tee-Khang I argue that an 
adaptation to Tibetan exile and Indian local biologies was required because this new 
socioecological setting altered the configuration of the poison/medicine interface. As such, 
this chapter illustrates that the boundaries between medicine (efficacy) and poison 
(toxicity) are dynamic as well as contingent and how considerations of safety  W and its 
antonyms danger and risk  W mediate this interface and reconfigure what men versus duk 
are. 
 
5.2 PADMA  Garuda-5: Grippe-Formel, the flu formula 
While Garuda medicines can quite easily be ordered online from dubious websites 
operating in legal grey zones75, Garuda-5  W and arguably Tibetan medicine as a whole  W 
remains a fringe phenomenon in Europe. PADMA AG, the only pharmaceutical company 
                                                     
75 ƉĂĐŬŽĨ ? ? ‘'ĂƌƵĚĂ ?dŝďĞƚĂŶ,ĞƌďĂů&ŽƌŵƵůĂƚŝŽŶ ?ƉŝůůƐĐĂŶ ďĞŽƌĚĞƌĞĚĨŽƌ ? ? ?ĂƐĂ ‘ƚĂůŝƐŵĂŶ ?ĨƌŽŵǁǁǁ ?
ũĐƌŽǁƐŵĂƌŬĞƚƉůĂĐĞ ?ĐŽŵ ? ‘ůŝĨĨ'ĂƌƵĚĂWŝůů ?ĐĂŶďĞƉƵƌĐŚĂƐĞĚĨŽƌ ? ? ?ĨŽƌ ? ?ƉŝůůƐĂƚwww.tibetandoctors.com 
(both accessed 7 December 2015). Both webpages showcase conspicuous disclaimer statements indicating 




legally manufacturing multi-compound medicines based on Tibetan formulas in this part of 
the world, usually produces one small batch of Grippe-Formel once a year which may only 
be sold by licensed pharmacies and drug stores (German: Drogerien) or prescribed by 
doctors, dentists and naturopaths (Heilpraktiker) in one part of the small Kanton of 
Appenzell in the northeast of Switzerland. Unlike PADMA LAX, 28 and DIGESTIN which are 
nationally registered (and available in other countries under several product names), 
PADMA Grippe-Formel is part of a series of seven medical products registered exclusively 
in Appenzell Ausserrhoden. This Swiss province exceptionally allows this type of 
registration of over-the-counter products for self-medication purposes, based on a 
longstanding local tradition of natural (and alternative) healing practices that was recently 
recognised as a Living Swiss Tradition in accordance with the UNESCO Convention on 
Intangible Cultural Heritage (Bundesamt für Kultur, Schweizerischen Eidgenossenschaft 
2012). Its liberal health regulation, including on the acceptance of recipes compounded and 
dispensed on the premises of practitioners (the so-ĐĂůůĞĚ  ‘ŚŽƵƐĞ ƐƉĞĐŝĂůƚŝĞƐ ? ?
Hausspezialitäten) has fostered famed healers such as Dr Alfred Vogel (1902-1996), a 
flourishing alternative medicine industry, as well as medical tourism for more than two 
centuries. More than 250 Heilpraktiker are currently registered, a large number considering 
the total population of about 54,000 living in Appenzellerland. However, with the 
introduction of a new federal drug law in 2002 (Bundesrat der Schweizerischen 
Eidgenossenschaft 2002) cantonal registrations were no longer permitted after a six-year 
transition period, which was however subsequently extended until the end of 2013. A 
second revision package of the Therapeutic Products Act (Heilmittelgesetz) which came 
into force January 2014 extended this transition once again until end of 2017. Grippe-
Formel is legally saved for now, but this category of medicines is in a risky position as 
becamĞĐůĞĂƌƚŽŵĞŝŶƚŚĞĨŽůůŽǁŝŶŐĐŽŶǀĞƌƐĂƚŝŽŶǁŝƚŚWD ?ƐK ?ƵĚŝŽƌĞĐŽƌĚŝŶŐ ? ? ? ) P 
With the new Heilmittelgesetz Appenzell [cantonal registration] is again legal. When it is legal, 
ƚŚĞŶƚŚĞƉĞŽƉůĞǁŝůůƚĞƐƚŝƚ ?dŚĞǇǁŝůůƐĂǇ ‘ ?ƚŚŝƐŝƐ ?ŵĞĚŝĐŝŶĞ ?ŵĞĚŝĐŝŶĞ ?. This one guy checking 
ƚŚŝƐ  ?Ăƚ ƚŚĞƉƉĞŶǌĞůůŚĞĂůƚŚĚĞƉĂƌƚŵĞŶƚ ? ƐĂǇƐ  ‘ǇĞƐ ?ŶŽ ?ǇĞƐ  ?,ĞǁŝůůŵĂǇďĞŽŶĐĞŵĂŬĞĂ
mistake. That's what the federal guys [at Swissmedic] said to me, they are waiting for that. I 
ŚŽƉĞ ŝƚ ĚŽĞƐŶ ?ƚ ŚĂƉƉĞŶ ? ďƵƚ ƵŶĨŽƌƚƵŶĂƚĞůǇ ƚŽĚĂǇ Q Things get crazier because when 
international guys realise this, it will start, things will happen. 
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PADMA developed most of the Appenzell formulas in collaboration with amchi Pasang Arya 
in the nineties. But this time of bold experimentation soon came to an end when it became 
clear that these cantonal medicines also had to conform to Swissmedic quality 
requirements as they are produced in Zürich on the same site as nationally registered 
products, implying significantly more administration work as well as expenses. So far 
however, at least one interpretation of Garuda-5 has remained available officially  W as a 
medicine  W in a section of the Swiss market. We can only realise just how exceptional this 
is when we reconsider the composition of PADMA Grippe-Formel in the context of 
biomedical risk assessment. The infamous ingredient aconite is an exemplar of the 
European health and safety perspective on potent herbal substances.  
 
 
Figure 5.3. Current packaging of PADMA Grippe-Formel as sold over-the-counter in Appenzell Ausserrhoden. One box 
contains five blisters with 60 capsules in total, and is usually sold for around 29 Swiss Francs. (illustration taken from 




5.2.1 The muleta of the biomedical bull: aconite and its alarming alkaloids 
Khyung-nga has no chance in Europe. You can simply forget it. This aconite, for the 
authorities, is the red blanket in bull fighting. They run like a bull for this. It is incredible.   
(Herbert Schwabl, Audio recording 65) 
 
 
Figure 5.4. Photograph of an archival sample of Aconiti Tuber. It was stored in a plastic screw-top bottle, in a small 
labelled cardboard box with a safety data sheet, in the laboratory safety storage cabinet and marked by a yellow-black 
skull and crossbones triangle. Amongst plant ingredients used by PADMA, only the raw material and powder samples 
of aconite and of strychnine tree seeds (Strychnos nux-vomica L., present in PADMA LAX in small quantity as 
 ?Brechnusssamen ? )ŚĂǀĞƚŽďĞƐƚŽƌĞĚŝŶƚŚŝƐĐĂďŝŶĞƚ ? 
 
During the conversation quoted above, Herbert enumerated two prime causes that lead to 
trouble in the process of registering Tibetan formulas in Europe as traditional medicine 
 ?ďĞƐŝĚĞƐƉƌŽǀŝŶŐ ‘ƚƌĂĚŝƚŝŽŶĂůƵƐĞ ?ǁŝƚŚŝŶƵƌŽƉĞ ?ƐĞĞŚĂƉƚĞƌ ?). On the one hand there are 
issues of quality control particular to multi-compound herbal recipes such as the 
identification of the raw materials in mixtures (Chapter 4). On the other, the recognition of 
plants as active pharmaceutical ingredients which were previously unknown present 
another hurdle, especially for non-European traditions. The relevant authority will be 
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hesitant to be the first to recognise these novel entities, to stick its neck out, so to speak. 
Arguments based on comprehensive literature study as well as expert reviews need to be 
provided to establish its safety, even if the substances may be well-known food items such 
as pomegranate (an ingredient of PADMA DIGESTIN) and Nepalese plum (PADMA 
NERVOTONIN). In the case of Grippe-Formel (and PADMA 28) however, there is an extra 
complication: the potential toxicity of aconite (Figure 5.4).  
JVDV: tŚĂƚŵĂŬĞƐŝƚĚŝĨĨĞƌĞŶƚŝĨŝƚ ?ƐĂŚĞƌď ?ŶŽƚĂƚŽǆŝĐŵŽůĞĐƵůĞĨŽƌĞǆĂŵƉůĞ ?/ŐƵĞƐƐƚŚŝƐ
is much easier to standardise, to avoid the risk of getting the wrong dose? 
HS: No. The problem is the following: only the guys working with herbs are so naive to 
preƐĞŶƚƐƵĐŚƐƵďƐƚĂŶĐĞƐƚŽƚŚĞĂƵƚŚŽƌŝƚŝĞƐ ?ĞĐĂƵƐĞǁĞƐĂǇ ‘ŝƚ ?ƐŶĂƚƵƌĞ ? ?dŚĞŽƚŚĞƌ
ŐƵǇƐƐĂǇ ? ‘ŚŽǁĐŽŵĞǇŽƵƐƚĂƌƚǁŝƚŚƐƵĐŚĂĐƌĂǌǇƚŚŝŶŐ ?tĞŶĞǀĞƌĚŽƚŚŝƐƐŝŶĐĞĂůů
ƚŚĞƐĞ ?ƉŽŝƐŽŶŝŶŐ ?ƐĐĂŶĚĂůƐ ? ? 
JVDV: tŚǇŝƐƚŚĞƌĞ ‘ĐŽůůĂƚĞƌĂůĚĂŵĂŐĞ ?ŝŶƚŚŝƐĐĂƐĞ ? 
HS:  ‘>Ğƚ ?Ɛ ŵĂŬĞ ƐŽŵĞ ƐĂĨĞƚǇ ƐƚĂŶĚĂƌĚƐ ĂďŽƵƚ ƚŽǆŝĐŝƚǇ ůĞǀĞůƐ ? ĂŶĚ ƚŚŝƐ ĂŶĚ ƚŚŝƐ ? ? dŚĞ
ŶŽƌŵĂůŝŶĚƵƐƚƌǇƐĂǇƐ ‘ǇĞƐǁĞĂŐƌĞĞ ? ?dŚĞŶƚŚĞǇƐĂǇ ‘ǁĞŚĂǀĞƚŽǁŽƌŬďĂƐĞĚŽŶƚŚĞ
risk-ďĞŶĞĨŝƚƐĐĞŶĂƌŝŽ ? ?WĂƌĂĐĞƚĂŵŽůŽƌĂƐƉŝƌŝŶŚĂǀĞĂŚŝŐŚƚŽǆŝĐŝƚǇůĞǀĞů ?ǇŽƵĐĂŶŐĞƚ
kidney failƵƌĞ ? ƚŚĂƚ ŝƐ ƋƵŝƚĞ ŬŶŽǁŶ ?  ‘Ƶƚ ĂƐƉŝƌŝŶ ǁĞ ĐĂŶŶŽƚ ůŽƐĞ ? ŝƚ ŝƐ ƐƵĐŚ ĂŶ
ŝŵƉŽƌƚĂŶƚŵĞĚŝĐŝŶĞ ?ƐŽŚĞůƉĨƵů ?ƐŽŵĂŶǇƐƚƵĚŝĞƐ ? ?dŚĞŶǁĐŽŵĞǁŝƚŚƚŚĞKhyung-
nga formula. What is our proof? There is no benefit. Traditional medicine has the 
problem that the benefit is zero in this ratio. Even if the risk is small, with zero 
benefit it goes up to infinity. This is not told to the public, because the public would 
conceive this argument as cynical.  
 (Audio recording 105, 9 May 2015) 
 
Because the evaluation of safety is based on the risk/benefit ratio (see Wiesner 2014 for a 
short introductory overview of safety evaluation for THMPs), traditional herbal remedies 
are side-lined as they are not backed by expensive clinical trials that prove their efficacy or 
 ‘ďĞŶĞĨŝƚ ? ?76 PADMA Grippe-Formel seems to have escaped this logic of risk analysis through 
                                                     
76 PADMA Grippe-Formel is a cantonal registration as medicine, which is much less demanding in terms of 
safety, quality and efficacy requirements compared to regular national registrations for medicines or 
Traditional Herbal Medicinal Products (THMPs). For the latter two an extensive dossier has to be presented 
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the Appenzell loophole, but on a different scale the system is nonetheless maintained. The 
risk of exposure is restricted to tiny Appenzell Ausserrhoden, which accounts for less than 
one percent of the total Swiss population. In a federal state like Switzerland, with locally 
devolved responsibilities, these risks are so far deemed manageable. The risk/benefit ratio 
has also been applied to plants as single ingredient herbal remedies, notably by Konstantin 
Keller (1994). Formerly at the German federal health agency, Keller was part of ESCOP (the 
European Scientific Cooperative on Phytotherapy), an umbrella organisation aimed at 
representing the herbal medicine sector in discussions with European regulatory agencies 
which published a widely disseminated series of sixty  ‘ƐĐŝĞŶƚŝĨŝĐ ?  ?ŝ ?Ğ ? ĞǀŝĚĞŶĐĞ-based) 
monographs on commonly traded herbs in the late 1990s. ESCOP was generally in favour 
of free trade of herbs across the EU, and was striving towards increased harmonisation of 
ƚŚĞƌĞůĞǀĂŶƚ ůĞŐŝƐůĂƚŝŽŶƐ ?/ŶƚŚŝƐĐŽŶƚĞǆƚ ?<ĞůůĞƌĚƌĂĨƚĞĚĂƚĂďůĞ ůŝƐƚŝŶŐ ? ? ?  ‘ŵŽƐƚƌĞůĞǀĂŶƚ
ŚĞƌďĂůĚƌƵŐƐ ?ƵƐĞĚŝŶĂƚůĞĂƐƚŚĂůĨŽĨƚŚĞŵĞŵďĞƌ ƐƚĂƚĞƐ ?ƐĞĐŽŶĚƚĂďůĞƚŝƚůĞĚ ‘Herbal drugs 
with serious risks without anǇĂĐĐĞƉƚĞĚďĞŶĞĨŝƚ ? lists Aconitum (all species and parts, due 
to toxic alkaloids) as the first of a series of  ‘obsolete herbs ? ?<ĞůůĞƌ (1994, p. 44) concluded 
ƚŚĂƚ P  ‘Without plausible benefits, discussion on drug risks is hardly possible. Therefore a 
systematic risk evaluation should include the plausible pƌŽŽĨŽĨĞĨĨŝĐĂĐǇ ?. Ironically, with 
the introduction of Traditional Herbal Registration clinically proven efficacy has become 
irrelevant, effectively barring potentially potent herbs from entering the market via these 
channels (Chapter 6). 
 
Nevertheless, alkaloids continue to be researched intensively in the search for new 
biomedical drug leads especially since the pharmaceutical success stories of anti-cancer 
chemotherapeutic compounds such as paclitaxel (Taxol®, see Walsh and Goodman 2002) 
and vincristine (Oncovin®) from the 1960s onwards, which were initially extracted from 
plants. This is the point at which questions of biopiracy and intellectual property rights 
                                                     
to the authorities in a predetermined format, containing expert reviews of and modules on quality as well as 
clinical (with humans, for traditional registration only proof of traditional use within EU) and non-clinical (on 
animals and in vitro) studies of all ingredients and the formula in its entirety. Aconite would need extra 
attention: poisoning case reports should be discussed under the clinical, and toxicological studies under the 
non-clinical sections. In the case of PADMA 28 for example, PADMA had to argue that the single (two capsules) 
and maximum daily doses (six capsules) are well within safety limits through a comparison with homeopathic 
products (Audio recording 103 with Elisabeth from PADMA regulatory affairs). 
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come to the fore also for Tibetan medicine. Even though clinical research on Tibetan 
medicine in European languages is rather limited and very heterogeneous (see PADMA 
2015, Reuter et al. 2013, Witt et al. 2012 for recent reviews), anthropologist Vincanne 
Adams (2002) critically appraises the criminalisation of Sowa Rigpa and its practitioners as 
well as the shift in ownership of medical knowledge that can accompany randomised 
controlled trials and the pursuit and trademarking of active ingredients. When Tibetan 
medicines are assumed to be reducible to magic bullet molecules  W ǁŚŝĐŚŝƐŶŽƚWD ?Ɛ
approach  W ƚŚĞ ĚŽŽƌ ƚŽ ƉĂƚĞŶƚŝŶŐ ƚŚĞƐĞ  ‘ŶĞǁ ? ŝŶǀĞŶƚŝŽŶƐ ďĂƐĞĚ ŽŶ ŶĂƚƵƌĂů ƉƌŽĚƵĐƚƐ ŝƐ
opened. As was already noted by Adams, this is exactly what happened in a small clinical 
trial of the precious pill Red Coral-25 (jumar) for migraine by Aschoff et al. (1997). Not only 
is the study on migraine, a biomedical disease construct with no clear Tibetan equivalent 
as the authors themselves admit, it was also carried out with a much simplified 13-
compound formula to get rid of problematic ingredients such as mercury and musk. As the 
study shows some positive effects after two to four weeks for the twenty-two patients 
involved, the authors proceeded to tackle the problem of standardisation through the 
example of (black) aconite and its alkaloids as major active ingredients (see also Maier 
2004 ) ?ǇƚĂŬŝŶŐĂĐŽŶŝƚĞ ‘pars pro toto ?ĨŽƌƚŚĞĞŶƚŝƌĞĨŽƌŵƵůĂ ?ƚŚĞƌĞƐĞĂƌĐŚĞƌƐƐƵĐĐƵŵďĞĚ
to the temptations of orthodox biomedical drug development. Moreover, Aschoff filed a 
patent for the use of aconitine and/or aconine extracted from aconite tubers for migraine 
(application date 27 March 1995, DE 19511235 A1).77 This serves as an example that shows 
how aconite and its alkaloids are on the one hand phased out of complementary medicine 
while at the same time remaining a source of potential chemical drug leads along the lines 
ŽĨĚĂŵƐ ?ĂƌŐƵŵĞŶƚ ? 
 
5.2.2 The biomedical perspective: toxicology and pharmacovigilance 
The regulatory approach towards drug safety is based on the science of toxicology and its 
ĂƉƉůŝĐĂƚŝŽŶ ƚŽ ŵĂƌŬĞƚĞĚ ĚƌƵŐƐ ŝŶ ƚŚĞ ĚŝƐĐŝƉůŝŶĞ ĐĂůůĞĚ  ‘ƉŚĂƌŵĂĐŽǀŝŐŝůĂŶĐĞ ? ? Ɛ ƚŚĞƐĞ
                                                     
77 The patent was discontinued on 22 January 2009. I discussed the use and detoxification of aconite in 
Tibetan medicine  W which he believes is generally being phased out or greatly reduced in a similar vein to 
mercury  W via e-mail correspondence with Aschoff (13 April 2014). No answers were obtained in relation to 
my queries on the patent. 
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(re)define and shape the poison/medicine dichotomy by charting dose-response 
relationships and through risk assessments, a short excursus is warranted. In a 1454-page 
long toxicology science textbook, a poison is defined as: 
any agent capable of producing a deleterious response in a biological system, seriously 
ŝŶũƵƌŝŶŐĨƵŶĐƚŝŽŶŽƌƉƌŽĚƵĐŝŶŐĚĞĂƚŚ ?dŚŝƐŝƐŶŽƚ ?ŚŽǁĞǀĞƌ ?ĂƵƐĞĨƵůǁŽƌŬŝŶŐĚĞĮŶŝƚŝŽŶĨŽƌƚŚĞ
very simple reason that virtually every known chemical has the potential to produce injury 
or death if it is ƉƌĞƐĞŶƚŝŶĂƐƵĨĮĐŝĞŶƚĂŵŽƵŶƚ ? ?<ůĂĂƐƐĞŶ ? ? ? ? ?Ɖ ? ? ? ) 
The above brings us to the Swiss/German/Austrian renaissance physician-alchemist 
Paracelsus whose revolutionary views remain integral to toxicology: (1) experimentation 
with single chemical entities (as opposed to mixtures) is essential to determine their effects, 
(2) one should distinguish between their therapeutic and toxic properties, which (3) are not 
always clearly distinguishable, except by dose, and (4) the effects of chemicals have a 
degree of specificity. The characteristics of exposure further depend on the route, site, 
duration and frequency of exposure. Coming back to the dose-response relationship: 
Whatever response is selected for measurement, the relationship between the degree of 
response of the biological system and the amount of toxicant administered assumes a form 
that occurs so consistently as to be considered the most fundamental and pervasive concept 
in toxicology. (Klaassen 2013, p. 22) 
InterestingůǇ ?ƚŚĞĐŽŶĐĞƉƚŽĨ ‘ŚŽƌŵĞƐŝƐ ?ƐƵŐŐĞƐƚƐƚŚĂƚ ‘some nonnutritional toxic substances 
ŵĂǇĂůƐŽ ŝŵƉĂƌƚďĞŶĞĮĐŝĂůŽƌƐƚŝŵƵůĂƚŽƌǇĞĨĨĞĐƚƐĂƚ ůŽǁĚŽƐĞƐďƵƚƚŚĂƚ ?ĂƚŚŝŐŚĞƌĚŽƐĞs, 
ƚŚĞǇƉƌŽĚƵĐĞĂĚǀĞƌƐĞĞĨĨĞĐƚƐ ? (p. 25, see Calabrese and Blain 2005), resulting in a U-shaped 
dose-response curve. Even though this approach is based on a set of assumptions that is 
complicated and confounded by multiple factors I did not discuss here, it is interesting to 






Figure 5.5. Hypothetical dose-response curve depicting a hormetic effect (reproduced from Klaassen 2013, p. 25). At 
low doses a protective or beneficial response is stimulated (blue dotted line), but if the threshold is crossed the net 
effect will be adverse (red line). A similar graph is found in case of essential nutrients, where the dose determines 
whether the result is deficiency, homeostasis or toxicity.  
 
Pharmacovigilance on the other hand, a pharmacological discipline commonly defined as 
 ‘the study of the safety of marketed drugs under the practical conditions of clinical usage 
ŝŶůĂƌŐĞĐŽŵŵƵŶŝƚŝĞƐ ? (Andrews and Moore 2014, p. 1), strives to monitor drug safety and 
to identify adverse drug reactions previously unrecognised in clinical trials, to assess risks 
and benefits, and to communicate and respond to drug safety concerns. We live in a risk 
society (Risikogesellschaft, Beck 1992, original in German in 1986). This reporting and 
evaluation system equally pertains to herbal medicines, which presents scientists, 
regulators, and companies with a set of unique challenges (Shaw et al. 2012): (1) plants 
have complex and variable chemical profiles influenced by geography, genotype, plant part, 
harvesting time and conditions, and the storage, processing and combination of herbs, (2) 
the regulation and classification of herbal products varies, (3) nomenclature and labelling 
are multiple (diverse healing traditions), (4) the sourcing of herbal remedies is complicated 
(self-medication, over-the-counter, medical professionals or herbalists, etc.), and (5) herb-
drug interactions are underreported. 
 
Pharmacovigilance at PADMA is mostly outsourced to a specialised pharmaceutical 
consulting company in Austria. They are contracted to offer services such as the processing 
of individual case reports on side effects and the publication of a Periodic Safety Update 
Report (PSUR), which reviews safety data relevant to a particular product. 
Patients/consumers can communicate adverse reactions via their doctor, pharmacist or 
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chemist, but can also phone PADMA directly for general enquiries or to communicate 
complaints. Depending on the severity of the adverse reaction (UAW, unerwünschter  W 
ůŝƚĞƌĂůůǇ ‘ŶŽƚǁŝƐŚĞĚĨŽƌ ?Žƌ ‘ƵŶǁĂŶƚĞĚ ? W  Arzneimittelwirkung), the decision trees followed 
will lead to different measures to be taken. The most commonly reported side effect for 
PADMA 28 out of the roughly 40-45 UAWs per year is stomach upset, which can probably 
be linked to its camphor content (Erich, Audio recording 67). This ĨĂůůƐƵŶĚĞƌƚŚĞŵĞĚŝĐŝŶĞ ?Ɛ
possible side effects meŶƚŝŽŶĞĚ ŝŶ ƚŚĞ ƉĂĐŬĂŐĞ ŝŶƐĞƌƚ P  ‘[g]astrointestinal disorders and 
cutaneous reactions or itching may very rarely occur. Isolated cases of palpitations and 
slight restlessness have been obseƌǀĞĚ ŝŶƉƌĞĚŝƐƉŽƐĞĚ ŝŶĚŝǀŝĚƵĂůƐ ?. For Grippe-Formel, it 
states that no side effects have been documented so far. Surprisingly, when I asked amchi 
Dönckie  W a female Tibetan trained at Lhasa Mentsikhang and operating as health advisor 
(Gesundheitsberaterin) in Zürich and Vienna  W if she made use of Garuda-5, she responded 
negatively due to the fear of negative reactions (Audio recording 97): 
D: This I am not using very much. The reason is because you have western medicine, 
which is good for acute problems like infection. Of course, I am not preferring 
antibiotics. But western people are reacting strongly to khyung-nga and these 
ƐƚƌŽŶŐŵĞĚŝĐŝŶĞƐ ?/ĚŽŶ ?ƚĚĂƌĞƚŽŐŝǀĞƚŚŝƐŬŝŶĚƚŽŽŵƵĐŚ ? 
JVDV:  You are saying in the West people are reacting differently to these medicines like 
khyung-nga? 
            D: Yes. I think so. They are eating more medicines than Tibetans are doing, which 
harms their body, makes them very sensitive; the reaction is very nervous. They are 
ǀĞƌǇ QŶŽƚĐŽŵŵŽŶŵĞĚŝĐŝŶĞƐ ?/ƚŝƐǁĞůů-known for Tibetans, maybe because they 
are not taking western medicines. Maybe they [westerners] react stronger to 
medicines because of this.  
 
Her somewhat circular statement which seems to attribute the increased possibility for 
adverse effects when taking Garuda-5 to a heightened exposure to the side effects of 
biomedical pharmaceuticals urged me to revisit the production, prescription, and effects 
of Garuda-5 at Men-Tsee-Khang in India under the next heading, paying attention to local 
biologies. It also reminded me of an opposite tendency in German-speaking Europe where 
practitioners and patients explicitly market and seek out the use of PADMA 28 with aconite 
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 W the so-ĐĂůůĞĚ  ‘ŽƌŝŐŝŶĂů ? ^ǁŝƐƐ ĨŽƌŵƵůĂ  W as superior to derivative products available in 
other countries, even if it is only a 1 mg or 0.25% difference per capsule of which 
experimental studies indicate no significant difference in anti-inflammatory action.  
 
Moving on from toxicological and pharmacovigilance theory to a consideration of 
practitioners and patients/consumers in Europe, (herbal) drug safety remains a cause for 
concern. Kloos (2010, p. 102-105) describes how the diagnosis of a Genevan woman who 
developed severe anaemia after taking traditional Tibetan pills for half a year in 2001 led 
to laboratory analyses that indicated excessive heavy metal contamination (with lead in 
this case), and consequently to health warnings in Swiss public media.78 This in turn caused 
a panic amongst Swiss patients (and more tests indicating mercury contamination), made 
it more difficult to import Tibetan medicines into Europe, and indirectly led to the closure 
of Men-Tsee-<ŚĂŶŐ ?Ɛ ŵƐƚĞƌĚĂŵ ďƌĂŶĐŚ ĐůŝŶŝĐ  ?ǁŚŝĐŚ ǁĂƐ ƚŚĞ ŽŶůǇ ŽŶĞ ŽƵƚƐŝĚĞ /ŶĚŝĂ ). 
Eventually, these events transformed the (self-)regulation of Sowa Rigpa in exile through 
the establishment of the Central Council of Tibetan Medicine. High concentrations of heavy 
metals continue to be reported in Asian remedies available in the West (see Cooper et al. 
2007 for Chinese medicine in Australia, and Martena et al. 2010 for a Dutch market study 
including Tibetan medicines) or via the internet (e.g. Saper et al. 2008 for Ayurvedic 
products from a US perspective). However, these studies do not actually evaluate clinical 
effects or consider Men-Tsee-Khang pills in particular (but see Sallon et al. 2006), nor do 
they sufficiently take into account which metal compounds are formed and their 
bioavailability, let alone the impact of multi-compound synergistic effects and of Asian 
pharmacological detoxification procedures. Nevertheless, it is clear that the classical 
textual concepts of poisons and their detoxification, unsuitable medicine and wrong 
treatment cannot grasp the issue of heavy metal (cross-)contamination, which is 
ƉĂƌƚŝĐƵůĂƌůǇǁŽƌƌŝƐŽŵĞŝŶƚŽĚĂǇ ?ƐĐŽŶƚĞǆƚŽĨŵĂss-production and mass-consumption (lack 
of practitioner-patient feedback, increasing importance of batch-to-batch variability), 
increased average lifespan (chronic toxicity), and biomedical (regulatory) hegemony.  
                                                     
78 A similar case of severe mercury poisoning was recently covered in a German newspaper (Pillen aus der 
Hexenküche, Der Spiegel 36 (2015, p. 111-112). A 55-year old woman from Hamburg was hospitalised after 
taking Ayurvedic pills from Sri Lanka daily for more than two months. 
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Leaving aside heavy metals and other sources of contamination invisible to the naked eye 
(micro-organisms, pesticides, etc.), aconite may well be one of the potentially most toxic 
substances used in Tibetan medicine, especially the black type called manqin in Ma et al. 
(2015). Aconite poisoning  W mainly in the form of acute and possibly fatal cardio- and 
neurotoxicity  W is a rare but well-known phenomenon especially in East Asian countries that 
is often related to faulty identification and processing of Chinese medicines (Chan 2011, 
2009; Nyirimigabo et al. 2015; Singhuber et al. 2009)79. A very small number of serious 
cases with Aconitum napellus have also been reported in Switzerland, as this species grows 
abundantly in mountainous areas (Jaspersen-Schib et al. 1996, and more recently 
Compagnoni et al. 2013). Chan (2009) reports that the estimated lethal dose for humans is 
about one gram of fresh plant material or 5 ml of alcoholic tincture, corresponding to 2 mg 
of aconitine and considering that the alkaloid content of the different plant parts varies 
significantly (roots and tubers > flowers > leaves and stems).80  
 
PADMA reduces the risk of aconite toxicity in PADMA 28 and Grippe-Formel by 
standardising the concentration of ether-soluble alkaloids to 0.5% through the addition of 
mannitol to the powdered roots, while also carefully measuring the amount of aconite 
powder (one and five mg respectively per capsule) added to the mixture and thoroughly 
homogenising it mechanically. A formally documented and inspected quality system is in 
place aimed at minimising risks (as laid out in Chapter 4), in which the quality control lab 
occupies a central place. At Men-Tsee-Khang, the lab is able to detect the 
presence/absence (not the quantity) of alkaloids, but standardisation is not carried out. Yet, 
                                                     
79 Nevertheless, based on a large-ƐĐĂůĞƉƌĂĐƚŝƚŝŽŶĞƌƐƵƌǀĞǇ ‘the species used in CMM [Chinese materia medica] 
currently most used by EU practitionerƐĂƌĞƵŶůŝŬĞůǇƚŽĐĂƵƐĞƐĞƌŝŽƵƐĂĚǀĞƌƐĞĞǀĞŶƚƐ ? ?tŝůůŝĂŵƐŽŶĞƚĂů ? ? ? ? ? ?
p. 461; see also van der Valk et al. in press). 
80 Chan (2009, p.  ? ? ? )ƐƵŵŵĂƌŝƐĞƐƚŚĞƚŽǆŝĐŽůŽŐǇŽĨĂĐŽŶŝƚĞĂƐĨŽůůŽǁƐ P ‘dŚĞĐĂƌĚŝŽƚŽǆŝĐŝƚǇĂŶĚŶĞƵƌŽƚŽǆŝĐŝƚǇ
of aconitine and related alkaloids are due to their actions on the voltage-sensitive sodium channels of the cell 
membranes of excitable tissues, including the myocaƌĚŝƵŵ ?ŶĞƌǀĞƐ ?ĂŶĚŵƵƐĐůĞƐ ? ?dŚŝƐƌĞƐƵůƚƐŝŶƚŚĞĨŽůůŽǁŝŶŐ
ĐůŝŶŝĐĂů ĞĨĨĞĐƚƐ P  ‘WĂƚŝĞŶƚƐ ƉƌĞƐĞŶƚ ƉƌĞĚŽŵŝŶĂŶƚůǇ ǁŝƚŚ Ă ĐŽŵďŝŶĂƚŝŽŶ ŽĨ ŶĞƵƌŽůŽŐŝĐĂů ? ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ? ĂŶĚ
gastrointestinal features. The neurological features can be sensory (paresthesia and numbness of face, 
perioral area, and the four limbs), motor (muscle weakness in the four limbs), or both. The cardiovascular 
features include hypotension, chest pain, palpitations, bradycardia, sinus tachycardia, ventricular ectopics, 
ventricular tachycardia, and ventricular fibrillation. The gastrointestinal features include nausea, vomiting, 
abdominal pain, and diarrhea. The main causes of death are refractory ventricular arrhythmias and asystole 




I argue that production as a whole can be interpreted as a step-wise 
detoxification/purification process, which I cover for Men-Tsee-Khang after elucidating 
their perspective on the safety of Tibetan medicine(s) under the next heading. 
 
5.3  ‘This is why everyone knows that Tibetan medicines have no side effects ? 
On the third day of the ICTAM VIII conference in South Korea81, Men-Tsee-Khang doctor 
Jamyang Dolma presented on  ‘The Effectiveness and safety of traditional Tibetan medicine 
in the treatment of challenging diseases ?. Jamyang first emphasised that Sowa Rigpa has a 
long history of empirical observation and research, which ensures its safety and efficacy, 
and that practitioners do not question the reliability of the classical texts nor the efficacy 
of their system. However, globalisation has brought ƚŚĞŶĞĞĚĨŽƌ ‘ĞǀŝĚĞŶĐĞ ?ĂŶĚŵŽĚĞƌŶ
scientific studies even if these do not fit well with traditional concepts. She then 
summarised the results of clinical research undertaken by Men-Tsee-Khang on diabetes, 
hepatitis B and hypertension, and on processed mercury. Her conclusion was that Tibetan 
medicine has been proven ƚŽďĞǀĞƌǇďĞŶĞĨŝĐŝĂů ?ƚŚĂƚ ‘it ŝƐƚŽƚĂůůǇƐĂĨĞ ?, and that authenticity 
is the key to its safety and efficacy.  
 
About a week later, during a five-day introductory course on Tibetan medicine in English at 
Men-Tsee-Khang college (16-21 September 2013), amchi Nyima Gyaltsen gave a lecture on 
the Seven Essential Limbs  W which detail the proper processing of herbs into medicine 
according to the Four tantras  W and cĂŵĞƚŽĂƐŝŵŝůĂƌĐŽŶĐůƵƐŝŽŶ P ‘This [adhering to these 
textual standards] is why everyone knows that Tibetan ŵĞĚŝĐŝŶĞƐ ŚĂǀĞ ŶŽ ƐŝĚĞ ĞĨĨĞĐƚƐ ? 
(Notebook III; Diary 2013, p. 71). These bold public statements do not imply, however, that 
amchi mindlessly accept that all their medicines are equally beneficial and by extension 
 ‘ƐĂĨĞ ?  ?the two are commonly confounded by amchi as noted by Gerke 2015) in all 
circumstances. In their statements, Tibetan doctors assume that the practitioner-patient 
interaction modulates prescription and use as Rigzin Sangmo from the R&D Department 
                                                     
81 ICTAM VIII was held 9-13 September 2013, and stands for International Conference of Traditional Asian 




exemplified in her coming to terms with my questions on the existence of side effects (Diary, 
 ?DĂǇ ? ? ? ? ) P ‘for example, if you take cold [potency] medicines for a very long time this 
might negatively affect your digestion, but the practitioner can foresee this and adapt the 
medicines ĂĐĐŽƌĚŝŶŐůǇ ?. The practitioner attunes the qualities of the medicine to the 
ŚƵŵŽƌĂůƐŝƚƵĂƚŝŽŶŽĨƚŚĞƉĂƚŝĞŶƚ ?^ŚĞĚŝƐůŝŬĞĚĂƚƚƌŝďƵƚŝŶŐ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?ƚŽdŝďĞƚĂŶŵĞĚicine 
 W one of the negative hallmarks attributed to biomedical drugs for which Sowa Rigpa is 
globally represented as a natural, harmless complement or alternative82  W but did not deny 
ƚŚĞ ƉŽƐƐŝďŝůŝƚǇ ŽĨ  ‘ĂĚǀĞƌƐĞ ƌĞĂĐƚŝŽŶƐ ? ƐƵĐŚ ĂƐ ĐŽŶƐƚŝƚƵƚŝŽŶĂů ŝŶĐŽŵƉĂƚŝďŝlity or allergies. 
Saying that Tibetan medicine has side effects is often taken as a smear on the whole system, 
Ă ůĂĐŬ ŽĨ ƚƌƵƐƚ ŝŶ ƚŚĞ ƉƌĂĐƚŝƚŝŽŶĞƌ ?Ɛ ƚƌĂĚŝƚŝŽŶĂů ĞǆƉĞƌƚŝƐĞ ? ƚŚĞ ĐůĂƐƐŝĐĂů ƚĞǆƚƐ Žƌ ĞǀĞŶ ƚŚĞ
Medicine Buddha in extremis. These statements are part of a larger discursive trope 
expressed by both practitioners and patients of Sowa Rigpa that influences healthcare 
perceptions and decisions in the ubiquitous scenario of medical pluralism in Dharamsala 
(Prost 2008, p. 36-41 and 58-60). It also feeds into its globalisation and spread into 
alternative medicine and wellness markets (Janes 2002). Stereotypically, biomedical 
pharmaceuticals are strong, have rapid effects but might bring about adverse reactions 
whereas Tibetan medicine is soft, slow-acting, natural and eradicates the root-cause of the 
disease (see Besch 2006, p. 191-194 for the same trope in Spiti).  
 
In our conversation, Rigzin further pointed out the difficulty of conducting clinical research 
and rigorously following up patients at Men-Tsee-Khang clinics given the limited resources. 
Patients who are unhappy with the treatment usually explore other options and do not 
return and fill in the study questionnaires, and cured patients might not return. In this 
situation, it turns out to be nearly impossible to identify negative reactions statistically, 
outside the doctor-patient interface. On top of that, what a Tibetan in Dharamsala might 
consider a minor nuisance as part of the healing process, European patients may consider 
a problematic side effect. Even engaging with Indian road traffic abundantly made clear to 
                                                     
82 In the clinical interactions I observed between amchi and Tibetan patients (see section 5.3.3), Tibetan 
medicines were not rarely employed to abate the side effects perceived by patients undergoing strong and 
prolonged biomedical treatments (e.g. for tuberculosis, hepatitis, and HIV), and to support and protect 
weakened organs. A similar usage of mani rilbu was noted by Kloos (2010, p. 114). 
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me the very different perceptions of risk and danger. As Tsultrim Kalsang explained to me, 
taking medicines can have unpleasant but necessary effects (Audio recording 108b): 
Sometimes people taking khyung-nga or other strong medicine feel uncomfortable. It is not 
going to worsen, sometimes it gives more [healing] effect [in the end]. It takes time. If it 
continues like this, then you have to stop [taking the medicine]. Two or three days is ok. You 
need some movement, without movement there is no effect. A little bit worse, going down 
[purgation] or up [emesis]. If I have a medicine for constipation and get loose motion, then 
ƚŚĞŵĞĚŝĐŝŶĞŐŝǀĞƐĞĨĨĞĐƚ ?/ƚĚŽĞƐŶ ?ƚŵĞĂŶƚŚĞƌĞŝƐĂŶŽƚŚĞƌĚŝƐĞĂse. It is the effect. If I take 
medicine for constipation with no effect: no movement, still same as before. [Then] what is 
the use of medicine? 
 
Nevertheless, wrongly combined and constitutionally incompatible foods  W and by 
extension medicines  W can become poisons according to Tibetan medical conceptions. 
Pasang Arya elaborated on this in response to a question by one of the participants in the 
Tibetan Medicine Education Center (TME) advanced course which I attended (online 
seminar, 7 November 2015): 
student: In your experience, do you find that those with food intolerance are also sometimes 
more intolerant of herbal medicines? 
PA: Definitely (starts laughing). I have enough experience with herbs intolerance. It is 
ĨƵŶŶǇ ?ƌĞĂůůǇ ?^ƚŝůů/ĚŝĚŶ ?ƚŐĞƚĂƌĞĂůůy good answer for that. Some people, for spices 
like cardamom, have an intolerance or allergy. Some with cinnamon. Some with 
simple herbs. Some people with Sendu-5, [PADMA] Digestin. It is very simple: 
pomegranate, cinnamon, cardamom, Piper longum and galanga. These five very 
simple ingredients are generally used in food. [But] some take it and get sores in 
ƚŚĞŵŽƵƚŚ ?ŽƌƉŝŵƉůĞƐŽŶƚŚĞůŝƉƐ ? ? Q ?'ĞŶĞƌĂůůǇ ?ŝŶdŝďĞƚĂŶŵĞĚŝĐŝŶĞ/ƚŚŝŶŬ ?ƚŚŝƐŝƐ
called] menkyi öpo mépa: not-suiting medicine. It does not suit the patient. When 
the patient takes it, he gets nausea and vomits, that kind of concept. 
WĂƐĂŶŐ ƉƌŽǀŝĚĞĚ Ă ƐƚĂƌƚŝŶŐ ƉŽŝŶƚ ĨŽƌ Ă dŝďĞƚĂŶ ŵĞĚŝĐĂů ĞǆƉůĂŶĂƚŝŽŶ ĨŽƌ  ‘ƵŶƐƵŝƚĂďůĞ
meĚŝĐŝŶĞ ? ? ƐƚƌĞƐƐŝŶŐ ƚŚĞ ŶĞĞĚ ĨŽƌ ŽƌĂů ŝŶƐƚƌƵĐƚŝŽŶ  ?mengak) and knowledge-in-practice 
beyond texts. Tenzin Thaye at Men-Tsee-<ŚĂŶŐ ?ƐƉŚĂƌŵĂĐǇŐĂǀĞ the example of camphor 
as a possible source of intolerance. Being convinced that PADMA produces very good and 
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very strong medicines, he was inspired by the success of PADMA 28 to use more camphor 
medicines in his daily practice (Audio recording 86).  
JVDV: And the medicines PADMA is making, what do you think about these medicines? 
TT: Of course it is good, it should be very strong medicine. I mean, I saw the film Sowa 
Rigpa they made. And a lot of patients like it, so it is very good. I said it should be 
very strong, because you know, on camphor we have a very impressive saying in 
Tibet: it is the king of the medicine, especially [due to its] very cold and rough nature. 
ƵƚŝĨǇŽƵĚŽŶ ?ƚƉƌĞƉĂƌĞŝƚ or compound it in a very good way, it is very very harmful. 
It should not be like poison, but very harmful. Because its rough nature increases 
lung ?EŽǁ ?ĂƚƉƌĞƐĞŶƚŝŶdŝďĞƚ ?ǁĞƌĞĂůůǇĚŽŶ ?ƚƵƐĞƚŚĂƚŵƵĐŚĐĂŵƉŚŽƌ ?ŵƵĐŚůĞƐƐ ?
 ? QdŚĞƐĂǇŝŶŐŐŽĞƐƚŚĂƚƚŚŝƐŬŝng of medicine] will be harmful more than healing, kill 
ŵŽƌĞƉĞŽƉůĞƚŚĂŶŚĞůƉƉĞŽƉůĞ ? ? Q ?tsenduk, [black] aconite is the king of poison. 
This will be helpful more than harmful. These two are compared. 
 
This saying comparing the effects of camphor and aconite  W the kings of medicine83 and 
poison respectively  W warns us that what is beneficial and what is toxic is not always 
straightforward, and may even turn out to be opposite to our expectations. Similarly, amchi 
Choelothar mentioned that gabur is often taken out of formulations as it is dangerous to 
use for patients suffering from ngyen né; infectious epidemics such as Hepatitis B and 
Tuberculosis, which are locally prevalent (Barbara Gerke, Personal Communication, 2 June 
2016). 
 
During my fieldwork and in conversations with practitioners and patients, I came across 
only very few instances where Tibetan medicines were deemed to have had a negative 
ŝŶĨůƵĞŶĐĞŽŶƉĞŽƉůĞ ?ƐŚĞĂůƚŚ ?ǆĐĞƉƚĨŽƌƚŚĞǁŝĚĞůǇƌĞƉŽƌƚĞĚĐĂƐĞŽĨŚĞĂǀǇŵĞƚĂůƉŽŝƐŽŶŝŶŐ
in Switzerland and rare cases of mild stomach upset after taking PADMA 28, two other 
repeatedly mentioned formulas will be discussed hĞƌĞ ?dŚĞĐŽŵƉŽƵŶĚŶĂŵĞĚ ‘'ŽůĚĞŶ- ? ?
(serdok-ngapa) used to be produced in pill-form by Men-Tsee-Khang, but patients 
complained that the awful taste made it impossible to take these pills and even made them 
                                                     
83 Arura, chebulic myrobalan is also referred to as the king of medicine (menkyi gyälpo), Drungtso and 
Drungtso 2005, p. 346). 
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vomit (Notebook III, amchi Pema Tsetso). In response to these reports, nowadays Serdok-
5 is made in granular form and dispensed in sealed plastic pouches to facilitate ingestion. 
From my personal experience in taking this medicine for weeks with boiled water at noon 
time in Dharamsala to treat an excess of tripa and yellow sclera, I can attest that its strong 
sour/bitter taste is still exceptionally unpleasant compared to other Tibetan medicines. 
Some reported unintended consequences of taking Garuda-5 however are much more 
severe, but have equally led to adaptations in its production. Possible reactions include 
burning and numbing sensations of lips and tongue, dizziness, fainting (Audio recording 110, 
amchi Penpa Tshering), and weakened heart rhythm (Audio recording 111, amchi Tsering 
Norbu).  
 
5.3.1 Dealing with aconite toxicity, the shadow of the Garuda at Men-Tsee-Khang: dogma, 
detox or dosage? 
When I asked Tsultrim Kalsang if nowadays less aconite was being used because people 
realised how toxic it is, he explicitly responded that this was not the case (Audio recording 
80). The amount of Garuda-5 that will be prescribed first of all depends on the condition of 
the patient (being careful with children and the elderly) and the nature and severity of the 
disease (a stronger disease may need a higher dose). But the amount of aconite in the 
formula has not changed, it is standard and mentioned in authoritative texts. The formulas 
are fixed. Depending on which subtype of bongnak and its strength (i.e. how poisonous it 
is, as judged by root colour, appearance and sensation on the tongue) however, the 
method for detoxification may vary (Audio recording 108). The quality and availability of 
natural resources, itself determined by their habitat and harvesting patterns, impacts 
pharmaceutical practice. Practitioners need to be sensitive to this local ecology. Tsultrim 
has repeatedly been consulted by the pharmacy to confirm that the roots are of the right 
kind. Prolonged boiling of the roots in water, or treatment with cow milk or urine can be 
undertaken if necessary to transform the poison into medicine.84  
                                                     
84 Several experimental chemical analyses have confirmed that traditional processing methods are effective 
at the extraction of diester diterpene alkaloids (DDAs) and their conversion into less toxic monoesters (MDAs) 
(Jaiswal et al. 2013, Nyirimigabo et al. 2015, Singhuber et al. 2009). 
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But Tsultrim is an expert on plants, not a trained pharmacy expert. Penpa, who is involved 
in the day-to-day production of medicines, offered a slightly different and more practical 
perspective (Audio recording 81). He admitted that in effect the quantity of aconite is 
usually reduced to levels below what is indicated in formularies: 
It is the case. Because in earlier times people were stronger, not because of [the presence of] 
this poison. They could take this amount of tsenduk. These days people more easily get the 
ĞĨĨĞĐƚ ?^ŽǁĞŚĂǀĞƚŽƌĞĚƵĐĞŝƚ ? ? Q ?EŽƚŽŶůǇƚŚŝƐtsenduk, also these burning [cones]: moxa. 
Before we used big cones. Now we cannot use the bigger size, we use very small [ones]. 
Earlier, people were used to hard work. [They had] good energy in their body, they could take 
ĂůůƚŚŝƐ ?dŚĞƐĞĚĂǇƐƉĞŽƉůĞĂƌĞŵŽƌĞƌĞůĂǆĞĚ ? ? Q ?hƐƵĂůůǇtsenduk is not in huge quantity in 
the medicine, but we had to reduce this [further] slightly. 
 ‘The bodies of people nowadays have become frail due to a lack of manual labour ?, was an 
observation echoed by several Tibetan doctors I met. Undoubtedly taking the idealised 
harsh lifestyle of nomads and farmers on the high Tibetan plateau as a reference, medicines 
must now be adapted to the docile bodies of Tibetan exile, IndiaŶĂŶĚ ‘tĞƐƚĞƌŶ ?ƉĂƚŝĞŶƚƐ ?
Amchi must not only recognise the impact of local ecologies, but also pay attention to how 
these interact with and shape bodies. In the case of aconite we can therefore speak of local 
ecologies of toxicity, a concept that provides a Tibetan medical corrective for the so often 
reified poison/medicine dichotomy.  
 
As was confirmed by Tsering Norbu, who worked in the pharmaceutical department for 
several years in the early nineties, bongnak roots are boiled in distilled water at Men-Tsee-
Khang but are sometimes also used directly (Audio recording 111). The author of a large 
book of more than six hundred pages in Tibetan that compiles materia medica and the 
formulas in which they are represented from traditional texts, he found that boiling in 
water was actually not described as a detoxification method for bongnak.  
Maybe some experienced doctors [in the past] did it like that. But [another form of] 
detoxification is mentioned. First you have to make ash, [still hot with] fire in the wood. A 
Little bit of fire. After all the wood is burned, [one takes] a little bit warm ash. Put powder of 
Aconitum in a pan, then put it in the ash, and cover [the pan] with paper. After a few minutes, 
the paper becomes wet. The powder colour becomes a little yellow, then ... Not detoxified, 
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not like mercury. Mercury has many processes. [But its] energy has become less, that is the 
idea. 
Tséring Norbu said he has seen this being done in Lhasa Mentsikhang when he was there 
in the eighties. This detoxification method based on heat is laid out in Déumar Géshé 
Tendzin WŚƵŶƚƐŽŬ ?Ɛ ĚĞƚŽǆŝĨŝĐĂƚŝŽŶtext (1970, based on 17th century text). 85  Lastly, I 
discussed the issue with Penpa Tsering (Audio recording 110). He is a very experienced and 
well-known pharmacologist who resigned from Men-Tsee-Khang to lead his own 
production named Kundey Khangsar Tibetan Herbal Products, not far from Dharamsala.86 
Although he agrees with the other, more junior Penpa currently working in the 
pharmaceutical department that people were stronger in ancient times, he claims it is not 
possible to identify the variety of different bongnak subtypes on the market reliably as 
Tsultrim does. In line with Tsering Norbu, Penpa Tsering maintains that menchen does not 
need to be detoxified as is done in Ayurveda:  aru, Garuda- ? ?ƐŵĂŝŶŝŶŐƌĞĚŝĞŶƚ ?ĐŽŶƚƌŽůƐŝƚƐ
toxicity.87 There is considerable variation in potency due to harvesting time and location 
amongst other factors, and this should be taken into account through experience and by 
lowering the quantity accordingly.  
JVDV: You say you have to know how toxic menchen is to know the dosis. How do you 
know how toxic it is? Can you taste it or see it? 
PT: No, no. [Only] after making the pills. We have to see by experience how much we 
have to put. After making the pills, we are trying them. If it is okay [then we can use 
ƚŚĞŵ ? ?ŝĨƚŚĞƚŽǆŝĐŝƚǇŝƐŚŝŐŚƚŚĞŶǁĞĚŽŶ ?ƚhave to use that one. We can do like this 
also: we mix [the pills] again, compounding, putting less or not putting [extra] 
                                                     
85 I have not been able to verify if and which aconite detoxification methods are currently being undertaking 
at Lhasa Mentsikhang, but Tibetan doctors in Dharamsala are confident that there too the amount of bongnak 
has been lowered. Generally, compounding and detoxification techniques are only described superficially or 
not at all in the major menjor textbooks (cf. Blaikie 2014, Cardi 2005-2006). 
86 Amchi Penpa Tsering graduated from Men-Tsee-Khang college in 1986 as part of the fifth batch of medical 
students. He expressed an interest in the pharmacy, and was one of the two students of his year chosen by 
Tenzin Namgyal because of his hard-working attitude during herb collection excursions. He worked in 
production continuously for more than seven years and gained considerable experience under his guidance 
and under Tenzin Chödrak. From 1997 to 2004 he started manufacturing Tibetan medicine independently as 
side work, but as he was transferred to the publication department, administrative work prevented him from 
continuing. He finally resigned in 2008 and started working in his private factory again. In 2009, he was 
appointed Visiting Physician to the Dalai Lama. In July 2012 his pharmacy became the first after Men-Tsee-
Khang itself to register at CCTM after passing the inspection.  
87 Blaikie (2014, p. 286) reports that khyung-nga is also extremely popular in Ladakh, where the detoxification 
of bongnak ŝŶĐůƵĚĞƐ ‘several hours of constant grinding by hand while mixing in precise proportions of arura 
(Terminalia chebula ) ?ǁŚŝĐŚŶĞƵƚƌĂůŝƐĞƐŝƚƐƉŽŝƐŽŶ ? ? 
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menchen. Putting other things will lessen the toxicity. 
JVDV: You only test the pills.  
PT: Yes. 
JVDV: Sometimes [if you sense a] burning feeling, then you know it was maybe too high? 
PT: Yes yes, after half an hour or one hour if the toxic[ity] is high, then adverse 
[reactions] happen. 
JVDV: What kind of feeling? 
PT: The tongue and lips. And sometimes we cannot walk also, or cannot see well. Strong, 
sometimes very strong. People fell down. 
JVDV: Have you seen that? 
PT: Yes, many cases. It happened to some patients as well. Before you [the pharmacist, 
has to] check well, that is important. After giving it to patients, if there are some 
problems, then sometimes [the prescribing] doctor will taste.  
JVDV: Also in Men-Tsee-Khang they had this problem in the past, I heard? 
PT: Yes, many times. So, the doctor who compounds should check well, be very careful, 
ƚŚĂƚ ?ƐŝŵƉŽƌƚĂŶƚ ? 
 
Experimenting with black aconite and Garuda-5 is clearly not without danger to 
pharmacists and patients.88 In case adverse effects do occur, Tibetans may have some 
noodle soup (thukpa) or yoghurt and take a rest. If they complain to the practitioner, the 
dose may be reduced (e.g. only one or two small black pills instead of three or four).  
 
5.3.2 Pharmaceutical production as a purification process 
Here I will briefly outline the main steps in the manufacturing process of rilbu at Men-Tsee-
<ŚĂŶŐ ?ƐƉŚĂƌŵĂĐĞƵƚŝĐĂůĚĞƉĂƌƚŵĞŶƚ ?dŚŝƐmay be read in tandem with Chapter 3, where 
WD ?Ɛ ƉƌŽĚƵĐƚŝŽŶ ůŝŶĞ ǁĂƐdescribed. Then, I will provide some more detail on one 
particular production event of Garuda-5 that I partly observed and discussed at length with 
Penpa to illustrate the specificity of this formula. The making of Tibetan medicine can be 
interpreted as a stepwise process in which potency is maximised while toxicity is minimised. 
                                                     
88 ƐǁĂƐƉƵƚĨŽƌǁĂƌĚďǇƚŬŝŶ ? ? ? ? ? ) ?ŝŶĚŝŐĞŶŽƵƐŚĞĂůĞƌƐŚĂǀĞ ďĞĞŶŬŶŽǁŶƚŽƵƐĞ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?ĂƐĚŽƐĂŐĞ
markers. In Chinese medicine, boiled aconite roots are also reported to be tested traditionally through taste: 
the absence of tingling and numbing sensations from trying the decoction implies they are ready for use 




compounded and to supervise the whole procedure (Notebook VII). Most of the around 
170 medical formulations are produced only once a year or less, but a few very popular 
ones  W such as Agar-8, Agar-35, Dashel-37, and particularly  ‘Ma  ? ?(sold as a granulate in 
typical herbal tea packaging)  W up to three or four times a year. The pharmacy employs 
more than sixty staff, including a handful of amchi and three laboratory analysts. During 
the productive time of the year (outside of the Winter and Monsoon seasons), the 
pharmacy workers operate in shifts from Monday to Saturday, 7 AM to 6 PM. During this 
period, the grinding and sieving of raw materials, and the rolling, coating and drying of pills 
are daily activities. Before raw materials can be used as ingredients, they first need to pass 
ďǇ ƚŚĞ ƉŚĂƌŵĂĐǇ ?Ɛ ĐůĞĂŶŝŶŐ ƐĞĐƚŝŽŶ where unwanted parts and foreign materials are 
removed by various means, including washing, manual sorting and separation of heavy and 
light particles using air ventilators. This is the most labour-intensive production step, 
providing work for up to twenty people.  
 
The actual formulation of a new medicine usually started at WĞŶƉĂ ?ƐŽĨĨŝĐĞ ?,ĞĐŽƉŝĞƐ the 
sequence of ingredients and amounts from a previously produced batch record onto a new 
product ingredient list 89 , ensuring a continuity in Men-Tsee-KhanŐ ?Ɛ ƉƌŽĚƵĐƚŝŽŶ
independent of external written sources. A duplicate list is then presented to the manager 
in charge of the store section, who maintains a storage register and organises workers to 
gather the necessary bags of materials. Labourers from the cleaning and store sections 
work together to weigh the needed quantities of each material, which are poured out and 
mingled on a large canvas sheet and then transported to the grinding section (there are 
ƚǁŽ ‘ƉƵůǀĞƌŝǌŝŶŐĂŶĚƐŝĞǀŝŶŐƌŽŽŵƐ ? ) ?dŚĞƌĞ ?ƚŚĞĐƌƵĚĞŵĂƚĞƌŝĂůƐĂƌĞĨŝƌƐƚŐƌŽƵŶĚƚŽŐĞƚŚĞƌ
coarsely, and then as increasingly finer powder in two or three steps. The powder is again 
bagged, and after sieving (the finest mesh is 100 micron) it is ready to be rolled into pills at 
the coating section. This is the second-most labour-intensive section. Up to a dozen 
                                                     
89  This list is not exhaustive in the sense that very small quantities of ritually blessed and empowered 
substances (see Kloos 2010 p. 112-126) are sometimes added to these sensu stricto formula ingredients later 
on during the pill rolling process, dissolved into boiled water. At this point and during pill coating, other 
supplementary components may be added as well, for instance to affect pill colour (mostly red, yellow or 
black), to improve powder coagulation, and to put formula ingredients in decoction (thang) or solid extract 
(khenda) form. The different coating decoction mixtures vary from pill to pill. 
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workers are active in a repetitive procedure of adding increasing portions of powder and 
boiled liquid together in a rotating stainless steel barrel (also called coating pans, five of 
ƚŚĞƐĞĂƌĞĂǀĂŝůĂďůĞ ) ?ǁŚŝĐŚĨŝƌƐƚŐĞŶĞƌĂƚĞƐ  ‘ƉŝůůƐĞĞĚƐ ? ?rilsön, smaller than barley grains). 
These pill seeds are then partially dried on low wooden frames covered with cloth before 
the barrel procedure is repeated to add bulk to and coat the pills further. When the rilbu 
reach their standard size, they are made shiny by rotating them once more and then size-
checked. A lot of effort goes into ensuring uniform batches of equally sized and coloured, 
round pills. Size sorting machinery (as observed by Saxer 2013, p. 78) is available and has 
been used in the past by Men-Tsee-Khang, but amchi consider the results inferior to 
manual sorting which also makes it easier to attend to different pill sizes. A similar 
assessment is made for the oven-type equipment used to dry pills. Even though it is much 
quicker than air-drying outside or inside, it is not a preferred option as it may reduce the 
potency. The final drying session takes two to three days, depending on weather conditions. 
When fully dried  W which is checked by manually testing pill hardness using the teeth and 
confirmed in the laboratory, where hardness and moisture content are quantified  W the 
pills are bagged and transported to the counting and packaging section. There, they are 
counted and sealed into food-grade plastic bags of 1,000 dosages (usually 3,000 pills) and 
put in larger sacks of 20,000 dosages. Finally, the sacks are kept in the medicine sales and 
store section from where they are dispatched to branch clinics upon receiving an order. It 
is useful to provide some more numbers to get an idea of the size and intensity of this 
operation. For example, more than seventeen tons of raw material were purchased by the 
department and more than thirty batches of different pills (about one every two days) were 
manufactured in the peak production time I witnessed from April to May 2014 (Notebook 
IX). The hugely popular Agar-35 formula is compounded at least two times a year, and on 
April 22nd 667 kg of raw materials were made into more than five lakhs of pills (i.e. more 
than half a million daily doses).90  
 
                                                     
90 Agar-35 ?Žƌ ‘ĂŐlewood- ? ? ? ?is of particular interest not only because of its popularity as a gentle and safe 
treatment for lung disorder and upper back pain amongst others (Tsarong 1986), but also because it is one 
of the formulas that contains all four of the herbs that are the subjects of this dissertation. While the amount 
of each component is relatively small in this formula of thirty-five ingredients, the potentially poisonous 




Figure 5.6. The main steps of rilbu production at Men-Tsee-Khang, left to right and top to bottom. Pre-processing 
(manual sorting of pangpö), weighing and compounding of raw materials (in this case Tikta-8), grinding, mixing, pill 
rolling, size checking, drying (Agar-35), and counting, labelling and packaging. Photographs taken by the author, 




On February 27th 2014, 634 kg of Garuda- ?ǁĂƐĐŽŵƉŽƵŶĚĞĚƵŶĚĞƌWĞŶƉĂ ?ƐƐƵƉĞƌǀŝƐŝŽŶ ?
following the recipe outlined in Tables 5.1 and 5.2 in the first section of this chapter. 
Afterwards, we discussed this particular production event in considerable detail (Audio 
recording 90). Aru, the principal ingredient, was first cleaned by blowing off the dust from 
the fruits using a large fan and then by carefully picking out the seeds and other foreign 
materials by hand. Ruta ǁĂƐ ĂůƐŽ ĚƵƐƚĞĚ ĨŝƌƐƚ ? dŚĞ  ‘ŽƵƚĞƌ ďĂƌŬ ?  ?ĐŽƌƚex) of this root is 
generally not removed, although practitioners are aware that this is the best practice 
prescribed in the texts. This would require a lot of extra labour since large volumes of it are 
used in many compounds. If they are very muddy, the roots are washed with cold tap water. 
The pre-processing of shudak roots is identical. Arriving at the third ingredient, menchen, 
WĞŶƉĂŶŽƚĞĚ ƚŚĂƚ P  ‘dŚŝƐ ƚŝŵĞǁĞƉƵƚŶŽƚ ƐŽŵƵĐŚ ?ďĞĐĂƵƐĞ ŝƚ ŝƐ ǀĞƌǇ ƐƚƌŽŶŐĞŶĞƌŐǇ ?  ? Q ?
These days first we have to clean it, thĞŶǁĞŚĂǀĞƚŽďŽŝůŝƚĨŽƌĂůŝƚƚůĞďŝƚƚŽƌĞĚƵĐĞƚŚŝƐ Q
,ŽǁƚŽƐĂǇ QWŽƚĞŶĐǇ ?ǇĞƐŵĂǇďĞduk ? ? This quote points to the slippage or partial overlap 
between potency and toxicity. It also highlights the perception and manipulation of 
variation in pharmacological action. Aconite root is the only ingredient that needs proper 
dukdön in this formula. Senior pharmacy doctors advise on how long the roots should be 
boiled depending on the nature of each batch and based on their experience. The fifth 
formula component, gulnak, is purchased as a resin that is added as a decoction at the time 
of pill rolling. When he explained to me that the typical dark black colour of the khyung-
nga ƉŝůůƐŝƐďĂƐĞĚŽŶĚĞƚŽǆŝĨŝĞĚ ‘ŝƌŽŶƉŽǁĚĞƌ ? ?chakché), I was puzzled. Only after going over 
the process several times and after a good laugh about magnetic Tibetan pills did I come to 
realise that iron is actually not added directly to the medicine. Solid iron powder is put in 
boiled water with aru powder for seven to ten days. The aru absorbs the nüpa of iron, 
becoming very dark in colour. The iron is then drained out using a magnet, and the 
remaining powder (chaktsi ?  ‘ŝƌŽŶ ĞƐƐĞŶĐĞ ? ) ŝƐ ĚƌŝĞĚ ĂŶĚ ůĂƚĞƌ ĂĚĚĞĚ ƚŽ ƚŚĞ Ɖŝůů ĐŽĂƚŝŶŐ
decoction.91 When the pill coating is finished, the tiny black pills are dried outside in the 
sun like all medicines (except precious pills containing ngülchu, or if the weather does not 
allow it). Since the pills are small, they dry more quickly than usual. 
 
                                                     
91 The practical procedure for making chaktsi is briefly described in Dawa (2003, p. 399). 
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In the practical context of menjor, safety and being free of side effects is not a given but 
the ideal result of a complicated series of carefully executed procedures. As Cardi (2005-
2006) details, Tibetan practitioners regard single-ingredient herbal medicines as inferior in 
efficacy and potentially harmful compared to multi-compound formulas where the 
therapeutic actions of the ingredients are coordinated, potential harmful effects balanced 
out, and where composition may be adjusted to individual patients. Throughout the entire 
procedure  W which takes place along the lines of the Seven Essential Limbs and involves 
gathering the raw materials, drying, storing, pre-processing (dukdön, including cleaning and 
more complex detoxification practices), grinding into powder, mixing, rolling pills and 
finally drying again (at least at Men-Tsee-Khang, see Blaikie (2014) and Saxer (2013) for 
more details on the different steps in other places)  W the aim is to obtain a potent medicine 
ƚŚĂƚ ŝƐ ĂůƐŽ  ‘ƐŵŽŽƚŚ ? ? dŚĞ ĐŽĂƌƐĞ ƉŽƚĞŶĐŝĞƐ ŽĨ ƚŚĞ ŝŶŐƌĞĚŝĞŶƚƐ ĂƌĞ ĞůŝŵŝŶĂƚĞĚ ƚŚƌŽƵŐŚ
cleaning and ĚĞƚŽǆŝĨŝĐĂƚŝŽŶƚŽƉƌĞǀĞŶƚŚĂŵƉĞƌŝŶŐŽĨƚŚĞƉĂƚŝĞŶƚ ?Ɛ ‘digestive fire ? (médrö). 
The medicine is then further made smooth (jam tselwa) by adding supportive ingredients 
that counteract unwanted effects and protect certain organs if needed. Related to this, 
Blaikie (2014) observed that many Ladakhi amchi (as well as Tibetan amchi in China) are 
suspicious of factory-made Tibetan medicines as it is impossible to know precisely  W and 
thus prescribe appropriately  W the contents and properties of formulas not made by 
themselves. From a Tibetan medical viewpoint then, unwanted effects are likely to arise if 
the medicines have been ƉŽŽƌůǇŵĂŶƵĨĂĐƚƵƌĞĚ ?,ŽǁĞǀĞƌ ? ‘the suitability of a medicine can 
be completely assessed only by matching it with the patient, his general health state, age, 
ďĞŚĂǀŝŽƵƌĂŶĚŐĞŶĚĞƌ ? (Cardi 2005-2006, p. 98). 
 
5.3.3 Khyung-  i Gangkyi clinic: personalised prescription as a safety buffer 
I sat next to Sonam Wangmo92 for a few hours on a weekly basis from April to May 2014 
(Fieldnotes VII-IX), observing doctor-patient interactions in consultation room C3 of the 
                                                     
92 Amchi Sonam Wangmo was born in Sikkim. She was inspired to become a Tibetan physician through the 
ĞǆĂŵƉůĞƐĞƚďǇŚĞƌŐƌĞĂƚŐƌĂŶĚŵŽƚŚĞƌ ?ĂŶĚĂĨƚĞƌǁĂƚĐŚŝŶŐĂ ‘ůĂĚǇĚŽĐƚŽƌ ?ŽŶƚĞůĞǀŝƐŝŽŶwhen she was young. 
She moved to Dharamsala to join the tenth batch of Men-Tsee-Khang medical students, and finished her 
Kachupa studies in 1999 after a one-year internship at Gangkyi branch clinic. After ten years of clinical practice, 
she obtained the Menrampa degree at Men-Tsee-Khang college. In 2014, she already had more than fifteen 
years experience in Tibetan medical diagnosis and prescription. She was part of an official two-month clinical 
tour to Kazachstan, and has also been privately invited by patients to Denmark and Germany. 
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Gangkyi clinic.93 ^ŽŶĂŵ ?Ɛ ĨƵůů ŶĂŵĞ ŝƐ ƉĂŝŶƚĞĚ ŝŶ dŝďĞƚĂŶ ĂŶĚ ZŽŵĂŶ ƐĐƌŝƉƚ ŽŶ Ă ŐƌĞĞŶ
plaque above the door post, which is covered with a thin curtain that leaves little space for 
the privacy many Westerners are used to in healthcare settings at home. The room is 
decorated with a Men-Tsee-Khang Tibetan calendar and a photo of His Holiness. The 
regular patients were mostly middle-aged and elderly Tibetans94, but Indian tourists and 
groups of Europeans, Russians, Australians, Japanese and many other countries also 
frequent this clinic situated next to Men-Tsee-Khang college and close to the Central 
Tibetan Administration (CTA) (Audio recording 74).  
 
A typical consultation lasts about ten minutes, or even less for regular patients, and 
ƉƌŽĐĞĞĚƐ ĂƐ ĨŽůůŽǁƐ ? dŚĞ ƉĂƚŝĞŶƚ ĐŽŵĞƐ ŝŶ ? ƐŝƚƐĚŽǁŶ Ăƚ ƌ tĂŶŐŵŽ ?ƐŽĨĨŝĐĞ ƚĂďůĞ ? ĂŶĚ
hands over their medicine prescription booklet (mendep). The amchi looks at the first page 
ĨŽƌ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŶĂŵĞ ĂŶĚ ĂŐĞ ? ĂŶĚ ƚŚĞŶ ĐŽŶsults the last written page to see which 
medicines were prescribed at the previous consultation. The patient explains her current 
health status in a few words and/or the doctor asks a few short questions. The pulse is read 
from both wrists during half a minute of focussed silence, after which the doctor may 
generate some more observations and questions to be confirmed by the patient.95 A few 
pieces of dietary and behaviourĂůĂĚǀŝĐĞĂƌĞƉƌŽǀŝĚĞĚƐƵĐŚĂƐ ‘eat less butter and greasy 
ĨŽŽĚƐ ? or  ‘dress warm and avŽŝĚĐŽůĚĂŶĚĚĂŵƉƉůĂĐĞƐ ?. Pills are prescribed for morning, 
lunch and evening time on a receipt to be given to the cashier and dispensary. Patients 
above sixty-five years of age and CTA and Men-Tsee-Khang staff members and their families 
are treated free of charge. Monks, nuns, and poor people (including newly arrived refugees) 
get a concessional rate at half of the normal charge, which is already cheap (100 rupees or 
1.5 USD consultation fee and about 10 extra per day for the pills) compared to biomedical 
                                                     
93 This branch clinic was the tenth to be established (in 1983) of the fifty-nine operating clinics established by 
the end of 2015. It is equipped with a dispensary, cashier, three consultation rooms and several wooden 
benches for the queuing patients. 
94  See Prost (2008, p. 43-53) for a list and discussion of diseases and disorders prevalent in the exile 
community and their purported causes, and for the link with social inequalities between different generations 
of (migration of) Tibetans (p. 54-73).  
95 Urine analysis is very rarely conducted in this clinic. As part of the diagnosis, Sonam also pays attention to 
skin complexion and occasionally investigates the eyes, tongue and finger nails of patients in more detail. 




consultation and medicine. The amchi fills in the prescription booklet, signs the receipt, and 
also notes down the date, patient name and country, and the medicines down in a large 
record book. 
 
I asked a number of doctors what khyung-nga is commonly used for, and the keywords I 
got back were  ‘ŝŶĨĞĐƚŝŽŶ ? ? ‘ŝŶĨůĂŵŵĂƚŝŽŶ ? ?ĂŶĚ ‘ƉĂŝŶ ?. Typical examples I was given were to 
keep one pill in your mouth in case of painful toothache, or to take a few against knee pain 
or acute headache caused by sin. Several amchi and patients referred to Garuda- ?ĂƐ ‘ĂƐŽƌƚ
ŽĨĂŶƚŝďŝŽƚŝĐ ? ǁŝƚŚƚŚĞĨŽƌŵƵůĂ ?ƐĨĂƐƚ-acting antibacterial effects in mind. Personally, this 
activity range reminded me of common nonsteroidal anti-inflammatory drugs with 
analgesic properties such as Ibuprofen. During my time at the clinic, I witnessed more than 
a dozen cases where Garuda-5 was prescribed albeit only once in isolation. Amchi-la 
confirmed that lay people know that khyung-nga works, and they will specifically ask for it 
when in need. Tibetan medicines however are not usually prescribed as a single multi-
compound formula consisting of processed and complex natural ingredients, but as a 
combination of formulas to be taken before breakfast, after lunch and after dinner. Garuda-
5 in particular is one of the several formulas that is sometimes compounded and frequently 
prescribed together with others, to be taken at the same time of day: a third-order 
combination or compounding of compounds. This flexibility and complexity is required 
according to Sonam to treat contemporary problems and diseases, which have become 
more complicated. In contrast to nowadays, senior doctors in ancient times were very sure 
about their diagnosis and preferred to wait and see the effect of single formulas, which 
they may have prescribed three times a day for seven days.96 I will now briefly describe two 
consultations I witnessed which included Garuda-5 in different configurations. 
 
On a rainy and foggy morning, my spouse Wim went for a consultation with Sonam. He 
wanted to test the amchi ?ƐƉƵůƐĞƌĞĂĚŝŶŐƐŬŝůůďǇŶŽƚŐŝǀŝŶŐĂŶǇ ŝŶĨŽƌŵĂƚŝŽŶŝŶĂĚǀĂŶĐĞ ?
Feeling his left pulse, she enquireĚŝĨŚĞŚĂĚƐůĞĞƉŝŶŐƉƌŽďůĞŵƐ ? ‘Yes, sometimes I just wake 
                                                     
96 Penpa Tsering equally felt that khyung-nga is prescribed much more by Tibetan doctors nowadays, as 
bacterial and viral diseases have become more prevalent (Audio recording 110). 
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up ŚĞƌĞĞǀĞŶŝĨƚŚĞƌĞŝƐŶŽƐŽƵŶĚ ? ? She feels his pulse on both sideƐ ? ‘You have a sore throat 
ĂŶĚƐŝŶƵƐƉƌŽďůĞŵƐ ? ?tŝŵŶŽĚƐ ? ‘sĞƌǇŽĨƚĞŶ ? ? ‘Yes, I am sneezing a lot. I think it is a pollen 
ĂůůĞƌŐǇ ? ? The doctor focuses for a longer ǁŚŝůĞ ? ŚŽůĚŝŶŐ ŚŝƐ ƚǁŽ ǁƌŝƐƚƐ ?  ‘^ƚŽŵĂĐŚ ? ůŝƚƚůĞ
ŝŶĚŝŐĞƐƚŝŽŶ ? ? ‘Yes! That is a third problem, I have very irregular bowel movements ŚĞƌĞ ? ? 
We were both impressed by her accurate diagnosis. After thinking this over a few seconds, 
^ŽŶĂŵĂĚĚĞĚƚŚĂƚŚĞŵĂǇŚĂǀĞ ‘ĂůŝƚƚůĞ'ŝĂƌĚŝĂ ?. She asks if he has taken any medicine for 
that. The answer is negative.  ‘ŽŶ ?ƚĞĂƚĞŐŐƐ ?Ɖapaya or spicy food like chili, rice is okay. 
Come back again after ten days for a check-ƵƉ ? ? The amchi decided to prescribe three 
Mangjor precious pills, a popular medicine indicated for gastro-intestinal problems due to 
poisoning and unaccustomed foods. These had to be taken in intervals of three days, and 
other medication should be suspended at this time. He was also prescribed one Dashel-37 
pill every morning for the stomach, and Pangkhyung  W three Pangyen-15 for the sore throat 
and to take out mucus, taken together with three Garuda-5 pills for infection and 
inflammation in the nose, throat and stomach  W in the afternoon. After dinner it was 
recommended that he should take Yuril-13 for the intestines, because stomach upset 















Figure 5.7 ? tŝŵ ?Ɛ ŵĞĚŝĐŝŶĞ ? ƉƌĞƐĐƌŝďĞĚ ďǇamchi Sonam Wangmo on 6 May 2014. The white sheet is the actual 
prescription; the blue one is the receipt given after payment at the cashier, which is stamped after receiving the pills 
from the dispensary. The rilbu are counted manually and packed in small plastic or paper bags (see Figure 5.8 for more 
detail). The three Mangjor precious pills are individually packaged and accompanied by a leaflet describing the main 
ingredients, indications, preparation instructions, cautions, and mantras to be recited. Wim experienced no adverse 





Figure 5.8. Detail of the rilbu prescribed to Wim. This photograph also shows the three different sizes of pills produced 
by Men-Tsee-Khang. The largest are around 1.3 cm diameter (black), medium size 0.8 cm (brownish), and the smallest 
(black, Garuda-5) about 0.3 cm. 
 
Later the same day, an energetic seventy-year-old Indian woman from the nearby village 
of Sidhbari entered the consultation room while her husband waited outside. Dressed very 
youthfully and wearing strong perfume, she sat down and put her iPhone on the office 
table. She immediately started summing up her ailments in English interspersed with Hindi, 
with a serious skin disorder that had spread over her arms and legs at the ƚŽƉŽĨƚŚĞůŝƐƚ ? ‘It 
is not psoriasis or scabies, an allopathic doctor saiĚŝƚǁĂƐĂůůĞƌŐŝĐĞĐǌĞŵĂďƵƚ/ĚŝĚŶ ?ƚǁĂŶƚ
the cortisone. The skin peels off, but it keeps coming back. I take thyroxin every day. I took 
Tibetan medicine for years for bronchial asthma, it got better but was not completely 
ĐƵƌĞĚ ? ? ‘And your blood pressure ? ? ‘EŽŚŝŐŚďůŽŽĚƉƌĞƐƐƵƌĞ ? ? After taking the pulse, Sonam 
noted that internal fever is present, a very hot pulse. The lady also had a tripa constitution. 
Amchi-la advised to avoid lemon and sour yoghurt. The patient was a strict lacto-vegetarian. 
Her sleep was bad; she wakes up every half an hour. Sonam summoned another senior 
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female amchi from the adjacent room to discuss the case. Together they concluded that 
there was indeed a chronic hidden fever and that chuser was disturbed. The doctor 
explained to the patient that because of her age, less strong medicines were advisable. Two 
different combinations of medicines had to be taken alternatively for this purpose, to 
reduce the dose. The medicines should be taken rather soon after eating, with hot water. 
To smoothe the skin, tripa lotion (produced by Men-Tsee-<ŚĂŶŐ ?ƐƐĞƉĂƌĂƚĞŚĞƌďĂůƉƌŽĚƵĐƚƐ
department) was prescribed. After the patient had left, Sonam explained to me that taking 
high doses of strong medicine could result in low blood pressure, which may lead to fainting. 
These reactions are not considered side effects or even an  ‘ŽǀĞƌĚŽƐĞ ? ?ďƵƚĂƌĞŝŶƚĞƌƉƌĞƚĞĚ
ĂƐĂĐŽŶƐĞƋƵĞŶĐĞŽĨƉƌĞƐĐƌŝďŝŶŐŵĞĚŝĐŝŶĞƐ ŝŶĂƉƉƌŽƉƌŝĂƚĞĨŽƌƚŚĞƉĂƚŝĞŶƚ ?ƐĐƵƌƌĞŶƚƐƚĂƚĞ ?
Thangchen-25 was prescribed in the morning time to purify the blood and separate the 
hidden fever from it. After lunch, ngulchu-18 was prescribed to reduce chuser and to ward 
off afflictions by naga. Skin problems are commonly related to these serpent spirits 
(although this was not mentioned to the patient), and here ngülchu is particularly effective. 
Two combinations to be taken on alternate days were prescribed for the evening: Gurgum-
13 plus Khyung-nga-nila97, for the liver and impure blood, and to fight infection related to 
lymph respectively), and Pökar-10 plus Khyung-nga-nila. The latter is helpful against itching 
skin. 
 
5.4 Poisonous medicines and medical poisons: potent substances, risk and the body 
ecologic 
In this chapter, I have attempted to move beyond the simplistic application of the 
poison/medicine dichotomy ƚŽ ƉŽƚĞŶƚ ƐƵďƐƚĂŶĐĞƐ ? /Ŷ WD ?Ɛ ^ǁŝƐƐ ĂŶĚ ƵƌŽƉĞĂŶ
ƐĐĞŶĂƌŝŽƐ ?ƚŚĞƉŽƚĞŶĐǇŽĨdŝďĞƚĂŶŵĞĚŝĐŝŶĞƐŝƐŵĂƌŐŝŶĂůŝƐĞĚĂƐƉĂƌƚŽĨƚŚĞ ‘ĐŽŵƉůĞŵĞŶƚĂƌǇ ?
herbal sector and through biomedically biased assessments of safety and efficacy based on 
risk/benefit ratios. Such evaluations further reinforced pharmaceutical regulations that cut 
                                                     
97 I was not able to retrieve the ingredients of this medicine from contemporary formularies. The pills have 
the same size and appearance as the Garuda-5 formula, to which some extra components are added to make 
it more effective against sores and skin problems (Penpa Tséring, Audio recording 110). Pasang Arya learned 
about khyung-nga-nila from the famed Tenzin Chödrak, and remembered that lapis lazuli (mumen, hence 
 ‘nila ?ǁŚŝĐŚŝƐ^ĂŶƐŬƌŝƚĨŽƌ ‘ďůƵĞ ? )ĂŶĚƉƵƌŝfied mercury is added (Personal Communication, 6 August 2016). 
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off powerful plants like aconite from being used medicinally, rendering them obsolete. 
Aconite and its alarming alkaloids have been demonised while remaining a potential source 
for chemical drug leads. These are hindered far less in drug discovery trials and registration, 
ƌĞůǇŝŶŐŽŶƚŚĞƐĞƉĂƌĂƚŝŽŶŽĨ ‘ŵĂŝŶ ?ĨƌŽŵ ‘ƐŝĚĞĞĨĨĞĐƚƐ ?; side effects that haunt even the most 
ubiquitously used pharmaceutical. At the same time, medicines of Asian origin suffer from 
a bad image especially amongst health authorities and the biomedical establishment due 
ƚŽůĂĐŬŽĨĞǀŝĚĞŶĐĞĂŶĚŝŶƚŚĞǁĂŬĞŽĨĚĞĂĚůǇƉŽŝƐŽŶŝŶŐƐĐĂŶĚĂůƐ ?EŽŶĞƚŚĞůĞƐƐ ?WD ?Ɛ
Grippe-Formel has been able to survive on the niche market of Appenzell Ausserrrhoden, a 
fragile refugium, which so far protects this formula from extinction.  
 
Set at the foot of the Indian Western Himalayas, Men-Tsee-Khang has not escaped the 
ripples caused by the shockwaves of heavy metal contamination and poisoning by Tibetan 
and Ayurvedic medicines brought to light by laboratories and hospitals in Switzerland and 
ďĞǇŽŶĚ ?dŚĞƐĞ ‘ĨĂĐƚƐ ?ŶŽƚǁŝƚŚƐƚĂŶĚŝŶŐ ?ŵĂŶǇdŝďĞƚĂŶĚŽĐƚŽƌƐĐŽŶƚŝŶƵĞƚo claim that Sowa 
Rigpa is side-effect free as long as it is manufactured authentically and correctly prescribed. 
It is clearly delusional and also epistemologically unfitting to expect Men-Tsee-Khang to 
ŝŵƉůĞŵĞŶƚĂƉŚĂƌŵĂĐŽǀŝŐŝůĂŶĐĞƐǇƐƚĞŵŽƌƚŽƐƚĂƌƚƚĂŬŝŶŐƐƚŽĐŬŽĨ ‘ĂĚǀĞƌƐĞƌĞĂĐƚŝŽŶƐ ?ƚŚĞ
way science-driven toxicologists would. On the other hand, given the data I have collected, 
it is also impossible to maintain that Tibetan pills do not have the potential to harm the 
patient. The more interesting question then becomes who takes responsibility for this 
danger, and how it might be averted by both doctors and patients. Garuda-5 presents us 
with a particular case in which a very popular medicine for inflammatory pain has brought 
about unintended consequences in some patients in exile, challenging dogmatic 
interpretations of classical medical texts and formularies. The formulation and actual 
production of rilbu can be seen as a step-wise purification/detoxification process that 
removes, transforms and baůĂŶĐĞƐŽƵƚŽƌ  ‘ƐŵŽŽƚŚĞƐ ? ƚŚĞƵƐĞůĞƐƐ ? ĐŽĂƌƐĞĂŶĚƉŽŝƐŽŶŽƵƐ
elements of materia medica. In the daily workings of the pharmacy however, practical 
experience-based decisions have to be taken on the exact details of this process. Which 
ƚǇƉĞƐŽĨĂĐŽŶŝƚĞĐĂŶďĞƵƐĞĚĂƐ ‘ƚŚĞŐƌĞĂƚŵĞĚŝĐŝŶĞ ? ?menchen), what amount, should the 
roots be pre-boiled or not? Different opinions and methods abound, but all amchi agree 
that extreme caution should be exercised. The menjor experts I interviewed further agreed 
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that the actual amount of aconite to be added depends on the strength of the raw material 
and on the strength of patient bodies nowadays, resulting in a considerably lower dosage 
than what is recorded in historical and contemporary references. The real danger then lies 
in the uncritical adoption of textual formulas by unexperienced producers, or not attending 
to the local ecologies of toxicity manifested in the interaction between Tibetan medicinal 
plants, skilled producers-with-machines (cf. Chapter 3), and the local biologies of patient 
ďŽĚŝĞƐ ?/ŶƚŚĞĐůŝŶŝĐ ?ƉƌĂĐƚŝƚŝŽŶĞƌƐĚŝĂŐŶŽƐĞƚŚĞƉĂƚŝĞŶƚ ?ƐĐŽŶƐƚŝƚƵƚŝŽŶand imbalances of the 
elements and prescribe medicines as part of a larger treatment regimen that further 
considers intricate relationships with food and environment. Garuda-5 fulfils its medicinal 
role within this clinical encounter as a compound among compounds, which I described as 
another level of the balancing act that maximises its healing potential. If we approach the 
activity of potent substances as a multidimensional spectrum constituted by its contingent 
socio-material surroundings, there is no more need for a rigid poison-medicine opposition 
or simplistic dose dependencies. 
 
As pronounced by Shepard (2004), a sensory ecology approach that recognises the 
interwoven biological and cultural dimensions of the role of the senses in medicinal plant 
selection, notions of aetiology and efficacy, and human-environment interactions in 
general is necessary to understand both cross-cultural similarities and differences. In his 
comparison of two rainforest communities in south-eastern Peru, Shepard (2004, p. 256) 
found that in both medicines are equally poisons but for divergent reasons:  ‘Unlike the 
allopathic notion of medicine-as-poison among the Matsigenka, Yora medicines are 
poisons not through opposition but through similarity  W indeed, identity with the 
pathogenic agent ?. The Yora thus construe efficacy in homeopathic terms in which 
medicine, illness and poison share the same spirit-related agency and nature as captured 
by the term rao. A similar notion is used for instance in South Africa:  
The [Zulu] term muthi (spelled muti in Xhosa transliterations) derives from the Nguni root -
thi, signifying 'tree.' Usually translated into English as either 'medicine' or 'poison,' with the 
anodyne 'herbs' used in ambiguous instances, muthi refers to substances fabricated by an 
expert hand, substances designed by persons possessing secret knowledge to achieve either 
positive ends of healing, involving cleansing, strengthening, and protecting persons from evil 
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forces, or negative ends of witchcraft, bringing illness, misfortune, and death to others or 
illicit wealth and power to the witch. (Ashforth 2005, p. 211-212) 
The power of muthi is based on the mostly invisible agency of human-spirit-substance 
communication whereas the healing/witchcraft distinction is one of moral legitimacy and 
dependent on the motives of the user, expressed in white versus black muthi categorisation. 
But even healing muthi is often intended to bring death to the witch who inflicted the 
patient. This ambivalence is however being concealed by Post-Apartheid (1994) state 
ĞĨĨŽƌƚƐ ƚŽ ƌĞǀĂůƵĂƚĞĂŶĚ ƌĞŐƵůĂƚĞ ƚŚŝƐŽĨƚĞŶ ƐĞĐƌĞƚŬŶŽǁůĞĚŐĞĂƐ  ‘ĨƌŝĐĂŶ ƐĐŝĞŶĐĞ ?, while 
eradicating witchcraft as superstition. This concealment of ambivalence also occurs in the 
public discourses of practitioners (as in amchi JamyaŶŐ ŽůŵĂ ?Ɛ ƉƌĞƐĞŶƚĂƚŝŽŶ ? ƋƵŽƚĞĚ
above), and by means of the RCT apparatus (initially through the separation of main and 
side effects) and drug registration regimes. Although Ayurveda and Chinese medicine have 
ƐĞƉĂƌĂƚĞǁŽƌĚƐĨŽƌ  ‘ŵĞĚŝĐŝŶĞ ?ĂŶĚ  ‘ƉŽŝƐŽŶ ? ũƵƐƚ like Sowa Rigpa, it is now clear that this 
need not imply that their intentions and outcomes can be that easily distinguished.98 In 
Tibetan medicine men and duk are formally distinguished and separately discussed in texts. 
Men-Tsee-Khang doctor Sonam Dolma (2013) for instance, heavily relying on classical 
Tibetan medical sources and contemporary commentaries, states that in general anything 
beneficial can be referred to as men in Tibetan language while anything harmful is duk, but 
that in Tibetan medicine and pharmacology both acquire multiple and more precise 
meanings based on the principles of elements, tastes and post-digestive tastes, potencies, 
and attributes. 
 
But careful producers and prescribers of Tibetan medicines know better. A closer reading 
and observation of reformulation, manufacturing and prescription practices reveals that 
this distinction is fluid, contextual and relative. A rigid medicine/poison dichotomy simply 
cannot be maintained upon closer inspection, not even in modern Western toxicology. 
However, issues of medical toxicity  W and the potency of aconite in the Garuda-5 formula 
in particular  W are negotiated very differently in India and Europe. PADMA Grippe-Formel 
                                                     
98 For interpretations beyond the conventional poison/medicine dichotomy of historical Chinese medical 
ƚĞǆƚƐ ?ƌĞĨĞƌƚŽƚŚĞĨŽƵŶĚĂƚŝŽŶĂůǁŽƌŬďǇWĂƵůhŶƐĐŚƵůĚ ? ? ? ? ? )ĂŶĚKďƌŝŶŐĞƌ ?Ɛ ? ? ? ? ? )ĂŶĂůǇƐŝs and comparison 
with the Greek term pharmakon. 
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cannot escape Swiss pharmaceutical regulation and its stringent logic of chemically-based 
risk analysis and pharmacovigilance, whereas Men-Tsee-<ŚĂŶŐ ?Ɛkhyung-nga is tied to 
classical textual ideals which are flexibly adapted to local bodies and ecologies through a 
diversity of practitioner-dependent practices. From a pharmaceutical risk-based population 
ƉĞƌƐƉĞĐƚŝǀĞ ŝƚ ĂƉƉĞĂƌƐ ĂƐ ŝĨ WD ?Ɛ 'ĂƌƵĚĂ-5 capsules are safer, come with ůĞƐƐ  ‘ƐŝĚĞ
ĞĨĨĞĐƚƐ ?ĂŶĚƚŚƵƐŚĂǀĞ an acceptable risk/benefit ratio while Men-Tsee-<ŚĂŶŐ ?ƐůŝƚƚůĞďůĂĐŬ
pills could be riskier (but this will never be proven due to lack of interest and funds). While 
important, it is not sufficient here to only consider that the latter may not be EU GMP-
produced and as stringently laboratory-controlled and standardised as explanations. The 
formulas have different compositions, include different herbs and Men-Tsee-<ŚĂŶŐ ?Ɛ
Garuda-5 may contain relatively more than six times more aconite. The aconite itself has 
also been processed differently. Despite the potential issue of batch-by-batch variability 
which doctors may not always be able to control99, Khyung-nga is a very popular medicine 
perceived to be highly beneficial by both practitioners and patients in Dharamsala and 
beyond. Its reputed strong efficacy is well-known and handled with care. In this case 
perhaps the risk is higher, but most likely the benefit is too, pointing out a general loss of 
potent herbal substances in the West. But I argue that the very opposition between risk 
and benefit is misleading when considering the fluidity of and correlation between toxic 
and therapeutic effects. Moreover, we should take into account that the very definition of 
risk and choosing between risky options is a politically and economically infused, value-
laden selection process that is contingent on subjective, individual comparisons with daily-
life dangers. India and Switzerland are painfully contrastive life worlds in this respect. As 
Kadetz (2015b) proposed, we should not presume the universality of biomedical safety 
notions based on ethnocentric and paternalistic assumptions. Indeed, a critical amchi might 
contend that the over-the-counter availability of PADMA 28 (with its high camphor content) 
and Grippe-Formel comes with considerable danger to patients if taken outside the doctor-
patient relationship that ensures attunement to local biologies, lived experience and 
insight into ecologies of toxicity (see also Schrempf 2015). Although biomedical definitions 
                                                     
99 Dr Paldjor who practices in Sidhbari (close to Dharamsala) for instance provides foreign patients with a 
small written note that advises them to discontinue the medicines and to consult a doctor in case a strong 
ƚŝŶŐůŝŶŐ ĨĞĞůŝŶŐ ŽŶ ƚŚĞ ƚŽŶŐƵĞ Žƌ ŽƚŚĞƌ  ‘ƵŶĐŽŵĨŽƌƚĂďůĞŶĞƐƐ ? ŝƐ ĞǆƉĞƌŝĞŶĐĞĚ  ?ĂƌďĂƌĂ 'ĞƌŬĞ ? WĞƌƐŽŶĂů
Communication, 20 May 2016). This seems to indicate that not only prescribing doctors but also those who 
manufacture pills are unsure how strong their medicines will turn out, not fully trusting their own medicines.  
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are spreading and hybridising with Asian medicines, safety, efficacy and toxicity remain 
situational, multi-dimensional concepts. The poison/medicine interface is not a dichotomy, 



















6 -25:  
the regulatory reformulations of 
PADMA 28 and the European politics 
of  ‘^ŵĂůůƚĞƌŶative Pharma ? 
 
 
In a sense the journey of Tibetan Medicines to the Western world reached a new stage in 
1969 with the foundation of the pharmaceutical company Padma Ltd in Zurich, Switzerland, 
which specializes in the manufacture of Tibetan remedies. Registration of medicines started 
right away. In a pioneering act the Swiss authorities granted drug status for Padma Lax in 
 ? ? ? ? ? ‘ĨŽƌŵƵůĂ ? ? ? ? ?^ ǁŝƐƐŵĞĚŝĐEƌ ? ? ? ? ? ? )ĂŶĚĨŽƌWĂĚŵ  ? ?ŝŶ  ? ? ? ? ?^ǁŝƐƐŵĞĚŝĐEƌ ? ? ? ? ? ? ) ?
ďŽƚŚĚĞŶŽŵŝŶĂƚĞĚĂƐ ‘dŝďĞƚĂŶZĞŵĞĚŝĞƐ ? ?/ƚŚas to be noted that in contrast to today's self-
conception of Complementary and Alternative Medicine (CAM) in the 1970s this 
development is one constitutive factor for the birth of the CAM movement in Switzerland as 
it is found today (Rist and Schwabl 2009) ? &ƌŽŵ ƚŚŝƐ ƉŽŝŶƚ ŽŶǁĂƌĚ ƐƚĂƌƚĞĚ ƚŚĞ  ‘ŵŽĚĞƌŶ ?
tradition of a Tibetan pharmacology in Europe.  
(WD ?ƐKĂŶĚ,ĞĂĚŽĨZĞŐƵůĂƚŽƌǇĨĨĂŝƌƐ, Schwabl and Vennos 2015, p. 110)  
 
In this chapter, I directly draw on Laurent Pordié and Jean-WĂƵů 'ĂƵĚŝůůŝğƌĞ ?Ɛ (2014a) 
ĐŽŶĐĞƉƚŽĨƚŚĞ ‘ƌĞĨŽƌŵƵůĂƚŝŽŶƌĞŐŝŵĞ ?, which was laid out as an overarching framework for 
this thesis in the Introduction. Combining this with critical works on drug regulation and 
through historical contextualisation, I aim to show how these aspects have impacted the 
transformations of PADMA 28: the best-researched and commercially most successful 
Tibetan proprietary medicine on the European continent. More than fifty clinical studies 
and overview articles have been published (of which more than 40% deal with 
atherosclerosis), and more than twenty experimental studies (PADMA 2015). In monetary 
ƚĞƌŵƐ ?WD ?ƐĂŶŶƵĂůƚƵƌŶŽǀĞƌŝƐĂďŽƵƚƚĞŶŵŝůůŝŽŶ^ǁŝƐƐ&ƌĂŶĐƐ ?ŽĨǁŚŝĐŚ roughly 90% is 
related to sales of its lead product PADMA 28 (Herbert, Personal Communication, 19 
August 2016). Spanning more than a century, the long journey of Tibetan medical 
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practitioners and their knowledge and the consecutive translations and transformations en 
route from Buryatia via St. Petersburg and Poland to Switzerland is a testament to the 
adaptability of the Sowa Rigpa knowing practice (Saxer 2004). This flexibility however, as 
noted by Schwabl and Vennos (2015, p. 109),  ‘stands in contrast to the concepts of Western 
phytopharmacology and today's regulatory reality ŝŶƵƌŽƉĞ ?. EU and national regulations 
enforce Ă  ‘ƐŽůŝĚŝĨŝĐĂƚŝŽŶ ?ŽĨ ŝŶĚŝĐĂƚŝŽŶƐ  ?ƌĞĚƵĐƚŝŽŶĂŶĚƐƚĂŶĚ ƌĚŝƐĂƚŝŽŶ ?relying on clinical 
trials and experimental studies), a fixation of ingredients (in terms of Galenic form and 
posology), laboratory analyses of identity, quality and purity based on risk assessment, and 
strictly regulated packaging, labelling and communication with patients. In the case of 
PADMA 28, ƚŚĞ ‘ŽƌŝŐŝŶĂů ?Gabur-25 from the Aginsky recipe book in Buryatia was reduced 
to twenty-two ingredients and several European substitute herbs were introduced, while 
the first modĞƌŶůĂďĞůůĞĚŝŶĚŝĐĂƚŝŽŶďĞĐĂŵĞ ‘circulatory disorders with symptoms such as 
a tingling sensation, formication, feeling of heaviness and tension in the legs and arms, 
numbness of the hands ĂŶĚ ĨĞĞƚ ĂŶĚ ĐĂůĨ ĐƌĂŵƉƐ ? (English translation of Swiss Product 
Information for Patients). 
 
On top of the multi-ůĂǇĞƌĞĚ ‘ƉƌĞ-ŚŝƐƚŽƌŝĐĂů ?ƌĞĨŽƌŵƵůĂƚŝŽŶƐďĞĨŽƌĞŝƚƐĞǆŝƐƚĞŶĐĞ ?WD ? ? ?Ɛ
transformation is continuing as the PADMA 28 product series expands and as it is 
introduced to other countries with different national and regulatory realities. In order to 
understand the regulatory reformulations of PADMA 28 in the European context, I first 
ƵŶĐŽǀĞƌƐŽŵĞŽĨŝƚƐƚƌĂŶƐŶĂƚŝŽŶĂů ‘ƉƌĞhistory ? leading up to its (re)birth in Switzerland as a 
proprietary medical product. Next, I focus on two more recent reformulations to showcase 
the extended negotiations and occasionally far-reaching transformations involved in the 
ĂĚĂƉƚĂƚŝŽŶ ŽĨ WD ?ƐGabur-25 to other national contexts to reveal the macro- and 
micropolitics involved in this iterative medicine approval process. Austria is taken as a case 
study since a comparison between the market approval procedures in this country before 
and after the EU directive on Traditional Herbal Medicinal Products (THMPs) clearly 
illustrates the growing influence of supranational policies, and the opportunities and 
limitiations they entail for Sowa Rigpa. I conclude by relating these findings to how PADMA 
positions itself discursively by deƉůŽǇŝŶŐƚŚĞƚƌŽƉĞ ‘ǁĞĂƌĞĂƐŵĂůůĐŽŵƉĂŶǇ ? and related 
statements of limited agency, contrasting these with ƚŚĞĐŽŵƉĂŶǇ ?ƐƉŝŽŶĞĞƌŝŶŐ political 
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ƌŽůĞĂƚƚŚĞƚƌŽƵďůŝŶŐŝŶƚĞƌĨĂĐĞŽĨƚŚĞh ?ƐƉŚĂƌŵĂĐĞƵƚŝĐal and complementary industries. I 
contend that PADMA and its products, along with other similar companies, occupy a 
distinctively liminal position in the European regulatory, political and economic landscape 
as  ‘^ŵĂůůƚĞƌŶĂƚŝǀĞ ?Žƌ ‘^ŵĂůůĂŶĚůƚĞƌŶĂƚŝǀĞWŚĂƌŵĂ ? ? 
 
6.1 A  ‘prehistory ? of PADMA 28, and its first (re) carnations 
Before PADMA 28 was first registered as a medicine in Switzerland in 1977, it had already 
changed substantially in name, form and content as it traveled through time and space 
(Schwabl and Vennos 2015). A particular instantiation of the Tibetan  ‘ĂŵƉŚŽƌ- ? ? ? ?gabur-
nyernga) formula was first adapted to the Buryat environment in the eighteenth century, 
and later morphed into the Russian  ? ? ? ?Ž H ?-25 as it was taken by amchi Sultim Badma to 
St. Petersburg in 1857 (Badmajew et al. 1982, Saxer 2004). Later members of the 
Badmajew100 family then brought the formula through the Iron Curtain to Switzerland in 
the early 1960s, after producing and prescribing Tibetan medicines in Poland for several 
decades which were violently interrupted by the two World Wars. A numbered list of 
Tibetan formulas in Cyrillic script was handed over to the Swiss pharmaceutical industrialist 
Karl Lutz, on which Gabur-25 ǁĂƐĨŽƌŵƵůĂŶ ? ? ? ?dŚĞĂĚŵĂ ?ũĞǁ ) ?ƐƚǁĞŶƚǇ-eighth formula 
then emerged as PADMA 28, which also happens to contain the Tibetan transliteration for 
 ‘ůŽƚƵƐ ? ?péma).101  
 
The history of Tibetan medicine in Buryatia, and its interactions with and introduction to 
Europe, and the role therein of the Badmajew family, has only been examined by few 
authors. Bolsokhoyeva (2007) discusses the development of Tibetan medical faculties 
                                                     
100 Saxer (2004) notes that Russian transliterations vary and that Badmajew family members spell their name 
in different ways: Badmaev, Badmayev, Badmajew or Badmajeff. All are (Russian-Orthodox) Christianised 
ǀĞƌƐŝŽŶƐŽĨ^ƵůƚŝŵĂĚŵĂ ?ƐƐĞĐŽŶĚŶĂŵĞ ?ǁŚŝůĞƚŚĞůĂƚƚĞƌƚǁŽĂƌĞŵŽƌĞƚǇƉŝĐĂůůǇWŽůŝƐŚ ?/ŽƉƚĨŽƌĂĚŵĂũĞǁ
here as it is preferred by Peter Badmajew Jr. in his publications (Badmajew et al. 1982, Badmajew 2013) and 
because he was the one involved in the founding of PADMA. 
101 WD  ? ? ? WD ?Ɛ ŵŽƐƚ ǁĞůů-known product name for its reformulated Gabur-25, confuses many 
Tibetan doctors because  W in contrast to how Sowa Rigpa medicines are commonly named  W ƚŚĞŵĞĚŝĐŝŶĞ ?Ɛ
name does not indicate the lead ingredient (which is camphor, not lotus) and contains less than twenty-eight 
(or twenty-five) components. Although mentioned in Tsarong (1986), Gabur-25 was never produced by Men-
Tsee-Khang according to amchi Penpa, who checked the records and asked the long-time Head of the 
Pharmacy (Barbara Gerke, Personal Communication, 3 June 2016). 
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(menwa dratsang) as part of Buddhist monasteries in the Aginsk Buryat Autonomous Area. 
Tibetan medicine came along with Buddhism, both of which allegedly first reached the 
mostly nomadic, shamanic peoples inhabiting the region by a group of traveling Tibetan 
and Mongolian monks in the early eighteenth century. Successful treatments by lamas and 
doctors significantly contributed to the ensuing mass conversion of the local population to 
Buddhism by the nineteenth century. The first medical school was soon established based 
on the educational structure of the famed monastic Chagpori college in Tibet (see also 
Bolsokhoyeva 1999). Indeed, reports from pioneering scientific expeditions to Siberia by 
German-speaking scholars  W starting with Daniel Gottlieb Messerschmidt (1685 W1735) and 
Johann Georg Gmelin (1709 W1755), amongst others  W provide evidence of the early 
establishment, as well as the advanced surgical instruments and elaborate pharmacopoeia 
utilised by local practitioners of Buryat Sowa Rigpa102 (Bolsokhoyeva 2007, Surkova et al. 
2012). According to Bolsokhoyeva (2007), the monumental Aginsk formulary of 151 folios 
and nearly 1,200 medicinal recipes with specified ingredient dosages is still the most 
comprehensive and most useful reference for modern Buryat amchi. It was most probably 
written in the eighteenth century by Lozang Shérap (his Russian-Buryat name was Sumati 
WƌĂĚǎŶą ) ?ĂŶĂƚŝǀĞdŝbetan who resided in the area and who may have lived until 1799. The 
manuscript was published locally by means of xylographic woodblock prints in 1924. 
PADMA only managed to obtain a copy much later however  W that is, after the initial 
registrations of PADMA LAX and 28  W  from Donatas Butkus around 2000 ?/ŶWD ?ƐĐŽƉǇ
of the woodblock prints I was able to locate Gabur-25 (Figure 6.1). 
 
                                                     
102 Tibetan medicine in Buryatia is a melange of Buryat folk medicine, Turkic and Mongolian influences, and 
the Buddhist medicine from Tibet. Tibetan and Mongolian knowledge were gradually adapted to local 
circumstances through original Buryat Mongolian translations of Tibetan medical texts and an extensive body 





In 2008 ?ƚŚĞĞŶƚŝƌĞǁŽƌŬŽĨ^ ƵŵĂƚŝWƌĂĚǎŶąǁĂs translated into Russian by Dandar Dashiyev, 
who took care to document the Buryatian substitutes that are in common use instead of 
relying on the substantially different  W and more Tibet-centred  W botanical identifications 
ŝŶ WĂƌĨŝŽŶŽǀŝƚĐŚ ?ƐTibetan Medical Paintings (1992). Table 6.1 is a comparison of the 
composition of Gabur-25 between the recipe mentioned in the final volume of the Four 
Tantras (which was available in its Mongolian translation in the early nineteenth century in 
Buryatia, and was translated and commented on by the Badmajews), the recipe prescribed 
ŝŶ ƚŚĞ ŐŝŶƐŬǇ ĨŽƌŵƵůĂƌǇ ? ĂŶĚ WD  ? ? ?Ɛ ĐƵƌƌĞŶƚ ^ǁŝƐƐ ĐŽŵƉŽƐŝƚŝŽŶ ?  ůƚŚŽƵŐŚ ƚŚĞ
botanical identification of Tibetan materia medica is itself a difficult and often problematic 
process (see Chapter 1), this painful commensuration exercise provides some insight into 
how Gabur-25 came to be reassembled as PADMA 28. Nonetheless, this table also 
demonstrates the futility of such a comparative exercise, ignoring and solidifying the 
dynamism of the manifold historical struggles and reformulations involved.  
 
 
Figure 6.1. The recipe and indications for Gabur-25 (gabur-nyernga ) ? ŽŶ ƚŚĞ ƌĞǀĞƌƐĞ ŽĨ ĨŽůŝŽ  ? ? ŽĨ >ŽǌĂŶŐ ^ŚĠƌĂƉ ?Ɛ
Amrita Extract Beneficial to All (Künphän Düdtsi). The composition of the formula is tabulated below in Table 6.1. Here 
ĨŽůůŽǁƐĂƚƌĂŶƐůĂƚŝŽŶŽĨƚŚĞŽƚŚĞƌŝŶĨŽƌŵĂƚŝŽŶƉƌŽǀŝĚĞĚ ? ?/ŶĐĂƐĞŽĨĐŽůĚŝůůŶĞƐƐĞƐ ?Gabur-25 should be compounded with 
the addition of the three hot medicines. Gabur-25 is indicated for dispersed, disturbed, and infectious hot disorders, 
fever caused by toxins, new and chronic fever in the solid and hollow organs, and gout, arthritis, erysipelas and pus in 
the chest. It is particularly effective for expelling chronic and dispersed fevers ? (disease translations based on Drungtso 
and Drungtso 2005). An in-text comment on the ingredient dodrek mar ĨƵƌƚŚĞƌƐƚĂƚĞƐ ?for the removal of toxins, warm 
up iŶĂƉĂŶƵŶƚŝůŝƚƚƵƌŶƐǇĞůůŽǁ ?. Gabur-25 is listed under the heading of formulas that treat béken disorders, in the 
chapter on powder medicines. 
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Table 6.1 ?&ŽƌŵƵůĂĐŽŵƉŽƐŝƚŝŽŶĐŽŵƉĂƌŝƐŽŶŽĨƚǁŽŬĞǇdŝďĞƚĂŶƚĞǆƚƐǁŝƚŚWD ? ? ?ƐĐƵƌƌĞŶƚŝŶŐƌĞĚŝĞŶƚƐ ?ƉƌŽǀŝĚĞĚǁŝƚŚĂƚƚempts at botanical identification.103 PADMA 28 incorporates 
elements from both Men-Tsee-Khang and Buryat interpretations of Gabur-25, supplemented by alterations likely based on the experience of the Badmajew family and judgements by the 
Swiss Study Group for Tibetan Medicine and relying on the availability of Indian and European flora. Species in yellow correspond to the Men-Tsee-Khang interpretation (with lighter shade 
a documented substitute), blue to the Buryat situation, and green marks overall correspondence. An asterisk  ? ? )ŵĂƌŬƐWD ? ?ŝŶŐƌĞĚŝĞŶƚƐŵĞŶƚŝŽŶĞĚŝŶ<ŽǁĂůĞǁƐŬŝ ?Ɛ  ? ? ? ? ? )ůŝƐƚŽĨ
sůĂĚŝŵŝƌĂĚŵĂũĞǁ ?Ɛ ?ŝŵƉŽƌƚĂŶƚƉůĂŶƚƐ ? ? 
                                                     
103 I ĐŽŶƐƵůƚĞĚ ĂƐŚŝĞǀ ?Ɛ  ? ? ?08) Russian translation of >ŽǌĂŶŐ ^ŚĠƌĂƉ ?Ɛrecipe book with the kind combined assistance of Andreas Kunz (a slavicist) and Laura Rohs (an 
ethnobotanist specialising in Eastern Europe). 
quantity mg/cap.
1 gabur Cinnamomum camphora (Linn.) Presl. ga bu 006 Cinnamomum camphora Nees Saussurea costus (Falc.) Lipschitz * 40
2 chugang calcite cu gang 020 Bambusa textilis Mcllure Cetraria islandica (L.) Acharius s.l. * 40
3 gurgum Carthamus tinctorius L. kha che 007 Crocus sativus L. Azadirachta indica A. Juss. * 35
4 dzati Myristica fragrans Houtt. li shi 008 Eugenia caryophylla Thunb. Elettaria cardamomum (Roxb.) Maton var. minuscula Burkill * 30
5 lishi Syzygium aromaticum (L.) Merr. et L.M. Perry dzA ti 012 Myristica fragans Houtt. Terminalia chebula Retz. * 30
6 kakola Amomum subulatum Roxb. sug smel 017 Elettaria cardamomum Zhite et Maton Pterocarpus santalinus L.f. * 30
7 sukmel Elettaria cardamomum Maton ka ko la 017 Amomum medium Lour. Pimenta dioica (L.) Merr. 25
8 agaru Aquilaria agallocha Roxb. ar nag 010 Aquilaria agallocha Roxb. Aegle marmelos (L.) Corrêa 20
9 tsenden karpo Santalum album Linn. tsan dan dkar 018 Santalum album L. Calcium sulphate hemihydrate 20
10 tsenden marpo Pterocarpus santalinum L.f. dmar 013 Pterocarpus santalinum L. Aquilegia vulgaris L. * 15
11 üpel ngönpo Meconopsis spp. u tpel 011 Aquilegia spp. Glycyrrhiza glabra L. * 15
12 péma gesar Nelumbo nucifera Gaerth. pad 023 Rosa spp. Plantago lanceolata L. s.l. 15
13 naga gesar Bombax ceiba L. nA ge sar 023 Quisqualis indica Lour. Polygonum aviculare L. s.l. * 15
14 ruta Saussurea lappa (Decne.) Schi.Bip. zir dkar 018 Lactuca scariola L. Potentilla aurea L. 15
15 zira karpo Cuminum cyminum L. ru rta 018 Echinops dahuricus Fisch. Syzygium aromaticum (L.) Merr. et L. M. Perry * 12
16 baléka Aristolochia moupinensis Franch. shing mngar 018 Glycyrrhiza uralensis Fisch. Kaempferia galanga L. 10
17 shingtsha Cinnamomum zeylanicum Blume spang spos 016 Valeriana officinalis L. Sida cordifolia L. * 10
18 chusin dermo Selaginella involvens Linn. ba le ka 010 Menispermum dauricum DC. sĂůĞƌŝĂŶĂŽĨĮĐŝŶĂůŝƐ> ?Ɛ ?ů ? ? 10
19 pusheltsé Dendrobium chrysanthum Wallich ex Lindley chu srin sder mo 013 Selaginella tamariscina (Bauv.) Spring. Lactuca sativa var. capitata L. * 6
20 pangpö Nardostachys grandiflora DC. pu shel 012 Iris flavissima Pall. ĂůĞŶĚƵůĂŽĨĮĐŝŶĂůŝƐ> ? 5
21 dodrek marpo Permela tinctorium Despr. (Dawa 1998) rdo dreg dmar 018 Girophora mullenbergil Ach. Cinnamomum camphora (L.) Sieb. 4
22 busuhang Medicago lupulina L. 'bu su hang 010 Medicago spp. Aconitum napellus L. 1
23 aru Terminalia chebula Retz. a 018 Terminalia chebula Retz.
24 baru Terminalia belerica Roxb. bar 010 Terminalia belerica (Gaertn.) Roxb.
25 kyuru Emblica officinalis Gaertn. skyur 012 Emblica officinalis Gaertn.
extra kara Saccharum officinarum L. ka ra 040 Saccharum officinarum L. excipients; gelatine capsules
PADMA's PADMA 28 (derived from Badmajew's formula 28, 
scientific names adapted from Schwabl and Vennos 2015, p. 110)
Gyüzhi Fourth 
Tantra  Gabur -
25 formula
Dashiev's (2008) Russian translation 
of the Aginsk recipe book (formula 
290, p. 60): contemporary Buryat 
identifications
Lozang Shérap's Amrita 
Extract Beneficial to All 
( folio number 31, 
reverse)
Men-Tsee-Khang scientific identifications 
(Dawa 1999, 2009; Tsultrim Kalsang 2008)
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>Ğƚ ?ƐŚĂǀĞĂůŽŽŬĂƚƚŚĞĨŽƵƌƉůĂŶƚƐƵďũĞĐƚƐŽĨƚŚŝƐthesis, all of which are represented in 
some form in the table. As was noted in Chapter 1, aru (Terminalia chebula) seems to 
belong to a hard core of the Sowa Rigpa pharmacopoeia that is nearly impossible to 
substitute even though options are mentioned in the classical literature. The type of aru 
used may vary according to the formula (cf. Chapter 2, Figure 2.2), and while Men-Tsee-
Khang takes care to remove the hard stones of the dried fruits this is not the case in PADMA 
28.104 In Buryatia a substitute for ruta is used that would not even be recognised by native 
Tibetans (as confirmed by Dawa 1998, translated into English in 1999), while PADMA opted 
for the endangered but cultivated roots of Saussurea costus. Several Meconopsis species 
are used in Dharamsala for utpel, but this rare alpine Himalayan herb was substituted by 
Aquilegia in Buryatia and adopted as such in PADMA 28. Again, this is a plant unknown to 
the Men-Tsee-Khang lineage of Sowa Rigpa. Lastly, Aconitum napellus is a very potent plant 
ŝŶŐƌĞĚŝĞŶƚ  ?ĐĨ ? ŚĂƉƚĞƌ  ? ) ƉƌĞƐĞŶƚ ŝŶ WD ?Ɛ ŵŽƐƚƐƵĐĐĞƐƐĨƵů ĨŽƌŵƵůĂ ĞǀĞŶ ƚŚŽƵŐh it 
accounts for only one milligram. It remains a mystery as to whether this Badmajew 
invention is supposed to be a substitute, or for what reason it was added. One can also 
wonder why nutmeg, greater cardamom, white sandalwood, Terminalia bellerica and 
Emblica officinalis were not included as there exist few doubts on their identification. 
Sourcing difficulties may be one part of the answer, but the full story is sadly lost to history. 
Retrospectively, PADMA acknowledged that some translation errors might have been 
made in the early years (e.g. Audio recording 38). But they add that this is of no relevance 
ŝŶ ƚŽĚĂǇ ?Ɛ ĐŽŶƚĞǆƚ ĂƐ ƚŚĞ ĨŽƌŵƵůĂƐ ŚĂǀĞ ƐŽůŝĚŝĨŝĞĚ ŝŶ ƌĞŐƵůĂƚŽƌǇ ĚŽĐƵŵĞŶƚƐ ĂŶĚ ƐŝŶĐĞ
PADMA 28  W as the most researched Tibetan formula on the planet (cf. PADMA 2015)  W has 
been proven to work in clinical trials, experimental studies, meta-analyses, and through 
numerous patient accounts. Perhaps PADMA 28 is not deemed to be the classical, textual 
ĂŶĚƚƌĂĚŝƚŝŽŶĂů ‘ƉƌŝƐƚŝŶĞũĞǁĞů ?ďǇƚƌĂĚŝƚŝŽŶĂůƐĐŚŽůĂƌƐ ?ďƵt its contents are not arbitrary. It 
is a living artefact, which will likely continue to evolve in the future. 
 
                                                     
104 PADMA products that were developed in a later stage with the help of amchi Pasang Arya, such as 
NERVOTONIN (sokdzin-chupa) and HEPATEN (drébu-sumthang), do however use pitted fruits. This also comes 
with potential disadvantages as their removal raises modern quality issues such as an increased risk of 
microbial contamination as the fruits are broken (Audio recording 104). 
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The historical circumstances under which this reformulation  W in effect an 
ethnopharmacological approximation exercise, described in Pordié and Gaudillière (2014a) 
by industrial Ayurvedic R& ƌĞƐĞĂƌĐŚĞƌƐ ĂƐ  ‘ƌĞǀĞƌƐĞ ĞŶŐŝŶĞĞƌŝŶŐ ?  W took place deserves 
some more attention. The final steps taken by the Badmajew family from Poland to 
Switzerland and the difficulties and translations constituting the birth of the first PADMA 
medicines are described in more detail in a small book co-authored by Peter Badmajew Jr., 
his son Vladimir Jr. and free-lance writer Lynn Park (Badmajew et al. 1982) as well as in 
DĂƌƚŝŶ^ĂǆĞƌ ?ƐDĂƐƚĞƌƐĚŝƐƐĞƌƚĂƚŝŽŶƚŚĂƚĂĐĐŽŵƉĂŶŝĞĚ his identically titled documentary 
(Saxer 2004). ĂƐĞĚ ŽŶ ƚŚĞƐĞ ƐŽƵƌĐĞƐ ĂŶĚ ĚŝƐĐƵƐƐŝŽŶƐ ŽŶ WD ?Ɛ ŽůĚĞƐƚ ĂƌĐŚŝǀĂů
documents with Herbert (Audio recording 95-96), I attempted to reconstruct the ensuing 
story. Fleeing the Bolshevik Revolution, it was VladiŵŝƌĂĚŵĂũĞǁ^ƌ ? ?WĞƚĞƌ ?ƐĨĂƚŚĞƌ ?ǁŚŽ
brought Tibetan medicine from Russia105 to Poland in the early 1920s. In 1925 Vladimir Sr. 
opened a clinic in Warsaw, initially selling his medicinal preparations through the Gesner 
Pharmacy. Vladimir quickly rose to fame and could count two consecutive Polish presidents 
amongst his patients. Aided by these elite political connections the national government 
subsequently legalised the production of Tibetan herbal remedies. Saxer summarises the 
transformation process that ensued as follows: 
Wlodzimierz [i.e. Vladimir Sr.] tried to substitute the ingredients he couldn't find. As he kept 
track of his prescriptions it is possible to follow these transformations. First, in the 1920s he 
sometimes used things like caffeine or acetylsalicylic acid (aspirin) in his drugs. When supplies 
from India and China picked up he again adjusted the prescriptions. The remedies were still 
ŽƌĚĞƌĞĚĂŶĚŶƵŵďĞƌĞĚĂĐĐŽƌĚŝŶŐƚŽWǇŽƚƌĂĚŵĂǇĞǀ ?Ɛ ?ŚŝƐƵŶĐůĞ ?Ɛ ?ƚŚĞǇŽƵŶŐĞƐƚďƌŽƚŚĞƌŽĨ
Sultim Badma] scheme, and the polish authorities registered them under these numbers and 
their Mongolian names. The ingredients, however, were already figured as botanical Latin 
names. Wlodzimierz started a semi-industrial production of Tibetan drugs. He contracted 
farmers to cultivate some of the herbs and built up a laboratory in Warsaw.  
(Saxer 2004, p. 60-61) 
 
                                                     
105 Medicine in St-Petersburg of the 1850s was already governed by the early Latin Pharmacopoeia Rossica, 
which was published there in 1778 by the Russian Academy of Science. It contained 770 monographs of which 
316 pertained to herbal preparations, and constitutes a unique blend of modern Western science and Russian 
folk-herbal traditions between West and East (Shikov et al. 2014).  
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Interestingly, the form in which the medicines were handed to patients also changed 
repeatedly: from fine powders in small paper wrappings in St. Petersburg (Saxer 2004), to 
tinctures dispensed by the Gesner Pharmacy in Warsaw (Badmajew 2013), to tablets 
ƉƌŽĚƵĐĞĚ ďǇ sůĂĚŝŵŝƌ ?Ɛ ŚĞƌďĂů ůĂďŽƌĂƚŽƌǇ ĨƌŽŵ  ? ? ? ? ƵŶƚŝů ŝ  ǁĂƐ ĚĞƐƚƌŽǇĞĚ ĚƵƌŝŶŐ ƚŚĞ
Warsaw uprising (Badmajew et al. 1982). PADMA would later produce its medicines in 
tablet form as well until 2008, when a shift towards gelatine capsules (and later vegicaps 
in some countries) was introduced (see Table 6.2 below).106 After World War II the new 
communist political climate meant it became increasingly difficult to practice. Vladimir was 
forced to re-register all his medicines. This was largely successful, but the Mongolian drug 
names were forbidden and not all ingredients were officially listed (Saxer 2004). After 
rebuilding his clinic and opening a second one in Krakow for more than a decade, he passed 
away in 1961, leaving his son Peter (who had become a fully qualified medical doctor and 
surgeon) as the sole heir of the Badmajew legacy in Poland. The political situation worsened 
further as the Polish authorities completely banned private herbal medicine distribution, 
ƐŚƵƚƚŝŶŐ ĚŽǁŶ ƚŚĞ ůĂďŽƌĂƚŽƌǇ ? ,ŽƉŝŶŐ ŚĞ ĐŽƵůĚ Ăƚ ůĞĂƐƚ ŬĞĞƉ ŚŝƐ ĨĂŵŝůǇ ?Ɛ ĨŽƌŵƵůĂƚŝŽŶƐ
available to patients, he approached and freely offered the recipes to the government-run 
industrial herbal company Herbapol on the condition that the products would specify 
 ‘according to Dr. ĂĚŵĂũĞǁ ?Ɛ ƉƌĞƐĐƌŝƉƚŝŽŶ ? (Badmajew et al. 1982, p. 18). The official 
ĚĞĐůŝŶĞĚƚŚŝƐŐĞŶĞƌŽƵƐƉƌŽƉŽƐĂů ?ůƚŚŽƵŐŚŚĞŚĂĚŚĞĂƌĚŽĨƚŚĞƐĞ ‘ŵŝƌĂĐůĞĐƵƌĞƐ ? ?ƚŚĞǇĚŝĚ
not comply to the strictly enforced state procedures.  
 
ŶĞǁƐƚĂŐĞŝŶ^ŽǁĂZŝŐƉĂ ?ƐŽĚǇƐƐĞǇƚŽƚŚĞtĞƐƚƵŶĨŽůĚĞĚĂƐƚŚĞ^ǁŝƐƐƉŚĂƌŵĂĐĞƵƚŝĐĂů
businessman Karl Lutz  W who had become fascinated by Tibetan medicine after reading 
Korvin-<ƌĂƐŝŶƐŬŝ ?Ɛ ƐǇŶĐƌĞƚŝĐ Śristian-Buddhist Die Tibetische Medizinphilosophie (1953), 
                                                     
106 PADMA switched from tablets to capsules because the latter requires less excipients (no binding agents 
necessary, so closer to original loose powder form) and because it increases the stability and shelflife of the 
product. From a classical Tibetan pharmacological perspective, however, formulas are generally formulated 
with a specific dosage form in mind (Gyüzhi ?Ɛ&ŽƵƌƚŚdĂŶƚƌĂ ůŝƐƚƐƚŚĞŵŝŶƐĞƉĂƌĂƚĞĐŚĂƉƚĞƌƐ ) ?ĂĐŚĚŽƐĂŐĞ
form emphasises a different pharmacological principle: decoctions (thang) are for instance formulated based 
on the taste of the ingredients, powders (chéma) based on potencies (nüpa), and pills (rilbu) based on post-
digestive taste (zhujé). This also influences their effect. Taste formulations are fast-acting and thus ideal for 
early and acute fevers, whereas post-digestive taste formulations are best for chronic disorders. This 
notwithstanding, nowadays Men-Tsee-Khang and other manufacturers in exile produce most formulas as 




and ex-patient and student of Vladimir Sr.  W invited Peter Badmajew Jr. to Switzerland in 
the summer of 1965. Over the next two years Karl Lutz and Peter struggled to source the 
necessary ingredients (mostly from India, via a company in London) and experimented for 
many days and nights in a small rented laboratory, working out procedures that could 
reproduce tŚĞƋƵĂůŝƚǇĂŶĚĞĨĨŝĐĂĐǇŽĨsůĂĚŝŵŝƌ ?ƐŵĞĚŝĐŝŶĞƐŝŶWŽůĂŶĚ ?tŚĞŶďŽƚŚŵĞŶǁĞƌĞ
satisfied with the result, Peter moved to the United States to build a new life for himself as 
a physician in Long Island, New York (Badmajew et al. 1982, Saxer 2004). This crude sketch 
of the knowledge transmission from a biomedical practitioner, who was the last to be part 
of an illustrious but waning lineage of Buryat Sowa Rigpa in Europe, to a pharmaceutical 
industrialist who genuinely valued its context and origins and their ensuing collaboration 
provides a sobering alternative to polarised debates on intellectual property rights. Instead 
of bringing ĂĐĐƵƐĂƚŝŽŶƐŽĨďŝŽƉŝƌĂĐǇ ? ‘ƐƚŽůĞŶŬŶŽǁůĞĚŐĞ ? )ĂŶĚƚŚĞĂƉƉƌŽƉƌŝĂƚŝŽŶŽĨƚƌĂĚŝƚŝŽŶ
 ? ‘ŝƚ ?ƐŶŽƚĂƵƚŚĞŶƚŝĐďĞĐĂƵƐĞŝƚ ?ƐĐŽŵŵĞƌĐŝĂů ? ) to the fore, these instances of pragmatic yet 
carefully negotiated reformulation evidence the adaptability and ensuing transformations 
of Tibetan medicine(s). 
 
More than a dozen of Tibetan remedies were produced and clinically tested on a very small 
scale under the guidance of the Study Group for Tibetan Medicine (Studiengruppe für 
Tibetische Medizin), which was founded by Lutz in Zürich in 1965, and aimed for the 
scientific promotion of Tibetisch-Lamaïstische Heilmittel and culture (Badmajew et al. 1982, 
Kowalewski 1973). This group included the monk Korvin-Krasinski, Zürich pharmacognosy 
professor Flück (who co-edited the fifth edition of the Swiss Pharmacopoeia), a pharmacist 
 ?ƌ ?ŶĚƌĞƐ^ƌ ? ?ǁŚŽǁĂƐĂůƐŽŝŶǀŽůǀĞĚŝŶƐĞƚƚŝŶŐƵƉWD  ?ƐƋƵĂůŝƚǇĐŽŶƚƌŽů ?ƐĞe Chapter 
4), a physician (Dr. Bubb), a drogist (Fritz Steiner), and others. They were attracted to the 
ŵǇƐƚĞƌǇŽĨdŝďĞƚ ?ĂƐĐĂƉƚƵƌĞĚŝŶ,ĞŝŶƌŝĐŚ,ĂƌƌĞƌ ?ƐSeben Jahre in Tibet, published in 1952), 
influenced by the Swiss psycho-ĂŶĂůǇƐƚĂƌů'ƵƐƚĂǀ:ƵŶŐ ?Ɛ(1875-1961) interest in Eastern 
philosophy and his integrative approach towards medicine and spirituality, and in touch 
with the leading European scholars of the time (including Fernand Meyer and Elisabeth 
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Finck). PADMA AG107 was formed in 1969. Lutz immediately proceeded to register formula 
number 179  W ŽŶĞŽĨsůĂĚŝŵŝƌ ?ƐĨĂǀŽƵƌŝƚĞƐĨŽƌĚŝŐĞƐƚŝǀĞĚŝƐŽƌĚĞƌƐ ?ĂĚŵĂũĞǁĞƚĂů ? ? ? ? ? ) ?
which he had prescribed widely as a preliminary treatment for patients with a variety of 
problems  W as PADMA Lax, which was accepted by the Swiss authorities in 1970. In the 
same year probably the first clinical study worldwide on a Tibetan remedy was published 
(involving 285 patients, on chronic constipation, Flück and Bubb 1970). This successful first 
recognition of Tibetan medicine by biomedical science led to further pioneering research 
on formula 28 at the Luzern cantonal hospital (Hürlimann 1978, on peripheral arterial 
occlusive disease), and the registration of PADMA 28 in 1977.108 The next big leap for 
PADMA  W the reimbursement of PADMA 28 by national health insurance in 1998, which 
was achieved shortly before the death of Karl Lutz after a decade-long battle which led to 
a court case  W shows clearly how vested political, professional and commercial interests 
feed into medical decision-making. The start of this fight and the early involvement of the 
Swiss drug administration, the chemical industry, the Swiss Society for Angiology (who 
sided with the industry), and the media is hinted at in Badmajew et al. (1982), which quotes 
Karl Lutz himself on the matter. This quote is an ideal prologue to the still on-going 
negotiations between PADMA and regulatory authorities in different countries, and the 
larger struggle of PADMA as part of the CAM movement in Europe. 
Whoever has the serious aim of introducing Tibetan medicine as a complement to the 
practice of scientifically oriented medicine has a hard and challenging task. Theoreticians and 
practitioners of medicine, pharmacologists, biologists and chemists, and generalists of both 
medicine and science all have difficulty accepting that herbal remedies can produce 
therapeutic effects that far surpass those of chemical preparations. That the ingredients in 
these remedies occur in such low dosages that they should by rights be ineffective and that 
they have no negative side effects only compounds their difficulty in comprehension. Anyone 
who knows the power of the chemical pharmaceutical industry and the extent of its influence 
                                                     
107 dŚĞŽƌŝŐŝŶĂůĐŽŵƉĂŶǇŶĂŵĞ ‘WD'für Tibetische Heilmittel ? ? ‘ĨŽƌdŝďĞƚĂŶƌĞŵĞĚŝĞƐ ? ) ?ǁĂƐƌĞũĞĐƚĞĚďǇ
the Swiss authorities as the idea apparently sounded absurd to the ears of officials at the time (cf. Saxer 2004, 
p. 65).  
108 Based on WD ?ƐĂƌĐŚŝǀĞĂŶĚdiscussions on some of its earliest documents with Herbert Schwabl (Audio 
recordings 95 and 96) it appears that the first application for the registration of formula 28 with the Swiss 
ƌĞŐƵůĂƚŽƌǇ ĂƵƚŚŽƌŝƚŝĞƐ  ?ŝŶ  ? ? ? ? ? ǁŝƚŚ  ‘WD sĂƐ ? ĂƐ ƉƌŽĚƵĐƚ ŶĂŵĞ ) ǁĂƐ ƌĞũĞĐƚĞĚ ŽŶ ƚŚĞ ŐƌŽƵŶĚƐ ŽĨ ƚŚĞ
suggested indications, which were found too strong. Reformulations can be short-lived. 
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on both scientific bodies and medical experts can easily imagine the resistance that these 
natural remedies will encounter. (Badmajew et al. 1982, p. 26-27) 
 
 
Figure 6.2 ?WD ? ? ?ƐŽƌŝŐŝŶĂůƉĂĐŬĂŐŝŶŐ ?ĨŝƌƐƚƵƐĞĚŝŶ ? ? ? ? ?KŶĞƉĂĐŬĂŐĞĐŽŶƚĂŝŶĞĚƚŚƌĞĞďůŝƐƚĞƌƐof twenty tablets 
each. The package in the photograph is part of the fourth batch. Photographed ďǇƚŚĞĂƵƚŚŽƌŝŶWD ?ƐĂƌĐŚŝǀĞ ? 
 
The historical period just covered, from the nineteenth century until the 1970s, was one of 
fundamental transformations not only for Sowa Rigpa and PADMA. At the time when Sultim 
Badma  W the founding father of the Badmajew family lineage outside Buryatia  W opened 
the first Tibetan pharmacy in St-Petersburg in 1857, the Industrial Revolution led by the 
mechanisation of the cotton textile industry had already swept across continental Europe. 
Founded on a newly created federal constitution (Bundesverfassung der Schweizerischen 
Eidgenossenschaft, 1848), the Swiss Confederation had already operated its own weaving 
mills since at least 1830, and by 1850 roughly 150,000 workers were employed in the cotton, 
silk, linen and wool branches (Fritzsche 1996). Although this Baumwollwut (cotton mania) 
did not compare favourably to the English industry competition-wise, other proto-
industries such as workshop-based, high-quality watch- and clock-making dominated the 
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world market. The 1860s brought mass-produced condensed milk and baby foods (Heinrich 
Nestlé, 1814-1890), and in the 1880s chocolate became a Swiss trademark. In this period, 
the highly-specialised Basel chemical industry was born out of the production of dyestuffs 
and manned by graduates from the world-class Zürich Polytechnic (ETH, Eidgenössische 
Technische Hochschule), including the companies CIBA, Geigy and Sandoz (which all merged 
into the market-leading Swiss multinational Novartis in 1996). Another Basel 
pharmaceutical giant, Hoffmann-La Roche, was founded in 1896. As the next generation of 
Badmajews set up their practice in the Second Polish Republic during the Interbellum, the 
electrified technological production lines of the Second Industrial Revolution were running 
at full capacity: Roche became a leader in vitamin production and also developed Valium, 
whereas CIBA-Geigy became the number one synthetic dye producer and discovered DDT. 
Through mergers Sandoz expanded its food product range around the malted dairy drink 
powder Ovomaltine after World War II (Aftalion 1991). Besides this history of industrial and 
chemical revolutions, the so-ĐĂůůĞĚ ‘^ǁŝƐƐŵŝƌĂĐůĞ ? of post-war prosperity was clearly tied 
to its (armed) neutrality and the absence of war damage.109 When Peter Badmajew first 
ĐĂŵĞƚŽ^ǁŝƚǌĞƌůĂŶĚŝŶƚŚĞ ? ? ? ?Ɛ ?ůĞĂĚŝŶŐƚŽWD ?ƐĨŽƵŶĚĂƚŝŽŶŝŶ ? ? ? ? ?ƚŚŝƐĐŽƵŶƚƌǇ ?Ɛ
neutrality, stability and national sovereignty had already amassed enormous wealth in its 
banking sector. Over the years it housed an increasing number of international institutions 
especially in Geneva, including United Nations agencies (e.g. the WHO, founded 1948), the 
World Economic Forum (1971) and the World Intellectual Property Organization (1974). 
 
6.2 Regulatory reformulations post-  
Switzerland joined the Council of Europe in 1963 and the UN only in 2002. But it was never 
and still is not a member of the European Union. The story of post-war European 
integration has often been told as a march towards peace and prosperity through the 
tempering of heroic nationalism, supranational governance and economic integration and 
as a calculated response to accelerating globalisation (Dinan 2014). As the Cold War 
                                                     
109 The importance of the pharmaceutical industry for the Swiss economy nowadays is still very significant 
and growing (Grass and Mösle 2015). Pharmaceuticals are the number one export (amounting to 71 billion 
CHF), and thus an important contributor to national economic growth. The combined directly and indirectly 
employed workforce is estimated at 224,266 persons or about 2.7 percent of the population.  
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intensified, a coalition of national (especially French and German) interests gave rise to the 
European Coal and Steel Community (1950) and later that same decade to the European 
Economic Community. The Monetary Union from 1999 onwards confirmed that economic 
integration remained ĂƚŝƚƐŚĞĂƌƚ ?ƵƌŽƉĞ ?ƐĐŽŶƚĞŵƉŽƌĂƌǇŚŝƐƚŽƌǇŝƐŽĨƚen interpreted as a 
directional, desirable, and inevitable development by progressive Euro-idealists, but the 
ƚĞůĞŽůŽŐŝĐĂůĚŝƐƚŽƌƚŝŽŶŽĨƚŚŝƐ ‘ŽƌƚŚŽĚŽǆƐƚŽƌǇ ?ĚŽĞƐŶŽƚĂůůŽǁĨŽƌŵŽƌĞĐƌŝƚŝĐĂůŝŶƐŝŐŚƚƐŝŶƚŽ
its premises of exclusion, modernisation, bureaucratisation, capitalism and neoliberalism 
(Gilbert 2008).  
 
With the above in mind, the Europeanisation of pharmaceutical regulatory policy and its 
aim to harmonise and create a unified European market for medicines has to be scrutinised 
(Abraham and Lewis 2003, Permanand and Mossialos 2005). Commencing with the first 
directive that established Community rules for medicine regulation in 1965 and later the 
simultaneous recognition of drug marketing authorisations in multiple EU member states 
in 1975, the European Agency for the Evaluation of Medicinal Products (EMEA) was 
established ŝŶ  ? ? ? ? ?dŚĞŵŝƐƐŝŽŶŽĨ ƚŚŝƐ  ‘ǀŝƌƚƵĂůĂŐĞŶĐǇ ?ŚŽǁĞǀĞƌ ? ĐŽŶƐŝƐƚŝŶŐŽĨ ƐĞůĞĐƚĞĚ
national regulatory assessors, presumes Mertonian universalism 110  within regulatory 
science and that national political interests will be submerged into a single European 
epistemic community (Abraham and Lewis 2003). However, national regulators themselves 
were skeptical and feared a lowering of safety standards for the sake of commercial 
interests. According to Abraham and Lewis (2003) the conflicting aims of EMEA (lowering 
healthcare costs, affordable drugs, wide access to high-quality medicines, and a successful 
industry), its technocratic approach and the creation of a single market together with the 
push toward more rapid approval times has ironically led to national inter-agency 
ĐŽŵƉĞƚŝƚŝŽŶĨŽƌ ‘ƌĞŐƵůĂƚŽƌǇǁŽƌŬ ?ĂŶĚĐŽŵƉƌŽŵŝƐĞŽŶƐĐŝĞŶƚŝĨŝĐƌĞǀŝĞw and transparency.  
 
Davis and Abraham (2013) ?ƐůĂƚĞƐƚǀŽůƵŵe entitled Unhealthy Pharmaceutical Regulation 
takes the same issues forward. This time however, the work was explicitly embedded 
                                                     
110 American sociologist Robert K. Merton (1910-2003) drafted a set of normative ideals that ought to dictate 
scientific methodology. Universalism, the ability to evaluate truth claims in terms of impersonal, universal 
criteria, is one of these (Merton 1938, p. 267-278). 
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within the neoliberal era  W which arbitrarily began with the rise to power of New Right 
politicians such as Reagan and Thatcher in the 1980s  W ĂŶĚ ǁŝƚŚ ƚŚĞ  ‘ůŝŐŚƚ ƚŽƵĐŚ ?
governance and the ensuing financial crisis of the financial sector in the late 2000s. Again, 
the observed deregulatory pharmaceutical reforms were supposed to simultaneously be in 
the interest of both industrial innovation (and thus commerce) and public health. State 
intervention was minimised at the behest of a competitive free market logic wherein 
informed/expert consumer/patients are fetishised. In this pro-business environment, the 
pharmaceutical industry gained privileged access to the state while regulatory standards 
were adapted to suit commercial interests. The governance space of the European 
knowledge-based economies  W particularly in the areas of science, technology and 
medicine  W was nonetheless typically characterized as  ‘ĂŐŽůĚĞŶĞƌĂŽĨƌĞŐƵůĂƚŝŽŶ ?ĂŶĚĂ
 ‘ǁŽƌůĚŽĨƐƚĂŶĚĂƌĚƐ ?(Faulkner, 2012). In this respect, not only science and society were 
being co-produced (Jasanoff 2004) but equally innovation and governance. 
 
Table 6.2 lists the nine differently branded and packaged products that together constitute 
ƚŚĞ ĐƵƌƌĞŶƚ WD  ? ?  ‘ĨĂŵŝůǇ ? ? ƚ ƚŚĞ ƚŝŵĞ ŽĨǁƌŝƚŝŶŐ ŚŝƐ ƉƌŽĚƵĐƚ ƐĞƌŝĞƐ ĨĂůůƐ ŝŶƚŽ ĨŝǀĞ
different legal categories and is available in fourteen different countries in three different 
compositions. Previous incarnations which are no longer produced and product 
registrations that were cancelled (as in Latvia, where it was not a commercial success) are 
not included. To narrow down the scope of this chapter I will focus on two historical 
instances of reformulation that have both taken place in Austria, whŝĐŚƐĞƌǀĞƐĂƐWD ?Ɛ
springboard to the European Union. In section 6.2.1 I look at the negotiations that led to 
the national registration of PADMA 28 as a Verzehrprodukt  ? ‘ĚŝŐĞƐƚŝǀĞƉƌŽĚƵĐƚ ? )ŝŶƵƐƚƌŝĂ
in 1992 before the introduction of the binding EU-wide 2001 legislation on the marketing 
authorisation procedures, manufacturing, labelling and packaging, distribution, advertising 
and pharmacovigilance of medical products for human use (Directive 2001/83/EC) and its 
amendment with special provisions regarding Traditional Herbal Medicinal Products 
(THMPs, Directive 2004/24/EC, 31 March 2004). In section 6.2.2 I then discuss the 
registration of PADMA Circosan as a THMP in Austria in 2010 (and three years later in the 




Table 6.2. List of all PADMA 28 family products currently on the market. Before 2008-2009, all were produced as 
tablets. Nowadays the only galenic forms provided are hard gelatine capsules and vegicaps (in Denmark and Italy). 
Products either fall under the jurisdiction of food or medicine legislation, which are implemented differently in 
different countries.  
 
 
In one of his papers, in which he builds on the notion of the reformulation regime, Pordié 
(2014) questions the thinginess (la choséité, referring to their solidity) as well as the claims 
of objectivity that are usually associated with things in industrial Ayurvedic innovation 
processes. The latter is posited to be as relative, dynamic and ephemeral as the former. 
Observing how Western regulatory environments directly determine the selection and 
development of formulations into products at the Himalaya Drug Company in Bangalore, 
he argues that the supposedly scientific objectivity of drug development is severely 
ĐŽŵƉƌŽŵŝƐĞĚĂŶĚƚŚĂƚƚŚŝƐĐŽŶƐƚƌĂŝŶŝŶŐŽĨƚŚĞ ‘ƐƉĂĐĞŽĨƉŽƐƐŝďŝůŝƚǇ ? ?ŝŶƚĞƌŵƐŽĨŝŶŐƌĞĚŝĞŶƚƐ ?
galenic form, clinical targets, etc.) is usually omitted in published papers and corporate 
invention discourses. It is exactly this often unrecognised pervious and ephemeral nature 
of drugs which allows for consecutive transformations to take place, while retaining the 
ƐĂŵĞ ‘ŽŶƚŽůŽŐŝĐĂůǁĞŝŐŚƚ ? ?/ƚŝƐƚŚĞƐĞƌĞŐƵůĂƚŽƌǇƌĞĨŽƌŵƵůĂƚŝŽŶƐ that I want to discuss in the 
case of PADMA 28. 
 
tŚĂƚŝƐƐƵďƐƚĂŶƚŝĂůůǇĚŝĨĨĞƌĞŶƚŝŶƚŚĞĐĂƐĞŽĨWDŝƐŶŽƚŽŶůǇƚŚĞĐŽŵƉĂŶǇ ?ƐůŽĐĂƚŝŽŶĂŶĚ
medical tradition but more so the repeated, explicit and also public discussion of the 
insidious influences of pharmaceutical governance in PADMA-authored publications. This 
sustained narrative on the very real and complex negotiations with regulatory authorities 
(Schwabl 2009, 2013; Schwabl et al. 2006; Schwabl and Vennos 2015) which often results 
product name legal category country availability (year of first, most recent registration) remarks on composition
PADMA 28 OTC medicine Switzerland (1977, 2008) original PADMA 28 formula
PADMA Basic food supplement
USA (early 1980s, ?), Poland (2005, 2008), Netherlands (?), 
Canada (2012), Hungary (2012), Bulgaria (2015), Estonia (2015)
without aconite
PADMA 28 well-established use Denmark (1997, in progress) without aconite
PADMA Circosan OTC medicine Lithuania (1999, 2011) original PADMA 28 formula
PADMED Circosan 
/ Arteria-vita
OTC medicine reimbursed on 
prescription (Swiss system)
Switzerland (2009) / Switzerland (2012) original PADMA 28 formula
PADMA Circosan THMP Austria (2010), UK (2013) without aconite
PADMA Plus / 
PADMA Basic Plus
food supplement Denmark (2012) / Italy (2016)
Aquilegia -> Crataegus, Saussurea -> Inula (smaller 
amount), Sida -> Leonurus, Melia -> Phyllanthus, 
Kaempferia -> Zingiber, Potentilla aurea -> P. 
anserina, + Terminalia bellerica; vegicaps
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in suboptimal compromise from the corporate perspective in terms of which products are 
allowed where, in what legal category and with what indications serves several purposes. 
&ŝƌƐƚ ŽĨ Ăůů ? ŝƚ ĐŽƌƌŽďŽƌĂƚĞƐ WD ?Ɛ ůŽŶg history of battles lost and won over the 
establishment of Tibetan medicine(s) in Switzerland and the larger, ever dynamic European 
context  W ƚŚƵƐůĞŐŝƚŝŵŝƐŝŶŐWD ?ƐǀĞƌǇĞǆŝƐƚĞŶĐĞ Was well as its pioneering position in 
the registration of Asian polyheƌďĂůƉƌŽĚƵĐƚƐ ?^ĞĐŽŶĚůǇ ?ƚŚŝƐ ‘ƚŚĞůŝŵŝƚĂƚŝŽŶƐŽĨĐŚĞŵŝĐĂů-
ƉŚĂƌŵĂĐĞƵƚŝĐĂůƌĞŐƵůĂƚŝŽŶ ?ŶĂƌƌĂƚŝǀĞŝƐĂůƐŽĂĐƌŝƚŝƋƵĞŽĨƚŚĞĐƵƌƌĞŶƚstatus quo that is taken 
forward in national and European political struggles as part of the CAM movement. Lastly, 
this restrictive environment is also presented as an explanation and sometimes almost 
apologies to practitioners and patients of Tibetan medicine who want to know why more 
products are not available, why the Tibetan names and terms are not used, and why the 
classical formulas cannot be used as they are, and so on. The impact of regulations plays 
into identity politics, situating PADMA  W sometimes uncomfortably  W as a neo-traditional 
entity straddling East/West, alternative/conventional and (modern) traditional/modern 
divides.  
 
6.2.1 A pre-hĚŝƌĞĐƚŝǀĞĞǆĂŵƉůĞ PƵƐƚƌŝĂ ?ƐVerzehrprodukt in the Nineties 
In the late 1980s, Herbert Schwabl first came in touch with PADMA and Karl Lutz as he was 
finishing his doctorate in physics. ^ĐŚǁĂďů ?Ɛinterest in quantum mechanics and other 
nonlinear phenomena as well as research by his department at the Technical University of 
sŝĞŶŶĂŽŶ ‘ƵŶĞǆƉůĂŝŶĂďůĞ ?ĞĨĨĞĐƚƐƐƵĐŚƚŚĞĞĨĨŝĐĂĐǇŽĨŚŽŵĞŽƉĂƚŚǇĂŶĚŽƚŚĞƌĂůƚĞƌŶĂƚŝǀĞ
therapies had brought the two men together. At a certain point, the PhD student enquired 
why PADMA 28 was available in Switzerland and Poland, but not in Austria (Audio recording 
65). Lutz replied that this was a very complicated matter, but Herbert was not fazed by his 
warning and asked if he could try to get it approved in Vienna. Although finding a distributor 
who trusted him and the quirky Tibetan medicines turned out to be tricky, he started 
compiling the dossier to apply for a special Austrian type of food supplement status called 
Verzehrprodukt (loosely defined as a product that can be eaten without nutritional value). 
Herbert corresponded with an official from the Ministry for Health, Sports and Consumer 
Protection (Bundesministerium für Gesundheit, Sport und Konsumentenschutz) in the 
capital, and soon received a list of questions to which he in turn replied (Audio recording 
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96). This was at a time when Austria still had its own unique legal system and Viennese 
tradition of bureaucracy and diplomacy, before it became an EU member on January 1st 
1995. Although this Tibetan multi-component formula must have raised some eyebrows, 
for the bureaucrat it remained just one amongst many other products.  
 
Finally, after more than a dozen different versions of official letters with replies on specific 
issues such as reproducibility of the composition and toxicity assessments (reaching up to 
thirty pages, which Herbert remembered as tough but not full-on medical-scientific), he 
was formally introduced to the person in charge via an acquaintance. Luckily young Herbert 
was well-connected in his home country: his father-in-ůĂǁ ‘was the secretary of somebody 
ǁŚŽŬŶĞǁƐŽŵĞďŽĚǇ ?. Even though the talks continued on a personal level, it was all official: 
 ‘ŝƚ ?ƐĂƐŵĂůůĐŽƵŶƚƌǇǇŽƵŬŶŽǁ ?ŝƚ ?ƐŶŽƚĂŶŽŶǇŵŽƵƐ ?. The final negotiation at the head of 
departmĞŶƚ ?ƐŽĨĨŝĐĞůĂƐƚĞĚũƵƐƚĨŝǀĞŵŝŶƵƚĞƐ ?dŚĞŽĨĨŝĐŝĂůĂĐŬŶŽǁůĞĚŐĞĚ,ĞƌďĞƌƚ ?ƐĚĞƚĂŝůĞĚ
argumentation  W especially on aconite, which included seventeen subsections (from the 
quantification of alkaloids to the traditional uses of aconite roots)  W and wanted to proceed, 
but on the aconite he simply replieĚŝŶƚǇƉŝĐĂůsŝĞŶŶĞƐĞĚŝĂůĞĐƚ P ‘Vergessens es ?, just forget 
it. From then it was clear he would get the product approved if and only if this herb was 
left out of the formula.  
 
In this strict yet personal and consensus-driven environment, PADMA 28 was then 
approved as a Verzehrprodukt in 1992, without the aconite, and later renamed PADMA 
Basic. After Austria joined the EU, PADMA then attempted to re-register the same product 
under the name PADMA 28 as a medicine with well-established use (which involves 
providing evidence of at least a decade of systematic and documented use, as well as 
scientific studies, cf. Directive 2001/83/EC), but it was rejected. Elisabeth McHugh, who 
joined PADMA in 1997 and is the most senior employee at the Regulatory Affairs 
department, recalled that talks initially were favourable (Audio recording 103). The final 
stumbling block was that the authorities were of the opinion that the available clinical data 
were insufficient for a regular medicine, considering the medical claim. The application was 
withdrawn. In contrast, Denmark did accept PADMA 28 (again without aconite) as a well-
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established medicine in 1997. But as the THMP Directive was on the horizon, plans were 
set in motion to apply once again in Austria within this new legal category. 
 
6.2.2 Traditional Herbal Medicinal Products (THMPs): PADMA Circosan in Austria (2010) 
and the UK (2013) 
The new European Directive 2004/24/EC, also referred to the Traditional Herbal Medicinal 
Products Directive (THMPD), has come into full effect since 30th April 2011 following a 
seven-year transition period. Henceforth, the sale of manufactured unlicensed herbal 
medicines has become illegal in the European Union. Over-the-counter medical products 
(intended to treat diseases as opposed to food supplements which support and maintain 
healthy body functioning) thus need a licence via either a Marketing Authorisation or a 
simplified Traditional Herbal Registration (European Commission 2004, Schwabl and 
Vennos 2015). The new, last-mentioned option states requirements for: documentation of 
safety and traditional use  W no clinical trials, which are replaced by evidencing historical 
usage over thirty years, of which fifteen within EU member states  W and quality, labelling 
and advertising restrictions. Importantly, the indication is only based on long-standing use 
(rendering clinical research findings obsolete) and as stated in Article 16a (section 1, 
ƉĂƌĂŐƌĂƉŚ  ?Ă ) ?Ɖ ?  ? ? )  ‘they have indications exclusively appropriate to traditional herbal 
medicinal products which, by virtue of their composition and purpose, are intended and 
designed for use without the supervision of a medical practitioner for diagnostic purposes 
Figure 6.3. Austrian PADMA 28 of the early 1990s, registered in 1992 as a type of food supplement (Verzehrprodukt). 
&ƌŽŶƚĂŶĚďĂĐŬŽĨƉĂĐŬĂŐĞƐƉŚŽƚŽŐƌĂƉŚĞĚďǇƚŚĞĂƵƚŚŽƌŝŶWD ?ƐĂƌĐŚŝǀĞ ? 
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or for prescription or monitoring of treatment ?. This amendment also established the 
European Committee on Herbal Medicinal Products (HMPC) under the European Medicines 
Agency (EMA) in London, which has produced more than a hundred community herbal 
monographs that specify the intended uses and patients of the herbal product under 
review, as well as safety information. This may then be freely used in well-established-use 
and traditional-use applications for registration based on the idea that the same data 
provided then does not have to be supplied over and over again by companies for these 
commonly used herbs. THMPs are by definition only allowed to contain herbal substances 
and preparations as well as some mineral ingredients with ancillary modes of action. 
Although the composition of the formulation may be derived from empirical (i.e. 
 ‘ƚƌĂĚŝƚŝŽŶĂů ? )ŬŶŽǁůĞĚŐĞǁŝƚŚŽƵƚƚŚĞƉƌŽǀŝƐŝŽŶŽĨĂďŝŽŵĞĚŝĐĂů-scientific rationale (which is 
promising for Asian classical formulas, EMA/HMPC 2014)  W the manufacturer is obliged to 
analytically show the presence of each ingredient in the finished product (EMA/HMPC 
2007). 
 
This sounds self-evident, but a multi-compound preparation (of more than twenty 
ingredients in the case of PADMA 28) pushes the limits of conventional techniques. Schwabl 
et al. (2006) trace the clash of this western-scientific rationale of analytical reductionism 
with poly-herbal formulations back to the controversial but influential Renaissance 
physician Paracelsus (see Chapter 5), who argued for the use of single herbs (the so-called 
Simplicia ?ŵĞĚŝĐŝŶĂů ‘ƐŝŵƉůĞƐ ? )ƚŽƚƌĞĂƚƐƉĞĐŝĨŝĐĐŽŶĚŝƚŝŽŶƐŝŶƚŚĞǀĞŝŶŽĨƌŝƐƚŽƚĞůŝĂŶŵŽŶŽ-
consequentionalism. This penchant for mono-herbal remedies was then developed further 
ŝŶ ‘ƌĂƚŝŽŶĂůƉŚǇƚŽƚŚĞƌĂƉǇ ? ?ǁŚŝĐŚĂĐĐŽƌĚŝŶŐƚŽĂƉŽƉƵůĂƌ handbook (Schulz et al. 2004) aims 
ƚŽ ‘make medicines safer by isolating aŶĚŵŽĚŝĨǇŝŶŐƉůĂŶƚĐŽŶƐƚŝƚƵĞŶƚƐ ? (p. 2), evaluating 
ŐŝŶŬŐŽĨŽƌĐŽŐŶŝƚŝǀĞĚĞĨŝĐŝĞŶĐǇ ?^ƚ ?:ŽŚŶ ?ƐǁŽƌƚĂƐĂŶĂŶƚŝ-depressant, and so on. The search 
for isolated monocausal principles may be suitable for synthetic chemicals, but Tibetan 
formulas act as one pharmacologically active unit with polyvalent, pleiotropic effects 
(Schwabl et al. 2013). In the context of European mediciŶĞůĞŐŝƐůĂƚŝŽŶƚŚĞƌĞŝƐŝŶĚĞĞĚ ‘no 




dŚĞǁŽƌĚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ƚŚƵƐƚĂŬĞƐŽŶĂǀĞƌǇƐƉĞĐŝĨŝĐ ?ůŝŵŝƚĞĚ ?ĂŶĚŵŽĚĞƌŶĂŶĚƐƚĂŶĚĂƌĚŝƐĞĚ )
meaning in this EU legislative context. Indeed, as Schwabl (2009) argues, the very definition 
 W including the arbitrary spatiotemporal delineation of valid tradition  W correlates with the 
rise of complementary and alternative medicine with its typical remit in prevention, living 
with chronic biomedical diseases and healthy lifestyles. Probably based on the WHO 
glorification of the integration of (the already re-invented) TCM into state-sanctioned 
Chinese healthcare, this brand of tradition nonetheless effectively excludes many non-
European medicines with longstanding (but in this case irrelevant) histories from entering 
the market. In this more or less hostile regulatory environment, PADMA succeeded in 
obtaining Traditional Herbal Registrations for PADMA Circosan (a version of PADMA 28 
without aconite) in Austria in 2010 (HERB-00037) and in the United Kingdom in 2013 
(39568/0001). The Austrian registration is the very first time a complex Asian medicine-
derived product was approved as a THMP in the whole of the EU. The first TCM product 
came two years later in the Netherlands  W an extract of Dioscorea nipponica rhizomes in 
capsule form for the treatment of myocardial ischemia (Lindstrom 2012)  W but consisted of 
only one herb known as a Chinese folk remedy. Only a handful of non-European products 
have been registered so far but many more are in the pipeline (Mader 2013).  
 
Once again Herbert was involved in deciding if and where PADMA should apply for a THR 
license (Audio recording 98):  
dŚĞƌĞĂƌĞƚǁŽĂƐƉĞĐƚƐ ?KŶĞŝƐƚŚĞƚĞĐŚŶŝĐĂů ? ‘ĐĂŶǇŽƵĚŽŝƚ ? ? ?tĞĚĞĐŝĚĞĚ ‘ǇĞƐ ?ǁĞĐĂŶ ? ?^ ĞĐŽŶĚ ?
 ‘ŝƐƚŚĞĂƵƚŚŽƌŝƚǇǁŝůůŝŶŐƚŽ ? ? ?dŚĂƚǁĂƐĂŶĞŐŽƚŝĂƚŝŽŶǁŝƚŚƚŚĞƵƐƚƌŝĂŶĂƵƚŚŽƌŝƚǇ ?/ŬŶĞǁthat 
the person responsible came from the university, he was a professor of pharmacognosy 
before. He was really in love with plants one could say, someone who supports the whole 
field of herbal medicine. So he was the man to break the ice, so to speak. It was a coincidence 
that was in Austria, but there is also a good tradition of Austrian bureaucrats [from 
universities, with relevant expertise, not lawyers or chemists]. 
 I was forwarded to the registration expert (Elisabeth, who spoke to me non-stop for nearly 
three hours, Audio recording 103) to get at least some feel for the complexities involved in 
this extensive administrative, legal and bureaucratic negotiation procedure. Having worked 
in this field for PADMA for more than fifteen years and having studied for two years on a 
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MA degree in regulatory affairs in Bonn, she was the perfect person to offer me a crash 
course. First she made sure I understood the distinctions between (1) legally binding 
legislation (such as the EU directives) and publications (the European Pharmacopoeia, the 
HMPC herbal monographs), (2) official guidance documentation that further specify how 
ƚŚĞ ůĂǁƐ ƐŚŽƵůĚ ďĞ ŝŶƚĞƌƉƌĞƚĞĚ  ?ŝŶĐůƵĚŝŶŐ h  ‘ŶŽƚŝĐĞƐ ƚŽ ĂƉƉůŝĐĂŶƚƐ ? ĂŶĚ D ?,DW
guidelines) and (3) national (and individual assessor ?s) interpretations of these laws and 
regulations, because it is the interactions between these three levels that determine the 
maneuvering space. Although now the EU has exactly the same laws in all its member states 
for THMPs (but not Switzerland, which I do not go into further here), how they deal with it 
varies considerably. Before the European Commission stepped in the differences were of 
course even larger, but as yet licensing fees, distribution channels (e.g. pharmacy only or 
general sales), restricted herb lists, etc., have not been harmonised.  
 
Politically, the British agency (the Medicines and Healthcare Products Regulatory Agency, 
MHRA) was at the forefront of getting the traditional directive going: the UK had several 
active medical traditions on its territory and many unlicensed products on the market, so 
the European commission was pushing them to set things straight. PADMA 28 Potentilla 
&ŽƌŵƵůĂ ?ƐĂŵĞĐŽŵƉŽƐŝƚŝŽŶ ?ǁŝƚŚŽƵƚĂĐŽŶŝƚĞ )ǁĂƐĂǀĂŝůĂďůĞ ‘ĞǆĞŵƉƚĨƌŽŵůŝĐĞŶƐŝŶŐ ?ďĞĨŽƌĞ
the EU directive, and PADMA was keen on extending the license. Talks were initiated and 
surprisingly, the main issue at the time turned out to be camphor. D-camphor (along with 
others such as menthol) was considered chemically too pure to be described as a herbal 
substance accoƌĚŝŶŐƚŽĂŶ,DWƐƚĂƚĞŵĞŶƚ ?ZĞŵŽǀŝŶŐƚŚŝƐůĞĂĚŝŶŐƌĞĚŝĞŶƚĨƌŽŵWD ?Ɛ
 ‘ĂŵƉŚŽƌ- ? ? ?ǁĂƐŶŽƚĂŶŽƉƚŝŽŶ ?WDŽƉƚĞĚƚŽĞǆƉƌĞƐƐ ŝƚĂƐĂŚĞƌďĂůƉƌĞƉĂƌĂƚŝŽŶ  ?a 
solid fraction of the essential oil of the camphor tree) instead, but this strategy did not 
conform to the pharmacopoeia entry, which raised further difficulties. The Commission and 
HMPC were slow in responding to the many company complaints on this issue. MHRA did 
ŶŽƚŬŶŽǁŚŽǁƚŽƉƌŽĐĞĞĚ ? ƐŽWD ?Ɛh<ĂƉƉůŝĐĂƚŝŽŶǁĂƐƚĞŵƉŽƌĂƌŝůǇďůŽĐŬĞĚ ?ƚ ƚŚĞ
Austrian agency (then called AGES PharmMed) however,  ‘ƚŚĞǇǁĞƌĞŵŽƌĞĐŽƵƌĂŐĞŽƵƐ ?. The 
old-school ex-pharmacognosy professor agreed camphor could be regarded as a herbal 
preparation and said it should be possible to find a solution (before any change in 
legislations and recommendations). PADMA then submitted the dossier there and only 
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laƚĞƌĂŐĂŝŶŝŶƚŚĞh< ?ǁŚĞŶƚŚĞǇ ‘had gained a bit more self-ĐŽŶĨŝĚĞŶĐĞ ? and also changed 
their view towards these substances. A letter by Herbert to the European Directorate and 
a chance meeting in Brussels supported by a number of similar cases then led the European 
Commission to push HMPC to renegotiate the problem formally. It was finally harmonised 
with the publication of a report accepting entities such as camphor as herbal preparations 
provided they were from a natural source and tested according to the pharmacopoeia 
(EMA/HMPC, 2013). 
 
A second hurdle to be negotiated was aconite. Here, both the Austrian and UK agencies 
firmly held their ground. They would not take the responsibiůŝƚǇŽĨŚĂǀŝŶŐĂ ‘ƉŽŝƐŽŶŽƵƐŚĞƌď ?
in a traditional medicine tŚĂƚŝƐƐƵƉƉŽƐĞĚƚŽďĞŚĂƌŵůĞƐƐ ‘and you know, good for nothing 
ƌĞĂůůǇ ?, Elisabeth added cynically. The counter-argument was that if a patient swallowed a 
large packet of sixty capsules, they could theoretically get alkaloid poisoning. PADMA 
ƌĞŐƵůĂƚŽƌǇĂĨĨĂŝƌƐ ?ƉĞŽƉůĞ ƌĞƚŽƌƚĞĚƚŚĂƚ ƚŚŝƐ ŝƐƉƌĂĐƚŝĐĂůůǇ ŝŵƉŽƐƐŝďůĞ ? ĂƐŽŶĞ ǁŽƵůĚ ƐƚĂƌƚ
vomiting long before that. In my head I was comparing this to the potentially deadly 
consequences of ingesting a whole package of paracetamol, but this drug is in a different 
legal category and backed by clinical studies that shift the proven risk/benefit ratio (see 
Chapter 5). This battle was lost, aconite was removed. 
 
A third point of contention was the indication. Although the proof for traditional use was 
accepted, the submitted suggestions based on this were found to be too strong. After 
writing back-and-forth for a few rounds, a simplified but broader indication was agreed 
upon in Austria which included some of the weaker symptoms for peripheral arterial 
occlusive disease (see Figure 6.4 ) ?/ŶƚĞƌĞƐƚŝŶŐůǇ ?ƚŚŝƐǁĂƐŶŽƚƉŽƐƐŝďůĞŝŶ^ǁŝƚǌĞƌůĂŶĚ ?ƐŽǀĞƌ-
the-counter products (where some additional, different regulations apply) as there it was 
argued a doctor would be needed to diagnose that disease. Somewhat related to this, in 
Austria PADMA decided to distribute Circosan to pharmacies only (not including Drogerien, 
which has a different status in Switzerland) whereas in the UK it may be found in 





Figure 6.4. PADMA Circosan, the Austrian THMP that was accepted in 2010 as the first one based on Asian medicine 
in the country and the first complicated multi-compound traditional herbal medicine in Europe. The indication 
translates as  ?cold hands and feet with tingling [sensations] and calf pain when walking ?. Photo courtesy PADMA AG. 
Since 2015 a new package design was introduced in alignment with the package illustrations in Chapters 3 and 5). 
 
It is impossible to go over all the details of this negotiation process, which is much more 
extensive (in the number and depth of arguments and documentation/literature reviews 
that have to be provided) and complicated (in terms of the number of guidelines involved) 
than hinted ĂƚŚĞƌĞ ?dŽŐĞƚĂŶ ŝĚĞĂ ?ĂƐƉĂƌƚŽĨWD ?ƐUK THMP application PADMA ?Ɛ
regulatory department received back a large volume with more than ninety questions from 
a team of quality, regulatory and clinical assessors, which was only the start of an exchange 
limited by deadlines (see MHRA 2013 for a public summary of the results). For the 
registration of PADMA Digestin  W a much simpler five-ingredient formula (Sendu-5)  W as a 
traditional herbal medicine in Switzerland the application project was started in 2006, the 
dossier submitted in 2008, registered in 2010, and finally marketed in 2011. It took two 
people five years, producing five large cartons full of paper. Even though the THMP 
directive was a much-needed and much-welcomed simplification of the registration 
procedures for traditional herbal medicines (which many argue should be amended further, 
Cranz and Anquez-Traxler 2014, Schwabl et al. 2015), PADMA employees feel that in a way 
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regulations keep getting stricter and stricter. With 2004/24/EC in place, it has become 
much more difficult to get a plant-based product licensed as a regular medicine even 
though it is still ĂůĞŐĂůŽƉƚŝŽŶ P ‘Actually, the [Big] Pharma world managed to box herbal 
medicines into insŝŐŶŝĨŝĐĂŶĐĞ ?, especially from an indication point-of-view. There is no point 
anymore to conduct clinical research now (at least for THMPs), which generates a negative 
spiral of efficacy. This perceived problematic process of political exclusion leads us to 
section 6.3, where I go into the identity and macro-politics in which PADMA is active. 
 
6.3   ‘We are a small compan being Small and Alternative (Pharma), lobbying Big 
The founding of PADMA in post-war Switzerland of the 1960s and the subsequent spread 
of its products across a historically dynamic Europe clearly reflects a host of broader 
ƐŽĐŝĞƚĂůƚƌĂŶƐĨŽƌŵĂƚŝŽŶƐ ?dŚĞĐŽŵŵŽĚŝƚŝƐĂƚŝŽŶĂŶĚƐĐŝĞŶƚŝĨŝĐǀĂůŝĚĂƚŝŽŶŽĨ  ‘ƚƌĂĚŝƚŝŽŶĂů ?Žƌ
 ‘ŝŶĚŝŐĞŶŽƵƐ ? ŬŶŽǁůĞĚŐĞ  W historically contingent categories that rely on a false 
tradition/modern dichotomy and that obscure the dynamic fluidity of situated practices 
ĂŶĚ ƚŚĞŝƌ ĂƉƉƌŽƉƌŝĂƚŝŽŶ ďǇ ĂŶĚ ŽĨ  ‘ƐĐŝĞŶƚŝĨŝĐ ? ŬŶŽǁůĞĚŐĞ (Ellen and Harris 2000)  W is a 
hallmark of globalisation, the cross-border intensification of economic, political and 
sociocultural relations (Alexiades 2009). More specifically, the shift over the last five 
ĚĞĐĂĚĞƐ ƚŽǁĂƌĚƐ ƉŽƐƚŵŽĚĞƌŶ  ‘ůĂƚĞ ? ĐĂƉŝƚĂůŝƐŵ ? ĞĐŽŶŽŵŝĐŝŶƚĞŐƌĂƚŝŽŶ ŝŶ ƚĂŶĚĞŵ ǁŝƚŚ
regional specialisation and decentralised production, deregulation and neoliberalism has 
ĨŽƌĞŐƌŽƵŶĚĞĚĂƌŚĞƚŽƌŝĐŽĨĚŝǀĞƌƐŝƚǇĂŶĚƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨƐƉĞĐŝĂůŝƐĞĚ ‘ŶŝĐŚĞ ?ŵĂƌŬĞƚƐŝŶ
response to lifestyle choice demands.  PADMA is a niche company which in its mass-
marketing partly relies on this demand for de- and re-contextualised cultural commodities 
in postcolonial times, making it impossible for PADMA to ignore politics of knowledge and 
identity in terms of ownership, authenticity and scientificity. 
 
In light of the on-going dismantling of the welfare state and the recent economic crisis, Big 
Pharma globally is reorganising its R&D and innovation strategies, particularly in the field 
of natural product discovery (David et al. 2015, Laird 2013). A succession of company 
mergers and acquisitions over the past decades has damaged the inĚƵƐƚƌǇ ?Ɛ
competitiveness and ability to innovate, while drug patents are expiring and new market 
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launches are in decline (Scannell et al. 2012). Even though it is still the most research-
intensive industry, and even though pharmaceutical markets are still growing (especially 
outside the US, Europe and Japan) and revenues are enormous, many internal R&D 
departments of large multinationals have closed down over the last decade as innovative 
research has shifted to  W external collaboration with or acquisition of  W smaller companies 
and (spinoffs from) academia (Laird 2013). Scientific and technological advances have 
made natural product research much faster, easier and cost-ĞĨĨĞĐƚŝǀĞ ? ďƵƚ ŝŶ ƚŽĚĂǇ ?Ɛ
business realities it has largely gone out of fashion. Furthermore, the focus has shifted from 
plants  W ŝŶ ǁŚŝĐŚ ŝŶƚĞƌĞƐƚ ƐƵƌŐĞĚ ŝŶ ƚŚĞ ďŝŽƉƌŽƐƉĞĐƚŝŶŐ  ‘ŐƌĞŶ ƌƵƐŚ ? ŽĨ ƚŚĞ  ? ? ? ?Ɛ ǁŝƚŚ
advances in automated high-throughput screening  W to terrestrial and marine micro-
organisms and the use of large, public-domain genome-based product libraries to find 
possible drug leads. Moving from organisms to genes, the role of traditional medical 
knowledge has declined further and the implementation of the Access and Benefit Sharing 
principles for genetic resources as specified in the Convention of Biological Diversity (1992) 
and the Nagoya Protocol (2010) complicated further. Nonetheless, herbal medicines have 
historically been of central importance and the current market for standardised 
phytopharmaceuticals is growing globally. New trends in poly-pharmacology, systems 
biology, personalised medicine and evidence-based phytotherapy aim to capture their 
multiple, synergistic effects.  
 
PADMA is at the forefront of these cutting-edge developments (Schwabl and Vennos 2008, 
Schwabl et al. 2013, Zick et al. 2009), yet during my fieldwork there I noticed how 
employees and management in each department and on every level explicitly deployed 
ŶŽƚŝŽŶƐŽĨ ‘ƐŵĂůůŶĞƐƐ ?ǁŚĞŶĞǆƉůĂŝŶŝŶŐƚŚĞŝƌǁŽƌŬ ĂŶĚWD ?ƐƐŝƚƵĂƚŝŽŶƚŽŵĞ ?ǀĞŶŝŶ
informative presentations addressing the public (e.g. at Tibet Fest in Basel, 16 August 2014), 
the limitations, struggles and frustrations of getting Tibetan medicines on European 
markets were emphasised. The context varied, but the message was consistent: 
- In terms of the introduction of Good DistrŝďƵƚŝŽŶWƌĂĐƚŝĐĞ ?'W ) P ‘Because we are a small 
company, we cannot talk to the biggest guys because they are very expensive and offer 
solutions which are way too big for us. We have to find a transport company that is able 
and willing to deal with the small compaŶǇǁĞĂƌĞ ? (Audio recording 48); 
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- Following ƵƉŽŶƌĞŐƵůĂƚŽƌǇĚĞǀĞůŽƉŵĞŶƚƐ P ‘We have a regulatory service. We get e-mails 
of changes in European legislation that would affect us. Every day about two to three e-
ŵĂŝůƐ ? tĞ ĚŽŶ ?ƚ even have the staff capacity to read and understand all the legalities 
happening in Europe at a given time. For a small enterprise this is even not ƉŽƐƐŝďůĞ ? (Audio 
recording 50); 
- WƵƌĐŚĂƐŝŶŐƌĂǁŵĂƚĞƌŝĂůƐ P ‘KŶĞƚŚŝŶŐŝƐǁĞĚŽŶ ?ƚŚĂǀĞƚŚƐǇƐƚĞŵƐŚĞƌĞ/Ăŵ used to as a 
purchaser. A small company ĚŽĞƐŶ ?ƚŚĂǀĞƚŚĞŵŽŶĞǇĨŽƌ^W111. SAP is for everybody who 
wants a good deal. It is one thing if you work in a big company if you have 2,000 sheets, but 
[with] an Ablauf [procedural] system. If you want to change this, you must have this, talk 
to this person... In a small company, a shit problem just happens and you just have to solve 
ŝƚ ? (Audio recording 52, related to this, there is the economies of scale problem in ordering 
small volumes of herbs); 
- Risk analysis as part of quality assurance P ‘so it's a risk for the company, a financial risk but 
not for the patient. But if you separate these two, it's too much work for a company like 
us ‘(Audio recording 63); Equally, when PADMA does GMP inspections with suppliers more 
than a hundred times larger than themselves, there are limitations (Audio recording 7); 
- The lack of funding for large-scale marketing research (Audio recording 7), ĂŶĚ ĨŽƌ  ‘big 
clinicaůƐƚƵĚŝĞƐ ? (Audio recording 64). 
This non-exhaustive list confirms that PADMA self-identifies as a small company, comparing 
itself and the efficiency of its operations to the leading multinational corporations  W 
generated in the post-war and post-1990s era of globalisation, as discussed above  W in both 
the herbal and chemical pharmaceutical industries. This disadvantaged position vis-à-vis 
Big or perhaps more aptly Global Pharma112 also plays out in political arenas. PADMA is not 
just a small enterprise (around thirty staff, and an annual turnover of 30-40 tons of raw 
material or 10 million Swiss Francs), it is also located in a small country (less than nine 
                                                     
111  SAP is the leading information system for enterprise resource planning for larger corporations, a 
centralised database marketed by the German multinational SAP SE.  
112 According to Craig and Adams (2008, p. 6-7):  ‘Global Pharma is not simply about pills and proĮts; it is an 
index for bio-medical scientiĮc legitimacy, a means of invoking oĸcial sanction for the sale of medicines and 
the authority to make claims about what medicines can or cannot do iŶ ĂŶ ŝŶƚĞƌŶĂƚŝŽŶĂů ĂƌĞŶĂ ?  ? Q /ƚ ?
ĞŶĐŽŵƉĂƐƐĞƐĞīorts to standardise and regulate the production of drugs, as well as the biopolitics inherent 
in how clinical trials are designed and funded, how subjects are recruited, results are read, ĂŶĚ “ƌŝƐŬƐ ?ĂŶĚ
 “ďĞŶĞĮƚƐ ?ĂƌĞĐŚĂƌĂĐƚĞƌŝƐĞĚŝŶƚŚĞĐŽŶƚĞǆƚŽĨƌĞƐĞĂƌĐŚ ?ŵĂƌŬĞƚŝŶŐ ?ĂŶĚĐůŝŶŝĐĂůƵƐĞ ? ?These authors however 
include similar activities emanating from 'non-tĞƐƚĞƌŶ ĐĞŶƚƌĞƐ ŽĨ ƐĐŝĞŶĐĞ ? ĂƐ ǁĞůů ĂƐ ƚŚĞ ĂƌƚŝĐƵůĂƚŝŽŶ ŽĨ
 ‘ĐŽŵƉůĞŵĞŶƚĂƌǇ ? ? ‘ĂůƚĞƌŶĂƚŝǀĞ ?ĂŶĚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ŵĞĚŝĐŝŶĞƐƵŶĚĞƌƚŚĞƵŵďƌĞůůĂŽĨƚŚŝƐƚĞƌŵ ?ǁŚŝĐŚƚŚĞǇĂĚŵŝƚ




million inhabitants, compared to 500 million in the EU), catering for one of the smallest 
traditions within the CAM community (with only a handful of immigrant amchi and only a 
few more than a hundred Europeans with some form of Sowa Rigpa training, Schwabl 2009). 
The CAM sector is itself minute in the total European economic context, even though CAM 
use has been substantial, widespread and growing from the 1980s onwards (Eardley et al. 
2012, Harris et al. 2012). In one of our first conversations at his office (Audio recording 7), 
,ĞƌďĞƌƚƐŬĞƚĐŚĞĚWD ?ƐŵĂƌŐŝŶĂůĂƐǁĞůůĂƐĂŵďŝŐƵŽƵƐƉŽƐŝƚŝŽŶĂƐĨŽůůŽǁƐ P 
We are in an environment. Here are the companies (he draws a circle on a piece of paper). 
We are part of complementary medicine (a section of the circle). From a top-down approach 
we are part of the pharmaceutical industry (another section). From the political point of view 
again we are borderline. We have the conservatives, and Left-wing. We would think 
complementary medicine would appeal to the Left and the Greens and the industry part 
would appeal to them [the Conservatives], but there are contradictions. Of course we are a 
pharmaceutical industry, but our company is too small for real Right conservatives. We 
calculated that the whole complementary medicine industry from the production side in 
Switzerland counts for 500 or maybe 800 employees. For the Right wing, forget it. Our section 
of herbal medicine in Europe has 800,000 employees, nothing! The RŝŐŚƚ ƐĂǇƐ  ‘ǇŽƵ ĂƌĞ
ŝŶĚƵƐƚƌǇ ?ďƵƚŶŽƚŝŵƉŽƌƚĂŶƚ ? ?ŽŵƉůĞŵĞŶƚĂƌy medicine could appeal to the Green parties, 
ďƵƚƚŚĞůĞĨƚŚĂƐĂƐƚƵƉŝĚĂƚƚŝƚƵĚĞ ?/ǁŽƵůĚƐĂǇ ?ƚŽǁĂƌĚƚŚĞĐŽŶƐƵŵĞƌ P ‘ƚŚĞĐŽŶƐƵŵĞƌŚĂƐƚŽďĞ
ƉƌŽƚĞĐƚĞĚ ? ?ƚŚĞǇƐĂǇ ?dŚĞǇƐay you have to prove [safety] with evidence, and CAM according 
to the standard talk has no evidence. For them we are also not good enough. Therefore, 
consumer protection agencies or associations are very often against complementary 
medicine because it has no evidence. The Right wing says it is the choice of the consumer. In 
terms of this  W the liberal aspect that everybody has his choice  W the Right are on our side. 
And from the industry point the Left wing supports us. We live in a complete mess politically. 
 ? Q ? We have this left and right dichotomy, we actually have to go to both with completely 
different agendas. And this is a problem of the industry, for the whole CAM trade. 
In this sense, CAM is a double outsider: not fully Left nor Right-wing, not mainstream but 
still an industry. Within this industry it is small companies in particular that are struggling 
to keep up with pharmaceutical regulations. The big guys have an expert staff of lawyers 
and even have the capital to send out representatives to the regulatory agencies to be cued 
in to the latest developments. In a way, this upward spiral of increasingly intricate 
registration procedures and GMP standards helps multinationals to curb the competition 
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of those that cannot keep up in this rat race. Some separate regulations have been 
developed more recently for micro, small and medium-sized enterprises (SMEs), including 
the provision of financial and administrative assistance (EC 2049/2005) by EMA as well as 
the establishment of an SME office and user guide to facilitate communication with the 
agency during the application for an EU marketing authorization (EMA 2014). These 
European-ůĞǀĞůƌĞŐŝƐƚƌĂƚŝŽŶƉƌŽĐĞĚƵƌĞƐŚŽǁĞǀĞƌƌĞŵĂŝŶŽƵƚŽĨƌĞĂĐŚŽĨWD ?ƐĐĂƉĂĐŝƚǇ ?
and generally do not work for multi-compound ŚĞƌďĂů ƐƵďƐƚĂŶĐĞƐǁŝƚŚĂ  ‘ŶŽŶ-ƐĐŝĞŶƚŝĨŝĐ ?
composition. There are also concessions when it comes to GMP compliance such as the 
clarifications laid down in the Swiss Pharmacopoeia (Ph. Helvetica 11, 2012, section 21.1) 
on the production of medicines in small quantities. Especially in Switzerland, which has a 
lot of small companies, the authorities (Swissmedic) had to acknowledge that they cannot 
be dealt with in exactly the same way. Moreover, the Swiss constituency has repeatedly 
spoken out in favour of complementary medicine in this country through its direct 
democracy voting system (see following section), which has led amongst others to the 
adoption of national legislation to further simplify the registration of complementary and 
phyto-medicines (Swissmedic 2006), with a separate chapter on Asian medications which 
for instance accepts (traditional) bibliographical documentation as a rationale for 
ingredient combinations. These concessions notwithstanding, there is still generally a big 
bias towards Big and especially chemical Pharma, leading to Big-centric regulations. 
 
Prevalent conspiracy theories notwithstanding, CAM critic Edzard Ernst (2008) notes that 
Big Pharma hardly takes any notice of complementary medicine, as can be inferred for 
example from its lack of interest in herb-drug interactions. Although a number of important 
conventional drug entities were originally discovered in plants (but now commonly derived 
synthetically) the drug discovery and development processes nowadays usually involve the 
screening of high-throughput chemical compound libraries with no or little direct 
ethnopharmacological input. The standard pharmaceutical business model is to find new 
chemical or molecular entities as promising clinical candidates and then to patent this 
innovation in the hope of securing twenty years of exclusive sales before generic 
competitors may be introduced. As traditional medicines with a documented historical use 
cannot be patented (except if novel uses and/or structures are derived from it, entering 
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into the ethical minefield of bioprospecting), large pharmaceutical companies would never 
be interested in producing a variation of Gabur-25 or PADMA 28 even though they have 
the means to carry out the clinical trials (Audio recording 65).  
 
The problem faced by PADMA however is the far-reaching influence of Big Pharma on 
politicians and regulators, leading to well-known (neoliberal) commercial, scientific and 
regulatory biases on their behalf (see Law 2006 and Goldacre 2013, as well as the work by 
Abraham cited above). Although not necessarily intentional, the impact of these Big 
regulations which presume the narrow applicability of classical chemistry and 
ƉŚĂƌŵĂĐŽůŽŐǇŽŶǁŚĂƚ/ĐĂůů^ŵĂůůůƚĞƌŶĂƚŝǀĞWŚĂƌŵĂŝƐĚĞƐƚƌƵĐƚŝǀĞ ?dŚĞƐĞ ‘^ŵĂůůƚĞƌŶĂƚŝǀĞ
WŚĂƌŵĂ ? Đompanies align with the CAM movement but are industrial, and manufacture 
non-chemically pure, non-sterile, non-patented products, the majority of which reaches 
the public through over-the-counter public sales.113 CAM Pharma can thus be more or less 




As a small company on its own, PADMA has few if any reasonable options in terms of 
political influence. Companies are entitled to send letters to regulatory agencies such as 
the EMA HMPC (the Committee on Herbal Medicinal Products of the European Medicines 
Agency) or Swissmedic to bring broader legislative or regulatory issues to the fore, but the 
efficiency of this strategy is questionable. This was also evident to Herbert, who was 
affiliated to the Austrian green movement in his university years, where he adopted a 
                                                     
113  I acknowledge that the highly diverse and dynamic field of CAM is not that easily captured in rigid 
definitions. The Swiss company Weleda for instance (founded in 1921, headquarters in Arlesheim near Basel, 
main production in Germany)  W  ‘ƚŚĞǁŽƌůĚ ?ƐůĞĂĚŝŶŐŵĂŶƵĨĂĐƚƵƌĞƌŽĨĐĞƌƚŝĨŝĞĚŶĂƚƵƌĂůĂŶĚŽƌŐĂŶŝĐĐŽƐŵĞƚŝĐƐ
ĂŶĚĂŶƚŚƌŽƉŽƐŽƉŚŝĐƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? ?The Weleda Group and Weleda AG 2015, p. 2)  W operates in over fifty 
countries worldwide, has a workforce of approximately 2,000 employees, and achieved a turnover of 364,3 
ŵŝůůŝŽŶĞƵƌŽ ŝŶ  ? ? ? ? ?dŚĞĚĞƐŝŐŶĂƚŝŽŶ  ‘ƐŵĂůů ?ŵĂǇƐĞĞŵƵŶĨŝƚƚŝŶŐŚĞƌĞ ?^ƚŝůů ?EŽǀĂƌƚŝƐ  ?ĂůƐŽďĂƐĞĚ ŝŶĂƐĞů )
employed 118,700 people and had a revenue of more than fifty billion US dollars in 2015 (Novartis 2016). 
Novartis Consumer Health recently merged with Gebro Pharma into GSK-Gebro Consumer Healthcare GmbH, 
a market leader of the Austrian OTC market. The latter had earlier taken over the Swiss Alpinamed AG in 2000 
which specialises in herbal extracts. So for now, Novartis owns a herbal company even though this was not 
ƚŚĞŝƌŵĂŝŶŝŶƚĞŶƚŝŽŶ ?dŚŝƐŝƐĂŶŽƚŚĞƌĞǆĂŵƉůĞŽĨƚŚĞŽǀĞƌůĂƉďĞƚǁĞĞŶŝŐĂŶĚ ‘^ŵĂůůƚĞƌŶĂƚŝǀĞ ?WŚĂƌŵĂ ? 
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ƌĞĂůŝƐƚ ĂĐƚŝǀŝƐƚ ƉŽƐŝƚŝŽŶ ŽĨ  ‘ŐĞƚƚŝŶŐ ƚŚŝŶŐƐ ŵŽǀŝŶŐ ? ĞǀŶ ŝĨ ƚŚŝƐ ŵĞĂŶƚ ƐŽŵĞƚŝŵĞƐ
compromising on ideals in practice (Audio recording 7). When he arrived in Switzerland 
with his wife Alexandra and started working at PADMA in the 1990s, PADMA was not part 
of any association. Over the years, Herbert managed to first get observer status at an 
association of homeopathic and anthroposophic medicine producers, which later 
expanded to the SVKH (Schweizerischer Verband der komplementärmedizinische 
Heilmittelhersteller ) ŽĨ ǁŚŝĐŚ ŚĞ ŝƐ ŶŽǁ ƚŚĞ ƉƌĞƐŝĚĞŶƚ ? ƚŚĞ  ‘^ǁŝƐƐ ƐƐŽĐŝĂƚŝŽŶ ĨŽƌ
Complementary Medicines Producers ?ǁŚŝĐŚĐƵƌƌĞŶƚůǇŚĂƐƚǁĞŶƚǇ-nine herbal companies 
amongst its members and falls under the larger umbrella organization Dakomed 
(Dachverband Komplementärmedizin).  
 
Although therapeutic pluralism in Switzerland has been a topic of interest since the 1970s, 
ƚŚĞ ƚĞƌŵ  ‘ĐŽŵƉůĞŵĞŶƚĂƌǇ ? ŽŶůǇ ĂƉƉĞĂƌĞĚ ŝŶ ƚŚĞ 1990s as these practices became 
increasingly politicised (Martin and Debons 2015). Large research programmes evaluating 
CAM prevalence and efficacy, cost and implications of integration into health insurance 
were launched, such as the so-called Programm Evaluation Komplementärmedizin (PEK). 
Although the results that came out of this in 2006 were positive, the health minister had 
already decided to delist the complementary medicines from public health insurance, 
seemingly for political reasons (Rist and Schwabl 2009). In this context the umbrella 
organization Forum für Ganzheitsmedizin (in which PADMA and particularly Herbert took a 
leading role) was moved to set up a federal popular initiative in 2004 (Ja zur 
Complementärmedizin) to let the public vote for increased state support; a unique aspect 
of Swiss direct democracy. After more than 140,000 signatures were collected, parliament 
prepared a slightly modified counterproposal Zukunft mit Komplementärmedizin for 
popular vote on 17 May 2009: 67% voted in favour. This proposal included (1) the re-
inclusion of the five complementary modalities in public insurance (reinstated on probation 
for the period 2012-2017), (2) national diplomas for therapists, (3) integration of CAM into 
higher education (including for doctors and pharmacists), and (4) the installation of a 
simplified and less expensive registration procedure for complementary medical products. 
The proposal was passed and is being integrated into the constitution (although the extent 
of its effective implementation is still criticised by the CAM community), positioning 
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Switzerland as a pioneer on the European continent. In 2014, SVKH and Dakomed were 
once again using their political leverage to negotiate the contents of the new Swiss law on 
medicines (Heilmittelgesetz) at the Swiss parliament and government (Audio recording 51). 
Both institutions need to be lobbied: the former to influence the law-making process, the 
latter for its interpretation and execution. Although they could instigate members of 
paƌůŝĂŵĞŶƚƚŽƌĂŝƐĞĂŶƵŵďĞƌŽĨ ‘ŶĂƐƚǇƋƵĞƐƚŝŽŶƐ ? ?ĐŽŵƉůĞŵĞŶƚĂƌǇŵĞĚŝĐŝŶĞŝƐĐŽŶƐƚƌĂŝŶĞĚ
by a double bind: if too much pressure is put on the small herbal/traditional regulatory 
department within the drug authority they may be closed down altogether, which would 
be disastrous. In conversations between the agency and Big industry however, the tables 
are turned: politicians and regulators take care to create a good economic environment for 
these companies, otherwise they might leave the country and lead to significant 
unemployment. 
 
To be able to negotiate with the health authorities in other European countries more 
directly and efficiently for the registration of its products, company management decided 
to create an Austrian branch called PADMA Europe a few years ago. As an EU member, 
Austria could then serve as a springboard to other countries as Switzerland is much more 
isolated politically from its neighbours. But again, for political purposes it was deemed 
necessary to overcome the enmity and differences between different CAM fields to work 
together towards common goals. EUROCAM therefore unites a number of European and 
international stakeholder organisations  W including the European Herbal and Traditional 
Medicine Practitioners Association (EHTPA), of which the British Association of Traditional 
Tibetan Medicine (BATTM) is part (Holmes and Sweeney 2003)  W to influence decision-
making at the European Commission and Parliament. On the 27th of June 2013, Herbert 
travelled to Brussels for a parliamentary hearing on complementary medicine (Audio 
ƌĞĐŽƌĚŝŶŐ  ? ) ?,ĞƉƌĞƐĞŶƚĞĚŚŝŵƐĞůĨĂƐĂƌĞƉƌĞƐĞŶƚĂƚŝǀĞŽĨ  ‘^ǁŝƐƐƚƌĂĚŝƚŝŽŶĂůŵĞĚŝĐŝŶĞ ?ƚŽ
overcome European power games within CAM between European and Asian traditions. 
Together with Michael McIntyre (who is still fighting for the statutory regulation of 
practitioners in the UK through EHTPA; McIntyre 2003, McIntyre et al. 2015), Herbert 
provided the input on herbal medicines. Based on the smallness of CAM in the European 
context, thĞŐĞŶĞƌĂůƐƚƌĂƚĞŐǇŝƐƚŽƵŶŝƚĞ ‘ĂůůƚŚĞĐƌĂǌǇƉĞŽƉůĞ ?, to become less of a fringe 
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group, as it would be deemed ridiculous to demand a specific Tibetan medicine legislation. 
There is a need for a clear and concise message as a united stakeholder group and to work 
on both long term (better legislation) and short term (better implementation of existing 
laws) aims (EUROCAM 2015). Big Pharma has its own lobbying groups. One example, which 
partially overlaps with the remit of CAM, is the AESGP (the Association of the European 
Self-Medication Industry) which represents European producers of non-prescription 
medicines, supplements and self-care medical devices. Although this organisation in 
principle covers the large majority of herbal medicines and although this association 
equally strongly recommends a more just evaluation of THMPs (Cranz and Anquez-Traxler 
2014), it does not exclusively cater for natural products and also does not take on a CAM 
discourse. Much larger and chemical companies dominate this group, making it more 
difficult for alternative pharmaceutical companies to interact with them (Audio recording 
54).  
 
6.4 PADMA, regulatory reformulation and innovation 
WDůĞŐŝƚŝŵŝƐĞƐŝƚƐŵĂŶǇĂĚĂƉƚĂƚŝŽŶƐŽĨ ‘ĐůĂƐƐŝĐĂůdŝďĞƚĂŶĨŽƌŵƵůĂĞ ?ŽŶƚŚĞŐƌŽƵŶĚƐƚŚĂƚ
pharmacy practices have always been dynamic and context-dependent, as do the Indian 
ĐŽŵƉĂŶŝĞƐƚŚĂƚĚƌŝǀĞǇƵƌǀĞĚĂ ?ƐƌĞĨŽƌŵƵůĂƚŝŽŶƌĞŐŝŵĞ ?zĞƚ ?WŽƌĚŝĠĂŶĚ,ĂƌĚŽŶ ? ? ? ? ?, p. 3) 
distinguish these mass-ƉƌŽĚƵĐĞĚ ŝŶĚƵƐƚƌŝĂů ƌĞĨŽƌŵƵůĂƚŝŽŶƐǁŚŝĐŚ  “ďĞŐŝŶ ŝŶ ƚŚĞŵŝŶĚƐŽĨ
researchers and in drug company boardrooŵƐ ? ĨƌŽŵ  ‘ĐůĂƐƐŝĐĂů ? ƉƌĂĐƚŝĐĞƐ  ‘ŽŶ ǀĞƌǇ ƐŵĂůů
ƉƌŽĚƵĐƚŝŽŶ ƐĐĂůĞƐ ? which occur largely within the practitioner-patient interface. The 
prehistory of PADMA 28, however, unveils the problematic nature of this divide  W as does 
ůĂŝŬŝĞ ?Ɛ ǁŽƌŬ  Wby sketching the manifold transformations, dynamic relations and 
ƵŶƉƌĞĚŝĐƚĂďůĞŽƵƚĐŽŵĞƐŽĨƚŚĞ ‘ĚŝƐĐŽǀĞƌǇ ?ŽĨƚŚŝƐĚƌƵŐ ?Based on multi-sited fieldwork in 
China and Europe with companies and private practitioners, Schrempf (2015) relies on the 
same analytical categories. Classical Tibetan formulations are prescribed (and produced) 
by amchi according to Sowa Rigpa principles. Tibetan industrialised pharmaceuticals are 
mass-manufactured by companies adhering to pharmaceutical scientific validation regimes, 
are mostly prescribed by biomedical doctors, as well as targeting over-the-counter 
ĐŽŵƉůĞŵĞŶƚĂƌǇĂŶĚĂůƚĞƌŶĂƚŝǀĞ ? ‘ŶĂƚƵƌĂů ?ĂŶĚ ‘ŚĞƌďĂů ?ŚĞĂůƚŚĂŶĚǁĞůůŶĞƐƐŶŝĐŚĞŵĂƌŬĞƚƐ ?
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Schrempf further distinguishes a hybrid polyherbal industrial formulation regime, 
exemplified by PADMA in her work, which generates multi-compound medicines and 
supplements consisting primarily of herbs (and few minerals) but excluding animal or metal 
ingredients. These reformulations are indeed the outcome of specific negotiations in-
between Tibetan and biomedical notions and practices, the result of which defies 
explanations by both knowledge systems in isolation.  
 
The pharmaceuticalisation of Tibetan medicines in Europe marginalises non-institutional 
 ‘ƚƌĂĚŝƚŝŽŶĂů ?ĂŐĞŶƚƐĂŶĚƐŵĂůů-scale formulation practices (see again Schrempf 2015, as well 
as Ma 2015 for Korean medicine). In the European context, medicine and food regulations 
ƚƵƌŶŽƵƚƚŽďĞĚĞƚĞƌŵŝŶŝŶŐĨĂĐƚŽƌƐ ŝŶWD ? ? ?ƐŵƵůƚŝƉůĞƌĞĨŽƌŵƵůĂƚŝŽŶƐ ?ĂŶŝŶĨůƵĞŶĐĞ
often downplayed by agents of commercial R&D (Pordié 2014). But PADMA openly laments 
the solidification that is the direct result of conscious efforts by the company to adhere to 
biomedical, pharmaceutical and regulatory standards (Schwabl and Vennos 2015). This 
partial self-critique is part of a bigger ŶĂƌƌĂƚŝǀĞƚŚĂƚƐŚĂƉĞƐWD ?Ɛ ŝĚĞŶƚŝƚǇĂƐĂƐŵĂůů
company with limited agency which nevertheless  W heroically, as in David and Goliath  W 
takes up a pioneering role in the regulatory and political landscapes, lobbying nationally 
and internationally for a re-evaluation of the unfairly imposed restrictions on herbal 
remedies as part of the larger CAM movement. Carving out its own modern Tibetan-
(Buryat-Russian-Polish)-Swiss tradition, PADMA is an innovation catalyst at the forefront of 
the Tibetan reformulation regime in Europe. This might be conceived as an honour, but 
more often it is a very mixed blessing as both the company and its products never seem to 
fit snuggly into the Procrustean beds constructed by either the chemical-pharmaceutically 
dominated regulatory agencies or seekers of alternative or classical authenticity. This small, 
innovative Swiss-European niche company straddles in-between the chemical and 
alternative industries and their supporters and detractors from the Left and the Right, 
betwixt tradition and innovation, and East and West. It is a liminal institution that drives 
the reformulation of Tibetan medicine(s) towards new political, economic and regulatory 







It is counterintuitive to formally conclude on something I consider to be perpetually in flux: 
the becomings of Tibetan alternative pharmaceuticals are not unidirectional, and never 
finished. Furthermore, in this translocal ethnography in-between Men-Tsee-Khang and 
PADMA there is no single, independent vantage point from which to make value 
judgements or predictions on the future of Sowa Rigpa. It would also not be enlightening 
to compare my initial working hypotheses with what was subsequently found, as my focus 
and with it my conceptual frameworks ŚĂǀĞ ƚŚĞŵƐĞůǀĞƐ ŵŽƌƉŚĞĚ ĨƌŽŵ ƉƉĂĚƵƌĂŝ ?Ɛ
ƌĞŐŝŵĞƐŽĨǀĂůƵĞ ?tĂůůĞƌƐƚĞŝŶ ?ƐĐŽŵŵŽĚŝƚǇĐŚĂŝŶƐĂŶĚ>ĂƚŽƵƌŝĂŶĂĐƚŽƌ-networks to Pordié 
ĂŶĚ 'ĂƵĚŝůůŝğƌĞ ?Ɛ  ‘ƌĞĨŽƌŵƵůĂƚŝŽŶ ƌĞŐŝŵĞ ? ? /ŶŐŽůĚŝĂŶ ŵĞƐŚǁŽrks and ontologies in 
technoscientific practice. Each of the previous six chapters represents a different aspect of 
becoming, a cross-cutting layer of the on-going processes of reformulation that surface in 
each life stage  W here both literally and metaphorically  W of plants-becoming-medicines. 
Even though methodologically my aim was to follow some of the more salient life lines of 
ĨŽƵƌŵĂŝŶŚĞƌďĂůĂĐƚŽƌƐ ?/ĐŽƵůĚŶ ?ƚŚĞůƉďƵƚƚŽŐĞƚƐŝĚĞ-tracked and hopelessly entangled 
with the identities of materia medica (Chapter 1), Ayurveda-dominated markets (Chapter 
2), pharmaceutical workers-and-machinery (Chapter 3), laboratories (re)constructing 
 ‘ƋƵĂůŝƚǇ ? ?ŚĂƉƚĞƌ ? ) ?ƚŚĞŝŵƉĂƐƐĞƐŽĨƚŚĞƉŽŝƐŽŶ ?ŵĞĚŝĐŝŶĞĚŝĐŚŽƚŽŵǇ ?ŚĂƉƚĞƌ ? ) ?ĂŶĚǁŝƚŚ
the regulatory politics of medicine registration and reformulation in the EU (Chapter 6). 
Nonetheless, I hope that these nonlinear diversions have served to illuminate the multiple 
and transitory nature of Tibetan medicines. 
 
Tibetan medicines are both more and less than what is written in classical pharmacy 
records. The practical identification of their ingredients rest on particular equivalences 
based on situated knowing practices which do not always stand up to textual ideals 
(Chapter 1), especially when considering the ambivalent uncertainties of sourcing materia 
medica (Chapter 2). Through enskilled production a formula comes alive as an ecology of 
materials even within industrial settings (Chapter 3). In and beyond laboratories, these 
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materials co-produce a set of hybrid technoscienƚŝĨŝĐ ‘ƋƵĂůŝƚŝĞƐ ? ?ŚĂƉƚĞƌ ? )ƚŚĂƚŝŵƉŝŶŐĞŽŶ
their spectrum of medico-toxicological potency when expressed in local biologies and social 
ecologies of toxicity through risk assessments, reformulations, production and prescription 
practices (Chapter 5). Tibetan medicinal recipes thus constitute dynamic assemblages privy 
to identity politics and moral economies. Their inherent multiplicity allows one and the 
same formula to manifest in innumerable similar but different avatars, as was evidenced 
by Blaikie (2015) for Samnor in Ladakh and Himalayan India, and for Gabur- ? ? ?ƐƌĞŐƵůĂƚŽƌǇ
reformulations into the PADMA 28 product family (Chapter 6). Through my step-wise 
analysis of the manufacture of Tibetan alternative pharmaceuticals, I thus simultaneously 
denaturaůŝƐĞ ƐĂůŝĞŶƚ ĨĞĂƚƵƌĞƐ ŽĨ  ‘'ůŽďĂů WŚĂƌŵĂ ? ? ĐŽŶƚƌŝďƵƚŝŶŐ ŵŽƌĞ ďƌŽĂĚůǇ ƚŽ ŵĞĚŝĐĂů
anthropology and critical analyses of drug production.  
 
A conclusion amongst conclusions 
Along my dwellings and wanderings in-between India and Switzerland, I never lost track of 
four excellent and recent doctoral monographs on Sowa Rigpa: Kloos (2010) on cultural 
survival in exile, Craig (2012, based on her PhD defended in 2006) on the social ecologies 
of efficacy in Nepal and the Tibetan Autonomous Region (TAR) in China, Saxer (2013 [2010]) 
on the rapid rise of a Tibetan medicine industry in the TAR, and Blaikie (2014) on pharmacy 
and exchange in Ladakh. These anthropologists and their dissertations acted as exemplars 
ĂŶĚ ƚƌĂǀĞů ĐŽŵƉĂŶŝŽŶƐ  ?^ĂǆĞƌ ?Ɛ ďŽŽŬ ĞǀĞŶ ƐƵĐĐƵŵďĞĚ ƚŽƚŚĞ /Ŷdian Monsoon), so my 
conclusions naturally resonate with theirs and with works of a similar calibre on Ayurveda 
(Banerjee 2009, Bode 2008) and Chinese medicine (Scheid 2002, Zhan 2009).  
 
Kloos  ? ? ? ? ? ? Ɖ ?  ? ? ? ) ĐŽŶĐůƵĚĞƐ ƚŚĂƚ  ‘dŝďĞƚĂŶ ŵĞĚŝĐŝŶĞ  “ƉƌĞƐĞƌǀĞƐ ? Tibetan culture and 
produces a modern Tibetan nation by instantiating, materialising and validating Tibetan 
Buddhist ethics  W and thus Tibetan culture and nation  W in its medical knowledge, its 
institutionƐ ? ĚŽĐƚŽƌƐ ? ƉŝůůƐ ? ĂŶĚ ĞĨĨŝĐĂĐǇ ?. He emphasises Sowa ZŝŐƉĂ ?Ɛ ĂŵďŝǀĂůĞŶƚ
engagements with modernity in a transnational context, documenting its on-going and 
open-ended transformation into a medical system as an alternative modernity which 
promises to heal modern ruptures with the wholeness and ethics of tradition. Besides our 
289 
 
overlapping focus on Men-Tsee-Khang, in my thesis I relate most strongly to his chapter 
Science and the Preservation of Tradition (p. 274-334, developed further in Kloos 2015). 
The impotence of both tradition (in the face of a greedy and  ‘ĐŽƌƌƵƉƚ ?ŵĂƌŬĞƚĞĐŽŶŽŵǇ ?ĂƐ
I analysed in Chapter 2) and modern science (unable to grasp by means of technology the 
experiential and sensorial potency of Tibetan materia medica) in ensuring high-quality 
medicine necessitates and simultaneously undermines scientific quality control, heralding 
Ă ‘ƐŝůĞŶƚƌĞǀŽůƵƚŝŽŶ ?ƚŚĂƚƌĞĚĞĨŝŶĞƐďŽƚŚƐĐŝĞŶĐĞĂŶĚdŝďĞƚĂŶŵĞĚŝĐŝŶĞ ?ƐŝĚĞŶƚŝƚǇ ?ĞĨĨŝĐĂĐǇ ?
ethics and knowledge. In my Chapter 4, I largely agree with this interpretation. However, I 
considerably shift the remit from amchi discourses towards the people and technologies 
directly involved in laboratory quality control, both in Men-Tsee-Khang and PADMA. This 
allowed me to uncover the multi-layered nature of the pharmaceutical quality concept and 
its reliance on risk assessment, which implies that it too is only measurable indirectly by 
approximation. I question a priori ĚŝƐƚŝŶĐƚŝŽŶƐďĞƚǁĞĞŶ ‘ƚƌĂĚŝƚŝŽŶĂů ?ĂŶĚ ‘ŵŽĚĞƌŶ ?ƉƌĂĐƚŝĐĞƐ
to ensure good-quality medicine by unearthing historical connections and frictions, instead 
arguing for ontologically entangled enactments in both institutions. I specify an alternative 
to considering science as either an ornament (merely documenting the glory of Tibetan 
medicine) or a revolution. In-between lies a more hybrid, fluid, partial, translocal and 
practical engagement: a liminal phenomenon that fundamentally reconfigures boundaries 
ďĞƚǁĞĞŶŬŶŽǁůĞĚŐĞ ‘ƐǇƐƚĞŵƐ ?ĂŶĚƚŚĞŝƌŽďũĞĐƚƐ ?&ŽůůŽǁŝŶŐ^d^ ?ĚĞƐĐƌŝďŝŶŐĂŶĚŵĞĂƐƵƌŝŶŐ
quality are acts of intervention even when their effects are limited and contested. 
 
Craig (2012) beautifully writes about the adaptive and never exclusively local nature of 
Sowa Rigpa, recognising the dramatic change of circumstances affecting practitioners and 
patients and the concomitant contradictions and compromises in the (inter)national quest 
for legitimacy according to institutional/government, commercial and technoscientific 
parameters. The evaluation of the safety, quality, efficacy and value of Tibetan medicine is 
increasingly linked to nationally reworked biomedical standards and associated with global 
markets and more hegemonic medical traditions such as Ayurveda and TCM, pressuring 
small-scale producers in particular. Her evocation of the biomedical R&D phrase 
 ‘ƚƌĂŶƐůĂƚŝŽŶĂů ƐĐŝĞŶĐĞ ? ĂƐ  ‘a mode of engagement wherein venture capital, academic 
medicine, and Big Pharma become invesƚĞĚŝŶŵŽǀŝŶŐŝŶŶŽǀĂƚŝŽŶƐĨƌŽŵ “bench to ŵĂƌŬĞƚ ? ?
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(Craig 2012, p. 259) to capture the transformations just mentioned, and her expansion of 
the term to include the political risks, ethical ambiguities and social-ecological impacts (i.e. 
ƚŚĞ ‘ƐŽĐŝĂůĞĐŽůŽŐŝĞƐ ? )ŝŶǁŚŝĐŚƚŚĞƐĞĂƌĞĞŶƚĂŶŐůĞĚŝƐĞƐƉĞĐŝĂůůǇĐŽŶĚƵĐŝǀĞƚŽŵǇĂƌŐƵŵĞŶƚ ?
Each of my chapters consists of such a dialogue, a translation exercise114 aiming to bridge 
inadequate dichotomies and to stretch beyond disciplinary and linguistic comfort zones (cf. 
Craig and Glover 2009): between (ethno)botany and Sowa Rigpa (1), herbal trade policy 
and practice (2), industrial mass-production and artisanal manufacture (3), differing 
enactments of quality (4), poison (duk) and medicine (men) (5), and between textual and 
actual formulations (6). Especially in Chapter 5, I draw ŽŶ ƌĂŝŐ ?Ɛ ŶƵĂŶĐĞĚ ĚĞĨŝŶŝƚŝŽŶ ŽĨ
efficacy as a multidimensional, embodied pharmaco-ritual nexus to recalibrate 
ŵĞĚŝĐŝŶĞ ?ƉŽŝƐŽŶĂŶĚ ‘ŵĂŝŶ ? ? ?ƐŝĚĞ ?ĞĨĨĞĐƚĚŝƐƚŝŶĐƚŝŽŶƐĂƐƚŚĞĐŽŶƚŝŶŐĞŶƚƌĞƐƵůƚŽĨĞĐŽůŽŐŝĐĂů
plant-practitioner-factory-patient body interactions. But as I have shown in Chapters 3 and 
 ? ?ŵǇǁŽƌŬĂƚWDŚĂƐƵƌŐĞĚŵĞƚŽƌĞǀŝƐŝƚƐǁĞĞƉŝŶŐŶŽƚŝŽŶƐŽĨ ‘ŝŐWŚĂƌŵĂ ? ?tŚĂƚŝƐ
 ‘ďŝŐ ? ?or high-tech) not only depends on the scale one is used to and what one compares to, 
it also raises the question of an unuttered opposite: Small Pharma. I recognise the horrors 
ŽĨ ƚŚĞ ĐĂƉŝƚĂůŝƐƚ  ‘ĐĂƐŝŶŽ ĞĐŽŶŽŵǇ ? ŽĨ ďŝŽŵĞĚŝĐĂů ĨĂĐƚ-making and the concomitant 
criminalisation of alternative medicine and its practitioners (Adams 2002), as well as the 
pharmaceuticalisation of societies by the academic-industrial-politico-legal complex (e.g. 
Bell et al. 2012, Petryna et al. 2006). But then again, this does not imply that the 
pharmaceutical industry should only consist of multinational multibillion-dollar chemical 
companies, nor that all its activities can be conveniently lumped together under the 
umbƌĞůůĂ ƚĞƌŵ  ‘'ůŽďĂů WŚĂƌŵĂ ?  ?as suggested by Craig and Adams 2008). Despite the 
similarities, overlaps and intersections, the heterodox foundations and/or aspirations of 
what are commonly labelled traditional, complementary and alternative medicines  W even 
if GMP-conform mass-produced, quality-controlled and marketed  W merit to be recognised 
ĨŽƌǁŚĂƚƚŚĞǇĂƌĞ PĂůƚĞƌŶĂƚŝǀĞƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ?dŚĞŽĨƚĞŶ  ‘ƐŵĂůů ?  ?Ăƚ ůĞĂƐƚƌĞůĂƚŝǀĞƚŽŝŐ
WŚĂƌŵĂ ?Ɛ ƚŽƉ ƚĞŶ ) ĂŶĚ ĂůƚĞƌŶĂƚŝǀĞ WŚĂƌŵĂ ĐŽŵƉĂŶŝĞƐ ǁŚŝĐŚƉƌŽĚƵĐĞ ƚŚĞƐĞ ŶŽŶ- or 
borderline-biomedical products (not usually isolated chemicals, nor patented or 
                                                     
114 As Adams (2002) notes, the transnational circulation of and the ensuing attempts to translate between 
Sowa Rigpa anĚďŝŽŵĞĚŝĐŝŶĞ ‘create the appearance that each is bounded, discrete, internally uniform, and 
different in contrast to the other ? ?Ɖ ? ? ? ? ?ŽƌŝŐŝŶĂůĞŵƉŚĂƐŝƐ ) ?ůĞĂĚŝŶŐƚŽĐŽŶƚĞƐƚĂƚŝŽŶďĞƚǁĞĞŶ ‘ŬŶŽǁůĞĚŐĞ
ƐǇƐƚĞŵƐ ? ǁŝƚŚŽƵƚ ĂĐŬŶŽǁůĞĚŐĞŵĞŶƚ ŽĨ ƚŚĞŝƌ ŝŶƚĞƌƚǁŝŶĞŵĞŶƚ ǁŝƚŚ ĞĂĐŚ ŽƚŚĞƌ ĂŶĚ ǁŝƚŚ ƉƌŽĨŝƚ-oriented 
markets and regulations. It has been my aim to avoid this double flaw throughout this thesis.  
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prescription medicines) generally align with different ideological and political agendas and 
equally suffer from chemical-pharmaceutical hegemony even though technoscientific 
ƉƌĂĐƚŝĐĞƐĂƌĞĂƉƉƌŽƉƌŝĂƚĞĚĂŶĚ ‘ƚƌĂĚŝƚŝŽŶĂů ?ĚƌƵŐƐƌĞŝŶǀĞŶƚĞĚƚŽ compete on the market. 
This is what Pordié and Gaudillière (2014a) call the reformulation or innovation regime in 
the case of Ayurvedic polyherbals, which I apply to Tibetan pharmaceuticals produced by 
both PADMA and Men-Tsee-<ŚĂŶŐ ĂƐ / ŚĂǀĞ ĂƌŐƵĞĚ ?  ‘^ŵĂůůƚĞƌŶĂƚŝǀĞ WŚĂƌŵĂ ? ĂŶĚ ĞǀĞŶ
herbal medicines in general are nowadays mostly pushed aside and ignored by Big Pharma, 
with rare but notable exceptions, as their commercial value is localised and minor even in 
the context of the booming Tibetan medicine industry in the TAR (Craig and Adams 2008, 
p. 7), which is not export-oriented and has received no significant foreign investment from 
transnational pharmaceutical companies thus far (Saxer 2013, p. 232). Chemical and 
Smallternative Pharma are not one and the same. 
 
This brings us to the third ethnography by Saxer (2013). In the conclusion he argues that in 
spite of his assumptions the industrialisation of Tibetan medicine cannot be captured by 
ƐƚĂŶĚĂƌĚ ŵŽĚĞƌŶŝƐĂƚŝŽŶ ŶĂƌƌĂƚŝǀĞƐ ? /ŶƐƚĞĂĚ ? ^ĂǆĞƌ ǁŝƚŶĞƐƐĞƐ Ă  ‘ŵŽƌĂů economy of 
dŝďĞƚĂŶŶĞƐƐ ? ?ŽŶůǇůŝŵŝƚĞĚŐůŽďĂůŝƐĂƚŝŽŶŝŶƚĞƌŵƐŽĨĂĐĐĞƐƐƚŽĐĂƉŝƚĂůĂŶĚŵĂƌŬĞƚƐŽƵƚƐŝĚĞ
China, and conflicts between regulations and traditional practices due to a rapid 
implementation rather than clashing epistemologies (see also Saxer 2012). The Sowa Rigpa 
industry is presented as an unpredictable, dynamic spatial-temporal assemblage marked 
by enduring problematisations (such as progress, culture and nation) and multiple 
peripheries (vis-à-vis biomedicine and TCM, and at the margins of large nation-states). I 
ǁĂƐ ŝŶƐƉŝƌĞĚďǇ^ĂǆĞƌ ?ƐĐŽŶĐĞƉƚŝŽŶŽĨ  ‘ďŽƌĚĞƌ ƌĞŐŝŵĞƐ ?ĂƐĂ ůŝŵŝŶĂů ƐƉĂĐĞ ŽĨƵŶƌƵůǇĂŶĚ
malleable state power, especially as applied to the importation and trade of medicinal 
plants from Nepal to China (Saxer 2009). In Chapter 2, I identified similar grey zones on 
Indian domestic herbal markets  W which operate in-between informality/illegality and 
formality/legality  W and in Indian export to Europe. I concur with Saxer (2009, p. 327) by 
ĚŽĐƵŵĞŶƚŝŶŐ ŚŽǁ  ‘[c]ross-border trade inherently makes all parties outsiders in some 
ĐŽŶƚĞǆƚƐĂŶĚŝŶƐŝĚĞƌƐŝŶŽƚŚĞƌƐ ?, highlighting the othering role of corruption discourses and 
regulation-ƌĞĂůŝƚǇŵŝƐŵĂƚĐŚĞƐ ?ĂŶĚƚŚĂƚ ‘the survival of a border regime rests, ironically, on 
ďŽƚŚŽĸĐŝĂůƐĂŶĚƚƌĂĚĞƌƐďƌĞĂŬŝŶŐ its ƌƵůĞƐŝŶŽƌĚĞƌƚŽŵĂŬĞŝƚǁŽƌŬ ? (ibid., p. 337). I further 
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explored these notions of marginality and liminality through the adoption of translocal and 
multispecies methodologies and by focusing on the positionality of two specific institutions, 
as opposed to generalising across an entire industry. My approach has the advantage that 
assemblages can be localised, characterised and interrogated on a micro-level and in 
(technoscientific) practice, allowing nonhuman agencies and materiality to be 
foregrounded. Furthermore, I contend that PADMA and Men-Tsee-Khang should not be 
lumped together with the generally much larger Chinese Sowa Rigpa companies as the 
ĨŽƌŵĞƌ ĚĞŵŽŶƐƚƌĂƚĞ ǁŚĂƚ / ƚĞŶƚĂƚŝǀĞůǇ ƚĞƌŵ  ‘ƋƵĂƐŝ- ŶĚƵƐƚƌŝĂů ? ĂƌƚŝƐĂŶĂů ƉƌŽĚƵĐƚŝŽŶ
characteristics (see Chapters 3 and 5 respectively). 
 
ůĂŝŬŝĞ ?Ɛ  ? ? ? ? ? ) ĂĚŵŝƌĂďůĞ ǁŽƌŬ ŽƉĞŶĞĚ ƵƉ ƐĞǀĞƌĂů ƉƌŽĚƵĐƚŝǀĞ ĂǀĞŶƵĞƐ ĨŽƌ ĨƵƌƚŚĞƌ
investigation. He was the first to relate Sowa Rigpa (in its Himalayan Indian and Ladakhi 
ĨŽƌŵƐ )ƚŽWŽƌĚŝĠĂŶĚ'ĂƵĚŝůůŝğƌĞ ?Ɛ ? ? ? ? ?a) reformulation regime by marking a number of 
contrasts with the Ayurvedic pharmaceutical industry (Blaikie 2015): a trend towards more 
complex formulations as opposed to regulation- and market-driven simplification, the 
confinement of issues of efficacy and quality to the individual and institutional levels, and 
the absence of a national pharmacopoeia and patented proprietary medicines thus far. 
Although there are bound to be changes as the recognition of Sowa Rigpa as an Indian 
System of Medicine is implemented further these differences starkly distinguish Men-Tsee-
Khang from PADMA, whose practices align more readily with Ayurvedic industrial 
innovation regimes (see Chapter 6). On the other hand, Men-Tsee-Khang equally does not 
fit well with Ladakhi small-scale producers and medium-ƐĐĂůĞ  ‘ƉƌŽƚŽ-ŝŶĚƵƐƚƌŝĂů ? ĐŽƚƚĂŐĞ
industries. It is also not (yet?) to be equated with the GMP-factory models espoused by 
Indian, Chinese and Bhutanese government institutions. In this respect both PADMA and 
Men-Tsee-Khang (and of course their products) are in the midst of becoming 
technoscientific and industrial, albeit asymmetrically. They are both operating in-between 
the small and the large, tradition and modernity, mainstream and alternative, and shaped 
by more hegemonic yet heterodox traditions and alternative medicine discourses. I 
ĞǆƉĂŶĚĞĚůĂŝŬŝĞ ?ƐĐůŽƐĞĂƚƚĞŶƚŝŽŶƚŽƚŚĞŵĂƚĞƌŝĂůŝƚǇ ?ƐŬŝůůĂŶĚƚĞĐŚŶŽůŽŐǇŽĨ^ŽǁĂZŝŐƉĂ
pharmacy to a European industrial setting, which is much more regimented and machine-
oriented yet in a way surprisingly similar in its reliance on skilful and sensorial engagements, 
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ƌĞůǇŝŶŐŽŶ/ŶŐŽůĚ ?ƐĞĐŽůŽŐǇŽĨŵĂƚĞƌŝĂůƐ ?&ƵƌƚŚĞƌŵŽƌĞ ?/ďĞŶĞĨŝƚƚĞĚĨƌŽŵŚŝƐĚŝƐĐƵƐƐŝŽŶŽĨ
the dubious role of medicinal plant cultivation and conservation, feeding into 
modernisation, commeƌĐŝĂůŝƐĂƚŝŽŶ ĂŶĚ ŝŶĚƵƐƚƌŝĂůŝƐĂƚŝŽŶ ǁŚŝůĞ Ăƚ ŽŶĐĞ ƐƵƉƉŽƌƚŝŶŐ  ‘ůŽĐĂů ?
practitioners-producers as well as political interests of elite amchi (Blaikie 2009). 
Conservation-development discourses turned out to play a central role in state efforts to 
formalise the Indian herbal trade through top-down legislations and interventions, but 
these idealistic and simplistic controls which blame ignorant harvesters and greedy traders 
fail to grasp the labyrinthine and shadowy nature of a trade where informality/illegality is 
ƚŚĞŶĞĐĞƐƐĂƌǇ ‘Ğǀŝů ?ŽĨƐǇƐƚĞŵŝĐŵĂůŐŽǀĞƌŶĂŶĐĞĂŶĚĐŽƌƌƵƉƚŝŽŶ ? 
 
&ŝŶĂůůǇ ? /ŚŽƉĞƚŚĂƚŵǇƚŚĞƐŝƐŚĂƐƐŚŽǁŶƚŚĞƌĞůĞǀĂŶĐĞƚŽ^ŽǁĂZŝŐƉĂŽĨ^ĐŚĞŝĚ ?Ɛ  ? ? ? ? ? )
Chinese medicine in contemporary China, which urges scholars from East and West to move 
away from essentialism and the repression of plurality; including connections with 
biomedicine. ^ ŝŵŝůĂƌůǇ ?/ƐǇŵƉĂƚŚŝƐĞǁŝƚŚŚĂŶ ?Ɛ ? ? ? ? ? ?Ɖ ? ? ? ? )ŵŽǀĞďĞǇŽŶĚ ‘ŐůŽďĂůŝƐĂƚŝŽŶ ? ?
conceptualiƐŝŶŐ ĚŝĨĨĞƌĞŶĐĞ  ‘as the contingent outcome rather than the starting point of 
translocĂů ĞŶĐŽƵŶƚĞƌƐ ĂŶĚ ĞŶƚĂŶŐůĞŵĞŶƚƐ ?. In this light, giving final answers to general 
ƋƵĞƐƚŝŽŶƐ ƐƵĐŚ ĂƐ  ‘ĂƌĞ ƚŚĞ ƉŝůůƐ ƉƌŽĚƵĐed by PADMA and Men-Tsee-Khang still Tibetan 
ŵĞĚŝĐŝŶĞƐ ? ? ĂŶĚ  ‘ĂƌĞ ƚŚĞǇ ĂůƚĞƌŶĂƚŝǀĞ ?ƉŚĂƌŵĂĐĞƵƚŝĐĂů ?ŝŶĚƵƐƚƌŝĂů ? ? ŝƐ ƐŽŵĞǁŚĂƚ
meaningless. Nonetheless, it is equally impossible to escape politics of identity and naming 
in academic practice (Hsu 2013) ?tŝƚŚƚŚĞĚĞƐŝŐŶĂƚŝŽŶ ‘ĂůƚĞƌŶĂƚŝǀĞƉŚĂƌŵĂĐĞƵƚŝĐĂůƐ ? ?/ƚŚƵƐ
consciously and contentiously position my work in-between dichotomous extremes by 
forging and exploring connections, flows and frictions between two seemingly unrelated 
manufacturers. These liminal, paradoxical yet politically subversive things oscillate betwixt 
and between tradition and modernity, orthodoxy and innovation, East and West. Men-
Tsee-Khang and PADMA could be interpreted as two possible instantiations of a quasi-
industrial techno-^ŽǁĂZŝŐƉĂ ?ďƵƚŽŶůǇ ŝĨŽŶĞĚŝƐƚŝŶŐƵŝƐŚĞƐ  ‘ŝŐ ?ĨƌŽŵ  ‘^ŵĂůůůƚĞƌŶĂƚŝǀĞ ?
















   
 
amchi am chi practitioner of Sowa Rigpa 
arura a ru ra Terminalia chebula Retz.* 
bardo bar do intermediate period between death 
and rebirth; moment of suspension of 
ordinary consciousness  
 
béken bad kan 
one of the nyépa sum, often translated 
as 'phlegm' 
bong(nga) kar(po) bong (nga) dkar 
(po) 
Aconitum heterophyllum Wall. ex 
Royle 
bong(nga) nak(po) bong (nga) nag (po) Aconitum sp.* 
chakché lcags phye iron powder 
chaktsi lcags rtsi iron essence 
changduk spyang dug Aconitum lycoctonum L. 
chétsa lce tsha Ranunculus sp.* 
chuser chu ser 'yellow fluid'; variously translated as 
'lymph' or 'serum'   
del rdal personal connections, network of 
exchange 
dodrek mar rdo dreg dmar a red type of lychen 
drébu-sum(thang) 
bras bu gsum 
(thang) 
(decoction of) 'the 'three fruits' (arura, 
barura, kyurura), marketed by PADMA 
as HEPATEN   
Düdtsi Bumzang ĚƵĚƌƚƐŝ ?ŝďƵŵ
bzang 
Excellent vase of elixirs; famous early 
20th-century formulary by Khyenrab 
Norbu   
duk dug poison, toxin 
dukdön dug don the removal of toxic or coarse aspects 
from medicinal raw materials; fifth of 
the Seven essential limbs   
duk sum dug gsum the 'three mental poisons' that 
manifest from ignorance in Buddhism   
gabur ga bur camphor 
gabur-nyernga ga bur nyer lnga Gabur-25, 'Camphor-25'; Tibetan 
medical formula on which PADMA 28 
is based   
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gadra ga bra Rubus ellipticus Sm.* 
gozang sgo bzang superior variety (often larger) 
gongen sgo sngan inferior variety (often smaller) 
gulnak gul nag black 'gugul', Commiphora wightii 
(Arn.) Bhandari   
gurgum gur gum Carthamus tinctorius L.* 
Gyüzhi Rgyud bzhi The Four Tantras; the core text of 
Sowa Rigpa 
honglen hong len Neopicrorhiza scrophulariiflora 
(Pennell) D.Y.Hong   
jam tselwa  ?ũĂŵďƚƐĂůďĂ to make smooth, to make more 
digestible 
Jangluk byang lugs the Northern school of Tibetan 
medicine 
jarkang bya rkang Delphinium sp.* 
jumar byu dmar red coral 
jungwa nga  ?ďǇƵŶŐďĂůŶŐĂ the five elements (earth, water, fire, 
wind and space)   
khenda mkhan da solid extract 
khyung-nga khyung lnga Garuda-5, a very popular Tibetan 
medicine in the form of tiny black pills   
Künphen Düdtsi kun phan bdud rtsi Amrita extract beneficial to all, most 
important Buryat formulary, authored 
by Lobsang Sherab (18th century)   
kyerpa karpo skyer pa dkar po  Berberis lycium Royle* 
latsi gla rtsi musk 
lung rlung wind (refering to the element, and the 
humour)   
lu klu serpent-like spirit, naga 
mengak man ngag oral instruction or teaching 
Mengak Lhenthap man ngag lhan 
thabs 
Oral Instructions for Practical 
Applications, important 17th-century 




manu ma nu Inula racemosa Hook.f.* 
men sman medicine; materia medica 
menchen sman chen 'great medicine', synonym of 
bongnak* 
mendep sman dep medicine prescription booklet 
menjor sman sbyor the compounding of medicine; 
pharmacy (discipline)   
menkyi gyelpo sman gyi rgyal po 'the king of medicine', usually arura 
menkyi öpo mépa sman kyi 'os po 
med pa 
unsuitable medicine 




menrampa sman rams pa title for highest degree awarded to 
doctors at Men-Tsee-Khang 
mentsikhang sman rtsis khang Tibetan medical and astrological 
institute; 'Men-Tsee-Khang' is the 
Anglicised spelling used by the 




menwa dratsang sman ba grwa 
tshang 
Tibetan medical faculty (of a 
monastery) 
médrö me drod digestive fire 
métok me tog flower, flowers (category) 
mukchung denyön smug chung 'den 
yon 
Meconopsis sp. 
mumen mu men lapis lazuli 
né nad disease, disorder 
ngomen sngo sman herbs medicine (category) 
ngowo ngo bo the essence or natural quality of a 
specific substance   
ngülchu dngul chu 'silver water', mercury 
ngyené ngyan nad epidemic, infectious disease 
nüpa (gyé) nus pa (rgyad) (the eight) powers or types of potency 
of medicines, sometimes called 
primary qualities   
nyépa (sum) nyes pa (gsum) the (three) dynamics or 'humours' 
pangpö spang spos Nardostachys jatamansi (D.Don) DC. 
payak pa yag Lancea tibetica Hook. f. and Thomson 
péma pad ma lotus, Nelumbo nucifera L. 
phenü phan nus efficacy 
phenthok phan thogs benefit 
phenyön phan yon beneficial qualities (of medicine) 
pho rik pho rigs male type (of medical substance) 
raduk ra dug Aconitum napellus L. 
rinchen rilbu rin chen ril bu precious pill, jewel pill 
rilbu ril bu Tibetan medical pill 
rilsön ril son small pill starters the size of barley 
seeds 
ro ro taste 
ruta ru rta Saussurea costus (Falc.) Lipsch.* 
samphel-norbu 
(samnor) 
ďƐĂŵ ?ƉŚĞůŶŽƌďƵ 'Wish-fulfilling Jewel', a popular 
Tibetan pill medicine for nerve 
disorders   
sendu-ngapa ƐĞ ?ďƌƵŶŐĂƉĂ Sendu-5, market by PADMA as 
DIGESTIN 
serdok ngapa gser mdog lnga pa Serdok-5, a Tibetan medical formula 
dispensed in granular form by Men-
Tsee-Khang   




Shelgong Shelthreng shel gong shel 
'phreng 
Crystal Orb / Crystal Garland; seminal 
18-century Tibetan materia medica 
text by Tenzin Phuntsok   
shingdong shing dong woody plants (category) 
shingmen shing sman woody medicine (category) 
shudak shu dag Acorus calamus L. 
sin srin intestinal parasites, or pathogens such 
as bacteria and viruses   
sogzin-chupa ƐƌŽŐ ?ǌŝŶĐŚƵƉĂ Sogzin-10, adaptation of 11-ingredient 
Tibetan formula marketed by PADMA 
as NERVOTONIN   
sowa rikpa gso ba rig pa Sowa Rigpa, the 'science/knowledge of 
healing; mostly known as Tibetan 
medicine   
tendrel rten 'brel dependent arising (Tibetan Buddhist 
tenet) 
thang thang decoction 
thangka thang ka Buddhist scroll painting 
thangmen thang sman medicine from the plains (category) 
thripa mkhris pa one of the nyépa sum, often translated 
as 'bile'   
thrishing  ?ŬŚƌŝƐŚŝŶŐ woody vines (category) 
thukpa thug pa Tibetan noodle soup 
thursel lung thur sel rlung downward-clearing wind 
trungpé  ?ŬŚƌƵŶŐdpe 
Tibetan medical genre or text on 
simples 
tsa rtswa grass, grasses/herbs (category) 
tsapmen tshabs sman substitution of medicine 
                             
tsenduk btsan dug 
'violent spirit poison', synonym for 
bongnak* 
(ajak) tserngön (a byag) tsher 
sngon 
Meconopsis spp.* 
tsimen rtsi sman exudent/essence medicine (category) 
tsotel btso thal 
'cooked ash', detoxified mercury 
sulphide 
utpel ngönpo u tpal sngon po Meconopsis grandis Prain 
utpel serpo u tpal ser po Meconopsis paniculata Prain 
Vaidur Ngönpo vai dhur sngon po Blue beryl; important 17-century 
edited version of the Four Tantras by 
Sangyä Gyamtso   
wang (po) lak(pa) dbang (po) lag (pa) Dactylorhiza hatagirea (D.Don) Soó 
yimong karpo dbyi mong dkar po Clematis sp.* (white type) 
yartsa günbu dbyar rtswa dgun 
'bu 




yenlak dün yan lag bdun 
Seven Essential Limbs, Gyüzhi section 
on the harvest and processing of 
(herbal) medicines 
yönten (chudün) yon tan (bcu bdun) (the seventeen) attributes or 
secondary qualities of medicines   
zashing zwa shing Urtica spp. 
Zurluk zur lugs 
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